
<html lang="en"     class="pb-page"  data-request-id="95b6eaf0-def9-4984-9132-aedf8ad40789"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-23;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.0c01248"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK)" /></meta><meta name="dc.Creator" content="Yang  Lu" /></meta><meta name="dc.Creator" content="Haiying  Sun" /></meta><meta name="dc.Description" content="Focal adhesion kinase (FAK) is a nonreceptor intracellular tyrosine kinase that plays an essential role in cancer cell adhesion, survival, proliferation, and migration through both its enzymatic ac..." /></meta><meta name="Description" content="Focal adhesion kinase (FAK) is a nonreceptor intracellular tyrosine kinase that plays an essential role in cancer cell adhesion, survival, proliferation, and migration through both its enzymatic ac..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 15, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01248" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01248" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01248" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01248" /></link>
        
    
    

<title>Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01248" /></meta><meta property="og:title" content="Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0016.jpeg" /></meta><meta property="og:description" content="Focal adhesion kinase (FAK) is a nonreceptor intracellular tyrosine kinase that plays an essential role in cancer cell adhesion, survival, proliferation, and migration through both its enzymatic activities and scaffolding functions. Overexpression of FAK has been found in many human cancer cells from different origins, which promotes tumor progression and influences clinical outcomes in different classes of human tumors. Therefore, FAK has been considered as a promising target for small molecule anticancer drug development. Many FAK inhibitors targeting different domains of FAK with various mechanisms of functions have been reported, including kinase domain inhibitors, FERM domain inhibitors, and FAT domain inhibitors. In addition, FAK-targeting PROTACs, which can induce the degradation of FAK, have also been developed. In this Perspective, we summarized the progress in the development of small molecular FAK inhibitors and proposed the perspectives for the future development of agents targeting FAK." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="Focal adhesion kinase (FAK) is a nonreceptor intracellular tyrosine kinase that plays an essential role in cancer cell adhesion, survival, proliferation, and migration through both its enzymatic activities and scaffolding functions. Overexpression of FAK has been found in many human cancer cells from different origins, which promotes tumor progression and influences clinical outcomes in different classes of human tumors. Therefore, FAK has been considered as a promising target for small molecule anticancer drug development. Many FAK inhibitors targeting different domains of FAK with various mechanisms of functions have been reported, including kinase domain inhibitors, FERM domain inhibitors, and FAT domain inhibitors. In addition, FAK-targeting PROTACs, which can induce the degradation of FAK, have also been developed. In this Perspective, we summarized the progress in the development of small molecular FAK inhibitors and proposed the perspectives for the future development of agents targeting FAK." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0016.jpeg" /></meta><meta name="twitter:title" content="Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK)" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01248"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01248">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01248&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01248&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01248&amp;href=/doi/10.1021/acs.jmedchem.0c01248" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 14382-14403</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01177" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c01312" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK)</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Yang Lu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yang Lu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yang++Lu">Yang Lu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">Â andÂ </span><li><span><span class="hlFld-ContribAuthor">Haiying Sun</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Haiying Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#4a222b233323242d397b737c730a293a3f642f2e3f642924"><span class="__cf_email__" data-cfemail="6c040d051505020b1f5d555a552c0f1c1942090819420f02">[emailÂ protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Haiying++Sun">Haiying Sun</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5380-5329" title="Orcid link">http://orcid.org/0000-0001-5380-5329</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01248&amp;href=/doi/10.1021%2Facs.jmedchem.0c01248" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 14382â14403</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 15, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>17 July 2020</li><li><span class="item_label"><b>Published</b> online</span>15 October 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 December 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01248" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01248</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D14382%26pageCount%3D22%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYang%2BLu%252C%2BHaiying%2BSun%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D23%26contentID%3Dacs.jmedchem.0c01248%26title%3DProgress%2Bin%2Bthe%2BDevelopment%2Bof%2BSmall%2BMolecular%2BInhibitors%2Bof%2BFocal%2BAdhesion%2BKinase%2B%2528FAK%2529%26numPages%3D22%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D14403%26publicationDate%3DDecember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01248"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1837</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">5</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01248" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yang&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Haiying&quot;,&quot;last_name&quot;:&quot;Sun&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;15&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;14382-14403&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01248&quot;},&quot;abstract&quot;:&quot;Focal adhesion kinase (FAK) is a nonreceptor intracellular tyrosine kinase that plays an essential role in cancer cell adhesion, survival, proliferation, and migration through both its enzymatic activities and scaffolding functions. Overexpression of FAK has been found in many human cancer cells from different origins, which promotes tumor progression and influences clinical outcomes in different classes of human tumors. Therefore, FAK has been considered as a promising target for small molecule anticancer drug development. Many FAK inhibitors targeting different domains of FAK with various mechanisms of functions have been reported, including kinase domain inhibitors, FERM domain inhibitors, and FAT domain inhibitors. In addition, FAK-targeting PROTACs, which can induce the degradation of FAK, have also been developed. In this Perspective, we summarized the progress in the development of small molecular FAK inhibitors and proposed the perspectives for the future development of agents targeting FAK.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01248&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01248" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01248&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01248" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01248&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01248" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01248&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01248&amp;href=/doi/10.1021/acs.jmedchem.0c01248" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01248" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01248" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01248%26sid%3Dliteratum%253Aachs%26pmid%3D33058670%26genre%3Darticle%26aulast%3DLu%26date%3D2020%26atitle%3DProgress%2Bin%2Bthe%2BDevelopment%2Bof%2BSmall%2BMolecular%2BInhibitors%2Bof%2BFocal%2BAdhesion%2BKinase%2B%2528FAK%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D23%26spage%3D14382%26epage%3D14403%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291305" title="Cell physiology">Cell physiology</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/23" title="Go to Volume 63, Issue 23"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/jmcmar.2020.63.issue-23/20201210/jmcmar.2020.63.issue-23.largecover.jpg" alt="Go to Volume 63, Issue 23"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Focal adhesion kinase (FAK) is a nonreceptor intracellular tyrosine kinase that plays an essential role in cancer cell adhesion, survival, proliferation, and migration through both its enzymatic activities and scaffolding functions. Overexpression of FAK has been found in many human cancer cells from different origins, which promotes tumor progression and influences clinical outcomes in different classes of human tumors. Therefore, FAK has been considered as a promising target for small molecule anticancer drug development. Many FAK inhibitors targeting different domains of FAK with various mechanisms of functions have been reported, including kinase domain inhibitors, FERM domain inhibitors, and FAT domain inhibitors. In addition, FAK-targeting PROTACs, which can induce the degradation of FAK, have also been developed. In this Perspective, we summarized the progress in the development of small molecular FAK inhibitors and proposed the perspectives for the future development of agents targeting FAK.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44714" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44714" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Focal adhesion kinase (FAK), also known as PTK2 (protein tyrosine kinase 2), is a cytoplasmic protein tyrosine kinase that plays important roles in cell adhesion, migration, survival, and proliferation, as well as embryonic development.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1â3)</a> FAK is a 125kD protein that consists of three domains, including an N-terminal FERM (four-point-one, ezrin, radixin, moesin) domain, a central catalytic kinase domain, and a C-terminal domain.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> There are at least 6 tyrosine phosphorylation sites (Y-397, Y-407, Y-576, Y-577, Y-861, and Y-925) across FAK, and these tyrosine residues play prominent roles in regulating the molecular functions of FAK.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Phosphorylation of these tyrosine residues can either provide binding sites for the recruitment of signaling proteins or regulate the catalytic activity of FAK.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> FAK is ubiquitously expressed in human tissues and can regulate many cellular processes upon activation.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Overexpression of FAK has been detected in many human cancer cells from different origins, and biological studies indicated that FAK activity is critical to the development and progression of various human cancers;<a onclick="showRef(event, 'ref8 ref9 ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10 ref11 ref12">(8â12)</a> therefore, FAK has been considered as a promising target for the development of novel anticancer drugs. Many small molecular FAK inhibitors have been developed, and several of them have been advanced into clinical evaluations. Based on their targeted domains, the FAK inhibitors can be roughly classified into three groups, including kinase domain inhibitors, FERM domain inhibitors, and FAT domain inhibitors. Using FAK kinase inhibitors as âwar headsâ, proteolysis-targeting chimeras (PROTACs), which can induce the degradation of FAK, have also been developed. In this review, we briefly introduced the structure and functions of FAK and mainly focused on the summarization of the recent progress in the development of small molecular FAK inhibitors. More detail structural characteristics and functions of different domains of FAK have been summarized in recently published reviews.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">1.  Structure and Functions of FAK</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03824" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03824" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">1.1.  N-Terminal FERM Domain</h3><div class="NLM_p">The FERM domain (residues 33â361) of FAK consists of three closely related subdomains, F1, F2, and F3, which form a three-lobed clover-like structure (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). The key tyrosine residue Y397 whose autophosphorylation is critical to the activation of FAK locates at the N-terminal of the FERM domain. The level and the extent of the autophosphorylation of Y397 are vital in controlling focal adhesion turnover.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The FERM domain can interact with the intracellular portion of many upstream membrane proteins, such as growth factor receptors and c-Met, and a number of downstream cytoplasmic proteins to mediate proteinâlipid and proteinâprotein interactions through its scaffolding function.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> For example, the F1 lobe (residues 33â127) and F2 lobe (residues 128â253) can interact with p53 and inhibit the pro-apoptotic function of p53;<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> the F2 lobe can fuse to a nuclear localization sequence (NLS), which stimulates FAK nuclear localization and increases cell growth and proliferation;<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> and the F3 lobe can directly bind to the MDM2 protein that leads to the ubiquitination and turnover of p53.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Taken together, the FERM domain of FAK plays an important role in triggering many signaling pathways and regulating proteinâmembrane and proteinâprotein interactions.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of FAK- and FAK-related signaling pathways in cancer progression.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">1.2.  Kinase Domain</h3><div class="NLM_p last">The central kinase domain of FAK displays high sequence homology to other tyrosine kinases, especially its closely related subgroup member proline-rich tyrosine kinase 2 (Pyk2).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Two important tyrosine residues Y576 and Y577, which participate in the regulation of the catalytic activity of the kinase domain locates on the activation loop of the kinase domain (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">1.3.  C-Terminal Domain</h3><div class="NLM_p last">The C-terminal domain (residues 686â917) is comprised of two domains, including a FAT (focal adhesion targeting) domain and two proline-rich regions (PRRs). The two proline-rich motifs in the C-terminal domain can interact with SH3 domain-containing proteins,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> while the FAT domain, as its name indicated, can interact with focal adhesion complex proteins, such as Paxillin,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Talin,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and Vinculin<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). In addition, the FAT domain can bind to the F2 lobe in the FERM domain, which leads to the dimerization of FAK and is significant in FAK activation and nuclear localization.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The C-terminal domain contains two critical tyrosine residues Y861 and Y925, which, upon phosphorylation, can provide binding sites for SH2 domain-containing proteins.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Therefore, the C-terminal domain is also involved in various proteinâprotein interactions.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">2.  FAK Activation</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58240" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58240" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">FAK typically exists in its dormant form in the cytosol with the FERM domain directly binding to the kinase domain to inhibit its catalytic activity. Activation of FAK is required for many cellular processes involved in cell survival, proliferation, and migration.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> Integrin is the primary and the most studied activator of FAK.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The integrin family of transmembrane receptors are heterodimers containing an Î± subunit and a Î² subunit and are responsible for mediating bidirectional signals between the extracellular matrix (ECM) and cell interior. Binding of integrin to FAK can induce the dimerization of FAK and the subsequent autophosphorylation of Y397 on the FERM domain. Phosphorylated Y397 then binds to and recruits Src-family PTKs and triggers the phosphorylation of Y576 and Y577 on the activation loop of the kinase domain, resulting in complete FAK activation.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Besides integrin, FAK can also be activated by various specific growth factors and G-proteins, such as epidermal growth factor (EGF), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), etc.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> For example, the FERM domain of FAK can interact with c-Met after the irritation of HGF, which causes the phosphorylation of Y197 and Y397 and induces the subsequent phosphorylation of Y576 and Y577 to fully activated FAK.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Lifting the autoinhibited state of FAK through conformation change is another procedure for FAK activation.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> FAK activation is also influenced by alterations of cellular physiochemical characteristics.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> It has been demonstrated that, while a decreased intracellular pH value can stabilize the interaction between the FERM domain and the kinase domain and reduce the phosphorylation of Y397, an increased cellular pH can promote the phosphorylation of Y397 and the activation of FAK.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">3.  FAK Functions in Cancer Development</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46276" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46276" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Biological studies indicated that overexpression of FAK and elevated FAK activity play important roles in the development and progression of human cancers. FAK promotes tumor progression in many aspects, including cancer cell survival and proliferation, cell migration and invasion, angiogenesis, and cancer stem cell formation.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">3.1.  Cell Survival</h3><div class="NLM_p last">As a scaffolding protein, FAK can bind to and modulate the functions of many proteins, which are critical to apoptosis to promote the survival of cancer cells. For example, tumor suppressor p53 is essential in preventing tumorigenesis, and receptor-interacting protein (RIP), a death domain protein, has also been found to exert its pro-apoptotic effects in a variety of cancer cells. FAK can promote cancer cell survival by binding to these pro-apoptotic proteins and blocking their functions.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a> Moreover, FAK can increase apoptosis resistance and promote cell survival by activating the PI3K/AKT pathway.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> It has been reported that VEGF-promoted cell survival is related to the FAK-associated PI3K activation.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">3.2.  Cell Proliferation</h3><div class="NLM_p last">FAK has been shown to promote cell proliferation through multiple mechanisms. It can upregulate the expression of cyclin D1, a key promoter in cell cycle progression, which accelerates the transition from the G1 to S phase.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Overexpression of FAK can facilitate the G1/S phase transition, and one study indicated that the injection of the FAK-related nonkinase (FRNK) mutant in cells suppressed cell proliferation and caused the G1/S phase cell cycle arrest.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Moreover, FAK can promote cell cycle progression by activating the Ras-ERK signaling pathway<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> and enhance cell proliferation by disturbing the p53-mediated cell cycle arrest.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">3.3.  Cell Migration and Invasion</h3><div class="NLM_p last">Migration and invasion are important processes for tumor progression and metastasis. FAK can enhance migration and invasion of cancer cells by promoting membrane protrusion and focal adhesion turnover; both of these two processes cause cytoskeletal rearrangements.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Tumor migration and invasion rely on the degradation of ECM that can be achieved by matrix metalloproteinases (MMPs).<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> FAK has been found to regulate the expression and activity of MMPs through multiple signaling pathways. For example, MMP-2 and MMP-9 can be activated through FAK/AKT signaling, which enhanced the migration and invasion in HCC.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Moreover, by inhibiting endophilin A2-dependent endocytosis, FAK promoted the surface expression of MT1-MMP and increased degradation of ECM, which strengthened the invasion in cancers.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Additionally, epithelial-to-mesenchymal transition (EMT) endows high motility and invasiveness of cells during cancer progression. Knockdown of FAK in breast cancer cells by microRNA-7 suppressed EMT and invasive capacity,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> while transfection of FAK in FAK-deficient cells waked the snail 1-dependent EMT, suggesting that FAK is a key regulator in the EMT process.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">3.4.  Angiogenesis</h3><div class="NLM_p last">Angiogenesis, the outgrowth of new capillaries derived from pre-existing blood vessels, is a hallmark of malignant tumors that facilitates swift tumor progression and metastasis.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Although multiple factors can promote angiogenesis, the most intensively studied one is VEGF. VEGF plays an important role in promoting endothelial cells (ECs) proliferation and increasing microvascular permeability.<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(51,52)</a> It has been found that FAK can promote angiogenesis in adult mice via increasing VEGFR2 transcription in ECs in both kinase-dependent and -independent manners.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Bernardo et al. found that endothelial-specific FAK deletion suppressed VEGF-induced angiogenesis in adult mice <i>in vivo</i>. The deletion of endothelial FAK can decrease the angiogenesis stimulated by bFGF (base fibroblast growth factor), indicating that FAK exerts significant functions in both VEGF-induced and bFGF-stimulated angiogenesis.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Guanâs group demonstrated that, compared with wild-type control mice, in transgenic mice with overexpressed FAK, the number of vessels in the skin wound healing model and the density of capillaries in the ischemia skeleton muscle model are both increased, suggesting that FAK can promote angiogenesis <i>in vivo</i>.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> In addition, FAK overexpression induced many large vascular tufts and preretinal neovascularization in a mouse model of retinopathy <i>in vivo</i>, whereas injection of FRNK achieved the opposite result.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">3.5.  Cancer Stem Cells</h3><div class="NLM_p last">FAK has been found to play an important role in embryonic development. It can support human embryonic stem cell (hESCs) survival and keep the balance between cell division and cell differentiation via an integrin-engaged signaling pathway.<a onclick="showRef(event, 'ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref57 ref58">(57,58)</a> Inhibition of FAK can cause a great loss of renewal ability and pluripotency in hESCs. FAK has also been shown to play a significant role in the regulation of cancer stem cells. Cancer stem cells (CSCs) are a specialized population of cells with similarities to normal stem cells in their capacities of self-renewal, differentiation, and formation of heterogeneous tumor cells.<a onclick="showRef(event, 'ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref59 ref60">(59,60)</a> In mouse models of breast cancers, FAK inhibition reduced the number of mammary CSCs, resulting in the decrease of self-renewal capacity <i>in vitro</i> and the reduction of tumorigenicity as well as the disruption of mammary CSCs maintenance <i>in vivo</i>.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a></div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">4.  The Development of FAK Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55571" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55571" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Because of the critical functions of FAK in human cancers, it has been considered as a promising target for the development of anticancer drugs. Many small molecular FAK inhibitors have been reported; in this section, we summarized the progress for the development of FAK inhibitors.</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">4.1.  Kinase Domain Inhibitors</h3><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16">4.1.1.  ATP-Competitive FAK Inhibitors</h4><div class="NLM_p">ATP-competitive inhibitors of FAK are the most studied FAK inhibitors. All of the FAK inhibitors that have entered clinical trials belong to this class. Six of the FAK inhibitors that have been evaluated in clinical trials are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. All Reported FAK Inhibitors in Clinical Trials</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">inhibitor</th><th class="colsep0 rowsep0" align="center">company</th><th class="colsep0 rowsep0" align="center">target</th><th class="colsep0 rowsep0" align="center">clinical trial</th><th class="colsep0 rowsep0" align="center">status</th><th class="colsep0 rowsep0" align="center">identifier</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GSK-2256098</td><td class="colsep0 rowsep0" align="left">GlaxoSmith</td><td class="colsep0 rowsep0" align="left">FAK</td><td class="colsep0 rowsep0" align="left">phase I</td><td class="colsep0 rowsep0" align="left">completed</td><td class="colsep0 rowsep0" align="left">NCT01138033</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Kline</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">completed</td><td class="colsep0 rowsep0" align="left">NCT00996671</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">completed</td><td class="colsep0 rowsep0" align="left">NCT02551653</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left">VS-6063 (PF-04554878) (Defactinib)</td><td class="colsep0 rowsep0" rowspan="3" align="left">Verastem</td><td class="colsep0 rowsep0" rowspan="3" align="left">FAK/Pyk2</td><td class="colsep0 rowsep0" rowspan="3" align="left">phase II</td><td class="colsep0 rowsep0" align="left">completed</td><td class="colsep0 rowsep0" align="left">NCT01943292</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">completed</td><td class="colsep0 rowsep0" align="left">NCT00787033</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">completed</td><td class="colsep0 rowsep0" align="left">NCT01951690</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">VS-6062 (PF-00562271)</td><td class="colsep0 rowsep0" align="left">Verastem</td><td class="colsep0 rowsep0" align="left">FAK/Pyk2</td><td class="colsep0 rowsep0" align="left">phase I</td><td class="colsep0 rowsep0" align="left">completed</td><td class="colsep0 rowsep0" align="left">NCT00666926</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">VS-4718 (PND-1186)</td><td class="colsep0 rowsep0" rowspan="2" align="left">Verastem</td><td class="colsep0 rowsep0" rowspan="2" align="left">FAK</td><td class="colsep0 rowsep0" rowspan="2" align="left">phase I</td><td class="colsep0 rowsep0" align="left">terminated</td><td class="colsep0 rowsep0" align="left">NCT01849744</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">withdrawn</td><td class="colsep0 rowsep0" align="left">NCT02215629</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CEP-37440</td><td class="colsep0 rowsep0" align="left">Teva Branded</td><td class="colsep0 rowsep0" align="left">FAK/ALK</td><td class="colsep0 rowsep0" align="left">phase I</td><td class="colsep0 rowsep0" align="left">completed</td><td class="colsep0 rowsep0" align="left">NCT01922752</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">BI-853520 (IN-10018)</td><td class="colsep0 rowsep0" align="left">Boehringer</td><td class="colsep0 rowsep0" rowspan="2" align="left">FAK</td><td class="colsep0 rowsep0" rowspan="2" align="left">phase I</td><td class="colsep0 rowsep0" align="left">completed</td><td class="colsep0 rowsep0" align="left">NCT01335269</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ingelheim</td><td class="colsep0 rowsep0" align="left">completed</td><td class="colsep0 rowsep0" align="left">NCT01905111</td></tr></tbody></table></div></div><div class="NLM_p">GSK2256098 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, compound <b>1</b>) is a highly selective inhibitor of FAK; it is a thousand fold more selective for FAK compared to the nearest FAK family member, Pyk2. GSK2256098 has been shown to efficiently inhibit the phosphorylation of Y397 in a series of cancer cells. For example, in OVCAR8, A549, and U87MG cells, GSK2256098 potently inhibits Y397 phosphorylation with IC<sub>50</sub> values of 15, 12, and 8.5 nM, respectively. GSK2256098 can suppress FAK-mediated downstream signaling pathways, such as AKT and ERK pathways, induce apoptosis in L3.6P1 cells via caspase-9/PARP-related pathways, and inhibit anchorage-independent cell growth in pancreatic ductal adenocarcinoma (PDAC).<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> GSK2256098 has been evaluated in several phase I clinical trials both as a single agent and in combination with other anticancer agents, such as trametinib.<a onclick="showRef(event, 'ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref63 ref64">(63,64)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of FAK inhibitors in clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">BI-853520 is a potent FAK inhibitor that inhibits the catalytic activity of FAK with an IC<sub>50</sub> value of 1 nM. The structure of BI-853520 has not yet been disclosed. It is highly selective to FAK, and the IC<sub>50</sub> value of BI-853520 to its subfamily close member Pyk2 is over 50,000 nM. BI-853520 has been found to inhibit Y397 phosphorylation in a series of human breast cancer cell lines and suppress tumor growth and progression in multiple mouse models of breast cancer.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> In addition, BI-853520 represses the growth, proliferation, and microvessel density of orthotopically growing human pleural mesothelioma xenografts in mice.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> BI-853520 showed modest antitumor activities in a first-in-human clinical trial for patients with nonhematologic malignancies.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> For some patients, the stable disease (SD) can last over 150 days. BI-853520 showed a manageable safety profile in another phase I study in Japanese and Taiwanese patients with solid tumors.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Six patients (29%) reached disease control, demonstrating the potential antitumor activity of BI-853520.</div><div class="NLM_p">CEP-37440 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, compound <b>2</b>) is a dual inhibitor of ALK (anaplastic lymphoma kinase). It shows strong and selective inhibition against FAK (IC<sub>50</sub> = 2 nM) and ALK (IC<sub>50</sub> = 3.1 nM). It effectively decreased the proliferation of a triple-negative FC-IBC02 cell line at 300 nM, and at 1000 nM, it completely suppressed the proliferation of these cells. CEP-37440 was efficacious in preclinical models of inflammatory breast cancer (IBC) both <i>in vitro</i> and <i>in vivo</i>. It displayed good oral ADME properties and bioavailability in several species, including CD-1 mice, SpragueâDawley rats, and cynomolgus monkeys, and exhibited excellent antitumor activities in various animal models of ALK-positive and FAK-positive cancers in a dose-dependent manner.<a onclick="showRef(event, 'ref69 ref70'); return false;" href="javascript:void(0);" class="ref ref69 ref70">(69,70)</a></div><div class="NLM_p">VS-4718 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, compound <b>3</b>) is a potent and selective FAK inhibitor that can inhibit FAK with an IC<sub>50</sub> value of 1.5 nM.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> VS-4718 showed a median relative IC<sub>50</sub> value (rIC<sub>50</sub>) of 1.22 Î¼M <i>in vitro</i> in a pediatric preclinical testing program (PPTP)<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> and displayed excellent tolerance at the dose of 50 mg/kg BID with only 1.2% mortality rate in PPTP preclinical xenografts <i>in vivo</i>. However, VS-4718 had a low <i>in vivo</i> activity as a single agent in PPTP therapy. VS-4718 decreased fibrosis of PDAC and lessened immunosuppressive cell populations in tumors, which lead to a promotion of sensitivity to chemotherapy and immunotherapy in previously unresponsive PDACs.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> It has been reported that elevated expression of ATP-binding cassette (ABC) transporters, including ABCB1, ABCG2, ABCC1, and other ABC transporters, plays an important role in multidrug resistance (MDR).<a onclick="showRef(event, 'ref74 ref75 ref76'); return false;" href="javascript:void(0);" class="ref ref74 ref75 ref76">(74â76)</a> VS-4718 has been shown to interact with ABCB1 and ABCG2 competitively and affect the activity of ABCB1 and ABCG2, demonstrating that the combination of VS-4718 with other antitumor drugs may inhibit the MDR mediated by ABCB1 or ABCG2.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></div><div class="NLM_p">VS-6062 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, compound <b>4</b>) is a dual ATP-competitive inhibitor of FAK and Pyk2 developed by Pfizer. VS-6062 inhibited FAK and PyK2 with IC<sub>50</sub> values of 1.5 nM and 14 nM, respectively. It can curb the growth and colony formation in Ewing sarcoma cell lines <i>in vitro</i> and suppress Ewing sarcoma tumor growth <i>in vivo</i>.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Moreover, VS-6062 significantly suppressed EOC and endothelial cell migration as well as endothelial cell tube formation <i>in vitro</i>, suggesting that VS-6062 is an efficacious antimetastatic and antiangiogenic agent.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> VS-6062 displayed nonlinear PK in a dose- and time-dependent manner, which was speculated to be caused by autoinhibition of CYP3A, since VS-6062 can inhibit its own pivotal metabolic enzyme CYP3A <i>in vitro</i> and <i>in vivo</i>. A phase I study in ninety-nine patients with advanced solid tumors<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> demonstrated that VS-6062 has a manageable safety profile.</div><div class="NLM_p">VS-6063 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, compound <b>5</b>) is another FAK inhibitor developed by Pfizer. It is a more potent FAK and Pyk2 dual inhibitor than VS-6062 with IC<sub>50</sub> values of both 0.6 nM to these two kinases.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> Preclinical studies indicated that VS-6063 potently inhibited the phosphorylation of Y397 in a time- and dose-dependent manner. Importantly, VS-6063 can overcome the YB-1-mediated paclitaxel resistance <i>in vitro</i>.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> The combination of VS-6063 with docetaxel significantly suppressed cell growth of castration-resistant prostate cancer (CRPC) cell lines and repressed tumor growth in the PC3 xenograft model, being more potent than either monotherapy.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a></div><div class="NLM_p">A phase I trial of VS-6063 in forty-six patients with advanced solid tumors<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> has been performed to evaluate the safety, toxicity, pharmacodynamics, and pharmacokinetics of VS-6063 using traditional 3 + 3 design. In this study, VS-6063 was orally administered BID for 21 days. The MTD was not found as the dose escalation test was terminated at the 750 mg BID, and the RP2D was 425 mg BID. Dose-limiting toxicities were tolerable and reversible, including headache, fatigue, and unconjugated hyperbilirubinemia. The most frequent adverse event was nausea (37%), suggesting that VS-6063 had an acceptable safety profile. PK data exhibited that doses above 425 mg caused a plateau of serum exposure. Food delayed the absorption of VS-6063 but has no effect in serum drug exposure. Another phase I study of VS-6063 conducted in Japanese patients with advanced solid tumors was the first trial in Asian patients. In this study, the same experimental approach as the former trial was used. Nine patients received treatment at three dose levels of 200, 400, and 600 mg BID, and no dose-limiting toxicity was observed, suggesting that VS-6063 was tolerable in these three doses. The most frequent adverse event was unconjugated hyperbilirubinemia with a grade in 1/2 (78%), showing that VS6003 has a manageable safety profile. VS-6063 showed a rapid absorption, and the median <i>T</i><sub>max</sub> was detected at 2 h after treatment in all doses. The RP2D in this study was 400 mg BID and was different from the former study in non-Japanese patients.</div><div class="NLM_p">Recently, a phase II, multicenter cohorts, open-label, single-arm study of VS-6063 treatment in patients with KRAS mutant nonsmall cell lung cancer (NSCLC) was reported.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> In this trial, fifty-five patients were divided into four cohorts based on the status of <i>TP53</i> and <i>CDKN2A</i>. The results indicated that VS-6063 had a tolerable safety profile and modest efficacy that was not associated with TP53 and CDKN2A.</div><div class="NLM_p">Besides the compounds in clinical trials, much more ATP-competitive FAK inhibitors have been explored in preclinical studies.</div><div class="NLM_p">PF-573228 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, compound <b>6</b>) is the first selective ATP-competitive FAK inhibitor reported by Pfizer.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> PF-573228 can potently inhibit FAK with an IC<sub>50</sub> value of 4 nM, effectively decrease Y397 phosphorylation in REF52 and PC3 cells, and suppress cell migration. It also inhibited the phosphorylation of Tyr31 in its downstream substrate paxillin in a dose-dependent manner.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> PF-573228 can influence cell viability in OVCAR-3 cells, and the cytotoxicity of PF-573228 in OVCAR-3 cells can be improved by metformin. Moreover, the overall cell mortality of the triple combination of PF-573228, metformin, and carboplatin was 94%, suggesting that combination therapy strengthened the efficacy in platinum-resistant ovarian cancer. In addition, PF-573228 suppressed cell growth and inhibited the formation of an anchorage-independent colony in MPM and PDAC cell lines. The numbers of dead organoids in autochthonous KC mice models also increased via PF-573228 treatment.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Through structural modifications of PF-573228, a large number of FAK inhibitors have been developed by Pfizer, including the two clinical leads VS-6062 and VS-6063.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structures of ATP-competitive FAK inhibitors <b>6</b>â<b>14</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2006, researchers at Novartis reported their ATP-competitive FAK inhibitors represented by TAE226 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, compound <b>7</b>). TAE226 also potently inhibits Pyk2, insulin receptor (InsR), and insulin-like growth factor-I receptor (IGF-IR).<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> TAE226 significantly inhibited autophosphorylation of Y397 in FAK and effectively blocked FAK-mediated signaling pathways, such as S6 ribosomal protein phosphorylation, ERK, and AKT.<a onclick="showRef(event, 'ref6 ref90'); return false;" href="javascript:void(0);" class="ref ref6 ref90">(6,90)</a> TAE226 has been evaluated in various cancer cell lines for its ability in inhibiting cell growth and was found to have a wide spectrum of antiproliferative activities with a mean GI<sub>50</sub> value of 0.76 Î¼M.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> In addition, TAE226 can suppress the migration and metastasis and increase apoptosis in ovarian and glioma tumor models.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> In <i>in vivo</i> studies, TAE226 can effectively inhibit tumor growth in esophageal and glioma models.<a onclick="showRef(event, 'ref93 ref94'); return false;" href="javascript:void(0);" class="ref ref93 ref94">(93,94)</a> Nevertheless, TAE226 has never entered into clinical trials due to its serious side effect on glucose metabolism<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> but has been extensively used as a positive control for comparison with other newly developed FAK inhibitors. The crystal structure of TAE226 complexed with the kinase domain of FAK has been determined, which clearly demonstrates the interaction of TAE226 with FAK.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> In the crystal structure, TAE226 adopts a U-shape conformation. The amino and carbonyl group of Cys502 on the hinge region of the kinase domain of FAK form two hydrogen bonds with the nitrogen atom in the central pyrimidine ring and the amino group in the 2-methoxyaniline moiety in TAE226 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). These hydrogen bonds anchor TAE226 to the ATP-binding site of FAK and determine the arrangements of the other substituted groups in TAE226. The carbon atoms in the central pyrimidine ring have hydrophobic interactions with Ala452 and Leu553, while the hydrophobic portion of the 2-methoxyaniline ring interacts with Ile428 and Gly505. The chlorine atom at the C5 position of the pyrimidine ring gets deepest into the ATP-binding pocket and is located near the gatekeeper residue Met499. The morpholine group in TAE226 has almost no interaction with FAK; its major function is to improve the pharmacokinetic properties of the molecule. The carbonyl group of the methyl carbamoyl moiety in TAE226 forms a hydrogen bond with the backbone nitrogen of Asp564 of the DFG motif on the activation loop of FAK. The 4-aniline ring, where the methyl carbamoyl moiety is linked to, makes hydrophobic contacts with the side chain of Leu567, the residue immediately following the DFG sequence. The interactions involving Asp564 and Leu567 stabilize a short helix that includes the DFG motif and are unique for FAK, which may account for the selectivity of TAE226 to FAK. In order to adopt this helical turn, the phi torsion angle of Asp564 is rotated by 113Â° compared to the active kinase domain. Most of the ATP-competitive FAK inhibitors contain a diaminopyridine, diamionpyrimidine, or similar aromatic ring core structure and have high structural similarity to TAE226; therefore, they should bind to FAK in similar modes as TAE226, and the binding modes of several ATP-competitive FAK inhibitors have been confirmed by several crystal structures.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Crystal structure of TAE226 complexed with the kinase domain of FAK (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JKK">2JKK</a>). Hydrogen bonds are shown in yellow dash lines. The residues that can form hydrogen bonds with TAE226 were shown in yellow.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>8</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) is an analogue of TAE226, which differs from TAE226 only in that a carbonyl group is inserted between the morpholine ring and the phenyl ring in TAE226. Compared with TAE226, <b>8</b> can more potently inhibit the activity of FAK with an IC<sub>50</sub> value of 5.17 nM. Compound <b>8</b> demonstrates excellent antiproliferative activity in AsPC-1, BxPC-3, and MCF-7/ADR cells with IC<sub>50</sub> values of 0.105, 0.09, and 0.59 Î¼M, respectively, to these three cells, and showed very low cytotoxicity toward normal human cells. Additionally, expressions of MEK and ERK proteins were rarely affected by <b>8</b>. In the xenograft model of AsPC-1 cancer in a mouse, oral administration of <b>8</b> with a dose of 60 mg/kg/day for 7 days can cause tumor regression, indicating that <b>8</b> has potent <i>in vivo</i> antitumor activity. The docking study exhibited that the introduced carbonyl group in <b>8</b> forms a new hydrogen bond with the amino group of Gln438, explaining why <b>8</b> has a stronger interaction with FAK than TAE226.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a></div><div class="NLM_p">Molecular hybridization is a frequently used method in drug design.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Dithiocarbamate has been widely used in the design of novel anticancer drugs;<a onclick="showRef(event, 'ref99 ref100 ref101 ref102 ref103'); return false;" href="javascript:void(0);" class="ref ref99 ref100 ref101 ref102 ref103">(99â103)</a> therefore, Yinâs group<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> incorporated the dithiocarbamate moiety with the classic 2,4-diarylaminopyrimidine scaffold for the design of novel FAK inhibitors. The most potent compound <b>9</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) inhibits the enzymatic activity of FAK with an IC<sub>50</sub> value of 0.07 nM and shows promising anticancer cellular activity in several cancer cell lines. Further investigation revealed that <b>9</b> induces apoptosis and causes cell cycle arrest at the G2/M phase in both MCF-7 and HCT116 cells in a dose-dependent manner. In addition, <b>9</b> effectively suppresses the migration of MCF-7 cells at low concentrations and potently inhibits tube formation in HUVEC cells, demonstrating its antiangiogenesis effect.</div><div class="NLM_p">The phosphoryl group has been widely applied in drug design because of its beneficial properties, such as enhancing water solubility and improving certain aspects of biological activities.<a onclick="showRef(event, 'ref105 ref106'); return false;" href="javascript:void(0);" class="ref ref105 ref106">(105,106)</a> Maâs group using a fragment-based drug design strategy designed a series of phosphamide-containing diphenylpyrimidine derivatives as ATP-competitive FAK inhibitors, represented by <b>10</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> Compound <b>10</b> shows more potent inhibition to the enzymatic activity of FAK than TAE226 and effectively inhibits proliferation of AsPC cells, while having a low cell cytotoxicity in HPDE6-C7 cells. Moreover, <b>10</b> can induce apoptosis in AsPC cells in a dose- and time-dependent manner.</div><div class="NLM_p">Compound <b>11</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) and its analogues are a class of sulfonamide-substituted pyrimidine derivatives designed and synthesized by Maâs group using a structure-based drug design strategy.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> Compound <b>11</b> potently antagonizes FAK with an IC<sub>50</sub> value of 86.7 nM and inhibits cell growth of AsPC-1 and Panc-1 cell lines with IC<sub>50</sub>s of 3.92 Î¼M and 0.53 Î¼M, respectively. Compound <b>11</b> also induces apoptosis in AsPC cells in a dose-dependent manner.</div><div class="NLM_p">Clinical lead VS-6062 is a dual inhibitor of FAK and Pyk2, but it has a 9-fold selectivity for FAK over Pyk2. Based on the docking studies of VS-6062 in binding to Pyk2 and FAK, Gilead Sciences, Inc. designed a series of macrocyclizated analogues of VS-6062 with the purpose to improve the selectivity to Pyk2.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> The representative compound <b>12</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) shows improved selectivity to PYK2 and can potently antagonize both FAK and Pyk2 with IC<sub>50</sub> values of 4.34 nM and 0.84 nM, respectively. Moreover, among all of the compounds they synthesized, <b>12</b> had the best metabolic stability in human microsomal stability assay.</div><div class="NLM_p">Compound <b>13</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) is a multikinase inhibitor developed by Kunickâs group. It has a unique 2-anilino-4-(benzimidazol-2-yl)-pyrimidine scaffold and can inhibit FAK, Aurora B, PLK1, and VEGF-R2, with IC<sub>50</sub> values of 3.4, 6, 1.2, and 7.2 Î¼M, respectively. Compound <b>13</b> displayed antiproliferative activity in many cancer cell lines from different origins, such as colon cancer, CNS cancer, renal cancer, and so on with submicromolar IC<sub>50</sub> values.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a></div><div class="NLM_p">The development of irreversible kinase inhibitors, which can covalently bind to and antagonize the target proteins, has always been attractive to medicinal chemists. Comparing with reversible kinase inhibitors, irreversible inhibitors have unique advantages, such as long drug residence time, potent biological activities, as well as the potential to overcome drug resistance.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> The crystal structure of FAK complexed with TAE226 clearly indicates that Cys427 on the glycine-rich loop of FAK locates close to the ATP-binding site; therefore, this cysteine residue can be used as the nucleophilic group for the design of covalent FAK inhibitors. Based on the structural information, Chenâs group designed a class of FAK inhibitors by introducing an acrylamide moiety to the core scaffold of TAE226 through a well-designed linker to ensure the acrylamide can be in proximity to Cys427. From these compounds, they identified <b>14</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) as the first irreversible FAK inhibitor. Compound <b>14</b> shows a more potent inhibiting activity to FAK than TAE226 with an IC<sub>50</sub> value of 0.6 nM and is highly selective to FAK. Moreover, <b>14</b> can potently suppress the autophosphorylation of FAK in SCC cells. The covalent binding of <b>14</b> to the kinase domain of FAK was confirmed by a series of biochemical and biological experiments as well as the crystal structure of the complex of <b>14</b> with the kinase domain of FAK.</div><div class="NLM_p">1,3,5-Triazine can be used as a bioisostere of 1,3-pyrimidine in drug design; therefore, Chenâs group<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> designed and synthesized a class of diarylamino-1,3,5-triazine derivatives as novel FAK inhibitors. The most efficacious compound <b>15</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) shows moderate kinase inhibitory activity with an IC<sub>50</sub> value of 0.4 Î¼M and can restrain autophosphorylation of Y397 in HUVEC cells at a low concentration. In addition, compound <b>15</b> potently inhibits fibroblast growth factor receptor 2 (FGFR2), a factor that plays a crucial role in angiogenesis. Comparing with TAE226, compound <b>15</b> does not have the 5-Cl atom on the pyrimidine ring in TAE226 and, thus, has decreased van der Waals interactions with Met499 in FAK; moreover, the 1,3,5-triazine ring in <b>15</b> has a lower electron density than the 1,3-pyrimidine ring in TAE226 and, thus, has the weaker ability in forming a hydrogen bond, which may account for the weaker FAK inhibitory activity of <b>15</b>.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Chemical structures of ATP-competitive FAK inhibitors <b>15</b>â<b>20</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Considering the importance of the chloro atom on the 1,3-pyrimidine ring in TAE226 to the kinase inhibitory activity, Chenâs group designed and synthesized a series of new compounds with a 1,2,4-triazine scaffold.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> In these compounds, the chloro atom at position 6 was maintained; however, the most potent compound <b>16</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, IC<sub>50</sub> = 0.23 Î¼M) in this series still shows lower inhibitory activity to FAK than TAE226 <i>in vitro</i>. A docking study indicated that the van der Waals interactions between the chloro atom and Met499 may not have much contribution to the binding of <b>16</b> to FAK, suggesting that the weaker hydrogen bonds between the amino triazine and the hinge region of FAK may have more influence on the inhibitory activity of <b>16</b> to FAK.</div><div class="NLM_p">Also, for improving the activity of <b>15</b>, Chenâs group designed a series of imidazo[1,2-<i>a</i>][1,3,5]triazines derivatives by fusing an imidazole ring with the triazine ring in <b>15</b>.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> The most potent compound in this series is <b>17</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), which shows potent inhibition to the enzymatic activity of FAK with an IC<sub>50</sub> value of 50 nM. Compound <b>17</b> is a more selective inhibitor of FAK than TAE226; it did not suppress IGF-IR and Pyk2 at 1 Î¼M and displayed excellent selectivity to FAK in a panel of more than 30 kinases. Compound <b>17</b> strongly inhibited FAK autophosphorylation and cell proliferation in a number of cancer cell lines expressing high levels of FAK, such as U-87MG, HCT-116, MDA-MB-231, and PC-3 cell lines. It also significantly induced apoptosis and inhibited cell progression by arrested cell cycle in the G2/M phase in th HCT-116 cell line at a low concentration. Further studies indicated that <b>17</b> can inhibit cell-matrix adhesion, migration, and invasion in U87-MG cells in a dose-dependent manner.</div><div class="NLM_p">4-Diaminopyridine and 2,4-diaminopyrimidine are the most frequently used scaffolds in the design of ATP-competitive FAK inhibitors; by replacing the 2,4-diaminopyrimidine scaffold with a 7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine-2,4-diamine scaffold, Chengâs group<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> designed a novel class of FAK inhibitors represented by <b>18</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). They proposed that the nitrogen atom in the newly introduced pyrrole ring could have an extra hydrogen bond interaction with Glu500 in the hinge region of FAK and thus enhance the interaction of <b>18</b> and its analogues with FAK and proved the binding mode of <b>18</b> with FAK by docking study. Compound <b>18</b> exhibited potent enzymatic inhibition to FAK with an IC<sub>50</sub> value of 5.4 nM and good kinase selectivity in a panel of 26 kinases. Moreover, <b>18</b> suppressed the migration and induced apoptosis of A549 cells in a concentration-dependent manner, showing low cytotoxicy to normal human cell line HK2 cells. In addition, <b>18</b> has good metabolic stability in mouse, rat, and human liver microsomes <i>in vitro</i> and only very weak inhibition against human cytochrome P450. These results indicated that the 7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine scaffold is a potential scaffold for the design of novel FAK inhibitors.</div><div class="NLM_p">By analyzing the binding mode of the FAK inhibitors with a classic diaminopyrimidine scaffold, Chengâs group has also designed a class of 2,7-disubstituted-thieno[3,2-<i>d</i>]pyrimidine derivatives to mimic the active conformation of the diaminopyrimidine derivatives.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> The most potent compound <b>19</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) in this series strongly inhibited the enzymatic activity of FAK with an IC<sub>50</sub> value of 28.2 nM. Compound <b>19</b> showed a more potent ability in inhibiting cell growth than TAE226 in U-87MG, A-549, and MDA-MB-231 cells. In MDA-MB-231 cells, <b>19</b> can induce apoptosis and cause cell cycle arrest at the G0/G1 phase and inhibit cell migration. Compound <b>19</b> also showed good <i>in vitro</i> metabolic stability in rat liver microsomes with a half-life of 133.8 min.</div><div class="NLM_p last">Based on a previously identified ALK inhibitor and a JAK2 (janus kinase 2) inhibitor, scientists in Cephalon Inc. developed a class of JAK2/FAK dual inhibitors with a pyrrolo[2,1-<i>f</i>][1,2,4]triazine scaffold; the representative compound <b>20</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) can effectively inhibit the enzymatic activity of JAK2 (IC<sub>50</sub> = 2.5 nM) and FAK (IC<sub>50</sub> = 5 nM).<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> Compound <b>20</b> has a desirable pharmacokinetic profile and is orally bioavailable. It can strongly inhibit pStat3 and reduce the level of FAK phosphorylation <i>in vitro</i>. The kinase inhibition activity of <b>20</b> is not limited to JAK2 and FAK; it has been found that, when screened at 1 Î¼M, <b>20</b> displayed >90% inhibition against 19 of 53 oncology-related kinases.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18">4.1.2.  Miscellaneous Kinase Domain Inhibitors of FAK</h4><div class="NLM_p">Zhuâs group found that a class of 1,3,4-thiadiazole ring containing compounds represented by <b>21</b><a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> and <b>22</b><a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> can function as FAK inhibitors (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). Docking studies demonstrated that these two compounds are well embedded in the ATP-binding pocket through a hydrogen bond, ÏâÏ interaction, and Ïâcation interaction. Compound <b>21</b> inhibits the activity of FAK with an EC<sub>50</sub> value of 10.79 Î¼M and induces apoptosis of HEPG2 cells in a dose-dependent manner, while <b>22</b> showed an IC<sub>50</sub> value of 5.32 Î¼M in inhibition of the activity of FAK and potently suppressed the cell growth of MCF-7 and B16âF10 cell lines with IC<sub>50</sub> values of 0.45 and 0.31 Î¼M, respectively.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Chemical structures of compounds <b>21</b>â<b>25</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">By replacing the 1,3,4-thiadiazole ring in <b>21</b> and <b>22</b> with a 1,3,4-oxadiazole-2(3<i>H</i>)-thione structure and the subsequent modifications of the substituted groups, Zhuâs group designed a class of FAK inhibitors represented by compound <b>23</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> Compound <b>23</b> can inhibit the activity of FAK with an IC<sub>50</sub> value of 0.78 Î¼M and suppress the proliferation of HepG2 and SM1116 cells with IC<sub>50</sub> values of 5.78 Î¼M and 47.15 Î¼M, respectively. A docking study suggested that <b>23</b> also binds to the ATP-binding site in FAK.</div><div class="NLM_p">Zhuâs group has also reported a class of 2-styryl-5-nitroimidazole derivatives as FAK inhibitors.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> The most potent compound in this series is <b>24</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>), which inhibits FAK with an IC<sub>50</sub> value of 0.45 Î¼M and induces apoptosis in HeLa cell in a dose-dependent manner. A docking study suggests that this compound also binds to the ATP-binding region in FAK.</div><div class="NLM_p last">Similar to the work in Zhuâs group, Altintopâs group designed and synthesized panels of 1,3,4- oxadiazole derivatives and evaluated their anticancer cellular activity in A549 and C6 cell lines.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> The most potent compound <b>25</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) displayed potent anticancer cellular activity in these two cell lines with IC<sub>50</sub> values of 39.33 Î¼M and 4.63 Î¼M, respectively. Moreover, compound <b>25</b> caused significant morphological changes and inhibited the activation of caspase-3 in both of these two cell lines. Mechanism studies indicated that <b>25</b> can potently inhibit the activities of FAK and AKT with IC<sub>50</sub> values of 19.50 Î¼M and 2.60 Î¼M, respectively. Docking studies exhibit that <b>25</b> binds to the active sites of the kinase domains in AKT and FAK. When binding to FAK, it can have ÏâÏ stacking with the Phe568 residue, form a salt-bridge, and present a Ïâcation interaction with Lys457 residue. Notably, the 6-methoxybenzothiazole moiety of <b>25</b> has great contributions in affinity with FAK. These studies demonstrated that <b>25</b> represents a new class of ATP-competitive FAK inhibitors.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19">4.1.3.  Allosteric Kinase Domain Inhibitors</h4><div class="NLM_p">Besides ATP-competitive type I and type II kinase inhibitors, the development of allosteric kinase inhibitors has attracted more and more attention from medicinal chemists. Allosteric kinase inhibitors do not compete with ATP, are more selective to the targeted kinase, and, therefore, have the potential to overcome the side effects due to the poor selectivity of ATP-competitive inhibitors.<a onclick="showRef(event, 'ref123 ref124'); return false;" href="javascript:void(0);" class="ref ref123 ref124">(123,124)</a> Through the high-throughput screen, Mikiâs group found two novel FAK inhibitors (compounds <b>26</b> and <b>27</b>, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) with a 1,5-dihydropyrazolo[4,3-<i>c</i>][2,1]benzothiazine scaffold.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> These compounds show a unique function in inhibiting FAK. They inhibit the FAK kinase with IC<sub>50</sub> values in the low micromolar range (IC<sub>50</sub> 4.2 Î¼M for <b>26</b> and 8.7 Î¼M for <b>27</b>) and are noncompetitive with ATP after long preincubation. The crystal structure of compound <b>26</b> complexed with the kinase domain of FAK (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EBV">4EBV</a>) indicated that <b>26</b> binds to an induced allosteric site in the kinase domain and has several polar and hydrophobic interactions with the protein.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> The pyrazole ring in <b>26</b> has a Ïâcation interaction with the side chain of Arg550. One of the nitrogen atoms in the pyrazole ring has a hydrogen-bonding interaction with a water molecule, while the other one has weak hydrogen-bonding interactions with the carboxylic acid group in the side chain of Asp604. Compound <b>27</b>, in which an ethyl group is introduced to the N<sup>2</sup> nitrogen of the pyrazole ring, is only two times less potent than <b>26</b> in inhibiting FAK, indicating that the hydrogen-bonding with the water molecule is not critical. The <i>p</i>-ethylphenyl group in <b>26</b> has hydrophobic interactions with the hydrophobic side chains of several residues.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Chemical structures of allosteric kinase domain inhibitors <b>26</b>â<b>30</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Crystal structure of compound <b>26</b> complexed with the kinase domain of FAK (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EBV">4EBV</a>). Hydrogen bonds are shown in yellow dash lines. Compound <b>26</b> was shown in violet. Residues Arg550 and Asp604 in FAK were shown in yellow.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Biological studies indicated that <b>26</b> and <b>27</b> can both bind to the FAK allosteric site in the unphosphorylated FAK, but only <b>26</b> can target phosphorylated FAK. Docking studies indicated that, when binding to phosphorylated FAK, the N<sup>2</sup> nitrogen atom in the pyrazole ring of compound <b>26</b> has a hydrogen-bonding interaction with Glu500, in <b>27</b>, this nitrogen atom is substituted by an ethyl group and, therefore, cannot form a hydrogen bond with Glu500 of phosphorylated FAK.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> Interestingly, compound <b>27</b> shows higher kinase selectivity than compound <b>26</b>, suggesting that <i>N</i>-substitution of the pyrazole ring had a significant improvement in kinase selectivity.</div><div class="NLM_p">Based on <b>26</b> and <b>27</b>, a series of <i>N</i>-methylated pyrazolo[4,3-<i>c</i>][2,1]benzothiazine derivatives were designed and synthesized by inserting various linkers between the 1-methylpyrazolo[4,3-<i>c</i>][2,1]benzothiazine core and the phenyl group and introduction of different substituted groups to the phenyl ring with the purpose to improve the physicochemical properties. Among these compounds, <b>28</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) exhibits potent enzymatic inhibition activity (IC<sub>50</sub> = 0.64 Î¼M) and cellular activity. Crystal structure indicated that the tricyclic core structure of <b>28</b> binds to FAK in the same mode as that in compound <b>26</b>. The amino group between the core structure and the 4-<i>tert</i>-butylbenzyl group forms a hydrogen bond with the backbone carbonyl of Gly563, while the <i>tert</i>-butyl group occupies the hydrophobic cavity formed by Met475, Leu486, Met499, and Val484.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4I4F">4I4F</a>)</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Crystal structure of compound <b>28</b> complexed with the kinase domain of FAK (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4I4F">4I4F</a>). Hydrogen bonds are shown in yellow dash lines. Compound <b>28</b> was shown in pale blue. Residues Arg550 and Asp604 in FAK were shown in yellow. Residues Met475, Val484, Leu486, and Met499 in FAK were shown in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The K454 residue located at the catalytic domain of FAK is a critical binding site of ATP and is crucial for the regulation of FAK to the survival and growth of cancer cells. Golubovskaya and co-workers performed a molecular docking study for compounds in the NCI database with the purpose of identifying novel FAK inhibitors targeting the K454 in the ATP-binding site. The interaction of the selected compounds with the kinase domain of FAK was evaluated in the MTT assay. In their study, they found compound <b>29</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) can directly bind to the FAK-kinase domain, decrease autophosphorylation of FAK, and inhibit the viability of a number of cancer cells <i>in vitro</i>. Because <b>29</b> is a derivative of mitoxantrone (<b>30</b>, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>), they have also evaluated the activity of <b>30</b> in inhibition of FAK and found <b>30</b> also can bind to the kinase domain of FAK, decrease FAK enzymatic activities, and block cancer cell viability <i>in vitro</i>. Moreover, mitoxantrone can also inhibit Pyk-2, IGF-1R, and c-Src Kinase activities at 20 Î¼M but has no effect on EGFR-1.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a></div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">4.2.  FERM Domain Inhibitors</h3><div class="NLM_p">Most of the reported FAK inhibitors are kinase inhibitors, but the kinase inhibitors cannot effectively inhibit the nonkinase activities of FAK; therefore, the development of small molecular compounds targeting the FERM domain of FAK also attracted a lot of attention from medicinal chemists. Based on their functions, FERM domain inhibitors can be classified into two classes: one is Y397 antagonists, which target the key Y397 residue and inhibit its autophosphorylation, and the another one is PPI inhibitors, which can block the proteinâprotein interactions between the FERM domain of FAK and its associated proteins.</div><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21">4.2.1.  Y397 Antagonists</h4><div class="NLM_p">Autophosphorylation of Y397 is critical to the activation of FAK. Therefore, small molecular compounds directly targeting Y397 and inhibiting its phosphorylation have been explored by several research groups.</div><div class="NLM_p">In 2008, Canceâs group reported the identification of a small molecular FAK inhibitor Y15 (compound <b>31</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>) by a computer-aided docking study for more than 140â¯000 small molecule compounds in the NCI database based on the crystal structure of the FERM domain.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> It has been found that Y15 directly bound to the Y397 site in the FERM domain and suppressed Y397 phosphorylation in a dose- and time-dependent manner. In <i>in vitro</i> studies, Y15 significantly decreased cancer cell viability in six cancer cell lines, including human breast cancer BT474, MCF-7, and T47D cell lines, human colon cancer HT29 cell line, lung cancer A549 cell line, and melanoma C8161 cell line, to the levels equal to or higher than positive control TAE226. Y15 also inhibited total FAK phosphorylation, and the phosphorylation of Y118 in its downstream target paxillin. Y15 did not suppress FAK enzymatic activity without the FERM domain, suggesting that Y15 is a specific inhibitor targeting Y397. Because of the low sequence homology of the FERM domains in Pyk2 and FAK, Y15 did not effectively repress Pyk2 even at a 100 Î¼M concentration, further confirming its specificity to FAK. In addition, Y15 inhibited cell adhesion and increased cell detachment in a dose-dependent manner. In an <i>in vivo</i> study using the human breast cancer cell BT474 tumor model in nude mice, a subcutaneous injection of Y15 at a dose of 30 mg/kg effectively inhibited tumor growth.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Chemical structures of Y397 antagonists <b>31</b>â<b>34</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Y11 (Compound <b>32</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>) is another FAK inhibitor targeting the Y397 site of FAK identified by Canceâs group using an approach combined by computer modeling and a functional assay. Biochemical and biological studies indicated that Y11 significantly and specifically decreased FAK autophosphorylation, inhibited viability and clonogenicity of colon cancer SW620 cells and breast cancer BT474 cells, and increased cell detachment and apoptosis <i>in vitro</i>. Compound Y11 significantly decreased tumor growth in a colon cancer cell xenograft model in mice, and tumors from the treated mice showed decreased Y397 autophosphorylation and activation of poly(ADP ribose) polymerase and caspase-3.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a></div><div class="NLM_p">Sipholenol A-4-<i>O</i>-3â²,4â²-dichlorobenzoate (SPA, compound <b>33</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>) is a derivative from natural product Sipholenol A.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Sayedâs group found SPA can inhibit the growth of breast cancer BT-474, MDA-MB-231, T-47D, and MCF-7 cells with IC<sub>50</sub> values of 20.1, 7.5, 25.1, and 15.2 Î¼M, respectively, suppress breast cancer cell migration and invasion, and decreased Brk and FAK activation in a dose-dependent manner.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> A docking study suggested that SPA can fit perfectly at the FERM domain and inhibit autophosphorylation of Y397, and the inhibition of autophosphorylation of Y397 was confirmed by Western blot analysis. Moreover, an <i>in vivo</i> study indicated that SPA can suppress breast tumor growth and <i>K</i><sub>i</sub>-67, CD31, p-Brk, and p-FAK expression in the orthotopic breast cancer model in nude mice.</div><div class="NLM_p last">Through a computer docking study, Wengâs group found that a natural product HCD (compound <b>34</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>) can directly bind to the FERM domain of FAK and specifically suppressed the phosphorylation of Y397.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> Biological studies indicated that HCD can arrest the cell cycle at the G0/G1 phase and improve the expression of p53 in a dose-dependent manner in N18 and C6 cells. Moreover, HCD triggered the change of morphology, causing shrinkage, blebbing, and the formation of pores. Additionally, HCD potently inhibited the cell viability and proliferation in mouse neuroblastoma N18 and rat glioma C6 cell lines.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22">4.2.2.  PPI Inhibitors</h4><div class="NLM_p">MDM2 is an endogenous inhibitor of p53. Biological studies indicated that binding of FAK to MDM2 can lead to the ubiquitination and proteasomal degradation of p53; therefore, interrupting the interactions between FAK and MDM2 is a promising therapeutic approach for cancer treatment. Golubovskaya and co-workers docked more than 200â¯000 small molecules from the NCI database to the MDM2-binding pocket in FAK and found 5â²-<i>O</i>-Tritylthymidine (compound <b>35</b>, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>) can significantly decrease the viability in different cancer cells.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> Compound <b>35</b> was found to directly bind to the FAK N-terminal domain, decrease complex of FAK and MDM2 proteins in breast and colon cancer cells, and reactivate p53 activity. Moreover, <b>35</b> can increase detachment and apoptosis in a dose-dependent manner in breast cancer BT474 cells and in colon cancer HCT116 cells <i>in vitro</i> and decrease breast and colon tumor growth <i>in vivo</i>.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Chemical structures of proteinâprotein interaction inhibitors <b>35</b>â<b>37</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The aforementioned biological studies exhibit that the FERM domain of FAK can bind to p53 and block the pro-apoptotic function of p53; thus, disturbing the interaction between FAK and p53 is a promising method to restore the activity of p53. Canceâs group generated a model of the FAK and p53 interaction and performed virtual screening of >200â¯000 small molecule compounds from the NCI database and identified compound <b>36</b> (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>), which can bind to the FAK-N-terminal domain and disrupt the FAK and p53 interaction.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> Biological studies indicated that <b>36</b> decreases the viability and clonogenicity of HCT116 cells in a p53-dependent manner, and reactivate FAK-inhibited transcriptional activity of p53. Combination of <b>36</b> with chemo drugs, such as doxorubicin or 5-fluorouracil, more efficiently decreased cancer cell viability than each agent used alone in HCT116 cells in a p53-dependent manner, indicating that targeting the FAK and p53 interaction can be a novel therapeutic approach to reactivate p53 and decrease cancer cell viability, clonogenicity, and tumor growth.</div><div class="NLM_p last">As mentioned before, FAK is a significant convergence point for extracellular stimulations through multiple receptor tyrosine kinases; therefore, targeting the protein interaction of FAK with growth factor receptors, including cMET and insulin-like growth factor receptor-1 (IGF-1R), may be a novel therapeutic approach.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> Through virtual screening of the NCI database and the subsequent functional evaluations, Hachwaldâs group found a small molecule compound, INT2â31 (<b>37</b>, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>), that decreases phosphorylation of AKT via disrupting the interaction of FAK with cMET and IGF-1R.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> Compound <b>37</b> decreases phosphorylation of Y397 in Panc-1 cells and Miapaca-2 cells and increased phosphorylation of FAK Y407 in Miapaca-2 cells without inhibiting the kinase activity of FAK. In addition, <b>37</b> decreased the viability of several cancer cell lines but exhibited low effects on normal cells. Moreover, INT2â31 potently inhibited tumor growth in an orthotopic pancreatic cancer xenograft model of both Miapaca2 and Panc-1 tumors <i>in vivo</i>, and th combination of INT2â31 with Gemcitabine significantly induced apoptosis and promoted sensitivity of Panc-1 and Miapaca2 cells.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a></div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23">4.3.  FAT Domain Inhibitors</h3><div class="NLM_p">The FAT domain of FAK is also involved in a series of proteinâprotein interactions, and small molecules targeting the FAT domain of FAK have also been reported. VEGFR-3 is a receptor tyrosine kinase that plays an important role in lymphangiogenesis. It has been found that VEGFR-3 can physically interact with the FAT domain of FAK in cancer cells, and the interaction between the FAT domain and VEGFR-3 can significantly strengthen the survival of cancer cells;<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> therefore, small molecular compounds targeting the interaction between FAK and VEGFR-3 have the potential to be developed as novel molecular therapeutics. Canceâs group docks various compounds from the NCI/DTP database to the crystal structure of the FAT domain in FAK and identified compound <b>38</b> (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>), which showed high affinity to FAK and excellent inhibition of the viability in a series of cancer cells.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> In addition, <b>38</b> can induce VEGFR-3-dependent apoptosis in breast cancer cells. Immunohistochemical experiments further ensured that <b>38</b> can target the FAK-VEGFR-3 interaction and suppressed the phosphorylation of both FAK and VEGFR-3 in a dose-dependent manner. Compound <b>38</b> has been evaluated in a tumor xenograft female mouse model for breast cancer cells BT474 and MCF7, which stably overexpressed VEGFR-3, and the results indicated that <b>38</b> can effectively inhibit tumor growth. Moreover, <b>38</b> exerted significant synergy with chemotherapy drugs for breast cancer. Using <b>38</b> as a lead compound, they have designed and synthesized a series of analogues of <b>38</b> through structural modifications and identified compound <b>39</b> (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>), which showed increased cytotoxicity in multiple cancer cell lines compared to <b>38</b>.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> More importantly, <b>39</b> showed greater selectivity for cancer cells, which overexpress both FAK and VEGFR3, as compared to those with moderate levels of both proteins.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Chemical structures of FAT domain inhibitors <b>38</b> and <b>39</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24">4.4.  FAK PROTACs</h3><div class="NLM_p">Recently the development of proteolysis-targeting chimeras (PROTACs) to induce the degradation of their targeted proteins has become a âhot areaâ in drug development.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> A PROTAC is a bifunctional heterodimeric compound in which a ligand for a protein of interest is linked through a linker to a ligand of an E3 ubiquitin ligase; therefore, it can concurrently bind to both the target protein and the E3 ubiquitin ligase and bring the target protein to the proximity of the E3 ubiquitin ligase that promotes the polyubiquitination of the target protein and subsequent degradation of the target protein by the proteasome (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>).<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> More than 600 E3 ligases have been found;<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> however, only a few of them have been actively pursued for the design of PROTACs, such as the cereblon complex (CRBN), von Hippel-Lindau complex (VHL), IAPs, and MDM2. Comparing with inhibitors of target proteins, PROTACs have several advantages.<a onclick="showRef(event, 'ref144 ref145'); return false;" href="javascript:void(0);" class="ref ref144 ref145">(144,145)</a> Instead of inhibiting the target proteins, PROTACs can induce their degradation and therefore are more prominent antagonists of the target proteins. PROTACs do not need to bind to the active sites of the proteins of interest, so it is possible for PROTACs to target undruggable proteins; after inducing the degradation of the proteins they bind to, PROTACs can be released and reused. Therefore, PROTACs can antagonize target proteins in doses lower than stoichiometric doses. Because of these advantages, in the past few years, a large number of PROTACs targeting many different classes of proteins have been developed, and the number is still rapidly increasing.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> Many elegant reviews for the development of PROTACs have also been published.<a onclick="showRef(event, 'ref146 ref147 ref148 ref149 ref150 ref151'); return false;" href="javascript:void(0);" class="ref ref146 ref147 ref148 ref149 ref150 ref151">(146â151)</a> Kinases are among the most pursued targets for the development of PROTACs, and many kinase-targeting PROTACs have been reported.<a onclick="showRef(event, 'ref152 ref153 ref154 ref155'); return false;" href="javascript:void(0);" class="ref ref152 ref153 ref154 ref155">(152â155)</a> FAK has both kinase-dependent and nonkinase-dependent functions; kinase inhibitors of FAK can inhibit the kinase-dependent functions of FAK but cannot effectively antagonize its nonkinase-dependent functions. Because of the mechanisms of functions of PROTACs, it can be expected that PROTACs, which induce the degradation of FAK can antagonize both kinase-dependent and nonkinase-dependent functions of FAK.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a></div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Schematic of the PROTAC-acting mechanism.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2018, Grayâs group designed a multikinase degrader TL12â186 (compound <b>40</b>, <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>) by conjugating a highly promiscuous kinase inhibitor with a cereblon-binding ligand pomalidomide and found 28 kinases, including BTK, PTK2, PTK2B, FLT3, AURKA, AURKB, TEC, ULK1, ITK, and nine members of the CDK family, are degradable.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> Later on, based on pyrimidine-based ALK inhibitors TAE684 (compound <b>41</b>) or LDK378 (compound <b>42</b>, <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>), they designed a class of ALK degraders represented by compounds <b>43</b> and <b>44</b> (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>) and found these compounds induce the degradation of not only ALK but also FAK, Aurora A, FER, and RSK1.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> These studies proved the feasibility for the development of FAK degraders.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Chemical structures of compounds <b>40</b>â<b>44</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Also, in 2018, Crewâs group reported their study for the development of FAK selective degraders.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> In their work, a series of PROTACs were designed by conjugating a FAK ligand derived from VS-6063 by slight modifications with a peptide-based VHL ligand or thalidomide, another frequently used CREB ligand through ether linkers with various lengths. All of these PROTACs showed good inhibitory effects against FAK and can potentially induce the degradation of FAK, although PROTACs with too long or too short linkers showed slightly decreased degradative activities. Among these PROTACs, compound <b>45</b> (PROTAC <b>3</b>, <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>) is the most potent FAK degrader, which shows a DC<sub>50</sub> value of 3 nM and <i>D</i><sub>max</sub> over 99%. Interestingly, PROTAC <b>3</b> displayed better selectivity to FAK than defactinib in DiscoverX KINOMEscan. PROTAC <b>3</b> showed significant effects on downstream signaling and strongly suppressed the phosphorylation of paxillin and AKT. More importantly, the effects of PROTAC <b>3</b> in suppressing the downstream signaling of FAK are much stronger than that of defactinib. PROTAC <b>3</b> also effectively inhibited migration and impaired invasion of MDA-MB-231 cells, and again, more significantly than defactinib.</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Chemical structures of compounds <b>45</b>â<b>49</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2019, scientists at Boehringer Ingelheim designed and synthesized a series of FAK degraders represented by BI-3663 (compound <b>46</b>, <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>) and BI-0319 (compound <b>47</b>, <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>) by tethering a previously identified FAK inhibitor BI-4464 (compound <b>48</b>, <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>) through an ether linker with a peptide-based VHL ligand and pomalidomide, respectively.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> Through a series of biochemical and biological assays, they confirmed that BI-3663 (<i>D</i><sub>max</sub> = 95%) and BI-0319 (<i>D</i><sub>max</sub> = 80%) can effectively and specifically degrade FAK protein in 12 cell lines. However, BI-3663 and BI-0319 did not show more potent antiproliferative activity than FAK inhibitor BI-4644 in all tested cell lines in either short- or long-term assays <i>in vitro</i>, suggesting that the scaffolding function of FAK may not be required for the proliferation of the tested cell lines.</div><div class="NLM_p last">On the basis of FAK inhibitor VS-60622 or VS-6063, Raoâs group build a library of FAK PROTACs by conjugating the âwar headsâ for FAK with CRBN ligand pomalidomide through linkers with various lengths and polarity using the âclick reactionâ as the key reaction.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> The representative compound FC-11 (compound <b>49</b>, <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>) causes rapid and effective degradation of FAK with a DC<sub>50</sub> at picomolar potencies in five different cell lines. They noticed that the degradation of FAK induced by FC-11 can be recovered if PROTAC molecules were washed off, suggesting that FAK has a rapid turnover. Notably, FC-11 inhibited FAK autophosphorylation more potently than VS-6062. Consistent with what scientists at Boehringer Ingelheim have found, FAK degraders did not show more potent antiproliferation activity than FAK inhibitors.</div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">5.  Conclusions and Future Perspective</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85220" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85220" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Because of the critical functions of FAK in the progression of human cancers, it has been considered as a promising target for the development of anticancer drugs. Many FAK inhibitors targeting different domains of FAK with various functions have been developed; among them, the most studied are kinase domain inhibitors. Six ATP-competitive kinase inhibitors have been evaluated in clinical trials and showed overall manageable safety profiles in phase I trials. VS-6063 has been evaluated in the phase II trial and showed a modest antitumor effect. The major factor that influences the clinical study is the selection of patients most likely to benefit from the therapy; therefore, identifying biomarkers for evaluating the effect of FAK inhibitors will be critical for the success of the clinical development of FAK inhibitors. In preclinical studies, it has been found that Merlin negative and E-cadherin low expressed cancer cells are more sensitive to FAK inhibitors.<a onclick="showRef(event, 'ref161 ref162 ref163'); return false;" href="javascript:void(0);" class="ref ref161 ref162 ref163">(161â163)</a> However, these were not confirmed in phase I trials; therefore, it is still not clear which biomarkers can be used to evaluate the efficacy of FAK inhibitors. More studies for the identification of proper biomarkers are urgently needed. FAK has both kinase-dependent and nonkinase-dependent functions; therefore, it is possible that studies for the identification of biomarkers of kinase inhibitors can be compromised by the nonkinase-dependent functions of FAK. Because FAK-targeted PROTACs can promote the degradation of FAK, the recently developed PROTACs can be used in the studies for the identifications of biomarkers for the evaluation of the efficacy of FAK inhibitors.</div><div class="NLM_p">To antagonize the nonkinase-dependent functions of FAK, small molecules targeting the FERM domain and FAT domain of FAK have also been explored. These compounds were mainly identified by virtual screens and are still in early-stage development. Several groups have found that although PROTACs can effectively induce the degradation of FAK, they did not show more potent anticancer cellular activity than corresponding FAK inhibitors, suggested that nonkinase functions of FAK may be not required for promoting the proliferation of the cancer cells. More studies will be needed to clarify the relationship between the nonkinase-dependent functions of FAK and cancer cell proliferation.</div><div class="NLM_p">In the development of kinase inhibitors, there is always a dilemma between selectivity and efficacy. Selective kinase inhibitors can more efficiently decrease the side effects associated with off-target functions of the compounds, while multitarget kinase inhibitors can more effectively overcome the drug resistance and are usually therapeutically more potent. In addition, cancer cells frequently contain more than one dysfunctional signaling pathways; therefore, carefully selected multitarget inhibitors, which can concurrently antagonize multiple certain targets, can be therapeutically more favorable. In FDA-approved kinase inhibitor drugs, some of them are selective inhibitors, while a number of them can target multiple kinases.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> A similar situation appeared in the development of FAK inhibitors; both selective FAK inhibitors and multitarget FAK inhibitors have been actively studied. Among the six FAK inhibitors in clinical trials, GSK2256098, BI-853520, and VS-4718 are highly selective to FAK, but CEP-37440, VS-6062, and VS-6063 are multitarget inhibitors. CEP-37440 is a dual inhibitor of FAK and ALK, while both VS-6062 and VS-6063 are dual inhibitors of FAK and Pyk2. For improving the selectivity, allosteric kinase domain inhibitors have been identified, and irreversible FAK inhibitors have also been designed. In the future study, the development of more specific FAK inhibitors and the identification of more potent compounds that can antagonize multiple targets still will be the focus for the development of FAK inhibitors.</div><div class="NLM_p">The combination of more anticancer therapies for the treatment of human cancers is a frequently used strategy. A number of clinical trials for the evaluation of FAK inhibitors in combination studies have been conducted. For example, clinical trials examining combination treatment with VS-6063 and immune checkpoint inhibitor pembrolizumab (NCT02546531 and NCT02758687) and a combination of GSK2256098 with MEK inhibitor trametinib<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> have been performed and showed promising results. In the future, combination studies of FAK inhibitors with other anticancer therapies still will be a major direction for the clinical development of FAK inhibitors.</div><div class="NLM_p last">Collectively, continuous efforts in medicinal chemistry, biological chemistry, and biology may lead to the identification of new FAK-based therapies for the treatment of human cancers.</div></div><div class="NLM_back"><div class="NLM_notes" id="notes1"><p class="first last">The authors declare no competing financial interest.</p></div><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01248" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27410" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27410" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haiying Sun</span> - <span class="hlFld-Affiliation affiliation">Jiangsu Key Laboratory of Drug Design
and Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5380-5329" title="Orcid link">http://orcid.org/0000-0001-5380-5329</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3159505848585f564200080708715241441f5455441f525f"><span class="__cf_email__" data-cfemail="660e070f1f0f080115575f505f2605161348030213480508">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yang Lu</span> - <span class="hlFld-Affiliation affiliation">Jiangsu Key Laboratory of Drug Design
and Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61218" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61218" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Yang Lu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=BIO-d7e2275-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yang Lu</b> obtained her Bachelorâs degree in pharmacy in 2018 from China Pharmaceutical University and then entered Professor Haiying Sunâs group as a master student. Her research focuses on the design, synthesis, and evaluation of small molecular inhibitors of FAK and IAPs.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Haiying Sun</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=BIO-d7e2280-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Haiying Sun</b> received his Ph.D. degree in 2000 from Shanghai Institute of Organic Chemistry under the supervision of Professor Dawei Ma. After that, he did his postdoctoral research with Professor Alan P. Kozikowski at Georgetown University and Professor Shaomeng Wang at the University of Michigan between 2000 and 2003. In 2003, he was appointed to be a Research Investigator at the Department of Internal Medicine of the University of Michigan and was promoted to be a Research Assistant Professor in 2008. He joined the Department of Medicinal Chemistry at China Pharmaceutical University as a full professor in 2014. He has published 40+ papers in worldwide distinguished journals in the field of organic and medicinal chemistry and was awarded more than 10 PCT patents.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32005" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32005" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Financial support from Funding of Double First-rate Discipline Innovation Teams (CPU2018GY05 and CPU2018GF05) is acknowledged.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ABC</td><td class="NLM_def"><p class="first last">ATP-binding cassette</p></td></tr><tr><td class="NLM_term">AKT/PYK</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">ALK</td><td class="NLM_def"><p class="first last">anaplastic lymphoma kinase</p></td></tr><tr><td class="NLM_term">bFGF</td><td class="NLM_def"><p class="first last">base fibroblast growth factor</p></td></tr><tr><td class="NLM_term">CRBN</td><td class="NLM_def"><p class="first last">cereblon</p></td></tr><tr><td class="NLM_term">CRPC</td><td class="NLM_def"><p class="first last">astration-resistant prostate cancer</p></td></tr><tr><td class="NLM_term">CSCs</td><td class="NLM_def"><p class="first last">cancer stem cells</p></td></tr><tr><td class="NLM_term">ECM</td><td class="NLM_def"><p class="first last">extracellular matrix</p></td></tr><tr><td class="NLM_term">ECs</td><td class="NLM_def"><p class="first last">endothelial cells</p></td></tr><tr><td class="NLM_term">EGF</td><td class="NLM_def"><p class="first last">epidermal growth factor</p></td></tr><tr><td class="NLM_term">EMT</td><td class="NLM_def"><p class="first last">epithelial-to-mesenchymal transition</p></td></tr><tr><td class="NLM_term">FAK</td><td class="NLM_def"><p class="first last">focal adhesion kinase</p></td></tr><tr><td class="NLM_term">FAT</td><td class="NLM_def"><p class="first last">focal adhesion targeting</p></td></tr><tr><td class="NLM_term">FERM</td><td class="NLM_def"><p class="first last">four-point-one, ezrin, radixin, moesin</p></td></tr><tr><td class="NLM_term">FGFR2</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor 2</p></td></tr><tr><td class="NLM_term">FRNK</td><td class="NLM_def"><p class="first last">FAK-related nonkinase</p></td></tr><tr><td class="NLM_term">hESCs</td><td class="NLM_def"><p class="first last">human embryonic stem cells</p></td></tr><tr><td class="NLM_term">HGF</td><td class="NLM_def"><p class="first last">hepatocyte growth factor</p></td></tr><tr><td class="NLM_term">IBC</td><td class="NLM_def"><p class="first last">inflammatory breast cancer</p></td></tr><tr><td class="NLM_term">IGF-IR</td><td class="NLM_def"><p class="first last">factor-I receptor</p></td></tr><tr><td class="NLM_term">InsR</td><td class="NLM_def"><p class="first last">insulin receptor</p></td></tr><tr><td class="NLM_term">JAK2</td><td class="NLM_def"><p class="first last">janus kinase 2</p></td></tr><tr><td class="NLM_term">MDM2</td><td class="NLM_def"><p class="first last">murine double minute 2</p></td></tr><tr><td class="NLM_term">MDR</td><td class="NLM_def"><p class="first last">multidrug resistance</p></td></tr><tr><td class="NLM_term">MMPs</td><td class="NLM_def"><p class="first last">matrix metalloproteinases</p></td></tr><tr><td class="NLM_term">NLS</td><td class="NLM_def"><p class="first last">nuclear localization sequence</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">nonsmall cell lung cancer</p></td></tr><tr><td class="NLM_term">PDAC</td><td class="NLM_def"><p class="first last">pancreatic ductal adenocarcinoma</p></td></tr><tr><td class="NLM_term">PDGF</td><td class="NLM_def"><p class="first last">platelet-derived growth factor</p></td></tr><tr><td class="NLM_term">PPI</td><td class="NLM_def"><p class="first last">proteinâprotein interaction</p></td></tr><tr><td class="NLM_term">PPTP</td><td class="NLM_def"><p class="first last">pediatric preclinical testing program</p></td></tr><tr><td class="NLM_term">PROTACs</td><td class="NLM_def"><p class="first last">proteolysis-targeting chimeras</p></td></tr><tr><td class="NLM_term">PRRs</td><td class="NLM_def"><p class="first last">proline-rich regions</p></td></tr><tr><td class="NLM_term">PTK2</td><td class="NLM_def"><p class="first last">protein tyrosine kinase 2</p></td></tr><tr><td class="NLM_term">Pyk2</td><td class="NLM_def"><p class="first last">proline-rich tyrosine kinase 2</p></td></tr><tr><td class="NLM_term">RIP</td><td class="NLM_def"><p class="first last">receptor-interacting protein</p></td></tr><tr><td class="NLM_term">SD</td><td class="NLM_def"><p class="first last">stable disease</p></td></tr><tr><td class="NLM_term">VEGF</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor</p></td></tr><tr><td class="NLM_term">VHL</td><td class="NLM_def"><p class="first last">von Hippel-Lindau</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81463" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81463" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 165 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schaller, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas Parsons, J.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase and associated proteins</span>. <i>Curr. Opin. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">705</span>â <span class="NLM_lpage">710</span>, <span class="refDoi">Â DOI: 10.1016/0955-0674(94)90097-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2F0955-0674%2894%2990097-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=7833050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADyaK2MXhtVOltrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1994&pages=705-710&author=M.+D.+Schallerauthor=J.+Thomas+Parsons&title=Focal+adhesion+kinase+and+associated+proteins&doi=10.1016%2F0955-0674%2894%2990097-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion kinase and associated proteins</span></div><div class="casAuthors">Schaller, Michael D.; Parsons, J. Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">705-10</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    </div><div class="casAbstract">A review with 44 refs.  Focal adhesion kinase (pp125FAK), a protein kinase, has recently been suggested to regulate aspects of signalling induced by integrins and by certain growth factor and hormone receptors.  New studies indicate that the domains of pp125FAK regulate its interactions with integrin subunits, other protein tyrosine kinases, and the focal adhesion-assocd. protein paxillin.  Through these interactions, pp125FAK may regulate signalling via different extracellular ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ0aT0RrcfCbVg90H21EOLACvtfcHk0lh0GEp3v3Ypeg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXhtVOltrk%253D&md5=3ae3cd6cd92d0509efd017cc69d25af5</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2F0955-0674%2894%2990097-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0955-0674%252894%252990097-3%26sid%3Dliteratum%253Aachs%26aulast%3DSchaller%26aufirst%3DM.%2BD.%26aulast%3DThomas%2BParsons%26aufirst%3DJ.%26atitle%3DFocal%2520adhesion%2520kinase%2520and%2520associated%2520proteins%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D1994%26volume%3D6%26spage%3D705%26epage%3D710%26doi%3D10.1016%2F0955-0674%2894%2990097-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanks, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calalb, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. K.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">8487</span>â <span class="NLM_lpage">8491</span>, <span class="refDoi">Â DOI: 10.1073/pnas.89.18.8487</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1073%2Fpnas.89.18.8487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1528852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADyaK3sXmt1alsb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1992&pages=8487-8491&author=S.+K.+Hanksauthor=M.+B.+Calalbauthor=M.+C.+Harperauthor=S.+K.+Patel&title=Focal+adhesion+protein-tyrosine+kinase+phosphorylated+in+response+to+cell+attachment+to+fibronectin&doi=10.1073%2Fpnas.89.18.8487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin</span></div><div class="casAuthors">Hanks, Steven K.; Calalb, Mihail B.; Harper, Melinda C.; Patel, Sheetal K.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8487-91</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">A homol.-based cDNA cloning approach was used to identify a widely expressed protein-tyrosine kinase designated as focal adhesion kinase (FadK).  The entire mouse FadK amino acid sequence was deduced from cDNA clones, revealing a large (119-kDa) non-membrane-spanning protein-tyrosine kinase that lacks Src-homol. SH2 and SH3 domains.  Immunostaining of BALB/c3T3 fibroblasts revealed that FadK is concd. in focal adhesions.  FadK is phosphorylated on tyrosine in growing cultures of BALB/c 3T3 cells but contains little or no phosphotyrosine in cells detached by trypsinization.  The tyrosine-phosphorylated state is regained within minutes when the cells are replated onto fibronectin.  Activation of FadK may be an important early step in intracellular signal transduction pathways triggered in response to cell interactions with the extracellular matrix.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM5F6sZrlzsLVg90H21EOLACvtfcHk0li1kAjO8LBcHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXmt1alsb8%253D&md5=09a01a31b19ae6acc88515f3352688c4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1073%2Fpnas.89.18.8487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.89.18.8487%26sid%3Dliteratum%253Aachs%26aulast%3DHanks%26aufirst%3DS.%2BK.%26aulast%3DCalalb%26aufirst%3DM.%2BB.%26aulast%3DHarper%26aufirst%3DM.%2BC.%26aulast%3DPatel%26aufirst%3DS.%2BK.%26atitle%3DFocal%2520adhesion%2520protein-tyrosine%2520kinase%2520phosphorylated%2520in%2520response%2520to%2520cell%2520attachment%2520to%2520fibronectin%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1992%26volume%3D89%26spage%3D8487%26epage%3D8491%26doi%3D10.1073%2Fpnas.89.18.8487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L.</span></span> <span> </span><span class="NLM_article-title">The roles of nuclear focal adhesion kinase (FAK) on cancer: a focused review</span>. <i>J. Exp. Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">250</span>â <span class="NLM_lpage">350</span>, <span class="refDoi">Â DOI: 10.1186/s13046-019-1265-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1186%2Fs13046-019-1265-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=31186061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BB3M3lsVKjtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&pages=250-350&author=J.+Zhouauthor=Q.+Yiauthor=L.+Tang&title=The+roles+of+nuclear+focal+adhesion+kinase+%28FAK%29+on+cancer%3A+a+focused+review&doi=10.1186%2Fs13046-019-1265-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The roles of nuclear focal adhesion kinase (FAK) on Cancer: a focused review</span></div><div class="casAuthors">Zhou Jin; Tang Liling; Yi Qian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of experimental & clinical cancer research : CR</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">250</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">FAK is a tyrosine kinase overexpressed in cancer cells and plays an important role in the progression of tumors to a malignant phenotype.  Except for its typical role as a cytoplasmic kinase downstream of integrin and growth factor receptor signaling, related studies have shown new aspects of the roles of FAK in the nucleus.  FAK can promote p53 degradation through ubiquitination, leading to cancer cell growth and proliferation.  FAK can also regulate GATA4 and IL-33 expression, resulting in reduced inflammatory responses and immune escape.  These findings establish a new model of FAK from the cytoplasm to the nucleus.  Activated FAK binds to transcription factors and regulates gene expression.  Inactive FAK synergizes with different E3 ligases to promote the turnover of transcription factors by enhancing ubiquitination.  In the tumor microenvironment, nuclear FAK can regulate the formation of new blood vessels, affecting the tumor blood supply.  This article reviews the roles of nuclear FAK in regulating gene expression.  In addition, the use of FAK inhibitors to target nuclear FAK functions will also be emphasized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJvFbWKSujK36oPH0mYWL1fW6udTcc2ebgAsS1j2O467ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3lsVKjtQ%253D%253D&md5=2204d3c10aac92625041db67af555aeb</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1186%2Fs13046-019-1265-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-019-1265-1%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DYi%26aufirst%3DQ.%26aulast%3DTang%26aufirst%3DL.%26atitle%3DThe%2520roles%2520of%2520nuclear%2520focal%2520adhesion%2520kinase%2520%2528FAK%2529%2520on%2520cancer%253A%2520a%2520focused%2520review%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D38%26spage%3D250%26epage%3D350%26doi%3D10.1186%2Fs13046-019-1265-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauck, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aprikian, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begin, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapdelaine, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chevalier, S.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">164</span>â <span class="NLM_lpage">171</span>, <span class="refDoi">Â DOI: 10.1002/(SICI)1097-0215(19961009)68:2<169::AID-IJC4>3.0.CO;2-W</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1002%2F%28SICI%291097-0215%2819961009%2968%3A2%3C169%3A%3AAID-IJC4%3E3.0.CO%3B2-W" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=8900422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADyaK28XntlKjtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=1996&pages=164-171&author=L.+Tremblayauthor=W.+Hauckauthor=A.+G.+Aprikianauthor=L.+R.+Beginauthor=A.+Chapdelaineauthor=S.+Chevalier&title=Focal+adhesion+kinase+%28pp125FAK%29+expression%2C+activation+and+association+with+paxillin+and+p50CSK+in+human+metastatic+prostate+carcinoma&doi=10.1002%2F%28SICI%291097-0215%2819961009%2968%3A2%3C169%3A%3AAID-IJC4%3E3.0.CO%3B2-W"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma</span></div><div class="casAuthors">Tremblay, Lise; Hauck, Wendy; Aprikian, Armen G.; Begin, Louis R.; Chapdelaine, Alcide; Chevalier, Simone</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">164-171</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss</span>)
        </div><div class="casAbstract">Pp125FAK, a protein tyrosine kinase (PTK) co-localized with integrins in focal adhesion plaques, is known to transduce signals involved in the regulation of cell adhesion and motility as well as the anchorage-independent growth of transformed cells.  The authors investigated whether pp125FAK could be part of a signaling pathway that contributes to the progression of human prostate carcinoma (PCa).  Up-regulation of pp125FAK expression, its activation by phosphorylation on tyrosine and its assocn. with paxillin and p50CSK were preferentially obsd. in PCa tissues from patients with metastases, whereas normal and hyperplastic prostates and localized PCa tissues showed undetectable or low levels of both FAK mRNA and protein and an absence of pp125FAK signaling complexes.  The increase in expression and activation of pp125FAK in metastatic PCa tissues was also corroborated by the findings in human PCa cell lines.  Indeed, higher levels of pp125FAK mRNA were obsd. in highly tumorigenic PC-3 cells as was the presence of activated pp125FAK, as opposed to an inactive form in LNCaP cells, which have a lower tumorigenic ability.  In addn., pp125FAK formed signaling complexes with both paxillin and p50CSK in PC-3 cells as in metastatic PCa tissues.  Together, the results show that an increase in FAK mRNA and protein, as well as pp125FAK activation and assocn. with signaling proteins, correlates with progression and invasion in human PCa tissues and cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreuJ1bwa8wzLVg90H21EOLACvtfcHk0li1kAjO8LBcHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XntlKjtbk%253D&md5=ffbc05e8990d1c18bc411ce7f49f5d04</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291097-0215%2819961009%2968%3A2%3C169%3A%3AAID-IJC4%3E3.0.CO%3B2-W&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291097-0215%252819961009%252968%253A2%253C169%253A%253AAID-IJC4%253E3.0.CO%253B2-W%26sid%3Dliteratum%253Aachs%26aulast%3DTremblay%26aufirst%3DL.%26aulast%3DHauck%26aufirst%3DW.%26aulast%3DAprikian%26aufirst%3DA.%2BG.%26aulast%3DBegin%26aufirst%3DL.%2BR.%26aulast%3DChapdelaine%26aufirst%3DA.%26aulast%3DChevalier%26aufirst%3DS.%26atitle%3DFocal%2520adhesion%2520kinase%2520%2528pp125FAK%2529%2520expression%252C%2520activation%2520and%2520association%2520with%2520paxillin%2520and%2520p50CSK%2520in%2520human%2520metastatic%2520prostate%2520carcinoma%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D1996%26volume%3D68%26spage%3D164%26epage%3D171%26doi%3D10.1002%2F%28SICI%291097-0215%2819961009%2968%3A2%3C169%3A%3AAID-IJC4%3E3.0.CO%3B2-W" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timpson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horvath, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, R. J.</span></span> <span> </span><span class="NLM_article-title">FAK signaling in human cancer as a target for therapeutics</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">132</span>â <span class="NLM_lpage">149</span>, <span class="refDoi">Â DOI: 10.1016/j.pharmthera.2014.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.pharmthera.2014.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=25316657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGlu7rN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2015&pages=132-149&author=B.+Y.+Leeauthor=P.+Timpsonauthor=L.+G.+Horvathauthor=R.+J.+Daly&title=FAK+signaling+in+human+cancer+as+a+target+for+therapeutics&doi=10.1016%2Fj.pharmthera.2014.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">FAK signaling in human cancer as a target for therapeutics</span></div><div class="casAuthors">Lee, Brian Y.; Timpson, Paul; Horvath, Lisa G.; Daly, Roger J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">132-149</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Focal adhesion kinase (FAK) is a key regulator of growth factor receptor- and integrin-mediated signals, governing fundamental processes in normal and cancer cells through its kinase activity and scaffolding function.  Increased FAK expression and activity occurs in primary and metastatic cancers of many tissue origins, and is often assocd. with poor clin. outcome, highlighting FAK as a potential determinant of tumor development and metastasis.  Indeed, data from cell culture and animal models of cancer provide strong lines of evidence that FAK promotes malignancy by regulating tumorigenic and metastatic potential through highly-coordinated signaling networks that orchestrate a diverse range of cellular processes, such as cell survival, proliferation, migration, invasion, epithelial-mesenchymal transition, angiogenesis and regulation of cancer stem cell activities.  Such an integral role in governing malignant characteristics indicates that FAK represents a potential target for cancer therapeutics.  While pharmacol. targeting of FAK scaffold function is still at an early stage of development, a no. of small mol.-based FAK tyrosine kinase inhibitors are currently undergoing pre-clin. and clin. testing.  In particular, PF-00562271, VS-4718 and VS-6063 show promising clin. activities in patients with selected solid cancers.  Clin. testing of rationally designed FAK-targeting agents with implementation of predictive response biomarkers, such as merlin deficiency for VS-4718 in mesothelioma, may help improve clin. outcome for cancer patients.  In this article, we have reviewed the current knowledge regarding FAK signaling in human cancer, and recent developments in the generation and clin. application of FAK-targeting pharmacol. agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLnxnFQsOShLVg90H21EOLACvtfcHk0lgC_ok96kNrJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGlu7rN&md5=7359c2a7671631f97a9d46ccef1ab68f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2014.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2014.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DB.%2BY.%26aulast%3DTimpson%26aufirst%3DP.%26aulast%3DHorvath%26aufirst%3DL.%2BG.%26aulast%3DDaly%26aufirst%3DR.%2BJ.%26atitle%3DFAK%2520signaling%2520in%2520human%2520cancer%2520as%2520a%2520target%2520for%2520therapeutics%26jtitle%3DPharmacol.%2520Ther.%26date%3D2015%26volume%3D146%26spage%3D132%26epage%3D149%26doi%3D10.1016%2Fj.pharmthera.2014.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naomoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakurama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motoki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomono, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukazawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirakawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamatsuji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takaoka, M.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase as potential target for cancer therapy (review)</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">973</span>â <span class="NLM_lpage">979</span>, <span class="refDoi">Â DOI: 10.3892/or_00000524</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.3892%2For_00000524" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=19787209" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCjtb7O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=973-979&author=H.+Haoauthor=Y.+Naomotoauthor=X.+Baoauthor=N.+Watanabeauthor=K.+Sakuramaauthor=K.+Nomaauthor=T.+Motokiauthor=Y.+Tomonoauthor=T.+Fukazawaauthor=Y.+Shirakawaauthor=T.+Yamatsujiauthor=J.+Matsuokaauthor=Z.+G.+Wangauthor=M.+Takaoka&title=Focal+adhesion+kinase+as+potential+target+for+cancer+therapy+%28review%29&doi=10.3892%2For_00000524"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion kinase as potential target for cancer therapy (Review)</span></div><div class="casAuthors">Hao, Huifang; Naomoto, Yoshio; Bao, Xiaohong; Watanabe, Nobuyuki; Sakurama, Kazufumi; Noma, Kazuhiro; Motoki, Takayuki; Tomono, Yasuko; Fukazawa, Takuya; Shirakawa, Yasuhiro; Yamatsuji, Tomoki; Matsuoka, Junji; Wang, Z. G.; Takaoka, Munenori</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">973-979</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Oncology Reports</span>)
        </div><div class="casAbstract">A review.  Focal adhesion kinase (FAK) is a 125-kDa non-receptor and non-membrane protein tyrosine.  FAK can function with integrins and growth factor receptors to promote cell survival dependent kinase activity and nuclear FAK promotes cell proliferation and survival through FERM (FAK, ezrin, radixin, moesin) domain-enhanced p53 degrdn. independent kinase activity.  Many previous studies have indicated that FAK plays a crit. role in the biol. processes of normal and cancer cells and FAK has been proposed as a potential target in cancer therapy.  Small mol. inhibitors (PF-573,228; PF-562,271 and NVP-226) for use as potential cancer therapies have been developed.  However, the detailed mechanism of the role for FAK in tumor cell generation and progression remain unclear, so future work is needed to explore these issues.  New inhibitors that can be effectively inhibit the function of FAK still need to be explored due to the low specificity, and resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-fIMPplLyU7Vg90H21EOLACvtfcHk0lgC_ok96kNrJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCjtb7O&md5=9d5aacc37270d88d72b0d7534611b512</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3892%2For_00000524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For_00000524%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DH.%26aulast%3DNaomoto%26aufirst%3DY.%26aulast%3DBao%26aufirst%3DX.%26aulast%3DWatanabe%26aufirst%3DN.%26aulast%3DSakurama%26aufirst%3DK.%26aulast%3DNoma%26aufirst%3DK.%26aulast%3DMotoki%26aufirst%3DT.%26aulast%3DTomono%26aufirst%3DY.%26aulast%3DFukazawa%26aufirst%3DT.%26aulast%3DShirakawa%26aufirst%3DY.%26aulast%3DYamatsuji%26aufirst%3DT.%26aulast%3DMatsuoka%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DZ.%2BG.%26aulast%3DTakaoka%26aufirst%3DM.%26atitle%3DFocal%2520adhesion%2520kinase%2520as%2520potential%2520target%2520for%2520cancer%2520therapy%2520%2528review%2529%26jtitle%3DOncol.%2520Rep.%26date%3D2009%26volume%3D22%26spage%3D973%26epage%3D979%26doi%3D10.3892%2For_00000524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sulzmaier, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlaepfer, D. D.</span></span> <span> </span><span class="NLM_article-title">FAK in cancer: mechanistic findings and clinical applications</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">598</span>â <span class="NLM_lpage">610</span>, <span class="refDoi">Â DOI: 10.1038/nrc3792</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fnrc3792" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=25098269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht12nu7vJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=598-610&author=F.+J.+Sulzmaierauthor=C.+Jeanauthor=D.+D.+Schlaepfer&title=FAK+in+cancer%3A+mechanistic+findings+and+clinical+applications&doi=10.1038%2Fnrc3792"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">FAK in cancer: mechanistic findings and clinical applications</span></div><div class="casAuthors">Sulzmaier, Florian J.; Jean, Christine; Schlaepfer, David D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">598-610</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Focal adhesion kinase (FAK) is a cytoplasmic protein tyrosine kinase that is overexpressed and activated in several advanced-stage solid cancers.  FAK promotes tumor progression and metastasis through effects on cancer cells, as well as stromal cells of the tumor microenvironment.  The kinase-dependent and kinase-independent functions of FAK control cell movement, invasion, survival, gene expression and cancer stem cell self-renewal.  Small mol. FAK inhibitors decrease tumor growth and metastasis in several preclin. models and have initial clin. activity in patients with limited adverse events.  In this Review, we discuss FAK signalling effects on both tumor and stromal cell biol. that provide rationale and support for future therapeutic opportunities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmKc7m7dsY67Vg90H21EOLACvtfcHk0lgC_ok96kNrJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht12nu7vJ&md5=f498bcf7af890d2f92eda68e42f979d1</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrc3792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3792%26sid%3Dliteratum%253Aachs%26aulast%3DSulzmaier%26aufirst%3DF.%2BJ.%26aulast%3DJean%26aufirst%3DC.%26aulast%3DSchlaepfer%26aufirst%3DD.%2BD.%26atitle%3DFAK%2520in%2520cancer%253A%2520mechanistic%2520findings%2520and%2520clinical%2520applications%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D598%26epage%3D610%26doi%3D10.1038%2Fnrc3792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sood, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffin, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeYoung, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruman, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gershenson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaller, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrix, M. J.</span></span> <span> </span><span class="NLM_article-title">Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">1087</span>â <span class="NLM_lpage">1095</span>, <span class="refDoi">Â DOI: 10.1016/S0002-9440(10)63370-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2FS0002-9440%2810%2963370-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=15466376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptFSmtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2004&pages=1087-1095&author=A.+K.+Soodauthor=J.+E.+Coffinauthor=G.+B.+Schneiderauthor=M.+S.+Fletcherauthor=B.+R.+DeYoungauthor=L.+M.+Grumanauthor=D.+M.+Gershensonauthor=M.+D.+Schallerauthor=M.+J.+Hendrix&title=Biological+significance+of+focal+adhesion+kinase+in+ovarian+cancer%3A+role+in+migration+and+invasion&doi=10.1016%2FS0002-9440%2810%2963370-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion</span></div><div class="casAuthors">Sood, Anil K.; Coffin, Jeremy E.; Schneider, Galen B.; Fletcher, Mavis S.; DeYoung, Barry R.; Gruman, Lynn M.; Gershenson, David M.; Schaller, Michael D.; Hendrix, Mary J. C.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1087-1095</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that is activated by integrin clustering.  There are limited data regarding the functional role of FAK in ovarian cancer migration and invasion.  In the current study, FAK expression was evaluated in ovarian cell lines (nontransformed and cancer), 12 benign ovarian samples, and in 79 invasive epithelial ovarian cancers.  All three ovarian cancer cell lines overexpressed FAK compared to the nontransformed cells.  The dominant-neg. construct called FAK-related non-kinase (FRNK) was introduced into two ovarian cancer cell tines (SKOV3 and 222).  FRNK promoted FAK dephosphorylation without changing total FAK levels in these cell lines.  Furthermore, FRNK decreased the in vitro invasive ability of ovarian cancer cells by 56 to 85% and decreased migration by 52 to 68%.  FRNK-transfected cells also displayed poor cell spreading.  Immunohistochem. anal. revealed that the surface epithelium from all benign ovarian samples had weak FAK expression.  In contrast, 68% of invasive ovarian cancers overexpressed FAK.  FAK overexpression was significantly assocd. with high tumor stage, high tumor grade, pos. lymph nodes and presence of distant metastasis (all P values <0.05).  FAK overexpression was also assocd. with shorter overall survival (P = 0.008).  Multivariate anal. revealed that FAK overexpression and residual disease >1 cm were independent predictors of poor survival.  These data indicate that FAK is overexpressed in most invasive ovarian cancers and plays a functionally significant role in ovarian cancer migration and invasion.  Thus, FAK may be an important therapeutic target in ovarian carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohH5AA1GLo_LVg90H21EOLACvtfcHk0lgTLbrYRSaKgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptFSmtrw%253D&md5=2809d3d73de06418f39b5616f0ae2e02</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2963370-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252963370-6%26sid%3Dliteratum%253Aachs%26aulast%3DSood%26aufirst%3DA.%2BK.%26aulast%3DCoffin%26aufirst%3DJ.%2BE.%26aulast%3DSchneider%26aufirst%3DG.%2BB.%26aulast%3DFletcher%26aufirst%3DM.%2BS.%26aulast%3DDeYoung%26aufirst%3DB.%2BR.%26aulast%3DGruman%26aufirst%3DL.%2BM.%26aulast%3DGershenson%26aufirst%3DD.%2BM.%26aulast%3DSchaller%26aufirst%3DM.%2BD.%26aulast%3DHendrix%26aufirst%3DM.%2BJ.%26atitle%3DBiological%2520significance%2520of%2520focal%2520adhesion%2520kinase%2520in%2520ovarian%2520cancer%253A%2520role%2520in%2520migration%2520and%2520invasion%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2004%26volume%3D165%26spage%3D1087%26epage%3D1095%26doi%3D10.1016%2FS0002-9440%2810%2963370-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beierle, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massoll, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartwich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurenova, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golubovskaya, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cance, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrady, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">London, W. B.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase expression in human neuroblastoma: immunohistochemical and real-time PCR analyses</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">3299</span>â <span class="NLM_lpage">3305</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-07-1511</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1158%2F1078-0432.CCR-07-1511" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=18519756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmslygs7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=3299-3305&author=E.+A.+Beierleauthor=N.+A.+Massollauthor=J.+Hartwichauthor=E.+V.+Kurenovaauthor=V.+M.+Golubovskayaauthor=W.+G.+Canceauthor=P.+McGradyauthor=W.+B.+London&title=Focal+adhesion+kinase+expression+in+human+neuroblastoma%3A+immunohistochemical+and+real-time+PCR+analyses&doi=10.1158%2F1078-0432.CCR-07-1511"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Focal Adhesion Kinase Expression in Human Neuroblastoma: Immunohistochemical and Real-time PCR Analyses</span></div><div class="casAuthors">Beierle, Elizabeth A.; Massoll, Nicole A.; Hartwich, Joseph; Kurenova, Elena V.; Golubovskaya, Vita M.; Cance, William G.; McGrady, Patrick; London, Wendy B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3299-3305</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The focal adhesion kinase (FAK) is a nonreceptor protein tyrosine kinase important in signaling between cells and their extracellular matrix.  Studies have shown that FAK expression is up-regulated in several human tumors and is related to tumor progression.  We recently found an increase in p125FAK expression in human neuroblastoma cells lines and wished to det. its expression in human neuroblastoma specimens and evaluate for a possible correlation between p125FAK expression and known prognostic factors for neuroblastoma.  We hypothesized that p125FAK expression would be up-regulated in advanced human neuroblastomas.  Using immunohistochem. techniques with monoclonal antibody 4.47 specific for p125FAK expression, we analyzed 70 formalin-fixed, paraffin-embedded human neuroblastoma specimens for p125FAK staining.  In addn., real-time PCR was used to det. the abundance of FAK mRNA in 17 matched human neuroblastoma mRNA specimens.  FAK staining was present in 51 of the 70 tumor specimens (73%).  Immunohistochem. staining of p125FAK in the ganglion-type tumor cells correlated with advanced International Neuroblastoma Staging System tumor stages and FAK mRNA abundance.  In addn., p125FAK staining was significantly increased in stage IV tumors with amplification of the N-MYC oncogene.  These novel findings provide evidence that FAK is expressed by advanced-stage neuroblastoma and provide a rationale for targeting FAK in the treatment of this tumor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ05dypioR1bVg90H21EOLACvtfcHk0lgTLbrYRSaKgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmslygs7c%253D&md5=214b9cf6ca82f325422ba519958fad95</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-1511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-1511%26sid%3Dliteratum%253Aachs%26aulast%3DBeierle%26aufirst%3DE.%2BA.%26aulast%3DMassoll%26aufirst%3DN.%2BA.%26aulast%3DHartwich%26aufirst%3DJ.%26aulast%3DKurenova%26aufirst%3DE.%2BV.%26aulast%3DGolubovskaya%26aufirst%3DV.%2BM.%26aulast%3DCance%26aufirst%3DW.%2BG.%26aulast%3DMcGrady%26aufirst%3DP.%26aulast%3DLondon%26aufirst%3DW.%2BB.%26atitle%3DFocal%2520adhesion%2520kinase%2520expression%2520in%2520human%2520neuroblastoma%253A%2520immunohistochemical%2520and%2520real-time%2520PCR%2520analyses%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D3299%26epage%3D3305%26doi%3D10.1158%2F1078-0432.CCR-07-1511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furuyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyoda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koizumi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kida, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, K.</span></span> <span> </span><span class="NLM_article-title">Clinical significance of focal adhesion kinase in resectable pancreatic cancer</span>. <i>World J. Surg.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">219</span>â <span class="NLM_lpage">226</span>, <span class="refDoi">Â DOI: 10.1007/s00268-005-0165-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1007%2Fs00268-005-0165-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=16425085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BD28%252FltFOhsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2006&pages=219-226&author=K.+Furuyamaauthor=R.+Doiauthor=T.+Moriauthor=E.+Toyodaauthor=D.+Itoauthor=K.+Kamiauthor=M.+Koizumiauthor=A.+Kidaauthor=Y.+Kawaguchiauthor=K.+Fujimoto&title=Clinical+significance+of+focal+adhesion+kinase+in+resectable+pancreatic+cancer&doi=10.1007%2Fs00268-005-0165-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical significance of focal adhesion kinase in resectable pancreatic cancer</span></div><div class="casAuthors">Furuyama Kenichiro; Doi Ryuichiro; Mori Tomohiko; Toyoda Eiji; Ito Daisuke; Kami Kazuhiro; Koizumi Masayuki; Kida Atsushi; Kawaguchi Yoshiya; Fujimoto Koji</div><div class="citationInfo"><span class="NLM_cas:title">World journal of surgery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">219-26</span>
        ISSN:<span class="NLM_cas:issn">0364-2313</span>.
    </div><div class="casAbstract">Focal adhesion kinase (FAK) is a non-receptor, cytoplasmic protein tyrosine kinase that is involved in the regulation of cellular signaling, migration, apoptosis, and cell cycle progression.  Previous reports have shown that FAK is expressed in various kinds of cancer tissues and cancer cell lines; however, no information is available about human pancreatic carcinoma specimens.  Tissue such specimens were obtained from 50 patients who underwent pancreatic resection for pancreatic invasive ductal carcinoma at our institute from 1996 to 2002.  Immunohistochemical analysis of FAK was performed in the resected specimens.  Focal adhesion kinase expression in seven human pancreatic cancer cell lines was analyzed by reverse transcription polymerase chain reaction (PCR) analysis and Western blot analysis.  Focal adhesion kinase expression was detected in 24 of 50 cases (48%).  There was a statistically significant correlation between FAK expression and tumor size (P=0.004), although FAK expression did not significantly correlate with other factors such as tumor histological grade, lymph node metastasis, distant metastasis, histological stage, and overall survival.  Reverse transcription PCR analysis and Western blot analysis showed that FAK was expressed in all seven pancreatic cancer cell lines.  Focal adhesion kinase expression was not directly related to clinicopathological factors except tumor size in pancreatic carcinoma.  Focal adhesion kinase expression may not be a prognostic marker for pancreatic cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTIG5v5mnIkWbt7lRqEFUJVfW6udTcc2ebpmGgSKznQxbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28%252FltFOhsQ%253D%253D&md5=efab3182eaa09482332afb178f1aaa8b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs00268-005-0165-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00268-005-0165-z%26sid%3Dliteratum%253Aachs%26aulast%3DFuruyama%26aufirst%3DK.%26aulast%3DDoi%26aufirst%3DR.%26aulast%3DMori%26aufirst%3DT.%26aulast%3DToyoda%26aufirst%3DE.%26aulast%3DIto%26aufirst%3DD.%26aulast%3DKami%26aufirst%3DK.%26aulast%3DKoizumi%26aufirst%3DM.%26aulast%3DKida%26aufirst%3DA.%26aulast%3DKawaguchi%26aufirst%3DY.%26aulast%3DFujimoto%26aufirst%3DK.%26atitle%3DClinical%2520significance%2520of%2520focal%2520adhesion%2520kinase%2520in%2520resectable%2520pancreatic%2520cancer%26jtitle%3DWorld%2520J.%2520Surg.%26date%3D2006%26volume%3D30%26spage%3D219%26epage%3D226%26doi%3D10.1007%2Fs00268-005-0165-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Nimwegen, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkoeijen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Buren, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Water, B. V.</span></span> <span> </span><span class="NLM_article-title">Requirement for focal adhesion kinase in the early phase of mammary adenocarcinoma lung metastasis formation</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">4698</span>â <span class="NLM_lpage">4706</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-04-4126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1158%2F0008-5472.CAN-04-4126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=15930288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Ohtbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=4698-4706&author=M.+J.+van%0ANimwegenauthor=S.+Verkoeijenauthor=L.+van+Burenauthor=D.+Burgauthor=B.+V.+de+Water&title=Requirement+for+focal+adhesion+kinase+in+the+early+phase+of+mammary+adenocarcinoma+lung+metastasis+formation&doi=10.1158%2F0008-5472.CAN-04-4126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement for Focal Adhesion Kinase in the Early Phase of Mammary Adenocarcinoma Lung Metastasis Formation</span></div><div class="casAuthors">van Nimwegen, Maroesja J.; Verkoeijen, Saertje; Van Buren, Liesbeth; Burg, Danny; Van de Water, Bob</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4698-4706</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">An increased expression of focal adhesion kinase (FAK) in a variety of cancers is assocd. with a poor disease prognosis.  To study the role of FAK in breast tumor growth and metastasis formation, we used conditional doxycycline-regulated expression of a dominant-neg. acting splice variant of FAK, FAK-related non-kinase (FRNK), in MTLn3 mammary adenocarcinoma cells in a syngeneic Fischer 344 rat tumor and metastasis model.  In cell culture, doxycycline-mediated expression of FRNK inhibited MTLn3 cell spreading and migration in assocn. with reduced formation of focal adhesions and phosphorylation of FAK on Tyr397, but FRNK did not cause apoptosis.  Continuous expression of FRNK decreased the primary tumor growth in the mammary fat pad by 60%, which was not due to induction of apoptosis.  Lung metastasis formation was almost completely prevented when FRNK was already expressed 1 day before tumor cell injection, whereas expression of FRNK 11 days after injection did not affect lung metastasis formation.  FRNK expression during the first 5 days was sufficient to block metastasis formation, excluding the possibility of FRNK-induced dormancy of tumor cells.  Together, these data fit with a model wherein FAK is required for breast tumor cell invasion/migration processes that take place in the early phase of metastasis formation.  Our findings suggest that FAK is a good candidate for therapeutic intervention of metastasis formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrn9ojTuaPzrVg90H21EOLACvtfcHk0lg8ZHPTEfAsbg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Ohtbo%253D&md5=3936071404b3179fff382bf9b685ed64</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-4126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-4126%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BNimwegen%26aufirst%3DM.%2BJ.%26aulast%3DVerkoeijen%26aufirst%3DS.%26aulast%3Dvan%2BBuren%26aufirst%3DL.%26aulast%3DBurg%26aufirst%3DD.%26aulast%3Dde%2BWater%26aufirst%3DB.%2BV.%26atitle%3DRequirement%2520for%2520focal%2520adhesion%2520kinase%2520in%2520the%2520early%2520phase%2520of%2520mammary%2520adenocarcinoma%2520lung%2520metastasis%2520formation%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D4698%26epage%3D4706%26doi%3D10.1158%2F0008-5472.CAN-04-4126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Golubovskaya, V. M.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase as a cancer therapy target</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">735</span>â <span class="NLM_lpage">741</span>, <span class="refDoi">Â DOI: 10.2174/187152010794728648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.2174%2F187152010794728648" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=21214510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslagt7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=735-741&author=V.+M.+Golubovskaya&title=Focal+adhesion+kinase+as+a+cancer+therapy+target&doi=10.2174%2F187152010794728648"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion kinase as a cancer therapy target</span></div><div class="casAuthors">Golubovskaya, Vita M.</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">735-741</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that resides at the sites of at focal adhesions.  The 125 kDa FAK protein is encoded by the FAK gene located on human chromosome 8q24.  Structurally, FAK consists of an amino-terminal regulatory FERM domain, a central catalytic kinase domain, and a carboxy-terminal focal adhesion targeting domain.  FAK has been shown to be an important mediator of cell adhesion, growth, proliferation, survival, angiogenesis and migration, all of which are often disrupted in cancer cells.  Normal tissues have low expression of FAK, while primary and metastatic tumors significantly overexpress this protein.  This review summarizes expression of FAK by immunohistochem. staining in different tumor types and presents several FAK inhibition therapy approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojPHf4gDk2PbVg90H21EOLACvtfcHk0lg8ZHPTEfAsbg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslagt7o%253D&md5=0fdbd318a7e404803a18feff4c7773d4</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.2174%2F187152010794728648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152010794728648%26sid%3Dliteratum%253Aachs%26aulast%3DGolubovskaya%26aufirst%3DV.%2BM.%26atitle%3DFocal%2520adhesion%2520kinase%2520as%2520a%2520cancer%2520therapy%2520target%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2010%26volume%3D10%26spage%3D735%26epage%3D741%26doi%3D10.2174%2F187152010794728648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navajas, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lietha, D.</span></span> <span> </span><span class="NLM_article-title">FAK structure and regulation by membrane interactions and force in focal adhesions</span>. <i>Biomolecules</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">179</span>â <span class="NLM_lpage">194</span>, <span class="refDoi">Â DOI: 10.3390/biom10020179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.3390%2Fbiom10020179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjslCju7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=179-194&author=P.+T.+Martinezauthor=P.+L.+Navajasauthor=D.+Lietha&title=FAK+structure+and+regulation+by+membrane+interactions+and+force+in+focal+adhesions&doi=10.3390%2Fbiom10020179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">FAK structure and regulation by membrane interactions and force in focal adhesions</span></div><div class="casAuthors">Martinez, Paula Tapial; Navajas, Pilar Lopez; Lietha, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecules</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179</span>CODEN:
                <span class="NLM_cas:coden">BIOMHC</span>;
        ISSN:<span class="NLM_cas:issn">2218-273X</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase with key roles in the regulation of cell adhesion migration, proliferation and survival.  In cancer FAK is a major driver of invasion and metastasis and its upregulation is assocd. with poor patient prognosis.  FAK is autoinhibited in the cytosol, but activated upon localisation into a protein complex, known as focal adhesion complex.  This complex forms upon cell adhesion to the extracellular matrix (ECM) at the cytoplasmic side of the plasma membrane at sites of ECM attachment.  FAK is anchored to the complex via multiple sites, including direct interactions with specific membrane lipids and connector proteins that attach focal adhesions to the actin cytoskeleton.  In migrating cells, the contraction of actomyosin stress fibers attached to the focal adhesion complex apply a force to the complex, which is likely transmitted to the FAK protein, causing stretching of the FAK mol.  In this review we discuss the current knowledge of the FAK structure and how specific structural features are involved in the regulation of FAK signalling.  We focus on two major regulatory mechanisms known to contribute to FAK activation, namely interactions with membrane lipids and stretching forces applied to FAK, and discuss how they might induce structural changes that facilitate FAK activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC2hY9ihLIibVg90H21EOLACvtfcHk0li32AYtpCcr2Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjslCju7g%253D&md5=26ce7c20467ed267058d4df2ebffebfb</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.3390%2Fbiom10020179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fbiom10020179%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez%26aufirst%3DP.%2BT.%26aulast%3DNavajas%26aufirst%3DP.%2BL.%26aulast%3DLietha%26aufirst%3DD.%26atitle%3DFAK%2520structure%2520and%2520regulation%2520by%2520membrane%2520interactions%2520and%2520force%2520in%2520focal%2520adhesions%26jtitle%3DBiomolecules%26date%3D2020%26volume%3D10%26spage%3D179%26epage%3D194%26doi%3D10.3390%2Fbiom10020179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mousson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dujardin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Mey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronde, P.</span></span> <span> </span><span class="NLM_article-title">Targeting focal adhesion kinase using inhibitors of protein-protein interactions</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">278</span>â <span class="NLM_lpage">306</span>, <span class="refDoi">Â DOI: 10.3390/cancers10090278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.3390%2Fcancers10090278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVyhtrbP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=278-306&author=A.+Moussonauthor=E.+Sickauthor=P.+Carlauthor=D.+Dujardinauthor=J.+De+Meyauthor=P.+Ronde&title=Targeting+focal+adhesion+kinase+using+inhibitors+of+protein-protein+interactions&doi=10.3390%2Fcancers10090278"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting focal adhesion kinase using inhibitors of protein-protein interactions</span></div><div class="casAuthors">Mousson, Antoine; Sick, Emilie; Carl, Philippe; Dujardin, Denis; De Mey, Jan; Ronde, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">278/1-278/29</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Focal adhesion kinase (FAK) is a cytoplasmic non-receptor protein tyrosine kinase that is overexpressed and activated in many human cancers.  FAK transmits signals to a wide range of targets through both kinase-dependant and independent mechanism thereby playing essential roles in cell survival, proliferation, migration and invasion.  In the past years, small mols. that inhibit FAK kinase function have been developed and show reduced cancer progression and metastasis in several preclin. models.  Clin. trials have been conducted and these mols. display limited adverse effect in patients.  FAK contain multiple functional domains and thus exhibit both important scaffolding functions.  In this review, we describe the major FAK interactions relevant in cancer signalling and discuss how such knowledge provide rational for the development of Protein-Protein Interactions (PPI) inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-KUqDj7cnnbVg90H21EOLACvtfcHk0li32AYtpCcr2Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVyhtrbP&md5=4fbde422a29c412a95cbda787b11ee68</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.3390%2Fcancers10090278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers10090278%26sid%3Dliteratum%253Aachs%26aulast%3DMousson%26aufirst%3DA.%26aulast%3DSick%26aufirst%3DE.%26aulast%3DCarl%26aufirst%3DP.%26aulast%3DDujardin%26aufirst%3DD.%26aulast%3DDe%2BMey%26aufirst%3DJ.%26aulast%3DRonde%26aufirst%3DP.%26atitle%3DTargeting%2520focal%2520adhesion%2520kinase%2520using%2520inhibitors%2520of%2520protein-protein%2520interactions%26jtitle%3DCancers%26date%3D2018%26volume%3D10%26spage%3D278%26epage%3D306%26doi%3D10.3390%2Fcancers10090278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dontenwill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoeckel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronde, P.</span></span> <span> </span><span class="NLM_article-title">Regulation of focal adhesion dynamics and disassembly by phosphorylation of FAK at tyrosine 397</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">4415</span>â <span class="NLM_lpage">4425</span>, <span class="refDoi">Â DOI: 10.1242/jcs.02565</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1242%2Fjcs.02565" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=16159962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Wnur3K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2005&pages=4415-4425&author=A.+Hamadiauthor=M.+Boualiauthor=M.+Dontenwillauthor=H.+Stoeckelauthor=K.+Takedaauthor=P.+Ronde&title=Regulation+of+focal+adhesion+dynamics+and+disassembly+by+phosphorylation+of+FAK+at+tyrosine+397&doi=10.1242%2Fjcs.02565"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of focal adhesion dynamics and disassembly by phosphorylation of FAK at tyrosine 397</span></div><div class="casAuthors">Hamadi, Abdelkader; Bouali, Maya; Dontenwill, Monique; Stoeckel, Herrade; Takeda, Kenneth; Ronde, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4415-4425</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">One of the major tyrosine phosphorylation activities linked to integrin signaling is that of focal adhesion kinase (FAK).  High amts. of FAK are located at specialized subcellular compartments known as focal adhesions.  FAK tyrosine phosphorylation at focal adhesions is increased by various stimuli including integrin engagement during migration processes, growth factors and oncogene transformation.  Phosphorylation of FAK at various tyrosine residues regulates focal adhesion turnover by mechanisms that are not well understood.  We made a fluorescent FAK mutant (Y397F-FAK/YCam) to analyze, in living cells, how phosphorylation of FAK regulates the turnover of focal adhesions.  We found that expression of Y397F-FAK/YCam in human astrocytoma cells decreases the level of phosphorylation of FAK at endogenous Tyr-397 residues and at both endogenous and exogenous Tyr-576 residues, in the putative activation loop of the kinase.  This corresponds to a decrease in phosphorylation of FAK at focal adhesions in Y397F-FAK/YCam cells, since the cellular localization of FAK phosphoTyr-576 in cells expressing Y397F-FAK/YCam or FAK/YCam was not different.  Furthermore, FRAP anal. showed that phosphorylation of FAK at Tyr-397 increases specifically the time-residency of FAK at focal adhesions but not in cytosol.  This in turn induces disassembly of focal adhesions at the cell tail and promotes cell motility as shown by the decrease in microtubule-mediated turnover of Y397F-FAK/YCam-contg. focal adhesions.  Our data show that phosphorylation of FAK at Tyr-397 is a key determinant of how FAK controls focal adhesion turnover.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd9I1y9b-DyLVg90H21EOLACvtfcHk0li32AYtpCcr2Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Wnur3K&md5=8d8d473b1137ee5af167fc54ff1194c2</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1242%2Fjcs.02565&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.02565%26sid%3Dliteratum%253Aachs%26aulast%3DHamadi%26aufirst%3DA.%26aulast%3DBouali%26aufirst%3DM.%26aulast%3DDontenwill%26aufirst%3DM.%26aulast%3DStoeckel%26aufirst%3DH.%26aulast%3DTakeda%26aufirst%3DK.%26aulast%3DRonde%26aufirst%3DP.%26atitle%3DRegulation%2520of%2520focal%2520adhesion%2520dynamics%2520and%2520disassembly%2520by%2520phosphorylation%2520of%2520FAK%2520at%2520tyrosine%2520397%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2005%26volume%3D118%26spage%3D4415%26epage%3D4425%26doi%3D10.1242%2Fjcs.02565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dunty, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabarra-Niecko, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceccarelli, D. F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaller, M. D.</span></span> <span> </span><span class="NLM_article-title">FERM domain interaction promotes FAK signaling</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">5353</span>â <span class="NLM_lpage">5368</span>, <span class="refDoi">Â DOI: 10.1128/MCB.24.12.5353-5368.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1128%2FMCB.24.12.5353-5368.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=15169899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkvFOqtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=5353-5368&author=J.+M.+Duntyauthor=V.+Gabarra-Nieckoauthor=M.+L.+Kingauthor=D.+F.+J.+Ceccarelliauthor=M.+J.+Eckauthor=M.+D.+Schaller&title=FERM+domain+interaction+promotes+FAK+signaling&doi=10.1128%2FMCB.24.12.5353-5368.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">FERM domain interaction promotes FAK signaling</span></div><div class="casAuthors">Dunty, Jill M.; Gabarra-Niecko, Veronica; King, Michelle L.; Ceccarelli, Derek F. J.; Eck, Michael J.; Schaller, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5353-5368</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">From the results of deletion analyses, the FERM domain of FAK has been proposed to inhibit enzymic activity and repress FAK signaling.  We have identified a sequence in the FERM domain that is important for FAK signaling in vivo.  Point mutations in this sequence had little effect upon catalytic activity in vitro.  However, the mutant exhibits reduced tyrosine phosphorylation and dramatically reduced Src family kinase binding.  Further, the abilities of the mutant to transduce biochem. signals and to promote cell migration were severely impaired.  The results implicate a FERM domain interaction in cell adhesion-dependent activation of FAK and downstream signaling.  We also show that the purified FERM domain of FAK interacts with full-length FAK in vitro, and mutation of this sequence disrupts the interaction.  These findings are discussed in the context of models of FAK regulation by its FERM domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgEt5IZQluLLVg90H21EOLACvtfcHk0li8FqVrnzNKig"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkvFOqtL4%253D&md5=95bac015a863e4d8fe394559b399c822</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1128%2FMCB.24.12.5353-5368.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.24.12.5353-5368.2004%26sid%3Dliteratum%253Aachs%26aulast%3DDunty%26aufirst%3DJ.%2BM.%26aulast%3DGabarra-Niecko%26aufirst%3DV.%26aulast%3DKing%26aufirst%3DM.%2BL.%26aulast%3DCeccarelli%26aufirst%3DD.%2BF.%2BJ.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSchaller%26aufirst%3DM.%2BD.%26atitle%3DFERM%2520domain%2520interaction%2520promotes%2520FAK%2520signaling%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2004%26volume%3D24%26spage%3D5353%26epage%3D5368%26doi%3D10.1128%2FMCB.24.12.5353-5368.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehart, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. S.</span></span> <span> </span><span class="NLM_article-title">Understanding the roles of FAK in cancer: inhibitors, genetic models, and new insights</span>. <i>J. Histochem. Cytochem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">114</span>â <span class="NLM_lpage">128</span>, <span class="refDoi">Â DOI: 10.1369/0022155414561498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1369%2F0022155414561498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=25380750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2MXislWrtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2015&pages=114-128&author=H.+Yoonauthor=J.+P.+Dehartauthor=J.+M.+Murphyauthor=S.+S.+Lim&title=Understanding+the+roles+of+FAK+in+cancer%3A+inhibitors%2C+genetic+models%2C+and+new+insights&doi=10.1369%2F0022155414561498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding the roles of FAK in cancer: inhibitors, genetic models, and new insights</span></div><div class="casAuthors">Yoon, Hyunho; Dehart, Joshua P.; Murphy, James M.; Lim, Ssang-Taek Steve</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Histochemistry and Cytochemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">114-128/1-114-128/15, 15 pp.</span>CODEN:
                <span class="NLM_cas:coden">JHCYAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-1554</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Focal adhesion kinase (FAK) is a protein tyrosine kinase that regulates cellular adhesion, motility, proliferation and survival in various types of cells.  Interestingly, FAK is activated and/or overexpressed in advanced cancers, and promotes cancer progression and metastasis.  For this reason, FAK became a potential therapeutic target in cancer, and small mol. FAK inhibitors have been developed and are being tested in clin. phase trials.  These inhibitors have demonstrated to be effective by inducing tumor cell apoptosis in addn. to reducing metastasis and angiogenesis.  Furthermore, several genetic FAK mouse models have made advancements in understanding the specific role of FAK both in tumors and in the tumor environment.  In this review, we discuss FAK inhibitors as well as genetic mouse models to provide mechanistic insights into FAK signaling and its potential in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro8FZcK4GQb7Vg90H21EOLACvtfcHk0li8FqVrnzNKig"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXislWrtb8%253D&md5=64ffaaef86e9fc737ba3bd825a64dd02</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1369%2F0022155414561498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1369%252F0022155414561498%26sid%3Dliteratum%253Aachs%26aulast%3DYoon%26aufirst%3DH.%26aulast%3DDehart%26aufirst%3DJ.%2BP.%26aulast%3DMurphy%26aufirst%3DJ.%2BM.%26aulast%3DLim%26aufirst%3DS.%2BS.%26atitle%3DUnderstanding%2520the%2520roles%2520of%2520FAK%2520in%2520cancer%253A%2520inhibitors%252C%2520genetic%2520models%252C%2520and%2520new%2520insights%26jtitle%3DJ.%2520Histochem.%2520Cytochem.%26date%3D2015%26volume%3D63%26spage%3D114%26epage%3D128%26doi%3D10.1369%2F0022155414561498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Golubovskaya, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kweh, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massoll, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell
Thompson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cance, W. G.</span></span> <span> </span><span class="NLM_article-title">P53 regulates FAK expression in human tumor cells</span>. <i>Mol. Carcinog.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">373</span>â <span class="NLM_lpage">382</span>, <span class="refDoi">Â DOI: 10.1002/mc.20395</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1002%2Fmc.20395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=17999388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1cXls1ajsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=373-382&author=V.+M.+Golubovskayaauthor=R.+Finchauthor=F.+Kwehauthor=N.+A.+Massollauthor=M.+Campbell%0AThompsonauthor=M.+R.+Wallaceauthor=W.+G.+Cance&title=P53+regulates+FAK+expression+in+human+tumor+cells&doi=10.1002%2Fmc.20395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">p53 regulates FAK expression in human tumor cells</span></div><div class="casAuthors">Golubovskaya, Vita M.; Finch, Richard; Kweh, Frederick; Massoll, Nicole A.; Campbell-Thompson, Martha; Wallace, Margaret R.; Cance, William G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Carcinogenesis</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">373-382</span>CODEN:
                <span class="NLM_cas:coden">MOCAE8</span>;
        ISSN:<span class="NLM_cas:issn">0899-1987</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Attenuation of the p53 protein is one of the most common abnormalities in human tumors.  Another important marker of tumorigenesis is focal adhesion kinase (FAK), a 125-kDa tyrosine kinase that is overexpressed at the mRNA and protein levels in a variety of human tumors.  FAK is a crit. regulator of adhesion, motility, metastasis, and survival signaling.  We have characterized the FAK promoter and demonstrated that p53 can inhibit the FAK promoter activity in vitro.  In the present study, we showed that p53 can bind the FAK promoter-chromatin region in vivo by chromatin immunopptn. (ChIP) assay.  Furthermore, we demonstrated down-regulation of FAK mRNA and protein levels by adenoviral overexpression of p53.  We introduced plasmids with different mutations in the DNA-binding domain of p53 (R175H, p53 R248W and R273H) into HCT p53-/- cells and showed that these mutations of p53 did not bind FAK promoter and did not inhibit FAK promoter activity, unlike wild type p53.  We analyzed primary breast and colon cancers for p53 mutations and FAK expression, and showed that FAK expression was increased in tumors contg. mutations of p53 compared to tumors with wild type p53.  In addn., tumor-derived missense mutations in the DNA-binding domain (R282, R249, and V173) also led to increased FAK promoter activity.  Thus, the present data show that p53 can regulate FAK expression during tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDfe6O9z8h8bVg90H21EOLACvtfcHk0li8FqVrnzNKig"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXls1ajsbs%253D&md5=3e5110d3f2ea61af0c3e27f0cad77532</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fmc.20395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmc.20395%26sid%3Dliteratum%253Aachs%26aulast%3DGolubovskaya%26aufirst%3DV.%2BM.%26aulast%3DFinch%26aufirst%3DR.%26aulast%3DKweh%26aufirst%3DF.%26aulast%3DMassoll%26aufirst%3DN.%2BA.%26aulast%3DCampbell%2BThompson%26aufirst%3DM.%26aulast%3DWallace%26aufirst%3DM.%2BR.%26aulast%3DCance%26aufirst%3DW.%2BG.%26atitle%3DP53%2520regulates%2520FAK%2520expression%2520in%2520human%2520tumor%2520cells%26jtitle%3DMol.%2520Carcinog.%26date%3D2008%26volume%3D47%26spage%3D373%26epage%3D382%26doi%3D10.1002%2Fmc.20395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ossovskaya, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ota, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlaepfer, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilic, D.</span></span> <span> </span><span class="NLM_article-title">FAK nuclear export signal sequences</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>582</i></span>,  <span class="NLM_fpage">2402</span>â <span class="NLM_lpage">2406</span>, <span class="refDoi">Â DOI: 10.1016/j.febslet.2008.06.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.febslet.2008.06.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=18549812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvVKnsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=582&publication_year=2008&pages=2402-2406&author=V.+Ossovskayaauthor=S.+Limauthor=N.+Otaauthor=D.+D.+Schlaepferauthor=D.+Ilic&title=FAK+nuclear+export+signal+sequences&doi=10.1016%2Fj.febslet.2008.06.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">FAK nuclear export signal sequences</span></div><div class="casAuthors">Ossovskaya, Valeria; Lim, Ssang-Taek; Ota, Nobuyuki; Schlaepfer, David D.; Ilic, Dusko</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">582</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2402-2406</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Ubiquitously expressed focal adhesion kinase (FAK), a crit. component in transducing signals from sites of cell contacts with extracellular matrix, was named after its typical localization in focal adhesions.  A nuclear localization of FAK has been also reported and its scaffolding role in nucleus and requirement for p53 ubiquitination were only recently described.  Whereas FAK nuclear localization signal (NLS) was found in F2 lobe of FERM domain, nuclear export signal (NES) sequences have not been yet detd.  Here we demonstrate that FAK has two NES sequences, NES1 in F1 lobe of FERM domain and NES2 in kinase domain.  Although, both NES1 and NES2 are evolutionary conserved, and present as well in FAK-related protein kinase Pyk2, only NES2 demonstrates full biol. nuclear export activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5QBtb9Ydw-LVg90H21EOLACvtfcHk0liCJcgr1TXRFg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvVKnsrY%253D&md5=0153bf6d951f3c786dd89f671525b49d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.febslet.2008.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.febslet.2008.06.004%26sid%3Dliteratum%253Aachs%26aulast%3DOssovskaya%26aufirst%3DV.%26aulast%3DLim%26aufirst%3DS.%26aulast%3DOta%26aufirst%3DN.%26aulast%3DSchlaepfer%26aufirst%3DD.%2BD.%26aulast%3DIlic%26aufirst%3DD.%26atitle%3DFAK%2520nuclear%2520export%2520signal%2520sequences%26jtitle%3DFEBS%2520Lett.%26date%3D2008%26volume%3D582%26spage%3D2402%26epage%3D2406%26doi%3D10.1016%2Fj.febslet.2008.06.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eilers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span> <span> </span><span class="NLM_article-title">Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">1253</span>â <span class="NLM_lpage">1263</span>, <span class="refDoi">Â DOI: 10.1038/bjc.2016.331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fbjc.2016.331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=27736841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yqs73O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2016&pages=1253-1263&author=W.+Ouauthor=M.+Luauthor=G.+Eilersauthor=H.+Liauthor=J.+Dingauthor=X.+Mengauthor=Y.+Wuauthor=Q.+Heauthor=Q.+Shengauthor=H.+M.+Zhouauthor=J.+A.+Fletcher&title=Co-targeting+of+FAK+and+MDM2+triggers+additive+anti-proliferative+effects+in+mesothelioma+via+a+coordinated+reactivation+of+p53&doi=10.1038%2Fbjc.2016.331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53</span></div><div class="casAuthors">Ou, Wen-Bin; Lu, Minmin; Eilers, Grant; Li, Hailong; Ding, Jiongyan; Meng, Xuli; Wu, Yuehong; He, Quan; Sheng, Qing; Zhou, Hai-Meng; Fletcher, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1253-1263</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Improved mesothelioma patient survival will require development of novel and more effective pharmacol. interventions.  TP53 genomic mutations are uncommon in mesothelioma, and recent data indicate that p53 remains functional, and therefore is a potential therapeutic target in these cancers.  In addn., the tumor suppressor NF2 is inactivated by genomic mechanisms in more than 80% of mesothelioma, causing upregulation of FAK activity.  Because FAK is a neg. regulator of p53, NF2 regulation of FAK-p53-MDM2 signalling loops were evaluated.  Methods: Interactions of FAK-p53 or NF2-FAK were evaluated by phosphotyrosine-p53 immunoaffinity purifn. and tandem mass spectrometry, and p53, FAK, and NF2 immunopptns.  Activation and/or expression of FAK, p53, and NF2 were also evaluated in mesotheliomas.  Effects of combination MDM2 and FAK inhibitors/shRNAs were assessed by measuring mesothelioma cell viability/growth, expression of cell cycle checkpoints, and cell cycle alterations.  Results: We obsd. constitutive activation of FAK, a known neg. regulator of p53, in each of 10 mesothelioma cell lines and each of nine mesothelioma surgical specimens, and FAK was assocd. with p53 in five of five mesothelioma cell lines.  In four mesotheliomas with wild-type p53, FAK silencing by RNAi induced expression and phosphorylation of p53.  However, FAK regulation of mesothelioma proliferation was not restricted to p53-dependent pathways, as demonstrated by immunoblots after FAK knockdown in JMN1B mesothelioma cells, which have mutant/inactivated p53, compared with four mesothelioma cell lines with nonmutant p53.  Additive effects were obtained through a coordinated reactivation of p53, by FAK knockdown/inhibition and MDM2 inhibition, as demonstrated by immunoblots, cell viability, and cell-cycle analyses, showing increased p53 expression, apoptosis, anti-proliferative effects, and cell-cycle arrest, as compared with either intervention alone.  Our results also indicate that NF2 regulates the interaction of FAK-p53 and MDM2-p53.  Conclusions: These findings highlight novel therapeutic opportunities in mesothelioma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreeIWtKftmtLVg90H21EOLACvtfcHk0liCJcgr1TXRFg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yqs73O&md5=6cfbd37273fd2bf42dfb7d4fc93bdc96</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2016.331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2016.331%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DEilers%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DQ.%26aulast%3DSheng%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DH.%2BM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DCo-targeting%2520of%2520FAK%2520and%2520MDM2%2520triggers%2520additive%2520anti-proliferative%2520effects%2520in%2520mesothelioma%2520via%2520a%2520coordinated%2520reactivation%2520of%2520p53%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2016%26volume%3D115%26spage%3D1253%26epage%3D1263%26doi%3D10.1038%2Fbjc.2016.331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard-Trifilo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uryu, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canete-Soler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlaepfer, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nalbant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bokoch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterman-Storer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlaepfer, D. D.</span></span> <span> </span><span class="NLM_article-title">PyK2 and FAK connections to p190Rho guanine nucleotide exchange factor regulate RhoA activity, focal adhesion formation, and cell motility</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">187</span>â <span class="NLM_lpage">203</span>, <span class="refDoi">Â DOI: 10.1083/jcb.200708194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1083%2Fjcb.200708194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=18195107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsFyltQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2008&pages=187-203&author=Y.+Limauthor=S.+T.+Limauthor=A.+Tomarauthor=M.+Gardelauthor=J.+A.+Bernard-Trifiloauthor=X.+L.+Chenauthor=S.+A.+Uryuauthor=R.+Canete-Solerauthor=J.+Zhaiauthor=H.+Linauthor=W.+W.+Schlaepferauthor=P.+Nalbantauthor=G.+Bokochauthor=D.+Ilicauthor=C.+Waterman-Storerauthor=D.+D.+Schlaepfer&title=PyK2+and+FAK+connections+to+p190Rho+guanine+nucleotide+exchange+factor+regulate+RhoA+activity%2C+focal+adhesion+formation%2C+and+cell+motility&doi=10.1083%2Fjcb.200708194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">PyK2 and FAK connections to p190Rho guanine nucleotide exchange factor regulate RhoA activity, focal adhesion formation, and cell motility</span></div><div class="casAuthors">Lim, Yangmi; Lim, Ssang-Taek; Tomar, Alok; Gardel, Margaret; Bernard-Trifilo, Joie A.; Chen, Xiao Lei; Uryu, Sean A.; Canete-Soler, Rafaela; Zhai, Jinbin; Lin, Hong; Schlaepfer, William W.; Nalbant, Perihan; Bokoch, Gary; Ilic, Dusko; Waterman-Storer, Clare; Schlaepfer, David D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">187-203</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Integrin binding to matrix proteins such as fibronectin (FN) leads to formation of focal adhesion (FA) cellular contact sites that regulate migration.  RhoA GTPases facilitate FA formation, yet FA-assocd. RhoA-specific guanine nucleotide exchange factors (GEFs) remain unknown.  Here, we show that proline-rich kinase-2 (Pyk2) levels increase upon loss of focal adhesion kinase (FAK) in mouse embryonic fibroblasts (MEFs).  Addnl., we demonstrate that Pyk2 facilitates deregulated RhoA activation, elevated FA formation, and enhanced cell proliferation by promoting p190RhoGEF expression.  In normal MEFs, p190RhoGEF knockdown inhibits FN-assocd. RhoA activation, FA formation, and cell migration.  Knockdown of p190RhoGEF-related GEFH1 does not affect FA formation in FAK-/- or normal MEFs.  P190RhoGEF overexpression enhances RhoA activation and FA formation in MEFs dependent on FAK binding and assocd. with p190RhoGEF FA recruitment and tyrosine phosphorylation.  These studies elucidate a compensatory function for Pyk2 upon FAK loss and identify the FAK-p190RhoGEF complex as an important integrin-proximal regulator of FA formation during FN-stimulated cell motility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn0jRG0IgcFrVg90H21EOLACvtfcHk0liCJcgr1TXRFg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsFyltQ%253D%253D&md5=cf060fb45adb1bdfb8eee719d2b9874a</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1083%2Fjcb.200708194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.200708194%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DY.%26aulast%3DLim%26aufirst%3DS.%2BT.%26aulast%3DTomar%26aufirst%3DA.%26aulast%3DGardel%26aufirst%3DM.%26aulast%3DBernard-Trifilo%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DX.%2BL.%26aulast%3DUryu%26aufirst%3DS.%2BA.%26aulast%3DCanete-Soler%26aufirst%3DR.%26aulast%3DZhai%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DSchlaepfer%26aufirst%3DW.%2BW.%26aulast%3DNalbant%26aufirst%3DP.%26aulast%3DBokoch%26aufirst%3DG.%26aulast%3DIlic%26aufirst%3DD.%26aulast%3DWaterman-Storer%26aufirst%3DC.%26aulast%3DSchlaepfer%26aufirst%3DD.%2BD.%26atitle%3DPyK2%2520and%2520FAK%2520connections%2520to%2520p190Rho%2520guanine%2520nucleotide%2520exchange%2520factor%2520regulate%2520RhoA%2520activity%252C%2520focal%2520adhesion%2520formation%252C%2520and%2520cell%2520motility%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2008%26volume%3D180%26spage%3D187%26epage%3D203%26doi%3D10.1083%2Fjcb.200708194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohba, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, T.</span></span> <span> </span><span class="NLM_article-title">Interaction of two proline-rich sequences of cell adhesion kinase beta with SH3 domains of p130Cas-related proteins and a GTPase-activating protein, Graf</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>330</i></span>,  <span class="NLM_fpage">1249</span>â <span class="NLM_lpage">1254</span>, <span class="refDoi">Â DOI: 10.1042/bj3301249</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1042%2Fbj3301249" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=9494093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADyaK1cXit1eqtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=1998&pages=1249-1254&author=T.+Ohbaauthor=M.+Ishinoauthor=H.+Aotoauthor=T.+Sasaki&title=Interaction+of+two+proline-rich+sequences+of+cell+adhesion+kinase+beta+with+SH3+domains+of+p130Cas-related+proteins+and+a+GTPase-activating+protein%2C+Graf&doi=10.1042%2Fbj3301249"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of two proline-rich sequences of cell adhesion kinase Î² with SH3 domains of p130Cas-related proteins and a GTPase-activating protein, Graf</span></div><div class="casAuthors">Ohba, Takeaki; Ishino, Masaho; Aoto, Hiroshi; Sasaki, Terukatsu</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1249-1254</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Cell adhesion kinase Î² (CAKÎ²) is a protein tyrosine kinase closely related to focal adhesion kinase (FAK) in structure.  CAKÎ² contains two proline-rich sequences within its C-terminal region.  Since proline-rich sequences present in the corresponding region of FAK are known to mediate protein-protein interactions by binding to SH3 domains, we investigated binding of CAKÎ² to a panel of SH3 domains.  Affinity pptn. from rat brain lysate revealed selective interactions of CAKÎ² with glutathione S-transferase (GST)-fused SH3 domains of p130cas (Cas)-related proteins and Graf.  Mutational anal. indicated that the proline-rich sequences of CAKÎ² mediate this interaction.  Each of the two proline-rich sequences fused to GST bound directly to these SH3 domains in dot blot anal.  A competitive binding assay revealed that the first proline-rich sequence of CAKÎ² preferentially assocd. with the SH3 domain of Cas.  The second proline-rich sequence of CAKÎ² bound to the SH3 domain of Graf with higher specificity than the corresponding proline-rich sequence of FAK.  Finally, we showed co-immunopptn. of CAKÎ² with Graf from rat brain lysate.  These results indicate that CAKÎ² assocs. in vivo with Graf through its SH3 domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCAW0bA2k04LVg90H21EOLACvtfcHk0lgnc7IQIEuX2A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXit1eqtb0%253D&md5=9d0bdc53b99a4dc34234d5543f3b645b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1042%2Fbj3301249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj3301249%26sid%3Dliteratum%253Aachs%26aulast%3DOhba%26aufirst%3DT.%26aulast%3DIshino%26aufirst%3DM.%26aulast%3DAoto%26aufirst%3DH.%26aulast%3DSasaki%26aufirst%3DT.%26atitle%3DInteraction%2520of%2520two%2520proline-rich%2520sequences%2520of%2520cell%2520adhesion%2520kinase%2520beta%2520with%2520SH3%2520domains%2520of%2520p130Cas-related%2520proteins%2520and%2520a%2520GTPase-activating%2520protein%252C%2520Graf%26jtitle%3DBiochem.%2520J.%26date%3D1998%26volume%3D330%26spage%3D1249%26epage%3D1254%26doi%3D10.1042%2Fbj3301249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scheswohl, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrell, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajfur, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaller, M. D.</span></span> <span> </span><span class="NLM_article-title">Multiple paxillin binding sites regulate FAK function</span>. <i>J. Mol. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">11</span>, <span class="refDoi">Â DOI: 10.1186/1750-2187-3-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1186%2F1750-2187-3-1" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=1-11&author=D.+M.+Scheswohlauthor=J.+R.+Harrellauthor=Z.+Rajfurauthor=G.+Gaoauthor=S.+L.+Campbellauthor=M.+D.+Schaller&title=Multiple+paxillin+binding+sites+regulate+FAK+function&doi=10.1186%2F1750-2187-3-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1186%2F1750-2187-3-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1750-2187-3-1%26sid%3Dliteratum%253Aachs%26aulast%3DScheswohl%26aufirst%3DD.%2BM.%26aulast%3DHarrell%26aufirst%3DJ.%2BR.%26aulast%3DRajfur%26aufirst%3DZ.%26aulast%3DGao%26aufirst%3DG.%26aulast%3DCampbell%26aufirst%3DS.%2BL.%26aulast%3DSchaller%26aufirst%3DM.%2BD.%26atitle%3DMultiple%2520paxillin%2520binding%2520sites%2520regulate%2520FAK%2520function%26jtitle%3DJ.%2520Mol.%2520Signaling%26date%3D2014%26volume%3D3%26spage%3D1%26epage%3D11%26doi%3D10.1186%2F1750-2187-3-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uryu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderwood, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlaepfer, D. D.</span></span> <span> </span><span class="NLM_article-title">FAK promotes recruitment of talin to nascent adhesions to control cell motility</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>196</i></span>,  <span class="NLM_fpage">223</span>â <span class="NLM_lpage">232</span>, <span class="refDoi">Â DOI: 10.1083/jcb.201108078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1083%2Fjcb.201108078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=22270917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFymtLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=196&publication_year=2012&pages=223-232&author=C.+Lawsonauthor=S.+T.+Limauthor=S.+Uryuauthor=X.+L.+Chenauthor=D.+A.+Calderwoodauthor=D.+D.+Schlaepfer&title=FAK+promotes+recruitment+of+talin+to+nascent+adhesions+to+control+cell+motility&doi=10.1083%2Fjcb.201108078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">FAK promotes recruitment of talin to nascent adhesions to control cell motility</span></div><div class="casAuthors">Lawson, Christine; Lim, Ssang-Taek; Uryu, Sean; Chen, Xiao Lei; Calderwood, David A.; Schlaepfer, David D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">196</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">223-232</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Cell migration is a dynamic process that involves the continuous formation, maturation, and turnover of matrix-cell adhesion sites.  New (nascent) adhesions form at the protruding cell edge in a tension-independent manner and are comprised of integrin receptors, signaling, and cytoskeletal-assocd. proteins.  Integrins recruit focal adhesion kinase (FAK) and the cytoskeletal protein talin to nascent adhesions.  Canonical models support a role for talin in mediating FAK localization and activation at adhesions.  Here, alternatively, we show that FAK promotes talin recruitment to nascent adhesions occurring independently of talin binding to Î²1 integrins.  The direct binding site for talin on FAK was identified, and a point mutation in FAK (E1015A) prevented talin assocn. and talin localization to nascent adhesions but did not alter integrin-mediated FAK recruitment and activation at adhesions.  Moreover, FAK E1015A inhibited cell motility and proteolytic talin cleavage needed for efficient adhesion dynamics.  These results support an alternative linkage for FAK-talin interactions within nascent adhesions essential for the control of cell migration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKeUkveqKk5LVg90H21EOLACvtfcHk0ligcBMkAHMI9g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFymtLY%253D&md5=1913ece822fd74862aa7e803773fab7e</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1083%2Fjcb.201108078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.201108078%26sid%3Dliteratum%253Aachs%26aulast%3DLawson%26aufirst%3DC.%26aulast%3DLim%26aufirst%3DS.%2BT.%26aulast%3DUryu%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DX.%2BL.%26aulast%3DCalderwood%26aufirst%3DD.%2BA.%26aulast%3DSchlaepfer%26aufirst%3DD.%2BD.%26atitle%3DFAK%2520promotes%2520recruitment%2520of%2520talin%2520to%2520nascent%2520adhesions%2520to%2520control%2520cell%2520motility%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2012%26volume%3D196%26spage%3D223%26epage%3D232%26doi%3D10.1083%2Fjcb.201108078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Subauste, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamson, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, K. M.</span></span> <span> </span><span class="NLM_article-title">Vinculin modulation of paxillin-FAK interactions regulates ERK to control survival and motility</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">371</span>â <span class="NLM_lpage">381</span>, <span class="refDoi">Â DOI: 10.1083/jcb.200308011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1083%2Fjcb.200308011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=15138291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvFKjs70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2004&pages=371-381&author=M.+C.+Subausteauthor=O.+Pertzauthor=E.+D.+Adamsonauthor=C.+E.+Turnerauthor=S.+Jungerauthor=K.+M.+Hahn&title=Vinculin+modulation+of+paxillin-FAK+interactions+regulates+ERK+to+control+survival+and+motility&doi=10.1083%2Fjcb.200308011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Vinculin modulation of paxillin-FAK interactions regulates ERK to control survival and motility</span></div><div class="casAuthors">Subauste, M. Cecilia; Pertz, Olivier; Adamson, Eileen D.; Turner, Christopher E.; Junger, Sachiko; Hahn, Klaus M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">371-381</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Cells lacking vinculin are highly metastatic and motile.  The reasons for this finding have remained unclear.  Both enhanced survival and motility are crit. to metastasis.  Here, we show that vinculin null (vin-/-) cells and cells expressing a vinculin Y822F mutant have increased survival due to up-regulated activity of extracellular signal-regulated kinase (ERK).  This increase is shown to result from vinculin's modulation of paxillin-FAK interactions.  A vinculin fragment (amino acids 811-1066) contg. the paxillin binding site restored apoptosis and suppressed ERK activity in vin-/- cells.  Both vinY822F and vin-/- cells exhibit increased interaction between paxillin and focal adhesion kinase (FAK) and increased paxillin and FAK phosphorylation.  Transfection with paxillin Y31FY118F dominant-neg. mutant in these cells inhibits ERK activation and restores apoptosis.  The enhanced motility of vin-/- and vinY822F cells is also shown to be due to a similar mechanism.  Thus, vinculin regulates survival and motility via ERK by controlling the accessibility of paxillin for FAK interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHaQzHRKIsTbVg90H21EOLACvtfcHk0ligcBMkAHMI9g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvFKjs70%253D&md5=1c39db7eed2fc8c0baceee41c0eef961</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1083%2Fjcb.200308011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.200308011%26sid%3Dliteratum%253Aachs%26aulast%3DSubauste%26aufirst%3DM.%2BC.%26aulast%3DPertz%26aufirst%3DO.%26aulast%3DAdamson%26aufirst%3DE.%2BD.%26aulast%3DTurner%26aufirst%3DC.%2BE.%26aulast%3DJunger%26aufirst%3DS.%26aulast%3DHahn%26aufirst%3DK.%2BM.%26atitle%3DVinculin%2520modulation%2520of%2520paxillin-FAK%2520interactions%2520regulates%2520ERK%2520to%2520control%2520survival%2520and%2520motility%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2004%26volume%3D165%26spage%3D371%26epage%3D381%26doi%3D10.1083%2Fjcb.200308011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muralidharan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vila-Perello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raleigh, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muir, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, A. G.,  III</span></span> <span> </span><span class="NLM_article-title">Tuning protein autoinhibition by domain destabilization</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">550</span>â <span class="NLM_lpage">555</span>, <span class="refDoi">Â DOI: 10.1038/nsmb.2039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fnsmb.2039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=21532593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVGlsL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=550-555&author=J.+H.+Choauthor=V.+Muralidharanauthor=M.+Vila-Perelloauthor=D.+P.+Raleighauthor=T.+W.+Muirauthor=A.+G.+Palmer&title=Tuning+protein+autoinhibition+by+domain+destabilization&doi=10.1038%2Fnsmb.2039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Tuning protein autoinhibition by domain destabilization</span></div><div class="casAuthors">Cho, Jae-Hyun; Muralidharan, Vasant; Vila-Perello, Miquel; Raleigh, Daniel P.; Muir, Tom W.; Palmer, Arthur G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">550-555</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activation of many multidomain signaling proteins requires rearrangement of autoinhibitory interdomain interactions that occlude activator binding sites.  In one model for activation, the major inactive conformation exists in equil. with activated-like conformations that can be stabilized by ligand binding or post-translational modifications.  We established the mol. basis for this model for the archetypal signaling adaptor protein Crk-II by measuring the thermodn. and kinetics of the equil. between autoinhibited and activated-like states.  We used fluorescence and NMR spectroscopies together with segmental isotopic labeling by means of expressed protein ligation.  The results demonstrate that intramol. domain-domain interactions both stabilize the autoinhibited state and induce the activated-like conformation.  A combination of favorable interdomain interactions and unfavorable intradomain structural changes fine-tunes the population of the activated-like conformation and allows facile response to activators.  This mechanism suggests a general strategy for optimization of autoinhibitory interactions of multidomain proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8jZJW-7MyXrVg90H21EOLACvtfcHk0ligcBMkAHMI9g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVGlsL4%253D&md5=25f58c41f6da3b172b58225979e83f52</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2039%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DJ.%2BH.%26aulast%3DMuralidharan%26aufirst%3DV.%26aulast%3DVila-Perello%26aufirst%3DM.%26aulast%3DRaleigh%26aufirst%3DD.%2BP.%26aulast%3DMuir%26aufirst%3DT.%2BW.%26aulast%3DPalmer%26aufirst%3DA.%2BG.%26atitle%3DTuning%2520protein%2520autoinhibition%2520by%2520domain%2520destabilization%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2011%26volume%3D18%26spage%3D550%26epage%3D555%26doi%3D10.1038%2Fnsmb.2039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boerner, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaller, M. D.</span></span> <span> </span><span class="NLM_article-title">SH2- and SH3-mediated interactions between focal adhesion kinase and Src</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>273</i></span>,  <span class="NLM_fpage">577</span>â <span class="NLM_lpage">583</span>, <span class="refDoi">Â DOI: 10.1074/jbc.273.1.577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1074%2Fjbc.273.1.577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=9417118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADyaK1cXjvFSktw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1998&pages=577-583&author=J.+W.+Thomasauthor=B.+Ellisauthor=R.+J.+Boernerauthor=W.+B.+Knightauthor=G.+C.+Whiteauthor=M.+D.+Schaller&title=SH2-+and+SH3-mediated+interactions+between+focal+adhesion+kinase+and+Src&doi=10.1074%2Fjbc.273.1.577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">SH2- and SH3-mediated interactions between focal adhesion kinase and Src</span></div><div class="casAuthors">Thomas, Jeffrey W.; Ellis, Byron; Boerner, Renee J.; Knight, Wilson B.; White, Gilbert C., II; Schaller, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">577-583</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Intramol. SH2 and SH3 interactions mediate enzymic repression of the Src kinases.  One mechanism of activation is disruption of these interactions by the formation of higher affinity SH2 and SH3 interactions with specific ligands.  We show that a consensus Src SH3-binding site residing upstream of the Src SH2-binding site in FAK can function as a ligand for the Src SH3 domain.  Surface plasmon resonance expts. indicate that a FAK peptide contg. both the Src SH2- and SH3-binding sites exhibits increased affinity for Src.  Furthermore, the presence of both sites in vitro more potently activates c-Src.  A FAK mutant (FAKPro-2) with substitutions destroying the SH3-binding site shows reduced binding to Src in vivo.  This mutation also reduces Src-dependent tyrosine phosphorylation on the mutant itself and downstream substrates, such as paxillin.  These observations suggest that an SH3-mediated interaction between Src-like kinases and FAK may be important for complex formation and downstream signaling in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoetwSyBSedc7Vg90H21EOLACvtfcHk0ljCjn9I6Xpa1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjvFSktw%253D%253D&md5=7d953ac8521f7caf21981585ff0d3551</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1074%2Fjbc.273.1.577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.273.1.577%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DJ.%2BW.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DBoerner%26aufirst%3DR.%2BJ.%26aulast%3DKnight%26aufirst%3DW.%2BB.%26aulast%3DWhite%26aufirst%3DG.%2BC.%26aulast%3DSchaller%26aufirst%3DM.%2BD.%26atitle%3DSH2-%2520and%2520SH3-mediated%2520interactions%2520between%2520focal%2520adhesion%2520kinase%2520and%2520Src%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1998%26volume%3D273%26spage%3D577%26epage%3D583%26doi%3D10.1074%2Fjbc.273.1.577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sulzmaier, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlaepfer, D. D.</span></span> <span> </span><span class="NLM_article-title">FAK in cancer: mechanistic findings and clinical applications</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">598</span>â <span class="NLM_lpage">610</span>, <span class="refDoi">Â DOI: 10.1038/nrc3792</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fnrc3792" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=25098269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht12nu7vJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=598-610&author=F.+J.+Sulzmaierauthor=C.+Jeanauthor=D.+D.+Schlaepfer&title=FAK+in+cancer%3A+mechanistic+findings+and+clinical+applications&doi=10.1038%2Fnrc3792"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">FAK in cancer: mechanistic findings and clinical applications</span></div><div class="casAuthors">Sulzmaier, Florian J.; Jean, Christine; Schlaepfer, David D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">598-610</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Focal adhesion kinase (FAK) is a cytoplasmic protein tyrosine kinase that is overexpressed and activated in several advanced-stage solid cancers.  FAK promotes tumor progression and metastasis through effects on cancer cells, as well as stromal cells of the tumor microenvironment.  The kinase-dependent and kinase-independent functions of FAK control cell movement, invasion, survival, gene expression and cancer stem cell self-renewal.  Small mol. FAK inhibitors decrease tumor growth and metastasis in several preclin. models and have initial clin. activity in patients with limited adverse events.  In this Review, we discuss FAK signalling effects on both tumor and stromal cell biol. that provide rationale and support for future therapeutic opportunities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmKc7m7dsY67Vg90H21EOLACvtfcHk0ljCjn9I6Xpa1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht12nu7vJ&md5=f498bcf7af890d2f92eda68e42f979d1</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnrc3792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3792%26sid%3Dliteratum%253Aachs%26aulast%3DSulzmaier%26aufirst%3DF.%2BJ.%26aulast%3DJean%26aufirst%3DC.%26aulast%3DSchlaepfer%26aufirst%3DD.%2BD.%26atitle%3DFAK%2520in%2520cancer%253A%2520mechanistic%2520findings%2520and%2520clinical%2520applications%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D598%26epage%3D610%26doi%3D10.1038%2Fnrc3792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, J. T.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase: the first ten years</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">1409</span>â <span class="NLM_lpage">1416</span>, <span class="refDoi">Â DOI: 10.1242/jcs.00373</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1242%2Fjcs.00373" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=12640026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtlyrtLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2003&pages=1409-1416&author=J.+T.+Parsons&title=Focal+adhesion+kinase%3A+the+first+ten+years&doi=10.1242%2Fjcs.00373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion kinase: The first ten years</span></div><div class="casAuthors">Parsons, J. Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1409-1416</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  The protein tyrosine kinase focal adhesion kinase (FAK) plays a prominent role in integrin signaling.  FAK activation, demonstrated by an increase in phosphorylation of Tyr397 as well as other sites in the protein, is best understood in the context of the engagement of integrins at the cell surface.  Activation of FAK results in recruitment of a no. of SH2-domain- and SH3-domain-contg. proteins, which mediate signaling to several downstream pathways.  FAK-dependent activation of these pathways has been implicated in a diverse array of cellular processes, including cell migration, growth factor signaling, cell cycle progression and cell survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUsZCpbwOe67Vg90H21EOLACvtfcHk0ljCjn9I6Xpa1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtlyrtLw%253D&md5=7fdb8c6c1ab6d5f46991d1b79d84105a</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1242%2Fjcs.00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.00373%26sid%3Dliteratum%253Aachs%26aulast%3DParsons%26aufirst%3DJ.%2BT.%26atitle%3DFocal%2520adhesion%2520kinase%253A%2520the%2520first%2520ten%2520years%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2003%26volume%3D116%26spage%3D1409%26epage%3D1416%26doi%3D10.1242%2Fjcs.00373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sieg, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauck, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klingbeil, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damsky, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlaepfer, D. D.</span></span> <span> </span><span class="NLM_article-title">FAK integrates growth-factor and integrin signals to promote cell migration</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">249</span>â <span class="NLM_lpage">256</span>, <span class="refDoi">Â DOI: 10.1038/35010517</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2F35010517" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10806474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktlOqs7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2000&pages=249-256&author=D.+J.+Siegauthor=C.+R.+Hauckauthor=D.+Ilicauthor=C.+K.+Klingbeilauthor=E.+Schaeferauthor=C.+H.+Damskyauthor=D.+D.+Schlaepfer&title=FAK+integrates+growth-factor+and+integrin+signals+to+promote+cell+migration&doi=10.1038%2F35010517"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">FAK integrates growth-factor and integrin signals to promote cell migration</span></div><div class="casAuthors">Sieg, David J.; Hauck, Christof R.; Ilic, Dusko; Kingbeil, Candice K.; Schaefer, Erik; Damsky, Caroline H.; Schlaepfer, David D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">249-256</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we show that cells lacking focal adhesion kinase (FAK) are refractory to motility signals from platelet-derived and epidermal growth factors (PDGF and EGF resp.), and that stable re-expression of FAK rescues these defects.  FAK assocs. with activated PDGF- and EGF-receptor (PDGFR and EGFR) signalling complexes, and expression of the band-4.1-like domain at the FAK amino terminus is sufficient to mediate an interaction with activated EGFR.  However, efficient EGF-stimulated cell migration also requires FAK to be targeted, by its carboxy-terminal domain, to sites of integrin-receptor clustering.  Although the kinase activity of FAK is not needed to promote PDGF- or EGF-stimulated cell motility, kinase-inactive FAK is transphosphorylated at the indispensable Src-kinase-binding site, FAK Y397, after EGF stimulation of cells.  Our results establish that FAK is an important receptor-proximal link between growth-factor-receptor and integrin signalling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8_jbj9KKEerVg90H21EOLACvtfcHk0ljCjn9I6Xpa1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktlOqs7o%253D&md5=8dd638fbecfd120065bedda6eb0a3ecd</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2F35010517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35010517%26sid%3Dliteratum%253Aachs%26aulast%3DSieg%26aufirst%3DD.%2BJ.%26aulast%3DHauck%26aufirst%3DC.%2BR.%26aulast%3DIlic%26aufirst%3DD.%26aulast%3DKlingbeil%26aufirst%3DC.%2BK.%26aulast%3DSchaefer%26aufirst%3DE.%26aulast%3DDamsky%26aufirst%3DC.%2BH.%26aulast%3DSchlaepfer%26aufirst%3DD.%2BD.%26atitle%3DFAK%2520integrates%2520growth-factor%2520and%2520integrin%2520signals%2520to%2520promote%2520cell%2520migration%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2000%26volume%3D2%26spage%3D249%26epage%3D256%26doi%3D10.1038%2F35010517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michael, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumbauld, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanks, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A. J.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase modulates cell adhesion strengthening via integrin activation</span>. <i>Mol. Biol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2508</span>â <span class="NLM_lpage">2519</span>, <span class="refDoi">Â DOI: 10.1091/mbc.e08-01-0076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1091%2Fmbc.e08-01-0076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=19297531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotVyquro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2009&pages=2508-2519&author=K.+E.+Michaelauthor=D.+W.+Dumbauldauthor=K.+L.+Burnsauthor=S.+K.+Hanksauthor=A.+J.+Garcia&title=Focal+adhesion+kinase+modulates+cell+adhesion+strengthening+via+integrin+activation&doi=10.1091%2Fmbc.e08-01-0076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion kinase modulates cell adhesion strengthening via integrin activation</span></div><div class="casAuthors">Michael, Kristin E.; Dumbauld, David W.; Burns, Kellie L.; Hanks, Steven K.; Garcia, Andres J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Biology of the Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2508-2519</span>CODEN:
                <span class="NLM_cas:coden">MBCEEV</span>;
        ISSN:<span class="NLM_cas:issn">1939-4586</span>.
    
            (<span class="NLM_cas:orgname">American Society for Cell Biology</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) is an essential nonreceptor tyrosine kinase regulating cell migration, adhesive signaling, and mechanosensing.  Using FAK-null cells expressing FAK under an inducible promoter, we demonstrate that FAK regulates the time-dependent generation of adhesive forces.  During the early stages of adhesion, FAK expression in FAK-null cells enhances integrin activation to promote integrin binding and, hence, the adhesion strengthening rate.  Importantly, FAK expression regulated integrin activation, and talin was required for the FAK-dependent effects.  A role for FAK in integrin activation was confirmed in human fibroblasts with knocked-down FAK expression.  The FAK autophosphorylation Y397 site was required for the enhancements in adhesion strengthening and integrin-binding responses.  This work demonstrates a novel role for FAK in integrin activation and the time-dependent generation of cell-ECM forces.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos_2S15_hJBLVg90H21EOLACvtfcHk0lgzSTZFhtHmRw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotVyquro%253D&md5=103a7bad610a0bbd7710025f20978ba0</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1091%2Fmbc.e08-01-0076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1091%252Fmbc.e08-01-0076%26sid%3Dliteratum%253Aachs%26aulast%3DMichael%26aufirst%3DK.%2BE.%26aulast%3DDumbauld%26aufirst%3DD.%2BW.%26aulast%3DBurns%26aufirst%3DK.%2BL.%26aulast%3DHanks%26aufirst%3DS.%2BK.%26aulast%3DGarcia%26aufirst%3DA.%2BJ.%26atitle%3DFocal%2520adhesion%2520kinase%2520modulates%2520cell%2520adhesion%2520strengthening%2520via%2520integrin%2520activation%26jtitle%3DMol.%2520Biol.%2520Cell%26date%3D2009%26volume%3D20%26spage%3D2508%26epage%3D2519%26doi%3D10.1091%2Fmbc.e08-01-0076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rozengurt, E.</span></span> <span> </span><span class="NLM_article-title">Mitogenic signaling pathways induced by G protein-coupled receptors</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>213</i></span>,  <span class="NLM_fpage">589</span>â <span class="NLM_lpage">602</span>, <span class="refDoi">Â DOI: 10.1002/jcp.21246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1002%2Fjcp.21246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=17786953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht12jtbfI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=213&publication_year=2007&pages=589-602&author=E.+Rozengurt&title=Mitogenic+signaling+pathways+induced+by+G+protein-coupled+receptors&doi=10.1002%2Fjcp.21246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Mitogenic signaling pathways induced by G protein-coupled receptors</span></div><div class="casAuthors">Rozengurt, Enrique</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">213</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">589-602</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptor (GPCR) agonists, including neurotransmitters, hormones, chemokines, and bioactive lipids, act as potent cellular growth factors and have been implicated in a variety of normal and abnormal processes, including development, inflammation, and malignant transformation.  Typically, the binding of an agonistic ligand to its cognate GPCR triggers the activation of multiple signal transduction pathways that act in a synergistic and combinatorial fashion to relay the mitogenic signal to the nucleus and promote cell proliferation.  A rapid increase in the activity of phospholipases C, D, and A2 leading to the synthesis of lipid-derived 2nd messengers, Ca2+ fluxes, and subsequent activation of protein phosphorylation cascades, including PKC/PKD, Raf/MEK/ERK, and Akt/mTOR/p70S6K, is an important early response to mitogenic GPCR agonists.  The EGF receptor (EGFR) tyrosine kinase has emerged as a transducer in the signaling by GPCRs, a process termed transactivation.  GPCR signal transduction also induces striking morphol. changes and rapid tyrosine phosphorylation of multiple cellular proteins, including non-receptor tyrosine kinases Src, focal adhesion kinase (FAK), and adaptor proteins CAS and paxillin.  The pathways stimulated by GPCRs are extensively interconnected by synergistic and antagonistic crosstalks that play a crit. role in signal transmission, integration, and dissemination.  Here, the author reviews recent advances in defining the pathways that play a role in transducing mitogenic responses induced by GPCR agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeYdFoM9JEc7Vg90H21EOLACvtfcHk0lgzSTZFhtHmRw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht12jtbfI&md5=6ee41ac5020b6449e434fc3574b46501</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fjcp.21246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.21246%26sid%3Dliteratum%253Aachs%26aulast%3DRozengurt%26aufirst%3DE.%26atitle%3DMitogenic%2520signaling%2520pathways%2520induced%2520by%2520G%2520protein-coupled%2520receptors%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2007%26volume%3D213%26spage%3D589%26epage%3D602%26doi%3D10.1002%2Fjcp.21246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dales, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charafe-Jauffret, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpentier-Meunier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrac-Meyer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacquemier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andonian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavaut, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allasia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charpin, C.</span></span> <span> </span><span class="NLM_article-title">Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">49</span>â <span class="NLM_lpage">58</span>, <span class="refDoi">Â DOI: 10.3892/ijo.31.1.49</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.3892%2Fijo.31.1.49" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=17549404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BD2szjs1ymtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2007&pages=49-58&author=S.+Garciaauthor=J.+P.+Dalesauthor=E.+Charafe-Jauffretauthor=S.+Carpentier-Meunierauthor=L.+Andrac-Meyerauthor=J.+Jacquemierauthor=C.+Andonianauthor=M.+N.+Lavautauthor=C.+Allasiaauthor=P.+Bonnierauthor=C.+Charpin&title=Overexpression+of+c-Met+and+of+the+transducers+PI3K%2C+FAK+and+JAK+in+breast+carcinomas+correlates+with+shorter+survival+and+neoangiogenesis&doi=10.3892%2Fijo.31.1.49"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis</span></div><div class="casAuthors">Garcia Stephane; Dales Jean-Philippe; Charafe-Jauffret Emmanuelle; Carpentier-Meunier Severine; Andrac-Meyer Lucile; Jacquemier Jocelyne; Andonian Claudine; Lavaut Marie-Noelle; Allasia Claude; Bonnier Pascal; Charpin Colette</div><div class="citationInfo"><span class="NLM_cas:title">International journal of oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-58</span>
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    </div><div class="casAbstract">c-Met is responsible for cell motility and tumour spreading. c-Met expression and signal transducers reflecting c-Met functionality were investigated in breast carcinomas, in correlation with patient outcome and tumour vasculature.  Tissue microarrays of 930 breast carcinomas were constructed, categorised according to patients' follow-up (4- to 10-year follow-up; median, 6.5 years).  Standardised immunocytochemical procedures were performed using anti-c-Met, -PI3K, -FAK, -JAK, and -CD146, -FYN and an automated autostainer (Ventana).  High-throughput densitometry measuring the extent of immunoprecipitates was assessed by image analysis (SAMBA). c-Met overexpression correlated with poor survival along with PI3K and FAK reflecting c-Met functionality and CD146 and FYN expression in endothelial cells.  Automated quantification of immunocytochemical precipitates using image analysis was shown to provide an objective means of measuring cellular proteins that are potentially relevant for current practice in pathological diagnosis and for specific therapy combining inhibitors of both c-Met and downstream transducer pathways, and of tumour angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS9oRTX60a0VthSDZx9hyjKfW6udTcc2eawv_tU3DkQ57ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2szjs1ymtQ%253D%253D&md5=ffced0cd1ff6c06df0e44b8d3b1e3262</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.3892%2Fijo.31.1.49&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.31.1.49%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia%26aufirst%3DS.%26aulast%3DDales%26aufirst%3DJ.%2BP.%26aulast%3DCharafe-Jauffret%26aufirst%3DE.%26aulast%3DCarpentier-Meunier%26aufirst%3DS.%26aulast%3DAndrac-Meyer%26aufirst%3DL.%26aulast%3DJacquemier%26aufirst%3DJ.%26aulast%3DAndonian%26aufirst%3DC.%26aulast%3DLavaut%26aufirst%3DM.%2BN.%26aulast%3DAllasia%26aufirst%3DC.%26aulast%3DBonnier%26aufirst%3DP.%26aulast%3DCharpin%26aufirst%3DC.%26atitle%3DOverexpression%2520of%2520c-Met%2520and%2520of%2520the%2520transducers%2520PI3K%252C%2520FAK%2520and%2520JAK%2520in%2520breast%2520carcinomas%2520correlates%2520with%2520shorter%2520survival%2520and%2520neoangiogenesis%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2007%26volume%3D31%26spage%3D49%26epage%3D58%26doi%3D10.3892%2Fijo.31.1.49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lietha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceccarelli, D. F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaller, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Structural basis for the autoinhibition of focal adhesion kinase</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">1177</span>â <span class="NLM_lpage">1187</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2007.05.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.cell.2007.05.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=17574028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntVOnt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2007&pages=1177-1187&author=D.+Liethaauthor=X.+Caiauthor=D.+F.+J.+Ceccarelliauthor=Y.+Liauthor=M.+D.+Schallerauthor=M.+J.+Eck&title=Structural+basis+for+the+autoinhibition+of+focal+adhesion+kinase&doi=10.1016%2Fj.cell.2007.05.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the autoinhibition of focal adhesion kinase</span></div><div class="casAuthors">Lietha, Daniel; Cai, Xinming; Ceccarelli, Derek F. J.; Li, Yiqun; Schaller, Michael D.; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1177-1187</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Appropriate tyrosine kinase signaling depends on coordinated sequential coupling of protein-protein interactions with catalytic activation.  Focal adhesion kinase (FAK) integrates signals from integrin and growth factor receptors to regulate cellular responses including cell adhesion, migration, and survival.  Here, we describe crystal structures representing both autoinhibited and active states of FAK.  The inactive structure reveals a mechanism of inhibition in which the N-terminal FERM domain directly binds the kinase domain, blocking access to the catalytic cleft and protecting the FAK activation loop from Src phosphorylation.  Addnl., the FERM domain sequesters the Tyr397 autophosphorylation and Src recruitment site, which lies in the linker connecting the FERM and kinase domains.  The active phosphorylated FAK kinase adopts a conformation that is immune to FERM inhibition.  Our biochem. and structural anal. shows how the architecture of autoinhibited FAK orchestrates an activation sequence of FERM domain displacement, linker autophosphorylation, Src recruitment, and full catalytic activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrePRTd6WBaCLVg90H21EOLACvtfcHk0lhNYSRXTuRH2g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntVOnt7g%253D&md5=db42c6f45345fbf5bba3f92fb6362aa5</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.05.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.05.041%26sid%3Dliteratum%253Aachs%26aulast%3DLietha%26aufirst%3DD.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DCeccarelli%26aufirst%3DD.%2BF.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DSchaller%26aufirst%3DM.%2BD.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructural%2520basis%2520for%2520the%2520autoinhibition%2520of%2520focal%2520adhesion%2520kinase%26jtitle%3DCell%26date%3D2007%26volume%3D129%26spage%3D1177%26epage%3D1187%26doi%3D10.1016%2Fj.cell.2007.05.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimenti, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barber, D. L.</span></span> <span> </span><span class="NLM_article-title">PH sensing by FAK-His58 regulates focal adhesion remodeling</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>202</i></span>,  <span class="NLM_fpage">849</span>â <span class="NLM_lpage">859</span>, <span class="refDoi">Â DOI: 10.1083/jcb.201302131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1083%2Fjcb.201302131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=24043700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2ksbnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=202&publication_year=2013&pages=849-859&author=C.+H.+Choiauthor=B.+A.+Webbauthor=M.+S.+Chimentiauthor=M.+P.+Jacobsonauthor=D.+L.+Barber&title=PH+sensing+by+FAK-His58+regulates+focal+adhesion+remodeling&doi=10.1083%2Fjcb.201302131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">pH sensing by FAK-His58 regulates focal adhesion remodeling</span></div><div class="casAuthors">Choi, Chang-Hoon; Webb, Bradley A.; Chimenti, Michael S.; Jacobson, Matthew P.; Barber, Diane L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">202</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">849-859</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Intracellular pH (pHi) dynamics regulates diverse cellular processes, including remodeling of focal adhesions.  We now report that focal adhesion kinase (FAK), a key regulator of focal adhesion remodeling, is a pH sensor responding to physiol. changes in pH.  The initial step in FAK activation is autophosphorylation of Tyr397, which increased with higher pHi.  We used a genetically encoded biosensor to show increased pH at focal adhesions as they mature during cell spreading.  We also show that cells with reduced pHi had attenuated FAK-pY397 as well as defective cell spreading and focal adhesions.  Mutagenesis studies indicated FAK-His58 is crit. for pH sensing and mol. dynamics simulations suggested a model in which His58 deprotonation drives conformational changes that may modulate accessibility of Tyr397 for autophosphorylation.  Expression of FAK-H58A in fibroblasts was sufficient to restore defective autophosphorylation and cell spreading at low pHi.  These data are relevant to understanding cancer metastasis, which is dependent on increased pHi and FAK activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxuZ0Fzfcr8rVg90H21EOLACvtfcHk0lhNYSRXTuRH2g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2ksbnJ&md5=027c96457ed53114d80d213b03ba13e2</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1083%2Fjcb.201302131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.201302131%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DC.%2BH.%26aulast%3DWebb%26aufirst%3DB.%2BA.%26aulast%3DChimenti%26aufirst%3DM.%2BS.%26aulast%3DJacobson%26aufirst%3DM.%2BP.%26aulast%3DBarber%26aufirst%3DD.%2BL.%26atitle%3DPH%2520sensing%2520by%2520FAK-His58%2520regulates%2520focal%2520adhesion%2520remodeling%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2013%26volume%3D202%26spage%3D849%26epage%3D859%26doi%3D10.1083%2Fjcb.201302131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cance, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golubovskaya, V. M.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase versus p53: apoptosis or survival?</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">22</span>â <span class="NLM_lpage">29</span>, <span class="refDoi">Â DOI: 10.1126/stke.120pe22</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1126%2Fstke.120pe22" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2008&pages=22-29&author=W.+G.+Canceauthor=V.+M.+Golubovskaya&title=Focal+adhesion+kinase+versus+p53%3A+apoptosis+or+survival%3F&doi=10.1126%2Fstke.120pe22"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1126%2Fstke.120pe22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fstke.120pe22%26sid%3Dliteratum%253Aachs%26aulast%3DCance%26aufirst%3DW.%2BG.%26aulast%3DGolubovskaya%26aufirst%3DV.%2BM.%26atitle%3DFocal%2520adhesion%2520kinase%2520versus%2520p53%253A%2520apoptosis%2520or%2520survival%253F%26jtitle%3DSci.%2520Signaling%26date%3D2008%26volume%3D1%26spage%3D22%26epage%3D29%26doi%3D10.1126%2Fstke.120pe22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonoda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichikawa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriko, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadashi, K.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase determines the fate of death or survival of cells in response to TNF alpha in the presence of actinomycin D</span>. <i>Biochim. Biophys. Acta, Gen. Subj.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>1770</i></span>,  <span class="NLM_fpage">518</span>â <span class="NLM_lpage">526</span>, <span class="refDoi">Â DOI: 10.1016/j.bbagen.2006.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bbagen.2006.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2sXit1Ggs7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1770&publication_year=2007&pages=518-526&author=R.+Takahashiauthor=Y.+Sonodaauthor=D.+Ichikawaauthor=N.+Yoshidaauthor=A.+Y.+Erikoauthor=K.+Tadashi&title=Focal+adhesion+kinase+determines+the+fate+of+death+or+survival+of+cells+in+response+to+TNF+alpha+in+the+presence+of+actinomycin+D&doi=10.1016%2Fj.bbagen.2006.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion kinase determines the fate of death or survival of cells in response to TNFÎ± in the presence of actinomycin D</span></div><div class="casAuthors">Takahashi, Reiko; Sonoda, Yoshiko; Ichikawa, Daiju; Yoshida, Naomi; Eriko, Aizu-Yokota; Tadashi, Kasahara</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1770</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">518-526</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The authors speculated that focal adhesion kinase (FAK) might play a crit. role in the TNFÎ±-induced cell death.  In this study, the authors found that FAK-/- cells are more sensitive to TNFÎ±-induced apoptosis in the presence of actinomycin D (Act D) compared to FAK+/- cells.  Prosurvival pathways are activated by the rapid recruitment of complex I, comprising TNFR1, TRADD, RIP and TRAF2, which leads to the activation of the NF-ÎºB pathway.  Proapoptotic pathways are activated by complex II, the death-inducing signaling complex (DISC), which contains TNFR1, TRADD, RIP, and FADD, and procaspase-8 proteins.  As TNFR1, TRADD, and RIP are included in both Complex I and DISC, the authors speculated that RIP might be a key protein.  Coimmunopptn. assays revealed that RIP is included in complex I in FAK+/- cells, and FAK was assocd. with RIP.  RIP is included in DISC in FAK-/- cells.  FAK might be a key protein in the formation of complex I and the activation of NF-ÎºB.  Furthermore, Akt was activated in FAK+/- cells, but not FAK-/- cells.  In conclusion, the authors first demonstrated that FAK dets. the pathway leading to death or survival in TNFÎ±/ActD-stimulated fibroblasts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHn6ryPWMnp7Vg90H21EOLACvtfcHk0lgPA86d6KJJeQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXit1Ggs7s%253D&md5=05a9c20853d2aab0e42cc06814075a81</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2006.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2006.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DR.%26aulast%3DSonoda%26aufirst%3DY.%26aulast%3DIchikawa%26aufirst%3DD.%26aulast%3DYoshida%26aufirst%3DN.%26aulast%3DEriko%26aufirst%3DA.%2BY.%26aulast%3DTadashi%26aufirst%3DK.%26atitle%3DFocal%2520adhesion%2520kinase%2520determines%2520the%2520fate%2520of%2520death%2520or%2520survival%2520of%2520cells%2520in%2520response%2520to%2520TNF%2520alpha%2520in%2520the%2520presence%2520of%2520actinomycin%2520D%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2007%26volume%3D1770%26spage%3D518%26epage%3D526%26doi%3D10.1016%2Fj.bbagen.2006.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thamilselvan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craig, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basson, M. D.</span></span> <span> </span><span class="NLM_article-title">FAK association with multiple signal proteins mediates pressure-induced colon cancer cell adhesion via a Src-dependent PI3K/Akt pathway</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1730</span>â <span class="NLM_lpage">1741</span>, <span class="refDoi">Â DOI: 10.1096/fj.06-6545com</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1096%2Ffj.06-6545com" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=17317726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsVWlu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=1730-1741&author=V.+Thamilselvanauthor=D.+H.+Craigauthor=M.+D.+Basson&title=FAK+association+with+multiple+signal+proteins+mediates+pressure-induced+colon+cancer+cell+adhesion+via+a+Src-dependent+PI3K%2FAkt+pathway&doi=10.1096%2Ffj.06-6545com"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">FAK association with multiple signal proteins mediates pressure-induced colon cancer cell adhesion via a Src-dependent PI3K/Akt pathway</span></div><div class="casAuthors">Thamilselvan, Vijayalakshmi; Craig, David H.; Basson, Marc D.</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1730-1741, 10.1096/fj.06-6545com</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Cancer cell adhesion is traditionally viewed as random, occurring if the cell's receptors match the substrate.  Cancer cells are subjected to pressure and shear during growth against a constraining stroma, surgical manipulation, and passage through the venous and lymphatic system.  Cells shed into a cavity such as the abdomen postoperatively also experience increased pressure from postoperative edema.  Increased extracellular pressure stimulates integrin-mediated cancer cell adhesion via FAK and Src.  PI 3-kinase (PI3K) inhibitors (LY294002 or wortmannin), Akt inhibitors, or Akt1 siRNA blocked adhesion stimulated by 15 mmHg pressure in SW620 or primary human malignant colonocytes.  Pressure activated PI3K, tyrosine-phosphorylated and membrane-translocated the p85 subunit, and phosphorylated Akt.  PI3K inhibitor (LY294002) prevented pressure-stimulated Akt Ser473 and FAK Tyr397, but not FAK576 or Src416 phosphorylation.  PP2 inhibited PI3K activity and Akt phosphorylation.  FAK siRNA did not affect pressure-induced PI3K activation but blocked Akt phosphorylation.  Pressure also stimulated FAK or FAKY397F mutant translocation to the membrane.  Akt inhibitor IV blocked pressure-induced Akt and FAK translocation.  Pressure activated Src- and PI3K-dependently induced p85 interaction with FAK, and FAK with Î²1 integrin.  These results delineate a novel force-activated inside-out Src/PI3K/FAK/Akt pathway by which cancer cells regulate their own adhesion.  These signals may be potential targets for inhibition of metastatic adhesion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLWDplUiEzRrVg90H21EOLACvtfcHk0lgPA86d6KJJeQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsVWlu7c%253D&md5=599d5f49555224bc7dceb8873d3017ba</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1096%2Ffj.06-6545com&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.06-6545com%26sid%3Dliteratum%253Aachs%26aulast%3DThamilselvan%26aufirst%3DV.%26aulast%3DCraig%26aufirst%3DD.%2BH.%26aulast%3DBasson%26aufirst%3DM.%2BD.%26atitle%3DFAK%2520association%2520with%2520multiple%2520signal%2520proteins%2520mediates%2520pressure-induced%2520colon%2520cancer%2520cell%2520adhesion%2520via%2520a%2520Src-dependent%2520PI3K%252FAkt%2520pathway%26jtitle%3DFASEB%2520J.%26date%3D2007%26volume%3D21%26spage%3D1730%26epage%3D1741%26doi%3D10.1096%2Ffj.06-6545com" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rounds, S.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase and endothelial cell apoptosis</span>. <i>Microvasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">56</span>â <span class="NLM_lpage">63</span>, <span class="refDoi">Â DOI: 10.1016/j.mvr.2011.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.mvr.2011.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=21624380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFOqtr7P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2012&pages=56-63&author=Q.+Luauthor=S.+Rounds&title=Focal+adhesion+kinase+and+endothelial+cell+apoptosis&doi=10.1016%2Fj.mvr.2011.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion kinase and endothelial cell apoptosis</span></div><div class="casAuthors">Lu, Qing; Rounds, Sharon</div><div class="citationInfo"><span class="NLM_cas:title">Microvascular Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-63</span>CODEN:
                <span class="NLM_cas:coden">MIVRA6</span>;
        ISSN:<span class="NLM_cas:issn">0026-2862</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Focal adhesion kinase (FAK) is a key component of cell-substratum adhesions, known as focal adhesion complexes.  Growing evidence indicates that FAK is important in maintenance of normal cell survival and that disruption of FAK signaling results in loss of substrate adhesion and anoikis (apoptosis) of anchorage-dependent cells, such as endothelial cells.  Basal FAK activity in non-stimulated endothelial cells is important in maintaining cell adhesion to integrins via PI3 kinase/Akt signaling.  FAK activity is dependent upon small GTPase signaling.  FAK also appears to be important in cardiomyocyte hypertrophy and hypoxia/reoxygenation-induced cell death.  This review summarizes the signaling pathways of FAK in prevention of apoptosis and the role of FAK in mediating adenosine and homocysteine-induced endothelial cell apoptosis and in cardiovascular diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3cXCIr_k1WrVg90H21EOLACvtfcHk0lgPA86d6KJJeQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFOqtr7P&md5=9a6077f2f9c96dd99b2158c07bc8603e</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.mvr.2011.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mvr.2011.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DQ.%26aulast%3DRounds%26aufirst%3DS.%26atitle%3DFocal%2520adhesion%2520kinase%2520and%2520endothelial%2520cell%2520apoptosis%26jtitle%3DMicrovasc.%2520Res.%26date%3D2012%26volume%3D83%26spage%3D56%26epage%3D63%26doi%3D10.1016%2Fj.mvr.2011.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pestell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, J. L.</span></span> <span> </span><span class="NLM_article-title">Transcriptional activation of cyclin D1 promoter by FAK contributes to cell cycle progression</span>. <i>Mol. Biol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">4066</span>â <span class="NLM_lpage">4077</span>, <span class="refDoi">Â DOI: 10.1091/mbc.12.12.4066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1091%2Fmbc.12.12.4066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=11739801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD3MXpt1Giu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2001&pages=4066-4077&author=J.+Zhaoauthor=R.+Pestellauthor=J.+L.+Guan&title=Transcriptional+activation+of+cyclin+D1+promoter+by+FAK+contributes+to+cell+cycle+progression&doi=10.1091%2Fmbc.12.12.4066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Transcriptional activation of cyclin D1 promoter by FAK contributes to cell cycle progression</span></div><div class="casAuthors">Zhao, Jihe; Pestell, Richard; Guan, Jun-Lin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Biology of the Cell</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4066-4077</span>CODEN:
                <span class="NLM_cas:coden">MBCEEV</span>;
        ISSN:<span class="NLM_cas:issn">1059-1524</span>.
    
            (<span class="NLM_cas:orgname">American Society for Cell Biology</span>)
        </div><div class="casAbstract">Integrin-mediated cell adhesion to the extracellular matrix is required for normal cell growth.  Cyclin D1 is a key regulator of G1-to-S phase progression of the cell cycle.  Our previous studies have demonstrated that integrin signaling through focal adhesion kinase (FAK) plays a role in the regulation of cell cycle progression, which correlates with changes in the expression of cyclin D1 and the cdk inhibitor, p21, induced by FAK.  In this report, we first investigated the roles of both cyclin D1 and p21 in the regulation of cell cycle progression by FAK.  We found that overexpression of a dominant-neg. FAK mutant ÎC14 suppressed cell cycle progression in p21-/- cells as effectively as in the control p21+/+ cells.  Furthermore, we found that overexpression of ectopic cyclin D1 could rescue cell cycle inhibition by ÎC14.  These results suggested that cyclin D1, but not p21, was the primary functional target of FAK signaling pathways in cell cycle regulation.  We then investigated the mechanisms underlying the regulation of cyclin D1 expression by FAK signaling.  Using Northern blotting and cyclin D1 promoter/luciferase assays, we showed that FAK signaling regulated cyclin D1 expression at the transcriptional level.  Using a series of cyclin D1 promoter mutants in luciferase assays as well as electrophoretic mobility shift assays (EMSA), we showed that the EtsB binding site mediated cyclin D1 promoter regulation by FAK.  Finally, we showed that FAK regulation of cyclin D1 depends on integrin-mediated cell adhesion and is likely through its activation of the Erk signaling pathway.  Together, these studies demonstrate that transcriptional regulation of cyclin D1 by FAK signaling pathways contributes to the regulation of cell cycle progression in cell adhesion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYtJnIF79xkrVg90H21EOLACvtfcHk0lgPA86d6KJJeQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXpt1Giu7k%253D&md5=7e28c47174f9d4d5350ac0e8a85606ac</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1091%2Fmbc.12.12.4066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1091%252Fmbc.12.12.4066%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DPestell%26aufirst%3DR.%26aulast%3DGuan%26aufirst%3DJ.%2BL.%26atitle%3DTranscriptional%2520activation%2520of%2520cyclin%2520D1%2520promoter%2520by%2520FAK%2520contributes%2520to%2520cell%2520cycle%2520progression%26jtitle%3DMol.%2520Biol.%2520Cell%26date%3D2001%26volume%3D12%26spage%3D4066%26epage%3D4077%26doi%3D10.1091%2Fmbc.12.12.4066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagoshi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tachikawa, T.</span></span> <span> </span><span class="NLM_article-title">Expression of FAK-related non-kinase (FRNK) coincides with morphological change in the early stage of cell adhesion</span>. <i>Med. Mol. Morphol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">154</span>â <span class="NLM_lpage">160</span>, <span class="refDoi">Â DOI: 10.1007/s00795-006-0325-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1007%2Fs00795-006-0325-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=16998626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvFaktL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2006&pages=154-160&author=Y.+Nagoshiauthor=G.+Yamamotoauthor=T.+Irieauthor=T.+Tachikawa&title=Expression+of+FAK-related+non-kinase+%28FRNK%29+coincides+with+morphological+change+in+the+early+stage+of+cell+adhesion&doi=10.1007%2Fs00795-006-0325-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of FAK-related non-kinase (FRNK) coincides with morphological change in the early stage of cell adhesion</span></div><div class="casAuthors">Nagoshi, Yuuki; Yamamoto, Gou; Irie, Tarou; Tachikawa, Tetsuhiko</div><div class="citationInfo"><span class="NLM_cas:title">Medical Molecular Morphology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">154-160</span>CODEN:
                <span class="NLM_cas:coden">MMMECK</span>;
        ISSN:<span class="NLM_cas:issn">1860-1480</span>.
    
            (<span class="NLM_cas:orgname">Springer Tokyo</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK), a protein tyrosine kinase, has recently been suggested to play a role in signal transduction through integrins.  In fact, FAK is involved in cell proliferation and cell motility by performing signal transduction through integrins.  FAK-related non-kinase (FRNK) has been found to be an inhibitor of FAK.  As the expression level of FRNK in the cell is very low, the study of FRNK up to now has been preferentially performed by gene overexpression, and the role of constitutive FRNK in cells remains unclear.  We hypothesized that FRNK is involved in the adhesion of cells to the extracellular matrix (ECM) and investigated the expression of FRNK by time kinetic anal. shortly after cell seeding.  We found that FRNK expression was significantly increased in the cells during the early stage of cell adhesion to the ECM.  These data indicated that FRNK plays an important role in cell adhesion during the very early stages of cell culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-LqH1MbbiwbVg90H21EOLACvtfcHk0lhYr8cmAb78Zg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvFaktL8%253D&md5=089747908550ca7b0c127886d5b288d1</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1007%2Fs00795-006-0325-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00795-006-0325-8%26sid%3Dliteratum%253Aachs%26aulast%3DNagoshi%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DG.%26aulast%3DIrie%26aufirst%3DT.%26aulast%3DTachikawa%26aufirst%3DT.%26atitle%3DExpression%2520of%2520FAK-related%2520non-kinase%2520%2528FRNK%2529%2520coincides%2520with%2520morphological%2520change%2520in%2520the%2520early%2520stage%2520of%2520cell%2520adhesion%26jtitle%3DMed.%2520Mol.%2520Morphol.%26date%3D2006%26volume%3D39%26spage%3D154%26epage%3D160%26doi%3D10.1007%2Fs00795-006-0325-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hood, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frausto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiosses, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheresh, D. A.</span></span> <span> </span><span class="NLM_article-title">Differential alphav integrin-mediated Ras-ERK signaling during two pathways of angiogenesis</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">933</span>â <span class="NLM_lpage">943</span>, <span class="refDoi">Â DOI: 10.1083/jcb.200304105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1083%2Fjcb.200304105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=12952943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD3sXntFeqsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2003&pages=933-943&author=J.+D.+Hoodauthor=R.+Fraustoauthor=W.+B.+Kiossesauthor=M.+A.+Schwartzauthor=D.+A.+Cheresh&title=Differential+alphav+integrin-mediated+Ras-ERK+signaling+during+two+pathways+of+angiogenesis&doi=10.1083%2Fjcb.200304105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Differential Î±v integrin-mediated Ras-ERK signaling during two pathways of angiogenesis</span></div><div class="casAuthors">Hood, John D.; Frausto, Ricardo; Kiosses, William B.; Schwartz, Martin A.; Cheresh, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">933-943</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Antagonists of Î±vÎ²3 and Î±vÎ²5 disrupt angiogenesis in response to bFGF and VEGF, resp.  These Î±v integrins differentially contribute to sustained Ras-extracellular signal-related kinase (Ras-ERK) signaling in blood vessels, a requirement for endothelial cell survival and angiogenesis.  Inhibition of FAK or Î±vÎ²5 disrupted VEGF-mediated Ras and c-Raf activity on the chick chorioallantoic membrane, whereas blockade of FAK or integrin Î±vÎ²3 had no effect on bFGF-mediated Ras activity, but did suppress c-Raf activation.  Furthermore, retroviral delivery of active Ras or c-Raf promoted ERK activity and angiogenesis, which anti-Î±vÎ²5 blocked upstream of Ras, whereas anti-Î±vÎ²3 blocked downstream of Ras, but upstream of c-Raf.  The activation of c-Raf by bFGF/Î±vÎ²3 not only depended on FAK, but also required p21-activated kinase-dependent phosphorylation of serine 338 on c-Raf, whereas VEGF-mediated c-Raf phosphorylation/activation depended on Src, but not Pak.  Thus, integrins Î±vÎ²3 and Î±vÎ²5 differentially regulate the Ras-ERK pathway, accounting for distinct vascular responses during two pathways of angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU0UDA9OptFbVg90H21EOLACvtfcHk0lhYr8cmAb78Zg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXntFeqsbs%253D&md5=2f60d0c4cd182cbfbb68f1cf932cfbd4</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1083%2Fjcb.200304105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.200304105%26sid%3Dliteratum%253Aachs%26aulast%3DHood%26aufirst%3DJ.%2BD.%26aulast%3DFrausto%26aufirst%3DR.%26aulast%3DKiosses%26aufirst%3DW.%2BB.%26aulast%3DSchwartz%26aufirst%3DM.%2BA.%26aulast%3DCheresh%26aufirst%3DD.%2BA.%26atitle%3DDifferential%2520alphav%2520integrin-mediated%2520Ras-ERK%2520signaling%2520during%2520two%2520pathways%2520of%2520angiogenesis%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2003%26volume%3D162%26spage%3D933%26epage%3D943%26doi%3D10.1083%2Fjcb.200304105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vo, T.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howerton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larocque, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlaepfer, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilic, D.</span></span> <span> </span><span class="NLM_article-title">Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">9</span>â <span class="NLM_lpage">22</span>, <span class="refDoi">Â DOI: 10.1016/j.molcel.2007.11.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.molcel.2007.11.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=18206965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlWjt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=9-22&author=S.-T.+Limauthor=X.+L.+Chenauthor=Y.+Limauthor=D.+A.+Hansonauthor=T.-T.+Voauthor=K.+Howertonauthor=N.+Larocqueauthor=S.+J.+Fisherauthor=D.+D.+Schlaepferauthor=D.+Ilic&title=Nuclear+FAK+promotes+cell+proliferation+and+survival+through+FERM-enhanced+p53+degradation&doi=10.1016%2Fj.molcel.2007.11.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation</span></div><div class="casAuthors">Lim, Ssang-Taek; Chen, Xiao Lei; Lim, Yangmi; Hanson, Dan A.; Vo, Thanh-Trang; Howerton, Kyle; Larocque, Nicholas; Fisher, Susan J.; Schlaepfer, David D.; Ilic, Dusko</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-22</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">FAK is known as an integrin- and growth factor-assocd. tyrosine kinase promoting cell motility.  Here we show that, during mouse development, FAK inactivation results in p53- and p21-dependent mesodermal cell growth arrest.  Reconstitution of primary FAK-/-p21-/- fibroblasts revealed that FAK, in a kinase-independent manner, facilitates p53 turnover via enhanced Mdm2-dependent p53 ubiquitination.  P53 inactivation by FAK required FAK FERM F1 lobe binding to p53, FERM F2 lobe-mediated nuclear localization, and FERM F3 lobe for connections to Mdm2 and proteasomal degrdn.  Staurosporine or loss of cell adhesion enhanced FERM-dependent FAK nuclear accumulation.  In primary human cells, FAK knockdown raised p53-p21 levels and slowed cell proliferation but did not cause apoptosis.  Notably, FAK knockdown plus cisplatin triggered p53-dependent cell apoptosis, which was rescued by either full-length FAK or FAK FERM re-expression.  These studies define a scaffolding role for nuclear FAK in facilitating cell survival through enhanced p53 degrdn. under conditions of cellular stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdS7DXtKran7Vg90H21EOLACvtfcHk0lhYr8cmAb78Zg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlWjt7g%253D&md5=e10f327978a82ada4df353390b0edced</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2007.11.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2007.11.031%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DS.-T.%26aulast%3DChen%26aufirst%3DX.%2BL.%26aulast%3DLim%26aufirst%3DY.%26aulast%3DHanson%26aufirst%3DD.%2BA.%26aulast%3DVo%26aufirst%3DT.-T.%26aulast%3DHowerton%26aufirst%3DK.%26aulast%3DLarocque%26aufirst%3DN.%26aulast%3DFisher%26aufirst%3DS.%2BJ.%26aulast%3DSchlaepfer%26aufirst%3DD.%2BD.%26aulast%3DIlic%26aufirst%3DD.%26atitle%3DNuclear%2520FAK%2520promotes%2520cell%2520proliferation%2520and%2520survival%2520through%2520FERM-enhanced%2520p53%2520degradation%26jtitle%3DMol.%2520Cell%26date%3D2008%26volume%3D29%26spage%3D9%26epage%3D22%26doi%3D10.1016%2Fj.molcel.2007.11.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cox, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stettner, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gladson, C. L.</span></span> <span> </span><span class="NLM_article-title">New concepts regarding focal adhesion kinase promotion of cell migration and proliferation</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">35</span>â <span class="NLM_lpage">52</span>, <span class="refDoi">Â DOI: 10.1002/jcb.20956</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1002%2Fjcb.20956" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=16823799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BD28rhtFGgug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2006&pages=35-52&author=B.+D.+Coxauthor=M.+Natarajanauthor=M.+R.+Stettnerauthor=C.+L.+Gladson&title=New+concepts+regarding+focal+adhesion+kinase+promotion+of+cell+migration+and+proliferation&doi=10.1002%2Fjcb.20956"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">New concepts regarding focal adhesion kinase promotion of cell migration and proliferation</span></div><div class="casAuthors">Cox Braden D; Natarajan Meera; Stettner Michelle R; Gladson Candece L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of cellular biochemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-52</span>
        ISSN:<span class="NLM_cas:issn">0730-2312</span>.
    </div><div class="casAbstract">Focal adhesion kinase (FAK) is a non-receptor cytoplasmic tyrosine kinase that plays a key role in the regulation of proliferation and migration of normal and tumor cells.  FAK associates with integrin receptors and recruits other molecules to the site of this interaction thus forming a signaling complex that transmits signals from the extracellular matrix to the cell cytoskeleton.  Crk-associated substrate (CAS) family members appear to play a pivotal role in FAK regulation of cell migration.  Cellular Src bound to FAK phosphorylates CAS proteins leading to the recruitment of a Crk family adaptor molecule and activation of a small GTPase and c-Jun N-terminal kinase (JNK) promoting membrane protrusion and cell migration.  The relocalization of CAS and signaling through specific CAS family members appears to determine the outcome of this pathway.  FAK also plays an important role in regulating cell cycle progression through transcriptional control of the cyclin D1 promoter by the Ets B and Kruppel-like factor 8 (KLF8) transcription factors.  FAK regulation of cell cycle progression in tumor cells requires Erk activity, cyclin D1 transcription, and the cyclin-dependent kinase (cdk) inhibitor p27Kip1.  The ability of FAK to integrate integrin and growth factor signals resulting in synergistic promotion of cell migration and proliferation, and its potential regulation by nuclear factor kappa B (NFkappaB) and p53 and a ubiquitously expressed inhibitory protein, suggest that it is remarkable in its capacity to integrate multiple extracellular and intracellular stimuli.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJXl7Nm0CVcjAEfvC7EH1LfW6udTcc2ebpWtvcIoT1M7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28rhtFGgug%253D%253D&md5=418bfd01c7dacb9607c4c591973b30b5</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Fjcb.20956&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.20956%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DB.%2BD.%26aulast%3DNatarajan%26aufirst%3DM.%26aulast%3DStettner%26aufirst%3DM.%2BR.%26aulast%3DGladson%26aufirst%3DC.%2BL.%26atitle%3DNew%2520concepts%2520regarding%2520focal%2520adhesion%2520kinase%2520promotion%2520of%2520cell%2520migration%2520and%2520proliferation%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2006%26volume%3D99%26spage%3D35%26epage%3D52%26doi%3D10.1002%2Fjcb.20956" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Provenzano, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keely, P. J.</span></span> <span> </span><span class="NLM_article-title">The role of focal adhesion kinase in tumor initiation and progression</span>. <i>Cell Adhes. Migr.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">347</span>â <span class="NLM_lpage">350</span>, <span class="refDoi">Â DOI: 10.4161/cam.3.4.9458</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.4161%2Fcam.3.4.9458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=19690467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BD1MjovF2hsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2009&pages=347-350&author=P.+P.+Provenzanoauthor=P.+J.+Keely&title=The+role+of+focal+adhesion+kinase+in+tumor+initiation+and+progression&doi=10.4161%2Fcam.3.4.9458"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The role of focal adhesion kinase in tumor initiation and progression</span></div><div class="casAuthors">Provenzano Paolo P; Keely Patricia J</div><div class="citationInfo"><span class="NLM_cas:title">Cell adhesion & migration</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">347-50</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Focal adhesion kinase (FAK) is a nonreceptor tyrosine kinase that acts as a primary regulator of focal adhesion signaling to regulate cell proliferation, survival and migration.  While FAK is known to directly influence many fundamental adhesion and growth factor signaling pathways important in cancer and FAK is overexpressed in multiple human cancers studies addressing a causal role for FAK in tumor initiation and progression using transgenic models of human cancer had not been performed.  Recently, using tissue-specific FAK-knockout in mouse models of human cancer, the consequences of FAK ablation in carcinoma were demonstrated by multiple independent research groups.  Strong consensus evidence indicates that epithelial cells are able to transform in the absence of FAK, but do not undergo a malignant conversion to invasive carcinoma, and as such, metastasis is impaired.  This is likely the consequence of decreased Src and p130Cas activation in concert with misregulated actin cytoskeleton dynamics and Rho GTPase signaling.  Hence, FAK, as well as the FAK-regulating/regulated signaling network, are viable candidates for cancer metastasis therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQSKpjb2A3ZN4HWj6b1v8uTfW6udTcc2ebpWtvcIoT1M7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MjovF2hsg%253D%253D&md5=b3f87614a88c83c60c13b5c8c8273867</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.4161%2Fcam.3.4.9458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcam.3.4.9458%26sid%3Dliteratum%253Aachs%26aulast%3DProvenzano%26aufirst%3DP.%2BP.%26aulast%3DKeely%26aufirst%3DP.%2BJ.%26atitle%3DThe%2520role%2520of%2520focal%2520adhesion%2520kinase%2520in%2520tumor%2520initiation%2520and%2520progression%26jtitle%3DCell%2520Adhes.%2520Migr.%26date%3D2009%26volume%3D3%26spage%3D347%26epage%3D350%26doi%3D10.4161%2Fcam.3.4.9458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Z. X.</span></span> <span> </span><span class="NLM_article-title">Sonic hedgehog signaling pathway induces cell migration and invasion through focal adhesion kinase/AKT signaling-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9 in liver cancer</span>. <i>Carcinogenesis</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">10</span>â <span class="NLM_lpage">19</span>, <span class="refDoi">Â DOI: 10.1093/carcin/bgs274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1093%2Fcarcin%2Fbgs274" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=22948179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFShtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=10-19&author=J.+S.+Chenauthor=X.+H.+Huangauthor=Q.+Wangauthor=J.+Q.+Huangauthor=L.+J.+Zhangauthor=X.+L.+Chenauthor=J.+Leiauthor=Z.+X.+Cheng&title=Sonic+hedgehog+signaling+pathway+induces+cell+migration+and+invasion+through+focal+adhesion+kinase%2FAKT+signaling-mediated+activation+of+matrix+metalloproteinase+%28MMP%29-2+and+MMP-9+in+liver+cancer&doi=10.1093%2Fcarcin%2Fbgs274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Sonic hedgehog signaling pathway induces cell migration and invasion through focal adhesion kinase/AKT signaling-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9 in liver cancer</span></div><div class="casAuthors">Chen, Jing-Song; Huang, Xiao-hui; Wang, Qian; Huang, Jiong-Qiang; Zhang, Long-juan; Chen, Xi-Lin; Lei, Jian; Cheng, Zhi-Xiang</div><div class="citationInfo"><span class="NLM_cas:title">Carcinogenesis</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10-19</span>CODEN:
                <span class="NLM_cas:coden">CRNGDP</span>;
        ISSN:<span class="NLM_cas:issn">0143-3334</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The aberrant activation of sonic hedgehog (SHH) pathway contributes to initiation and progression of various malignancies.  However, the roles and underlying mechanisms of SHH signaling pathway in invasion and metastasis of liver cancer have not been well understood.  In this study, we found that SHH signaling was activated and correlated with invasion and metastasis in hepatocellular carcinoma (HCC).  Enhanced SHH signaling by recombinant human SHH N-terminal peptide (rSHH-N) promoted hepatoma cell adhesion, migration and invasion, whereas blockade of SHH signaling with SHH neutralizing antibody or cyclopamine suppressed hepatoma cell adhesion, migration and invasion.  Furthermore, matrix metalloproteinase (MMP)-2 and MMP-9 expressions and activities were upregulated and downregulated by rSHH-N and SHH signaling inhibitor, resp.  The rSHH-N-mediated hepatoma cell migration and invasion was blocked by MMP-specific inhibitors or neutralizing antibodies to MMP-2 and MMP-9.  In addn., phosphorylations of AKT and focal adhesion kinase (FAK) were increased and decreased by rSHH-N and SHH signaling inhibitor, resp.  Further investigations showed that activation of AKT and FAK were required for rSHH-N-mediated upregulation of MMP-2 and MMP-9, cell migration and invasion.  Finally, we found that SHH protein expression was pos. correlated with phosphorylatd FAK Tyr397, phosphorylatd AKT Ser473, MMP-2 and MMP-9 protein expressions in HCC samples.  Taken together, our findings suggest that SHH pathway induces cell migration and invasion through FAK/AKT signaling-mediated MMP-2 and MMP-9 prodn. and activation in liver cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGG0YUNI5-47Vg90H21EOLACvtfcHk0lj59-k5wzVtmw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFShtw%253D%253D&md5=c10ad0d036d241386f3c4282342d0409</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1093%2Fcarcin%2Fbgs274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcarcin%252Fbgs274%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%2BS.%26aulast%3DHuang%26aufirst%3DX.%2BH.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DJ.%2BQ.%26aulast%3DZhang%26aufirst%3DL.%2BJ.%26aulast%3DChen%26aufirst%3DX.%2BL.%26aulast%3DLei%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DZ.%2BX.%26atitle%3DSonic%2520hedgehog%2520signaling%2520pathway%2520induces%2520cell%2520migration%2520and%2520invasion%2520through%2520focal%2520adhesion%2520kinase%252FAKT%2520signaling-mediated%2520activation%2520of%2520matrix%2520metalloproteinase%2520%2528MMP%2529-2%2520and%2520MMP-9%2520in%2520liver%2520cancer%26jtitle%3DCarcinogenesis%26date%3D2013%26volume%3D34%26spage%3D10%26epage%3D19%26doi%3D10.1093%2Fcarcin%2Fbgs274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, J. L.</span></span> <span> </span><span class="NLM_article-title">FAK-mediated src phosphorylation of endophilin A2 inhibits endocytosis of MT1-MMP and promotes ECM degradation</span>. <i>Dev. Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">185</span>â <span class="NLM_lpage">196</span>, <span class="refDoi">Â DOI: 10.1016/j.devcel.2005.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.devcel.2005.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=16054026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2MXovFSgsrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2005&pages=185-196&author=X.+Wuauthor=B.+Ganauthor=Y.+Yooauthor=J.+L.+Guan&title=FAK-mediated+src+phosphorylation+of+endophilin+A2+inhibits+endocytosis+of+MT1-MMP+and+promotes+ECM+degradation&doi=10.1016%2Fj.devcel.2005.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">FAK-mediated Src phosphorylation of endophilin A2 inhibits endocytosis of MT1-MMP and promotes ECM degradation</span></div><div class="casAuthors">Wu, Xiaoyang; Gan, Boyi; Yoo, Youngdong; Guan, Jun-Lin</div><div class="citationInfo"><span class="NLM_cas:title">Developmental Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">185-196</span>CODEN:
                <span class="NLM_cas:coden">DCEEBE</span>;
        ISSN:<span class="NLM_cas:issn">1534-5807</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) is an important mediator of integrin signaling in the regulation of cell proliferation, survival, migration, and invasion.  To understand how FAK contributes to cell invasion, we explored the regulation of matrix metalloproteinases (MMPs) by FAK.  We found that v-Src-transformed cells activate a FAK-dependent mechanism that attenuates endocytosis of MT1-MMP.  This in turn increases cell-surface expression of MT1-MMP and cellular degrdn. of extracellular matrix.  Further, we identified an interaction between FAK's second Pro-rich motif and endophilin A2's SH3 domain.  This interaction served as an autophosphorylation-dependent scaffold to allow Src phosphorylation of endophilin A2 at Tyr315.  Tyr315 phosphorylation inhibited endophilin/dynamin interactions, and blockade of Tyr315 phosphorylation promoted endocytosis of MT1-MMP.  Together, these results suggest a regulatory mechanism of cell invasion whereby FAK promotes cell-surface presentation of MT1-MMP by inhibiting endophilin A2-dependent endocytosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnxJDusftK47Vg90H21EOLACvtfcHk0ljjSNytbvWpBg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXovFSgsrs%253D&md5=0943cc91d3f9f1b3bafc985708f6d318</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.devcel.2005.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.devcel.2005.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DX.%26aulast%3DGan%26aufirst%3DB.%26aulast%3DYoo%26aufirst%3DY.%26aulast%3DGuan%26aufirst%3DJ.%2BL.%26atitle%3DFAK-mediated%2520src%2520phosphorylation%2520of%2520endophilin%2520A2%2520inhibits%2520endocytosis%2520of%2520MT1-MMP%2520and%2520promotes%2520ECM%2520degradation%26jtitle%3DDev.%2520Cell%26date%3D2005%26volume%3D9%26spage%3D185%26epage%3D196%26doi%3D10.1016%2Fj.devcel.2005.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobie, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span> <span> </span><span class="NLM_article-title">MicroRNA-7 inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via targeting FAK expression</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e41523</span> <span class="refDoi">Â DOI: 10.1371/journal.pone.0041523</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1371%2Fjournal.pone.0041523" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=22876288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFKht7nF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&author=X.+Kongauthor=G.+Liauthor=Y.+Yuanauthor=Y.+Heauthor=X.+Wuauthor=W.+Zhangauthor=Z.+Wuauthor=T.+Chenauthor=W.+Wuauthor=P.+E.+Lobieauthor=T.+Zhu&title=MicroRNA-7+inhibits+epithelial-to-mesenchymal+transition+and+metastasis+of+breast+cancer+cells+via+targeting+FAK+expression&doi=10.1371%2Fjournal.pone.0041523"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">MicroRNA-7 inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via targeting FAK expression</span></div><div class="casAuthors">Kong, Xiangjun; Li, Gaopeng; Yuan, Yan; He, Yan; Wu, Xiaoli; Zhang, Weijie; Wu, Zhengsheng; Chen, Tingting; Wu, Wenyong; Lobie, Peter E.; Zhu, Tao</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e41523</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) is an important mediator of extracellular matrix integrin signaling, cell motility, cell proliferation and cell survival.  Increased FAK expression is obsd. in a variety of solid human tumors and increased FAK expression and activity frequently correlate with metastatic disease and poor prognosis.  Herein we identify miR-7 as a direct regulator of FAK expression.  MiR-7 expression is decreased in malignant vs. normal breast tissue and its expression correlates inversely with metastasis in human breast cancer patients.  Forced expression of miR-7 produced increased E-cadherin and decreased fibronectin and vimentin expression in breast cancer cells.  The levels of miR-7 expression was pos. correlated with E-cadherin mRNA and neg. correlated with vimentin mRNA levels in breast cancer samples.  Forced expression of miR-7 in aggressive breast cancer cell lines suppressed tumor cell monolayer proliferation, anchorage independent growth, 3D growth in Matrigel, migration and invasion.  Conversely, inhibition of miR-7 in the HBL-100 mammary epithelial cell line promoted cell proliferation and anchorage independent growth.  Rescue of FAK expression reversed miR-7 suppression of migration and invasion.  MiR-7 also inhibited primary breast tumor development, local invasion and metastatic colonization of breast cancer xenografts.  Thus, miR-7 expression is decreased in metastatic breast cancer, correlates with the level of epithelial differentiation of the tumor and inhibits metastatic progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5ivAoV6FlMLVg90H21EOLACvtfcHk0ljjSNytbvWpBg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFKht7nF&md5=e9d4e6c80f87bc0304a1623e036b84fe</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0041523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0041523%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DLobie%26aufirst%3DP.%2BE.%26aulast%3DZhu%26aufirst%3DT.%26atitle%3DMicroRNA-7%2520inhibits%2520epithelial-to-mesenchymal%2520transition%2520and%2520metastasis%2520of%2520breast%2520cancer%2520cells%2520via%2520targeting%2520FAK%2520expression%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26doi%3D10.1371%2Fjournal.pone.0041523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlaepfer, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dressler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, S. J.</span></span> <span> </span><span class="NLM_article-title">Snail1 controls epithelial-mesenchymal lineage commitment in focal adhesion kinase-null embryonic cells</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>195</i></span>,  <span class="NLM_fpage">729</span>â <span class="NLM_lpage">738</span>, <span class="refDoi">Â DOI: 10.1083/jcb.201105103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1083%2Fjcb.201105103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=22105351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Shsb3F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=195&publication_year=2011&pages=729-738&author=X.+Y.+Liauthor=X.+Zhouauthor=R.+G.+Roweauthor=Y.+Huauthor=D.+D.+Schlaepferauthor=D.+Ilicauthor=G.+Dresslerauthor=A.+Parkauthor=J.+L.+Guanauthor=S.+J.+Weiss&title=Snail1+controls+epithelial-mesenchymal+lineage+commitment+in+focal+adhesion+kinase-null+embryonic+cells&doi=10.1083%2Fjcb.201105103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Snail1 controls epithelial-mesenchymal lineage commitment in focal adhesion kinase-null embryonic cells</span></div><div class="casAuthors">Li, Xiao-Yan; Zhou, Xiaoming; Rowe, R. Grant; Hu, Yuexian; Schlaepfer, David D.; Ilic, Dusko; Dressler, Gregory; Park, Ann; Guan, Jun-Lin; Weiss, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">195</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">729-738</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Mouse embryonic cells isolated from focal adhesion kinase (FAK)-null animals at embryonic day 7.5 display multiple defects in focal adhesion remodeling, microtubule dynamics, mechanotransduction, proliferation, directional motility, and invasion.  To date, the ability of FAK to modulate cell function has been ascribed largely to its control of posttranscriptional signaling cascades in this embryonic cell population.  In this paper, we demonstrate that FAK unexpectedly exerts control over an epithelial-mesenchymal transition (EMT) program that commits embryonic FAK-null cells to an epithelial status highlighted by the expression of E-cadherin, desmoplakin, and cytokeratins.  FAK rescue reestablished the mesenchymal characteristics of FAK-null embryonic cells to generate committed mouse embryonic fibroblasts via an extracellular signal-related kinase- and Akt-dependent signaling cascade that triggered Snail1 gene expression and Snail1 protein stabilization.  These findings identify FAK as a novel regulator of Snail1-dependent EMT in embryonic cells and suggest that multiple defects in FAK-/- cell behavior can be attributed to an inappropriate commitment of these cells to an epithelial, rather than fibroblastic, phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqWY6u9fxsH7Vg90H21EOLACvtfcHk0liGQA-vJUKIVg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Shsb3F&md5=a2d30bd912fa7ea6dc001d59140b1e42</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1083%2Fjcb.201105103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.201105103%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%2BY.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DRowe%26aufirst%3DR.%2BG.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DSchlaepfer%26aufirst%3DD.%2BD.%26aulast%3DIlic%26aufirst%3DD.%26aulast%3DDressler%26aufirst%3DG.%26aulast%3DPark%26aufirst%3DA.%26aulast%3DGuan%26aufirst%3DJ.%2BL.%26aulast%3DWeiss%26aufirst%3DS.%2BJ.%26atitle%3DSnail1%2520controls%2520epithelial-mesenchymal%2520lineage%2520commitment%2520in%2520focal%2520adhesion%2520kinase-null%2520embryonic%2520cells%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2011%26volume%3D195%26spage%3D729%26epage%3D738%26doi%3D10.1083%2Fjcb.201105103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Spiegelaere, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casteleyn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den Broeck, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plendl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahramsoltani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simoens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djonov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornillie, P.</span></span> <span> </span><span class="NLM_article-title">Intussusceptive angiogenesis: a biologically relevant form of angiogenesis</span>. <i>J. Vasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">390</span>â <span class="NLM_lpage">404</span>, <span class="refDoi">Â DOI: 10.1159/000338278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1159%2F000338278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=22739226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BC38jltl2quw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2012&pages=390-404&author=W.+De%0ASpiegelaereauthor=C.+Casteleynauthor=W.+Van+den+Broeckauthor=J.+Plendlauthor=M.+Bahramsoltaniauthor=P.+Simoensauthor=V.+Djonovauthor=P.+Cornillie&title=Intussusceptive+angiogenesis%3A+a+biologically+relevant+form+of+angiogenesis&doi=10.1159%2F000338278"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Intussusceptive angiogenesis: a biologically relevant form of angiogenesis</span></div><div class="casAuthors">De Spiegelaere Ward; Casteleyn Christophe; Van den Broeck Wim; Plendl Johanna; Bahramsoltani Mahtab; Simoens Paul; Djonov Valentin; Cornillie Pieter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of vascular research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">390-404</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Angiogenesis, i.e. the development and growth of blood vessels, is a major topic of research as it plays an important role in normal development and in various pathologies.  Recent evidence revealed the existence of different mechanisms of blood vessel growth, including sprouting and intussusceptive angiogenesis, vascular mimicry, and blood vessel cooption.  The latter two have only been observed in tumor growth, but sprouting and intussusceptive angiogenesis also occur in healthy, physiologically growing tissues.  Despite this variety of angiogenic mechanisms, most of the current research is focused on the mechanism of sprouting angiogenesis because this mechanism was first described and because most existing experimental models are related to sprouting angiogenesis.  Consequently, the mechanism of intussusceptive angiogenesis is often overlooked in angiogenesis research.  Here, the mechanism of intussusceptive angiogenesis is reviewed and the current techniques and models for investigating intussusceptive angiogenesis are summarized.  In addition, other mechanisms of vascular growth are briefly reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ5rIFf53X9dXp3bfzSLaX5fW6udTcc2eaX261N0f2Ggbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38jltl2quw%253D%253D&md5=46b1458050b12c337bc8c9443c27f478</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1159%2F000338278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000338278%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSpiegelaere%26aufirst%3DW.%26aulast%3DCasteleyn%26aufirst%3DC.%26aulast%3DVan%2Bden%2BBroeck%26aufirst%3DW.%26aulast%3DPlendl%26aufirst%3DJ.%26aulast%3DBahramsoltani%26aufirst%3DM.%26aulast%3DSimoens%26aufirst%3DP.%26aulast%3DDjonov%26aufirst%3DV.%26aulast%3DCornillie%26aufirst%3DP.%26atitle%3DIntussusceptive%2520angiogenesis%253A%2520a%2520biologically%2520relevant%2520form%2520of%2520angiogenesis%26jtitle%3DJ.%2520Vasc.%2520Res.%26date%3D2012%26volume%3D49%26spage%3D390%26epage%3D404%26doi%3D10.1159%2F000338278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, O. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, M. J.</span></span> <span> </span><span class="NLM_article-title">Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2003</span>â <span class="NLM_lpage">2012</span>, <span class="refDoi">Â DOI: 10.1016/j.cellsig.2007.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.cellsig.2007.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=17658244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFylsLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2007&pages=2003-2012&author=K.+Holmesauthor=O.+L.+Robertsauthor=A.+M.+Thomasauthor=M.+J.+Cross&title=Vascular+endothelial+growth+factor+receptor-2%3A+structure%2C+function%2C+intracellular+signalling+and+therapeutic+inhibition&doi=10.1016%2Fj.cellsig.2007.05.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition</span></div><div class="casAuthors">Holmes, Katherine; Roberts, Owain Ll; Thomas, Angharad M.; Cross, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2003-2012</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Vascular endothelial growth factors (VEGFs) regulate vascular development, angiogenesis and lymphangiogenesis by binding to a no. of receptors.  VEGFR-1 is required for the recruitment of hematopoietic stem cells and the migration of monocytes and macrophages, VEGFR-2 regulates vascular endothelial function and VEGFR-3 regulates lymphatic endothelial cell function.  Over the last decade, considerable progress has been made in delineating the VEGFR-2 specific intracellular signaling cascades leading to proliferation, migration, survival and increased permeability, each of which contributes to the angiogenic response.  Furthermore, therapeutic inhibition of VEGFR-2 action is now having an impact in the clinic for the treatment of a no. of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTYxPMokVV57Vg90H21EOLACvtfcHk0liGQA-vJUKIVg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFylsLs%253D&md5=44a935f36d29b000d2a9ff514709e9c2</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2007.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2007.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DHolmes%26aufirst%3DK.%26aulast%3DRoberts%26aufirst%3DO.%2BL.%26aulast%3DThomas%26aufirst%3DA.%2BM.%26aulast%3DCross%26aufirst%3DM.%2BJ.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520receptor-2%253A%2520structure%252C%2520function%252C%2520intracellular%2520signalling%2520and%2520therapeutic%2520inhibition%26jtitle%3DCell.%2520Signalling%26date%3D2007%26volume%3D19%26spage%3D2003%26epage%3D2012%26doi%3D10.1016%2Fj.cellsig.2007.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eliceiri, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puente, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stupack, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlaepfer, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheppard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheresh, D. A.</span></span> <span> </span><span class="NLM_article-title">Src-mediated coupling of focal adhesion kinase to integrin Î±vÎ²5 in vascular endothelial growth factor signaling</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">149</span>â <span class="NLM_lpage">159</span>, <span class="refDoi">Â DOI: 10.1083/jcb.200109079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1083%2Fjcb.200109079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=11927607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1Knsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2002&pages=149-159&author=B.+P.+Eliceiriauthor=X.+S.+Puenteauthor=J.+D.+Hoodauthor=D.+G.+Stupackauthor=D.+D.+Schlaepferauthor=X.+Z.+Huangauthor=D.+Sheppardauthor=D.+A.+Cheresh&title=Src-mediated+coupling+of+focal+adhesion+kinase+to+integrin+%CE%B1v%CE%B25+in+vascular+endothelial+growth+factor+signaling&doi=10.1083%2Fjcb.200109079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Src-mediated coupling of focal adhesion kinase to integrin Î±vÎ²5 in vascular endothelial growth factor signaling</span></div><div class="casAuthors">Eliceiri, Brian P.; Puente, Xose S.; Hood, John D.; Stupack, Dwayne G.; Schlaepfer, David D.; Huang, Xiaozhu Z.; Sheppard, Dean; Cheresh, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">149-159</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Vascular endothelial growth factor (VEGF) promotes vascular permeability (VP) and neovascularization, and is required for development.  The authors find that VEGF-stimulated Src activity in chick embryo blood vessels induces the coupling of focal adhesion kinase (FAK) to integrin Î±vÎ²5, a crit. event in VEGF-mediated signaling and biol. responsiveness.  In contrast, FAK is constitutively assocd. with Î²1 and Î²3 integrins in the presence or absence of growth factors.  In cultured endothelial cells, VEGF, but not basic fibroblast growth factor, promotes the Src-mediated phosphorylation of FAK on tyrosine 861, which contributes to the formation of a FAK/Î±vÎ²5 signaling complex.  Moreover, formation of this FAK/Î±vÎ²5 complex is significantly reduced in pp60c-src-deficient mice.  Supporting these results, mice deficient in either pp60c-src or integrin Î²5, but not integrin Î²3, have a reduced VP response to VEGF.  This FAK/Î±vÎ²5 complex was also detected in epidermal growth factor-stimulated epithelial cells, suggesting a function for this complex outside the endothelium.  The authors' findings indicate that Src can coordinate specific growth factor-and extracellular matrix inputs by recruiting integrin Î±vÎ²5 into a FAK-contg. signaling complex during growth factor-mediated biol. responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzzJeqoz_BELVg90H21EOLACvtfcHk0lizCwQ7gPCeWA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1Knsbw%253D&md5=189ae93bcda7c1272c3ec217ce0d494d</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1083%2Fjcb.200109079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.200109079%26sid%3Dliteratum%253Aachs%26aulast%3DEliceiri%26aufirst%3DB.%2BP.%26aulast%3DPuente%26aufirst%3DX.%2BS.%26aulast%3DHood%26aufirst%3DJ.%2BD.%26aulast%3DStupack%26aufirst%3DD.%2BG.%26aulast%3DSchlaepfer%26aufirst%3DD.%2BD.%26aulast%3DHuang%26aufirst%3DX.%2BZ.%26aulast%3DSheppard%26aufirst%3DD.%26aulast%3DCheresh%26aufirst%3DD.%2BA.%26atitle%3DSrc-mediated%2520coupling%2520of%2520focal%2520adhesion%2520kinase%2520to%2520integrin%2520%25CE%25B1v%25CE%25B25%2520in%2520vascular%2520endothelial%2520growth%2520factor%2520signaling%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2002%26volume%3D157%26spage%3D149%26epage%3D159%26doi%3D10.1083%2Fjcb.200109079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, J. L.</span></span> <span> </span><span class="NLM_article-title">Nuclear FAK and its kinase activity regulate VEGFR2 transcription in angiogenesis of adult mice</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2550</span>â <span class="NLM_lpage">2560</span>, <span class="refDoi">Â DOI: 10.1038/s41598-018-20930-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fs41598-018-20930-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=29416084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BC1MvovV2gsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=2550-2560&author=S.+Sunauthor=H.+J.+Wuauthor=J.+L.+Guan&title=Nuclear+FAK+and+its+kinase+activity+regulate+VEGFR2+transcription+in+angiogenesis+of+adult+mice&doi=10.1038%2Fs41598-018-20930-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Nuclear FAK and its kinase activity regulate VEGFR2 transcription in angiogenesis of adult mice</span></div><div class="casAuthors">Sun Shaogang; Wu Hsin-Jung; Guan Jun-Lin</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2550</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Focal adhesion kinase (FAK) is essential in embryonic angiogenesis by regulating endothelial cell (EC) survival and barrier functions through its kinase-independent and -dependent activities.  Here, we generated EC-specific tamoxifen-inducible FAK knockout and FAK kinase-defective (KD) mutant knockin mice to investigate the role of FAK and its kinase activity in angiogenesis of adult animals.  Unlike previous observations of their differential defects in embryonic vascular development, both FAK ablation and inactivation of its kinase activity resulted in deficient angiogenesis in wound-healing as well as retinal angiogenesis models.  Consistent with these phenotypes, loss of FAK or its kinase activity decreased EC proliferation and migration to similar extents, suggesting FAK primarily acts as a kinase for the regulation of adult EC-mediated angiogenesis.  Further mechanistic analyses were carried out using an established mouse EC line MS1 cells.  Interestingly, we found that FAK regulated the expression of VEGFR2, a central mediator of various EC functions and angiogenesis, which requires both FAK kinase activity and its translocation into the nucleus.  Moreover, nuclear FAK was detected in the RNA polymerase II complex associated with VEGFR2 promoter, suggesting its direct participation in the transcriptional regulation of VEGFR2.  Together, our results provide significant insights into the signaling mechanisms of FAK in angiogenesis that may contribute to future design of more effective angiogenesis related therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRWIOh1FM9PF4kFb3mqPUYDfW6udTcc2eYMinX_1-v7Nrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvovV2gsw%253D%253D&md5=eb4e2071267f246b4f404a8272a708b3</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fs41598-018-20930-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-018-20930-z%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DH.%2BJ.%26aulast%3DGuan%26aufirst%3DJ.%2BL.%26atitle%3DNuclear%2520FAK%2520and%2520its%2520kinase%2520activity%2520regulate%2520VEGFR2%2520transcription%2520in%2520angiogenesis%2520of%2520adult%2520mice%26jtitle%3DSci.%2520Rep.%26date%3D2018%26volume%3D8%26spage%3D2550%26epage%3D2560%26doi%3D10.1038%2Fs41598-018-20930-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tavora, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batista, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadeja, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostourou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruttiger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodivala-Dilke, K. M.</span></span> <span> </span><span class="NLM_article-title">Endothelial FAK is required for tumour angiogenesis</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">516</span>â <span class="NLM_lpage">528</span>, <span class="refDoi">Â DOI: 10.1002/emmm.201000106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1002%2Femmm.201000106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=21154724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFehsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=516-528&author=B.+Tavoraauthor=S.+Batistaauthor=L.+E.+Reynoldsauthor=S.+Jadejaauthor=S.+Robinsonauthor=V.+Kostourouauthor=I.+Hartauthor=M.+Fruttigerauthor=M.+Parsonsauthor=K.+M.+Hodivala-Dilke&title=Endothelial+FAK+is+required+for+tumour+angiogenesis&doi=10.1002%2Femmm.201000106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelial FAK is required for tumour angiogenesis</span></div><div class="casAuthors">Tavora, Bernardo; Batista, Silvia; Reynolds, Louise E.; Jadeja, Shalini; Robinson, Stephen; Kostourou, Vassiliki; Hart, Ian; Fruttiger, Marcus; Parsons, Maddy; Hodivala-Dilke, Kairbaan M.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">516-528</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase that plays a fundamental role in integrin and growth factor mediated signalling and is an important player in cell migration and proliferation, processes vital for angiogenesis.  However, the role of FAK in adult pathol. angiogenesis is unknown.  We have generated endothelial-specific tamoxifen-inducible FAK knockout mice by crossing FAK-floxed (FAKfl/fl) mice with the platelet derived growth factor b (Pdgfb)-iCreER mice.  Tamoxifen-treatment of Pdgfb-iCreER;FAKfl/fl mice results in FAK deletion in adult endothelial cells (ECs) without any adverse effects.  Importantly however, endothelial FAK-deletion in adult mice inhibited tumor growth and reduced tumor angiogenesis.  Furthermore, in in vivo angiogenic assays FAK deletion impairs vascular endothelial growth factor (VEGF)-induced neovascularization.  In addn., in vitro deletion of FAK in ECs resulted in reduced VEGF-stimulated Akt phosphorylation and correlating reduced cellular proliferation as well as increased cell death.  Our data suggest that FAK is required for adult pathol. angiogenesis and validates FAK as a possible target for anti-angiogenic therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7F0jECcbicrVg90H21EOLACvtfcHk0lizCwQ7gPCeWA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFehsg%253D%253D&md5=e1727f709428667a487c2dd61ee9ff9a</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1002%2Femmm.201000106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Femmm.201000106%26sid%3Dliteratum%253Aachs%26aulast%3DTavora%26aufirst%3DB.%26aulast%3DBatista%26aufirst%3DS.%26aulast%3DReynolds%26aufirst%3DL.%2BE.%26aulast%3DJadeja%26aufirst%3DS.%26aulast%3DRobinson%26aufirst%3DS.%26aulast%3DKostourou%26aufirst%3DV.%26aulast%3DHart%26aufirst%3DI.%26aulast%3DFruttiger%26aufirst%3DM.%26aulast%3DParsons%26aufirst%3DM.%26aulast%3DHodivala-Dilke%26aufirst%3DK.%2BM.%26atitle%3DEndothelial%2520FAK%2520is%2520required%2520for%2520tumour%2520angiogenesis%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2010%26volume%3D2%26spage%3D516%26epage%3D528%26doi%3D10.1002%2Femmm.201000106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokol, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcaraz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassalli, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, J. L.</span></span> <span> </span><span class="NLM_article-title">Overexpression of focal adhesion kinase in vascular endothelial cells promotes angiogenesis in transgenic mice</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">421</span>â <span class="NLM_lpage">430</span>, <span class="refDoi">Â DOI: 10.1016/j.cardiores.2004.07.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.cardiores.2004.07.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=15537495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpslOqur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=421-430&author=X.+Pengauthor=H.+Uedaauthor=H.+Zhouauthor=T.+Stokolauthor=T.+L.+Shenauthor=A.+Alcarazauthor=T.+Nagyauthor=J.+D.+Vassalliauthor=J.+L.+Guan&title=Overexpression+of+focal+adhesion+kinase+in+vascular+endothelial+cells+promotes+angiogenesis+in+transgenic+mice&doi=10.1016%2Fj.cardiores.2004.07.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of focal adhesion kinase in vascular endothelial cells promotes angiogenesis in transgenic mice</span></div><div class="casAuthors">Peng, Xu; Ueda, Hiroki; Zhou, Hongming; Stokol, Tracy; Shen, Tang-Long; Alcaraz, Ana; Nagy, Tamas; Vassalli, Jean-Dominique; Guan, Jun-Lin</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">421-430</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Objective: Focal adhesion kinase is implicated in the regulation of cell adhesion, migration, survival, and cell-cycle progression.  However, the functions of focal adhesion kinase in endothelial cell (EC) in vivo remain unclear.  This study aims to examine the role of FAK in EC function and angiogenesis in vivo by transgenic mice approach.  Method: We generated transgenic mice which overexpressed chicken FAK in vascular endothelial cell under the control of the Tie-2 promoter and enhancer.  FAK transgene was detected by RT-PCR, immunopptn., and Western blot.  The effect of FAK overexpression on angiogenesis was detd. using skin wound healing and ischemia skeleton muscle models.  Results: Expression of FAK transgene was detected in all vessel-rich tissues.  Expression of FAK protein was verified by antibody specific for the exogenous chicken FAK in lung homogenates and isolated EC.  In the wound-induced angiogenesis model, the no. of vessels in the granulation tissue of healing wound was significantly increased in the transgenic mouse compared to that of wild-type control mice.  Similarly, in the ischemia skeletal muscle model, the d. of capillaries was significantly increased in the transgenic mouse.  Conclusion: These results indicate that FAK may play an important role in the promotion of angiogenesis in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1cPqtDruvXbVg90H21EOLACvtfcHk0lijZz4buWlYGg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpslOqur4%253D&md5=580dc9765012b88f180df1478cc2a50c</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.cardiores.2004.07.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cardiores.2004.07.012%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DUeda%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DStokol%26aufirst%3DT.%26aulast%3DShen%26aufirst%3DT.%2BL.%26aulast%3DAlcaraz%26aufirst%3DA.%26aulast%3DNagy%26aufirst%3DT.%26aulast%3DVassalli%26aufirst%3DJ.%2BD.%26aulast%3DGuan%26aufirst%3DJ.%2BL.%26atitle%3DOverexpression%2520of%2520focal%2520adhesion%2520kinase%2520in%2520vascular%2520endothelial%2520cells%2520promotes%2520angiogenesis%2520in%2520transgenic%2520mice%26jtitle%3DCardiovasc.%2520Res.%26date%3D2004%26volume%3D64%26spage%3D421%26epage%3D430%26doi%3D10.1016%2Fj.cardiores.2004.07.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kornberg, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spoerri, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caballero, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, M. B.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase overexpression induces enhanced pathological retinal angiogenesis</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">4463</span>â <span class="NLM_lpage">4469</span>, <span class="refDoi">Â DOI: 10.1167/iovs.03-1201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1167%2Fiovs.03-1201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=15557455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BD2crosVGkug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2004&pages=4463-4469&author=L.+J.+Kornbergauthor=L.+C.+Shawauthor=P.+E.+Spoerriauthor=S.+Caballeroauthor=M.+B.+Grant&title=Focal+adhesion+kinase+overexpression+induces+enhanced+pathological+retinal+angiogenesis&doi=10.1167%2Fiovs.03-1201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion kinase overexpression induces enhanced pathological retinal angiogenesis</span></div><div class="casAuthors">Kornberg Lori J; Shaw Lynn C; Spoerri Polyxenie E; Caballero Sergio; Grant Maria B</div><div class="citationInfo"><span class="NLM_cas:title">Investigative ophthalmology & visual science</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4463-9</span>
        ISSN:<span class="NLM_cas:issn">0146-0404</span>.
    </div><div class="casAbstract">PURPOSE:  Focal adhesion kinase (FAK) is involved in processes integral to angiogenesis, such as cell growth, survival, and migration.  FAK is activated by angiogenic growth factors, such as insulin-like growth factor (IGF)-I, vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF).  The study was conducted to determine whether overexpression of FAK or FAK-related nonkinase (FRNK), an inhibitor of FAK, could influence human retinal endothelial cell (HREC) migration and in vivo angiogenesis.  METHODS:  Migration in response to a combination of growth factors was examined in transfected HRECs overexpressing FAK or FRNK.  The effect of FAK or FRNK overexpression on preretinal neovascularization was examined in a mouse model of oxygen-induced retinopathy.  RESULTS:  Overexpression of FAK in HRECs resulted in a 102% +/- 13% increase (P = 1.4 x 10(-4)) in cell migration, whereas overexpression of FRNK resulted in a 20% +/- 8% decrease (P = 0.01).  Overexpression of FAK in mouse eyes led to formation of numerous large vascular tufts resembling glomeruli and a 57% +/- 7% increase in preretinal neovascularization (P = 3 x 10(-9)), whereas FRNK resulted in a 55% +/- 15% reduction (P = 5 x 10(-5)).  CONCLUSIONS:  Modulating the FAK/FRNK system may provide a novel approach to inhibiting pathologic retinal angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSUCQIXDWngcdts4TFFB11gfW6udTcc2eYXI-N5JQZoT7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2crosVGkug%253D%253D&md5=30309e15374c6057b8f868ee7818d92e</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1167%2Fiovs.03-1201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.03-1201%26sid%3Dliteratum%253Aachs%26aulast%3DKornberg%26aufirst%3DL.%2BJ.%26aulast%3DShaw%26aufirst%3DL.%2BC.%26aulast%3DSpoerri%26aufirst%3DP.%2BE.%26aulast%3DCaballero%26aufirst%3DS.%26aulast%3DGrant%26aufirst%3DM.%2BB.%26atitle%3DFocal%2520adhesion%2520kinase%2520overexpression%2520induces%2520enhanced%2520pathological%2520retinal%2520angiogenesis%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2004%26volume%3D45%26spage%3D4463%26epage%3D4469%26doi%3D10.1167%2Fiovs.03-1201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vitillo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iskender, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiting, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimber, S. J.</span></span> <span> </span><span class="NLM_article-title">Integrin-associated focal adhesion kinase protects human embryonic stem cells from apoptosis, detachment, and differentiation</span>. <i>Stem Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">167</span>â <span class="NLM_lpage">176</span>, <span class="refDoi">Â DOI: 10.1016/j.stemcr.2016.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.stemcr.2016.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=27509133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtleqt7%252FP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=167-176&author=L.+Vitilloauthor=M.+Baxterauthor=B.+Iskenderauthor=P.+Whitingauthor=S.+J.+Kimber&title=Integrin-associated+focal+adhesion+kinase+protects+human+embryonic+stem+cells+from+apoptosis%2C+detachment%2C+and+differentiation&doi=10.1016%2Fj.stemcr.2016.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Integrin-Associated Focal Adhesion Kinase Protects Human Embryonic Stem Cells from Apoptosis, Detachment, and Differentiation</span></div><div class="casAuthors">Vitillo, Loriana; Baxter, Melissa; Iskender, Banu; Whiting, Paul; Kimber, Susan J.</div><div class="citationInfo"><span class="NLM_cas:title">Stem Cell Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-176</span>CODEN:
                <span class="NLM_cas:coden">SCRTFL</span>;
        ISSN:<span class="NLM_cas:issn">2213-6711</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Human embryonic stem cells (hESCs) can be maintained in a fully defined niche on extracellular matrix substrates, to which they attach through integrin receptors.  However, the underlying integrin signaling mechanisms, and their contribution to hESC behavior, are largely unknown.  Here, we show that focal adhesion kinase (FAK) transduces integrin activation and supports hESC survival, substrate adhesion, and maintenance of the undifferentiated state.  After inhibiting FAK kinase activity we show that hESCs undergo cell detachment-dependent apoptosis or differentiation.  We also report deactivation of FAK downstream targets, AKT and MDM2, and upregulation of p53, all key players in hESC regulatory networks.  Loss of integrin activity or FAK also induces cell aggregation, revealing a role in the cell-cell interactions of hESCs.  This study provides insight into the integrin signaling cascade activated in hESCs and reveals in FAK a key player in the maintenance of hESC survival and undifferentiated state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogTTbcfl_k9LVg90H21EOLACvtfcHk0lijZz4buWlYGg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtleqt7%252FP&md5=603f2498d735901be97fdb02ff08d91d</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.stemcr.2016.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.stemcr.2016.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DVitillo%26aufirst%3DL.%26aulast%3DBaxter%26aufirst%3DM.%26aulast%3DIskender%26aufirst%3DB.%26aulast%3DWhiting%26aufirst%3DP.%26aulast%3DKimber%26aufirst%3DS.%2BJ.%26atitle%3DIntegrin-associated%2520focal%2520adhesion%2520kinase%2520protects%2520human%2520embryonic%2520stem%2520cells%2520from%2520apoptosis%252C%2520detachment%252C%2520and%2520differentiation%26jtitle%3DStem%2520Cell%2520Rep.%26date%3D2016%26volume%3D7%26spage%3D167%26epage%3D176%26doi%3D10.1016%2Fj.stemcr.2016.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vitillo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimber, S. J.</span></span> <span> </span><span class="NLM_article-title">Integrin and FAK regulation of human pluripotent stem cells</span>. <i>Curr. Stem Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">358</span>â <span class="NLM_lpage">365</span>, <span class="refDoi">Â DOI: 10.1007/s40778-017-0100-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1007%2Fs40778-017-0100-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=29177133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1GqtbbO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=358-365&author=L.+Vitilloauthor=S.+J.+Kimber&title=Integrin+and+FAK+regulation+of+human+pluripotent+stem+cells&doi=10.1007%2Fs40778-017-0100-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Integrin and FAK Regulation of Human Pluripotent Stem Cells</span></div><div class="casAuthors">Vitillo, Loriana; Kimber, Susan J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Stem Cell Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">358-365</span>CODEN:
                <span class="NLM_cas:coden">CSCRFC</span>;
        ISSN:<span class="NLM_cas:issn">2198-7866</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Purpose of review: Human pluripotent stem cells (hPSCs) are anchorage-dependent cells that can be cultured on a variety of matrixes and express integrins and the machinery for integrin signaling.  Until recently, there has been limited understanding of exactly how integrin signaling regulates pluripotent stem cell (PSC) behavior.  This review summarizes our knowledge of how integrins and focal adhesion kinase (FAK) regulate different aspects of hPSC biol.  Recent findings: The latest research suggests that mouse and human embryonic stem cells utilize similar integrin signaling players but with different biol. outcomes, reflecting the known developmental difference in their pluripotent status.  Notably, attachment cues via FAK signaling are crucial for hPSCs survival and pluripotency maintenance.  FAK may be found cortically but also in the nucleus of hPSCs intersecting core pluripotency networks.  Summary: Integrins and FAK have been consigned to the conventional role of cell adhesion receptor systems in PSCs.  This review highlights data indicating that they are firmly integrated in pluripotency circuits, with implications for both research PSC culture and scale up and use in clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFq8wH6gWCyrVg90H21EOLACvtfcHk0ljlJwsHvIcKlQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1GqtbbO&md5=284b07a20c848e8004678d51160e5aec</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1007%2Fs40778-017-0100-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40778-017-0100-x%26sid%3Dliteratum%253Aachs%26aulast%3DVitillo%26aufirst%3DL.%26aulast%3DKimber%26aufirst%3DS.%2BJ.%26atitle%3DIntegrin%2520and%2520FAK%2520regulation%2520of%2520human%2520pluripotent%2520stem%2520cells%26jtitle%3DCurr.%2520Stem%2520Cell%2520Rep.%26date%3D2017%26volume%3D3%26spage%3D358%26epage%3D365%26doi%3D10.1007%2Fs40778-017-0100-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, C. T.</span></span> <span> </span><span class="NLM_article-title">The increasing complexity of the cancer stem cell paradigm</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>324</i></span>,  <span class="NLM_fpage">1670</span>â <span class="NLM_lpage">1673</span>, <span class="refDoi">Â DOI: 10.1126/science.1171837</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1126%2Fscience.1171837" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=19556499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsFOmtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=2009&pages=1670-1673&author=J.+M.+Rosenauthor=C.+T.+Jordan&title=The+increasing+complexity+of+the+cancer+stem+cell+paradigm&doi=10.1126%2Fscience.1171837"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">The Increasing Complexity of the Cancer Stem Cell Paradigm</span></div><div class="casAuthors">Rosen, Jeffrey M.; Jordan, Craig T.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">324</span>
        (<span class="NLM_cas:issue">5935</span>),
    <span class="NLM_cas:pages">1670-1673</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  The investigation and study of cancer stem cells (CSCs) have received enormous attention over the past 5 to 10 years but remain topics of considerable controversy.  Opinions about the validity of the CSC hypothesis, the biol. properties of CSCs, and the relevance of CSCs to cancer therapy differ widely.  In the following commentary, we discuss the nature of the debate, the parameters by which CSCs can or cannot be defined, and the identification of new potential therapeutic targets elucidated by considering cancer as a problem in stem cell biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjo2Ctm2OEuLVg90H21EOLACvtfcHk0ljlJwsHvIcKlQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsFOmtb8%253D&md5=6bf760e35c322979d09acb7d8725fcbb</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1126%2Fscience.1171837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1171837%26sid%3Dliteratum%253Aachs%26aulast%3DRosen%26aufirst%3DJ.%2BM.%26aulast%3DJordan%26aufirst%3DC.%2BT.%26atitle%3DThe%2520increasing%2520complexity%2520of%2520the%2520cancer%2520stem%2520cell%2520paradigm%26jtitle%3DScience%26date%3D2009%26volume%3D324%26spage%3D1670%26epage%3D1673%26doi%3D10.1126%2Fscience.1171837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Islam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, A. K. Y.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cell: fundamental experimental pathological concepts and updates</span>. <i>Exp. Mol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">184</span>â <span class="NLM_lpage">191</span>, <span class="refDoi">Â DOI: 10.1016/j.yexmp.2015.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.yexmp.2015.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=25659759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVShurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2015&pages=184-191&author=F.+Islamauthor=B.+Qiaoauthor=R.+A.+Smithauthor=V.+Gopalanauthor=A.+K.+Y.+Lam&title=Cancer+stem+cell%3A+fundamental+experimental+pathological+concepts+and+updates&doi=10.1016%2Fj.yexmp.2015.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer stem cell: Fundamental experimental pathological concepts and updates</span></div><div class="casAuthors">Islam, Farhadul; Qiao, Bin; Smith, Robert A.; Gopalan, Vinod; Lam, Alfred K.-Y.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental and Molecular Pathology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">184-191</span>CODEN:
                <span class="NLM_cas:coden">EXMPA6</span>;
        ISSN:<span class="NLM_cas:issn">0014-4800</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Cancer stem cells (CSCs) are a subset of cancer cells which play a key role in predicting the biol. aggressiveness of cancer due to its ability of self-renewal and multi-lineage differentiation (stemness).  The CSC model is a dynamic one with a functional subpopulation of cancer cells rather than a stable cell population responsible for tumor regeneration.  Hypotheses regarding the origins of CSCs include (1) malignant transformation of normal stem cells; (2) mature cancer cell de-differentiation with epithelial-mesenchymal transition and (3) induced pluripotent cancer cells.  Surprisingly, the cancer stem cell hypothesis originated in the late nineteenth century and the existence of hematopoietic stem cells was demonstrated a century later, demonstrating that the concept was possible.  In the last decade, CSCs have been identified and isolated in different cancers.  The hallmark traits of CSCs include their heterogeneity, interaction with microenvironments and plasticity.  Understanding these basic concepts of CSCs is important for translational applications using CSCs in the management of patients with cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLXSCUdViS17Vg90H21EOLACvtfcHk0ljlJwsHvIcKlQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVShurg%253D&md5=4972b1065d99c28eeb4f1c0e7002b043</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.yexmp.2015.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexmp.2015.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DIslam%26aufirst%3DF.%26aulast%3DQiao%26aufirst%3DB.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26aulast%3DGopalan%26aufirst%3DV.%26aulast%3DLam%26aufirst%3DA.%2BK.%2BY.%26atitle%3DCancer%2520stem%2520cell%253A%2520fundamental%2520experimental%2520pathological%2520concepts%2520and%2520updates%26jtitle%3DExp.%2520Mol.%2520Pathol.%26date%3D2015%26volume%3D98%26spage%3D184%26epage%3D191%26doi%3D10.1016%2Fj.yexmp.2015.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guan, J. L.</span></span> <span> </span><span class="NLM_article-title">Integrin signaling through FAK in the regulation of mammary stem cells and breast cancer</span>. <i>IUBMB Life</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">268</span>â <span class="NLM_lpage">276</span>, <span class="refDoi">Â DOI: 10.1002/iub.303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1002%2Fiub.303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=20101634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktVCkt7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=268-276&author=J.+L.+Guan&title=Integrin+signaling+through+FAK+in+the+regulation+of+mammary+stem+cells+and+breast+cancer&doi=10.1002%2Fiub.303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Integrin signaling through FAK in the regulation of mammary stem cells and breast cancer</span></div><div class="casAuthors">Guan, Jun-Lin</div><div class="citationInfo"><span class="NLM_cas:title">IUBMB Life</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">268-276</span>CODEN:
                <span class="NLM_cas:coden">IULIF8</span>;
        ISSN:<span class="NLM_cas:issn">1521-6543</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Inc.</span>)
        </div><div class="casAbstract">A review.  Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase identified as a key mediator of intracellular signaling by integrins, a major family of cell surface receptors for extracellular matrix, in the regulation of different cellular functions in a variety of cells.  Upon activation by integrins through disruption of an autoinhibitory mechanism, FAK undergoes autophosphorylation and forms a complex with Src and other cellular proteins to trigger downstream signaling through its kinase activity or scaffolding function.  A no. of integrins are identified as surface markers for mammary stem cells (MaSCs), and both integrins and FAK are found to play crucial roles in the maintenance of MaSCs in studies using mouse models, suggesting that integrin signaling through FAK may serve as a functional marker for MaSCs.  Consistent with previous studies linking increased expression and activation of FAK to human breast cancer, these findings suggest a novel cellular mechanism of FAK promotion of mammary tumorigenesis by maintaining the pools of MaSCs as targets of oncogenic transformation.  Furthermore, FAK inactivation in mouse models of breast cancer also reduced the pool of mammary cancer stem cells (MaCSCs), decreased their self-renewal in vitro, and compromised their tumorigenicity and maintenance in vivo, suggesting a potential role of integrin signaling through FAK in breast cancer growth and progression through its functions in MaCSCs.  This review discusses these recent advances and future studies into the mechanism of integrin signaling through FAK in breast cancer through regulation of MaCSCs that may lead to development of novel therapies for this deadly disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvsXqcHLeK-LVg90H21EOLACvtfcHk0ljlJwsHvIcKlQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktVCkt7w%253D&md5=8ae587cfc215d598bdb5811d14936fba</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1002%2Fiub.303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fiub.303%26sid%3Dliteratum%253Aachs%26aulast%3DGuan%26aufirst%3DJ.%2BL.%26atitle%3DIntegrin%2520signaling%2520through%2520FAK%2520in%2520the%2520regulation%2520of%2520mammary%2520stem%2520cells%2520and%2520breast%2520cancer%26jtitle%3DIUBMB%2520Life%26date%3D2010%26volume%3D62%26spage%3D268%26epage%3D276%26doi%3D10.1002%2Fiub.303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zajac-Kaye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochwald, S. N.</span></span> <span> </span><span class="NLM_article-title">A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">3143</span>â <span class="NLM_lpage">3149</span>, <span class="refDoi">Â DOI: 10.4161/15384101.2014.949550</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.4161%2F15384101.2014.949550" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=25486573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCgsLfN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=3143-3149&author=J.+Zhangauthor=D.+H.+Heauthor=M.+Zajac-Kayeauthor=S.+N.+Hochwald&title=A+small+molecule+FAK+kinase+inhibitor%2C+GSK2256098%2C+inhibits+growth+and+survival+of+pancreatic+ductal+adenocarcinoma+cells&doi=10.4161%2F15384101.2014.949550"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells</span></div><div class="casAuthors">Zhang, Jianliang; He, Di-Hua; Zajac-Kaye, Maria; Hochwald, Steven N.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3143-3149</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) hyperactivation is common in pancreatic ductal adenocarcinoma (PDAC).  A small mol., GSK2256098 (GlaxoSmithKline), has been developed to inhibit FAK activity through targeting the phosphorylation site of FAK, tyrosine (Y) 397.  We sought to det. whether GSK2256098 inhibition of FAK Y397 phosphorylation attenuates PDAC-assocd. cell proliferation, motility and survival.  Cultured PDAC cells were used as cellular models of GSK2256098-impaired abnormal growth.  Western blot anal., cell viability anal., clonogenic survival, soft-agar and wound healing assays were performed.  The responses of 6 PDAC cell lines in regards to FAK Y397 phosphorylation or activity to GSK2256098 treatments (0.1-10 Î¼M) ranged from low (less than 20% inhibition) to high (more than 90% inhibition).  The least and most sensitive cell lines (PANC-1 and L3.6P1) were selected for further anal.  GSK2256098 inhibition of FAK Y397 phosphorylation correlated with decreased levels of phosphorylated Akt and ERK in L3.6P1 cells.  GSK2256098 decreased cell viability, anchorage-independent growth, and motility in a dose dependent manner.  Current studies demonstrate that small mol. kinase inhibitors targeting FAK Y397 phosphorylation can inhibit PDAC cell growth.  Assessments of FAK Y397 phosphorylation in biopsies may be used as a biomarker to select the subgroup of responsive patients and/or monitor the effects of GSK2256098 on FAK-modulated tumor growth during treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAxUbBT_oKFLVg90H21EOLACvtfcHk0lhfZtCbLdtUYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCgsLfN&md5=dc429dd3c276670338da9eec6dce6d2e</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.4161%2F15384101.2014.949550&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252F15384101.2014.949550%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DD.%2BH.%26aulast%3DZajac-Kaye%26aufirst%3DM.%26aulast%3DHochwald%26aufirst%3DS.%2BN.%26atitle%3DA%2520small%2520molecule%2520FAK%2520kinase%2520inhibitor%252C%2520GSK2256098%252C%2520inhibits%2520growth%2520and%2520survival%2520of%2520pancreatic%2520ductal%2520adenocarcinoma%2520cells%26jtitle%3DCell%2520Cycle%26date%3D2014%26volume%3D13%26spage%3D3143%26epage%3D3149%26doi%3D10.4161%2F15384101.2014.949550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N. F</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkenau, H.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, R. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auger, K. R</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenox, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plisson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Searle, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saleem, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagden, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulholland, P.</span></span> <span> </span><span class="NLM_article-title">A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098</span>. <i>Neuro-Oncology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1634</span>â <span class="NLM_lpage">1642</span>, <span class="refDoi">Â DOI: 10.1093/neuonc/noy078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1093%2Fneuonc%2Fnoy078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=29788497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlKisb3E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2018&pages=1634-1642&author=N.+F+Brownauthor=M.+Williamsauthor=H.-T.+Arkenauauthor=R.+A+Flemingauthor=J.+Tolsonauthor=L.+Yanauthor=J.+Zhangauthor=R.+Singhauthor=K.+R+Augerauthor=L.+Lenoxauthor=D.+Coxauthor=Y.+Lewisauthor=C.+Plissonauthor=G.+Searleauthor=A.+Saleemauthor=S.+Blagdenauthor=P.+Mulholland&title=A+study+of+the+focal+adhesion+kinase+inhibitor+GSK2256098+in+patients+with+recurrent+glioblastoma+with+evaluation+of+tumor+penetration+of+%5B11C%5DGSK2256098&doi=10.1093%2Fneuonc%2Fnoy078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098</span></div><div class="casAuthors">Brown, Nicholas F.; Williams, Matthew; Arkenau, Hendrik-Tobias; Fleming, Ronald A.; Tolson, Jerry; Yan, Li; Zhang, Jianping; Swartz, Lisa; Singh, Rajendra; Auger, Kurt R.; Lenox, Laurie; Cox, David; Lewis, Yvonne; Plisson, Christophe; Searle, Graham; Saleem, Azeem; Blagden, Sarah; Mulholland, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Neuro-Oncology (Cary, NC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1634-1642</span>CODEN:
                <span class="NLM_cas:coden">NEURJR</span>;
        ISSN:<span class="NLM_cas:issn">1523-5866</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background.  GSK2256098 is a novel oral focal adhesion kinase (FAK) inhibitor.  Preclin. studies demonstrate growth inhibition in glioblastoma cell lines.  However, rodent studies indicate limited blood-brain barrier (BBB) penetration.  In this expansion cohort within a phase I study, the safety, tolerability, pharmacokinetics (PK), and clin. activity of GSK2256098 were evaluated in patients with recurrent glioblastoma.  Biodistribution and kinetics of [11C]GSK2256098 were assessed in a substudy using positron-emission tomog. (PET).  Patients were treated with GSK2256098 until disease progression or withdrawal due to adverse events (AEs).  Serial PK samples were collected on day 1.  On a single day between days 9 and 20, patients received a microdose of i.v. [11C]GSK2256098 and were scanned with PET over 90 min with parallel PK sample collection.  Response was assessed by MRI every 6 wk.  Thirteen patients were treated in 3 dose cohorts (1000 mg, 750 mg, 500 mg; all dosed twice daily).  The max. tolerated dose was 1000 mg twice daily.  Dose-limiting toxicities were related to cerebral edema.  Treatment-related AEs (>25%) were diarrhea, fatigue, and nausea.  Eight patients participated in the PET substudy, with [11C]GSK2256098 VT (vol. of distribution) ests. of 0.9 in tumor tissue, 0.5 in surrounding T2 enhancing areas, and 0.4 in normal brain.  Best response of stable disease was obsd. in 3 patients, including 1 patient on treatment for 11.3 mo.  Conclusions.  GSK2256098 was tolerable in patients with relapsed glioblastoma.  GSK2256098 crossed the BBB at low levels into normal brain, but at markedly higher levels into tumor, consistent with tumor-assocd. BBB disruption.  Addnl. clin. trials of GSK2256098 are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWQtMrUNJlabVg90H21EOLACvtfcHk0lhfZtCbLdtUYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlKisb3E&md5=7d3a897bb8ee9360e7cf424c40dec48d</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1093%2Fneuonc%2Fnoy078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fneuonc%252Fnoy078%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DN.%2BF%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DArkenau%26aufirst%3DH.-T.%26aulast%3DFleming%26aufirst%3DR.%2BA%26aulast%3DTolson%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DAuger%26aufirst%3DK.%2BR%26aulast%3DLenox%26aufirst%3DL.%26aulast%3DCox%26aufirst%3DD.%26aulast%3DLewis%26aufirst%3DY.%26aulast%3DPlisson%26aufirst%3DC.%26aulast%3DSearle%26aufirst%3DG.%26aulast%3DSaleem%26aufirst%3DA.%26aulast%3DBlagden%26aufirst%3DS.%26aulast%3DMulholland%26aufirst%3DP.%26atitle%3DA%2520study%2520of%2520the%2520focal%2520adhesion%2520kinase%2520inhibitor%2520GSK2256098%2520in%2520patients%2520with%2520recurrent%2520glioblastoma%2520with%2520evaluation%2520of%2520tumor%2520penetration%2520of%2520%255B11C%255DGSK2256098%26jtitle%3DNeuro-Oncology%26date%3D2018%26volume%3D20%26spage%3D1634%26epage%3D1642%26doi%3D10.1093%2Fneuonc%2Fnoy078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mak, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagden, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebot, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazumdar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazzah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzuto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greystoke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auger, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkenau, H. T.</span></span> <span> </span><span class="NLM_article-title">A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">975</span>â <span class="NLM_lpage">981</span>, <span class="refDoi">Â DOI: 10.1038/s41416-019-0452-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fs41416-019-0452-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=30992546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFWmsLrF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2019&pages=975-981&author=G.+Makauthor=J.+C.+Soriaauthor=S.+P.+Blagdenauthor=R.+Plummerauthor=R.+A.+Flemingauthor=N.+Nebotauthor=J.+Zhangauthor=J.+Mazumdarauthor=D.+Roganauthor=A.+Gazzahauthor=I.+Rizzutoauthor=A.+Greystokeauthor=L.+Yanauthor=J.+Tolsonauthor=K.+R.+Augerauthor=H.+T.+Arkenau&title=A+phase+Ib+dose-finding%2C+pharmacokinetic+study+of+the+focal+adhesion+kinase+inhibitor+GSK2256098+and+trametinib+in+patients+with+advanced+solid+tumours&doi=10.1038%2Fs41416-019-0452-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours</span></div><div class="casAuthors">Mak, Gabriel; Soria, Jean-Charles; Blagden, Sarah P.; Plummer, Ruth; Fleming, Ronald A.; Nebot, Noelia; Zhang, Jianping; Mazumdar, Jolly; Rogan, Debra; Gazzah, Anas; Rizzuto, Ivana; Greystoke, Alastair; Yan, Li; Tolson, Jerry; Auger, Kurt R.; Arkenau, Hendrik-Tobias</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">975-981</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Background: Combined focal adhesion kinase (FAK) and MEK inhibition may provide greater anticancer effect than FAK monotherapy.  Methods: This dose-finding phase Ib study (adaptive 3 + 3 design) detd. the max. tolerated dose (MTD) of trametinib and the FAK inhibitor GSK2256098 in combination.  Eligible patients had mesothelioma or other solid tumors with probable mitogen activated protein kinase pathway activation.  Adverse events (AEs), dose-limiting toxicities, disease progression and pharmacokinetics/pharmacodynamics were analyzed.  Results: Thirty-four subjects were enrolled.  The GSK2256098/trametinib MTDs were 500 mg twice daily (BID)/0.375 mg once daily (QD) (high/low) and 250 mg BID/0.5 mg QD (low/high).  The most common AEs were nausea, diarrhoea, decreased appetite, pruritus, fatigue and rash; none were grade 4.  Systemic exposure to trametinib increased when co-administered with GSK2256098, vs. trametinib monotherapy; GSK2256098 pharmacokinetics were unaffected by concomitant trametinib.  Median progression-free survival (PFS) was 11.8 wk (95% CI: 6.1-24.1) in subjects with mesothelioma and was longer with Merlin-neg. vs. Merlin-pos. tumors (15.0 vs 7.3 wk).  Conclusions: Trametinib exposure increased when co-administered with GSK2256098, but not vice versa.  Mesothelioma patients with loss of Merlin had longer PFS than subjects with wild-type, although support for efficacy with this combination was limited.  Safety profiles were acceptable up to the MTD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovNTEJjHaRLLVg90H21EOLACvtfcHk0lhfZtCbLdtUYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFWmsLrF&md5=3303a98dfafb0360b04050962b8d7cc5</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fs41416-019-0452-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41416-019-0452-3%26sid%3Dliteratum%253Aachs%26aulast%3DMak%26aufirst%3DG.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DBlagden%26aufirst%3DS.%2BP.%26aulast%3DPlummer%26aufirst%3DR.%26aulast%3DFleming%26aufirst%3DR.%2BA.%26aulast%3DNebot%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DMazumdar%26aufirst%3DJ.%26aulast%3DRogan%26aufirst%3DD.%26aulast%3DGazzah%26aufirst%3DA.%26aulast%3DRizzuto%26aufirst%3DI.%26aulast%3DGreystoke%26aufirst%3DA.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DTolson%26aufirst%3DJ.%26aulast%3DAuger%26aufirst%3DK.%2BR.%26aulast%3DArkenau%26aufirst%3DH.%2BT.%26atitle%3DA%2520phase%2520Ib%2520dose-finding%252C%2520pharmacokinetic%2520study%2520of%2520the%2520focal%2520adhesion%2520kinase%2520inhibitor%2520GSK2256098%2520and%2520trametinib%2520in%2520patients%2520with%2520advanced%2520solid%2520tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2019%26volume%3D120%26spage%3D975%26epage%3D981%26doi%3D10.1038%2Fs41416-019-0452-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tiede, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer-Schaller, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalathur, R. K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagiani, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmassmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stillhard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafliger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraut, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweifer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waizenegger, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bill, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christofori, G.</span></span> <span> </span><span class="NLM_article-title">The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer</span>. <i>Oncogenesis</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">73</span>â <span class="NLM_lpage">91</span>, <span class="refDoi">Â DOI: 10.1038/s41389-018-0083-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fs41389-018-0083-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=30237500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BB3czhtVamtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=73-91&author=S.+Tiedeauthor=N.+Meyer-Schallerauthor=R.+K.+R.+Kalathurauthor=R.+Ivanekauthor=E.+Fagianiauthor=P.+Schmassmannauthor=P.+Stillhardauthor=S.+Hafligerauthor=N.+Krautauthor=N.+Schweiferauthor=I.+C.+Waizeneggerauthor=R.+Billauthor=G.+Christofori&title=The+FAK+inhibitor+BI+853520+exerts+anti-tumor+effects+in+breast+cancer&doi=10.1038%2Fs41389-018-0083-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer</span></div><div class="casAuthors">Tiede Stefanie; Meyer-Schaller Nathalie; Kalathur Ravi Kiran Reddy; Ivanek Robert; Fagiani Ernesta; Schmassmann Philip; Stillhard Patrick; Hafliger Simon; Bill Ruben; Christofori Gerhard; Kalathur Ravi Kiran Reddy; Ivanek Robert; Kraut Norbert; Schweifer Norbert; Waizenegger Irene C</div><div class="citationInfo"><span class="NLM_cas:title">Oncogenesis</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">73</span>
        ISSN:<span class="NLM_cas:issn">2157-9024</span>.
    </div><div class="casAbstract">Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase that regulates a plethora of downstream signaling pathways essential for cell migration, proliferation and death, processes that are exploited by cancer cells during malignant progression.  These well-established tumorigenic activities, together with its high expression and activity in different cancer types, highlight FAK as an attractive target for cancer therapy.  We have assessed and characterized the therapeutic potential and the biological effects of BI 853520, a novel small chemical inhibitor of FAK, in several preclinical mouse models of breast cancer.  Treatment with BI 853520 elicits a significant reduction in primary tumor growth caused by an anti-proliferative activity by BI 853520.  In contrast, BI 853520 exerts effects with varying degrees of robustness on the different stages of the metastatic cascade.  Together, the data demonstrate that the repression of FAK activity by the specific FAK inhibitor BI 853520 offers a promising anti-proliferative approach for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSPh9ctMIKK5LxanA7vODO6fW6udTcc2eZecConz8GiF7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czhtVamtA%253D%253D&md5=9875efe4b07431bf3399fd19a3f7f289</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fs41389-018-0083-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41389-018-0083-1%26sid%3Dliteratum%253Aachs%26aulast%3DTiede%26aufirst%3DS.%26aulast%3DMeyer-Schaller%26aufirst%3DN.%26aulast%3DKalathur%26aufirst%3DR.%2BK.%2BR.%26aulast%3DIvanek%26aufirst%3DR.%26aulast%3DFagiani%26aufirst%3DE.%26aulast%3DSchmassmann%26aufirst%3DP.%26aulast%3DStillhard%26aufirst%3DP.%26aulast%3DHafliger%26aufirst%3DS.%26aulast%3DKraut%26aufirst%3DN.%26aulast%3DSchweifer%26aufirst%3DN.%26aulast%3DWaizenegger%26aufirst%3DI.%2BC.%26aulast%3DBill%26aufirst%3DR.%26aulast%3DChristofori%26aufirst%3DG.%26atitle%3DThe%2520FAK%2520inhibitor%2520BI%2520853520%2520exerts%2520anti-tumor%2520effects%2520in%2520breast%2520cancer%26jtitle%3DOncogenesis%26date%3D2018%26volume%3D7%26spage%3D73%26epage%3D91%26doi%3D10.1038%2Fs41389-018-0083-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laszlo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valko, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozsvar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garay, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoda, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klikovits, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockhammer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aigner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klepetko, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grusch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tovari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waizenegger, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dome, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegedus, B.</span></span> <span> </span><span class="NLM_article-title">The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma</span>. <i>J. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">231</span>â <span class="NLM_lpage">242</span>, <span class="refDoi">Â DOI: 10.1007/s00109-018-1725-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1007%2Fs00109-018-1725-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=30539198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFWrur7I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2019&pages=231-242&author=V.+Laszloauthor=Z.+Valkoauthor=J.+Ozsvarauthor=I.+Kovacsauthor=T.+Garayauthor=M.+A.+Hodaauthor=T.+Klikovitsauthor=P.+Stockhammerauthor=C.+Aignerauthor=M.+Grogerauthor=W.+Klepetkoauthor=W.+Bergerauthor=M.+Gruschauthor=J.+Tovariauthor=I.+C.+Waizeneggerauthor=B.+Domeauthor=B.+Hegedus&title=The+FAK+inhibitor+BI+853520+inhibits+spheroid+formation+and+orthotopic+tumor+growth+in+malignant+pleural+mesothelioma&doi=10.1007%2Fs00109-018-1725-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma</span></div><div class="casAuthors">Laszlo, Viktoria; Valko, Zsuzsanna; Ozsvar, Judit; Kovacs, Ildiko; Garay, Tamas; Hoda, Mir Alireza; Klikovits, Thomas; Stockhammer, Paul; Aigner, Clemens; Groeger, Marion; Klepetko, Walter; Berger, Walter; Grusch, Michael; Tovari, Jozsef; Waizenegger, Irene C.; Dome, Balazs; Hegedus, Balazs</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Medicine (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">231-242</span>CODEN:
                <span class="NLM_cas:coden">JMLME8</span>;
        ISSN:<span class="NLM_cas:issn">0946-2716</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: No tyrosine kinase inhibitors are approved for malignant pleural mesothelioma (MPM).  Preclin. studies identified focal adhesion kinase (FAK) as a target in MPM.  Accordingly, we assessed the novel, highly selective FAK inhibitor (BI 853520) in 2D and 3D cultures and in vivo.  IC50 values were measured by adherent cell viability assay.  Cell migration and 3D growth were quantified by video microscopy and spheroid formation, resp.  Phosphorylation of FAK, Akt, S6, and Erk was measured by immunoblot.  The mRNA expression of the putative tumor stem cell markers SOX2, Nanog, CD44, ALDH1, c-myc, and Oct4 was analyzed by qPCR.  Cell proliferation, apoptosis, and tumor tissue microvessel d. (MVD) were investigated in orthotopic MPM xenografts.  In all 12 MPM cell lines, IC50 exceeded 5 Î¼M and loss of NF2 did not correlate with sensitivity.  No synergism was found with cisplatin in adherent cells.  BI 853520 decreased migration in 3 out of 4 cell lines.  FAK phosphorylation was reduced upon treatment but activation of Erk, Akt, or S6 remained unaffected.  Nevertheless, BI 853520 inhibited spheroid growth and significantly reduced tumor wt., cell proliferation, and MVD in vivo.  BI 853520 has limited effect in adherent cultures but demonstrates potent activity in spheroids and in orthotopic tumors in vivo.  Based on our findings, further studies are warranted to explore the clin. utility of BI 853520 in human MPM.  Key messages: Response to FAK inhibition in MPM is independent of NF2 expression or histotype.  FAK inhibition strongly interfered with MPM spheroid formation.  BI 853520 has been shown to exert anti-tumor effect in MPM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprwFPhW-QqqrVg90H21EOLACvtfcHk0lhp_r8Huf85bA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFWrur7I&md5=8bc9bddf2ab350890cbc3c72490f101d</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1007%2Fs00109-018-1725-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00109-018-1725-7%26sid%3Dliteratum%253Aachs%26aulast%3DLaszlo%26aufirst%3DV.%26aulast%3DValko%26aufirst%3DZ.%26aulast%3DOzsvar%26aufirst%3DJ.%26aulast%3DKovacs%26aufirst%3DI.%26aulast%3DGaray%26aufirst%3DT.%26aulast%3DHoda%26aufirst%3DM.%2BA.%26aulast%3DKlikovits%26aufirst%3DT.%26aulast%3DStockhammer%26aufirst%3DP.%26aulast%3DAigner%26aufirst%3DC.%26aulast%3DGroger%26aufirst%3DM.%26aulast%3DKlepetko%26aufirst%3DW.%26aulast%3DBerger%26aufirst%3DW.%26aulast%3DGrusch%26aufirst%3DM.%26aulast%3DTovari%26aufirst%3DJ.%26aulast%3DWaizenegger%26aufirst%3DI.%2BC.%26aulast%3DDome%26aufirst%3DB.%26aulast%3DHegedus%26aufirst%3DB.%26atitle%3DThe%2520FAK%2520inhibitor%2520BI%2520853520%2520inhibits%2520spheroid%2520formation%2520and%2520orthotopic%2520tumor%2520growth%2520in%2520malignant%2520pleural%2520mesothelioma%26jtitle%3DJ.%2520Mol.%2520Med.%26date%3D2019%26volume%3D97%26spage%3D231%26epage%3D242%26doi%3D10.1007%2Fs00109-018-1725-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Jonge, M. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steeghs, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lolkema, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotte, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirte, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Biessen, D. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul Razak, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vos, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verheijen, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pronk, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, L. L.</span></span> <span> </span><span class="NLM_article-title">Phase I study of BI 853520, an inhibitor of focal adhesion kinase, in patients with advanced or metastatic nonhematologic malignancies</span>. <i>Target. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">43</span>â <span class="NLM_lpage">55</span>, <span class="refDoi">Â DOI: 10.1007/s11523-018-00617-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1007%2Fs11523-018-00617-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=30756308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BB3cfis1ymsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=43-55&author=M.+J.+A.+De%0AJongeauthor=N.+Steeghsauthor=M.+P.+Lolkemaauthor=S.+J.+Hotteauthor=H.+W.+Hirteauthor=D.+A.+J.+van+der+Biessenauthor=A.+R.+Abdul+Razakauthor=F.+De+Vosauthor=R.+B.+Verheijenauthor=D.+Schnellauthor=L.+C.+Pronkauthor=M.+Jansenauthor=L.+L.+Siu&title=Phase+I+study+of+BI+853520%2C+an+inhibitor+of+focal+adhesion+kinase%2C+in+patients+with+advanced+or+metastatic+nonhematologic+malignancies&doi=10.1007%2Fs11523-018-00617-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies</span></div><div class="casAuthors">de Jonge Maja J A; Lolkema Martijn P; van der Biessen Diane A J; Steeghs Neeltje; Verheijen Remy B; Lolkema Martijn P; De Vos Filip Y F L; Hotte Sebastien J; Hirte Hal W; Abdul Razak Albiruni R; Siu Lillian L; Schnell David; Pronk Linda C; Jansen Monique</div><div class="citationInfo"><span class="NLM_cas:title">Targeted oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-55</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Overexpression/activation of focal adhesion kinase (FAK) in human malignancies has led to its evaluation as a therapeutic target.  We report the first-in-human phase I study of BI 853520, a novel, potent, highly selective FAK inhibitor.  OBJECTIVE:  Our objectives were to identify the maximum tolerated dose (MTD), and to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), biomarker expression, and preliminary activity.  PATIENTS AND METHODS:  The study comprised a standard 3 + 3 dose-escalation phase followed by an expansion phase in patients with selected advanced, nonhematologic malignancies.  RESULTS:  Thirty-three patients received BI 853520 in the dose-escalation phase; the MTD was 200 mg once daily (QD).  Dose-limiting toxicities included proteinuria and fatigue, both of which were grade 3.  Preliminary PK data supported QD dosing.  In the expansion cohort, 63 patients received BI 853520 200 mg QD.  Drug-related adverse events (AEs) in > 10% of patients included proteinuria (57%), nausea (57%), fatigue (51%), diarrhea (48%), vomiting (40%), decreased appetite (19%), and peripheral edema (16%).  Most AEs were grade 1-2; grade 3 proteinuria, reported in 13 patients (21%), was generally reversible upon treatment interruption.  Nineteen patients underwent dose reduction due to AEs, and three drug-related serious AEs were reported, none of which were fatal.  Preliminary PD analysis indicated target engagement.  Of 63 patients, 49 were evaluable; 17 (27%) achieved a best response of stable disease (4 with 150 + days), and 32 (51%) patients had progressive disease.  CONCLUSIONS:  BI 853520 has a manageable and acceptable safety profile, favorable PK, and modest antitumor activity at an MTD of 200 mg QD in patients with selected advanced nonhematologic malignancies.  CLINICALTRIALS.  GOV IDENTIFIER:  NCT01335269.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcjPd2J9N9MIhLSh9fo81bfW6udTcc2eYuyDNOuxFSVbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfis1ymsQ%253D%253D&md5=f4dc4b1f7c08a07ddfe93c1a26d4ef0b</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1007%2Fs11523-018-00617-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-018-00617-1%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BJonge%26aufirst%3DM.%2BJ.%2BA.%26aulast%3DSteeghs%26aufirst%3DN.%26aulast%3DLolkema%26aufirst%3DM.%2BP.%26aulast%3DHotte%26aufirst%3DS.%2BJ.%26aulast%3DHirte%26aufirst%3DH.%2BW.%26aulast%3Dvan%2Bder%2BBiessen%26aufirst%3DD.%2BA.%2BJ.%26aulast%3DAbdul%2BRazak%26aufirst%3DA.%2BR.%26aulast%3DDe%2BVos%26aufirst%3DF.%26aulast%3DVerheijen%26aufirst%3DR.%2BB.%26aulast%3DSchnell%26aufirst%3DD.%26aulast%3DPronk%26aufirst%3DL.%2BC.%26aulast%3DJansen%26aufirst%3DM.%26aulast%3DSiu%26aufirst%3DL.%2BL.%26atitle%3DPhase%2520I%2520study%2520of%2520BI%2520853520%252C%2520an%2520inhibitor%2520of%2520focal%2520adhesion%2520kinase%252C%2520in%2520patients%2520with%2520advanced%2520or%2520metastatic%2520nonhematologic%2520malignancies%26jtitle%3DTarget.%2520Oncol.%26date%3D2019%26volume%3D14%26spage%3D43%26epage%3D55%26doi%3D10.1007%2Fs11523-018-00617-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shitara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarashina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pronk, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. C.</span></span> <span> </span><span class="NLM_article-title">Phase I study of the focal adhesion kinase inhibitor BI 853520 in Japanese and Taiwanese patients with advanced or metastatic solid tumors</span>. <i>Target. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">57</span>â <span class="NLM_lpage">65</span>, <span class="refDoi">Â DOI: 10.1007/s11523-019-00620-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1007%2Fs11523-019-00620-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=30725402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BB3cjps1Cmsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=57-65&author=T.+Doiauthor=J.+C.+Yangauthor=K.+Shitaraauthor=Y.+Naitoauthor=A.+L.+Chengauthor=A.+Sarashinaauthor=L.+C.+Pronkauthor=Y.+Takeuchiauthor=C.+C.+Lin&title=Phase+I+study+of+the+focal+adhesion+kinase+inhibitor+BI+853520+in+Japanese+and+Taiwanese+patients+with+advanced+or+metastatic+solid+tumors&doi=10.1007%2Fs11523-019-00620-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors</span></div><div class="casAuthors">Doi Toshihiko; Yang James Chih-Hsin; Cheng Ann-Lii; Lin Chia-Chi; Shitara Kohei; Naito Yoichi; Sarashina Akiko; Pronk Linda C; Takeuchi Yoshito</div><div class="citationInfo"><span class="NLM_cas:title">Targeted oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-65</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Focal adhesion kinase (FAK) inhibitors have demonstrated anti-tumor activity preclinically and are currently being evaluated in humans.  A first-in-human study evaluating the novel FAK inhibitor BI 853520 in a predominantly Caucasian population with advanced or metastatic non-hematologic malignancies demonstrated acceptable tolerability and favorable pharmacokinetics.  OBJECTIVE:  This study was undertaken to investigate the safety, tolerability, and maximum tolerated dose (MTD) of BI 853520 in Japanese and Taiwanese patients with advanced solid tumors.  PATIENTS AND METHODS:  In this open-label, phase I, dose-finding study, BI 853520 was administered once daily (QD) in a continuous daily dosing regimen with 28-day cycles and escalating doses to sequential cohorts of patients.  Twenty-one patients (62% male; median age 65 years) were treated at two sites in Japan and Taiwan.  RESULTS:  The median duration of treatment was 1.2 months (range 0.2-7.7).  As no dose-limiting toxicities were observed during cycle 1 in the 50, 100, or 200 mg cohorts, the MTD of BI 853520 was determined to be 200 mg QD.  Drug-related adverse events were reported in 19 patients (90%), and all except one were of grade 1 or 2.  Pharmacokinetic parameters were supportive of a once-daily dosing schedule.  A confirmed objective response rate of 5% and disease control rate of 29% were achieved; median duration of disease control was 3.7 months.  CONCLUSIONS:  This trial demonstrated a manageable and acceptable safety profile, favorable pharmacokinetics, and potential anti-tumor activity of BI 853520 in pretreated Japanese and Taiwanese patients with advanced or metastatic solid tumors.  CLINICAL TRIALS REGISTRATION:  NCT01905111.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTpzuGISfNqg8zK395ZObgVfW6udTcc2eYuyDNOuxFSVbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjps1Cmsg%253D%253D&md5=aecf271c8c3f0e5fc5a56a53eeaab421</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1007%2Fs11523-019-00620-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-019-00620-0%26sid%3Dliteratum%253Aachs%26aulast%3DDoi%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DShitara%26aufirst%3DK.%26aulast%3DNaito%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DA.%2BL.%26aulast%3DSarashina%26aufirst%3DA.%26aulast%3DPronk%26aufirst%3DL.%2BC.%26aulast%3DTakeuchi%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DC.%2BC.%26atitle%3DPhase%2520I%2520study%2520of%2520the%2520focal%2520adhesion%2520kinase%2520inhibitor%2520BI%2520853520%2520in%2520Japanese%2520and%2520Taiwanese%2520patients%2520with%2520advanced%2520or%2520metastatic%2520solid%2520tumors%26jtitle%3DTarget.%2520Oncol.%26date%3D2019%26volume%3D14%26spage%3D57%26epage%3D65%26doi%3D10.1007%2Fs11523-019-00620-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ott, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Learn, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingrich, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisko, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesaros, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quail, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrzanski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albom, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angeles, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells-Knecht, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aimone, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruckheimer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ator, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of clinical candidate CEP-37440, a selective inhibitor of focal adhesion kinase (FAK) and anaplastic lymphoma kinase (ALK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7478</span>â <span class="NLM_lpage">7496</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00487</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00487" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlaru77P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7478-7496&author=G.+R.+Ottauthor=M.+Chengauthor=K.+S.+Learnauthor=J.+Wagnerauthor=D.+E.+Gingrichauthor=J.+G.+Liskoauthor=M.+Curryauthor=E.+F.+Mesarosauthor=A.+K.+Ghoseauthor=M.+R.+Quailauthor=W.+Wanauthor=L.+Luauthor=P.+Dobrzanskiauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=K.+Wells-Knechtauthor=Z.+Huangauthor=L.+D.+Aimoneauthor=E.+Bruckheimerauthor=N.+Andersonauthor=J.+Friedmanauthor=S.+V.+Fernandezauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=B.+D.+Dorsey&title=Discovery+of+clinical+candidate+CEP-37440%2C+a+selective+inhibitor+of+focal+adhesion+kinase+%28FAK%29+and+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1021%2Facs.jmedchem.6b00487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Ott, Gregory R.; Cheng, Mangeng; Learn, Keith S.; Wagner, Jason; Gingrich, Diane E.; Lisko, Joseph G.; Curry, Matthew; Mesaros, Eugen F.; Ghose, Arup K.; Quail, Matthew R.; Wan, Weihua; Lu, Lihui; Dobrzanski, Pawel; Albom, Mark S.; Angeles, Thelma S.; Wells-Knecht, Kevin; Huang, Zeqi; Aimone, Lisa D.; Bruckheimer, Elizabeth; Anderson, Nathan; Friedman, Jay; Fernandez, Sandra V.; Ator, Mark A.; Ruggeri, Bruce A.; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7478-7496</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Analogs structurally related to anaplastic lymphoma kinase (ALK) inhibitor (CEP-28122) were optimized for metabolic stability.  The results from this endeavor not only led to improved metabolic stability, pharmacokinetic parameters, and in vitro activity against clin. derived resistance mutations but also led to the incorporation of activity for focal adhesion kinase (FAK).  FAK activation, via amplification and/or overexpression, is characteristic of multiple invasive solid tumors and metastasis.  The discovery of the clin. stage, dual FAK/ALK inhibitor 27b (CEP-37440), including details surrounding SAR, in vitro/in vivo pharmacol., and pharmacokinetics, is reported herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9Ojryum63_LVg90H21EOLACvtfcHk0ljHFc-eE1F2vA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlaru77P&md5=3fcd1342d901b2379d0efbd118d3049f</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00487%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DLearn%26aufirst%3DK.%2BS.%26aulast%3DWagner%26aufirst%3DJ.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DLisko%26aufirst%3DJ.%2BG.%26aulast%3DCurry%26aufirst%3DM.%26aulast%3DMesaros%26aufirst%3DE.%2BF.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DDobrzanski%26aufirst%3DP.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DWells-Knecht%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DBruckheimer%26aufirst%3DE.%26aulast%3DAnderson%26aufirst%3DN.%26aulast%3DFriedman%26aufirst%3DJ.%26aulast%3DFernandez%26aufirst%3DS.%2BV.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DDiscovery%2520of%2520clinical%2520candidate%2520CEP-37440%252C%2520a%2520selective%2520inhibitor%2520of%2520focal%2520adhesion%2520kinase%2520%2528FAK%2529%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7478%26epage%3D7496%26doi%3D10.1021%2Facs.jmedchem.6b00487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salem, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsalahi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chervoneva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aburto, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Addya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristofanilli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, S. V.</span></span> <span> </span><span class="NLM_article-title">The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">37</span>â <span class="NLM_lpage">51</span>, <span class="refDoi">Â DOI: 10.1186/s13058-016-0694-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1186%2Fs13058-016-0694-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=27009091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisVOhsL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=37-51&author=I.+Salemauthor=M.+Alsalahiauthor=I.+Chervonevaauthor=L.+D.+Aburtoauthor=S.+Addyaauthor=G.+R.+Ottauthor=B.+A.+Ruggeriauthor=M.+Cristofanilliauthor=S.+V.+Fernandez&title=The+effects+of+CEP-37440%2C+an+inhibitor+of+focal+adhesion+kinase%2C+in+vitro+and+in+vivo+on+inflammatory+breast+cancer+cells&doi=10.1186%2Fs13058-016-0694-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells</span></div><div class="casAuthors">Salem, Israa; Alsalahi, Manal; Chervoneva, Inna; Aburto, Lucy D.; Addya, Sankar; Ott, Gregory R.; Ruggeri, Bruce A.; Cristofanilli, Massimo; Fernandez, Sandra V.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37/1-37/15</span>CODEN:
                <span class="NLM_cas:coden">BRCRFS</span>;
        ISSN:<span class="NLM_cas:issn">1465-542X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Inflammatory breast cancer (IBC) is an aggressive type of advanced breast cancer with a poor prognosis.  We recently found that focal adhesion kinase 1 (FAK1) is upregulated and phosphorylated (active) in IBC.  In this study, we investigated the effect of CEP-37440, a dual inhibitor of FAK1 and anaplastic lymphoma kinase (ALK), using human IBC cell lines and preclin. models of IBC.  Cell proliferation assays were performed in the presence of several concns. of CEP-37440 using IBC and triple-neg. breast cancer non-IBC cell lines.  In vitro, we studied the expression of total FAK1, phospho-FAK1 (Tyr 397), total ALK and phospho-ALK (Tyr 1604).  In vivo, we tested CEP-37440 using FC-IBC02, SUM149, and SUM190 IBC xenograft mouse models.  CEP-37440 at low concn. decreased the proliferation of the IBC cell lines FC-IBC02, SUM190, and KPL4, while not affecting the proliferation of normal breast epithelial cells.  At higher concn., CEP-37440 was also able to inhibit the proliferation of the IBC cell line MDA-IBC03 and the triple-neg. non-IBC cell lines MDA-MB-231 and MDA-MB-468; the IBC cell line SUM149 showed a slight response to the drug.  CEP-37440 decreased the cell proliferation of FC-IBC02, SUM190, and KPL4 by blocking the autophosphorylation kinase activity of FAK1 (Tyr 397).  None of the cells evaluated expressed ALK.  In vivo, after 7 wk of CEP-37440 treatment, the SUM190, FC-IBC02, and SUM149 breast tumor xenografts were smaller in mice treated with 55 mg/kg bid CEP-37440 compared to the controls; the tumor growth inhibition (TGI) was 79.7 %, 33 %, and 23 %, resp.  None of the FC-IBC02 breast xenografts mice treated with CEP-37440 developed brain metastasis while 20 % of the mice in the control group developed brain metastasis.  Expression array analyses in FC-IBC02 cells showed that CEP-37440 affects the expression of genes related to apoptosis, interferon signaling, and cytokines.  CEP-37440 is effective against some IBC cells that express phospho-FAK1 (Tyr 397), and its antiproliferative activity is related to its ability to decrease phospho-FAK1.  Our results suggest that combinational therapies could be more effective than using CEP-37440 as a single agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouzKOMoopU8rVg90H21EOLACvtfcHk0ljHFc-eE1F2vA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisVOhsL8%253D&md5=d69c00c3a502a33f80d58dcc04337596</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1186%2Fs13058-016-0694-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-016-0694-4%26sid%3Dliteratum%253Aachs%26aulast%3DSalem%26aufirst%3DI.%26aulast%3DAlsalahi%26aufirst%3DM.%26aulast%3DChervoneva%26aufirst%3DI.%26aulast%3DAburto%26aufirst%3DL.%2BD.%26aulast%3DAddya%26aufirst%3DS.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DCristofanilli%26aufirst%3DM.%26aulast%3DFernandez%26aufirst%3DS.%2BV.%26atitle%3DThe%2520effects%2520of%2520CEP-37440%252C%2520an%2520inhibitor%2520of%2520focal%2520adhesion%2520kinase%252C%2520in%2520vitro%2520and%2520in%2520vivo%2520on%2520inflammatory%2520breast%2520cancer%2520cells%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2016%26volume%3D18%26spage%3D37%26epage%3D51%26doi%3D10.1186%2Fs13058-016-0694-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanjoni, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uryu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, J.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mielgo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMahon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stupack, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlaepfer, D. D.</span></span> <span> </span><span class="NLM_article-title">PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">764</span>â <span class="NLM_lpage">777</span>, <span class="refDoi">Â DOI: 10.4161/cbt.9.10.11434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.4161%2Fcbt.9.10.11434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=20234191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKrtrnI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=764-777&author=I.+Tanjoniauthor=C.+Walshauthor=S.+Uryuauthor=A.+Tomarauthor=J.-O.+Namauthor=A.+Mielgoauthor=S.-T.+Limauthor=C.+Liangauthor=M.+Koenigauthor=N.+Patelauthor=C.+Kwokauthor=G.+McMahonauthor=D.+G.+Stupackauthor=D.+D.+Schlaepfer&title=PND-1186+FAK+inhibitor+selectively+promotes+tumor+cell+apoptosis+in+three-dimensional+environments&doi=10.4161%2Fcbt.9.10.11434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments</span></div><div class="casAuthors">Tanjoni, Isabelle; Walsh, Colin; Uryu, Sean; Tomar, Alok; Nam, Ju-Ock; Mielgo, Ainhoa; Lim, Ssang-Taek; Liang, Congxin; Koenig, Marcel; Sun, Connie; Patel, Neela; Kwok, Cheni; McMahon, Gerald; Stupack, Dwayne G.; Schlaepfer, David D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">764-777</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Tumor cells can grow in an anchorage-independent manner.  This is mediated in part through survival signals that bypass normal growth restraints controlled by integrin cell surface receptors.  Focal adhesion kinase (FAK) is a cytoplasmic protein-tyrosine kinase that assocs. with integrins and modulates various cellular processes including growth, survival and migration.  As increased FAK expression and tyrosine phosphorylation are assocd. with tumor progression, inhibitors of FAK are being tested for anti-tumor effects.  Here, we analyze PND-1186, a substituted pyridine reversible inhibitor of FAK activity with a 50% inhibitory concn. (IC50) of 1.5 nM in vitro.  PND-1186 has an IC50 of â¼100 nM in breast carcinoma cells as detd. by anti-phospho-specific immunoblotting to FAK Tyr-397.  PND-1186 did not alter c-Src or p130Cas tyrosine phosphorylation in adherent cells, yet functioned to restrain cell movement.  Notably, 1.0 Î¼M PND-1186 (>5-fold above IC50) had limited effects on cell proliferation.  However, under non-adherent conditions as spheroids and as colonies in soft agar, 0.1 Î¼M PND-1186 blocked FAK and p130Cas tyrosine phosphorylation, promoted caspase-3 activation, and triggered cell apoptosis.  PND-1186 inhibited 4T1 breast carcinoma s.c. tumor growth correlated with elevated tumor cell apoptosis and caspase 3 activation.  Addn. of PND-1186 to the drinking water of mice was well tolerated and inhibited ascites- and peritoneal membrane-assocd. ovarian carcinoma tumor growth assocd. with the inhibition of FAK Tyr-397 phosphorylation.  Our results with low-level PND-1186 treatment support the conclusion that FAK activity selectively promotes tumor cell survival in three-dimensional environments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsLnD2EGHjs7Vg90H21EOLACvtfcHk0lgYJKi7fdJnJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKrtrnI&md5=5cb6370e769d6e4f88ef5e27d70a7996</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.4161%2Fcbt.9.10.11434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.9.10.11434%26sid%3Dliteratum%253Aachs%26aulast%3DTanjoni%26aufirst%3DI.%26aulast%3DWalsh%26aufirst%3DC.%26aulast%3DUryu%26aufirst%3DS.%26aulast%3DTomar%26aufirst%3DA.%26aulast%3DNam%26aufirst%3DJ.-O.%26aulast%3DMielgo%26aufirst%3DA.%26aulast%3DLim%26aufirst%3DS.-T.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DKoenig%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DKwok%26aufirst%3DC.%26aulast%3DMcMahon%26aufirst%3DG.%26aulast%3DStupack%26aufirst%3DD.%2BG.%26aulast%3DSchlaepfer%26aufirst%3DD.%2BD.%26atitle%3DPND-1186%2520FAK%2520inhibitor%2520selectively%2520promotes%2520tumor%2520cell%2520apoptosis%2520in%2520three-dimensional%2520environments%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D764%26epage%3D777%26doi%3D10.4161%2Fcbt.9.10.11434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurmasheva, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorlick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keir, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lock, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carol, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houghton, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. A.</span></span> <span> </span><span class="NLM_article-title">Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the pediatric preclinical testing program</span>. <i>Pediatr. Blood Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>64</i></span>, <span class="NLM_elocation-id">e26304</span> <span class="refDoi">Â DOI: 10.1002/pbc.26304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1002%2Fpbc.26304" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2017&author=R.+T.+Kurmashevaauthor=R.+Gorlickauthor=E.+A.+Kolbauthor=S.+T.+Keirauthor=J.+M.+Marisauthor=R.+B.+Lockauthor=H.+Carolauthor=M.+Kangauthor=C.+P.+Reynoldsauthor=J.+Wuauthor=P.+J.+Houghtonauthor=M.+A.+Smith&title=Initial+testing+of+VS-4718%2C+a+novel+inhibitor+of+focal+adhesion+kinase+%28FAK%29%2C+against+pediatric+tumor+models+by+the+pediatric+preclinical+testing+program&doi=10.1002%2Fpbc.26304"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1002%2Fpbc.26304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpbc.26304%26sid%3Dliteratum%253Aachs%26aulast%3DKurmasheva%26aufirst%3DR.%2BT.%26aulast%3DGorlick%26aufirst%3DR.%26aulast%3DKolb%26aufirst%3DE.%2BA.%26aulast%3DKeir%26aufirst%3DS.%2BT.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26aulast%3DLock%26aufirst%3DR.%2BB.%26aulast%3DCarol%26aufirst%3DH.%26aulast%3DKang%26aufirst%3DM.%26aulast%3DReynolds%26aufirst%3DC.%2BP.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DHoughton%26aufirst%3DP.%2BJ.%26aulast%3DSmith%26aufirst%3DM.%2BA.%26atitle%3DInitial%2520testing%2520of%2520VS-4718%252C%2520a%2520novel%2520inhibitor%2520of%2520focal%2520adhesion%2520kinase%2520%2528FAK%2529%252C%2520against%2520pediatric%2520tumor%2520models%2520by%2520the%2520pediatric%2520preclinical%2520testing%2520program%26jtitle%3DPediatr.%2520Blood%2520Cancer%26date%3D2017%26volume%3D64%26doi%3D10.1002%2Fpbc.26304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegde, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knolhoff, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herndon, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nywening, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachter, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang-Gillam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeNardo, D. G.</span></span> <span> </span><span class="NLM_article-title">Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">851</span>â <span class="NLM_lpage">860</span>, <span class="refDoi">Â DOI: 10.1038/nm.4123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fnm.4123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=27376576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtV2msLfN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=851-860&author=H.+Jiangauthor=S.+Hegdeauthor=B.+L.+Knolhoffauthor=Y.+Zhuauthor=J.+M.+Herndonauthor=M.+A.+Meyerauthor=T.+M.+Nyweningauthor=W.+G.+Hawkinsauthor=I.+M.+Shapiroauthor=D.+T.+Weaverauthor=J.+A.+Pachterauthor=A.+Wang-Gillamauthor=D.+G.+DeNardo&title=Targeting+focal+adhesion+kinase+renders+pancreatic+cancers+responsive+to+checkpoint+immunotherapy&doi=10.1038%2Fnm.4123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy</span></div><div class="casAuthors">Jiang, Hong; Hegde, Samarth; Knolhoff, Brett L.; Zhu, Yu; Herndon, John M.; Meyer, Melissa A.; Nywening, Timothy M.; Hawkins, William G.; Shapiro, Irina M.; Weaver, David T.; Pachter, Jonathan A.; Wang-Gillam, Andrea; DeNardo, David G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">851-860</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Single-agent immunotherapy has achieved limited clin. benefit to date in patients with pancreatic ductal adenocarcinoma (PDAC).  This may be a result of the presence of a uniquely immunosuppressive tumor microenvironment (TME).  Crit. obstacles to immunotherapy in PDAC tumors include a high no. of tumor-assocd. immunosuppressive cells and a uniquely desmoplastic stroma that functions as a barrier to T cell infiltration.  We identified hyperactivated focal adhesion kinase (FAK) activity in neoplastic PDAC cells as an important regulator of the fibrotic and immunosuppressive TME.  We found that FAK activity was elevated in human PDAC tissues and correlated with high levels of fibrosis and poor CD8+ cytotoxic T cell infiltration.  Single-agent FAK inhibition using the selective FAK inhibitor VS-4718 substantially limited tumor progression, resulting in a doubling of survival in the p48-Cre;LSL-KrasG12D;Trp53flox/+ (KPC) mouse model of human PDAC.  This delay in tumor progression was assocd. with markedly reduced tumor fibrosis and decreased nos. of tumor-infiltrating immunosuppressive cells.  We also found that FAK inhibition rendered the previously unresponsive KPC mouse model responsive to T cell immunotherapy and PD-1 antagonists.  These data suggest that FAK inhibition increases immune surveillance by overcoming the fibrotic and immunosuppressive PDAC TME and renders tumors responsive to immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7vp95t6jl9bVg90H21EOLACvtfcHk0ljg9OQT1X_rww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtV2msLfN&md5=1f715175ab16c97f696999001422df4c</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1038%2Fnm.4123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4123%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DHegde%26aufirst%3DS.%26aulast%3DKnolhoff%26aufirst%3DB.%2BL.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DHerndon%26aufirst%3DJ.%2BM.%26aulast%3DMeyer%26aufirst%3DM.%2BA.%26aulast%3DNywening%26aufirst%3DT.%2BM.%26aulast%3DHawkins%26aufirst%3DW.%2BG.%26aulast%3DShapiro%26aufirst%3DI.%2BM.%26aulast%3DWeaver%26aufirst%3DD.%2BT.%26aulast%3DPachter%26aufirst%3DJ.%2BA.%26aulast%3DWang-Gillam%26aufirst%3DA.%26aulast%3DDeNardo%26aufirst%3DD.%2BG.%26atitle%3DTargeting%2520focal%2520adhesion%2520kinase%2520renders%2520pancreatic%2520cancers%2520responsive%2520to%2520checkpoint%2520immunotherapy%26jtitle%3DNat.%2520Med.%26date%3D2016%26volume%3D22%26spage%3D851%26epage%3D860%26doi%3D10.1038%2Fnm.4123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gottesman, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fojo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span> <span> </span><span class="NLM_article-title">Multidrug resistance in cancer: role of ATP-dependent transporters</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">48</span>â <span class="NLM_lpage">58</span>, <span class="refDoi">Â DOI: 10.1038/nrc706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fnrc706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=11902585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD38XhvF2jtL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=48-58&author=M.+M.+Gottesmanauthor=T.+Fojoauthor=S.+E.+Bates&title=Multidrug+resistance+in+cancer%3A+role+of+ATP-dependent+transporters&doi=10.1038%2Fnrc706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Multidrug resistance in cancer: role of ATP-dependent transporters</span></div><div class="casAuthors">Gottesman, Michael M.; Fojo, Tito; Bates, Susan E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-58</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chemotherapeutics are the most effective treatment for metastatic tumors.  However, the ability of cancer cells to become simultaneously resistant to different drugs, a trait known as multidrug resistance, remains a significant impediment to successful chemotherapy.  Three decades of multidrug-resistance research have identified a myriad of ways in which cancer cells can elude chemotherapy, and it has become apparent that resistance exists against every effective drug, even our newest agents.  Therefore, the ability to predict and circumvent drug resistance is likely to improve chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRJtnCZv-ZtrVg90H21EOLACvtfcHk0ljg9OQT1X_rww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhvF2jtL8%253D&md5=ec5284e1fe4a878c5ffc30ee83bccc9d</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1038%2Fnrc706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc706%26sid%3Dliteratum%253Aachs%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26aulast%3DFojo%26aufirst%3DT.%26aulast%3DBates%26aufirst%3DS.%2BE.%26atitle%3DMultidrug%2520resistance%2520in%2520cancer%253A%2520role%2520of%2520ATP-dependent%2520transporters%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26spage%3D48%26epage%3D58%26doi%3D10.1038%2Fnrc706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eckford, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharom, F. J.</span></span> <span> </span><span class="NLM_article-title">ABC efflux pump-based resistance to chemotherapy drugs</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">2989</span>â <span class="NLM_lpage">3011</span>, <span class="refDoi">Â DOI: 10.1021/cr9000226</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr9000226" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlslSmtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2009&pages=2989-3011&author=P.+D.+Eckfordauthor=F.+J.+Sharom&title=ABC+efflux+pump-based+resistance+to+chemotherapy+drugs&doi=10.1021%2Fcr9000226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">ABC Efflux Pump-Based Resistance to Chemotherapy Drugs</span></div><div class="casAuthors">Eckford, Paul D. W.; Sharom, Frances J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2989-3011</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Over 1 million new cases of all types of cancer are diagnosed each year in the United States alone, and 559, 650 cancer-related deaths were expected to occur in 2007.  Chemotherapeutic treatment of cancers is an important tool to combat this devastating disease.  However, chemotherapy can fail due to the development of tumor cell resistance to multiple drugs, a phenomenon known as multidrug resistance (MDR), and essentially all cancer-related deaths are considered to be a result of chemotherapy failure.  MDR can have many causes, but one important mechanism of drug resistance is the expression of active drug efflux pumps in the membranes of cancer cells.  The efflux pump proteins mediating MDR in human cancers belong to the ATP-Binding Cassette (ABC) superfamily of proteins.  This is a diverse group of (primarily) active membrane transporters and is one of the largest known protein families.  Its members include proteins that mediate a variety of transport processes, in both prokaryotes (e.g., membrane-embedded importers for sugars and amino acids, and drug exporters) and eukaryotes, where only ABC exporters are known.  The 49 ABC proteins identified in the human genome (there appear to be 48 functional proteins) are involved in the efflux of substrates such as phospholipids, sterols, bile salts, and amphipathic drugs.  While as many as 15 ABC transporters have been obsd. to export chemotherapy drugs using in vitro exptl. systems, only 3 transporters have thus far been implicated as major contributors to MDR in cancer.  Discovered over 30 years ago, P-glycoprotein (Pgp; MDR1; ABCB1), was the first mammalian ABC protein to be identified.  Multidrug resistance-assocd. protein 1 (MRP1 or ABCC1) and more recently ABCG2 (also termed the breast cancer resistance protein, BCRP, or mitoxantrone resistance protein, MXR) also appear to function as clin. relevant drug efflux pumps.  All three proteins were discovered as factors over-expressed in MDR cell lines in culture, and they have since been detected in MDR tumors in patients.  Considerable effort has been made to understand the structure and function of these three drug pumps, which possess a unique ability to recognize and transport a broad array of structurally diverse compds. out of the cell.  The development of compds. known as modulators, which are able to reverse MDR by blocking or inhibiting the ATP-dependent transport function of these proteins, is also an important goal of researchers in this field.  This review will summarize our understanding of the substrate specificity of the mammalian drug efflux pumps, their structure, the mol. mechanisms by which they exert their function, and the progress made to date in reversing pump-mediated MDR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZIkwCqe_qg7Vg90H21EOLACvtfcHk0ljg9OQT1X_rww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlslSmtbg%253D&md5=5009e7a7cac6977a296fd5bbf97d7df7</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Fcr9000226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr9000226%26sid%3Dliteratum%253Aachs%26aulast%3DEckford%26aufirst%3DP.%2BD.%26aulast%3DSharom%26aufirst%3DF.%2BJ.%26atitle%3DABC%2520efflux%2520pump-based%2520resistance%2520to%2520chemotherapy%2520drugs%26jtitle%3DChem.%2520Rev.%26date%3D2009%26volume%3D109%26spage%3D2989%26epage%3D3011%26doi%3D10.1021%2Fcr9000226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stavrovskaya, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stromskaya, T. P.</span></span> <span> </span><span class="NLM_article-title">Transport proteins of the ABC family and multidrug resistance of tumor cells</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">592</span>â <span class="NLM_lpage">604</span>, <span class="refDoi">Â DOI: 10.1134/S0006297908050118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1134%2FS0006297908050118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=18605983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsFKhu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=592-604&author=A.+A.+Stavrovskayaauthor=T.+P.+Stromskaya&title=Transport+proteins+of+the+ABC+family+and+multidrug+resistance+of+tumor+cells&doi=10.1134%2FS0006297908050118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Transport proteins of the ABC family and multidrug resistance of tumor cells</span></div><div class="casAuthors">Stavrovskaya, A. A.; Stromskaya, T. P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry (Moscow)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">592-604</span>CODEN:
                <span class="NLM_cas:coden">BIORAK</span>;
        ISSN:<span class="NLM_cas:issn">0006-2979</span>.
    
            (<span class="NLM_cas:orgname">Pleiades Publishing, Ltd.</span>)
        </div><div class="casAbstract">A review.  Some new data concerning the role of transport proteins of the ABC family in multidrug resistance (MDR) of human tumor cells, and problems connected with regulation of these proteins are considered.  MDR is a complex phenomenon that may be caused simultaneously by several mechanisms functioning in one and the same cell.  Among them there may be the alterations of activity of several transport proteins.  Activation of these proteins may be assocd. with alterations of activities of different cell protective systems and of the signal transduction pathways involved in regulation of proliferation, differentiation, and apoptosis.  Clin. significance of multifactor MDR is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrElh5UjnAuqbVg90H21EOLACvtfcHk0lhoTZJbDMOPdg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsFKhu78%253D&md5=c66e8b327c8ec154f22f9ac35a2b2735</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1134%2FS0006297908050118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1134%252FS0006297908050118%26sid%3Dliteratum%253Aachs%26aulast%3DStavrovskaya%26aufirst%3DA.%2BA.%26aulast%3DStromskaya%26aufirst%3DT.%2BP.%26atitle%3DTransport%2520proteins%2520of%2520the%2520ABC%2520family%2520and%2520multidrug%2520resistance%2520of%2520tumor%2520cells%26jtitle%3DBiochemistry%26date%3D2008%26volume%3D73%26spage%3D592%26epage%3D604%26doi%3D10.1134%2FS0006297908050118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ji, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, Z. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, Q. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D. H.</span></span> <span> </span><span class="NLM_article-title">VS-4718 antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells by inhibiting the efflux function of ABC transporters</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1236</span>â <span class="NLM_lpage">1247</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2018.01236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.3389%2Ffphar.2018.01236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=30425643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVGmtLjJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1236-1247&author=N.+Jiauthor=Y.+Yangauthor=C.+Y.+Caiauthor=Z.+N.+Leiauthor=J.+Q.+Wangauthor=P.+Guptaauthor=Q.+X.+Tengauthor=Z.+S.+Chenauthor=D.+Kongauthor=D.+H.+Yang&title=VS-4718+antagonizes+multidrug+resistance+in+ABCB1-+and+ABCG2-overexpressing+cancer+cells+by+inhibiting+the+efflux+function+of+ABC+transporters&doi=10.3389%2Ffphar.2018.01236"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">VS-4718 antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells by inhibiting the efflux function of ABC transporters</span></div><div class="casAuthors">Ji, Ning; Yang, Yuqi; Cai, Chao-Yun; Lei, Zi-Ning; Wang, Jing-Quan; Gupta, Pranav; Teng, Qiu-Xu; Chen, Zhe-Sheng; Kong, Dexin; Yang, Dong-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1236</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Overexpression of ATP-binding cassette (ABC) transporters is one of the most important mechanisms responsible for multi-drug resistance (MDR).  VS-4718, a tyrosine kinase inhibitor targeting focal adhesion kinase (FAK) with a potential anticancer effect, is currently evaluated in clin. trials.  In this study, we investigated whether VS-4718 could reverse MDR mediated by ABC transporters, including ABCB1, ABCG2, and ABCC1.  The results showed that VS-4718 significantly reversed ABCB1- and ABCG2-mediated MDR, but not MDR mediated by ABCC1.  Treatment of VS-4718 did not alter the protein level and subcellular localization of ABCB1 or ABCG2.  Mechanism studies indicated that the reversal effects of VS-4718 were related to attenuation of the efflux activity of ABCB1 and ABCG2 transporters.  ATPase anal. indicated that VS-4718 stimulated the ATPase activity of ABCB1 and ABCG2.  Docking study showed that VS-4718 interacted with the substrate-binding sites of both ABCB1 and ABCG2, suggesting that VS-4718 may affect the activity of ABCB1 and ABCG2 competitively.  This study provided a novel insight for MDR cancer treatment.  It indicated that combination of VS-4718 with antineoplastic drugs could attenuate MDR mediated by ABCB1 or ABCG2 in ABCB1- or ABCG2-overexpressing cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1TjxRKt8f37Vg90H21EOLACvtfcHk0lhoTZJbDMOPdg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVGmtLjJ&md5=412291789178a7f08247278a3a1091fc</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.01236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.01236%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DN.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DC.%2BY.%26aulast%3DLei%26aufirst%3DZ.%2BN.%26aulast%3DWang%26aufirst%3DJ.%2BQ.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DTeng%26aufirst%3DQ.%2BX.%26aulast%3DChen%26aufirst%3DZ.%2BS.%26aulast%3DKong%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DD.%2BH.%26atitle%3DVS-4718%2520antagonizes%2520multidrug%2520resistance%2520in%2520ABCB1-%2520and%2520ABCG2-overexpressing%2520cancer%2520cells%2520by%2520inhibiting%2520the%2520efflux%2520function%2520of%2520ABC%2520transporters%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D1236%26epage%3D1247%26doi%3D10.3389%2Ffphar.2018.01236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crompton, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlton, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorner, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calicchio, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohl, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegmaier, K.</span></span> <span> </span><span class="NLM_article-title">High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">2873</span>â <span class="NLM_lpage">2883</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-12-1944</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1158%2F0008-5472.CAN-12-1944" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=23536552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvVShtbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=2873-2883&author=B.+D.+Cromptonauthor=A.+L.+Carltonauthor=A.+R.+Thornerauthor=A.+L.+Christieauthor=J.+Duauthor=M.+L.+Calicchioauthor=M.+N.+Riveraauthor=M.+D.+Flemingauthor=N.+E.+Kohlauthor=A.+L.+Kungauthor=K.+Stegmaier&title=High-throughput+tyrosine+kinase+activity+profiling+identifies+FAK+as+a+candidate+therapeutic+target+in+Ewing+sarcoma&doi=10.1158%2F0008-5472.CAN-12-1944"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">High-Throughput Tyrosine Kinase Activity Profiling Identifies FAK as a Candidate Therapeutic Target in Ewing Sarcoma</span></div><div class="casAuthors">Crompton, Brian D.; Carlton, Anne L.; Thorner, Aaron R.; Christie, Amanda L.; Du, Jinyan; Calicchio, Monica L.; Rivera, Miguel N.; Fleming, Mark D.; Kohl, Nancy E.; Kung, Andrew L.; Stegmaier, Kimberly</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2873-2883</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Limited progress has been made in the treatment of advanced-stage pediatric solid tumors despite the accelerated pace of cancer discovery over the last decade.  Tyrosine kinase inhibition is one tractable therapeutic modality for treating human malignancy.  However, little is known about the kinases crit. to the development or maintenance of many pediatric solid tumors such as Ewing sarcoma.  Using a fluorescent, bead-based technol. to profile activated tyrosine kinases, we identified focal adhesion kinase (FAK,PTK2) as a candidate target in Ewing sarcoma.  FAK is a tyrosine kinase crit. for cellular adhesion, growth, and survival.  As such, it is a compelling target for cancer-based therapy.  In this study, we have shown that FAK is highly phosphorylated in primary Ewing sarcoma tumor samples and that downregulation of FAK by short hairpin RNA and treatment with a FAK-selective kinase inhibitor, PF-562271, impaired growth and colony formation in Ewing sarcoma cell lines.  Moreover, treatment of Ewing sarcoma cell lines with PF-562271 induced apoptosis and led to downregulation of AKT/mTOR and CAS activity.  Finally, we showed that small-mol. inhibition of FAK attenuated Ewing sarcoma tumor growth in vivo.  With FAK inhibitors currently in early-phase clin. trials for adult malignancies, these findings may bear immediate relevance to patients with Ewing sarcoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdtuvxP4NKR7Vg90H21EOLACvtfcHk0lhoTZJbDMOPdg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvVShtbc%253D&md5=bba21db9d669c827f91ee1f9426f9a94</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-1944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-1944%26sid%3Dliteratum%253Aachs%26aulast%3DCrompton%26aufirst%3DB.%2BD.%26aulast%3DCarlton%26aufirst%3DA.%2BL.%26aulast%3DThorner%26aufirst%3DA.%2BR.%26aulast%3DChristie%26aufirst%3DA.%2BL.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DCalicchio%26aufirst%3DM.%2BL.%26aulast%3DRivera%26aufirst%3DM.%2BN.%26aulast%3DFleming%26aufirst%3DM.%2BD.%26aulast%3DKohl%26aufirst%3DN.%2BE.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DStegmaier%26aufirst%3DK.%26atitle%3DHigh-throughput%2520tyrosine%2520kinase%2520activity%2520profiling%2520identifies%2520FAK%2520as%2520a%2520candidate%2520therapeutic%2520target%2520in%2520Ewing%2520sarcoma%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D2873%26epage%3D2883%26doi%3D10.1158%2F0008-5472.CAN-12-1944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baggerly, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armaiz-Pena, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanguino, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thanapprapasr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottsford-Miller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zand, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akbani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nick, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeGeest, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Berestein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutgendorf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, A. K.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">919</span>â <span class="NLM_lpage">929</span>, <span class="refDoi">Â DOI: 10.4161/cbt.28882</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.4161%2Fcbt.28882" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=24755674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslOqu7nE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=919-929&author=R.+L.+Stoneauthor=K.+A.+Baggerlyauthor=G.+N.+Armaiz-Penaauthor=Y.+Kangauthor=A.+M.+Sanguinoauthor=D.+Thanapprapasrauthor=H.+J.+Daltonauthor=J.+Bottsford-Millerauthor=B.+Zandauthor=R.+Akbaniauthor=L.+Diaoauthor=A.+M.+Nickauthor=K.+DeGeestauthor=G.+Lopez-Beresteinauthor=R.+L.+Colemanauthor=S.+Lutgendorfauthor=A.+K.+Sood&title=Focal+adhesion+kinase%3A+an+alternative+focus+for+anti-angiogenesis+therapy+in+ovarian+cancer&doi=10.4161%2Fcbt.28882"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion kinase : an alternative focus for anti-angiogenesis therapy in ovarian cancer</span></div><div class="casAuthors">Stone, Rebecca L.; Baggerly, Keith A.; Armaiz-Pena, Guillermo N.; Kang, Yu; Sanguino, Angela M.; Thanapprapasr, Duangmani; Dalton, Heather J.; Bottsford-Miller, Justin; Zand, Behrouz; Akbani, Rehan; Diao, Lixia; Nick, Alpa M.; DeGeest, Koen; Lopez-Berestein, Gabriel; Coleman, Robert L.; Lutgendorf, Susan; Sood, Anil K.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">919-929</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">This investigation describes the clin. significance of phosphorylated focal adhesion kinase (FAK) at the major activating tyrosine site (Y397) in epithelial ovarian cancer (EOC) cells and tumor-assocd. endothelial cells.  FAK gene amplification as a mechanism for FAK overexpression and the effects of FAK tyrosine kinase inhibitor VS-6062 on tumor growth, metastasis, and angiogenesis were examd.  FAK and phospho-FAKY397 were quantified in tumor (FAK-T; pFAK-T) and tumor-assocd. endothelial (FAK-endo; pFAK-endo) cell compartments of EOCs using immunostaining and qRT-PCR.  Assocns. between expression levels and clin. variables were evaluated.  Data from The Cancer Genome Atlas were used to correlate FAK gene copy no. and expression levels in EOC specimens.  The in vitro and in vivo effects of VS-6062 were assayed in preclin. models.  FAK-T and pFAK-T overexpression was significantly assocd. with advanced stage disease and increased microvessel d. (MVD).  High MVD was obsd. in tumors with elevated endothelial cell FAK (59%) and pFAK (44%).  Survival was adversely affected by FAK-T overexpression (3.03 vs 2.06 y, P = 0.004), pFAK-T (2.83 vs 1.78 y, P < 0.001), and pFAK-endo (2.33 vs 2.17 y, P = 0.005).  FAK gene copy no. was increased in 34% of tumors and correlated with expression levels (P < 0.001).  VS-6062 significantly blocked EOC and endothelial cell migration as well as endothelial cell tube formation in vitro.  VS-6062 reduced mean tumor wt. by 56% (P = 0.005), tumor MVD by 40% (P = 0.0001), and extraovarian metastasis (P < 0.01) in orthotopic EOC mouse models.  FAK may be a unique therapeutic target in EOC given the dual anti-angiogenic and anti-metastatic potential of FAK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUEr0JWPie47Vg90H21EOLACvtfcHk0liuVcCGEd1LCw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslOqu7nE&md5=f45619177d7ac6000dd774bd85864145</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.4161%2Fcbt.28882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.28882%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DR.%2BL.%26aulast%3DBaggerly%26aufirst%3DK.%2BA.%26aulast%3DArmaiz-Pena%26aufirst%3DG.%2BN.%26aulast%3DKang%26aufirst%3DY.%26aulast%3DSanguino%26aufirst%3DA.%2BM.%26aulast%3DThanapprapasr%26aufirst%3DD.%26aulast%3DDalton%26aufirst%3DH.%2BJ.%26aulast%3DBottsford-Miller%26aufirst%3DJ.%26aulast%3DZand%26aufirst%3DB.%26aulast%3DAkbani%26aufirst%3DR.%26aulast%3DDiao%26aufirst%3DL.%26aulast%3DNick%26aufirst%3DA.%2BM.%26aulast%3DDeGeest%26aufirst%3DK.%26aulast%3DLopez-Berestein%26aufirst%3DG.%26aulast%3DColeman%26aufirst%3DR.%2BL.%26aulast%3DLutgendorf%26aufirst%3DS.%26aulast%3DSood%26aufirst%3DA.%2BK.%26atitle%3DFocal%2520adhesion%2520kinase%253A%2520an%2520alternative%2520focus%2520for%2520anti-angiogenesis%2520therapy%2520in%2520ovarian%2520cancer%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2014%26volume%3D15%26spage%3D919%26epage%3D929%26doi%3D10.4161%2Fcbt.28882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mileshkin, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, E. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rischin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fingert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shreeve, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, L. L.</span></span> <span> </span><span class="NLM_article-title">Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1527</span>â <span class="NLM_lpage">1533</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2011.38.9346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1200%2FJCO.2011.38.9346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=22454420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC38XptlyrtL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=1527-1533&author=J.+R.+Infanteauthor=D.+R.+Camidgeauthor=L.+R.+Mileshkinauthor=E.+X.+Chenauthor=R.+J.+Hicksauthor=D.+Rischinauthor=H.+Fingertauthor=K.+J.+Pierceauthor=H.+Xuauthor=W.+G.+Robertsauthor=S.+M.+Shreeveauthor=H.+A.+Burrisauthor=L.+L.+Siu&title=Safety%2C+pharmacokinetic%2C+and+pharmacodynamic+phase+I+dose-escalation+trial+of+PF-00562271%2C+an+inhibitor+of+focal+adhesion+kinase%2C+in+advanced+solid+tumors&doi=10.1200%2FJCO.2011.38.9346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, pharmacokinetic, and pharmacodynamic Phase I dose-escalation trial ofPF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors</span></div><div class="casAuthors">Infante, Jeffrey R.; Camidge, D. Ross; Mileshkin, Linda R.; Chen, Eric X.; Hicks, Rodney J.; Rischin, Danny; Fingert, Howard; Pierce, Kristen J.; Xu, Huiping; Roberts, W. Gregory; Shreeve, S. Martin; Burris, Howard A.; Siu, Lillian L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1527-1533</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: PF-00562271 is a novel inhibitor of focal adhesion kinase (FAK).  The objectives of this study were to identify the recommended phase II dose (RP2D) and assess safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of PF-00562271.  Patients and Methods: Part 1 was a dose escalation without and with food.  Part 2 enrolled specific tumor types in an expansion at the RP2D and also assessed the effect of PF-00562271 on single-dose midazolam PK in a subgroup of patients.  Results: Ninety-nine patients (median age, 60 years; 98% with Eastern Cooperative Oncol. Group performance status of 0 or 1) were treated in 12 fasting and three fed cohorts.  The 125-mg twice-per-day fed dose was deemed the max.-tolerated dose (MTD) and RP2D.  Grade 3 dose-limiting toxicities included headache, nausea/vomiting, dehydration, and edema.  Nausea was the most frequently obsd. toxicity (60% of patients, all grades 1 or 2 at RP2D).  PF-00562271 exposure increased with increasing dose; serum concn.-time profiles showed characteristic nonlinear disposition.  Steady-state exposures were reached within 1 wk.  On coadministration, geometric mean values of midazolam maximal obsd. serum concn. and area under the serum concn.-time curve increased by 60% and more than two-fold, resp.  Of 14 patients evaluable by [18F]fluorodeoxyglucose positron emission tomog. in the expansion cohorts, seven metabolic responses were obsd.  With conventional imaging, 31 patients had stable disease at first restaging scans, and 15 of these remained stable for six or more cycles.  Conclusion: The MTD and RP2D of PF-00562271 is 125 mg twice per day with food.  PF-00562271 displayed time- and dose-dependent nonlinear PK and is likely a potent CYP 3A inhibitor.  This first-in-class study supports further investigation of FAK as a promising therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1Gt4MNB5hlrVg90H21EOLACvtfcHk0liuVcCGEd1LCw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptlyrtL8%253D&md5=a4f5c95a6cfb8c494a1044ccf463f031</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.38.9346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.38.9346%26sid%3Dliteratum%253Aachs%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DMileshkin%26aufirst%3DL.%2BR.%26aulast%3DChen%26aufirst%3DE.%2BX.%26aulast%3DHicks%26aufirst%3DR.%2BJ.%26aulast%3DRischin%26aufirst%3DD.%26aulast%3DFingert%26aufirst%3DH.%26aulast%3DPierce%26aufirst%3DK.%2BJ.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DW.%2BG.%26aulast%3DShreeve%26aufirst%3DS.%2BM.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DSiu%26aufirst%3DL.%2BL.%26atitle%3DSafety%252C%2520pharmacokinetic%252C%2520and%2520pharmacodynamic%2520phase%2520I%2520dose-escalation%2520trial%2520of%2520PF-00562271%252C%2520an%2520inhibitor%2520of%2520focal%2520adhesion%2520kinase%252C%2520in%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D1527%26epage%3D1533%26doi%3D10.1200%2FJCO.2011.38.9346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedley, D. W.</span></span> <span> </span><span class="NLM_article-title">Targeting focal adhesion kinase signaling in tumor growth and metastasis</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">77</span>â <span class="NLM_lpage">94</span>, <span class="refDoi">Â DOI: 10.1517/14728220903460340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1517%2F14728220903460340" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=20001212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFCitbvM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=77-94&author=J.+Schwockauthor=N.+Dhaniauthor=D.+W.+Hedley&title=Targeting+focal+adhesion+kinase+signaling+in+tumor+growth+and+metastasis&doi=10.1517%2F14728220903460340"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting focal adhesion kinase signaling in tumor growth and metastasis</span></div><div class="casAuthors">Schwock, Joerg; Dhani, Neesha; Hedley, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-94</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: Focal adhesion kinase (FAK), a crucial mediator of integrin and growth factor signaling, is a novel and promising target in cancer therapy.  FAK resides within focal adhesions which are contact points between extracellular matrix (ECM) and cytoskeleton, and increased expression of the kinase has been linked with cancer cell migration, proliferation and survival.  The aim of this review is to summarize the current research in the area and to assess the potential of different FAK-targeting strategies for cancer therapy.  Areas covered in this review: We briefly examine the evidence pointing towards FAK as potential anti-cancer target since its discovery in 1992.  Then, we summarize different approaches developed to interfere with FAK signaling and important results reported from these expts.  Finally, we discuss the potential of these strategies to accomplish inhibition of tumor growth and distant spread as well as potentially meaningful combinations with other therapeutic modalities in the context of the currently available evidence.  What the reader will gain: The review emphasizes the link between FAK biol. and the consequences of interference with FAK signaling.  Based on this foundation an opinion is formed with regard to the future of FAK as therapeutic target.  Take home message: Inhibition of FAK harbors the potential to restrain malignant growth and progression with minimal side effects in normal tissues.  Small mol. inhibitors of the kinase should be examd. in further clin. studies and combinations with existing therapies need to be explored.  More efforts are required to identify markers which predict response towards FAK inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZSMva2-GtqbVg90H21EOLACvtfcHk0liuVcCGEd1LCw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFCitbvM&md5=feed68cfd6aece3dc89d3568a16c1b36</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1517%2F14728220903460340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728220903460340%26sid%3Dliteratum%253Aachs%26aulast%3DSchwock%26aufirst%3DJ.%26aulast%3DDhani%26aufirst%3DN.%26aulast%3DHedley%26aufirst%3DD.%2BW.%26atitle%3DTargeting%2520focal%2520adhesion%2520kinase%2520signaling%2520in%2520tumor%2520growth%2520and%2520metastasis%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2010%26volume%3D14%26spage%3D77%26epage%3D94%26doi%3D10.1517%2F14728220903460340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecot, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zand, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupaimoole, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradeep, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, A. K.</span></span> <span> </span><span class="NLM_article-title">Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">1485</span>â <span class="NLM_lpage">1495</span>, <span class="refDoi">Â DOI: 10.1093/jnci/djt210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1093%2Fjnci%2Fdjt210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=24062525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsF2ht7fO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2013&pages=1485-1495&author=Y.+Kangauthor=W.+Huauthor=C.+Ivanauthor=H.+J.+Daltonauthor=T.+Miyakeauthor=C.+V.+Pecotauthor=B.+Zandauthor=T.+Liuauthor=J.+Huangauthor=N.+B.+Jenningsauthor=R.+Rupaimooleauthor=M.+Taylorauthor=S.+Pradeepauthor=S.+Y.+Wuauthor=C.+Luauthor=Y.+Wenauthor=J.+Huangauthor=J.+Liuauthor=A.+K.+Sood&title=Role+of+focal+adhesion+kinase+in+regulating+YB-1-mediated+paclitaxel+resistance+in+ovarian+cancer&doi=10.1093%2Fjnci%2Fdjt210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Focal Adhesion Kinase in Regulating YB-1-Mediated Paclitaxel Resistance in Ovarian Cancer</span></div><div class="casAuthors">Kang, Yu; Hu, Wei; Ivan, Cristina; Dalton, Heather J.; Miyake, Takahito; Pecot, Chad V.; Zand, Behrouz; Liu, Tao; Huang, Jie; Jennings, Nicholas B.; Rupaimoole, Rajesha; Taylor, Morgan; Pradeep, Sunila; Wu, Sherry Y.; Lu, Chunhua; Wen, Yunfei; Huang, Jianfei; Liu, Jinsong; Sood, Anil K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1485-1495</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: We previously found focal adhesion kinase (FAK) inhibition sensitizes ovarian cancer to taxanes; however, the mechanisms are not well understood.  Methods: We characterized the biol. response of taxane-resistant and taxane-sensitive ovarian cancer models to a novel FAK inhibitor (VS-6063).  We used reverse-phase protein arrays (RPPA) to identify novel downstream targets in taxane-resistant cell lines.  Furthermore, we correlated clin. and pathol. data with nuclear and cytoplasmic expression of FAK and YB-1 in 105 ovarian cancer samples.  Statistical tests were two-sided, and P values were calcd. with Student t test or Fisher exact test.  Results: We found that VS-6063 inhibited FAK phosphorylation at the Tyr397 site in a time- and dose-dependent manner.  The combination of VS-6063 and paclitaxel markedly decreased proliferation and increased apoptosis, which resulted in 92.7% to 97.9% redns. in tumor wt.  RPPA data showed that VS-6063 reduced levels of AKT and YB-1 in taxane-resistant cell lines.  FAK inhibition enhanced chemosensitivity in taxane-resistant cells by decreasing YB-1 phosphorylation and subsequently CD44 in an AKT-dependent manner.  In human ovarian cancer samples, nuclear FAK expression was assocd. with increased nuclear YB-1 expression (Ï2 = 37.7; P < .001).  Coexpression of nuclear FAK and YB-1 was assocd. with statistically significantly worse median overall survival (24.9 vs 67.3 mo; hazard ratio = 2.64; 95% confidence interval = 1.38 to 5.05; P = .006).  Conclusions: We have identified a novel pathway whereby FAK inhibition with VS-6063 overcomes YB-1-mediated paclitaxel resistance by an AKT-dependent pathway.  These findings have implications for clin. trials aimed at targeting FAK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr21t0jEcw81LVg90H21EOLACvtfcHk0ljPsoTY-yOlfQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsF2ht7fO&md5=d851fd3dc80015f8345cde1bae22dff6</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjt210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjt210%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DIvan%26aufirst%3DC.%26aulast%3DDalton%26aufirst%3DH.%2BJ.%26aulast%3DMiyake%26aufirst%3DT.%26aulast%3DPecot%26aufirst%3DC.%2BV.%26aulast%3DZand%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DJennings%26aufirst%3DN.%2BB.%26aulast%3DRupaimoole%26aufirst%3DR.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DPradeep%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DS.%2BY.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DWen%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DSood%26aufirst%3DA.%2BK.%26atitle%3DRole%2520of%2520focal%2520adhesion%2520kinase%2520in%2520regulating%2520YB-1-mediated%2520paclitaxel%2520resistance%2520in%2520ovarian%2520cancer%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2013%26volume%3D105%26spage%3D1485%26epage%3D1495%26doi%3D10.1093%2Fjnci%2Fdjt210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castillo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spielman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grogan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kench, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stricker, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haynes, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Centenera, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shreeve, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horvath, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, R. J.</span></span> <span> </span><span class="NLM_article-title">Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer</span>. <i>Prostate</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">308</span>â <span class="NLM_lpage">317</span>, <span class="refDoi">Â DOI: 10.1002/pros.23476</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1002%2Fpros.23476" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=29314097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslSjsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=308-317&author=H.+M.+Linauthor=B.+Y.+Leeauthor=L.+Castilloauthor=C.+Spielmanauthor=J.+Groganauthor=N.+K.+Yeungauthor=J.+G.+Kenchauthor=P.+D.+Strickerauthor=A.+M.+Haynesauthor=M.+M.+Centeneraauthor=L.+M.+Butlerauthor=S.+M.+Shreeveauthor=L.+G.+Horvathauthor=R.+J.+Daly&title=Effect+of+FAK+inhibitor+VS-6063+%28defactinib%29+on+docetaxel+efficacy+in+prostate+cancer&doi=10.1002%2Fpros.23476"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer</span></div><div class="casAuthors">Lin, Hui-Ming; Lee, Brian Y.; Castillo, Lesley; Spielman, Calan; Grogan, Judith; Yeung, Nicole K.; Kench, James G.; Stricker, Phillip D.; Haynes, Anne-Maree; Centenera, Margaret M.; Butler, Lisa M.; Shreeve, S. Martin; Horvath, Lisa G.; Daly, Roger J.</div><div class="citationInfo"><span class="NLM_cas:title">Prostate (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">308-317</span>CODEN:
                <span class="NLM_cas:coden">PRSTDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-4137</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background : Docetaxel, the std. chemotherapy for metastatic castration-resistant prostate cancer (CRPC) also enhances the survival of patients with metastatic castration-sensitive prostate cancer (CSPC) when combined with androgen-deprivation therapy.  Focal Adhesion Kinase (FAK) activation is a mediator of docetaxel resistance in prostate cancer cells.  The aim of this study was to investigate the effect of the second generation FAK inhibitor VS-6063 on docetaxel efficacy in pre-clin. CRPC and CSPC models.  Methods : Docetaxel-resistant CRPC cells, mice with PC3 xenografts, and ex vivo cultures of patient-derived primary prostate tumors were treated with VS-6063 and/or docetaxel, or vehicle control.  Cell counting, immunoblotting, and immunohistochem. techniques were used to evaluate the treatment effects.  Results : Docetaxel and VS-6063 co-treatment caused a greater decrease in the viability of docetaxel-resistant CRPC cells, and a greater inhibition in PC3 xenograft growth compared to either monotherapy.  FAK expression in human primary prostate cancer was pos. assocd. with advanced tumor stage.  Patient-derived prostate tumor explants cultured with both docetaxel and VS-6063 displayed a higher percentage of apoptosis in cancer cells, than monotherapy treatment.  Conclusions : Our findings suggest that co-administration of the FAK inhibitor, VS-6063, with docetaxel represents a potential therapeutic strategy to overcome docetaxel resistance in prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3_T7Eg71A9LVg90H21EOLACvtfcHk0ljPsoTY-yOlfQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslSjsrY%253D&md5=106cdce4729a5ceb846787369b7d4321</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1002%2Fpros.23476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpros.23476%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DH.%2BM.%26aulast%3DLee%26aufirst%3DB.%2BY.%26aulast%3DCastillo%26aufirst%3DL.%26aulast%3DSpielman%26aufirst%3DC.%26aulast%3DGrogan%26aufirst%3DJ.%26aulast%3DYeung%26aufirst%3DN.%2BK.%26aulast%3DKench%26aufirst%3DJ.%2BG.%26aulast%3DStricker%26aufirst%3DP.%2BD.%26aulast%3DHaynes%26aufirst%3DA.%2BM.%26aulast%3DCentenera%26aufirst%3DM.%2BM.%26aulast%3DButler%26aufirst%3DL.%2BM.%26aulast%3DShreeve%26aufirst%3DS.%2BM.%26aulast%3DHorvath%26aufirst%3DL.%2BG.%26aulast%3DDaly%26aufirst%3DR.%2BJ.%26atitle%3DEffect%2520of%2520FAK%2520inhibitor%2520VS-6063%2520%2528defactinib%2529%2520on%2520docetaxel%2520efficacy%2520in%2520prostate%2520cancer%26jtitle%3DProstate%26date%3D2018%26volume%3D78%26spage%3D308%26epage%3D317%26doi%3D10.1002%2Fpros.23476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendell, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleary, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Razak, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandya, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedard, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houk, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shreeve, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span> <span> </span><span class="NLM_article-title">A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1100</span>â <span class="NLM_lpage">1107</span>, <span class="refDoi">Â DOI: 10.1007/s10637-015-0282-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1007%2Fs10637-015-0282-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=26334219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFSit7%252FN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=1100-1107&author=S.+F.+Jonesauthor=L.+L.+Siuauthor=J.+C.+Bendellauthor=J.+M.+Clearyauthor=A.+R.+Razakauthor=J.+R.+Infanteauthor=S.+S.+Pandyaauthor=P.+L.+Bedardauthor=K.+J.+Pierceauthor=B.+Houkauthor=W.+G.+Robertsauthor=S.+M.+Shreeveauthor=G.+I.+Shapiro&title=A+phase+I+study+of+VS-6063%2C+a+second-generation+focal+adhesion+kinase+inhibitor%2C+in+patients+with+advanced+solid+tumors&doi=10.1007%2Fs10637-015-0282-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors</span></div><div class="casAuthors">Jones, Suzanne F.; Siu, Lillian L.; Bendell, Johanna C.; Cleary, James M.; Razak, Albiruni R. A.; Infante, Jeffrey R.; Pandya, Shuchi S.; Bedard, Philippe L.; Pierce, Kristen J.; Houk, Brett; Roberts, W. Gregory; Shreeve, S. Martin; Shapiro, Geoffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1100-1107</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Objective VS-6063 (also known as defactinib or PF-04554878) is a second-generation inhibitor of focal adhesion kinase (FAK) and proline-rich tyrosine kinase-2 (Pyk2).  This phase I dose-escalation study was conducted in patients with advanced solid malignancies.  Methods Using a traditional 3 + 3 design, VS-6063 was administered orally twice daily (b.i.d.) in 21-day cycles to cohorts of three to six patients.  In cycle 1, a lead-in dose was administered to assess single-dose pharmacokinetics; steady-state pharmacokinetics was assessed after 15 days of continuous dosing.  Dose escalation was performed in the fasted state, and repeated in two addnl. cohorts in the fed state.  Results Forty-six patients were treated across nine dose levels (12.5-750 mg b.i.d.).  Dose-limiting toxicities, comprising headache (n = 1), fatigue (n = 1) and unconjugated hyperbilirubinemia (n = 3), occurred at the 300- or 425-mg b.i.d. dose level and were reversible.  Frequent adverse events included nausea (37 %), fatigue (33 %), vomiting (28 %), diarrhea (22 %) and headache (22 %).  A max.-tolerated dose was not defined.  Dose escalation was stopped at the 750-mg b.i.d. dose due to decreased serum exposure in the 500- and 750-mg vs. 300- and 425-mg groups.  Food delayed the time to peak serum concn. without affecting serum drug exposure.  No radiog. responses were reported.  Disease stabilization at â¼12 wk occurred in six of 37 (16 %) patients receiving doses â¥100 mg b.i.d.  Conclusions VS-6063 has an acceptable safety profile.  Treatment-related adverse events were mild to moderate, and reversible.  The recommended phase II fasting dose of VS-6063 is 425 mg b.i.d.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWgn43uEabk7Vg90H21EOLACvtfcHk0ljzQsF5vuyAIA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFSit7%252FN&md5=ddf589d6f9d3f95a3d70fb0fa9455841</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1007%2Fs10637-015-0282-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-015-0282-y%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DS.%2BF.%26aulast%3DSiu%26aufirst%3DL.%2BL.%26aulast%3DBendell%26aufirst%3DJ.%2BC.%26aulast%3DCleary%26aufirst%3DJ.%2BM.%26aulast%3DRazak%26aufirst%3DA.%2BR.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DPandya%26aufirst%3DS.%2BS.%26aulast%3DBedard%26aufirst%3DP.%2BL.%26aulast%3DPierce%26aufirst%3DK.%2BJ.%26aulast%3DHouk%26aufirst%3DB.%26aulast%3DRoberts%26aufirst%3DW.%2BG.%26aulast%3DShreeve%26aufirst%3DS.%2BM.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520VS-6063%252C%2520a%2520second-generation%2520focal%2520adhesion%2520kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2015%26volume%3D33%26spage%3D1100%26epage%3D1107%26doi%3D10.1007%2Fs10637-015-0282-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgensztern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cetnar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigel, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaglioni, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaikus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horobin, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, T. F.</span></span> <span> </span><span class="NLM_article-title">Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">60</span>â <span class="NLM_lpage">67</span>, <span class="refDoi">Â DOI: 10.1016/j.lungcan.2019.10.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.lungcan.2019.10.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=31739184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BB3MfgtlOltA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2020&pages=60-67&author=D.+E.+Gerberauthor=D.+R.+Camidgeauthor=D.+Morgenszternauthor=J.+Cetnarauthor=R.+J.+Kellyauthor=S.+S.+Ramalingamauthor=D.+R.+Spigelauthor=W.+Jeongauthor=P.+P.+Scaglioniauthor=S.+Zhangauthor=M.+Liauthor=D.+T.+Weaverauthor=L.+Vaikusauthor=M.+Keeganauthor=J.+C.+Horobinauthor=T.+F.+Burns&title=Phase+2+study+of+the+focal+adhesion+kinase+inhibitor+defactinib+%28VS-6063%29+in+previously+treated+advanced+KRAS+mutant+non-small+cell+lung+cancer&doi=10.1016%2Fj.lungcan.2019.10.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer</span></div><div class="casAuthors">Gerber David E; Scaglioni Pier P; Zhang Song; Camidge D Ross; Morgensztern Daniel; Cetnar Jeremey; Kelly Ronan J; Ramalingam Suresh S; Spigel David R; Jeong Woondong; Li Marilyn; Weaver David T; Vaikus Louis; Keegan Mitchell; Horobin Joanna C; Burns Timothy F</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">60-67</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  KRAS mutations, which occur in approximately 25% of lung adenocarcinoma cases, represent a major unmet clinical need in thoracic oncology.  Preclinical studies have demonstrated that KRAS mutant NSCLC cell lines and xenografts with additional alterations in either TP53 or CDKN2A (INK4A/ARF) loci are sensitive to focal adhesion kinase (FAK) inhibition.  Defactinib (VS-6063) is a selective oral inhibitor of FAK.  MATERIALS AND METHODS:  Patients with previously treated advanced KRAS mutant NSCLC were prospectively assigned to one of four molecularly defined cohorts based on the presence or absence of TP53 or CDKN2A alterations and received treatment with defactinib 400 mg orally BID until disease progression or intolerable toxicity.  The primary endpoint was progression-free survival (PFS) at 12 weeks.  RESULTS:  Fifty-five patients were enrolled.  Mean age was 62 years; 51% were female.  The median number of prior lines of therapy was 4 (range 1-8).  Fifteen (28%) patients met the 12-week PFS endpoint, with one patient achieving a partial response.  Median PFS was 45 days.  Clinical efficacy did not correlate with TP53 or CDKN2A status.  The most common adverse events were fatigue, gastrointestinal, and increased bilirubin, and were generally grade 1 or 2 in severity.  CONCLUSION:  In heavily pretreated patients with KRAS mutant NSCLC, defactinib monotherapy demonstrated modest clinical activity.  Efficacy was not associated with TP53 and CDKN2A status.  Defactinib was generally well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRHRrJNXQ9psJp6t8nS6Nc3fW6udTcc2eZt9Uuca3JCW7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MfgtlOltA%253D%253D&md5=298f9f8fb6364770cfc7302f4ae30069</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2019.10.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2019.10.033%26sid%3Dliteratum%253Aachs%26aulast%3DGerber%26aufirst%3DD.%2BE.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DMorgensztern%26aufirst%3DD.%26aulast%3DCetnar%26aufirst%3DJ.%26aulast%3DKelly%26aufirst%3DR.%2BJ.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DSpigel%26aufirst%3DD.%2BR.%26aulast%3DJeong%26aufirst%3DW.%26aulast%3DScaglioni%26aufirst%3DP.%2BP.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DWeaver%26aufirst%3DD.%2BT.%26aulast%3DVaikus%26aufirst%3DL.%26aulast%3DKeegan%26aufirst%3DM.%26aulast%3DHorobin%26aufirst%3DJ.%2BC.%26aulast%3DBurns%26aufirst%3DT.%2BF.%26atitle%3DPhase%25202%2520study%2520of%2520the%2520focal%2520adhesion%2520kinase%2520inhibitor%2520defactinib%2520%2528VS-6063%2529%2520in%2520previously%2520treated%2520advanced%2520KRAS%2520mutant%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DLung%2520Cancer%26date%3D2020%26volume%3D139%26spage%3D60%26epage%3D67%26doi%3D10.1016%2Fj.lungcan.2019.10.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schultze, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiedler, W.</span></span> <span> </span><span class="NLM_article-title">Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">777</span>â <span class="NLM_lpage">788</span>, <span class="refDoi">Â DOI: 10.1517/13543784.2010.489548</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1517%2F13543784.2010.489548" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=20465362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFOisLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=777-788&author=A.+Schultzeauthor=W.+Fiedler&title=Therapeutic+potential+and+limitations+of+new+FAK+inhibitors+in+the+treatment+of+cancer&doi=10.1517%2F13543784.2010.489548"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer</span></div><div class="casAuthors">Schultze, Alexander; Fiedler, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">777-788</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: Activation of the non-receptor tyrosine kinase focal adhesion kinase (FAK) has been implicated in progression of multiple mesenchymal and epithelial malignant tumors.  FAK plays an important role in regulation of proliferation, migration and apoptosis of neoplastic cells.  Areas covered in this review: We review the importance of FAK expression as a prognostic marker in cancer patients, discuss the available small-mol. inhibitors of FAK, summarize the available data from early-phase clin. trials with FAK inhibitors and cover the antiangiogenic properties of FAK inhibitors, as well as their potential to overcome chemoresistance.  What the reader will gain: This review enables the reader to overview current knowledge about FAK inhibition in cancer therapy and its role in the clin. setting.  The reader will be able to consider FAK inhibitors not only as direct antitumor but also as antineoangiogenic agents and drugs that can overcome the problem of chemoresistance.  Take home message: Emerging data from early-phase clin. trials with orally available small-mol. inhibitors of FAK are promising.  There are early indicators of clin. efficacy.  In the future, combination therapy with cytotoxic or antiangiogenic drugs may help to overcome chemoresistance and enhance efficacy of antivascular therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKbTg2U-JLsLVg90H21EOLACvtfcHk0ljzQsF5vuyAIA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFOisLk%253D&md5=3e9ead05b7770778b90f9ec48c317a56</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1517%2F13543784.2010.489548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2010.489548%26sid%3Dliteratum%253Aachs%26aulast%3DSchultze%26aufirst%3DA.%26aulast%3DFiedler%26aufirst%3DW.%26atitle%3DTherapeutic%2520potential%2520and%2520limitations%2520of%2520new%2520FAK%2520inhibitors%2520in%2520the%2520treatment%2520of%2520cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2010%26volume%3D19%26spage%3D777%26epage%3D788%26doi%3D10.1517%2F13543784.2010.489548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slack-Davis, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilghman, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwanicki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ung, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Autry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzzio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, J. T.</span></span> <span> </span><span class="NLM_article-title">Cellular characterization of a novel focal adhesion kinase inhibitor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>282</i></span>,  <span class="NLM_fpage">14845</span>â <span class="NLM_lpage">14852</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M606695200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1074%2Fjbc.M606695200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=17395594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltFemtbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=14845-14852&author=J.+K.+Slack-Davisauthor=K.+H.+Martinauthor=R.+W.+Tilghmanauthor=M.+Iwanickiauthor=E.+J.+Ungauthor=C.+Autryauthor=M.+J.+Luzzioauthor=B.+Cooperauthor=J.+C.+Kathauthor=W.+G.+Robertsauthor=J.+T.+Parsons&title=Cellular+characterization+of+a+novel+focal+adhesion+kinase+inhibitor&doi=10.1074%2Fjbc.M606695200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular Characterization of a Novel Focal Adhesion Kinase Inhibitor</span></div><div class="casAuthors">Slack-Davis, Jill K.; Martin, Karen H.; Tilghman, Robert W.; Iwanicki, Marcin; Ung, Ethan J.; Autry, Christopher; Luzzio, Michael J.; Cooper, Beth; Kath, John C.; Roberts, W. Gregory; Parsons, J. Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">14845-14852</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) is a member of a family of non-receptor protein-tyrosine kinases that regulates integrin and growth factor signaling pathways involved in cell migration, proliferation, and survival.  FAK expression is increased in many cancers, including breast and prostate cancer.  Here we describe perturbation of adhesion-mediated signaling with a FAK inhibitor, PF-573,228.  In vitro, this compd. inhibited purified recombinant catalytic fragment of FAK with an IC50 of 4 nM.  In cultured cells, PF-573,228 inhibited FAK phosphorylation on Tyr397 with an IC50 of 30-100 nM.  Treatment of cells with concns. of PF-573,228 that significantly decreased FAK Tyr397 phosphorylation failed to inhibit cell growth or induce apoptosis.  In contrast, treatment with PF-573,228 inhibited both chemotactic and haptotactic migration concomitant with the inhibition of focal adhesion turnover.  These studies show that PF-573,228 serves as a useful tool to dissect the functions of FAK in integrin-dependent signaling pathways in normal and cancer cells and forms the basis for the generation of compds. amenable for preclin. and patient trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_48hzQ-vWhrVg90H21EOLACvtfcHk0liCGD4IjcsWzQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltFemtbY%253D&md5=38e97c67d37fbcbde006e6937ae4e360</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M606695200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M606695200%26sid%3Dliteratum%253Aachs%26aulast%3DSlack-Davis%26aufirst%3DJ.%2BK.%26aulast%3DMartin%26aufirst%3DK.%2BH.%26aulast%3DTilghman%26aufirst%3DR.%2BW.%26aulast%3DIwanicki%26aufirst%3DM.%26aulast%3DUng%26aufirst%3DE.%2BJ.%26aulast%3DAutry%26aufirst%3DC.%26aulast%3DLuzzio%26aufirst%3DM.%2BJ.%26aulast%3DCooper%26aufirst%3DB.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DRoberts%26aufirst%3DW.%2BG.%26aulast%3DParsons%26aufirst%3DJ.%2BT.%26atitle%3DCellular%2520characterization%2520of%2520a%2520novel%2520focal%2520adhesion%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D14845%26epage%3D14852%26doi%3D10.1074%2Fjbc.M606695200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanteti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirzapoiazova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riehm, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhanasingh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mambetsariev, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaushik, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seshacharyulu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponnusamy, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindler, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasser, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batra, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgia, R.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">316</span>â <span class="NLM_lpage">327</span>, <span class="refDoi">Â DOI: 10.1080/15384047.2017.1416937</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1080%2F15384047.2017.1416937" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=29303405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjslOisL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=316-327&author=R.+Kantetiauthor=T.+Mirzapoiazovaauthor=J.+J.+Riehmauthor=I.+Dhanasinghauthor=B.+Mambetsarievauthor=J.+Wangauthor=P.+Kulkarniauthor=G.+Kaushikauthor=P.+Seshacharyuluauthor=M.+P.+Ponnusamyauthor=H.+L.+Kindlerauthor=M.+W.+Nasserauthor=S.+K.+Batraauthor=R.+Salgia&title=Focal+adhesion+kinase+a+potential+therapeutic+target+for+pancreatic+cancer+and+malignant+pleural+mesothelioma&doi=10.1080%2F15384047.2017.1416937"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma</span></div><div class="casAuthors">Kanteti, Rajani; Mirzapoiazova, Tamara; Riehm, Jacob J.; Dhanasingh, Immanuel; Mambetsariev, Bolot; Wang, Jiale; Kulkarni, Prakash; Kaushik, Garima; Seshacharyulu, Parthasarathy; Ponnusamy, Moorthy P.; Kindler, Hedy L.; Nasser, Mohd. W.; Batra, Surinder K.; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">316-327</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1555-8576</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The non-receptor cytoplasmic tyrosine kinase, Focal Adhesion Kinase (FAK) is known to play a key role in a variety of normal and cancer cellular functions such as survival, proliferation, migration and invasion.  It is highly active and overexpressed in various cancers including Pancreatic Ductal Adenocarcinoma (PDAC) and Malignant Pleural Mesothelioma (MPM).  Here, initially, we demonstrate that FAK is overexpressed in both PDAC and MPM cell lines.  Then we analyze effects of two small mol. inhibitors PF-573228, and PF-431396, which are dual specificity inhibitors of FAK and proline rich tyrosine kinase 2 (PYK2), as well as VS-6063, another small mol. inhibitor that specifically inhibits FAK but not PYK2 for cell growth, motility and invasion of PDAC and MPM cell lines.  Treatment with PF-573228, PF-431396 and VS-6063 cells resulted in a dose-dependent inhibition of growth and anchorage-independent colony formation in both cancer cell lines.  Furthermore, these compds. suppressed the phosphorylation of FAK at its active site, Y397, and functionally induced significant apoptosis and cell cycle arrest in both cell lines.  Using the ECIS (Elec. cell-substrate impedance sensing) system, we found that treatment of both PF compds. suppressed adherence and migration of PDAC cells on fibronectin.  Interestingly, 3D-tumor organoids derived from autochthonous KC (Kras;PdxCre) mice treated with PF-573228 revealed a significant decrease in tumor organoid size and increase in organoid cell death.  Taken together, our results show that FAK is an important target for mesothelioma and pancreatic cancer therapy that merit further translational studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwRiE9kWhYWrVg90H21EOLACvtfcHk0liCGD4IjcsWzQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjslOisL8%253D&md5=05e366f4dd47a6fb92bcf0ff61e79618</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1080%2F15384047.2017.1416937&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384047.2017.1416937%26sid%3Dliteratum%253Aachs%26aulast%3DKanteti%26aufirst%3DR.%26aulast%3DMirzapoiazova%26aufirst%3DT.%26aulast%3DRiehm%26aufirst%3DJ.%2BJ.%26aulast%3DDhanasingh%26aufirst%3DI.%26aulast%3DMambetsariev%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DKulkarni%26aufirst%3DP.%26aulast%3DKaushik%26aufirst%3DG.%26aulast%3DSeshacharyulu%26aufirst%3DP.%26aulast%3DPonnusamy%26aufirst%3DM.%2BP.%26aulast%3DKindler%26aufirst%3DH.%2BL.%26aulast%3DNasser%26aufirst%3DM.%2BW.%26aulast%3DBatra%26aufirst%3DS.%2BK.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DFocal%2520adhesion%2520kinase%2520a%2520potential%2520therapeutic%2520target%2520for%2520pancreatic%2520cancer%2520and%2520malignant%2520pleural%2520mesothelioma%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2018%26volume%3D19%26spage%3D316%26epage%3D327%26doi%3D10.1080%2F15384047.2017.1416937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukazawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakurama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motoki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takaoka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatakeyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omori, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanabe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirakawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamatsuji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naomoto, Y.</span></span> <span> </span><span class="NLM_article-title">TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1473</span>â <span class="NLM_lpage">1477</span>, <span class="refDoi">Â DOI: 10.3892/or_00000168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.3892%2For_00000168" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1994&pages=1473-1477&author=Z.+G.+Wangauthor=T.+Fukazawaauthor=T.+Nishikawaauthor=N.+Watanabeauthor=K.+Sakuramaauthor=T.+Motokiauthor=M.+Takaokaauthor=S.+Hatakeyamaauthor=O.+Omoriauthor=T.+Oharaauthor=S.+Tanabeauthor=Y.+Fujiwaraauthor=Y.+Shirakawaauthor=T.+Yamatsujiauthor=N.+Tanakaauthor=Y.+Naomoto&title=TAE226%2C+a+dual+inhibitor+for+FAK+and+IGF-IR%2C+has+inhibitory+effects+on+mTOR+signaling+in+esophageal+cancer+cells&doi=10.3892%2For_00000168"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.3892%2For_00000168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For_00000168%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%2BG.%26aulast%3DFukazawa%26aufirst%3DT.%26aulast%3DNishikawa%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DN.%26aulast%3DSakurama%26aufirst%3DK.%26aulast%3DMotoki%26aufirst%3DT.%26aulast%3DTakaoka%26aufirst%3DM.%26aulast%3DHatakeyama%26aufirst%3DS.%26aulast%3DOmori%26aufirst%3DO.%26aulast%3DOhara%26aufirst%3DT.%26aulast%3DTanabe%26aufirst%3DS.%26aulast%3DFujiwara%26aufirst%3DY.%26aulast%3DShirakawa%26aufirst%3DY.%26aulast%3DYamatsuji%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DN.%26aulast%3DNaomoto%26aufirst%3DY.%26atitle%3DTAE226%252C%2520a%2520dual%2520inhibitor%2520for%2520FAK%2520and%2520IGF-IR%252C%2520has%2520inhibitory%2520effects%2520on%2520mTOR%2520signaling%2520in%2520esophageal%2520cancer%2520cells%26jtitle%3DOncol.%2520Rep.%26date%3D1994%26volume%3D20%26spage%3D1473%26epage%3D1477%26doi%3D10.3892%2For_00000168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naomoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakurama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomono, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukazawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirakawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamatsuji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takaoka, M.</span></span> <span> </span><span class="NLM_article-title">Progress in researches about focal adhesion kinase in gastrointestinal tract</span>. <i>World J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">5916</span>â <span class="NLM_lpage">5923</span>, <span class="refDoi">Â DOI: 10.3748/wjg.15.5916</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.3748%2Fwjg.15.5916" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=20014455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFyrur3L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=5916-5923&author=H.+F.+Haoauthor=Y.+Naomotoauthor=X.+H.+Baoauthor=N.+Watanabeauthor=K.+Sakuramaauthor=K.+Nomaauthor=Y.+Tomonoauthor=T.+Fukazawaauthor=Y.+Shirakawaauthor=T.+Yamatsujiauthor=J.+Matsuokaauthor=M.+Takaoka&title=Progress+in+researches+about+focal+adhesion+kinase+in+gastrointestinal+tract&doi=10.3748%2Fwjg.15.5916"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in researches about focal adhesion kinase in gastrointestinal tract</span></div><div class="casAuthors">Hao, Hui Fang; Naomoto, Yoshio; Bao, Xiao-Hong; Watanabe, Nobuyuki; Sakurama, Kazufumi; Noma, Kazuhiro; Tomono, Yasuko; Fukazawa, Takuya; Shirakawa, Yasuhiro; Yamatsuji, Tomoki; Matsuoka, Junji; Takaoka, Munenori</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">5916-5923</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">1007-9327</span>.
    
            (<span class="NLM_cas:orgname">WJG Press and Beijing Baishideng BioMed Scientific Co., Ltd.</span>)
        </div><div class="casAbstract">A review.  Focal adhesion kinase (FAK) is a 125-kDa non-receptor protein tyrosine.  Growth factors or the clustering of integrins facilitate the rapid phosphorylation of FAK at Tyr-397 and this in turn recruits Src-family protein tyrosine kinases, resulting in the phosphorylation of Tyr-576 and Tyr-577 in the FAK activation loop and full catalytic FAK activation.  FAK plays a crit. role in the biol. processes of normal and cancer cells including the gastrointestinal tract.  FAK also plays an important role in the restitution, cell survival and apoptosis and carcinogenesis of the gastrointestinal tract.  FAK is overexpressed in cancer cells and its over-expression and elevated activities are assocd. with motility and invasion of cancer cells.  FAK has been proposed as a potential target in cancer therapy.  Small mol. inhibitors effectively inhibit the kinase activity of FAK and show a potent inhibitory effect for the proliferation and migration of tumor cells, indicating a high potential for application in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8-4ghHmavELVg90H21EOLACvtfcHk0ljuwslPln1QVQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFyrur3L&md5=1cf31a97462bbccac352c68eab1bf0ed</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.3748%2Fwjg.15.5916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.15.5916%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DH.%2BF.%26aulast%3DNaomoto%26aufirst%3DY.%26aulast%3DBao%26aufirst%3DX.%2BH.%26aulast%3DWatanabe%26aufirst%3DN.%26aulast%3DSakurama%26aufirst%3DK.%26aulast%3DNoma%26aufirst%3DK.%26aulast%3DTomono%26aufirst%3DY.%26aulast%3DFukazawa%26aufirst%3DT.%26aulast%3DShirakawa%26aufirst%3DY.%26aulast%3DYamatsuji%26aufirst%3DT.%26aulast%3DMatsuoka%26aufirst%3DJ.%26aulast%3DTakaoka%26aufirst%3DM.%26atitle%3DProgress%2520in%2520researches%2520about%2520focal%2520adhesion%2520kinase%2520in%2520gastrointestinal%2520tract%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2009%26volume%3D15%26spage%3D5916%26epage%3D5923%26doi%3D10.3748%2Fwjg.15.5916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomioka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatakeyama, S.</span></span> <span> </span><span class="NLM_article-title">Pharmacological profiling of a dual FAK/IGF-1R kinase inhibitor TAE226 in cellular and in vivo tumor models</span>. <i>BMC Res. Notes</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">347</span>â <span class="NLM_lpage">353</span>, <span class="refDoi">Â DOI: 10.1186/s13104-019-4389-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1186%2Fs13104-019-4389-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=31215459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1CqtbrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=347-353&author=S.+Fukamiauthor=D.+Tomiokaauthor=Y.+Murakamiauthor=T.+Hondaauthor=S.+Hatakeyama&title=Pharmacological+profiling+of+a+dual+FAK%2FIGF-1R+kinase+inhibitor+TAE226+in+cellular+and+in+vivo+tumor+models&doi=10.1186%2Fs13104-019-4389-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological profiling of a dual fak/igf-1r kinase inhibitor tae226 in cellular and in vivo tumor models</span></div><div class="casAuthors">Fukami, Shigemi; Tomioka, Daisaku; Murakami, Yutaka; Honda, Toshiyuki; Hatakeyama, Shinji</div><div class="citationInfo"><span class="NLM_cas:title">BMC Research Notes</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">347</span>CODEN:
                <span class="NLM_cas:coden">BRNMAT</span>;
        ISSN:<span class="NLM_cas:issn">1756-0500</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A dual inhibitor of focal adhesion kinase (FAK) and insulin-like growth factor 1 receptor (IGF-1R), TAE226, was evaluated in a panel of cancer cell lines, MIA PaCa-2 human pancreatic tumor and 4T1 murine breast tumor models.  The profiling data were generated during the drug discovery research prior to the first publication of TAE226 appeared in 2007.  In a panel of 37 cancer cell lines, TAE226 showed a mean GI50 value of 0.76Î¼mol/L.  In the MIA PaCa-2 model, TAE226 inhibited phosphorylation of Y397-FAK and phosphorylation of S473-Akt as IGF-1R signaling in the cell culture in vitro and the tumor in mice.  Oral administration of TAE226 induced tumor stasis at 30 mg/kg and tumor regression at 100 mg/kg in the s.c. tumor, and inhibited the orthotopic tumor growth in a dose-dependent manner.  Similarly in the 4T1 model, TAE226 inhibited phosphorylation of Y397-FAK and S473-Akt in the cell culture in vitro and the tumor in mice.  Oral administration of TAE226 inhibited the orthotopic tumor growth and metastasis to the lung in a dose-dependent manner.  Thus, TAE226 represents a novel class of selective and small mol. kinase inhibitor with a potent in vivo activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5SgxwAozCN7Vg90H21EOLACvtfcHk0ljuwslPln1QVQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1CqtbrL&md5=765476c3eba803257e56d29995953397</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1186%2Fs13104-019-4389-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13104-019-4389-7%26sid%3Dliteratum%253Aachs%26aulast%3DFukami%26aufirst%3DS.%26aulast%3DTomioka%26aufirst%3DD.%26aulast%3DMurakami%26aufirst%3DY.%26aulast%3DHonda%26aufirst%3DT.%26aulast%3DHatakeyama%26aufirst%3DS.%26atitle%3DPharmacological%2520profiling%2520of%2520a%2520dual%2520FAK%252FIGF-1R%2520kinase%2520inhibitor%2520TAE226%2520in%2520cellular%2520and%2520in%2520vivo%2520tumor%2520models%26jtitle%3DBMC%2520Res.%2520Notes%26date%3D2019%26volume%3D12%26spage%3D347%26epage%3D353%26doi%3D10.1186%2Fs13104-019-4389-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tai, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, T. L.</span></span> <span> </span><span class="NLM_article-title">Emerging roles of focal adhesion kinase in cancer</span>. <i>BioMed Res. Int.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">13</span>, <span class="refDoi">Â DOI: 10.1155/2015/690690</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1155%2F2015%2F690690" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=1-13&author=Y.+L.+Taiauthor=L.+C.+Chenauthor=T.+L.+Shen&title=Emerging+roles+of+focal+adhesion+kinase+in+cancer&doi=10.1155%2F2015%2F690690"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1155%2F2015%2F690690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F690690%26sid%3Dliteratum%253Aachs%26aulast%3DTai%26aufirst%3DY.%2BL.%26aulast%3DChen%26aufirst%3DL.%2BC.%26aulast%3DShen%26aufirst%3DT.%2BL.%26atitle%3DEmerging%2520roles%2520of%2520focal%2520adhesion%2520kinase%2520in%2520cancer%26jtitle%3DBioMed%2520Res.%2520Int.%26date%3D2015%26volume%3D2015%26spage%3D1%26epage%3D13%26doi%3D10.1155%2F2015%2F690690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hjelmeland, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keir, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohmori, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigner, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, J. N.</span></span> <span> </span><span class="NLM_article-title">A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth</span>. <i>Mol. Carcinog.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">488</span>â <span class="NLM_lpage">496</span>, <span class="refDoi">Â DOI: 10.1002/mc.20297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1002%2Fmc.20297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=17219439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2sXms1Olsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=488-496&author=Q.+Shiauthor=A.+B.+Hjelmelandauthor=S.+T.+Keirauthor=L.+Songauthor=S.+Wickmanauthor=D.+Jacksonauthor=O.+Ohmoriauthor=D.+D.+Bignerauthor=H.+S.+Friedmanauthor=J.+N.+Rich&title=A+novel+low-molecular+weight+inhibitor+of+focal+adhesion+kinase%2C+TAE226%2C+inhibits+glioma+growth&doi=10.1002%2Fmc.20297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth</span></div><div class="casAuthors">Shi, Qing; Hjelmeland, Anita B.; Keir, Stephen T.; Song, Linhua; Wickman, Sarah; Jackson, Dowdy; Ohmori, Osamu; Bigner, Darell D.; Friedman, Henry S.; Rich, Jeremy N.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Carcinogenesis</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">488-496</span>CODEN:
                <span class="NLM_cas:coden">MOCAE8</span>;
        ISSN:<span class="NLM_cas:issn">0899-1987</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Glioblastomas are highly lethal cancers that resist current therapies.  Novel therapies under development target mol. mechanisms that promote glioblastoma growth.  In glioblastoma patient specimens, the non-receptor tyrosine kinase focal adhesion kinase (FAK) is overexpressed.  Upon growth factor receptor stimulation or integrin engagement, FAK is activated by phosphorylation on crit. tyrosine residues.  Activated FAK initiates a signal transduction cascade which promotes glioma growth and invasion by increasing cellular adhesion, migration, invasion, and proliferation.  We find that human glioma cell lines express different levels of total FAK protein and activating phosphorylation of tyrosine residues Tyr397, Tyr861, and Tyr925.  As all glioma cell lines examd. expressed phosphorylated FAK, we examd. the efficacy of a novel low-mol. wt. inhibitor of FAK, TAE226, against human glioma cell lines.  TAE226 inhibited the phosphorylation of FAK as well as the downstream effectors AKT, extracellular signal-related kinase, and S6 ribosomal protein in multiple glioma cell lines.  TAE226 induced a concn.-dependent decrease in cellular proliferation with an assocd. G2 cell cycle arrest in every cell line and an increase in apoptosis in a cell-line-specific manner.  TAE226 also decreased glioma cell adhesion, migration, and invasion through an artificial extracellular matrix.  Together, these data demonstrate the potential benefit of TAE226 for glioma therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXL0wEDuHo9bVg90H21EOLACvtfcHk0ljuwslPln1QVQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXms1Olsrg%253D&md5=83711a44fe2472eae4baf568ee4332a4</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1002%2Fmc.20297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmc.20297%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DHjelmeland%26aufirst%3DA.%2BB.%26aulast%3DKeir%26aufirst%3DS.%2BT.%26aulast%3DSong%26aufirst%3DL.%26aulast%3DWickman%26aufirst%3DS.%26aulast%3DJackson%26aufirst%3DD.%26aulast%3DOhmori%26aufirst%3DO.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26aulast%3DFriedman%26aufirst%3DH.%2BS.%26aulast%3DRich%26aufirst%3DJ.%2BN.%26atitle%3DA%2520novel%2520low-molecular%2520weight%2520inhibitor%2520of%2520focal%2520adhesion%2520kinase%252C%2520TAE226%252C%2520inhibits%2520glioma%2520growth%26jtitle%3DMol.%2520Carcinog.%26date%3D2007%26volume%3D46%26spage%3D488%26epage%3D496%26doi%3D10.1002%2Fmc.20297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFortune, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohmori, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatakeyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Groot, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yung, W. K.</span></span> <span> </span><span class="NLM_article-title">Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1357</span>â <span class="NLM_lpage">1367</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-06-0476</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1158%2F1535-7163.MCT-06-0476" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=17431114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktFams7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=1357-1367&author=T.+J.+Liuauthor=T.+LaFortuneauthor=T.+Hondaauthor=O.+Ohmoriauthor=S.+Hatakeyamaauthor=T.+Meyerauthor=D.+Jacksonauthor=J.+de+Grootauthor=W.+K.+Yung&title=Inhibition+of+both+focal+adhesion+kinase+and+insulin-like+growth+factor-I+receptor+kinase+suppresses+glioma+proliferation+in+vitro+and+in+vivo&doi=10.1158%2F1535-7163.MCT-06-0476"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo</span></div><div class="casAuthors">Liu, Ta-Jen; LaFortune, Tiffany; Honda, Toshiyuki; Ohmori, Osamu; Hatakeyama, Shinji; Meyer, Thomas; Jackson, Dowdy; de Groot, John; Yung, W. K. Alfred</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1357-1367</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Multiple genetic aberrations in human gliomas contribute to their highly infiltrative and rapid growth characteristics.  Focal adhesion kinase (FAK) regulates tumor migration and invasion.  Insulin-like growth factor-I receptor (IGF-IR), whose expression correlates with tumor grade, is involved in proliferation and survival.  We hypothesized that inhibiting the phosphorylation of FAK and IGF-IR by NVP-TAE226 (hereafter called TAE226), a novel dual tyrosine kinase inhibitor of FAK and IGF-IR, would suppress the growth and invasion of glioma cells.  In culture, TAE226 inhibited extracellular matrix-induced autophosphorylation of FAK (Tyr397).  TAE226 also inhibited IGF-I-induced phosphorylation of IGF-IR and activity of its downstream target genes such as MAPK and Akt.  TAE226 retarded tumor cell growth as assessed by a cell viability assay and attenuated G2-M cell cycle progression assocd. with a decrease in cyclin B1 and phosphorylated cdc2 (Tyr15) protein expression.  TAE226 treatment inhibited tumor cell invasion by at least 50% compared with the control in an in vitro Matrigel invasion assay.  Interestingly, TAE226 treatment of tumor cells contg. wild-type p53 mainly exhibited G2-M arrest, whereas tumor cells bearing mutant p53 underwent apoptosis.  Induction of apoptosis by TAE226 was substantiated by detection of caspase-3/7 activation and poly(ADP-ribose) polymerase cleavage and by an Annexin V apoptosis assay.  More importantly, TAE226 treatment significantly increased the survival rate of animals in an intracranial glioma xenograft model.  Collectively, these data show that blocking the signaling pathways of FAK and IGF-IR with TAE226 has the potential to be an efficacious treatment for human gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQMIquqcQABrVg90H21EOLACvtfcHk0liwEmLx5B8cHQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktFams7o%253D&md5=1659c50e987e8bbb24c998e0aae14861</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0476%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DT.%2BJ.%26aulast%3DLaFortune%26aufirst%3DT.%26aulast%3DHonda%26aufirst%3DT.%26aulast%3DOhmori%26aufirst%3DO.%26aulast%3DHatakeyama%26aufirst%3DS.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DJackson%26aufirst%3DD.%26aulast%3Dde%2BGroot%26aufirst%3DJ.%26aulast%3DYung%26aufirst%3DW.%2BK.%26atitle%3DInhibition%2520of%2520both%2520focal%2520adhesion%2520kinase%2520and%2520insulin-like%2520growth%2520factor-I%2520receptor%2520kinase%2520suppresses%2520glioma%2520proliferation%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D1357%26epage%3D1367%26doi%3D10.1158%2F1535-7163.MCT-06-0476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schultze, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiedler, W.</span></span> <span> </span><span class="NLM_article-title">Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">593</span>â <span class="NLM_lpage">599</span>, <span class="refDoi">Â DOI: 10.2174/187152011796817727</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.2174%2F187152011796817727" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=21787277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Gns7%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=593-599&author=A.+Schultzeauthor=W.+Fiedler&title=Clinical+importance+and+potential+use+of+small+molecule+inhibitors+of+focal+adhesion+kinase&doi=10.2174%2F187152011796817727"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase</span></div><div class="casAuthors">Schultze, Alexander; Fiedler, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">593-599</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Since its first description Focal Adhesion Kinase (FAK), a cytoplasmic tyrosine kinase, was implicated in the formation and progression of solid and liq. malignant tumors.  Therefore orally available selective small mol. inhibitors of FAK were developed, 3 of them (PF-562-271, PF-04554878 and GSK2256098) are already in clin. testing.  This review discusses the recent data obtained from these Phase 1 trials.  We also discuss available data on the mechanisms of action of these inhibitors in carcinogenesis and demonstrate that FAK plays an important role in neoangiogenesis which is a crucial step in cancer growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGvtUUThNxpbVg90H21EOLACvtfcHk0liwEmLx5B8cHQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Gns7%252FM&md5=4754e8e948523f8c1e1fcc2dfc239123</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.2174%2F187152011796817727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152011796817727%26sid%3Dliteratum%253Aachs%26aulast%3DSchultze%26aufirst%3DA.%26aulast%3DFiedler%26aufirst%3DW.%26atitle%3DClinical%2520importance%2520and%2520potential%2520use%2520of%2520small%2520molecule%2520inhibitors%2520of%2520focal%2520adhesion%2520kinase%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D593%26epage%3D599%26doi%3D10.2174%2F187152011796817727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lietha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of the FAK kinase in complex with TAE226 and related bis-anilino pyrimidine inhibitors reveal a helical DFG conformation</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">e3800</span> <span class="refDoi">Â DOI: 10.1371/journal.pone.0003800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1371%2Fjournal.pone.0003800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=19030106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BD1cjmtF2muw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&author=D.+Liethaauthor=M.+J.+Eck&title=Crystal+structures+of+the+FAK+kinase+in+complex+with+TAE226+and+related+bis-anilino+pyrimidine+inhibitors+reveal+a+helical+DFG+conformation&doi=10.1371%2Fjournal.pone.0003800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the FAK kinase in complex with TAE226 and related bis-anilino pyrimidine inhibitors reveal a helical DFG conformation</span></div><div class="casAuthors">Lietha Daniel; Eck Michael J</div><div class="citationInfo"><span class="NLM_cas:title">PloS one</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e3800</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Focal Adhesion Kinase (FAK) is a non-receptor tyrosine kinase required for cell migration, proliferation and survival.  FAK overexpression has been documented in diverse human cancers and is associated with a poor clinical outcome.  Recently, a novel bis-anilino pyrimidine inhibitor, TAE226, was reported to efficiently inhibit FAK signaling, arrest tumor growth and invasion and prolong the life of mice with glioma or ovarian tumor implants.  Here we describe the crystal structures of the FAK kinase bound to TAE226 and three related bis-anilino pyrimidine compounds.  TAE226 induces a conformation of the N-terminal portion of the kinase activation loop that is only observed in FAK, but is distinct from the conformation in both the active and inactive states of the kinase.  This conformation appears to require a glycine immediately N-terminal to the "DFG motif", which adopts a helical conformation stabilized by interactions with TAE226.  The presence of a glycine residue in this position contributes to the specificity of TAE226 and related compounds for FAK.  Our work highlights the fact that kinases can access conformational space that is not necessarily utilized for their native catalytic regulation, and that such conformations can explain and be exploited for inhibitor specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQsjpXJZjhGaWZyxfu64m4ffW6udTcc2eb5GBKsdYFPkLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cjmtF2muw%253D%253D&md5=60c1f8e0ae9da7c5b6f638afdff195e1</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0003800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0003800%26sid%3Dliteratum%253Aachs%26aulast%3DLietha%26aufirst%3DD.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DCrystal%2520structures%2520of%2520the%2520FAK%2520kinase%2520in%2520complex%2520with%2520TAE226%2520and%2520related%2520bis-anilino%2520pyrimidine%2520inhibitors%2520reveal%2520a%2520helical%2520DFG%2520conformation%26jtitle%3DPLoS%2520One%26date%3D2008%26volume%3D3%26doi%3D10.1371%2Fjournal.pone.0003800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span> <span> </span><span class="NLM_article-title">Structure-based modification of carbonyl-diphenylpyrimidines (Car-DPPYs) as a novel focal adhesion kinase (FAK) inhibitor against various stubborn cancer cells</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">154</span>â <span class="NLM_lpage">162</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2019.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.ejmech.2019.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=30978560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnsVSgtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2019&pages=154-162&author=L.+Wangauthor=M.+Aiauthor=J.+Yuauthor=L.+Jinauthor=C.+Wangauthor=Z.+Liuauthor=X.+Shuauthor=Z.+Tangauthor=K.+Liuauthor=H.+Luoauthor=W.+Guanauthor=X.+Sunauthor=X.+Ma&title=Structure-based+modification+of+carbonyl-diphenylpyrimidines+%28Car-DPPYs%29+as+a+novel+focal+adhesion+kinase+%28FAK%29+inhibitor+against+various+stubborn+cancer+cells&doi=10.1016%2Fj.ejmech.2019.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based modification of carbonyl-diphenylpyrimidines (Car-DPPYs) as a novel focal adhesion kinase (FAK) inhibitor against various stubborn cancer cells</span></div><div class="casAuthors">Wang, Luhong; Ai, Min; Yu, Jiawen; Jin, Lingling; Wang, Changyuan; Liu, Zhihao; Shu, Xiaohong; Tang, Zeyao; Liu, Kexin; Luo, Hui; Guan, Wenshun; Sun, Xiuli; Ma, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">154-162</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A family of carbonyl-substituted diphenylpyrimidine derivs. (Car-DPPYs) with strong activity against focal adhesion kinase (FAK), were described in this manuscript.  Among them, compds. 7a(I) (IC50 = 5.17 nM) and 7f(II) (IC50 = 2.58 nM) displayed equal anti-FAK enzymic activity to the lead compd. TAE226 (6.79 nM).  In particular, I also exhibited strong antiproliferative activity against several stubborn cancer cells, including AsPC-1 cells (IC50 = 0.105 Î¼M), BxPC-3 cells (IC50 = 0.090 Î¼M), and MCF-7/ADR cells (IC50 = 0.59 Î¼M).  Addnl., I also showed great antitumor efficacy in vivo via aAsPC-1 cancer Xenograft mouse model.  The preliminary mechanism study by Western blot anal. revealed that I repressed FAK phosphorylation in AsPC cancer cells.  Taken together, the results indicate that I may serve as a promising preclin. candidate for treatment of stubborn cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3jTLS3BSpz7Vg90H21EOLACvtfcHk0lhm6zr2ChIWbg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnsVSgtbg%253D&md5=1e37d0d16bf3d6c86238ff2bcde12259</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DAi%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DShu%26aufirst%3DX.%26aulast%3DTang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DLuo%26aufirst%3DH.%26aulast%3DGuan%26aufirst%3DW.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DX.%26atitle%3DStructure-based%2520modification%2520of%2520carbonyl-diphenylpyrimidines%2520%2528Car-DPPYs%2529%2520as%2520a%2520novel%2520focal%2520adhesion%2520kinase%2520%2528FAK%2529%2520inhibitor%2520against%2520various%2520stubborn%2520cancer%2520cells%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D172%26spage%3D154%26epage%3D162%26doi%3D10.1016%2Fj.ejmech.2019.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Claudio
Viegas-Junior</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eliezer J. Barreiro</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlos Alberto Manssour Fraga</span></span> <span> </span><span class="NLM_article-title">Molecular hybridization: a useful tool in the design of new drug prototypes</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1829</span>â <span class="NLM_lpage">1852</span>, <span class="refDoi">Â DOI: 10.2174/092986707781058805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.2174%2F092986707781058805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=17627520" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=1829-1852&author=+Claudio%0AViegas-Juniorauthor=+Eliezer+J.+Barreiroauthor=+Carlos+Alberto+Manssour+Fraga&title=Molecular+hybridization%3A+a+useful+tool+in+the+design+of+new+drug+prototypes&doi=10.2174%2F092986707781058805"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.2174%2F092986707781058805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986707781058805%26sid%3Dliteratum%253Aachs%26aulast%3DClaudio%2BViegas-Junior%26aulast%3DEliezer%2BJ.%2BBarreiro%26aulast%3DCarlos%2BAlberto%2BManssour%2BFraga%26atitle%3DMolecular%2520hybridization%253A%2520a%2520useful%2520tool%2520in%2520the%2520design%2520of%2520new%2520drug%2520prototypes%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2007%26volume%3D14%26spage%3D1829%26epage%3D1852%26doi%3D10.2174%2F092986707781058805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.-F.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antitumor activity of novel dithiocarbamate substituted chromones</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">3687</span>â <span class="NLM_lpage">3696</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2009.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.ejmech.2009.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=19410339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1MXoslGhs7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2009&pages=3687-3696&author=W.+Huangauthor=Y.+Dingauthor=Y.+Miaoauthor=M.-Z.+Liuauthor=Y.+Liauthor=G.-F.+Yang&title=Synthesis+and+antitumor+activity+of+novel+dithiocarbamate+substituted+chromones&doi=10.1016%2Fj.ejmech.2009.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antitumor activity of novel dithiocarbamate substituted chromones</span></div><div class="casAuthors">Huang, Wei; Ding, Yu; Miao, Yan; Liu, Ming-Zhen; Li, Yan; Yang, Guang-Fu</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3687-3696</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of chromone derivs. bearing diverse dithiocarbamate moieties were designed and synthesized via a three-component reaction protocol.  Their in vitro antitumor activities were evaluated by MTT method against HCCLM-7, Hela, MDA-MB-435S, SW-480, Hep-2 and MCF-7.  Compds. I and II were identified as the most promising candidates due to their high potency and broad-spectrum.  Further flow-activated cell sorting anal. revealed that compds. I and II arrested the cell cycle of SW-480 and MDA-MB-435s, both in G2/M phase, with dose-dependent effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppumNJLdfY_LVg90H21EOLACvtfcHk0lhm6zr2ChIWbg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXoslGhs7o%253D&md5=1db9d61a1eaca2a40e3b72fa9f15bd5c</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2009.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2009.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DMiao%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DM.-Z.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DG.-F.%26atitle%3DSynthesis%2520and%2520antitumor%2520activity%2520of%2520novel%2520dithiocarbamate%2520substituted%2520chromones%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2009%26volume%3D44%26spage%3D3687%26epage%3D3696%26doi%3D10.1016%2Fj.ejmech.2009.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R. T.</span></span> <span> </span><span class="NLM_article-title">Novel EGFR inhibitors prepared by combination of dithiocarbamic acid esters and 4-anilinoquinazolines</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3637</span>â <span class="NLM_lpage">3640</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2011.04.096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmcl.2011.04.096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=21570843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntFKhs7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=3637-3640&author=R.+D.+Liauthor=X.+Zhangauthor=Q.+Y.+Liauthor=Z.+M.+Geauthor=R.+T.+Li&title=Novel+EGFR+inhibitors+prepared+by+combination+of+dithiocarbamic+acid+esters+and+4-anilinoquinazolines&doi=10.1016%2Fj.bmcl.2011.04.096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Novel EGFR inhibitors prepared by combination of dithiocarbamic acid esters and 4-anilinoquinazolines</span></div><div class="casAuthors">Li, Ri-Dong; Zhang, Xin; Li, Qiao-Yan; Ge, Ze-Mei; Li, Run-Tao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3637-3640</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">On the basis of combination strategy, a novel series of EGFR inhibitors were designed and synthesized by combination of dithiocarbamic acid esters and 4-anilinoquinazolines.  The effect of the synthesized compds. on cell proliferation was evaluated by MTT assay in three human cancer cell lines: MDA-MB-468, SK-BR-3 and HCT-116.  Some compds. were found more potent against all three cell lines and other compds. were found more potent against both MDA-MB-468 and SK-BR-3 than Lapatinib.  SAR studies revealed that the substituents on C6 and C7 positions of quinazoline, the amine component of dithiocarbamate moiety and the linker greatly affected the activity.  This work provides a promising new strategy for the prepn. of potent tyrosine kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo92wKhvesdvrVg90H21EOLACvtfcHk0lhm6zr2ChIWbg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntFKhs7s%253D&md5=e76bffa5c3d8b62e357442dfcf74686c</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.04.096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.04.096%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DR.%2BD.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DQ.%2BY.%26aulast%3DGe%26aufirst%3DZ.%2BM.%26aulast%3DLi%26aufirst%3DR.%2BT.%26atitle%3DNovel%2520EGFR%2520inhibitors%2520prepared%2520by%2520combination%2520of%2520dithiocarbamic%2520acid%2520esters%2520and%25204-anilinoquinazolines%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D3637%26epage%3D3640%26doi%3D10.1016%2Fj.bmcl.2011.04.096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kamal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sathish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayak, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasulu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavitha, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tangella, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thummuri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagul, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shankaraiah, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagesh, N.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of dithiocarbamate linked beta-carboline derivatives: DNA topoisomerase II inhibition with DNA binding and apoptosis inducing ability</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5511</span>â <span class="NLM_lpage">5526</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2015.07.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmc.2015.07.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=26264845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1CrtLrJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=5511-5526&author=A.+Kamalauthor=M.+Sathishauthor=V.+L.+Nayakauthor=V.+Srinivasuluauthor=B.+Kavithaauthor=Y.+Tangellaauthor=D.+Thummuriauthor=C.+Bagulauthor=N.+Shankaraiahauthor=N.+Nagesh&title=Design+and+synthesis+of+dithiocarbamate+linked+beta-carboline+derivatives%3A+DNA+topoisomerase+II+inhibition+with+DNA+binding+and+apoptosis+inducing+ability&doi=10.1016%2Fj.bmc.2015.07.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of dithiocarbamate linked Î²-carboline derivatives: DNA topoisomerase II inhibition with DNA binding and apoptosis inducing ability</span></div><div class="casAuthors">Kamal, Ahmed; Sathish, Manda; Nayak, V. Lakshma; Srinivasulu, Vunnam; Kavitha, Botla; Tangella, Yellaiah; Thummuri, Dinesh; Bagul, Chandrakant; Shankaraiah, Nagula; Nagesh, Narayana</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5511-5526</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of new Î²-carboline-dithiocarbamate derivs. bearing Ph, dithiocarbamate and H/methyl substitutions at position-1, 3 and 9, resp., were designed and synthesized.  These derivs. 8a-l and 13a-l and their starting precursors (7a-d and 12a-d) have been evaluated for their in vitro cytotoxic activity on selected human cancer cell lines.  Among the derivs. tested, 7c, 12c, 8a, 8d, 8i, 8j, 8k, 8l and 13d-l exhibited considerable cytotoxicity against most of the tested cancer cell lines (IC50 <10 Î¼M).  Interestingly, most of the derivs. (8a-l and 13a-l) exhibited enhanced activity than their precursors (7a-d and 12a-d), which indicates that the combination of dithiocarbamate with Î²-carboline enhances the cytotoxicity of 8a-l and 13a-l.  Moreover, the derivs. 8j and 13g exhibited significant cytotoxic activity with IC50 values of 1.34 Î¼M and 0.79 Î¼M on DU-145 cancer cells, resp.  Further, the induction of apoptosis by these derivs. was confirmed by Annexin V-FITC and Hoechst staining assays.  However, both biophys. as well as mol. docking studies suggested a combilexin-type of interaction between these derivs. and DNA, unlike simple Î²-carbolines.  With a view to understand their mechanism of action, DNA topoisomerase II (topo II) inhibition assay was also performed.  Overall, the present study emphasizes the importance of linking a dithiocarbamate moiety to the Î²-carboline scaffold for exhibiting profound activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2JbzggrG7v7Vg90H21EOLACvtfcHk0li5jS619H2NGA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1CrtLrJ&md5=8b85c9edc23342973d0ee6b5aa08cd5c</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.07.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.07.037%26sid%3Dliteratum%253Aachs%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DSathish%26aufirst%3DM.%26aulast%3DNayak%26aufirst%3DV.%2BL.%26aulast%3DSrinivasulu%26aufirst%3DV.%26aulast%3DKavitha%26aufirst%3DB.%26aulast%3DTangella%26aufirst%3DY.%26aulast%3DThummuri%26aufirst%3DD.%26aulast%3DBagul%26aufirst%3DC.%26aulast%3DShankaraiah%26aufirst%3DN.%26aulast%3DNagesh%26aufirst%3DN.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520dithiocarbamate%2520linked%2520beta-carboline%2520derivatives%253A%2520DNA%2520topoisomerase%2520II%2520inhibition%2520with%2520DNA%2520binding%2520and%2520apoptosis%2520inducing%2520ability%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D5511%26epage%3D5526%26doi%3D10.1016%2Fj.bmc.2015.07.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Y.</span></span> <span> </span><span class="NLM_article-title">New pyridin-3-ylmethyl carbamodithioic esters activate pyruvate kinase M2 and potential anticancer lead compounds</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4815</span>â <span class="NLM_lpage">4823</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2015.05.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmc.2015.05.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=26081759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFaqsLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=4815-4823&author=Y.+Zhangauthor=B.+Liuauthor=X.+Wuauthor=R.+Liauthor=X.+Ningauthor=Y.+Liuauthor=Z.+Liuauthor=Z.+Geauthor=R.+Liauthor=Y.+Yin&title=New+pyridin-3-ylmethyl+carbamodithioic+esters+activate+pyruvate+kinase+M2+and+potential+anticancer+lead+compounds&doi=10.1016%2Fj.bmc.2015.05.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">New pyridin-3-ylmethyl carbamodithioic esters activate pyruvate kinase M2 and potential anticancer lead compounds</span></div><div class="casAuthors">Zhang, Yu; Liu, Bin; Wu, Xingyu; Li, Ridong; Ning, Xianling; Liu, Yu; Liu, Zhenming; Ge, Zemei; Li, Runtao; Yin, Yuxin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4815-4823</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pyruvate kinase M2 (PKM2) is a key protein responsible for cancer's Warburg effect.  Activation of PKM2 may alter aberrant metab. in cancer cells, which suggests PKM2 as a tumor selective therapeutic target.  In this paper, the lead compd. 8 was first discovered as a new kind of PKM2 activator from a random screening of an inhouse compd. library.  Then, a series of lead compd. 8 analogs were designed, synthesized and evaluated for their activation of PKM2 and anticancer activities. 7-Azaindole analog 32 was identified as the most potent PKM2 activator.  Compds. with potent enzyme activity also exhibited selective anti-proliferation activity on cancer cell lines HCT116, Hela and H1299 compared with non-tumor cell line BEAS-2B.  The structure-activity relationships of these compds. were supported by mol. docking results.  Preliminary pharmacol. studies also showed that compd. 32 arrests the cell cycle at the G2/M phase in HCT116 cell line.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwdPOEDQGPNbVg90H21EOLACvtfcHk0li5jS619H2NGA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFaqsLc%253D&md5=bc3875399546250b821599b369a12804</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.05.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.05.041%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DNing%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DGe%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DYin%26aufirst%3DY.%26atitle%3DNew%2520pyridin-3-ylmethyl%2520carbamodithioic%2520esters%2520activate%2520pyruvate%2520kinase%2520M2%2520and%2520potential%2520anticancer%2520lead%2520compounds%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D4815%26epage%3D4823%26doi%3D10.1016%2Fj.bmc.2015.05.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. Q.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological activities of dithiocarbamates containing 2(5H)-furanone-piperazine</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">165</span>â <span class="NLM_lpage">170</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2018.05.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.ejmech.2018.05.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=29886320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFWisL%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2018&pages=165-170&author=M.+X.+Weiauthor=J.+Zhangauthor=F.+L.+Maauthor=M.+Liauthor=J.+Y.+Yuauthor=W.+Luoauthor=X.+Q.+Li&title=Synthesis+and+biological+activities+of+dithiocarbamates+containing+2%285H%29-furanone-piperazine&doi=10.1016%2Fj.ejmech.2018.05.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological activities of dithiocarbamates containing 2(5H)-furanone-piperazine</span></div><div class="casAuthors">Wei, Meng-Xue; Zhang, Jiao; Ma, Fu-Li; Li, Ming; Yu, Jia-Ying; Luo, Wei; Li, Xue-Qiang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">165-170</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of new dithiocarbamates contg. a 2(5H)-furanone-piperazine group was synthesized.  These compds. show good in vitro cytotoxic activity.  Among them, compd. I exhibits the best inhibitory activity against HeLa cell lines with an IC50 of 0.06 Â± 0.01 Î¼M for 72 h, and it has good inhibitory activity against SMMC-7721 cell lines with an IC50 of 0.006 Â± 0.04 Î¼M for 72 h, but the toxicity was lower against LO2 cell lines with an IC50 of 45.76 Â± 0.01 Î¼M.  The result showed that compd. I is far more cytotoxic towards cancer cell lines than towards benign cell lines compared with cytosine arabinoside (ARA) in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoadcy_kDbuX7Vg90H21EOLACvtfcHk0li5jS619H2NGA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFWisL%252FE&md5=947bfa4da48d898730c96224996dc570</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.05.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.05.056%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DM.%2BX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DF.%2BL.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DJ.%2BY.%26aulast%3DLuo%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DX.%2BQ.%26atitle%3DSynthesis%2520and%2520biological%2520activities%2520of%2520dithiocarbamates%2520containing%25202%25285H%2529-furanone-piperazine%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D155%26spage%3D165%26epage%3D170%26doi%3D10.1016%2Fj.ejmech.2018.05.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>177</i></span>,  <span class="NLM_fpage">32</span>â <span class="NLM_lpage">46</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2019.05.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.ejmech.2019.05.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=31129452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVKqtbnP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2019&pages=32-46&author=Y.+Suauthor=R.+Liauthor=X.+Ningauthor=Z.+Linauthor=X.+Zhaoauthor=J.+Zhouauthor=J.+Liuauthor=Y.+Jinauthor=Y.+Yin&title=Discovery+of+2%2C4-diarylaminopyrimidine+derivatives+bearing+dithiocarbamate+moiety+as+novel+FAK+inhibitors+with+antitumor+and+anti-angiogenesis+activities&doi=10.1016%2Fj.ejmech.2019.05.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities</span></div><div class="casAuthors">Su, Yue; Li, Ridong; Ning, Xianling; Lin, Zhiqiang; Zhao, Xuyang; Zhou, Juntuo; Liu, Jia; Jin, Yan; Yin, Yuxin</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">32-46</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 2,4-diarylaminopyrimidine derivs. contg. dithiocarbamate moiety were designed by mol. hybridization strategy and synthesized for screening as inhibitors of focal adhesion kinase (FAK).  Most of these compds. exhibit significant antiproliferative activities on human cancer cell lines expressing high levels of FAK at nanomolar concns.  The compd. I was identified as the most potent FAK inhibitor among these candidates.  I has excellent anti-proliferative effect with IC50 values from 0.001 Î¼M to 0.06 Î¼M on HCT116, PC-3, U87-MG and MCF-7 cell lines and relatively less cytotoxicity to a nonmalignant cell line MCF-10A compared with MCF-7 cells (SI value > 10).  I also exhibits significant FAK inhibitory activity (IC50 = 0.07 nM).  In addn., compd. I causes cell cycle arrest at G2/M and prompted apoptosis in both HCT116 and MCF-7 cells in a dose-dependent manner.  Further studies show that compd. I inhibits migration of MCF-7 and has anti-angiogenesis effect on HUVEC cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgwdZ9buP0o7Vg90H21EOLACvtfcHk0ljvvIjxaI75BA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVKqtbnP&md5=2189190e90190c7a4c1eceef341f29fb</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.05.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.05.048%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DNing%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DYin%26aufirst%3DY.%26atitle%3DDiscovery%2520of%25202%252C4-diarylaminopyrimidine%2520derivatives%2520bearing%2520dithiocarbamate%2520moiety%2520as%2520novel%2520FAK%2520inhibitors%2520with%2520antitumor%2520and%2520anti-angiogenesis%2520activities%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D177%26spage%3D32%26epage%3D46%26doi%3D10.1016%2Fj.ejmech.2019.05.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huttunen, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rautio, J.</span></span> <span> </span><span class="NLM_article-title">Prodrugs - an efficient way to breach delivery and targeting barriers</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2265</span>â <span class="NLM_lpage">2287</span>, <span class="refDoi">Â DOI: 10.2174/156802611797183230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.2174%2F156802611797183230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=21671868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Omt7%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=2265-2287&author=K.+M.+Huttunenauthor=J.+Rautio&title=Prodrugs+-+an+efficient+way+to+breach+delivery+and+targeting+barriers&doi=10.2174%2F156802611797183230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs - an efficient way to breach delivery and targeting barriers</span></div><div class="casAuthors">Huttunen, Kristiina M.; Rautio, Jarkko</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2265-2287</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The study of prodrugs that are chem. modified bioreversible derivs. of active drug compds. to alter their undesired properties has been expanded widely during the last decades.  Despite the com. success the prodrugs have afforded, the concept is still quite unknown among many scientist.  Furthermore, many scientists regard prodrugs as a pure interest of academic research groups and not as a feasible soln. to improve the delivery or targeting properties of new chem. entities, drug candidates failed in clin. trials, or drugs withdrawn from the market.  Although there are still unmet needs that require addressing, prodrugs should be seen as fine-tuning tools for the successful drug research and development.  This review represents the potential of prodrugs to improve the drug delivery by enhanced aq. soly. or permeability as well as describes several targeted prodrug strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkj5wHsNs0rbVg90H21EOLACvtfcHk0ljvvIjxaI75BA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Omt7%252FL&md5=9674c0c859bbc3b33dce4caac8e8add3</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.2174%2F156802611797183230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611797183230%26sid%3Dliteratum%253Aachs%26aulast%3DHuttunen%26aufirst%3DK.%2BM.%26aulast%3DRautio%26aufirst%3DJ.%26atitle%3DProdrugs%2520-%2520an%2520efficient%2520way%2520to%2520breach%2520delivery%2520and%2520targeting%2520barriers%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D2265%26epage%3D2287%26doi%3D10.2174%2F156802611797183230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kamiyama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabuchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kojima-Yuasa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsui-Yuasa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiratake, J.</span></span> <span> </span><span class="NLM_article-title">Phosphonate-based irreversible inhibitors of human gamma-glutamyl transpeptidase (GGT). GGsTop is a non-toxic and highly selective inhibitor with critical electrostatic interaction with an active-site residue Lys562 for enhanced inhibitory activity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">5340</span>â <span class="NLM_lpage">5352</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2016.08.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmc.2016.08.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=27622749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsV2rs7jO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=5340-5352&author=A.+Kamiyamaauthor=M.+Nakajimaauthor=L.+Hanauthor=K.+Wadaauthor=M.+Mizutaniauthor=Y.+Tabuchiauthor=A.+Kojima-Yuasaauthor=I.+Matsui-Yuasaauthor=H.+Suzukiauthor=K.+Fukuyamaauthor=B.+Watanabeauthor=J.+Hiratake&title=Phosphonate-based+irreversible+inhibitors+of+human+gamma-glutamyl+transpeptidase+%28GGT%29.+GGsTop+is+a+non-toxic+and+highly+selective+inhibitor+with+critical+electrostatic+interaction+with+an+active-site+residue+Lys562+for+enhanced+inhibitory+activity&doi=10.1016%2Fj.bmc.2016.08.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphonate-based irreversible inhibitors of human Î³-glutamyl transpeptidase (GGT). GGsTop is a non-toxic and highly selective inhibitor with critical electrostatic interaction with an active-site residue Lys562 for enhanced inhibitory activity</span></div><div class="casAuthors">Kamiyama, Akane; Nakajima, Mado; Han, Liyou; Wada, Kei; Mizutani, Masaharu; Tabuchi, Yukiko; Kojima-Yuasa, Akiko; Matsui-Yuasa, Isao; Suzuki, Hideyuki; Fukuyama, Keiichi; Watanabe, Bunta; Hiratake, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5340-5352</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Î³-Glutamyl transpeptidase (GGT, EC 2.3.2.2) that catalyzes the hydrolysis and transpeptidation of glutathione and its S-conjugates is involved in a no. of physiol. and pathol. processes through glutathione metab. and is an attractive pharmaceutical target.  We report here the evaluation of a phosphonate-based irreversible inhibitor, 2-amino-4-{[3-(carboxymethyl)phenoxy](methoyl)phosphoryl}butanoic acid (GGsTop) and its analogs as a mechanism-based inhibitor of human GGT.  GGsTop is a stable compd., but inactivated the human enzyme significantly faster than the other phosphonates, and importantly did not inhibit a glutamine amidotransferase.  The structure-activity relationships, X-ray crystallog. with Escherichia coli GGT, sequence alignment and site-directed mutagenesis of human GGT revealed a crit. electrostatic interaction between the terminal carboxylate of GGsTop and the active-site residue Lys562 of human GGT for potent inhibition.  GGsTop showed no cytotoxicity toward human fibroblasts and hepatic stellate cells up to 1 mM.  GGsTop serves as a non-toxic, selective and highly potent irreversible GGT inhibitor that could be used for various in vivo as well as in vitro biochem. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCZep_mhh5g7Vg90H21EOLACvtfcHk0ljvvIjxaI75BA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsV2rs7jO&md5=26bd230309dff2fabe956dd4ae99e71b</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.08.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.08.050%26sid%3Dliteratum%253Aachs%26aulast%3DKamiyama%26aufirst%3DA.%26aulast%3DNakajima%26aufirst%3DM.%26aulast%3DHan%26aufirst%3DL.%26aulast%3DWada%26aufirst%3DK.%26aulast%3DMizutani%26aufirst%3DM.%26aulast%3DTabuchi%26aufirst%3DY.%26aulast%3DKojima-Yuasa%26aufirst%3DA.%26aulast%3DMatsui-Yuasa%26aufirst%3DI.%26aulast%3DSuzuki%26aufirst%3DH.%26aulast%3DFukuyama%26aufirst%3DK.%26aulast%3DWatanabe%26aufirst%3DB.%26aulast%3DHiratake%26aufirst%3DJ.%26atitle%3DPhosphonate-based%2520irreversible%2520inhibitors%2520of%2520human%2520gamma-glutamyl%2520transpeptidase%2520%2528GGT%2529.%2520GGsTop%2520is%2520a%2520non-toxic%2520and%2520highly%2520selective%2520inhibitor%2520with%2520critical%2520electrostatic%2520interaction%2520with%2520an%2520active-site%2520residue%2520Lys562%2520for%2520enhanced%2520inhibitory%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D5340%26epage%3D5352%26doi%3D10.1016%2Fj.bmc.2016.08.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span> <span> </span><span class="NLM_article-title">Phosphamide-containing diphenylpyrimidine analogues (PA-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with enhanced activity against pancreatic cancer cell lines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">6313</span>â <span class="NLM_lpage">6321</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2017.09.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmc.2017.09.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=29102081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslagu7bE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=6313-6321&author=H.+Liuauthor=B.+Wuauthor=Y.+Geauthor=J.+Huangauthor=S.+Songauthor=C.+Wangauthor=J.+Yaoauthor=K.+Liuauthor=Y.+Liauthor=Y.+Liauthor=X.+Ma&title=Phosphamide-containing+diphenylpyrimidine+analogues+%28PA-DPPYs%29+as+potent+focal+adhesion+kinase+%28FAK%29+inhibitors+with+enhanced+activity+against+pancreatic+cancer+cell+lines&doi=10.1016%2Fj.bmc.2017.09.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphamide-containing diphenylpyrimidine analogues (PA-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with enhanced activity against pancreatic cancer cell lines</span></div><div class="casAuthors">Liu, He; Wu, Bin; Ge, Yang; Huang, Jiaxin; Song, Shijie; Wang, Changyuan; Yao, Jihong; Liu, Kexin; Li, Yanxia; Li, Yongming; Ma, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6313-6321</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A family of phosphamide-contg. diphenylpyrimidine analogs (PA-DPPYs) were synthesized as potent focal adhesion kinase (FAK) inhibitors.  The PA-DPPY derivs. could significantly inhibit the FAK enzymic activity at concns. lower than 10.69 nM.  Among them, compds. I and II were two of the most active FAK inhibitors, possessing IC50 values of 4.25 nM and 4.65 nM, resp.  In particular, compd. II also displayed strong activity against AsPC cell line, with an IC50 of 1.66 Î¼M, but show low activity against the normal HPDE6-C7 cells (IC50 > 20 Î¼M), indicating its low cell cytotoxicity.  Addnl., flow cytometry anal. showed that after treatment with II (8 Î¼M, 72 h), both AsPC and Panc cells growth were almost totally inhibited, with a cell viability rate of 16.8% and 18.1%, resp.  Overall, compd. II may be served as a valuable FAK inhibitor for the treatment of pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoChPrVzSD6obVg90H21EOLACvtfcHk0lgPBUdAHRXIsg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslagu7bE&md5=d179a0922f2b04149aef12ba0c3e0272</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.09.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.09.041%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DGe%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DX.%26atitle%3DPhosphamide-containing%2520diphenylpyrimidine%2520analogues%2520%2528PA-DPPYs%2529%2520as%2520potent%2520focal%2520adhesion%2520kinase%2520%2528FAK%2529%2520inhibitors%2520with%2520enhanced%2520activity%2520against%2520pancreatic%2520cancer%2520cell%2520lines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D6313%26epage%3D6321%26doi%3D10.1016%2Fj.bmc.2017.09.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of sulfonamide-substituted diphenylpyrimidine derivatives (Sul-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with antitumor activity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3989</span>â <span class="NLM_lpage">3996</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2017.05.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmc.2017.05.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=28576633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovVKgtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=3989-3996&author=M.+Quauthor=Z.+Liuauthor=D.+Zhaoauthor=C.+Wangauthor=J.+Zhangauthor=Z.+Tangauthor=K.+Liuauthor=X.+Shuauthor=H.+Yuanauthor=X.+Ma&title=Design%2C+synthesis+and+biological+evaluation+of+sulfonamide-substituted+diphenylpyrimidine+derivatives+%28Sul-DPPYs%29+as+potent+focal+adhesion+kinase+%28FAK%29+inhibitors+with+antitumor+activity&doi=10.1016%2Fj.bmc.2017.05.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of sulfonamide-substituted diphenylpyrimidine derivatives (Sul-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with antitumor activity</span></div><div class="casAuthors">Qu, Menghua; Liu, Zhihao; Zhao, Dan; Wang, Changyuan; Zhang, Jianbin; Tang, Zeyao; Liu, Kexin; Shu, Xiaohong; Yuan, Hong; Ma, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3989-3996</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A class of sulfonamide-substituted diphenylpyrimidines (Sul-DPPYs) were synthesized to improve activity against the focal adhesion kinase (FAK).  Most of these new Sul-DPPYs displayed moderate activity against the FAK enzyme with IC50 values of less than 100 nM; regardless, they could effectively inhibit several classes of refractory cancer cell lines with IC50 values of less than 10 Î¼M, including the pancreatic cancer cell lines (AsPC-1, Panc-1 and BxPC-3), the NSCLC-resistant H1975 cell line, and the B lymphocyte cell line (Ramos cells).  Results of flow cytometry indicated that inhibitor 7e promoted apoptosis of pancreatic cancer cells in a dose-dependent manner.  In addn., it almost completely induced the apoptosis at a concn. of 10 Î¼M.  Compd. 7e may be selected as a potent FAK inhibitor for the treatment of pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-GsN0yXpjyrVg90H21EOLACvtfcHk0lgPBUdAHRXIsg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovVKgtLk%253D&md5=ef2a94ac6339178f66a88f63467ccbf5</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.05.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.05.044%26sid%3Dliteratum%253Aachs%26aulast%3DQu%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DShu%26aufirst%3DX.%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DMa%26aufirst%3DX.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520sulfonamide-substituted%2520diphenylpyrimidine%2520derivatives%2520%2528Sul-DPPYs%2529%2520as%2520potent%2520focal%2520adhesion%2520kinase%2520%2528FAK%2529%2520inhibitors%2520with%2520antitumor%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D3989%26epage%3D3996%26doi%3D10.1016%2Fj.bmc.2017.05.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farand, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekhar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newby, Z. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Veldhuizen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loyer-Drew, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkataramani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zherebina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilbert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zablocki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mourey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Notte, G. T.</span></span> <span> </span><span class="NLM_article-title">Selectivity switch between FAK and Pyk2: macrocyclization of FAK inhibitors improves Pyk2 potency</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5926</span>â <span class="NLM_lpage">5930</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2016.10.092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmcl.2016.10.092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=27876318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFaitrjP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=5926-5930&author=J.+Farandauthor=N.+Maiauthor=J.+Chandrasekharauthor=Z.+E.+Newbyauthor=J.+Van+Veldhuizenauthor=J.+Loyer-Drewauthor=C.+Venkataramaniauthor=J.+Guerreroauthor=A.+Kwokauthor=N.+Liauthor=Y.+Zherebinaauthor=S.+Wilbertauthor=J.+Zablockiauthor=G.+Phillipsauthor=W.+J.+Watkinsauthor=R.+Moureyauthor=G.+T.+Notte&title=Selectivity+switch+between+FAK+and+Pyk2%3A+macrocyclization+of+FAK+inhibitors+improves+Pyk2+potency&doi=10.1016%2Fj.bmcl.2016.10.092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity switch between FAK and Pyk2: Macrocyclization of FAK inhibitors improves Pyk2 potency</span></div><div class="casAuthors">Farand, Julie; Mai, Nicholas; Chandrasekhar, Jayaraman; Newby, Zachary E.; Van Veldhuizen, Josh; Loyer-Drew, Jennifer; Venkataramani, Chandrasekar; Guerrero, Juan; Kwok, Amy; Li, Ning; Zherebina, Yelena; Wilbert, Sibylle; Zablocki, Jeff; Phillips, Gary; Watkins, William J.; Mourey, Robert; Notte, Gregory T.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5926-5930</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein, we describe the synthesis of Pyk2 inhibitors via macrocyclization of FAK and dual Pyk2-FAK inhibitors.  We identified one macrocycle as a highly potent Pyk2 inhibitor (IC50 = 0.7 nM), with â¼175-fold improvement in Pyk2 potency as compared to its acyclic counterpart.  In many cases, macrocyclization improved Pyk2 potency while weakening FAK potency, thereby improving the Pyk2/FAK selectivity ratio for this structural class of inhibitors.  Various macrocyclic linkers were studied in an attempt to optimize Pyk2 selectivity.  We obsd. macrocyclic atropisomerism during the synthesis of 19-membered macrocycles and successfully obtained crystallog. evidence of one atropisomer preferentially bound to Pyk2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyXQWxon-oWrVg90H21EOLACvtfcHk0lgPBUdAHRXIsg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFaitrjP&md5=7c114af68a6484040f4250f941d759bc</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.10.092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.10.092%26sid%3Dliteratum%253Aachs%26aulast%3DFarand%26aufirst%3DJ.%26aulast%3DMai%26aufirst%3DN.%26aulast%3DChandrasekhar%26aufirst%3DJ.%26aulast%3DNewby%26aufirst%3DZ.%2BE.%26aulast%3DVan%2BVeldhuizen%26aufirst%3DJ.%26aulast%3DLoyer-Drew%26aufirst%3DJ.%26aulast%3DVenkataramani%26aufirst%3DC.%26aulast%3DGuerrero%26aufirst%3DJ.%26aulast%3DKwok%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DZherebina%26aufirst%3DY.%26aulast%3DWilbert%26aufirst%3DS.%26aulast%3DZablocki%26aufirst%3DJ.%26aulast%3DPhillips%26aufirst%3DG.%26aulast%3DWatkins%26aufirst%3DW.%2BJ.%26aulast%3DMourey%26aufirst%3DR.%26aulast%3DNotte%26aufirst%3DG.%2BT.%26atitle%3DSelectivity%2520switch%2520between%2520FAK%2520and%2520Pyk2%253A%2520macrocyclization%2520of%2520FAK%2520inhibitors%2520improves%2520Pyk2%2520potency%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D5926%26epage%3D5930%26doi%3D10.1016%2Fj.bmcl.2016.10.092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Determann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totzke, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schachtele, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubbutat, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunick, C.</span></span> <span> </span><span class="NLM_article-title">2-Anilino-4-(benzimidazol-2-yl)pyrimidines- a multikinase inhibitor scaffold with antiproliferative activity toward cancer cell lines</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">254</span>â <span class="NLM_lpage">263</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2012.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.ejmech.2012.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=22560627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvVygsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2012&pages=254-263&author=R.+Determannauthor=J.+Dreherauthor=K.+Baumannauthor=L.+Preuauthor=P.+G.+Jonesauthor=F.+Totzkeauthor=C.+Schachteleauthor=M.+H.+Kubbutatauthor=C.+Kunick&title=2-Anilino-4-%28benzimidazol-2-yl%29pyrimidines-+a+multikinase+inhibitor+scaffold+with+antiproliferative+activity+toward+cancer+cell+lines&doi=10.1016%2Fj.ejmech.2012.04.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">2-Anilino-4-(benzimidazol-2-yl)pyrimidines - A multikinase inhibitor scaffold with antiproliferative activity toward cancer cell lines</span></div><div class="casAuthors">Determann, Renate; Dreher, Jan; Baumann, Knut; Preu, Lutz; Jones, Peter G.; Totzke, Frank; Schaechtele, Christoph; Kubbutat, Michael H. G.; Kunick, Conrad</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">254-263</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">2-Anilino-4-(benzimidazol-2-yl)-pyrimidines, synthesized by reaction of a readily available benzimidazole-substituted enaminone with suitable arylguanidines, were shown to inhibit four cancer-related protein kinases (Aurora B, PLK1, FAK, and VEGF-R2).  The most potent deriv. exhibited antiproliferative activity for several cancer cell lines of the NCI in vitro cell line panel in submicromolar concns.  Both the anilinopyrimidine structure and the substitution pattern at the aniline ring appear to be important for the protein kinase inhibitory activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7v4Z7M2wm37Vg90H21EOLACvtfcHk0lg9d61LpbRKAA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvVygsbY%253D&md5=ea27d61cfd92b93e25a20b4bf5a302cc</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DDetermann%26aufirst%3DR.%26aulast%3DDreher%26aufirst%3DJ.%26aulast%3DBaumann%26aufirst%3DK.%26aulast%3DPreu%26aufirst%3DL.%26aulast%3DJones%26aufirst%3DP.%2BG.%26aulast%3DTotzke%26aufirst%3DF.%26aulast%3DSchachtele%26aufirst%3DC.%26aulast%3DKubbutat%26aufirst%3DM.%2BH.%26aulast%3DKunick%26aufirst%3DC.%26atitle%3D2-Anilino-4-%2528benzimidazol-2-yl%2529pyrimidines-%2520a%2520multikinase%2520inhibitor%2520scaffold%2520with%2520antiproliferative%2520activity%2520toward%2520cancer%2520cell%2520lines%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D53%26spage%3D254%26epage%3D263%26doi%3D10.1016%2Fj.ejmech.2012.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, R. A.</span></span> <span> </span><span class="NLM_article-title">Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1061</span>â <span class="NLM_lpage">1073</span>, <span class="refDoi">Â DOI: 10.1016/j.drudis.2015.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.drudis.2015.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=26002380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptlOnu7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=1061-1073&author=R.+A.+Bauer&title=Covalent+inhibitors+in+drug+discovery%3A+from+accidental+discoveries+to+avoided+liabilities+and+designed+therapies&doi=10.1016%2Fj.drudis.2015.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies</span></div><div class="casAuthors">Bauer, Renato A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1061-1073</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Drugs that covalently bond to their biol. targets have a long history in drug discovery.  A look at drug approvals in recent years suggests that covalent drugs will continue to make impacts on human health for years to come.  Although fraught with concerns about toxicity, the high potencies and prolonged effects achievable with covalent drugs may result in less-frequent drug dosing and in wide therapeutic margins for patients.  Covalent inhibition can also dissoc. drug pharmacodynamics (PD) from pharmacokinetics (PK), which can result in desired drug efficacy for inhibitors that have short systemic exposure.  Evidence suggests that there is a reduced risk for the development of resistance against covalent drugs, which is a major challenge in areas such as oncol. and infectious disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMkBDsUEu4arVg90H21EOLACvtfcHk0lg9d61LpbRKAA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptlOnu7s%253D&md5=6ba5b016d2804c7d56838a2724b9a0b9</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DR.%2BA.%26atitle%3DCovalent%2520inhibitors%2520in%2520drug%2520discovery%253A%2520from%2520accidental%2520discoveries%2520to%2520avoided%2520liabilities%2520and%2520designed%2520therapies%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2015%26volume%3D20%26spage%3D1061%26epage%3D1073%26doi%3D10.1016%2Fj.drudis.2015.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarray, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Coq, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lietha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loukaci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepelletier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadj-Slimane, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis of novel diarylamino-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4552</span>â <span class="NLM_lpage">4556</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2013.06.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmcl.2013.06.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=23845217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtV2ltb7J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4552-4556&author=P.+Daoauthor=R.+Jarrayauthor=J.+Le+Coqauthor=D.+Liethaauthor=A.+Loukaciauthor=Y.+Lepelletierauthor=R.+Hadj-Slimaneauthor=C.+Garbayauthor=F.+Raynaudauthor=H.+Chen&title=Synthesis+of+novel+diarylamino-1%2C3%2C5-triazine+derivatives+as+FAK+inhibitors+with+anti-angiogenic+activity&doi=10.1016%2Fj.bmcl.2013.06.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of novel diarylamino-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity</span></div><div class="casAuthors">Dao, Pascal; Jarray, Rafika; Le Coq, Johanne; Lietha, Daniel; Loukaci, Ali; Lepelletier, Yves; Hadj-Slimane, Reda; Garbay, Christiane; Raynaud, Francoise; Chen, Huixiong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4552-4556</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We report herein the synthesis of novel diarylamino-1,3,5-triazine derivs. as FAK (focal adhesion kinase) inhibitors and the evaluation of their anti-angiogenic activity on HUVEC cells.  Generally, the effects of these compds. on endothelial cells could be correlated with their kinase inhibitory activity.  The most efficient compds. displayed inhibition of viability against HUVEC cells in the micromolar range, as obsd. with TAE-226, which was designed by Novartis Pharma AG.  X-ray crystallog. anal. of the co-crystal structure for compd. I revealed that the mode of interaction with the FAK kinase domain is highly similar to that obsd. in the complex of TAE-226.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm3OngYamrNbVg90H21EOLACvtfcHk0lg9d61LpbRKAA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtV2ltb7J&md5=d4329a4e242f2fb42c59f12136f9c1ce</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.06.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.06.038%26sid%3Dliteratum%253Aachs%26aulast%3DDao%26aufirst%3DP.%26aulast%3DJarray%26aufirst%3DR.%26aulast%3DLe%2BCoq%26aufirst%3DJ.%26aulast%3DLietha%26aufirst%3DD.%26aulast%3DLoukaci%26aufirst%3DA.%26aulast%3DLepelletier%26aufirst%3DY.%26aulast%3DHadj-Slimane%26aufirst%3DR.%26aulast%3DGarbay%26aufirst%3DC.%26aulast%3DRaynaud%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DH.%26atitle%3DSynthesis%2520of%2520novel%2520diarylamino-1%252C3%252C5-triazine%2520derivatives%2520as%2520FAK%2520inhibitors%2520with%2520anti-angiogenic%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4552%26epage%3D4556%26doi%3D10.1016%2Fj.bmcl.2013.06.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lietha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etheve-Quelquejeu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis of novel 1,2,4-triazine scaffold as FAK inhibitors with antitumor activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1727</span>â <span class="NLM_lpage">1730</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2017.02.072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmcl.2017.02.072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=28284808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktVCrsrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=1727-1730&author=P.+Daoauthor=D.+Liethaauthor=M.+Etheve-Quelquejeuauthor=C.+Garbayauthor=H.+Chen&title=Synthesis+of+novel+1%2C2%2C4-triazine+scaffold+as+FAK+inhibitors+with+antitumor+activity&doi=10.1016%2Fj.bmcl.2017.02.072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of novel 1,2,4-triazine scaffold as FAK inhibitors with antitumor activity</span></div><div class="casAuthors">Dao, Pascal; Lietha, Daniel; Etheve-Quelquejeu, Melanie; Garbay, Christiane; Chen, Huixiong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1727-1730</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Bis(arylamino)chloro-1,2,4-triazines I [R = 3,4,5-(MeO)3C6H2, 4-H2NCH2C6H4, 4-Cl-2-MeO-5-MeC6H2, 4-(4-morpholinyl)phenyl, 2-MeO-4-(4-morpholinyl)phenyl; R1 = 3-MeSO2NHC6H4, 2-MeNHCOC6H4] were prepd. as inhibitors of focal adhesion kinase (FAK) for potential use as antitumor agents; their inhibition of FAK, of human cancer cells, and of tumorigenesis in cancer cells was detd.  I [R = 2-MeO-4-(4-morpholinyl)phenyl; R1 = 2-MeNHCOC6H4] inhibited FAK with an IC50 value of 230 nM and was toxic to cancer cells with IC50 values of 13 Î¼M and 0.19 Î¼M; colony formation in cancer cells was inhibited by I [R = 2-MeO-4-(4-morpholinyl)phenyl; R1 = 2-MeNHCOC6H4] with IC50 values of 1.5 Î¼M and 1.0 Î¼M.  The structure of I [R = 2-MeO-4-(4-morpholinyl)phenyl; R1 = 2-MeNHCOC6H4] bound to FAK was detd. by mol. docking calcns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrttOnuoEdP27Vg90H21EOLACvtfcHk0li38XQnpurBrg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktVCrsrw%253D&md5=b8161c2296506e27dc336e6006678637</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.02.072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.02.072%26sid%3Dliteratum%253Aachs%26aulast%3DDao%26aufirst%3DP.%26aulast%3DLietha%26aufirst%3DD.%26aulast%3DEtheve-Quelquejeu%26aufirst%3DM.%26aulast%3DGarbay%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DH.%26atitle%3DSynthesis%2520of%2520novel%25201%252C2%252C4-triazine%2520scaffold%2520as%2520FAK%2520inhibitors%2520with%2520antitumor%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D1727%26epage%3D1730%26doi%3D10.1016%2Fj.bmcl.2017.02.072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomkiewicz-Raulet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen-Pon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camacho-Artacho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lietha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbeuval, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coumoul, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of novel imidazo[1,2-a][1,3,5]triazines and their derivatives as focal adhesion kinase inhibitors with antitumor activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">237</span>â <span class="NLM_lpage">251</span>, <span class="refDoi">Â DOI: 10.1021/jm500784e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500784e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtLzE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=237-251&author=P.+Daoauthor=N.+Smithauthor=C.+Tomkiewicz-Rauletauthor=E.+Yen-Ponauthor=M.+Camacho-Artachoauthor=D.+Liethaauthor=J.+P.+Herbeuvalauthor=X.+Coumoulauthor=C.+Garbayauthor=H.+Chen&title=Design%2C+synthesis%2C+and+evaluation+of+novel+imidazo%5B1%2C2-a%5D%5B1%2C3%2C5%5Dtriazines+and+their+derivatives+as+focal+adhesion+kinase+inhibitors+with+antitumor+activity&doi=10.1021%2Fjm500784e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of Novel Imidazo[1,2-a][1,3,5]triazines and Their Derivatives as Focal Adhesion Kinase Inhibitors with Antitumor Activity</span></div><div class="casAuthors">Dao, Pascal; Smith, Nikaia; Tomkiewicz-Raulet, Celine; Yen-Pon, Expedite; Camacho-Artacho, Marta; Lietha, Daniel; Herbeuval, Jean-Phillipe; Coumoul, Xavier; Garbay, Christiane; Chen, Huixiong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">237-251</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of triazinic inhibitors of focal adhesion kinase (FAK) have been recently shown to exert antiangiogenic activity against HUVEC cells and anticancer efficacy against several cancer cell lines.  We report herein that we further explored the heterocyclic core of these inhibitors by a fused imidazole ring with the triazine to provide imidazo[1,2-a][1,3,5]triazines, e.g., I.  Importantly, these new compds. displayed 10-7-10-8 M IC50 values, and the best inhibitor showed IC50 value of 50 nM against FAK enzymic activity.  Several inhibitors potently inhibited the proliferation of a panel of cancer cell lines expressing high levels of FAK.  Apoptosis anal. in U87-MG and HCT-116 cell lines suggested that these compds. delayed cell cycle progression by arresting cells in the G2/M phase of the cell cycle, retarding cell growth.  Further investigation demonstrated that these compds. strongly inhibited cell-matrix adhesion, migration, and invasion of U87-MG cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3lpXckaeVGrVg90H21EOLACvtfcHk0li38XQnpurBrg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtLzE&md5=0d2c7ef1b00e45bd462ea913b1bdc128</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Fjm500784e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500784e%26sid%3Dliteratum%253Aachs%26aulast%3DDao%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DN.%26aulast%3DTomkiewicz-Raulet%26aufirst%3DC.%26aulast%3DYen-Pon%26aufirst%3DE.%26aulast%3DCamacho-Artacho%26aufirst%3DM.%26aulast%3DLietha%26aufirst%3DD.%26aulast%3DHerbeuval%26aufirst%3DJ.%2BP.%26aulast%3DCoumoul%26aufirst%3DX.%26aulast%3DGarbay%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DH.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520novel%2520imidazo%255B1%252C2-a%255D%255B1%252C3%252C5%255Dtriazines%2520and%2520their%2520derivatives%2520as%2520focal%2520adhesion%2520kinase%2520inhibitors%2520with%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D237%26epage%3D251%26doi%3D10.1021%2Fjm500784e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">111716</span>â <span class="NLM_lpage">111732</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2019.111716</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.ejmech.2019.111716" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=31550660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVGns7rJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2019&pages=111716-111732&author=R.+Wangauthor=Y.+Chenauthor=X.+Zhaoauthor=S.+Yuauthor=B.+Yangauthor=T.+Wuauthor=J.+Guoauthor=C.+Haoauthor=D.+Zhaoauthor=M.+Cheng&title=Design%2C+synthesis+and+biological+evaluation+of+novel+7H-pyrrolo%5B2%2C3-d%5Dpyrimidine+derivatives+as+potential+FAK+inhibitors+and+anticancer+agents&doi=10.1016%2Fj.ejmech.2019.111716"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents</span></div><div class="casAuthors">Wang, Ruifeng; Chen, Yixuan; Zhao, Xiangxin; Yu, Sijia; Yang, Bowen; Wu, Tianxiao; Guo, Jing; Hao, Chenzhou; Zhao, Dongmei; Cheng, Maosheng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111716</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 7H-pyrrolo[2,3-d]pyrimidine derivs. possessing a dimethylphosphine oxide moiety I (20a-i, R5, R6, R7 = H, R3 = acylamino, sulfamoyl, phosphonomethyl, carbamoyl, amino; 25a-h, R3 = 4-piperidinylaminocarbonyl, R5 = H, halo, alkoxy, CF3, R6 = H, Me, F, R7 = H, F) and II (22a-g, R4 = Me. CHF2CH2, MeOCH2CH2, tetrahydropyranyl, piperidinyl, CH2CONMe2) were designed, synthesized and evaluated as novel Focal adhesion kinase (FAK) inhibitors.  Most compds. potently suppressed the enzymic activities of FAK, with IC50 values in the 10-8-10-9 M range, and potently inhibited the proliferation of breast (MDA-MB-231) and lung (A549) cancer cell lines.  The representative compd. 25b (R5 = OMe, R6 = R7 = H) exhibited potent enzyme inhibition (IC50 = 5.4 nM) and good selectivity when tested on a panel of 26 kinases.  Compd. 25b exhibited antiproliferative activity against A549 cells (IC50 = 3.2 Î¼M) and relatively less cytotoxicity to a normal human cell line HK2.  Compd. 25b also induced apoptosis and suppressed the migration of A549 cells in a concn.-dependent manner.  Further profiling of compd. 25b revealed it had good metabolic stability in mouse, rat and human liver microsomes in vitro and showed weak inhibitory activity against various subtypes of human cytochrome P 450.  The docking study of compd. 25b was performed to elucidate its possible binding modes and to provide a structural basis for further structure-guided design of FAK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdK0cQH-LWPbVg90H21EOLACvtfcHk0li38XQnpurBrg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVGns7rJ&md5=6d098ce43cad86c9b1ed612980ddb579</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111716%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DHao%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DD.%26aulast%3DCheng%26aufirst%3DM.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520novel%25207H-pyrrolo%255B2%252C3-d%255Dpyrimidine%2520derivatives%2520as%2520potential%2520FAK%2520inhibitors%2520and%2520anticancer%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D183%26spage%3D111716%26epage%3D111732%26doi%3D10.1016%2Fj.ejmech.2019.111716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">112024</span>â <span class="NLM_lpage">112040</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2019.112024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.ejmech.2019.112024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=31923858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFCjtLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2020&pages=112024-112040&author=R.+Wangauthor=S.+Yuauthor=X.+Zhaoauthor=Y.+Chenauthor=B.+Yangauthor=T.+Wuauthor=C.+Haoauthor=D.+Zhaoauthor=M.+Cheng&title=Design%2C+synthesis%2C+biological+evaluation+and+molecular+docking+study+of+novel+thieno%5B3%2C2-d%5Dpyrimidine+derivatives+as+potent+FAK+inhibitors&doi=10.1016%2Fj.ejmech.2019.112024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors</span></div><div class="casAuthors">Wang, Ruifeng; Yu, Sijia; Zhao, Xiangxin; Chen, Yixuan; Yang, Bowen; Wu, Tianxiao; Hao, Chenzhou; Zhao, Dongmei; Cheng, Maosheng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112024</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 2,7-disubstituted thieno[3,2-d]pyrimidine derivs. I [R1 = 2-methoxy, 3-acetyl, 3-methylsulfonyl, etc.], II [R2 = methylcarbamoyl, piperidine-3-carbonylamino, diethoxyphosphorylmethyl, etc.], III [R3 = H, Me, ethoxy, etc.; R4 = H, fluoro, methyl; R5 = H, fluoro] and IV [R6 = pyrrolidin-3-yl, tetrahydro-2H-pyran-4-yl, piperidin-3-ylmethyl, etc.] were synthesized and evaluated as novel focal adhesion kinase (FAK) inhibitors.  The novel 2,7-disubstituted thieno[3,2-d]pyrimidine scaffold was designed as a new kinase inhibitor platform that mimics the bioactive conformation of the well-known diaminopyrimidine motif.  Most of the compds. potently suppressed the enzymic activities of FAK and potently inhibited the proliferation of U-87MG, A-549 and MDA-MB-231 cancer cell lines.  Among these derivs., the optimized compd. III [R3 = R5 = H, R4 = fluoro] potently inhibited the enzyme (IC50 = 28.2 nM) and displayed stronger potency than TAE-226 in U-87MG, A-549 and MDA-MB-231 cells, with IC50 values of 0.16, 0.27, and 0.19Î¼M, resp.  Compd. III [R3 = R5 = H, R4 = fluoro] also exhibited relatively less cytotoxicity (IC50 = 3.32Î¼M) toward a normal human cell line, HK2.  According to the flow cytometry results, compd. III [R3 = R5 = H, R4 = fluoro] induced the apoptosis of MDA-MB-231 cells in a dose-dependent manner and effectively arrested MDA-MB-231 cells in G0/G1 phase.  Further investigations revealed that compd. III [R3 = R5 = H, R4 = fluoro] potently suppressed the migration of MDA-MB-231 cells.  Collectively, these data support the further development of compd. III [R3 = R5 = H, R4 = fluoro] as a lead compd. for FAK-targeted anticancer drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomCT88btJhfLVg90H21EOLACvtfcHk0ljKFceYUimBcw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFCjtLY%253D&md5=d606012fd0605da340ba78b6f7319ff7</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.112024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.112024%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DHao%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DD.%26aulast%3DCheng%26aufirst%3DM.%26atitle%3DDesign%252C%2520synthesis%252C%2520biological%2520evaluation%2520and%2520molecular%2520docking%2520study%2520of%2520novel%2520thieno%255B3%252C2-d%255Dpyrimidine%2520derivatives%2520as%2520potent%2520FAK%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D188%26spage%3D112024%26epage%3D112040%26doi%3D10.1016%2Fj.ejmech.2019.112024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zificsak, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingrich, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breslin, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milkiewicz, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theroff, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thieu, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Underiner, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aimone, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albom, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saville, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angeles, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâKane, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrzanski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span> <span> </span><span class="NLM_article-title">Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">133</span>â <span class="NLM_lpage">137</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2011.11.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmcl.2011.11.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=22169263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC38XivVOrsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=133-137&author=C.+A.+Zificsakauthor=D.+E.+Gingrichauthor=H.+J.+Breslinauthor=D.+D.+Dunnauthor=K.+L.+Milkiewiczauthor=J.+P.+Theroffauthor=T.+V.+Thieuauthor=T.+L.+Underinerauthor=L.+R.+Weinbergauthor=L.+D.+Aimoneauthor=M.+S.+Albomauthor=J.+L.+Masonauthor=L.+Savilleauthor=J.+Hustenauthor=T.+S.+Angelesauthor=J.+P.+Finnauthor=M.+Janauthor=T.+M.+O%E2%80%99Kaneauthor=P.+Dobrzanskiauthor=B.+D.+Dorsey&title=Optimization+of+a+novel+kinase+inhibitor+scaffold+for+the+dual+inhibition+of+JAK2+and+FAK+kinases&doi=10.1016%2Fj.bmcl.2011.11.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases</span></div><div class="casAuthors">Zificsak, Craig A.; Gingrich, Diane E.; Breslin, Henry J.; Dunn, Derek D.; Milkiewicz, Karen L.; Theroff, Jay P.; Thieu, Tho V.; Underiner, Ted L.; Weinberg, Linda R.; Aimone, Lisa D.; Albom, Mark S.; Mason, Jennifer L.; Saville, Lisa; Husten, Jean; Angeles, Thelma S.; Finn, James P.; Jan, Mahfuza; O'Kane, Teresa M.; Dobrzanski, Pawel; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">133-137</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The elaboration of a novel scaffold for the inhibition of JAK2 and FAK kinases was targeted in order to provide a dual inhibitor that could target divergent pathways for tumor cell progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFjTGeVZ-5KLVg90H21EOLACvtfcHk0ljKFceYUimBcw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivVOrsQ%253D%253D&md5=849448a392e70c11a0b1df1c9d54e8b5</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.11.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.11.049%26sid%3Dliteratum%253Aachs%26aulast%3DZificsak%26aufirst%3DC.%2BA.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DBreslin%26aufirst%3DH.%2BJ.%26aulast%3DDunn%26aufirst%3DD.%2BD.%26aulast%3DMilkiewicz%26aufirst%3DK.%2BL.%26aulast%3DTheroff%26aufirst%3DJ.%2BP.%26aulast%3DThieu%26aufirst%3DT.%2BV.%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DWeinberg%26aufirst%3DL.%2BR.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DMason%26aufirst%3DJ.%2BL.%26aulast%3DSaville%26aufirst%3DL.%26aulast%3DHusten%26aufirst%3DJ.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DFinn%26aufirst%3DJ.%2BP.%26aulast%3DJan%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Kane%26aufirst%3DT.%2BM.%26aulast%3DDobrzanski%26aufirst%3DP.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DOptimization%2520of%2520a%2520novel%2520kinase%2520inhibitor%2520scaffold%2520for%2520the%2520dual%2520inhibition%2520of%2520JAK2%2520and%2520FAK%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D133%26epage%3D137%26doi%3D10.1016%2Fj.bmcl.2011.11.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H. L.</span></span> <span> </span><span class="NLM_article-title">Synthesis, biological evaluation and molecular docking studies of 1,3,4-thiadiazole derivatives containing 1,4-benzodioxan as potential antitumor agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">6116</span>â <span class="NLM_lpage">6121</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2011.08.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmcl.2011.08.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=21889345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtF2qsr7M" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=6116-6121&author=J.+Sunauthor=Y.+S.+Yangauthor=W.+Liauthor=Y.+B.+Zhangauthor=X.+L.+Wangauthor=J.+F.+Tangauthor=H.+L.+Zhu&title=Synthesis%2C+biological+evaluation+and+molecular+docking+studies+of+1%2C3%2C4-thiadiazole+derivatives+containing+1%2C4-benzodioxan+as+potential+antitumor+agents&doi=10.1016%2Fj.bmcl.2011.08.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, biological evaluation and molecular docking studies of 1,3,4-thiadiazole derivatives containing 1,4-benzodioxan as potential antitumor agents</span></div><div class="casAuthors">Sun, Juan; Yang, Yu-Shun; Li, Wei; Zhang, Yan-Bin; Wang, Xiao-Liang; Tang, Jian-Feng; Zhu, Hai-Liang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6116-6121</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of 1,3,4-thiadiazole derivs. contg. 1,4-benzodioxane have been synthesized to screen for FAK inhibitory activity.  Compd. I showed the most potent biol. activity against HEPG2 cancer cell line (EC50 = 10.28 Î¼g/mL for HEPG2 and EC50 = 10.79 Î¼M for FAK), which was comparable to the pos. control.  Docking simulation was performed to position compd. I into the FAK structure active site to det. the probable binding model.  The results of antiproliferative and Western-blot assay demonstrated that compd. I possessed good antiproliferative activity against HEPG2 cancer cell line.  Therefore, compd. I with potent FAK inhibitory activity may be a potential anticancer agent against HEPG2 cancer cell.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6dV5qu00OrLVg90H21EOLACvtfcHk0ljs9AnvKsZuTA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtF2qsr7M&md5=8e668b7764f57f980403388c81743493</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.08.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.08.039%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DY.%2BS.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%2BB.%26aulast%3DWang%26aufirst%3DX.%2BL.%26aulast%3DTang%26aufirst%3DJ.%2BF.%26aulast%3DZhu%26aufirst%3DH.%2BL.%26atitle%3DSynthesis%252C%2520biological%2520evaluation%2520and%2520molecular%2520docking%2520studies%2520of%25201%252C3%252C4-thiadiazole%2520derivatives%2520containing%25201%252C4-benzodioxan%2520as%2520potential%2520antitumor%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D6116%26epage%3D6121%26doi%3D10.1016%2Fj.bmcl.2011.08.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H. L.</span></span> <span> </span><span class="NLM_article-title">Synthesis, biological evaluation, and molecular docking studies of 1,3,4-thiadiazol-2-amide derivatives as novel anticancer agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2789</span>â <span class="NLM_lpage">2795</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2012.03.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmc.2012.03.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=22503364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsFGisrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=2789-2795&author=X.+H.+Yangauthor=L.+Xiangauthor=X.+Liauthor=T.+T.+Zhaoauthor=H.+Zhangauthor=W.+P.+Zhouauthor=X.+M.+Wangauthor=H.+B.+Gongauthor=H.+L.+Zhu&title=Synthesis%2C+biological+evaluation%2C+and+molecular+docking+studies+of+1%2C3%2C4-thiadiazol-2-amide+derivatives+as+novel+anticancer+agents&doi=10.1016%2Fj.bmc.2012.03.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, biological evaluation, and molecular docking studies of 1,3,4-thiadiazol-2-amide derivatives as novel anticancer agents</span></div><div class="casAuthors">Yang, Xian-Hui; Xiang, Lu; Li, Xi; Zhao, Ting-Ting; Zhang, Hui; Zhou, Wen-Ping; Wang, Xiao-Ming; Gong, Hai-Bin; Zhu, Hai-Liang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2789-2795</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of 1,3,4-thiadiazol-2-amide derivs. (5a-5y) have been designed and synthesized, and their biol. activities were also evaluated as potential antiproliferation and FAK inhibitors.  Among all the compds., 5h showed the most potent activity in vitro, which inhibited the growth of MCF-7 and B16-F10 cell lines with IC50 values of 0.45 and 0.31 Î¼M, resp.  Compd. 5h also exhibited significant FAK inhibitory activity (IC50 = 5.32 Î¼M).  Docking simulation was performed to position compd. 5h into the FAK structure active site to det. the probable binding model.  The results of antiproliferative and Western-blot assay demonstrated that compd. 5h possessed good antiproliferative activity.  Therefore, compd. 5h with potent FAK inhibitory activity may be a potential anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzBY1xBDazwrVg90H21EOLACvtfcHk0ljs9AnvKsZuTA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsFGisrk%253D&md5=6c9546c5648719682ee04da9099d10a2</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.03.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.03.040%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%2BH.%26aulast%3DXiang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DT.%2BT.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DW.%2BP.%26aulast%3DWang%26aufirst%3DX.%2BM.%26aulast%3DGong%26aufirst%3DH.%2BB.%26aulast%3DZhu%26aufirst%3DH.%2BL.%26atitle%3DSynthesis%252C%2520biological%2520evaluation%252C%2520and%2520molecular%2520docking%2520studies%2520of%25201%252C3%252C4-thiadiazol-2-amide%2520derivatives%2520as%2520novel%2520anticancer%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D2789%26epage%3D2795%26doi%3D10.1016%2Fj.bmc.2012.03.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, F. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H. L.</span></span> <span> </span><span class="NLM_article-title">Discovery of a series of 1,3,4-oxadiazole-2(3H)-thione derivatives containing piperazine skeleton as potential FAK inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2593</span>â <span class="NLM_lpage">2600</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2017.03.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmc.2017.03.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=28363444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlt1Cjsbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=2593-2600&author=J.+Sunauthor=S.+Z.+Renauthor=X.+Y.+Luauthor=J.+J.+Liauthor=F.+Q.+Shenauthor=C.+Xuauthor=H.+L.+Zhu&title=Discovery+of+a+series+of+1%2C3%2C4-oxadiazole-2%283H%29-thione+derivatives+containing+piperazine+skeleton+as+potential+FAK+inhibitors&doi=10.1016%2Fj.bmc.2017.03.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a series of 1,3,4-oxadiazole-2(3H)-thione derivatives containing piperazine skeleton as potential FAK inhibitors</span></div><div class="casAuthors">Sun, Juan; Ren, Shen-Zhen; Lu, Xiao-Yuan; Li, Jing-Jing; Shen, Fa-Qian; Xu, Chen; Zhu, Hai-Liang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2593-2600</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) is an important drug target that plays a fundamental role in mediating signal transduction system.  We report herein the discovery of a novel class of 1,3,4-oxadiazole-2(3H)-thione derivs. contg. piperazine skeleton with improved potency toward FAK.  All of the 17 new synthesized compds. were assayed for the anticancer activities against four cancer cells, HepG2, Hela, SW116 and BGC823.  Because of the combination of 1,4-benzodioxan, 1,3,4-oxadiazole and piperazine ring, most of them exhibited remarkable antitumor activities.  Notably, compd. 5m showed the most potent biol. activities (IC50 = 5.78 Î¼M for HepG2, and IC50 = 47.15 Î¼M for SW1116), and its anti-FAK inhibitory activity (IC50 = 0.78 Î¼M) was also the best.  Computational docking studies also showed that compd. 5m has interaction with FAK key residues in the active site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTvkYSfXjf2rVg90H21EOLACvtfcHk0ljs9AnvKsZuTA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlt1Cjsbo%253D&md5=2cf62f6391c7310f09c1a78dc9f0d0f2</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.03.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.03.038%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DS.%2BZ.%26aulast%3DLu%26aufirst%3DX.%2BY.%26aulast%3DLi%26aufirst%3DJ.%2BJ.%26aulast%3DShen%26aufirst%3DF.%2BQ.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DH.%2BL.%26atitle%3DDiscovery%2520of%2520a%2520series%2520of%25201%252C3%252C4-oxadiazole-2%25283H%2529-thione%2520derivatives%2520containing%2520piperazine%2520skeleton%2520as%2520potential%2520FAK%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D2593%26epage%3D2600%26doi%3D10.1016%2Fj.bmc.2017.03.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makawana, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teraiya, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thumar, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H. L.</span></span> <span> </span><span class="NLM_article-title">Synthesis, biological evaluation, and molecular docking studies of novel 2-styryl-5-nitroimidazole derivatives containing 1,4-benzodioxan moiety as FAK inhibitors with anticancer activity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2947</span>â <span class="NLM_lpage">2954</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2014.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmc.2014.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=24792811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntFygtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=2947-2954&author=Y.+T.+Duanauthor=Y.+F.+Yaoauthor=W.+Huangauthor=J.+A.+Makawanaauthor=S.+B.+Teraiyaauthor=N.+J.+Thumarauthor=D.+J.+Tangauthor=X.+X.+Taoauthor=Z.+C.+Wangauthor=A.+Q.+Jiangauthor=H.+L.+Zhu&title=Synthesis%2C+biological+evaluation%2C+and+molecular+docking+studies+of+novel+2-styryl-5-nitroimidazole+derivatives+containing+1%2C4-benzodioxan+moiety+as+FAK+inhibitors+with+anticancer+activity&doi=10.1016%2Fj.bmc.2014.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, biological evaluation, and molecular docking studies of novel 2-styryl-5-nitroimidazole derivatives containing 1,4-benzodioxan moiety as FAK inhibitors with anticancer activity</span></div><div class="casAuthors">Duan, Yong-Tao; Yao, Yong-Fang; Huang, Wei; Makawana, Jigar A.; Teraiya, Shashikant B.; Thumar, Nilesh j.; Tang, Dan-Jie; Tao, Xiang-Xiang; Wang, Zhong-Chang; Jiang, Ai-Qin; Zhu, Hai-Liang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2947-2954</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of 2-styryl-5-nitroimidazole derivs. contg. 1,4-benzodioxan moiety has been designed, synthesized and their biol. activities were also evaluated as potential antiproliferation and focal adhesion kinase (FAK) inhibitors.  Among all the compds., (I) showed the most potent activity in vitro which inhibited the growth of A549 with IC50 value of 3.11 Î¼M and Hela with IC50 value of 2.54 Î¼M resp.  Compd. I also exhibited significant FAK inhibitory activity (IC50 = 0.45 Î¼M).  Docking simulation was performed for compd. I into the FAK structure active site to det. the probable binding model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_Wm3MnQHEprVg90H21EOLACvtfcHk0ljB4msmWrSVWQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntFygtb0%253D&md5=4cbefdd1f7ab66f6d7e3ae5f4ff9069c</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DY.%2BT.%26aulast%3DYao%26aufirst%3DY.%2BF.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DMakawana%26aufirst%3DJ.%2BA.%26aulast%3DTeraiya%26aufirst%3DS.%2BB.%26aulast%3DThumar%26aufirst%3DN.%2BJ.%26aulast%3DTang%26aufirst%3DD.%2BJ.%26aulast%3DTao%26aufirst%3DX.%2BX.%26aulast%3DWang%26aufirst%3DZ.%2BC.%26aulast%3DJiang%26aufirst%3DA.%2BQ.%26aulast%3DZhu%26aufirst%3DH.%2BL.%26atitle%3DSynthesis%252C%2520biological%2520evaluation%252C%2520and%2520molecular%2520docking%2520studies%2520of%2520novel%25202-styryl-5-nitroimidazole%2520derivatives%2520containing%25201%252C4-benzodioxan%2520moiety%2520as%2520FAK%2520inhibitors%2520with%2520anticancer%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D2947%26epage%3D2954%26doi%3D10.1016%2Fj.bmc.2014.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Altintop, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sever, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akalin Ciftci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turan-Zitouni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplancikli, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozdemir, A.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, in vitro and in silico evaluation of a new series of oxadiazole-based anticancer agents as potential Akt and FAK inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">905</span>â <span class="NLM_lpage">924</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2018.06.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.ejmech.2018.06.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=29966916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Kqtr3I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2018&pages=905-924&author=M.+D.+Altintopauthor=B.+Severauthor=G.+Akalin+Ciftciauthor=G.+Turan-Zitouniauthor=Z.+A.+Kaplancikliauthor=A.+Ozdemir&title=Design%2C+synthesis%2C+in+vitro+and+in+silico+evaluation+of+a+new+series+of+oxadiazole-based+anticancer+agents+as+potential+Akt+and+FAK+inhibitors&doi=10.1016%2Fj.ejmech.2018.06.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, in vitro and in silico evaluation of a new series of oxadiazole-based anticancer agents as potential Akt and FAK inhibitors</span></div><div class="casAuthors">Altintop, Mehlika Dilek; Sever, Belgin; Akalin Ciftci, Gulsen; Turan-Zitouni, Gulhan; Kaplancikli, Zafer Asim; Ozdemir, Ahmet</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">905-924</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In the current work, new 1,3,4-oxadiazole derivs. were synthesized and studied for their cytotoxic effects on A549 human lung adenocarcinoma, C6 rat glioma and NIH/3T3 mouse embryonic fibroblast cell lines.  Compds. N-(6-Fluorobenzothiazol-2-yl)-2-[[5-[((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)methyl]-1,3,4-oxadiazol-2-yl]thio]acetamide, N-(6-methoxybenzothiazol-2-yl)-2-[[5-[((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)methyl]-1,3,4-oxadiazol-2-yl]thio]acetamide and N-(5-Nitrothiazol-2-yl)-2-[[5-[((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)methyl]-1,3,4-oxadiazol-2-yl]thio]acetamide are the most potent anticancer agents against A549 and C6 cell lines and therefore their effects on apoptosis, caspase-3 activation, Akt, FAK, mitochondrial membrane potential and ultrastructural morphol. changes were evaluated.  N-(5-Nitrothiazol-2-yl)-2-[[5-[((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)methyl]-1,3,4-oxadiazol-2-yl]thio]acetamide increased early and late apoptotic cell population in A549 and C6 cells more than cisplatin and caused more mitochondrial membrane depolarization in both cell lines than cisplatin.  However, N-(6-methoxybenzothiazol-2-yl)-2-[[5-[((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)methyl]-1,3,4-oxadiazol-2-yl]thio]acetamide caused higher caspase-3 activation than cisplatin in both cell lines.  Compd. N-(6-methoxybenzothiazol-2-yl)-2-[[5-[((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)methyl]-1,3,4-oxadiazol-2-yl]thio]acetamide showed significant Akt inhibitory activity in both cell lines.  Moreover, compd. N-(6-methoxybenzothiazol-2-yl)-2-[[5-[((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)methyl]-1,3,4-oxadiazol-2-yl]thio]acetamide significantly inhibited FAK (Phospho-Tyr397) activity in C6 cell line.  Mol. docking simulations demonstrated that compd. N-(6-methoxybenzothiazol-2-yl)-2-[[5-[((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)methyl]-1,3,4-oxadiazol-2-yl]thio]acetamide fitted into the active sites of Akt and FAK with high affinity and substrate-specific interactions.  Furthermore, compds. N-(6-Fluorobenzothiazol-2-yl)-2-[[5-[((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)methyl]-1,3,4-oxadiazol-2-yl]thio]acetamide, N-(6-Methoxybenzothiazol-2-yl)-2-[[5-[((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)methyl]-1,3,4-oxadiazol-2-yl]thio]acetamide and N-(5-Nitrothiazol-2-yl)-2-[[5-[((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)methyl]-1,3,4-oxadiazol-2-yl]thio]acetamide caused apoptotic morphol. changes in both cell lines obtained from micrographs by TEM.  A computational study for the prediction of ADME properties of all compds. was also performed.  These compds. did not violate Lipinski's rule, making them potential orally bioavailable anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_8VEjQH4e5bVg90H21EOLACvtfcHk0ljB4msmWrSVWQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Kqtr3I&md5=cba9f08c9e5dcf6b335d0999622d64e0</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.06.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.06.049%26sid%3Dliteratum%253Aachs%26aulast%3DAltintop%26aufirst%3DM.%2BD.%26aulast%3DSever%26aufirst%3DB.%26aulast%3DAkalin%2BCiftci%26aufirst%3DG.%26aulast%3DTuran-Zitouni%26aufirst%3DG.%26aulast%3DKaplancikli%26aufirst%3DZ.%2BA.%26aulast%3DOzdemir%26aufirst%3DA.%26atitle%3DDesign%252C%2520synthesis%252C%2520in%2520vitro%2520and%2520in%2520silico%2520evaluation%2520of%2520a%2520new%2520series%2520of%2520oxadiazole-based%2520anticancer%2520agents%2520as%2520potential%2520Akt%2520and%2520FAK%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D155%26spage%3D905%26epage%3D924%26doi%3D10.1016%2Fj.ejmech.2018.06.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohren, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlovsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitehead, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuffa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spessard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banotai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaney, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebolt-Leopold, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flamme, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tecle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasemann, C. A.</span></span> <span> </span><span class="NLM_article-title">Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1192</span>â <span class="NLM_lpage">1197</span>, <span class="refDoi">Â DOI: 10.1038/nsmb859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fnsmb859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=15543157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVens7jM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=1192-1197&author=J.+F.+Ohrenauthor=H.+Chenauthor=A.+Pavlovskyauthor=C.+Whiteheadauthor=E.+Zhangauthor=P.+Kuffaauthor=C.+Yanauthor=P.+McConnellauthor=C.+Spessardauthor=C.+Banotaiauthor=W.+T.+Muellerauthor=A.+Delaneyauthor=C.+Omerauthor=J.+Sebolt-Leopoldauthor=D.+T.+Dudleyauthor=I.+K.+Leungauthor=C.+Flammeauthor=J.+Warmusauthor=M.+Kaufmanauthor=S.+Barrettauthor=H.+Tecleauthor=C.+A.+Hasemann&title=Structures+of+human+MAP+kinase+kinase+1+%28MEK1%29+and+MEK2+describe+novel+noncompetitive+kinase+inhibition&doi=10.1038%2Fnsmb859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition</span></div><div class="casAuthors">Ohren, Jeffrey F.; Chen, Huifen; Pavlovsky, Alexander; Whitehead, Christopher; Zhang, Erli; Kuffa, Peter; Yan, Chunhong; McConnell, Patrick; Spessard, Cindy; Banotai, Craig; Mueller, W. Thomas; Delaney, Amy; Omer, Charles; Sebolt-Leopold, Judith; Dudley, David T.; Leung, Iris K.; Flamme, Cathlin; Warmus, Joseph; Kaufman, Michael; Barrett, Stephen; Tecle, Haile; Hasemann, Charles A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1192-1197</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">MEK1 and MEK2 kinases are closely related, dual-specificity tyrosine/threonine protein kinases found in the Ras/Raf/MEK/ERK MAP kinase (MAPK) signaling pathway.  Approx. 30% of all human cancers have a constitutively activated MAPK pathway, and constitutive activation of MEK1 results in cellular transformation.  Here, the authors present the x-ray crystal structures of human MEK1 and MEK2 kinases, each detd. as a ternary complex with MgATP and an inhibitor to a resoln. of 2.4 and 3.2 Ã, resp.  The structures revealed that MEK1 and MEK2 each had a unique inhibitor-binding pocket adjacent to the MgATP-binding site.  The presence of the potent inhibitors induced several conformational changes in the unphosphorylated MEK1 and MEK2 kinases that locked them into a closed but catalytically inactive species.  Thus, the structures reported here reveal a novel, noncompetitive mechanism for protein kinase inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIY9begVVfW7Vg90H21EOLACvtfcHk0ljB4msmWrSVWQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVens7jM&md5=79ebbc2e3a9cdd3fbecb8bb35ea9dba3</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1038%2Fnsmb859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb859%26sid%3Dliteratum%253Aachs%26aulast%3DOhren%26aufirst%3DJ.%2BF.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DPavlovsky%26aufirst%3DA.%26aulast%3DWhitehead%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DE.%26aulast%3DKuffa%26aufirst%3DP.%26aulast%3DYan%26aufirst%3DC.%26aulast%3DMcConnell%26aufirst%3DP.%26aulast%3DSpessard%26aufirst%3DC.%26aulast%3DBanotai%26aufirst%3DC.%26aulast%3DMueller%26aufirst%3DW.%2BT.%26aulast%3DDelaney%26aufirst%3DA.%26aulast%3DOmer%26aufirst%3DC.%26aulast%3DSebolt-Leopold%26aufirst%3DJ.%26aulast%3DDudley%26aufirst%3DD.%2BT.%26aulast%3DLeung%26aufirst%3DI.%2BK.%26aulast%3DFlamme%26aufirst%3DC.%26aulast%3DWarmus%26aufirst%3DJ.%26aulast%3DKaufman%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DS.%26aulast%3DTecle%26aufirst%3DH.%26aulast%3DHasemann%26aufirst%3DC.%2BA.%26atitle%3DStructures%2520of%2520human%2520MAP%2520kinase%2520kinase%25201%2520%2528MEK1%2529%2520and%2520MEK2%2520describe%2520novel%2520noncompetitive%2520kinase%2520inhibition%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2004%26volume%3D11%26spage%3D1192%26epage%3D1197%26doi%3D10.1038%2Fnsmb859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leister, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnett, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Defeo-Jones, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huff, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, M. E.</span></span> <span> </span><span class="NLM_article-title">Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">761</span>â <span class="NLM_lpage">764</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2004.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmcl.2004.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=15664853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2MXnsVKquw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=761-764&author=C.+W.+Lindsleyauthor=Z.+Zhaoauthor=W.+H.+Leisterauthor=R.+G.+Robinsonauthor=S.+F.+Barnettauthor=D.+Defeo-Jonesauthor=R.+E.+Jonesauthor=G.+D.+Hartmanauthor=J.+R.+Huffauthor=H.+E.+Huberauthor=M.+E.+Duggan&title=Allosteric+Akt+%28PKB%29+inhibitors%3A+discovery+and+SAR+of+isozyme+selective+inhibitors&doi=10.1016%2Fj.bmcl.2004.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors</span></div><div class="casAuthors">Lindsley, Craig W.; Zhao, Zhijian; Leister, William H.; Robinson, Ronald G.; Barnett, Stanley F.; Defeo-Jones, Deborah; Jones, Raymond E.; Hartman, George D.; Huff, Joel R.; Huber, Hans E.; Duggan, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">761-764</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This letter describes the development of two series of potent and selective allosteric Akt kinase inhibitors that display an unprecedented level of selectivity for either Akt1, Akt2 or both Akt1/Akt2.  An iterative analog library synthesis approach quickly provided a highly selective Akt1/Akt2 inhibitor that induces apoptosis in tumor cells and inhibits Akt phosphorylation in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxuCBcX4Ew8LVg90H21EOLACvtfcHk0lg_9rz_Z-CJrA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXnsVKquw%253D%253D&md5=064636872476fd8e344dfa151dca218f</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DLeister%26aufirst%3DW.%2BH.%26aulast%3DRobinson%26aufirst%3DR.%2BG.%26aulast%3DBarnett%26aufirst%3DS.%2BF.%26aulast%3DDefeo-Jones%26aufirst%3DD.%26aulast%3DJones%26aufirst%3DR.%2BE.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DHuff%26aufirst%3DJ.%2BR.%26aulast%3DHuber%26aufirst%3DH.%2BE.%26aulast%3DDuggan%26aufirst%3DM.%2BE.%26atitle%3DAllosteric%2520Akt%2520%2528PKB%2529%2520inhibitors%253A%2520discovery%2520and%2520SAR%2520of%2520isozyme%2520selective%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D761%26epage%3D764%26doi%3D10.1016%2Fj.bmcl.2004.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwatani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okabe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skene, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aramaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosfield, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baba, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miki, H.</span></span> <span> </span><span class="NLM_article-title">Discovery and characterization of novel allosteric FAK inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">49</span>â <span class="NLM_lpage">60</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2012.06.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.ejmech.2012.06.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=22819505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFOks7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2013&pages=49-60&author=M.+Iwataniauthor=H.+Iwataauthor=A.+Okabeauthor=R.+J.+Skeneauthor=N.+Tomitaauthor=Y.+Hayashiauthor=Y.+Aramakiauthor=D.+J.+Hosfieldauthor=A.+Horiauthor=A.+Babaauthor=H.+Miki&title=Discovery+and+characterization+of+novel+allosteric+FAK+inhibitors&doi=10.1016%2Fj.ejmech.2012.06.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and characterization of novel allosteric FAK inhibitors</span></div><div class="casAuthors">Iwatani, Misa; Iwata, Hidehisa; Okabe, Atsutoshi; Skene, Robert J.; Tomita, Naoki; Hayashi, Yoko; Aramaki, Yoshio; Hosfield, David J.; Hori, Akira; Baba, Atsuo; Miki, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">49-60</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) regulates cell survival and proliferation pathways.  Here we report the discovery of a highly selective series of 1,5-dihydropyrazolo[4,3-c][2,1]benzothiazines that demonstrate a novel mode of allosteric inhibition of FAK.  These compds. showed slow dissocn. from unphosphorylated FAK and were noncompetitive with ATP after long preincubation.  Co-crystal structural anal. revealed that the compds. target a novel allosteric site within the C-lobe of the kinase domain, which induces disruption of ATP pocket formation leading to the inhibition of kinase activity.  The potency of allosteric inhibition was reduced by phosphorylation of FAK.  Coupled SAR anal. revealed that N-substitution of the fused pyrazole is crit. to achieve allosteric binding and high selectivity among kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkySXIj4BDgrVg90H21EOLACvtfcHk0lg_9rz_Z-CJrA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFOks7g%253D&md5=1b0f8d1e6c422b369645be532d16596e</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.06.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.06.035%26sid%3Dliteratum%253Aachs%26aulast%3DIwatani%26aufirst%3DM.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DOkabe%26aufirst%3DA.%26aulast%3DSkene%26aufirst%3DR.%2BJ.%26aulast%3DTomita%26aufirst%3DN.%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DAramaki%26aufirst%3DY.%26aulast%3DHosfield%26aufirst%3DD.%2BJ.%26aulast%3DHori%26aufirst%3DA.%26aulast%3DBaba%26aufirst%3DA.%26aulast%3DMiki%26aufirst%3DH.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520novel%2520allosteric%2520FAK%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D61%26spage%3D49%26epage%3D60%26doi%3D10.1016%2Fj.ejmech.2012.06.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tomita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oomori, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aramaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwatani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okabe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awazu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isono, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skene, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosfield, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baba, A.</span></span> <span> </span><span class="NLM_article-title">Structure-based discovery of cellular-active allosteric inhibitors of FAK</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1779</span>â <span class="NLM_lpage">1785</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2013.01.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmcl.2013.01.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=23414845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3sXis1Wrtrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=1779-1785&author=N.+Tomitaauthor=Y.+Hayashiauthor=S.+Suzukiauthor=Y.+Oomoriauthor=Y.+Aramakiauthor=Y.+Matsushitaauthor=M.+Iwataniauthor=H.+Iwataauthor=A.+Okabeauthor=Y.+Awazuauthor=O.+Isonoauthor=R.+J.+Skeneauthor=D.+J.+Hosfieldauthor=H.+Mikiauthor=T.+Kawamotoauthor=A.+Horiauthor=A.+Baba&title=Structure-based+discovery+of+cellular-active+allosteric+inhibitors+of+FAK&doi=10.1016%2Fj.bmcl.2013.01.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based discovery of cellular-active allosteric inhibitors of FAK</span></div><div class="casAuthors">Tomita, Naoki; Hayashi, Yoko; Suzuki, Shinkichi; Oomori, Yoshimasa; Aramaki, Yoshio; Matsushita, Yoshihiro; Iwatani, Misa; Iwata, Hidehisa; Okabe, Atsutoshi; Awazu, Yoshiko; Isono, Osamu; Skene, Robert J.; Hosfield, David J.; Miki, Hiroshi; Kawamoto, Tomohiro; Hori, Akira; Baba, Atsuo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1779-1785</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In order to develop potent and selective focal adhesion kinase (FAK) inhibitors, synthetic studies on pyrazolo[4,3-c][2,1]benzothiazines targeted for the FAK allosteric site were carried out.  Based on the X-ray structural anal. of the co-crystal of the lead compd., 8-(4-ethylphenyl)-5-methyl-1,5-dihydropyrazolo[4,3-c][2,1]benzothiazine 4,4-dioxide 1 with FAK, we designed and prepd. 1,5-dimethyl-1,5-dihydropyrazolo[4,3-c][2,1]benzothiazin derivs. which selectively inhibited kinase activity of FAK without affecting seven other kinases.  The optimized compd., N-(4-tert-butylbenzyl)-1,5-dimethyl-1,5-dihydropyrazolo[4,3-c][2,1]benzothiazin-8-amine 4,4-dioxide 30 possessed significant FAK kinase inhibitory activities both in cell-free (IC50 = 0.64 Î¼M) and in cellular assays (IC50 = 7.1 Î¼M).  These results clearly demonstrated a potential of FAK allosteric inhibitors as antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqr-Jxocxt917Vg90H21EOLACvtfcHk0lg_9rz_Z-CJrA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXis1Wrtrk%253D&md5=309362a2ca95be142bb6d8e29520f367</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.01.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.01.047%26sid%3Dliteratum%253Aachs%26aulast%3DTomita%26aufirst%3DN.%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DS.%26aulast%3DOomori%26aufirst%3DY.%26aulast%3DAramaki%26aufirst%3DY.%26aulast%3DMatsushita%26aufirst%3DY.%26aulast%3DIwatani%26aufirst%3DM.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DOkabe%26aufirst%3DA.%26aulast%3DAwazu%26aufirst%3DY.%26aulast%3DIsono%26aufirst%3DO.%26aulast%3DSkene%26aufirst%3DR.%2BJ.%26aulast%3DHosfield%26aufirst%3DD.%2BJ.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DKawamoto%26aufirst%3DT.%26aulast%3DHori%26aufirst%3DA.%26aulast%3DBaba%26aufirst%3DA.%26atitle%3DStructure-based%2520discovery%2520of%2520cellular-active%2520allosteric%2520inhibitors%2520of%2520FAK%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D1779%26epage%3D1785%26doi%3D10.1016%2Fj.bmcl.2013.01.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Golubovskaya, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baotran, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cance, W. G.</span></span> <span> </span><span class="NLM_article-title">Mitoxantrone targets the ATP-binding site of FAK, binds the FAK kinase domain and decreases FAK, Pyk-2, c-Src, and IGF-1R in vitro kinase activities</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">546</span>â <span class="NLM_lpage">554</span>, <span class="refDoi">Â DOI: 10.2174/1871520611313040003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.2174%2F1871520611313040003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=22292772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSmsrvN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=546-554&author=V.+M.+Golubovskayaauthor=H.+Baotranauthor=M.+Zhengauthor=A.+Magisauthor=D.+Ostrovauthor=W.+G.+Cance&title=Mitoxantrone+targets+the+ATP-binding+site+of+FAK%2C+binds+the+FAK+kinase+domain+and+decreases+FAK%2C+Pyk-2%2C+c-Src%2C+and+IGF-1R+in+vitro+kinase+activities&doi=10.2174%2F1871520611313040003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Mitoxantrone targets the ATP-binding site of FAK, binds the FAK kinase domain and decreases FAK, Pyk-2, c-Src, and IGF-1R in vitro kinase activities</span></div><div class="casAuthors">Golubovskaya, Vita M.; Ho, Baotran; Zheng, Min; Magis, Andrew; Ostrov, David; Cance, William G.</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">546-554</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Focal Adhesion Kinase (FAK) is a non-receptor kinase that is overexpressed in many types of tumors and plays a key role in cell adhesion, spreading, motility, proliferation, invasion, angiogenesis, and survival.  Recently, FAK has been proposed as a target for cancer therapy, and we performed computer modeling and screening of the National Cancer Institute (NCI) small mol. compds. database to target the ATP-binding site of FAK, K454.  More than 140,000 small mol. compds. were docked into the crystal structure of the kinase domain of FAK in 100 different orientations using DOCK5.1 that identified small mol. compds., targeting the K454 site, called A-compds.  To find the therapeutic efficacy of these compds., we examd. the effect of twenty small mol. compds. on cell viability by MTT assays in different cancer cell lines.  One compd., A18 (1,4-bis(diethylamino)-5,8-dihydroxy anthraquinone) was a mitoxantrone deriv. and significantly decreased viability in most of the cells comparable to the to the level of FAK kinase inhibitors TAE-226 (Novartis, Inc) and PF-573,228 (Pfizer).  The A18 compd. specifically blocked autophosphorylation of FAK like TAE-226 and PF-228.  ForteBio Octet Binding assay demonstrated that mitoxantrone 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione directly binds the FAK-kinase domain.  In addn., mitoxantrone significantly decreased the viability of breast cancer cells in a dose-dependent manner and inhibited the kinase activity of FAK and Y56/577 FAK phosphorylation at 10-20 Î¼M.  Mitoxantrone did not affect phosphorylation of EGFR, but decreased Pyk-2, c-Src, and IGF-1R kinase activities.  The data demonstrate that mitoxantrone decreases cancer viability, binds FAK-Kinase domain, inhibits its kinase activity, and also inhibits in vitro kinase activities of Pyk-2 and IGF-1R.  Thus, this novel function of the mitoxantrone drug can be crit. for future development of anti-cancer agents and FAK-targeted therapy research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojYXwoPe-7nbVg90H21EOLACvtfcHk0lhDV3ZxAZmi3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSmsrvN&md5=0e1775725e49e5d395b55afa2186a8b8</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.2174%2F1871520611313040003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520611313040003%26sid%3Dliteratum%253Aachs%26aulast%3DGolubovskaya%26aufirst%3DV.%2BM.%26aulast%3DBaotran%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DMagis%26aufirst%3DA.%26aulast%3DOstrov%26aufirst%3DD.%26aulast%3DCance%26aufirst%3DW.%2BG.%26atitle%3DMitoxantrone%2520targets%2520the%2520ATP-binding%2520site%2520of%2520FAK%252C%2520binds%2520the%2520FAK%2520kinase%2520domain%2520and%2520decreases%2520FAK%252C%2520Pyk-2%252C%2520c-Src%252C%2520and%2520IGF-1R%2520in%2520vitro%2520kinase%2520activities%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D546%26epage%3D554%26doi%3D10.2174%2F1871520611313040003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Golubovskaya, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kweh, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cance, W. G.</span></span> <span> </span><span class="NLM_article-title">A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">7405</span>â <span class="NLM_lpage">7416</span>, <span class="refDoi">Â DOI: 10.1021/jm800483v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800483v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlCgur%252FF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7405-7416&author=V.+M.+Golubovskayaauthor=C.+Nybergauthor=M.+Zhengauthor=F.+Kwehauthor=A.+Magisauthor=D.+Ostrovauthor=W.+G.+Cance&title=A+small+molecule+inhibitor%2C+1%2C2%2C4%2C5-benzenetetraamine+tetrahydrochloride%2C+targeting+the+y397+site+of+focal+adhesion+kinase+decreases+tumor+growth&doi=10.1021%2Fjm800483v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">A Small Molecule Inhibitor, 1,2,4,5-Benzenetetraamine Tetrahydrochloride, Targeting the Y397 Site of Focal Adhesion Kinase Decreases Tumor Growth</span></div><div class="casAuthors">Golubovskaya, Vita M.; Nyberg, Carl; Zheng, Min; Kweh, Frederick; Magis, Andrew; Ostrov, David; Cance, William G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7405-7416</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) is a nonreceptor kinase that is overexpressed in many types of tumors.  We developed a novel cancer-therapy approach, targeting the main autophosphorylation site of FAK, Y397, by computer modeling and screening of the National Cancer Institute (NCI) small mol. compds. database.  More than 140 000 small mol. compds. were docked into the N-terminal domain of the FAK crystal structure in 100 different orientations that identified 35 compds.  One compd., 14 (1,2,4,5-benzenetetraamine tetrahydrochloride), significantly decreased viability in most of the cells to the levels equal to or higher than control FAK inhibitor 1a (2-[5-chloro-2-[2-methoxy-4-(4-morpholinyl)phenylamino]pyrimidin-4-ylamino]-N-methylbenzamide, TAE226) from Novartis, Inc.  Compd. 14 specifically and directly blocked phosphorylation of Y397-FAK in a dose- and time-dependent manner.  It increased cell detachment and inhibited cell adhesion in a dose-dependent manner.  Furthermore, 14 effectively caused breast tumor regression in vivo.  Thus, targeting the Y397 site of FAK with 14 inhibitor can be effectively used in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7LO4qrMpaarVg90H21EOLACvtfcHk0lhDV3ZxAZmi3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlCgur%252FF&md5=d7402a373c3b94ab8115b48ab00a9c21</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1021%2Fjm800483v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800483v%26sid%3Dliteratum%253Aachs%26aulast%3DGolubovskaya%26aufirst%3DV.%2BM.%26aulast%3DNyberg%26aufirst%3DC.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DKweh%26aufirst%3DF.%26aulast%3DMagis%26aufirst%3DA.%26aulast%3DOstrov%26aufirst%3DD.%26aulast%3DCance%26aufirst%3DW.%2BG.%26atitle%3DA%2520small%2520molecule%2520inhibitor%252C%25201%252C2%252C4%252C5-benzenetetraamine%2520tetrahydrochloride%252C%2520targeting%2520the%2520y397%2520site%2520of%2520focal%2520adhesion%2520kinase%2520decreases%2520tumor%2520growth%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7405%26epage%3D7416%26doi%3D10.1021%2Fjm800483v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Golubovskaya, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yemma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrov, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelman, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cance, W. G.</span></span> <span> </span><span class="NLM_article-title">A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1(3,7)]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo</span>. <i>Carcinogenesis</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1004</span>â <span class="NLM_lpage">1013</span>, <span class="refDoi">Â DOI: 10.1093/carcin/bgs120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1093%2Fcarcin%2Fbgs120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=22402131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt1yit7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=1004-1013&author=V.+M.+Golubovskayaauthor=S.+Figelauthor=B.+T.+Hoauthor=C.+P.+Johnsonauthor=M.+Yemmaauthor=G.+Huangauthor=M.+Zhengauthor=C.+Nybergauthor=A.+Magisauthor=D.+A.+Ostrovauthor=I.+H.+Gelmanauthor=W.+G.+Cance&title=A+small+molecule+focal+adhesion+kinase+%28FAK%29+inhibitor%2C+targeting+Y397+site%3A+1-%282-hydroxyethyl%29-3%2C+5%2C+7-triaza-1-azoniatricyclo+%5B3.3.1.1%283%2C7%29%5Ddecane%3B+bromide+effectively+inhibits+FAK+autophosphorylation+activity+and+decreases+cancer+cell+viability%2C+clonogenicity+and+tumor+growth+in+vivo&doi=10.1093%2Fcarcin%2Fbgs120"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl) -3, 5, 7-triaza-1-azoniatricyclo [3.3.1.13,7]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo</span></div><div class="casAuthors">Golubovskaya, Vita M.; Figel, Sheila; Ho, Baotran T.; Johnson, Christopher P.; Yemma, Michael; Huang, Grace; Zheng, Min; Nyberg, Carl; Magis, Andrew; Ostrov, David A.; Gelman, Irwin H.; Cance, William G.</div><div class="citationInfo"><span class="NLM_cas:title">Carcinogenesis</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1004-1013</span>CODEN:
                <span class="NLM_cas:coden">CRNGDP</span>;
        ISSN:<span class="NLM_cas:issn">0143-3334</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) is a protein tyrosine kinase that is overexpressed in most solid types of tumors and plays an important role in the survival signaling.  Recently, we have developed a novel computer modeling combined with a functional assay approach to target the main autophosphorylation site of FAK (Y397).  Using these approaches, we identified 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.13,7]decane; bromide, called Y11, a small mol. inhibitor targeting Y397 site of FAK.  Y11 significantly and specifically decreased FAK autophosphorylation, directly bound to the N-terminal domain of FAK.  In addn., Y11 decreased Y397-FAK autophosphorylation, inhibited viability and clonogenicity of colon SW620 and breast BT474 cancer cells and increased detachment and apoptosis in vitro.  Moreover, Y11 significantly decreased tumor growth in the colon cancer cell mouse xenograft model.  Finally, tumors from the Y11-treated mice demonstrated decreased Y397-FAK autophosphorylation and activation of poly (ADP ribose) polymerase and caspase-3.  Thus, targeting the major autophosphorylation site of FAK with Y11 inhibitor is crit. for development of cancer therapeutics and carcinogenesis field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_gOZRHcVifrVg90H21EOLACvtfcHk0lhxoavrKjMFWQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt1yit7g%253D&md5=15da7f6f57dd78e0e69bc64970d4dec1</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1093%2Fcarcin%2Fbgs120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcarcin%252Fbgs120%26sid%3Dliteratum%253Aachs%26aulast%3DGolubovskaya%26aufirst%3DV.%2BM.%26aulast%3DFigel%26aufirst%3DS.%26aulast%3DHo%26aufirst%3DB.%2BT.%26aulast%3DJohnson%26aufirst%3DC.%2BP.%26aulast%3DYemma%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DG.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DNyberg%26aufirst%3DC.%26aulast%3DMagis%26aufirst%3DA.%26aulast%3DOstrov%26aufirst%3DD.%2BA.%26aulast%3DGelman%26aufirst%3DI.%2BH.%26aulast%3DCance%26aufirst%3DW.%2BG.%26atitle%3DA%2520small%2520molecule%2520focal%2520adhesion%2520kinase%2520%2528FAK%2529%2520inhibitor%252C%2520targeting%2520Y397%2520site%253A%25201-%25282-hydroxyethyl%2529-3%252C%25205%252C%25207-triaza-1-azoniatricyclo%2520%255B3.3.1.1%25283%252C7%2529%255Ddecane%253B%2520bromide%2520effectively%2520inhibits%2520FAK%2520autophosphorylation%2520activity%2520and%2520decreases%2520cancer%2520cell%2520viability%252C%2520clonogenicity%2520and%2520tumor%2520growth%2520in%2520vivo%26jtitle%3DCarcinogenesis%26date%3D2012%26volume%3D33%26spage%3D1004%26epage%3D1013%26doi%3D10.1093%2Fcarcin%2Fbgs120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sajeevan, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naman, C. B.</span></span> <span> </span><span class="NLM_article-title">A systematic review of recently reported marine derived natural product kinase inhibitors</span>. <i>Mar. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">493</span>â <span class="NLM_lpage">529</span>, <span class="refDoi">Â DOI: 10.3390/md17090493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.3390%2Fmd17090493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BB3cXms1WgsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&pages=493-529&author=T.+Liauthor=N.+Wangauthor=T.+Zhangauthor=B.+Zhangauthor=T.+P.+Sajeevanauthor=V.+Josephauthor=L.+Armstrongauthor=S.+Heauthor=X.+Yanauthor=C.+B.+Naman&title=A+systematic+review+of+recently+reported+marine+derived+natural+product+kinase+inhibitors&doi=10.3390%2Fmd17090493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">A systematic review of recently reported marine derived natural product kinase inhibitors</span></div><div class="casAuthors">Li, Te; Wang, Ning; Zhang, Ting; Zhang, Bin; Sajeevan, Thavarool P.; Joseph, Valsamma; Armstrong, Lorene; He, Shan; Yan, Xiaojun; Naman, C. Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Marine Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">493</span>CODEN:
                <span class="NLM_cas:coden">MDARE6</span>;
        ISSN:<span class="NLM_cas:issn">1660-3397</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Protein kinases are validated drug targets for a no. of therapeutic areas, as kinase deregulation is known to play an essential role in many disease states.  Many investigated protein kinase inhibitors are natural product small mols. or their derivs.  Many marine-derived natural products from various marine sources, such as bacteria and cyanobacteria, fungi, animals, algae, soft corals, sponges, etc. have been found to have potent kinase inhibitory activity, or desirable pharmacophores for further development.  This review covers the new compds. reported from the beginning of 2014 through the middle of 2019 as having been isolated from marine organisms and having potential therapeutic applications due to kinase inhibitory and assocd. bioactivities.  Moreover, some existing clin. drugs based on marine-derived natural product scaffolds are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG1uYwteAPuLVg90H21EOLACvtfcHk0lhxoavrKjMFWQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXms1WgsLw%253D&md5=d64a23e5d67fed4aef76c546a600c1e4</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.3390%2Fmd17090493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmd17090493%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DSajeevan%26aufirst%3DT.%2BP.%26aulast%3DJoseph%26aufirst%3DV.%26aulast%3DArmstrong%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DYan%26aufirst%3DX.%26aulast%3DNaman%26aufirst%3DC.%2BB.%26atitle%3DA%2520systematic%2520review%2520of%2520recently%2520reported%2520marine%2520derived%2520natural%2520product%2520kinase%2520inhibitors%26jtitle%3DMar.%2520Drugs%26date%3D2019%26volume%3D17%26spage%3D493%26epage%3D529%26doi%3D10.3390%2Fmd17090493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foudah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebrahim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayed, K.</span></span> <span> </span><span class="NLM_article-title">The marine-derived sipholenol A-4-O-3â²,4â²-dichlorobenzoate inhibits breast cancer growth and motility in vitro and in vivo through the suppression of Brk and FAK signaling</span>. <i>Mar. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2282</span>â <span class="NLM_lpage">2304</span>, <span class="refDoi">Â DOI: 10.3390/md12042282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.3390%2Fmd12042282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=24736807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BC2cnktlSgtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=2282-2304&author=M.+Aklauthor=A.+Foudahauthor=H.+Ebrahimauthor=S.+Meyerauthor=K.+Sayed&title=The+marine-derived+sipholenol+A-4-O-3%E2%80%B2%2C4%E2%80%B2-dichlorobenzoate+inhibits+breast+cancer+growth+and+motility+in+vitro+and+in+vivo+through+the+suppression+of+Brk+and+FAK+signaling&doi=10.3390%2Fmd12042282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">The marine-derived sipholenol A-4-O-3',4'-dichlorobenzoate inhibits breast cancer growth and motility in vitro and in vivo through the suppression of Brk and FAK signaling</span></div><div class="casAuthors">Akl Mohamed R; Foudah Ahmed I; Ebrahim Hassan Y; El Sayed Khalid A; Meyer Sharon A</div><div class="citationInfo"><span class="NLM_cas:title">Marine drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2282-304</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sipholenol A is a natural sipholane triterpenoid isolated from the Red Sea sponge, Callyspongia siphonella.  Previous studies showed the antimigratory and antiproliferative activities of the semisynthetic sipholenol A esters against breast cancer cell lines.  This study investigated the effects of sipholenol A-4-O-3',4'-dichlorobenzoate (SPA) on the growth, migration and invasion of diverse human breast cancer cells.  Results showed that SPA inhibited the growth of the human breast cancer cells, MDA-MB-231, MCF-7, BT-474 and T-47D, in a dose-dependent manner.  Immunofluorescent analysis showed that SPA significantly reduced Ki-67-positive cells in MDA-MB-231 cells.  Flow cytometry and Western blot analyses revealed that SPA treatment suppressed MDA-MB-231 cell growth by inducing cell cycle arrest at the G1 phase.  In addition, SPA suppressed breast cancer cell migration, invasion and decreased Brk and FAK activation in a dose-dependent manner.  Molecular docking study suggested a perfect fitting at the FAK's FERM domain, inhibiting the main autophosphorylation site, Y397, which was further confirmed by Western blot analysis.  Most known small molecule FAK inhibitors target the kinase domain, creating several off-target side effects.  The in vivo studies showed that SPA treatment suppressed breast tumor growth and Ki-67, CD31, p-Brk and p-FAK expression in orthotopic breast cancer in nude mice.  In conclusion, SPA inhibited the growth, invasion and migration of breast cancer cells possibly via deactivating Brk and FAK signaling, suggesting good potential for therapeutic use to control invasive breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQC_8YW6oK0rMNIRw0GKUoEfW6udTcc2ebBbD90zKU5CLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnktlSgtQ%253D%253D&md5=cf8be5a98501477bcda403432de12b67</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.3390%2Fmd12042282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmd12042282%26sid%3Dliteratum%253Aachs%26aulast%3DAkl%26aufirst%3DM.%26aulast%3DFoudah%26aufirst%3DA.%26aulast%3DEbrahim%26aufirst%3DH.%26aulast%3DMeyer%26aufirst%3DS.%26aulast%3DSayed%26aufirst%3DK.%26atitle%3DThe%2520marine-derived%2520sipholenol%2520A-4-O-3%25E2%2580%25B2%252C4%25E2%2580%25B2-dichlorobenzoate%2520inhibits%2520breast%2520cancer%2520growth%2520and%2520motility%2520in%2520vitro%2520and%2520in%2520vivo%2520through%2520the%2520suppression%2520of%2520Brk%2520and%2520FAK%2520signaling%26jtitle%3DMar.%2520Drugs%26date%3D2014%26volume%3D12%26spage%3D2282%26epage%3D2304%26doi%3D10.3390%2Fmd12042282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thiyagarajan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chia, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, C. F.</span></span> <span> </span><span class="NLM_article-title">A novel inhibitor, 16-hydroxy-cleroda-3,13-dien-16,15-olide, blocks the autophosphorylation site of focal adhesion kinase (Y397) by molecular docking</span>. <i>Biochim. Biophys. Acta, Gen. Subj.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1830</i></span>,  <span class="NLM_fpage">4091</span>â <span class="NLM_lpage">4101</span>, <span class="refDoi">Â DOI: 10.1016/j.bbagen.2013.04.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bbagen.2013.04.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVyrsbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1830&publication_year=2013&pages=4091-4101&author=V.+Thiyagarajanauthor=S.+H.+Linauthor=Y.+C.+Chiaauthor=C.+F.+Weng&title=A+novel+inhibitor%2C+16-hydroxy-cleroda-3%2C13-dien-16%2C15-olide%2C+blocks+the+autophosphorylation+site+of+focal+adhesion+kinase+%28Y397%29+by+molecular+docking&doi=10.1016%2Fj.bbagen.2013.04.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">A novel inhibitor, 16-hydroxy-cleroda-3,13-dien-16,15-olide, blocks the autophosphorylation site of focal adhesion kinase (Y397) by molecular docking</span></div><div class="casAuthors">Thiyagarajan, Varadharajan; Lin, Shih-Hung; Chia, Yi-Chen; Weng, Ching-Feng</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1830</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4091-4101</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) is a nonreceptor protein tyrosine plays an important role in a no. of cell signaling pathways, including cell migration, proliferation, and cell survival.  This study was aimed to identify novel and specific inhibitors from natural compds. via mol. docking of FAK (Y397).  The 3D structure of FAK (PDB ID: 2AL6) was used for docking 109 natural compds.  Based on high affinity and energy interaction, four of ten candidate compds., 16-hydroxy-cleroda-3,13-dien-16,15-olide (HCD), curcumin, quercetin, and catechin hydrate, were hit, and the inhibitory activity against FAK was validated in these compds. in C6 glioma and N18 neuroblastoma cell lines.  HCD showed a potential effect on cell viability by MTT assay and cell arrest in the G0-G1 phase, and a TUNEL assay confirmed further apoptosis.  Treatment with HCD decreased anti-apoptotic proteins and increased pro-apoptotic proteins.  Atomic force microscopy data depicted that the formation of filopodia on the intracellular surface decreased in treated cells compared with the control.  Zymog. showed that HCD inhibited the activity of MMP-2 and MMP-9.  The protein levels of FAK, pFAK, Rac1 and Cdc42, which are the key regulators for the formation of filopodia, were decreased.  Addnl., HCD regulated the expression of epithelial mesenchymal transition proteins.  HCD effectively interacted at the autophosphorylation site of FAK and interaction anal. indicated an H-bond with the Arg 86 and Arg 125 residues.  This study suggests that HCD could be a potential inhibitor of FAK and could be used for anti-tumorigenesis and anti-metastasis treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUUc9o-MA5QbVg90H21EOLACvtfcHk0lhwy9Q3AyqJPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVyrsbk%253D&md5=def84c65d830883c623813b63dd0c599</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2013.04.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2013.04.027%26sid%3Dliteratum%253Aachs%26aulast%3DThiyagarajan%26aufirst%3DV.%26aulast%3DLin%26aufirst%3DS.%2BH.%26aulast%3DChia%26aufirst%3DY.%2BC.%26aulast%3DWeng%26aufirst%3DC.%2BF.%26atitle%3DA%2520novel%2520inhibitor%252C%252016-hydroxy-cleroda-3%252C13-dien-16%252C15-olide%252C%2520blocks%2520the%2520autophosphorylation%2520site%2520of%2520focal%2520adhesion%2520kinase%2520%2528Y397%2529%2520by%2520molecular%2520docking%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2013%26volume%3D1830%26spage%3D4091%26epage%3D4101%26doi%3D10.1016%2Fj.bbagen.2013.04.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Golubovskaya, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palma, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baotran, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cance, W. G.</span></span> <span> </span><span class="NLM_article-title">A small-molecule Inhibitor, 5 â-O-tritylthymidine, targets FAK and Mdm-2 interaction, and blocks breast and colon tumorigenesis in vivo</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">532</span>â <span class="NLM_lpage">545</span>, <span class="refDoi">Â DOI: 10.2174/1871520611313040002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.2174%2F1871520611313040002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=22292771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSmsrvM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=532-545&author=V.+M.+Golubovskayaauthor=N.+L.+Palmaauthor=M.+Zhengauthor=H.+Baotranauthor=A.+Magisauthor=D.+Ostrovauthor=W.+G.+Cance&title=A+small-molecule+Inhibitor%2C+5+%E2%80%98-O-tritylthymidine%2C+targets+FAK+and+Mdm-2+interaction%2C+and+blocks+breast+and+colon+tumorigenesis+in+vivo&doi=10.2174%2F1871520611313040002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule inhibitor, 5'-O-Tritylthymidine, targets FAK and Mdm-2 interaction, and blocks breast and colon tumorigenesis in vivo</span></div><div class="casAuthors">Golubovskaya, Vita M.; Palma, Nadia L.; Zheng, Min; Ho, Baotran; Magis, Andrew; Ostrov, David; Cance, William G.</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">532-545</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Focal Adhesion Kinase (FAK) is overexpressed in many types of tumors and plays an important role in survival.  We developed a novel approach, targeting FAK-protein interactions by computer modeling and screening of NCI small mol. drug database.  In this report we targeted FAK and Mdm-2 protein interaction to decrease tumor growth.  By macromol. modeling we found a model of FAK and Mdm-2 interaction and performed screening of >200,000 small mol. compds. from NCI database with drug-like characteristics, targeting the FAK-Mdm-2 interaction.  We identified 5'-O-Tritylthymidine, called M13 compd. that significantly decreased viability in different cancer cells.  M13 was docked into the pocket of FAK and Mdm-2 interaction and was directly bound to the FAK-N terminal domain by ForteBio Octet assay.  In addn., M13 compd. affected FAK and Mdm-2 levels and decreased complex of FAK and Mdm-2 proteins in breast and colon cancer cells.  M13 re-activated p53 activity inhibited by FAK with Mdm-2 promoter.  M13 decreased viability, clonogenicity, increased detachment and apoptosis in a dose-dependent manner in BT474 breast and in HCT116 colon cancer cells in vitro.  M13 decreased FAK, activated p53 and caspase-8 in both cell lines.  In addn., M13 decreased breast and colon tumor growth in vivo.  M13 activated p53 and decreased FAK in tumor samples consistent with decreased tumor growth.  The data demonstrate a novel approach for targeting FAK and Mdm-2 protein interaction, provide a model of FAK and Mdm-2 interaction, identify M13 compd. targeting this interaction and decreasing tumor growth that is crit. for future targeted therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn7cfbykfJ87Vg90H21EOLACvtfcHk0lhwy9Q3AyqJPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSmsrvM&md5=414fc75bd609f73cb768fdfe183ed273</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.2174%2F1871520611313040002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520611313040002%26sid%3Dliteratum%253Aachs%26aulast%3DGolubovskaya%26aufirst%3DV.%2BM.%26aulast%3DPalma%26aufirst%3DN.%2BL.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DBaotran%26aufirst%3DH.%26aulast%3DMagis%26aufirst%3DA.%26aulast%3DOstrov%26aufirst%3DD.%26aulast%3DCance%26aufirst%3DW.%2BG.%26atitle%3DA%2520small-molecule%2520Inhibitor%252C%25205%2520%25E2%2580%2598-O-tritylthymidine%252C%2520targets%2520FAK%2520and%2520Mdm-2%2520interaction%252C%2520and%2520blocks%2520breast%2520and%2520colon%2520tumorigenesis%2520in%2520vivo%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D532%26epage%3D545%26doi%3D10.2174%2F1871520611313040002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Golubovskaya, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cance, W. G.</span></span> <span> </span><span class="NLM_article-title">Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">342</span>â <span class="NLM_lpage">355</span>, <span class="refDoi">Â DOI: 10.1186/1471-2407-13-342</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1186%2F1471-2407-13-342" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=23841915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1WjsLzM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=342-355&author=V.+M.+Golubovskayaauthor=B.+Hoauthor=M.+Zhengauthor=A.+Magisauthor=D.+Ostrovauthor=C.+Morrisonauthor=W.+G.+Cance&title=Disruption+of+focal+adhesion+kinase+and+p53+interaction+with+small+molecule+compound+R2+reactivated+p53+and+blocked+tumor+growth&doi=10.1186%2F1471-2407-13-342"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Disruption of Focal Adhesion Kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth</span></div><div class="casAuthors">Golubovskaya, Vita M.; Ho, Baotran; Zheng, Min; Magis, Andrew; Ostrov, David; Morrison, Carl; Cance, William G.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">342</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Focal Adhesion Kinase (FAK) is a 125 kDa non-receptor kinase that plays a major role in cancer cell survival and metastasis.  Methods: We performed computer modeling of the p53 peptide contg. the site of interaction with FAK, predicted the peptide structure and docked it into the three-dimensional structure of the N-terminal domain of FAK involved in the complex with p53.  We screened small mol. compds. that targeted the site of the FAK-p53 interaction and identified compds. (called Roslins, or R compds.) docked in silico to this site.  Results: By different assays in isogenic HCT116 p53+/+ and HCT116 p53-/- cells we identified a small mol. compd. called Roslin 2 (R2) that bound FAK, disrupted the binding of FAK and p53 and decreased cancer cell viability and clonogenicity in a p53-dependent manner.  In addn., dual-luciferase assays demonstrated that the R2 compd. increased p53 transcriptional activity that was inhibited by FAK using p21, Mdm-2, and Bax-promoter targets.  R2 also caused increased expression of p53 targets: p21, Mdm-2 and Bax proteins.  Furthermore, R2 significantly decreased tumor growth, disrupted the complex of FAK and p53, and up-regulated p21 in HCT116 p53+/+ but not in HCT116 p53-/- xenografts in vivo.  In addn., R2 sensitized HCT116 p53+/+ cells to doxorubicin and 5-fluorouracil.  Conclusions: Thus, disruption of the FAK and p53 interaction with a novel small mol. reactivated p53 in cancer cells in vitro and in vivo and can be effectively used for development of FAK-p53 targeted cancer therapy approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiQffBjvnrgrVg90H21EOLACvtfcHk0lhwy9Q3AyqJPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1WjsLzM&md5=e5326d7d8a0be1008b118841d8105227</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-13-342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-13-342%26sid%3Dliteratum%253Aachs%26aulast%3DGolubovskaya%26aufirst%3DV.%2BM.%26aulast%3DHo%26aufirst%3DB.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DMagis%26aufirst%3DA.%26aulast%3DOstrov%26aufirst%3DD.%26aulast%3DMorrison%26aufirst%3DC.%26aulast%3DCance%26aufirst%3DW.%2BG.%26atitle%3DDisruption%2520of%2520focal%2520adhesion%2520kinase%2520and%2520p53%2520interaction%2520with%2520small%2520molecule%2520compound%2520R2%2520reactivated%2520p53%2520and%2520blocked%2520tumor%2520growth%26jtitle%3DBMC%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D342%26epage%3D355%26doi%3D10.1186%2F1471-2407-13-342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pollak, M.</span></span> <span> </span><span class="NLM_article-title">Insulin and insulin-like growth factor signalling in neoplasia</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">915</span>â <span class="NLM_lpage">928</span>, <span class="refDoi">Â DOI: 10.1038/nrc2536</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fnrc2536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=19029956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7rL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=915-928&author=M.+Pollak&title=Insulin+and+insulin-like+growth+factor+signalling+in+neoplasia&doi=10.1038%2Fnrc2536"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin and insulin-like growth factor signalling in neoplasia</span></div><div class="casAuthors">Pollak, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">915-928</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Insulin and insulin-like growth factors (IGFs) are well known as key regulators of energy metab. and growth.  There is now considerable evidence that these hormones and the signal transduction networks they regulate have important roles in neoplasia.  Epidermiol., clin. and lab. research methods are being used to investigate novel cancer prevention and treatment strategies related to insulin and IGF signaling.  Pharmacol. strategies under study include the use of novel receptor-specific antibodies, receptor kinase inhibitors and AMP-activated protein kinase activators such as metformin.  There is evidence that insulin and IGF signaling may also be relevant to dietary and lifestyle factors that influence cancer risk and cancer prognosis.  Recent results are encouraging and have justified the expansion of many translational research programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4Q6Nlh1d68rVg90H21EOLACvtfcHk0lg3iui1fDpB5A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7rL&md5=9a7b5e7c67599c7396033f83276f2cb0</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1038%2Fnrc2536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2536%26sid%3Dliteratum%253Aachs%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DInsulin%2520and%2520insulin-like%2520growth%2520factor%2520signalling%2520in%2520neoplasia%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2008%26volume%3D8%26spage%3D915%26epage%3D928%26doi%3D10.1038%2Fnrc2536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golubovskaya, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurenova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massoll, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cance, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochwald, S. N.</span></span> <span> </span><span class="NLM_article-title">A novel strategy to inhibit FAK and IGF-1R decreases growth of pancreatic cancer xenografts</span>. <i>Mol. Carcinog.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">200</span>â <span class="NLM_lpage">209</span>, <span class="refDoi">Â DOI: 10.1002/mc.20590</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1002%2Fmc.20590" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=200-209&author=D.+Zhengauthor=V.+Golubovskayaauthor=E.+Kurenovaauthor=C.+Woodauthor=N.+A.+Massollauthor=D.+Ostrovauthor=W.+G.+Canceauthor=S.+N.+Hochwald&title=A+novel+strategy+to+inhibit+FAK+and+IGF-1R+decreases+growth+of+pancreatic+cancer+xenografts&doi=10.1002%2Fmc.20590"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1002%2Fmc.20590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmc.20590%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DD.%26aulast%3DGolubovskaya%26aufirst%3DV.%26aulast%3DKurenova%26aufirst%3DE.%26aulast%3DWood%26aufirst%3DC.%26aulast%3DMassoll%26aufirst%3DN.%2BA.%26aulast%3DOstrov%26aufirst%3DD.%26aulast%3DCance%26aufirst%3DW.%2BG.%26aulast%3DHochwald%26aufirst%3DS.%2BN.%26atitle%3DA%2520novel%2520strategy%2520to%2520inhibit%2520FAK%2520and%2520IGF-1R%2520decreases%2520growth%2520of%2520pancreatic%2520cancer%2520xenografts%26jtitle%3DMol.%2520Carcinog.%26date%3D2009%26volume%3D49%26spage%3D200%26epage%3D209%26doi%3D10.1002%2Fmc.20590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ucar, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magis, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebti, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurenova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zajac-Kaye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochwald, S. N.</span></span> <span> </span><span class="NLM_article-title">Inhibiting the interaction of cMET and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells in vitro and in vivo</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">595</span>â <span class="NLM_lpage">602</span>, <span class="refDoi">Â DOI: 10.2174/1871520611313040009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.2174%2F1871520611313040009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=23272972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSmsrjN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=595-602&author=D.+A.+Ucarauthor=A.+T.+Magisauthor=D.+H.+Heauthor=N.+J.+Lawrenceauthor=S.+M.+Sebtiauthor=E.+Kurenovaauthor=M.+Zajac-Kayeauthor=J.+Zhangauthor=S.+N.+Hochwald&title=Inhibiting+the+interaction+of+cMET+and+IGF-1R+with+FAK+effectively+reduces+growth+of+pancreatic+cancer+cells+in+vitro+and+in+vivo&doi=10.2174%2F1871520611313040009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting the interaction of cMET and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells in vitro and in vivo</span></div><div class="casAuthors">Ucar, Deniz A.; Magis, Andrew T.; He, Di-Hua; Lawrence, Nicholas J.; Sebti, Said M.; Kurenova, Elena; Zajac-Kaye, Maria; Zhang, Jianliang; Hochwald, Steven N.</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">595-602</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Pancreatic cancer is one of the most lethal diseases with no effective treatment.  Previously, we have shown that FAK is overexpressed in pancreatic cancer and plays a key role in cancer cell survival and proliferation.  FAK has been shown to interact with growth factor receptors including cMET and IGF-1R.  As a novel therapeutic approach, we targeted the protein interaction of FAK with growth factor receptors to block tumor growth, alter signaling pathways and sensitize cells to chemotherapy.  We have selected a small mol. compd. (INT2-31) that decreases phosphorylation of AKT via disrupting interaction of FAK with cMET and IGF-1R.  Our results demonstrate that interaction of a small mol. compd. with FAK decreases phosphorylation of FAK Y397 while increasing FAK Y407 phosphorylation, without inhibiting the kinase activity of FAK and dramatically reduces downstream signaling to AKT.  Our lead compd., INT2-31, demonstrates significant inhibition of tumor cell growth in two orthotopic models of pancreatic cancer.  In addn., INT2-31increases sensitivity to gemcitabine chemotherapy in a direct fresh biopsy xenograft model of pancreatic cancer growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhgvXiu8WtibVg90H21EOLACvtfcHk0lg3iui1fDpB5A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSmsrjN&md5=8c8608ccff031eaa449b458326248ac3</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.2174%2F1871520611313040009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520611313040009%26sid%3Dliteratum%253Aachs%26aulast%3DUcar%26aufirst%3DD.%2BA.%26aulast%3DMagis%26aufirst%3DA.%2BT.%26aulast%3DHe%26aufirst%3DD.%2BH.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26aulast%3DKurenova%26aufirst%3DE.%26aulast%3DZajac-Kaye%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHochwald%26aufirst%3DS.%2BN.%26atitle%3DInhibiting%2520the%2520interaction%2520of%2520cMET%2520and%2520IGF-1R%2520with%2520FAK%2520effectively%2520reduces%2520growth%2520of%2520pancreatic%2520cancer%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D595%26epage%3D602%26doi%3D10.2174%2F1871520611313040009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garces, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurenova, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golubovskaya, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cance, W. G.</span></span> <span> </span><span class="NLM_article-title">Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1446</span>â <span class="NLM_lpage">1454</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-05-1661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1158%2F0008-5472.CAN-05-1661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=16452200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVehug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=1446-1454&author=C.+A.+Garcesauthor=E.+V.+Kurenovaauthor=V.+M.+Golubovskayaauthor=W.+G.+Cance&title=Vascular+endothelial+growth+factor+receptor-3+and+focal+adhesion+kinase+bind+and+suppress+apoptosis+in+breast+cancer+cells&doi=10.1158%2F0008-5472.CAN-05-1661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular Endothelial Growth Factor Receptor-3 and Focal Adhesion Kinase Bind and Suppress Apoptosis in Breast Cancer Cells</span></div><div class="casAuthors">Garces, Christopher A.; Kurenova, Elena V.; Golubovskaya, Vita M.; Cance, William G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1446-1454</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) and vascular endothelial growth factor receptor-3 (VEGFR-3) are protein tyrosine kinases that are overexpressed in human cancer and play an important role in survival signaling.  In addn. to its involvement with cell survival, VEGFR-3 is a primary factor in lymphatic angiogenesis.  Because FAK function is regulated by its COOH terminus (FAK-CD), we used FAK-CD as a target to identify binding partners.  We isolated a peptide from a phage library that bound to FAK-CD, specifically the focal adhesion targeting domain of FAK and was homologous to VEGFR-3, suggesting these two tyrosine kinases phys. interact.  We have also shown that VEGFR-3 is overexpressed in human breast tumors and cancer cell lines.  For the first time, we have shown the phys. assocn. of FAK and VEGFR-3.  The assocn. between the NH2 terminus of VEGFR-3, contg. the peptide identified by phage display, and the COOH terminus of FAK was detected by in vitro and in vivo binding studies.  We then coupled a 12-amino-acid VEGFR-3 peptide, AV3, to a TAT cellular penetration sequence and showed that AV3 and not control-scrambled peptide caused specific displacement of FAK from the focal adhesions and affected colocalization of FAK and VEGFR-3.  In addn., AV3 peptide decreased proliferation and caused cell detachment and apoptosis in breast cancer cell lines but not in normal breast cells.  Thus, the FAK/VEGFR-3 interaction may have a potential use to develop novel mol. therapeutics to target the signaling between FAK and VEGFR-3 in human tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod9mUYmoenhrVg90H21EOLACvtfcHk0lg3iui1fDpB5A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVehug%253D%253D&md5=889ef9ed6935fe6ebe4b1ec6933369b6</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-1661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-1661%26sid%3Dliteratum%253Aachs%26aulast%3DGarces%26aufirst%3DC.%2BA.%26aulast%3DKurenova%26aufirst%3DE.%2BV.%26aulast%3DGolubovskaya%26aufirst%3DV.%2BM.%26aulast%3DCance%26aufirst%3DW.%2BG.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520receptor-3%2520and%2520focal%2520adhesion%2520kinase%2520bind%2520and%2520suppress%2520apoptosis%2520in%2520breast%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D1446%26epage%3D1454%26doi%3D10.1158%2F0008-5472.CAN-05-1661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurenova, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magis, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrov, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cance, W. G.</span></span> <span> </span><span class="NLM_article-title">Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">4716</span>â <span class="NLM_lpage">4724</span>, <span class="refDoi">Â DOI: 10.1021/jm900159g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900159g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1MXoslCnt70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4716-4724&author=E.+V.+Kurenovaauthor=D.+L.+Huntauthor=D.+Heauthor=A.+T.+Magisauthor=D.+A.+Ostrovauthor=W.+G.+Cance&title=Small+molecule+chloropyramine+hydrochloride+%28C4%29+targets+the+binding+site+of+focal+adhesion+kinase+and+vascular+endothelial+growth+factor+receptor+3+and+suppresses+breast+cancer+growth+in+vivo&doi=10.1021%2Fjm900159g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Chloropyramine Hydrochloride (C4) Targets the Binding Site of Focal Adhesion Kinase and Vascular Endothelial Growth Factor Receptor 3 and Suppresses Breast Cancer Growth in Vivo</span></div><div class="casAuthors">Kurenova, Elena V.; Hunt, Darell L.; He, Dihua; Magis, Andrew T.; Ostrov, David A.; Cance, William G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4716-4724</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">FAK is a tyrosine kinase that functions as a key orchestrator of signals leading to invasion and metastasis.  Since FAK interacts directly with a no. of crit. proteins involved in survival signaling in tumor cells, we hypothesized that targeting a key protein-protein interface with druglike small mols. was a feasible strategy for inhibiting tumor growth.  In this study, we targeted the protein-protein interface between FAK and VEGFR-3 and identified compd. C4 (chloropyramine hydrochloride) as a drug capable of (1) inhibiting the biochem. function of VEGFR-3 and FAK, (2) inhibiting proliferation of a diverse set of cancer cell types in vitro, and (3) reducing tumor growth in vivo.  Chloropyramine hydrochloride reduced tumor growth as a single agent, while concomitant administration with doxorubicin had a pronounced synergistic effect.  Our data demonstrate that the FAK-VEGFR-3 interaction can be targeted by small druglike mols. and this interaction can provide the basis for highly specific novel cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWNwqHRfkXabVg90H21EOLACvtfcHk0ljKO-XpwkP9sA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXoslCnt70%253D&md5=a9ea7e44d7de5a6d94d29f3b6b2f2a71</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1021%2Fjm900159g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900159g%26sid%3Dliteratum%253Aachs%26aulast%3DKurenova%26aufirst%3DE.%2BV.%26aulast%3DHunt%26aufirst%3DD.%2BL.%26aulast%3DHe%26aufirst%3DD.%26aulast%3DMagis%26aufirst%3DA.%2BT.%26aulast%3DOstrov%26aufirst%3DD.%2BA.%26aulast%3DCance%26aufirst%3DW.%2BG.%26atitle%3DSmall%2520molecule%2520chloropyramine%2520hydrochloride%2520%2528C4%2529%2520targets%2520the%2520binding%2520site%2520of%2520focal%2520adhesion%2520kinase%2520and%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%25203%2520and%2520suppresses%2520breast%2520cancer%2520growth%2520in%2520vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4716%26epage%3D4724%26doi%3D10.1021%2Fjm900159g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gogate, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurenova, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magis, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cance, W. G.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">154</span>â <span class="NLM_lpage">166</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2014.04.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.ejmech.2014.04.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=24780592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovValtLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2014&pages=154-166&author=P.+N.+Gogateauthor=M.+Ethirajanauthor=E.+V.+Kurenovaauthor=A.+T.+Magisauthor=R.+K.+Pandeyauthor=W.+G.+Cance&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+FAK+scaffold+inhibitors+targeting+the+FAK-VEGFR3+protein-protein+interaction&doi=10.1016%2Fj.ejmech.2014.04.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction</span></div><div class="casAuthors">Gogate, Priyanka N.; Ethirajan, Manivannan; Kurenova, Elena V.; Magis, Andrew T.; Pandey, Ravindra K.; Cance, William G.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">154-166</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) and vascular endothelial growth factor receptor 3 (VEGFR3) are tyrosine kinases, which function as key modulators of survival and metastasis signals in cancer cells.  Previously, we reported that small mol. chlorpyramine hydrochloride (C4) specifically targets the interaction between FAK and VEGFR3 and exhibits anti-tumor efficacy.  In this study, we designed and synthesized a series of 1 (C4) analogs on the basis of structure activity relationship and mol. modeling.  The resulting new compds. were evaluated for their binding to the FAT domain of FAK and anti-cancer activity.  Amongst all tested analogs, compd. 29 augmented anti-proliferative activity in multiple cancer cell lines with stronger binding to the FAT domain of FAK and disrupted the FAK-VEGFR3 interaction.  In conclusion, we hope that this work will contribute to further studies of more potent and selective FAK-VEGFR3 protein-protein interaction inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl_XFYonxwS7Vg90H21EOLACvtfcHk0ljKO-XpwkP9sA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovValtLw%253D&md5=d80c176ed988cdea856ce4202352fcf3</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.04.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.04.041%26sid%3Dliteratum%253Aachs%26aulast%3DGogate%26aufirst%3DP.%2BN.%26aulast%3DEthirajan%26aufirst%3DM.%26aulast%3DKurenova%26aufirst%3DE.%2BV.%26aulast%3DMagis%26aufirst%3DA.%2BT.%26aulast%3DPandey%26aufirst%3DR.%2BK.%26aulast%3DCance%26aufirst%3DW.%2BG.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520FAK%2520scaffold%2520inhibitors%2520targeting%2520the%2520FAK-VEGFR3%2520protein-protein%2520interaction%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D80%26spage%3D154%26epage%3D166%26doi%3D10.1016%2Fj.ejmech.2014.04.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Churcher, I.</span></span> <span> </span><span class="NLM_article-title">Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">444</span>â <span class="NLM_lpage">452</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b01272</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01272" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWqtbvJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=444-452&author=I.+Churcher&title=Protac-induced+protein+degradation+in+drug+discovery%3A+breaking+the+rules+or+just+making+new+ones%3F&doi=10.1021%2Facs.jmedchem.7b01272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?</span></div><div class="casAuthors">Churcher, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">444-452</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Targeted protein degrdn., using bifunctional small mols. (Protacs) to remove specific proteins from within cells, has emerged as a novel drug discovery strategy with the potential to offer therapeutic interventions not achievable with existing approaches.  In this perspective, the brief history of the field is surveyed from a drug discovery perspective with a focus on the key advances in knowledge which have led to the definition and exemplification of protein degrdn. concepts, and their resulting applications to medicine discovery.  The approach has the potential to bring disruptive change to drug discovery - the many potential advantages and outstanding challenges which lie ahead of this technol. are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9n8I_0MhtkbVg90H21EOLACvtfcHk0ljKO-XpwkP9sA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWqtbvJ&md5=e60f1777de8bd860c5001137d8583f1f</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01272%26sid%3Dliteratum%253Aachs%26aulast%3DChurcher%26aufirst%3DI.%26atitle%3DProtac-induced%2520protein%2520degradation%2520in%2520drug%2520discovery%253A%2520breaking%2520the%2520rules%2520or%2520just%2520making%2520new%2520ones%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D444%26epage%3D452%26doi%3D10.1021%2Facs.jmedchem.7b01272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bondeson, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mares, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, I. E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miah, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulholland, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Routly, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinn, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergamini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faelth-Savitski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willard, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casillas, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Votta, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">den Besten, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Famm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruidenier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harling, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churcher, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Catalytic in vivo protein knockdown by small-molecule PROTACs</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">611</span>â <span class="NLM_lpage">617</span>, <span class="refDoi">Â DOI: 10.1038/nchembio.1858</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fnchembio.1858" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=26075522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7rP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=611-617&author=D.+P.+Bondesonauthor=A.+Maresauthor=I.+E.+D.+Smithauthor=E.+Koauthor=S.+Camposauthor=A.+H.+Miahauthor=K.+E.+Mulhollandauthor=N.+Routlyauthor=D.+L.+Buckleyauthor=J.+L.+Gustafsonauthor=N.+Zinnauthor=P.+Grandiauthor=S.+Shimamuraauthor=G.+Bergaminiauthor=M.+Faelth-Savitskiauthor=M.+Bantscheffauthor=C.+Coxauthor=D.+A.+Gordonauthor=R.+R.+Willardauthor=J.+J.+Flanaganauthor=L.+N.+Casillasauthor=B.+J.+Vottaauthor=W.+den+Bestenauthor=K.+Fammauthor=L.+Kruidenierauthor=P.+S.+Carterauthor=J.+D.+Harlingauthor=I.+Churcherauthor=C.+M.+Crews&title=Catalytic+in+vivo+protein+knockdown+by+small-molecule+PROTACs&doi=10.1038%2Fnchembio.1858"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic in vivo protein knockdown by small-molecule PROTACs</span></div><div class="casAuthors">Bondeson, Daniel P.; Mares, Alina; Smith, Ian E. D.; Ko, Eunhwa; Campos, Sebastien; Miah, Afjal H.; Mulholland, Katie E.; Routly, Natasha; Buckley, Dennis L.; Gustafson, Jeffrey L.; Zinn, Nico; Grandi, Paola; Shimamura, Satoko; Bergamini, Giovanna; Faelth-Savitski, Maria; Bantscheff, Marcus; Cox, Carly; Gordon, Deborah A.; Willard, Ryan R.; Flanagan, John J.; Casillas, Linda N.; Votta, Bartholomew J.; den Besten, Willem; Famm, Kristoffer; Kruidenier, Laurens; Carter, Paul S.; Harling, John D.; Churcher, Ian; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">611-617</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The current predominant therapeutic paradigm is based on maximizing drug-receptor occupancy to achieve clin. benefit.  This strategy, however, generally requires excessive drug concns. to ensure sufficient occupancy, often leading to adverse side effects.  Here, we describe major improvements to the proteolysis targeting chimeras (PROTACs) method, a chem. knockdown strategy in which a heterobifunctional mol. recruits a specific protein target to an E3 ubiquitin ligase, resulting in the target's ubiquitination and degrdn.  These compds. behave catalytically in their ability to induce the ubiquitination of super-stoichiometric quantities of proteins, providing efficacy that is not limited by equil. occupancy.  We present two PROTACs that are capable of specifically reducing protein levels by >90% at nanomolar concns.  In addn., mouse studies indicate that they provide broad tissue distribution and knockdown of the targeted protein in tumor xenografts.  Together, these data demonstrate a protein knockdown system combining many of the favorable properties of small-mol. agents with the potent protein knockdown of RNAi and CRISPR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonhnajD3CxS7Vg90H21EOLACvtfcHk0ljr2QK6n1JnEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7rP&md5=31eb8756c5661f78ab4527a50dc1e251</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1858%26sid%3Dliteratum%253Aachs%26aulast%3DBondeson%26aufirst%3DD.%2BP.%26aulast%3DMares%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DI.%2BE.%2BD.%26aulast%3DKo%26aufirst%3DE.%26aulast%3DCampos%26aufirst%3DS.%26aulast%3DMiah%26aufirst%3DA.%2BH.%26aulast%3DMulholland%26aufirst%3DK.%2BE.%26aulast%3DRoutly%26aufirst%3DN.%26aulast%3DBuckley%26aufirst%3DD.%2BL.%26aulast%3DGustafson%26aufirst%3DJ.%2BL.%26aulast%3DZinn%26aufirst%3DN.%26aulast%3DGrandi%26aufirst%3DP.%26aulast%3DShimamura%26aufirst%3DS.%26aulast%3DBergamini%26aufirst%3DG.%26aulast%3DFaelth-Savitski%26aufirst%3DM.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DCox%26aufirst%3DC.%26aulast%3DGordon%26aufirst%3DD.%2BA.%26aulast%3DWillard%26aufirst%3DR.%2BR.%26aulast%3DFlanagan%26aufirst%3DJ.%2BJ.%26aulast%3DCasillas%26aufirst%3DL.%2BN.%26aulast%3DVotta%26aufirst%3DB.%2BJ.%26aulast%3Dden%2BBesten%26aufirst%3DW.%26aulast%3DFamm%26aufirst%3DK.%26aulast%3DKruidenier%26aufirst%3DL.%26aulast%3DCarter%26aufirst%3DP.%2BS.%26aulast%3DHarling%26aufirst%3DJ.%2BD.%26aulast%3DChurcher%26aufirst%3DI.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DCatalytic%2520in%2520vivo%2520protein%2520knockdown%2520by%2520small-molecule%2520PROTACs%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D11%26spage%3D611%26epage%3D617%26doi%3D10.1038%2Fnchembio.1858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clague, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heride, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbe, S.</span></span> <span> </span><span class="NLM_article-title">The demographics of the ubiquitin system</span>. <i>Trends Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">417</span>â <span class="NLM_lpage">426</span>, <span class="refDoi">Â DOI: 10.1016/j.tcb.2015.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.tcb.2015.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=25906909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVGqtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=417-426&author=M.+J.+Clagueauthor=C.+Herideauthor=S.+Urbe&title=The+demographics+of+the+ubiquitin+system&doi=10.1016%2Fj.tcb.2015.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">The demographics of the ubiquitin system</span></div><div class="casAuthors">Clague, Michael J.; Heride, Claire; Urbe, Sylvie</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">417-426</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The ubiquitin system is a major coordinator of cellular physiol. through regulation of both protein degrdn. and signalling pathways.  A key building block of a systems-level understanding has been generated by global proteomic studies, which provide copy no. ests. for each component.  The aggregate of ubiquitin, conjugating enzymes (E1, E2, and E3s), and deubiquitylases (DUBs) represents â¼1.3% of total cellular protein.  Complementary approaches have generated quant. measurements of various ubiquitin pools and further subdivision into different ubiquitin chain topologies.  Systematic studies aimed at assocg. specific enzymes (E2s and DUBs) with the dynamics of these different pools have also made significant progress.  Here, we delineate the emerging picture of the most significant determinants of the cellular ubiquitin economy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZQMwzCvXv5bVg90H21EOLACvtfcHk0ljr2QK6n1JnEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVGqtbw%253D&md5=38563c26b5d83eab2bb0dc193041d1e5</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2015.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2015.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DClague%26aufirst%3DM.%2BJ.%26aulast%3DHeride%26aufirst%3DC.%26aulast%3DUrbe%26aufirst%3DS.%26atitle%3DThe%2520demographics%2520of%2520the%2520ubiquitin%2520system%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2015%26volume%3D25%26spage%3D417%26epage%3D426%26doi%3D10.1016%2Fj.tcb.2015.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burslem, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McQuaid, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondeson, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crew, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">The advantages of targeted protein degradation over inhibition: an RTK case study</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">67</span>â <span class="NLM_lpage">77</span>, <span class="refDoi">Â DOI: 10.1016/j.chembiol.2017.09.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.chembiol.2017.09.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=29129716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2lsrjM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=67-77&author=G.+M.+Burslemauthor=B.+E.+Smithauthor=A.+C.+Laiauthor=S.+Jaime-Figueroaauthor=D.+C.+McQuaidauthor=D.+P.+Bondesonauthor=M.+Toureauthor=H.+Dongauthor=Y.+Qianauthor=J.+Wangauthor=A.+P.+Crewauthor=J.+Hinesauthor=C.+M.+Crews&title=The+advantages+of+targeted+protein+degradation+over+inhibition%3A+an+RTK+case+study&doi=10.1016%2Fj.chembiol.2017.09.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study</span></div><div class="casAuthors">Burslem, George M.; Smith, Blake E.; Lai, Ashton C.; Jaime-Figueroa, Saul; McQuaid, Daniel C.; Bondeson, Daniel P.; Toure, Momar; Dong, Hanqing; Qian, Yimin; Wang, Jing; Crew, Andrew P.; Hines, John; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-77.e3</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Proteolysis targeting chimera (PROTAC) technol. has emerged over the last two decades as a powerful tool for targeted degrdn. of endogenous proteins.  Herein we describe the development of PROTACs for receptor tyrosine kinases, a protein family yet to be targeted for induced protein degrdn.  The use of VHL-recruiting PROTACs against this protein family reveals several advantages of degrdn. over inhibition alone: direct comparisons of fully functional, target-degrading PROTACs with target-inhibiting variants that contain an inactivated E3 ligase-recruiting ligand show that degrdn. leads to more potent inhibition of cell proliferation and a more durable and sustained downstream signaling response, and thus addresses the kinome rewiring challenge seen with many receptor tyrosine kinase inhibitors.  Combined, these findings demonstrate the ability to target receptor tyrosine kinases for degrdn. using the PROTAC technol. and outline the advantages of this degrdn.-based approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4yDhRDWqNv7Vg90H21EOLACvtfcHk0lhS5AHUyMA_sA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2lsrjM&md5=0ac39a6f5836ea3772a0396356efb630</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DBurslem%26aufirst%3DG.%2BM.%26aulast%3DSmith%26aufirst%3DB.%2BE.%26aulast%3DLai%26aufirst%3DA.%2BC.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DMcQuaid%26aufirst%3DD.%2BC.%26aulast%3DBondeson%26aufirst%3DD.%2BP.%26aulast%3DToure%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DCrew%26aufirst%3DA.%2BP.%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DThe%2520advantages%2520of%2520targeted%2520protein%2520degradation%2520over%2520inhibition%253A%2520an%2520RTK%2520case%2520study%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D67%26epage%3D77%26doi%3D10.1016%2Fj.chembiol.2017.09.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neklesa, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted protein degradation by PROTACs</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">138</span>â <span class="NLM_lpage">144</span>, <span class="refDoi">Â DOI: 10.1016/j.pharmthera.2017.02.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.pharmthera.2017.02.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=28223226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtVemsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2017&pages=138-144&author=T.+K.+Neklesaauthor=J.+D.+Winklerauthor=C.+M.+Crews&title=Targeted+protein+degradation+by+PROTACs&doi=10.1016%2Fj.pharmthera.2017.02.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted protein degradation by PROTACs</span></div><div class="casAuthors">Neklesa, Taavi K.; Winkler, James D.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">138-144</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Targeted protein degrdn. using the PROTAC technol. is emerging as a novel therapeutic method to address diseases driven by the aberrant expression of a disease-causing protein.  PROTAC mols. are bifunctional small mols. that simultaneously bind a target protein and an E3-ubiquitin ligase, thus causing ubiquitination and degrdn. of the target protein by the proteasome.  Like small mols., PROTAC mols. possess good tissue distribution and the ability to target intracellular proteins.  Herein, we highlight the advantages of protein degrdn. using PROTACs, and provide specific examples where degrdn. offers therapeutic benefit over classical enzyme inhibition.  Foremost, PROTACs can degrade proteins regardless of their function.  This includes the currently "undruggable" proteome, which comprises approx. 85% of all human proteins.  Other beneficial aspects of protein degrdn. include the ability to target overexpressed and mutated proteins, as well as the potential to demonstrate prolonged pharmacodynamics effect beyond drug exposure.  Lastly, due to their catalytic nature and the pre-requisite ubiquitination step, an exquisitely potent mols. with a high degree of degrdn. selectivity can be designed.  Impressive preclin. in vitro and in vivo PROTAC data have been published, and these data have propelled the development of clin. viable PROTACs.  With the mol. wt. falling in the 700-1000 Da range, the delivery and bioavailability of PROTACs remain the largest hurdles on the way to the clinic.  Solving these issues and demonstrating proof of concept clin. data will be the focus of many labs over the next few years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4RSLWYqqBMrVg90H21EOLACvtfcHk0lhS5AHUyMA_sA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtVemsbg%253D&md5=08a74402a274a13c8c484cd68167a5a1</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.02.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.02.027%26sid%3Dliteratum%253Aachs%26aulast%3DNeklesa%26aufirst%3DT.%2BK.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520protein%2520degradation%2520by%2520PROTACs%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D174%26spage%3D138%26epage%3D144%26doi%3D10.1016%2Fj.pharmthera.2017.02.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deshaies, R. J.</span></span> <span> </span><span class="NLM_article-title">Multispecific drugs herald a new era of biopharmaceutical innovation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>580</i></span>,  <span class="NLM_fpage">329</span>â <span class="NLM_lpage">338</span>, <span class="refDoi">Â DOI: 10.1038/s41586-020-2168-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fs41586-020-2168-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=32296187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntFOqtLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=580&publication_year=2020&pages=329-338&author=R.+J.+Deshaies&title=Multispecific+drugs+herald+a+new+era+of+biopharmaceutical+innovation&doi=10.1038%2Fs41586-020-2168-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Multispecific drugs herald a new era of biopharmaceutical innovation</span></div><div class="casAuthors">Deshaies, Raymond J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">580</span>
        (<span class="NLM_cas:issue">7803</span>),
    <span class="NLM_cas:pages">329-338</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: The modern biopharmaceutical industry traces its roots to the dawn of the twentieth century, coincident with marketing of aspirin-a signature event in the history of modern drug development.  Although the archetypal discovery process did not change markedly in the first seven decades of the industry, the past fifty years have seen two successive waves of transformative innovation in the development of drug mols.: the rise of 'rational drug discovery' methodol. in the 1970s, followed by the invention of recombinant protein-based therapeutic agents in the 1980s.  An incipient fourth wave is the advent of multispecific drugs.  The successful development of prospectively designed multispecific drugs has the potential to reconfigure our ideas of how target-based therapeutic mols. can work, and what it is possible to achieve with them.  Here I review the two major classes of multispecific drugs: those that enrich a therapeutic agent at a particular site of action and those that link a therapeutic target to a biol. effector.  The latter class-being freed from the constraint of having to directly modulate the target upon binding-may enable access to components of the proteome that currently cannot be targeted by drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2zqgRhbT71LVg90H21EOLACvtfcHk0lhS5AHUyMA_sA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntFOqtLg%253D&md5=9fd080b5177e4de5163d76a385f7dcc1</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-2168-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-2168-1%26sid%3Dliteratum%253Aachs%26aulast%3DDeshaies%26aufirst%3DR.%2BJ.%26atitle%3DMultispecific%2520drugs%2520herald%2520a%2520new%2520era%2520of%2520biopharmaceutical%2520innovation%26jtitle%3DNature%26date%3D2020%26volume%3D580%26spage%3D329%26epage%3D338%26doi%3D10.1038%2Fs41586-020-2168-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span> <span> </span><span class="NLM_article-title">PROTACs: great opportunities for academia and industry</span>. <i>Signal Transduction Targeted Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">64</span>â <span class="NLM_lpage">96</span>, <span class="refDoi">Â DOI: 10.1038/s41392-019-0101-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fs41392-019-0101-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=31885879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BB3MbkvFCrtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=64-96&author=X.+Sunauthor=H.+Gaoauthor=Y.+Yangauthor=M.+Heauthor=Y.+Wuauthor=Y.+Songauthor=Y.+Tongauthor=Y.+Rao&title=PROTACs%3A+great+opportunities+for+academia+and+industry&doi=10.1038%2Fs41392-019-0101-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">PROTACs: great opportunities for academia and industry</span></div><div class="casAuthors">Sun Xiuyun; Gao Hongying; Yang Yiqing; He Ming; Wu Yue; Song Yugang; Tong Yan; Rao Yu; Sun Xiuyun; Gao Hongying; Yang Yiqing; Rao Yu</div><div class="citationInfo"><span class="NLM_cas:title">Signal transduction and targeted therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">64</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although many kinds of therapies are applied in the clinic, drug-resistance is a major and unavoidable problem.  Another disturbing statistic is the limited number of drug targets, which are presently only 20-25% of all protein targets that are currently being studied.  Moreover, the focus of current explorations of targets are their enzymatic functions, which ignores the functions from their scaffold moiety.  As a promising and appealing technology, PROteolysis TArgeting Chimeras (PROTACs) have attracted great attention both from academia and industry for finding available approaches to solve the above problems.  PROTACs regulate protein function by degrading target proteins instead of inhibiting them, providing more sensitivity to drug-resistant targets and a greater chance to affect the nonenzymatic functions.  PROTACs have been proven to show better selectivity compared to classic inhibitors.  PROTACs can be described as a chemical knockdown approach with rapidity and reversibility, which presents new and different biology compared to other gene editing tools by avoiding misinterpretations that arise from potential genetic compensation and/or spontaneous mutations.  PRTOACs have been widely explored throughout the world and have outperformed not only in cancer diseases, but also in immune disorders, viral infections and neurodegenerative diseases.  Although PROTACs present a very promising and powerful approach for crossing the hurdles of present drug discovery and tool development in biology, more efforts are needed to gain to get deeper insight into the efficacy and safety of PROTACs in the clinic.  More target binders and more E3 ligases applicable for developing PROTACs are waiting for exploration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQretvERU2xT-_Q9URG6Dx8fW6udTcc2eZvwKjkiJFJVLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MbkvFCrtA%253D%253D&md5=7d9545a21e3a78cededf2977a31e8f7d</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1038%2Fs41392-019-0101-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41392-019-0101-6%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DTong%26aufirst%3DY.%26aulast%3DRao%26aufirst%3DY.%26atitle%3DPROTACs%253A%2520great%2520opportunities%2520for%2520academia%2520and%2520industry%26jtitle%3DSignal%2520Transduction%2520Targeted%2520Ther.%26date%3D2019%26volume%3D4%26spage%3D64%26epage%3D96%26doi%3D10.1038%2Fs41392-019-0101-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schapira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calabrese, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted protein degradation: expanding the toolbox</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">949</span>â <span class="NLM_lpage">963</span>, <span class="refDoi">Â DOI: 10.1038/s41573-019-0047-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fs41573-019-0047-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=31666732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVKrtLrM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=949-963&author=M.+Schapiraauthor=M.+F.+Calabreseauthor=A.+N.+Bullockauthor=C.+M.+Crews&title=Targeted+protein+degradation%3A+expanding+the+toolbox&doi=10.1038%2Fs41573-019-0047-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted protein degradation: expanding the toolbox</span></div><div class="casAuthors">Schapira, Matthieu; Calabrese, Matthew F.; Bullock, Alex N.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">949-963</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review. Proteolysis-targeting chimeras (PROTACs) and related mols. that induce targeted protein degrdn. by the ubiquitin-proteasome system represent a new therapeutic modality and are the focus of great interest, owing to potential advantages over traditional occupancy-based inhibitors with respect to dosing, side effects, drug resistance and modulating 'undruggable' targets.  However, the technol. is still maturing, and the design elements for successful PROTAC-based drugs are currently being elucidated.  Importantly, fewer than 10 of the more than 600 E3 ubiquitin ligases have so far been exploited for targeted protein degrdn., and expansion of knowledge in this area is a key opportunity.  Here, we briefly discuss lessons learned about targeted protein degrdn. in chem. biol. and drug discovery and systematically review the expression profile, domain architecture and chem. tractability of human E3 ligases that could expand the toolbox for PROTAC discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwUvM27MU3WrVg90H21EOLACvtfcHk0li2wGFM6tp9BQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVKrtLrM&md5=9bfd48c6c47fc1cce15129495fea7079</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1038%2Fs41573-019-0047-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41573-019-0047-y%26sid%3Dliteratum%253Aachs%26aulast%3DSchapira%26aufirst%3DM.%26aulast%3DCalabrese%26aufirst%3DM.%2BF.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520protein%2520degradation%253A%2520expanding%2520the%2520toolbox%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26spage%3D949%26epage%3D963%26doi%3D10.1038%2Fs41573-019-0047-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paiva, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted protein degradation: elements of PROTAC design</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">111</span>â <span class="NLM_lpage">119</span>, <span class="refDoi">Â DOI: 10.1016/j.cbpa.2019.02.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.cbpa.2019.02.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=31004963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1MXns1yrt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2019&pages=111-119&author=S.+L.+Paivaauthor=C.+M.+Crews&title=Targeted+protein+degradation%3A+elements+of+PROTAC+design&doi=10.1016%2Fj.cbpa.2019.02.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted protein degradation: elements of PROTAC design</span></div><div class="casAuthors">Paiva, Stacey-Lynn; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111-119</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Targeted protein degrdn. using Proteolysis Targeting Chimeras (PROTACs) has emerged as a novel therapeutic modality in drug discovery.  PROTACs mediate the degrdn. of select proteins of interest (POIs) by hijacking the activity of E3 ubiquitin ligases for POI ubiquitination and subsequent degrdn. by the 26S proteasome.  This hijacking mechanism has been used to degrade various types of disease-relevant POIs.  In this review, we aim to highlight the recent advances in targeted protein degrdn. and describe the challenges that need to be addressed in order to efficiently develop potent PROTACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol6Nk0VkUdzLVg90H21EOLACvtfcHk0li2wGFM6tp9BQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXns1yrt7s%253D&md5=5783311db47da378180c14d67526a398</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2019.02.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2019.02.022%26sid%3Dliteratum%253Aachs%26aulast%3DPaiva%26aufirst%3DS.%2BL.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520protein%2520degradation%253A%2520elements%2520of%2520PROTAC%2520design%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D50%26spage%3D111%26epage%3D119%26doi%3D10.1016%2Fj.cbpa.2019.02.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bondeson, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burslem, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhimschi, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishchenko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Lessons in PROTAC design from selective degradation with a promiscuous warhead</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">78</span>â <span class="NLM_lpage">87</span>, <span class="refDoi">Â DOI: 10.1016/j.chembiol.2017.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.chembiol.2017.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=29129718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2lsrjN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=78-87&author=D.+P.+Bondesonauthor=B.+E.+Smithauthor=G.+M.+Burslemauthor=A.+D.+Buhimschiauthor=J.+Hinesauthor=S.+Jaime-Figueroaauthor=J.+Wangauthor=B.+D.+Hammanauthor=A.+Ishchenkoauthor=C.+M.+Crews&title=Lessons+in+PROTAC+design+from+selective+degradation+with+a+promiscuous+warhead&doi=10.1016%2Fj.chembiol.2017.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead</span></div><div class="casAuthors">Bondeson, Daniel P.; Smith, Blake E.; Burslem, George M.; Buhimschi, Alexandru D.; Hines, John; Jaime-Figueroa, Saul; Wang, Jing; Hamman, Brian D.; Ishchenko, Alexey; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">78-87.e5</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Inhibiting protein function selectively is a major goal of modern drug discovery.  Here, we report a previously understudied benefit of small mol. proteolysis-targeting chimeras (PROTACs) that recruit E3 ubiquitin ligases to target proteins for their ubiquitination and subsequent proteasome-mediated degrdn.  Using promiscuous CRBN- and VHL-recruiting PROTACs that bind >50 kinases, we show that only a subset of bound targets is degraded.  The basis of this selectivity relies on protein-protein interactions between the E3 ubiquitin ligase and the target protein, as illustrated by engaged proteins that are not degraded as a result of unstable ternary complexes with PROTAC-recruited E3 ligases.  In contrast, weak PROTAC:target protein affinity can be stabilized by high-affinity target:PROTAC:ligase trimer interactions, leading to efficient degrdn.  This study highlights design guidelines for generating potent PROTACs as well as possibilities for degrading undruggable proteins immune to traditional small-mol. inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoISOBudOLyFrVg90H21EOLACvtfcHk0lhD3MDtvS_iog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2lsrjN&md5=30fac502705a2344c4261cf531e6bf9d</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DBondeson%26aufirst%3DD.%2BP.%26aulast%3DSmith%26aufirst%3DB.%2BE.%26aulast%3DBurslem%26aufirst%3DG.%2BM.%26aulast%3DBuhimschi%26aufirst%3DA.%2BD.%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHamman%26aufirst%3DB.%2BD.%26aulast%3DIshchenko%26aufirst%3DA.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DLessons%2520in%2520PROTAC%2520design%2520from%2520selective%2520degradation%2520with%2520a%2520promiscuous%2520warhead%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D78%26epage%3D87%26doi%3D10.1016%2Fj.chembiol.2017.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neklesa, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted protein degradation by PROTACs</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">138</span>â <span class="NLM_lpage">144</span>, <span class="refDoi">Â DOI: 10.1016/j.pharmthera.2017.02.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.pharmthera.2017.02.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=28223226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtVemsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2017&pages=138-144&author=T.+K.+Neklesaauthor=J.+D.+Winklerauthor=C.+M.+Crews&title=Targeted+protein+degradation+by+PROTACs&doi=10.1016%2Fj.pharmthera.2017.02.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted protein degradation by PROTACs</span></div><div class="casAuthors">Neklesa, Taavi K.; Winkler, James D.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">138-144</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Targeted protein degrdn. using the PROTAC technol. is emerging as a novel therapeutic method to address diseases driven by the aberrant expression of a disease-causing protein.  PROTAC mols. are bifunctional small mols. that simultaneously bind a target protein and an E3-ubiquitin ligase, thus causing ubiquitination and degrdn. of the target protein by the proteasome.  Like small mols., PROTAC mols. possess good tissue distribution and the ability to target intracellular proteins.  Herein, we highlight the advantages of protein degrdn. using PROTACs, and provide specific examples where degrdn. offers therapeutic benefit over classical enzyme inhibition.  Foremost, PROTACs can degrade proteins regardless of their function.  This includes the currently "undruggable" proteome, which comprises approx. 85% of all human proteins.  Other beneficial aspects of protein degrdn. include the ability to target overexpressed and mutated proteins, as well as the potential to demonstrate prolonged pharmacodynamics effect beyond drug exposure.  Lastly, due to their catalytic nature and the pre-requisite ubiquitination step, an exquisitely potent mols. with a high degree of degrdn. selectivity can be designed.  Impressive preclin. in vitro and in vivo PROTAC data have been published, and these data have propelled the development of clin. viable PROTACs.  With the mol. wt. falling in the 700-1000 Da range, the delivery and bioavailability of PROTACs remain the largest hurdles on the way to the clinic.  Solving these issues and demonstrating proof of concept clin. data will be the focus of many labs over the next few years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4RSLWYqqBMrVg90H21EOLACvtfcHk0lhD3MDtvS_iog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtVemsbg%253D&md5=08a74402a274a13c8c484cd68167a5a1</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.02.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.02.027%26sid%3Dliteratum%253Aachs%26aulast%3DNeklesa%26aufirst%3DT.%2BK.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520protein%2520degradation%2520by%2520PROTACs%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D174%26spage%3D138%26epage%3D144%26doi%3D10.1016%2Fj.pharmthera.2017.02.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robb, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contreras, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kour, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonawane, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murry, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rana, S.</span></span> <span> </span><span class="NLM_article-title">Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC)</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">7577</span>â <span class="NLM_lpage">7580</span>, <span class="refDoi">Â DOI: 10.1039/C7CC03879H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1039%2FC7CC03879H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=28636052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpvFyjsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2017&pages=7577-7580&author=C.+M.+Robbauthor=J.+I.+Contrerasauthor=S.+Kourauthor=M.+A.+Taylorauthor=M.+Abidauthor=Y.+A.+Sonawaneauthor=M.+Zahidauthor=D.+J.+Murryauthor=A.+Natarajanauthor=S.+Rana&title=Chemically+induced+degradation+of+CDK9+by+a+proteolysis+targeting+chimera+%28PROTAC%29&doi=10.1039%2FC7CC03879H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC)</span></div><div class="casAuthors">Robb, Caroline M.; Contreras, Jacob I.; Kour, Smit; Taylor, Margaret A.; Abid, Mohammad; Sonawane, Yogesh A.; Zahid, Muhammad; Murry, Daryl J.; Natarajan, Amarnath; Rana, Sandeep</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">54</span>),
    <span class="NLM_cas:pages">7577-7580</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 9 (CDK9), a member of the cyclin-dependent protein kinase (CDK) family, is involved in transcriptional elongation of several target genes.  CDK9 is ubiquitously expressed and has been shown to contribute to a variety of malignancies such as pancreatic, prostate and breast cancers.  Here we report the development of a heterobifunctional small mol. proteolysis targeting chimera (PROTAC) capable of cereblon (CRBN)-mediated proteasomal degrdn. of CDK9.  In HCT116 cells, it selectively degrades CDK9 while sparing other CDK family members.  This is the first example of a PROTAC that selectively degrades CDK9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXgLtOTwvlnbVg90H21EOLACvtfcHk0lhD3MDtvS_iog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpvFyjsLw%253D&md5=a9aa8ebf8109f11206740efd1b5e09a2</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1039%2FC7CC03879H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7CC03879H%26sid%3Dliteratum%253Aachs%26aulast%3DRobb%26aufirst%3DC.%2BM.%26aulast%3DContreras%26aufirst%3DJ.%2BI.%26aulast%3DKour%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DM.%2BA.%26aulast%3DAbid%26aufirst%3DM.%26aulast%3DSonawane%26aufirst%3DY.%2BA.%26aulast%3DZahid%26aufirst%3DM.%26aulast%3DMurry%26aufirst%3DD.%2BJ.%26aulast%3DNatarajan%26aufirst%3DA.%26aulast%3DRana%26aufirst%3DS.%26atitle%3DChemically%2520induced%2520degradation%2520of%2520CDK9%2520by%2520a%2520proteolysis%2520targeting%2520chimera%2520%2528PROTAC%2529%26jtitle%3DChem.%2520Commun.%26date%3D2017%26volume%3D53%26spage%3D7577%26epage%3D7580%26doi%3D10.1039%2FC7CC03879H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J. Y.</span></span> <span> </span><span class="NLM_article-title">Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC)</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>505</i></span>,  <span class="NLM_fpage">542</span>â <span class="NLM_lpage">547</span>, <span class="refDoi">Â DOI: 10.1016/j.bbrc.2018.09.169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bbrc.2018.09.169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=30274779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVejs7fE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=505&publication_year=2018&pages=542-547&author=C.+H.+Kangauthor=D.+H.+Leeauthor=C.+O.+Leeauthor=J.+D.+Haauthor=C.+H.+Parkauthor=J.+Y.+Hwang&title=Induced+protein+degradation+of+anaplastic+lymphoma+kinase+%28ALK%29+by+proteolysis+targeting+chimera+%28PROTAC%29&doi=10.1016%2Fj.bbrc.2018.09.169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC)</span></div><div class="casAuthors">Kang, Chung Hyo; Lee, Dong Ho; Lee, Chong Ock; Du Ha, Jae; Park, Chi Hoon; Hwang, Jong Yeon</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">505</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">542-547</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recently, proteolysis targeting chimera (PROTAC) technol. is highlighted in drug discovery area as a new therapeutic approach.  PROTAC as a heterobifunctional mol. is comprised of two ligands, which recruit target protein and E3 ligase, resp.  To degrade the anaplastic lymphoma kinase (ALK) fusion protein, such as NPM-ALK or EML4-ALK, we generated several ALK-PROTAC mols. consisted of ceritinib, one of the ALK inhibitors, and ligand of von Hippel-Lindau (VHL) E3 ligase.  Among these mols., TD-004 effectively induced ALK degrdn. and inhibited the growth of ALK fusion pos. cell lines, SU-DHL-1 and H3122.  We also confirmed that TD-004 significantly reduced the tumor growth in H3122 xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8JUOZ5fYNW7Vg90H21EOLACvtfcHk0lg0knpu-x-EYw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVejs7fE&md5=cac9252fca98ebec4ad8e5aeed7b7550</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2018.09.169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2018.09.169%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DC.%2BH.%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DLee%26aufirst%3DC.%2BO.%26aulast%3DHa%26aufirst%3DJ.%2BD.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DHwang%26aufirst%3DJ.%2BY.%26atitle%3DInduced%2520protein%2520degradation%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520by%2520proteolysis%2520targeting%2520chimera%2520%2528PROTAC%2529%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2018%26volume%3D505%26spage%3D542%26epage%3D547%26doi%3D10.1016%2Fj.bbrc.2018.09.169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cromm, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samarasinghe, K. T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Addressing kinase-independent functions of Fak via PROTAC-mediated degradation</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">17019</span>â <span class="NLM_lpage">17026</span>, <span class="refDoi">Â DOI: 10.1021/jacs.8b08008</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.8b08008" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1CitLnF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2018&pages=17019-17026&author=P.+M.+Crommauthor=K.+T.+G.+Samarasingheauthor=J.+Hinesauthor=C.+M.+Crews&title=Addressing+kinase-independent+functions+of+Fak+via+PROTAC-mediated+degradation&doi=10.1021%2Fjacs.8b08008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation</span></div><div class="casAuthors">Cromm, Philipp M.; Samarasinghe, Kusal T. G.; Hines, John; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">17019-17026</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Enzymic inhibition proved to be a successful modality for the development of many small-mol. drugs.  In recent years, small-mol.-induced protein degrdn. has emerged as an orthogonal therapeutic strategy that has the potential to expand the druggable target space.  Focal adhesion kinase (Fak) is a key player in tumor invasion and metastasis, acting simultaneously as a kinase and a scaffold for several signaling proteins.  While previous efforts to modulate Fak activity were limited to kinase inhibitors with low success in clin. studies, protein degrdn. offers a possibility to simultaneously block Fak's kinase signaling and scaffolding capabilities.  Here, the authors report the development of a selective and potent Fak degrader, PROTAC-3, which outperforms a clin. candidate, defactinib, with respect to Fak activation as well as Fak-mediated cell migration and invasion.  These results underline the potential that PROTACs offer in expanding the druggable space and controlling protein functions that are not easily addressed by traditional small-mol. therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTn8r4NmDDObVg90H21EOLACvtfcHk0lg0knpu-x-EYw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1CitLnF&md5=b97b1a646a8f9dbf7a2bed640d0f001d</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Fjacs.8b08008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.8b08008%26sid%3Dliteratum%253Aachs%26aulast%3DCromm%26aufirst%3DP.%2BM.%26aulast%3DSamarasinghe%26aufirst%3DK.%2BT.%2BG.%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DAddressing%2520kinase-independent%2520functions%2520of%2520Fak%2520via%2520PROTAC-mediated%2520degradation%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2018%26volume%3D140%26spage%3D17019%26epage%3D17026%26doi%3D10.1021%2Fjacs.8b08008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Da, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span> <span> </span><span class="NLM_article-title">Targeted selective degradation of Brutonâs tyrosine kinase by PROTACs</span>. <i>Med. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">802</span>â <span class="NLM_lpage">808</span>, <span class="refDoi">Â DOI: 10.1007/s00044-020-02526-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1007%2Fs00044-020-02526-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktFWisL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2020&pages=802-808&author=S.+Liuauthor=Y.+Daauthor=F.+Wangauthor=R.+Yanauthor=Y.+Shuauthor=P.+Linauthor=J.+Lin&title=Targeted+selective+degradation+of+Bruton%E2%80%99s+tyrosine+kinase+by+PROTACs&doi=10.1007%2Fs00044-020-02526-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted selective degradation of Bruton's tyrosine kinase by PROTACs</span></div><div class="casAuthors">Liu, Shaodong; Da, Yang; Wang, Feng; Yan, Renjie; Shu, Yongzhi; Lin, Pei; Lin, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">802-808</span>CODEN:
                <span class="NLM_cas:coden">MCREEB</span>;
        ISSN:<span class="NLM_cas:issn">1054-2523</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: Bruton's tyrosine kinase (BTK) is crit. for B-cell receptor signaling and related to many types of human cancers.  However, the drug resistance and off-target effect of present traditional BTK inhibitors occurred over time.  As a new strategy for drug development, the proteolysis targeting chimera (PROTAC) has been proved to target varieties of proteins.  Here SPB5208 (4-(2-(2-(2-(2-(3-(4-amino-3-(4-phenoxy phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)ethoxy)ethoxy)ethoxy)ethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione) was synthesized as a new PROTAC degrdn. agent of BTK by linking Ibrutinib and Thalidomide.  In vitro study indicated that SPB5208 reduced the BTK enzyme activity with high selectivity and inhibited effectively cancer cell proliferation.  More than that, SPB5208 induced BTK protein degrdn. through a proteasome- and CRBN- dependent manner in JeKo-1 cells.  In addn., SPB5208 was also confirmed to induce significantly BTK protein degrdn. in vivo.  Thus, this study provides a new pharmacol. tool for further study of new BTK PROTAC and their mechanism of action in physiol. environment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEEHujG9LHG7Vg90H21EOLACvtfcHk0lg0knpu-x-EYw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktFWisL4%253D&md5=c0bb9269eb76f0aeb59592e8825d1e88</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1007%2Fs00044-020-02526-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00044-020-02526-3%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DDa%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DYan%26aufirst%3DR.%26aulast%3DShu%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DP.%26aulast%3DLin%26aufirst%3DJ.%26atitle%3DTargeted%2520selective%2520degradation%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520by%2520PROTACs%26jtitle%3DMed.%2520Chem.%2520Res.%26date%3D2020%26volume%3D29%26spage%3D802%26epage%3D808%26doi%3D10.1007%2Fs00044-020-02526-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span> <span> </span><span class="NLM_article-title">FAK-targeting PROTAC as a chemical tool for the investigation of non-enzymatic FAK function in mice</span>. <i>Protein Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">534</span>â <span class="NLM_lpage">539</span>, <span class="refDoi">Â DOI: 10.1007/s13238-020-00732-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1007%2Fs13238-020-00732-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=32451721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVaiurbL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=534-539&author=H.+Gaoauthor=C.+Zhengauthor=J.+Duauthor=Y.+Wuauthor=Y.+Sunauthor=C.+Hanauthor=K.+Keeauthor=Y.+Rao&title=FAK-targeting+PROTAC+as+a+chemical+tool+for+the+investigation+of+non-enzymatic+FAK+function+in+mice&doi=10.1007%2Fs13238-020-00732-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">FAK-targeting PROTAC as a chemical tool for the investigation of non-enzymatic FAK function in mice</span></div><div class="casAuthors">Gao, Hongying; Zheng, Chunwei; Du, Jian; Wu, Yue; Sun, Yonghui; Han, Chunsheng; Kee, Kehkooi; Rao, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Protein & Cell</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">534-539</span>CODEN:
                <span class="NLM_cas:coden">PCREFB</span>;
        ISSN:<span class="NLM_cas:issn">1674-800X</span>.
    
            (<span class="NLM_cas:orgname">Higher Education Press</span>)
        </div><div class="casAbstract">This article studies about FAK-targeting PROTAC as chem. tool for investigation of non-enzymic FAK function in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp520chSxI_vbVg90H21EOLACvtfcHk0lg0knpu-x-EYw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVaiurbL&md5=6e12490a063fba01cfa7dcf096fd77b7</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1007%2Fs13238-020-00732-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13238-020-00732-8%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DC.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DC.%26aulast%3DKee%26aufirst%3DK.%26aulast%3DRao%26aufirst%3DY.%26atitle%3DFAK-targeting%2520PROTAC%2520as%2520a%2520chemical%2520tool%2520for%2520the%2520investigation%2520of%2520non-enzymatic%2520FAK%2520function%2520in%2520mice%26jtitle%3DProtein%2520Cell%26date%3D2020%26volume%3D11%26spage%3D534%26epage%3D539%26doi%3D10.1007%2Fs13238-020-00732-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrovolsky, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doctor, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treon, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">A chemoproteomic approach to query the degradable kinome using a multi-kinase degrader</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">88</span>â <span class="NLM_lpage">99</span>, <span class="refDoi">Â DOI: 10.1016/j.chembiol.2017.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.chembiol.2017.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=29129717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2lsrjO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=88-99&author=H.+T.+Huangauthor=D.+Dobrovolskyauthor=J.+Paulkauthor=G.+Yangauthor=E.+L.+Weisbergauthor=Z.+M.+Doctorauthor=D.+L.+Buckleyauthor=J.+H.+Choauthor=E.+Koauthor=J.+Jangauthor=K.+Shiauthor=H.+G.+Choiauthor=J.+D.+Griffinauthor=Y.+Liauthor=S.+P.+Treonauthor=E.+S.+Fischerauthor=J.+E.+Bradnerauthor=L.+Tanauthor=N.+S.+Gray&title=A+chemoproteomic+approach+to+query+the+degradable+kinome+using+a+multi-kinase+degrader&doi=10.1016%2Fj.chembiol.2017.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader</span></div><div class="casAuthors">Huang, Hai-Tsang; Dobrovolsky, Dennis; Paulk, Joshiawa; Yang, Guang; Weisberg, Ellen L.; Doctor, Zainab M.; Buckley, Dennis L.; Cho, Joong-Heui; Ko, Eunhwa; Jang, Jaebong; Shi, Kun; Choi, Hwan Geun; Griffin, James D.; Li, Ying; Treon, Steven P.; Fischer, Eric S.; Bradner, James E.; Tan, Li; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-99.e6</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Heterobifunctional mols. that recruit E3 ubiquitin ligases, such as cereblon, for targeted protein degrdn. represent an emerging pharmacol. strategy.  A major unanswered question is how generally applicable this strategy is to all protein targets.  In this study, we designed a multi-kinase degrader by conjugating a highly promiscuous kinase inhibitor with a cereblon-binding ligand, and used quant. proteomics to discover 28 kinases, including BTK, PTK2, PTK2B, FLT3, AURKA, AURKB, TEC, ULK1, ITK, and nine members of the CDK family, as degradable.  This set of kinases is only a fraction of the intracellular targets bound by the degrader, demonstrating that successful degrdn. requires more than target engagement.  The results guided us to develop selective degraders for FLT3 and BTK, with potentials to improve disease treatment.  Together, this study demonstrates an efficient approach to triage a gene family of interest to identify readily degradable targets for further studies and pre-clin. developments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYNxhoPV3127Vg90H21EOLACvtfcHk0lhGuY-ezThLzg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2lsrjO&md5=703cfbaca3edd24176472158563f895f</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DH.%2BT.%26aulast%3DDobrovolsky%26aufirst%3DD.%26aulast%3DPaulk%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DWeisberg%26aufirst%3DE.%2BL.%26aulast%3DDoctor%26aufirst%3DZ.%2BM.%26aulast%3DBuckley%26aufirst%3DD.%2BL.%26aulast%3DCho%26aufirst%3DJ.%2BH.%26aulast%3DKo%26aufirst%3DE.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DK.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DTreon%26aufirst%3DS.%2BP.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DA%2520chemoproteomic%2520approach%2520to%2520query%2520the%2520degradable%2520kinome%2520using%2520a%2520multi-kinase%2520degrader%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D88%26epage%3D99%26doi%3D10.1016%2Fj.chembiol.2017.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Powell, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donovan, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loehr, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahcall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Chemically induced degradation of anaplastic lymphoma kinase (ALK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4249</span>â <span class="NLM_lpage">4255</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b01655</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01655" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1cXns1OitrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4249-4255&author=C.+E.+Powellauthor=Y.+Gaoauthor=L.+Tanauthor=K.+A.+Donovanauthor=R.+P.+Nowakauthor=A.+Loehrauthor=M.+Bahcallauthor=E.+S.+Fischerauthor=P.+A.+Janneauthor=R.+E.+Georgeauthor=N.+S.+Gray&title=Chemically+induced+degradation+of+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1021%2Facs.jmedchem.7b01655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Powell, Chelsea E.; Gao, Yang; Tan, Li; Donovan, Katherine A.; Nowak, Radoslaw P.; Loehr, Amanda; Bahcall, Magda; Fischer, Eric S.; Janne, Pasi A.; George, Rani E.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4249-4255</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We present the development of the first small mol. degraders that can induce anaplastic lymphoma kinase (ALK) degrdn., including in non-small-cell lung cancer (NSCLC), anaplastic large-cell lymphoma (ALCL), and neuroblastoma (NB) cell lines.  These degraders were developed through conjugation of known pyrimidine-based ALK inhibitors, TAE684 or LDK378, and the cereblon ligand pomalidomide.  We demonstrate that in some cell types degrader potency is compromised by expression of drug transporter ABCB1.  In addn., proteomic profiling demonstrated that these compds. also promote the degrdn. of addnl. kinases including PTK2 (FAK), Aurora A, FER, and RPS6KA1 (RSK1).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7mDH7Sj8EqbVg90H21EOLACvtfcHk0lhGuY-ezThLzg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXns1OitrY%253D&md5=486db11b3fbc2283700f38b09cc39bd7</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01655%26sid%3Dliteratum%253Aachs%26aulast%3DPowell%26aufirst%3DC.%2BE.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DDonovan%26aufirst%3DK.%2BA.%26aulast%3DNowak%26aufirst%3DR.%2BP.%26aulast%3DLoehr%26aufirst%3DA.%26aulast%3DBahcall%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DChemically%2520induced%2520degradation%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4249%26epage%3D4255%26doi%3D10.1021%2Facs.jmedchem.7b01655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Popow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnhof, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciulli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dank, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmaschitz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greb, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karolyi-Ozguer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koegl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rieger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinnenthal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roessler, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrenk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steurer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainor, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traxler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieshofer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoephel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettmayer, P.</span></span> <span> </span><span class="NLM_article-title">Highly selective PTK2 proteolysis-targeting chimeras to probe focal adhesion kinase scaffolding functions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">2508</span>â <span class="NLM_lpage">2520</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b01826</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01826" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisl2ls78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=2508-2520&author=J.+Popowauthor=H.+Arnhofauthor=G.+Baderauthor=H.+Bergerauthor=A.+Ciulliauthor=D.+Coviniauthor=C.+Dankauthor=T.+Gmaschitzauthor=P.+Grebauthor=J.+Karolyi-Ozguerauthor=M.+Koeglauthor=D.+B.+McConnellauthor=M.+Pearsonauthor=M.+Riegerauthor=J.+Rinnenthalauthor=V.+Roesslerauthor=A.+Schrenkauthor=M.+Spinaauthor=S.+Steurerauthor=N.+Trainorauthor=E.+Traxlerauthor=C.+Wieshoferauthor=A.+Zoephelauthor=P.+Ettmayer&title=Highly+selective+PTK2+proteolysis-targeting+chimeras+to+probe+focal+adhesion+kinase+scaffolding+functions&doi=10.1021%2Facs.jmedchem.8b01826"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions</span></div><div class="casAuthors">Popow, Johannes; Arnhof, Heribert; Bader, Gerd; Berger, Helmut; Ciulli, Alessio; Covini, David; Dank, Christian; Gmaschitz, Teresa; Greb, Peter; Karolyi-Oezguer, Jale; Koegl, Manfred; McConnell, Darryl B.; Pearson, Mark; Rieger, Maria; Rinnenthal, Joerg; Roessler, Vanessa; Schrenk, Andreas; Spina, Markus; Steurer, Steffen; Trainor, Nicole; Traxler, Elisabeth; Wieshofer, Corinna; Zoephel, Andreas; Ettmayer, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2508-2520</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Focal adhesion tyrosine kinase (PTK2) is often overexpressed in human hepatocellular carcinoma (HCC), and several reports have linked PTK2 depletion and/or pharmacol. inhibition to reduced tumorigenicity.  However, the clin. relevance of targeting PTK2 still remains to be proven.  Here, we present two highly selective and functional PTK2 proteolysis-targeting chimeras utilizing von Hippel-Lindau and cereblon ligands to hijack E3 ligases for PTK2 degrdn.  BI-3663 (cereblon-based) degrades PTK2 with a median DC50 of 30 nM to >80% across a panel of 11 HCC cell lines.  Despite effective PTK2 degrdn., these compds. did not phenocopy the reported antiproliferative effects of PTK2 depletion in any of the cell lines tested.  By disclosing these compds., we hope to provide valuable tools for the study of PTK2 degrdn. across different biol. systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsL2R_QBrfk7Vg90H21EOLACvtfcHk0lhGuY-ezThLzg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisl2ls78%253D&md5=f0ad27d3ff46ab12e8a90e8d40a6f3c6</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01826&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01826%26sid%3Dliteratum%253Aachs%26aulast%3DPopow%26aufirst%3DJ.%26aulast%3DArnhof%26aufirst%3DH.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DBerger%26aufirst%3DH.%26aulast%3DCiulli%26aufirst%3DA.%26aulast%3DCovini%26aufirst%3DD.%26aulast%3DDank%26aufirst%3DC.%26aulast%3DGmaschitz%26aufirst%3DT.%26aulast%3DGreb%26aufirst%3DP.%26aulast%3DKarolyi-Ozguer%26aufirst%3DJ.%26aulast%3DKoegl%26aufirst%3DM.%26aulast%3DMcConnell%26aufirst%3DD.%2BB.%26aulast%3DPearson%26aufirst%3DM.%26aulast%3DRieger%26aufirst%3DM.%26aulast%3DRinnenthal%26aufirst%3DJ.%26aulast%3DRoessler%26aufirst%3DV.%26aulast%3DSchrenk%26aufirst%3DA.%26aulast%3DSpina%26aufirst%3DM.%26aulast%3DSteurer%26aufirst%3DS.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DTraxler%26aufirst%3DE.%26aulast%3DWieshofer%26aufirst%3DC.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DEttmayer%26aufirst%3DP.%26atitle%3DHighly%2520selective%2520PTK2%2520proteolysis-targeting%2520chimeras%2520to%2520probe%2520focal%2520adhesion%2520kinase%2520scaffolding%2520functions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D2508%26epage%3D2520%26doi%3D10.1021%2Facs.jmedchem.8b01826" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of highly potent FAK-targeting PROTACs</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1855</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.9b00372</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00372" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVajtrfJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1855&author=H.+Gaoauthor=Y.+Wuauthor=Y.+Sunauthor=Y.+Yangauthor=G.+Zhouauthor=Y.+Rao&title=Design%2C+synthesis%2C+and+evaluation+of+highly+potent+FAK-targeting+PROTACs&doi=10.1021%2Facsmedchemlett.9b00372"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of Highly Potent FAK-Targeting PROTACs</span></div><div class="casAuthors">Gao, Hongying; Wu, Yue; Sun, Yonghui; Yang, Yiqing; Zhou, Guangbiao; Rao, Yu</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1855-1862</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK), a cytoplasmic protein tyrosine kinase, exerts kinase-dependent enzymic functions and kinase-independent scaffolding functions, both of which are crucial in cancer development, early embryonic development, and reprodn.  However, previous efforts for FAK blocking mainly focus on kinase inhibitors.  Proteolysis targeting chimeras (PROTACs) are heterobifunctional mols. that allow direct post-translational knockdown of proteins via ubiquitination of a target protein by E3 ubiquitin ligase and subsequent proteasomal degrdn.  Here, we designed and synthesized a FAK PROTAC library with FAK inhibitor (PF562271 or VS6063) and CRBN E3 ligand.  A novel FAK-targeting PROTAC, FC-11, showed a rapid and reversible FAK degrdn. with a picomolar of DC50 in various cell lines in vitro, which imply that FAK-PROTACs could be useful as expand tools for studying functions of FAK in biol. system and as potential therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDJ4SVK5xRNrVg90H21EOLACvtfcHk0liplaguqqTIWA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVajtrfJ&md5=79cacdc66925d21441732c26c9b268d4</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00372%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DG.%26aulast%3DRao%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520highly%2520potent%2520FAK-targeting%2520PROTACs%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D1855%26doi%3D10.1021%2Facsmedchemlett.9b00372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekido, Y.</span></span> <span> </span><span class="NLM_article-title">E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">5522</span>â <span class="NLM_lpage">5531</span>, <span class="refDoi">Â DOI: 10.1038/onc.2017.147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fonc.2017.147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=28553954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosVyrtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2017&pages=5522-5531&author=T.+Katoauthor=T.+Satoauthor=K.+Yokoiauthor=Y.+Sekido&title=E-cadherin+expression+is+correlated+with+focal+adhesion+kinase+inhibitor+resistance+in+Merlin-negative+malignant+mesothelioma+cells&doi=10.1038%2Fonc.2017.147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells</span></div><div class="casAuthors">Kato, T.; Sato, T.; Yokoi, K.; Sekido, Y.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">5522-5531</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Malignant mesothelioma (MM) is an aggressive tumor commonly caused by asbestos exposure after a long latency.  Focal adhesion kinase (FAK) inhibitors inhibit the cell growth of Merlin-deficient MM cells; however, their clin. efficacy has not been clearly detd.  The aim of this study was to evaluate the growth inhibitory effect of the FAK inhibitor VS-4718 on MM cell lines and identify biomarkers for its efficacy.  Although most Merlin-deficient cell lines were sensitive to VS-4718 compared with control MeT-5A cells, a subset of these cell lines exhibited resistance to this drug.  Microarray and qRT-PCR analyses using RNA isolated from Merlin-deficient MM cell lines revealed a significant correlation between E-cadherin mRNA levels and VS-4718 resistance.  Merlin- and E-cadherin-neg. Y-MESO-22 cells underwent apoptosis upon treatment with a low concn. of VS-4718, whereas Merlin-neg., E-cadherin-pos. Y-MESO-9 cells did not undergo VS-4718-induced apoptosis.  Furthermore, E-cadherin knockdown in Merlin-neg. MM cells significantly sensitized cells to VS-4718 and induced apoptotic cell death upon VS-4718 treatment.  Together, our results suggest that E-cadherin serves as a predictive biomarker for mol. target therapy with FAK inhibitors for patients with mesothelioma and that its expression endows MM cells with resistance to FAK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqc2AZl866IXrVg90H21EOLACvtfcHk0liplaguqqTIWA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosVyrtbk%253D&md5=34cc7fee7bf5ebae92ec406e34c1cf20</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1038%2Fonc.2017.147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2017.147%26sid%3Dliteratum%253Aachs%26aulast%3DKato%26aufirst%3DT.%26aulast%3DSato%26aufirst%3DT.%26aulast%3DYokoi%26aufirst%3DK.%26aulast%3DSekido%26aufirst%3DY.%26atitle%3DE-cadherin%2520expression%2520is%2520correlated%2520with%2520focal%2520adhesion%2520kinase%2520inhibitor%2520resistance%2520in%2520Merlin-negative%2520malignant%2520mesothelioma%2520cells%26jtitle%3DOncogene%26date%3D2017%26volume%3D36%26spage%3D5522%26epage%3D5531%26doi%3D10.1038%2Fonc.2017.147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jablonski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhanwar, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testa, J. R.</span></span> <span> </span><span class="NLM_article-title">Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">5960</span>â <span class="NLM_lpage">5968</span>, <span class="refDoi">Â DOI: 10.1038/sj.onc.1209587</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fsj.onc.1209587" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=16652148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVSnsL7L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=5960-5968&author=P.+I.+Poulikakosauthor=G.+H.+Xiaoauthor=R.+Gallagherauthor=S.+Jablonskiauthor=S.+C.+Jhanwarauthor=J.+R.+Testa&title=Re-expression+of+the+tumor+suppressor+NF2%2Fmerlin+inhibits+invasiveness+in+mesothelioma+cells+and+negatively+regulates+FAK&doi=10.1038%2Fsj.onc.1209587"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK</span></div><div class="casAuthors">Poulikakos, P. I.; Xiao, G-H.; Gallagher, R.; Jablonski, S.; Jhanwar, S. C.; Testa, J. R.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">5960-5968</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The neurofibromatosis type 2 NF2 gene product, merlin, is a tumor suppressor frequently inactivated in malignant mesothelioma (MM).  To investigate a possible correlation between merlin inactivation and MM invasiveness, we restored merlin expression in NF2-deficient MM cells.  Re-expression of merlin markedly inhibited cell motility, spreading and invasiveness, properties connected with the malignant phenotype of MM cells.  To test directly whether merlin inactivation promotes invasion in a nonmalignant system, we used small interfering RNA to silence Nf2 in mouse embryonic fibroblasts (MEFs) and found that downregulation of merlin resulted in enhanced cell spreading and invasion.  To delineate signaling events connected with this phenotype, we investigated the effect of merlin expression on focal adhesion kinase (FAK), a key component of cellular pathways affecting migration and invasion.  Expression of merlin attenuated FAK phosphorylation at the crit. phosphorylation site Tyr397 and disrupted the interaction of FAK with its binding partners Src and p85, the regulatory subunit of phosphatidylinositol-3-kinase.  In addn., NF2-null MM cells stably overexpressing FAK showed increased invasiveness, which decreased significantly when merlin expression was restored.  Collectively, these findings suggest that merlin inactivation is a crit. step in MM pathogenesis and is related, at least in part, with upregulation of FAK activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPtJjSYb6jmLVg90H21EOLACvtfcHk0liplaguqqTIWA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVSnsL7L&md5=0dfead504a7aaa68dfd7d00128d81781</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1209587&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1209587%26sid%3Dliteratum%253Aachs%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DXiao%26aufirst%3DG.%2BH.%26aulast%3DGallagher%26aufirst%3DR.%26aulast%3DJablonski%26aufirst%3DS.%26aulast%3DJhanwar%26aufirst%3DS.%2BC.%26aulast%3DTesta%26aufirst%3DJ.%2BR.%26atitle%3DRe-expression%2520of%2520the%2520tumor%2520suppressor%2520NF2%252Fmerlin%2520inhibits%2520invasiveness%2520in%2520mesothelioma%2520cells%2520and%2520negatively%2520regulates%2520FAK%26jtitle%3DOncogene%26date%3D2006%26volume%3D25%26spage%3D5960%26epage%3D5968%26doi%3D10.1038%2Fsj.onc.1209587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolev, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidal, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadariya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ring, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menges, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padval, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClatchey, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testa, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachter, J. A.</span></span> <span> </span><span class="NLM_article-title">Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">237</span>â <span class="NLM_lpage">260</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.3008639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1126%2Fscitranslmed.3008639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1GrtLfK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=237-260&author=I.+M.+Shapiroauthor=V.+N.+Kolevauthor=C.+M.+Vidalauthor=Y.+Kadariyaauthor=J.+E.+Ringauthor=Q.+Wrightauthor=D.+T.+Weaverauthor=C.+Mengesauthor=M.+Padvalauthor=A.+I.+McClatcheyauthor=Q.+Xuauthor=J.+R.+Testaauthor=J.+A.+Pachter&title=Merlin+deficiency+predicts+FAK+inhibitor+sensitivity%3A+a+synthetic+lethal+relationship&doi=10.1126%2Fscitranslmed.3008639"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship</span></div><div class="casAuthors">Shapiro, Irina M.; Kolev, Vihren N.; Vidal, Christian M.; Kadariya, Yuwaraj; Ring, Jennifer E.; Wright, Quentin; Weaver, David T.; Menges, Craig; Padval, Mahesh; McClatchey, Andrea I.; Xu, Qunli; Testa, Joseph R.; Pachter, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Science Translational Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">237</span>),
    <span class="NLM_cas:pages">237ra68/1-237ra68/12, 12</span>CODEN:
                <span class="NLM_cas:coden">STMCBQ</span>;
        ISSN:<span class="NLM_cas:issn">1946-6242</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The goal of targeted therapy is to match a selective drug with a genetic lesion that predicts for drug sensitivity.  In a diverse panel of cancer cell lines, we found that the cells most sensitive to focal adhesion kinase (FAK) inhibition lack expression of the neurofibromatosis type 2 (NF2) tumor suppressor gene product, Merlin.  Merlin expression is often lost in malignant pleural mesothelioma (MPM), an asbestos-induced aggressive cancer with limited treatment options.  Our data demonstrate that low Merlin expression predicts for increased sensitivity of MPM cells to a FAK inhibitor, VS-4718, in vitro and in tumor xenograft models.  Disruption of MPM cell-cell or cell-extracellular matrix (ECM) contacts with blocking antibodies suggests that weak cell-cell adhesions in Merlinneg. MPM cells underlie their greater dependence on cell-ECM-induced FAK signaling.  This provides one explanation of why Merlin-neg. cells are vulnerable to FAK inhibitor treatment.  Furthermore, we validated aldehyde dehydrogenase as a marker of cancer stem cells (CSCs) in MPM, a cell population thought to mediate tumor relapse after chemotherapy.  Whereas pemetrexed and cisplatin, std.-of-care agents for MPM, enrich for CSCs, FAK inhibitor treatment preferentially eliminates these cells.  These preclin. results provide the rationale for a clin. trial in MPM patients using a FAK inhibitor as a single agent after first-line chemotherapy.  With this design, the FAK inhibitor could potentially induce a more durable clin. response through redn. of CSCs along with a strong antitumor effect.  Furthermore, our data suggest that patients with Merlin-neg. tumors may esp. benefit from FAK inhibitor treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2DmeG3F2N1LVg90H21EOLACvtfcHk0ljXlNB_s_CU1w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1GrtLfK&md5=0f2c12151b444fdb0cab1795d8c3fdc0</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3008639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3008639%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DI.%2BM.%26aulast%3DKolev%26aufirst%3DV.%2BN.%26aulast%3DVidal%26aufirst%3DC.%2BM.%26aulast%3DKadariya%26aufirst%3DY.%26aulast%3DRing%26aufirst%3DJ.%2BE.%26aulast%3DWright%26aufirst%3DQ.%26aulast%3DWeaver%26aufirst%3DD.%2BT.%26aulast%3DMenges%26aufirst%3DC.%26aulast%3DPadval%26aufirst%3DM.%26aulast%3DMcClatchey%26aufirst%3DA.%2BI.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DTesta%26aufirst%3DJ.%2BR.%26aulast%3DPachter%26aufirst%3DJ.%2BA.%26atitle%3DMerlin%2520deficiency%2520predicts%2520FAK%2520inhibitor%2520sensitivity%253A%2520a%2520synthetic%2520lethal%2520relationship%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2014%26volume%3D6%26spage%3D237%26epage%3D260%26doi%3D10.1126%2Fscitranslmed.3008639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doroshow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kummar, S.</span></span> <span> </span><span class="NLM_article-title">United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies</span>. <i>Curr. Probl. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">110</span>â <span class="NLM_lpage">144</span>, <span class="refDoi">Â DOI: 10.1016/j.currproblcancer.2013.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.currproblcancer.2013.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=23972982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BC3sbitlelsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2013&pages=110-144&author=W.+Jeongauthor=J.+H.+Doroshowauthor=S.+Kummar&title=United+States+Food+and+Drug+Administration+approved+oral+kinase+inhibitors+for+the+treatment+of+malignancies&doi=10.1016%2Fj.currproblcancer.2013.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies</span></div><div class="casAuthors">Jeong Woondong; Doroshow James H; Kummar Shivaani</div><div class="citationInfo"><span class="NLM_cas:title">Current problems in cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">110-44</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRazKlkC8sbaczK395ZObgVfW6udTcc2eYlIJBYddOHVbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbitlelsA%253D%253D&md5=b33b5be32688befaec3c784353447211</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2Fj.currproblcancer.2013.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.currproblcancer.2013.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DJeong%26aufirst%3DW.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DKummar%26aufirst%3DS.%26atitle%3DUnited%2520States%2520Food%2520and%2520Drug%2520Administration%2520approved%2520oral%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520malignancies%26jtitle%3DCurr.%2520Probl.%2520Cancer%26date%3D2013%26volume%3D37%26spage%3D110%26epage%3D144%26doi%3D10.1016%2Fj.currproblcancer.2013.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mak, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagden, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebot, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazumdar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazzah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzuto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greystoke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auger, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkenau, H.-T.</span></span> <span> </span><span class="NLM_article-title">A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">975</span>â <span class="NLM_lpage">981</span>, <span class="refDoi">Â DOI: 10.1038/s41416-019-0452-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fs41416-019-0452-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=30992546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFWmsLrF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2019&pages=975-981&author=G.+Makauthor=J.-C.+Soriaauthor=S.+P.+Blagdenauthor=R.+Plummerauthor=R.+A.+Flemingauthor=N.+Nebotauthor=J.+Zhangauthor=J.+Mazumdarauthor=D.+Roganauthor=A.+Gazzahauthor=I.+Rizzutoauthor=A.+Greystokeauthor=L.+Yanauthor=J.+Tolsonauthor=K.+R.+Augerauthor=H.-T.+Arkenau&title=A+phase+Ib+dose-finding%2C+pharmacokinetic+study+of+the+focal+adhesion+kinase+inhibitor+GSK2256098+and+trametinib+in+patients+with+advanced+solid+tumours&doi=10.1038%2Fs41416-019-0452-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours</span></div><div class="casAuthors">Mak, Gabriel; Soria, Jean-Charles; Blagden, Sarah P.; Plummer, Ruth; Fleming, Ronald A.; Nebot, Noelia; Zhang, Jianping; Mazumdar, Jolly; Rogan, Debra; Gazzah, Anas; Rizzuto, Ivana; Greystoke, Alastair; Yan, Li; Tolson, Jerry; Auger, Kurt R.; Arkenau, Hendrik-Tobias</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">975-981</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Background: Combined focal adhesion kinase (FAK) and MEK inhibition may provide greater anticancer effect than FAK monotherapy.  Methods: This dose-finding phase Ib study (adaptive 3 + 3 design) detd. the max. tolerated dose (MTD) of trametinib and the FAK inhibitor GSK2256098 in combination.  Eligible patients had mesothelioma or other solid tumors with probable mitogen activated protein kinase pathway activation.  Adverse events (AEs), dose-limiting toxicities, disease progression and pharmacokinetics/pharmacodynamics were analyzed.  Results: Thirty-four subjects were enrolled.  The GSK2256098/trametinib MTDs were 500 mg twice daily (BID)/0.375 mg once daily (QD) (high/low) and 250 mg BID/0.5 mg QD (low/high).  The most common AEs were nausea, diarrhoea, decreased appetite, pruritus, fatigue and rash; none were grade 4.  Systemic exposure to trametinib increased when co-administered with GSK2256098, vs. trametinib monotherapy; GSK2256098 pharmacokinetics were unaffected by concomitant trametinib.  Median progression-free survival (PFS) was 11.8 wk (95% CI: 6.1-24.1) in subjects with mesothelioma and was longer with Merlin-neg. vs. Merlin-pos. tumors (15.0 vs 7.3 wk).  Conclusions: Trametinib exposure increased when co-administered with GSK2256098, but not vice versa.  Mesothelioma patients with loss of Merlin had longer PFS than subjects with wild-type, although support for efficacy with this combination was limited.  Safety profiles were acceptable up to the MTD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovNTEJjHaRLLVg90H21EOLACvtfcHk0lhJiBQvF1xaXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFWmsLrF&md5=3303a98dfafb0360b04050962b8d7cc5</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1038%2Fs41416-019-0452-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41416-019-0452-3%26sid%3Dliteratum%253Aachs%26aulast%3DMak%26aufirst%3DG.%26aulast%3DSoria%26aufirst%3DJ.-C.%26aulast%3DBlagden%26aufirst%3DS.%2BP.%26aulast%3DPlummer%26aufirst%3DR.%26aulast%3DFleming%26aufirst%3DR.%2BA.%26aulast%3DNebot%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DMazumdar%26aufirst%3DJ.%26aulast%3DRogan%26aufirst%3DD.%26aulast%3DGazzah%26aufirst%3DA.%26aulast%3DRizzuto%26aufirst%3DI.%26aulast%3DGreystoke%26aufirst%3DA.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DTolson%26aufirst%3DJ.%26aulast%3DAuger%26aufirst%3DK.%2BR.%26aulast%3DArkenau%26aufirst%3DH.-T.%26atitle%3DA%2520phase%2520Ib%2520dose-finding%252C%2520pharmacokinetic%2520study%2520of%2520the%2520focal%2520adhesion%2520kinase%2520inhibitor%2520GSK2256098%2520and%2520trametinib%2520in%2520patients%2520with%2520advanced%2520solid%2520tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2019%26volume%3D120%26spage%3D975%26epage%3D981%26doi%3D10.1038%2Fs41416-019-0452-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 5 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Qinggang Wang, Ricardo Gallardo-Macias, Rashmi, Mikhail Y. Golovko, Ahmed Adham Raafat Elsayed, Shyam K. More, Sema Oncel, Vadim J. Gurvich, <span class="NLM_string-name hlFld-ContribAuthor">Marc D. Basson</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Small-Molecule FAK Activators Promoting Mucosal Healing. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>12 </em>
                                    (3)
                                     , 356-364. <a href="https://doi.org/10.1021/acsmedchemlett.0c00311" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00311</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00311%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BNovel%252BSmall-Molecule%252BFAK%252BActivators%252BPromoting%252BMucosal%252BHealing%26aulast%3DWang%26aufirst%3DQinggang%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D04062020%26date%3D12022021%26date%3D16022021%26volume%3D12%26issue%3D3%26spage%3D356%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hanyi  Tan</span>, <span class="hlFld-ContribAuthor ">Yue  Liu</span>, <span class="hlFld-ContribAuthor ">Chaochao  Gong</span>, <span class="hlFld-ContribAuthor ">Jiawei  Zhang</span>, <span class="hlFld-ContribAuthor ">Jian  Huang</span>, <span class="hlFld-ContribAuthor ">Qian  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and evaluation of FAK inhibitors with a 5-fluoro-7H-pyrrolo[2,3-d]pyrimidine scaffold as anti-hepatocellular carcinoma agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>223 </em>, 113670. <a href="https://doi.org/10.1016/j.ejmech.2021.113670" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113670</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113670&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113670%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bevaluation%252Bof%252BFAK%252Binhibitors%252Bwith%252Ba%252B5-fluoro-7H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidine%252Bscaffold%252Bas%252Banti-hepatocellular%252Bcarcinoma%252Bagents%26aulast%3DTan%26aufirst%3DHanyi%26date%3D2021%26volume%3D223%26spage%3D113670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Muhamad  Mustafa</span>, <span class="hlFld-ContribAuthor ">Amer Ali  Abd El-Hafeez</span>, <span class="hlFld-ContribAuthor ">Dalia  Abdelhamid</span>, <span class="hlFld-ContribAuthor ">Gajanan D.  Katkar</span>, <span class="hlFld-ContribAuthor ">Yaser A.  Mostafa</span>, <span class="hlFld-ContribAuthor ">Pradipta  Ghosh</span>, <span class="hlFld-ContribAuthor ">Alaa M.  Hayallah</span>, <span class="hlFld-ContribAuthor ">Gamal El-Din A.  Abuo-Rahma</span>. </span><span class="cited-content_cbyCitation_article-title">A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>222 </em>, 113569. <a href="https://doi.org/10.1016/j.ejmech.2021.113569" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113569</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113569%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Bfirst-in-class%252Banticancer%252Bdual%252BHDAC2%25252FFAK%252Binhibitors%252Bbearing%252Bhydroxamates%25252Fbenzamides%252Bcapped%252Bby%252Bpyridinyl-1%25252C2%25252C4-triazoles%26aulast%3DMustafa%26aufirst%3DMuhamad%26date%3D2021%26volume%3D222%26spage%3D113569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fei  Yu</span>, <span class="hlFld-ContribAuthor ">Ming  Cai</span>, <span class="hlFld-ContribAuthor ">Liang  Shao</span>, <span class="hlFld-ContribAuthor ">Jihong  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Protein Kinases Degradation by PROTACs. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Chemistry</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.3389/fchem.2021.679120" title="DOI URL">https://doi.org/10.3389/fchem.2021.679120</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fchem.2021.679120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffchem.2021.679120%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Chemistry%26atitle%3DTargeting%252BProtein%252BKinases%252BDegradation%252Bby%252BPROTACs%26aulast%3DYu%26aufirst%3DFei%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Muhamad  Mustafa</span>, <span class="hlFld-ContribAuthor ">Gamal El-Din A.  Abuo-Rahma</span>, <span class="hlFld-ContribAuthor ">Amer Ali  Abd El-Hafeez</span>, <span class="hlFld-ContribAuthor ">Esam R.  Ahmed</span>, <span class="hlFld-ContribAuthor ">Dalia  Abdelhamid</span>, <span class="hlFld-ContribAuthor ">Pradipta  Ghosh</span>, <span class="hlFld-ContribAuthor ">Alaa M.  Hayallah</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of antiproliferative and anti-FAK inhibitory activity of 1,2,4-triazole derivatives containing acetamido carboxylic acid skeleton. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>40 </em>, 127965. <a href="https://doi.org/10.1016/j.bmcl.2021.127965" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127965</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127965%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bantiproliferative%252Band%252Banti-FAK%252Binhibitory%252Bactivity%252Bof%252B1%25252C2%25252C4-triazole%252Bderivatives%252Bcontaining%252Bacetamido%252Bcarboxylic%252Bacid%252Bskeleton%26aulast%3DMustafa%26aufirst%3DMuhamad%26date%3D2021%26volume%3D40%26spage%3D127965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of FAK- and FAK-related signaling pathways in cancer progression.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of FAK inhibitors in clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structures of ATP-competitive FAK inhibitors <b>6</b>â<b>14</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Crystal structure of TAE226 complexed with the kinase domain of FAK (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JKK">2JKK</a>). Hydrogen bonds are shown in yellow dash lines. The residues that can form hydrogen bonds with TAE226 were shown in yellow.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Chemical structures of ATP-competitive FAK inhibitors <b>15</b>â<b>20</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Chemical structures of compounds <b>21</b>â<b>25</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Chemical structures of allosteric kinase domain inhibitors <b>26</b>â<b>30</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Crystal structure of compound <b>26</b> complexed with the kinase domain of FAK (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EBV">4EBV</a>). Hydrogen bonds are shown in yellow dash lines. Compound <b>26</b> was shown in violet. Residues Arg550 and Asp604 in FAK were shown in yellow.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Crystal structure of compound <b>28</b> complexed with the kinase domain of FAK (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4I4F">4I4F</a>). Hydrogen bonds are shown in yellow dash lines. Compound <b>28</b> was shown in pale blue. Residues Arg550 and Asp604 in FAK were shown in yellow. Residues Met475, Val484, Leu486, and Met499 in FAK were shown in violet.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Chemical structures of Y397 antagonists <b>31</b>â<b>34</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Chemical structures of proteinâprotein interaction inhibitors <b>35</b>â<b>37</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Chemical structures of FAT domain inhibitors <b>38</b> and <b>39</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Schematic of the PROTAC-acting mechanism.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Chemical structures of compounds <b>40</b>â<b>44</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/medium/jm0c01248_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Chemical structures of compounds <b>45</b>â<b>49</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01248/20201203/images/large/jm0c01248_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01248&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i30">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20242" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20242" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 165 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schaller, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas Parsons, J.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase and associated proteins</span>. <i>Curr. Opin. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">705</span>â <span class="NLM_lpage">710</span>, <span class="refDoi">Â DOI: 10.1016/0955-0674(94)90097-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2F0955-0674%2894%2990097-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=7833050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADyaK2MXhtVOltrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1994&pages=705-710&author=M.+D.+Schallerauthor=J.+Thomas+Parsons&title=Focal+adhesion+kinase+and+associated+proteins&doi=10.1016%2F0955-0674%2894%2990097-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion kinase and associated proteins</span></div><div class="casAuthors">Schaller, Michael D.; Parsons, J. Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">705-10</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    </div><div class="casAbstract">A review with 44 refs.  Focal adhesion kinase (pp125FAK), a protein kinase, has recently been suggested to regulate aspects of signalling induced by integrins and by certain growth factor and hormone receptors.  New studies indicate that the domains of pp125FAK regulate its interactions with integrin subunits, other protein tyrosine kinases, and the focal adhesion-assocd. protein paxillin.  Through these interactions, pp125FAK may regulate signalling via different extracellular ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ0aT0RrcfCbVg90H21EOLACvtfcHk0litvzAgUGXoDg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXhtVOltrk%253D&md5=3ae3cd6cd92d0509efd017cc69d25af5</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2F0955-0674%2894%2990097-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0955-0674%252894%252990097-3%26sid%3Dliteratum%253Aachs%26aulast%3DSchaller%26aufirst%3DM.%2BD.%26aulast%3DThomas%2BParsons%26aufirst%3DJ.%26atitle%3DFocal%2520adhesion%2520kinase%2520and%2520associated%2520proteins%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D1994%26volume%3D6%26spage%3D705%26epage%3D710%26doi%3D10.1016%2F0955-0674%2894%2990097-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanks, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calalb, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. K.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">8487</span>â <span class="NLM_lpage">8491</span>, <span class="refDoi">Â DOI: 10.1073/pnas.89.18.8487</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1073%2Fpnas.89.18.8487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1528852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADyaK3sXmt1alsb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1992&pages=8487-8491&author=S.+K.+Hanksauthor=M.+B.+Calalbauthor=M.+C.+Harperauthor=S.+K.+Patel&title=Focal+adhesion+protein-tyrosine+kinase+phosphorylated+in+response+to+cell+attachment+to+fibronectin&doi=10.1073%2Fpnas.89.18.8487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin</span></div><div class="casAuthors">Hanks, Steven K.; Calalb, Mihail B.; Harper, Melinda C.; Patel, Sheetal K.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8487-91</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">A homol.-based cDNA cloning approach was used to identify a widely expressed protein-tyrosine kinase designated as focal adhesion kinase (FadK).  The entire mouse FadK amino acid sequence was deduced from cDNA clones, revealing a large (119-kDa) non-membrane-spanning protein-tyrosine kinase that lacks Src-homol. SH2 and SH3 domains.  Immunostaining of BALB/c3T3 fibroblasts revealed that FadK is concd. in focal adhesions.  FadK is phosphorylated on tyrosine in growing cultures of BALB/c 3T3 cells but contains little or no phosphotyrosine in cells detached by trypsinization.  The tyrosine-phosphorylated state is regained within minutes when the cells are replated onto fibronectin.  Activation of FadK may be an important early step in intracellular signal transduction pathways triggered in response to cell interactions with the extracellular matrix.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM5F6sZrlzsLVg90H21EOLACvtfcHk0litvzAgUGXoDg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXmt1alsb8%253D&md5=09a01a31b19ae6acc88515f3352688c4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1073%2Fpnas.89.18.8487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.89.18.8487%26sid%3Dliteratum%253Aachs%26aulast%3DHanks%26aufirst%3DS.%2BK.%26aulast%3DCalalb%26aufirst%3DM.%2BB.%26aulast%3DHarper%26aufirst%3DM.%2BC.%26aulast%3DPatel%26aufirst%3DS.%2BK.%26atitle%3DFocal%2520adhesion%2520protein-tyrosine%2520kinase%2520phosphorylated%2520in%2520response%2520to%2520cell%2520attachment%2520to%2520fibronectin%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1992%26volume%3D89%26spage%3D8487%26epage%3D8491%26doi%3D10.1073%2Fpnas.89.18.8487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L.</span></span> <span> </span><span class="NLM_article-title">The roles of nuclear focal adhesion kinase (FAK) on cancer: a focused review</span>. <i>J. Exp. Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">250</span>â <span class="NLM_lpage">350</span>, <span class="refDoi">Â DOI: 10.1186/s13046-019-1265-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1186%2Fs13046-019-1265-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=31186061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BB3M3lsVKjtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&pages=250-350&author=J.+Zhouauthor=Q.+Yiauthor=L.+Tang&title=The+roles+of+nuclear+focal+adhesion+kinase+%28FAK%29+on+cancer%3A+a+focused+review&doi=10.1186%2Fs13046-019-1265-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The roles of nuclear focal adhesion kinase (FAK) on Cancer: a focused review</span></div><div class="casAuthors">Zhou Jin; Tang Liling; Yi Qian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of experimental & clinical cancer research : CR</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">250</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">FAK is a tyrosine kinase overexpressed in cancer cells and plays an important role in the progression of tumors to a malignant phenotype.  Except for its typical role as a cytoplasmic kinase downstream of integrin and growth factor receptor signaling, related studies have shown new aspects of the roles of FAK in the nucleus.  FAK can promote p53 degradation through ubiquitination, leading to cancer cell growth and proliferation.  FAK can also regulate GATA4 and IL-33 expression, resulting in reduced inflammatory responses and immune escape.  These findings establish a new model of FAK from the cytoplasm to the nucleus.  Activated FAK binds to transcription factors and regulates gene expression.  Inactive FAK synergizes with different E3 ligases to promote the turnover of transcription factors by enhancing ubiquitination.  In the tumor microenvironment, nuclear FAK can regulate the formation of new blood vessels, affecting the tumor blood supply.  This article reviews the roles of nuclear FAK in regulating gene expression.  In addition, the use of FAK inhibitors to target nuclear FAK functions will also be emphasized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJvFbWKSujK36oPH0mYWL1fW6udTcc2eYpkpYhRLpafrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3lsVKjtQ%253D%253D&md5=2204d3c10aac92625041db67af555aeb</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1186%2Fs13046-019-1265-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-019-1265-1%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DYi%26aufirst%3DQ.%26aulast%3DTang%26aufirst%3DL.%26atitle%3DThe%2520roles%2520of%2520nuclear%2520focal%2520adhesion%2520kinase%2520%2528FAK%2529%2520on%2520cancer%253A%2520a%2520focused%2520review%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D38%26spage%3D250%26epage%3D350%26doi%3D10.1186%2Fs13046-019-1265-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauck, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aprikian, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begin, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapdelaine, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chevalier, S.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">164</span>â <span class="NLM_lpage">171</span>, <span class="refDoi">Â DOI: 10.1002/(SICI)1097-0215(19961009)68:2<169::AID-IJC4>3.0.CO;2-W</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1002%2F%28SICI%291097-0215%2819961009%2968%3A2%3C169%3A%3AAID-IJC4%3E3.0.CO%3B2-W" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=8900422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADyaK28XntlKjtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=1996&pages=164-171&author=L.+Tremblayauthor=W.+Hauckauthor=A.+G.+Aprikianauthor=L.+R.+Beginauthor=A.+Chapdelaineauthor=S.+Chevalier&title=Focal+adhesion+kinase+%28pp125FAK%29+expression%2C+activation+and+association+with+paxillin+and+p50CSK+in+human+metastatic+prostate+carcinoma&doi=10.1002%2F%28SICI%291097-0215%2819961009%2968%3A2%3C169%3A%3AAID-IJC4%3E3.0.CO%3B2-W"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma</span></div><div class="casAuthors">Tremblay, Lise; Hauck, Wendy; Aprikian, Armen G.; Begin, Louis R.; Chapdelaine, Alcide; Chevalier, Simone</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">164-171</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss</span>)
        </div><div class="casAbstract">Pp125FAK, a protein tyrosine kinase (PTK) co-localized with integrins in focal adhesion plaques, is known to transduce signals involved in the regulation of cell adhesion and motility as well as the anchorage-independent growth of transformed cells.  The authors investigated whether pp125FAK could be part of a signaling pathway that contributes to the progression of human prostate carcinoma (PCa).  Up-regulation of pp125FAK expression, its activation by phosphorylation on tyrosine and its assocn. with paxillin and p50CSK were preferentially obsd. in PCa tissues from patients with metastases, whereas normal and hyperplastic prostates and localized PCa tissues showed undetectable or low levels of both FAK mRNA and protein and an absence of pp125FAK signaling complexes.  The increase in expression and activation of pp125FAK in metastatic PCa tissues was also corroborated by the findings in human PCa cell lines.  Indeed, higher levels of pp125FAK mRNA were obsd. in highly tumorigenic PC-3 cells as was the presence of activated pp125FAK, as opposed to an inactive form in LNCaP cells, which have a lower tumorigenic ability.  In addn., pp125FAK formed signaling complexes with both paxillin and p50CSK in PC-3 cells as in metastatic PCa tissues.  Together, the results show that an increase in FAK mRNA and protein, as well as pp125FAK activation and assocn. with signaling proteins, correlates with progression and invasion in human PCa tissues and cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreuJ1bwa8wzLVg90H21EOLACvtfcHk0lhN3RBDtezEvw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XntlKjtbk%253D&md5=ffbc05e8990d1c18bc411ce7f49f5d04</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291097-0215%2819961009%2968%3A2%3C169%3A%3AAID-IJC4%3E3.0.CO%3B2-W&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291097-0215%252819961009%252968%253A2%253C169%253A%253AAID-IJC4%253E3.0.CO%253B2-W%26sid%3Dliteratum%253Aachs%26aulast%3DTremblay%26aufirst%3DL.%26aulast%3DHauck%26aufirst%3DW.%26aulast%3DAprikian%26aufirst%3DA.%2BG.%26aulast%3DBegin%26aufirst%3DL.%2BR.%26aulast%3DChapdelaine%26aufirst%3DA.%26aulast%3DChevalier%26aufirst%3DS.%26atitle%3DFocal%2520adhesion%2520kinase%2520%2528pp125FAK%2529%2520expression%252C%2520activation%2520and%2520association%2520with%2520paxillin%2520and%2520p50CSK%2520in%2520human%2520metastatic%2520prostate%2520carcinoma%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D1996%26volume%3D68%26spage%3D164%26epage%3D171%26doi%3D10.1002%2F%28SICI%291097-0215%2819961009%2968%3A2%3C169%3A%3AAID-IJC4%3E3.0.CO%3B2-W" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timpson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horvath, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, R. J.</span></span> <span> </span><span class="NLM_article-title">FAK signaling in human cancer as a target for therapeutics</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">132</span>â <span class="NLM_lpage">149</span>, <span class="refDoi">Â DOI: 10.1016/j.pharmthera.2014.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.pharmthera.2014.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=25316657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGlu7rN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2015&pages=132-149&author=B.+Y.+Leeauthor=P.+Timpsonauthor=L.+G.+Horvathauthor=R.+J.+Daly&title=FAK+signaling+in+human+cancer+as+a+target+for+therapeutics&doi=10.1016%2Fj.pharmthera.2014.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">FAK signaling in human cancer as a target for therapeutics</span></div><div class="casAuthors">Lee, Brian Y.; Timpson, Paul; Horvath, Lisa G.; Daly, Roger J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">132-149</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Focal adhesion kinase (FAK) is a key regulator of growth factor receptor- and integrin-mediated signals, governing fundamental processes in normal and cancer cells through its kinase activity and scaffolding function.  Increased FAK expression and activity occurs in primary and metastatic cancers of many tissue origins, and is often assocd. with poor clin. outcome, highlighting FAK as a potential determinant of tumor development and metastasis.  Indeed, data from cell culture and animal models of cancer provide strong lines of evidence that FAK promotes malignancy by regulating tumorigenic and metastatic potential through highly-coordinated signaling networks that orchestrate a diverse range of cellular processes, such as cell survival, proliferation, migration, invasion, epithelial-mesenchymal transition, angiogenesis and regulation of cancer stem cell activities.  Such an integral role in governing malignant characteristics indicates that FAK represents a potential target for cancer therapeutics.  While pharmacol. targeting of FAK scaffold function is still at an early stage of development, a no. of small mol.-based FAK tyrosine kinase inhibitors are currently undergoing pre-clin. and clin. testing.  In particular, PF-00562271, VS-4718 and VS-6063 show promising clin. activities in patients with selected solid cancers.  Clin. testing of rationally designed FAK-targeting agents with implementation of predictive response biomarkers, such as merlin deficiency for VS-4718 in mesothelioma, may help improve clin. outcome for cancer patients.  In this article, we have reviewed the current knowledge regarding FAK signaling in human cancer, and recent developments in the generation and clin. application of FAK-targeting pharmacol. agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLnxnFQsOShLVg90H21EOLACvtfcHk0lhN3RBDtezEvw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGlu7rN&md5=7359c2a7671631f97a9d46ccef1ab68f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2014.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2014.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DB.%2BY.%26aulast%3DTimpson%26aufirst%3DP.%26aulast%3DHorvath%26aufirst%3DL.%2BG.%26aulast%3DDaly%26aufirst%3DR.%2BJ.%26atitle%3DFAK%2520signaling%2520in%2520human%2520cancer%2520as%2520a%2520target%2520for%2520therapeutics%26jtitle%3DPharmacol.%2520Ther.%26date%3D2015%26volume%3D146%26spage%3D132%26epage%3D149%26doi%3D10.1016%2Fj.pharmthera.2014.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naomoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakurama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motoki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomono, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukazawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirakawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamatsuji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takaoka, M.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase as potential target for cancer therapy (review)</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">973</span>â <span class="NLM_lpage">979</span>, <span class="refDoi">Â DOI: 10.3892/or_00000524</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.3892%2For_00000524" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=19787209" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCjtb7O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=973-979&author=H.+Haoauthor=Y.+Naomotoauthor=X.+Baoauthor=N.+Watanabeauthor=K.+Sakuramaauthor=K.+Nomaauthor=T.+Motokiauthor=Y.+Tomonoauthor=T.+Fukazawaauthor=Y.+Shirakawaauthor=T.+Yamatsujiauthor=J.+Matsuokaauthor=Z.+G.+Wangauthor=M.+Takaoka&title=Focal+adhesion+kinase+as+potential+target+for+cancer+therapy+%28review%29&doi=10.3892%2For_00000524"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion kinase as potential target for cancer therapy (Review)</span></div><div class="casAuthors">Hao, Huifang; Naomoto, Yoshio; Bao, Xiaohong; Watanabe, Nobuyuki; Sakurama, Kazufumi; Noma, Kazuhiro; Motoki, Takayuki; Tomono, Yasuko; Fukazawa, Takuya; Shirakawa, Yasuhiro; Yamatsuji, Tomoki; Matsuoka, Junji; Wang, Z. G.; Takaoka, Munenori</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">973-979</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Oncology Reports</span>)
        </div><div class="casAbstract">A review.  Focal adhesion kinase (FAK) is a 125-kDa non-receptor and non-membrane protein tyrosine.  FAK can function with integrins and growth factor receptors to promote cell survival dependent kinase activity and nuclear FAK promotes cell proliferation and survival through FERM (FAK, ezrin, radixin, moesin) domain-enhanced p53 degrdn. independent kinase activity.  Many previous studies have indicated that FAK plays a crit. role in the biol. processes of normal and cancer cells and FAK has been proposed as a potential target in cancer therapy.  Small mol. inhibitors (PF-573,228; PF-562,271 and NVP-226) for use as potential cancer therapies have been developed.  However, the detailed mechanism of the role for FAK in tumor cell generation and progression remain unclear, so future work is needed to explore these issues.  New inhibitors that can be effectively inhibit the function of FAK still need to be explored due to the low specificity, and resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-fIMPplLyU7Vg90H21EOLACvtfcHk0lhM-jlEq3XxDg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCjtb7O&md5=9d5aacc37270d88d72b0d7534611b512</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3892%2For_00000524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For_00000524%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DH.%26aulast%3DNaomoto%26aufirst%3DY.%26aulast%3DBao%26aufirst%3DX.%26aulast%3DWatanabe%26aufirst%3DN.%26aulast%3DSakurama%26aufirst%3DK.%26aulast%3DNoma%26aufirst%3DK.%26aulast%3DMotoki%26aufirst%3DT.%26aulast%3DTomono%26aufirst%3DY.%26aulast%3DFukazawa%26aufirst%3DT.%26aulast%3DShirakawa%26aufirst%3DY.%26aulast%3DYamatsuji%26aufirst%3DT.%26aulast%3DMatsuoka%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DZ.%2BG.%26aulast%3DTakaoka%26aufirst%3DM.%26atitle%3DFocal%2520adhesion%2520kinase%2520as%2520potential%2520target%2520for%2520cancer%2520therapy%2520%2528review%2529%26jtitle%3DOncol.%2520Rep.%26date%3D2009%26volume%3D22%26spage%3D973%26epage%3D979%26doi%3D10.3892%2For_00000524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sulzmaier, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlaepfer, D. D.</span></span> <span> </span><span class="NLM_article-title">FAK in cancer: mechanistic findings and clinical applications</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">598</span>â <span class="NLM_lpage">610</span>, <span class="refDoi">Â DOI: 10.1038/nrc3792</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fnrc3792" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=25098269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht12nu7vJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=598-610&author=F.+J.+Sulzmaierauthor=C.+Jeanauthor=D.+D.+Schlaepfer&title=FAK+in+cancer%3A+mechanistic+findings+and+clinical+applications&doi=10.1038%2Fnrc3792"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">FAK in cancer: mechanistic findings and clinical applications</span></div><div class="casAuthors">Sulzmaier, Florian J.; Jean, Christine; Schlaepfer, David D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">598-610</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Focal adhesion kinase (FAK) is a cytoplasmic protein tyrosine kinase that is overexpressed and activated in several advanced-stage solid cancers.  FAK promotes tumor progression and metastasis through effects on cancer cells, as well as stromal cells of the tumor microenvironment.  The kinase-dependent and kinase-independent functions of FAK control cell movement, invasion, survival, gene expression and cancer stem cell self-renewal.  Small mol. FAK inhibitors decrease tumor growth and metastasis in several preclin. models and have initial clin. activity in patients with limited adverse events.  In this Review, we discuss FAK signalling effects on both tumor and stromal cell biol. that provide rationale and support for future therapeutic opportunities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmKc7m7dsY67Vg90H21EOLACvtfcHk0lhM-jlEq3XxDg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht12nu7vJ&md5=f498bcf7af890d2f92eda68e42f979d1</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrc3792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3792%26sid%3Dliteratum%253Aachs%26aulast%3DSulzmaier%26aufirst%3DF.%2BJ.%26aulast%3DJean%26aufirst%3DC.%26aulast%3DSchlaepfer%26aufirst%3DD.%2BD.%26atitle%3DFAK%2520in%2520cancer%253A%2520mechanistic%2520findings%2520and%2520clinical%2520applications%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D598%26epage%3D610%26doi%3D10.1038%2Fnrc3792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sood, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffin, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeYoung, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruman, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gershenson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaller, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrix, M. J.</span></span> <span> </span><span class="NLM_article-title">Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">1087</span>â <span class="NLM_lpage">1095</span>, <span class="refDoi">Â DOI: 10.1016/S0002-9440(10)63370-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2FS0002-9440%2810%2963370-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=15466376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptFSmtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2004&pages=1087-1095&author=A.+K.+Soodauthor=J.+E.+Coffinauthor=G.+B.+Schneiderauthor=M.+S.+Fletcherauthor=B.+R.+DeYoungauthor=L.+M.+Grumanauthor=D.+M.+Gershensonauthor=M.+D.+Schallerauthor=M.+J.+Hendrix&title=Biological+significance+of+focal+adhesion+kinase+in+ovarian+cancer%3A+role+in+migration+and+invasion&doi=10.1016%2FS0002-9440%2810%2963370-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion</span></div><div class="casAuthors">Sood, Anil K.; Coffin, Jeremy E.; Schneider, Galen B.; Fletcher, Mavis S.; DeYoung, Barry R.; Gruman, Lynn M.; Gershenson, David M.; Schaller, Michael D.; Hendrix, Mary J. C.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1087-1095</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that is activated by integrin clustering.  There are limited data regarding the functional role of FAK in ovarian cancer migration and invasion.  In the current study, FAK expression was evaluated in ovarian cell lines (nontransformed and cancer), 12 benign ovarian samples, and in 79 invasive epithelial ovarian cancers.  All three ovarian cancer cell lines overexpressed FAK compared to the nontransformed cells.  The dominant-neg. construct called FAK-related non-kinase (FRNK) was introduced into two ovarian cancer cell tines (SKOV3 and 222).  FRNK promoted FAK dephosphorylation without changing total FAK levels in these cell lines.  Furthermore, FRNK decreased the in vitro invasive ability of ovarian cancer cells by 56 to 85% and decreased migration by 52 to 68%.  FRNK-transfected cells also displayed poor cell spreading.  Immunohistochem. anal. revealed that the surface epithelium from all benign ovarian samples had weak FAK expression.  In contrast, 68% of invasive ovarian cancers overexpressed FAK.  FAK overexpression was significantly assocd. with high tumor stage, high tumor grade, pos. lymph nodes and presence of distant metastasis (all P values <0.05).  FAK overexpression was also assocd. with shorter overall survival (P = 0.008).  Multivariate anal. revealed that FAK overexpression and residual disease >1 cm were independent predictors of poor survival.  These data indicate that FAK is overexpressed in most invasive ovarian cancers and plays a functionally significant role in ovarian cancer migration and invasion.  Thus, FAK may be an important therapeutic target in ovarian carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohH5AA1GLo_LVg90H21EOLACvtfcHk0lhM-jlEq3XxDg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptFSmtrw%253D&md5=2809d3d73de06418f39b5616f0ae2e02</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2963370-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252963370-6%26sid%3Dliteratum%253Aachs%26aulast%3DSood%26aufirst%3DA.%2BK.%26aulast%3DCoffin%26aufirst%3DJ.%2BE.%26aulast%3DSchneider%26aufirst%3DG.%2BB.%26aulast%3DFletcher%26aufirst%3DM.%2BS.%26aulast%3DDeYoung%26aufirst%3DB.%2BR.%26aulast%3DGruman%26aufirst%3DL.%2BM.%26aulast%3DGershenson%26aufirst%3DD.%2BM.%26aulast%3DSchaller%26aufirst%3DM.%2BD.%26aulast%3DHendrix%26aufirst%3DM.%2BJ.%26atitle%3DBiological%2520significance%2520of%2520focal%2520adhesion%2520kinase%2520in%2520ovarian%2520cancer%253A%2520role%2520in%2520migration%2520and%2520invasion%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2004%26volume%3D165%26spage%3D1087%26epage%3D1095%26doi%3D10.1016%2FS0002-9440%2810%2963370-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beierle, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massoll, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartwich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurenova, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golubovskaya, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cance, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrady, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">London, W. B.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase expression in human neuroblastoma: immunohistochemical and real-time PCR analyses</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">3299</span>â <span class="NLM_lpage">3305</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-07-1511</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1158%2F1078-0432.CCR-07-1511" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=18519756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmslygs7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=3299-3305&author=E.+A.+Beierleauthor=N.+A.+Massollauthor=J.+Hartwichauthor=E.+V.+Kurenovaauthor=V.+M.+Golubovskayaauthor=W.+G.+Canceauthor=P.+McGradyauthor=W.+B.+London&title=Focal+adhesion+kinase+expression+in+human+neuroblastoma%3A+immunohistochemical+and+real-time+PCR+analyses&doi=10.1158%2F1078-0432.CCR-07-1511"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Focal Adhesion Kinase Expression in Human Neuroblastoma: Immunohistochemical and Real-time PCR Analyses</span></div><div class="casAuthors">Beierle, Elizabeth A.; Massoll, Nicole A.; Hartwich, Joseph; Kurenova, Elena V.; Golubovskaya, Vita M.; Cance, William G.; McGrady, Patrick; London, Wendy B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3299-3305</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The focal adhesion kinase (FAK) is a nonreceptor protein tyrosine kinase important in signaling between cells and their extracellular matrix.  Studies have shown that FAK expression is up-regulated in several human tumors and is related to tumor progression.  We recently found an increase in p125FAK expression in human neuroblastoma cells lines and wished to det. its expression in human neuroblastoma specimens and evaluate for a possible correlation between p125FAK expression and known prognostic factors for neuroblastoma.  We hypothesized that p125FAK expression would be up-regulated in advanced human neuroblastomas.  Using immunohistochem. techniques with monoclonal antibody 4.47 specific for p125FAK expression, we analyzed 70 formalin-fixed, paraffin-embedded human neuroblastoma specimens for p125FAK staining.  In addn., real-time PCR was used to det. the abundance of FAK mRNA in 17 matched human neuroblastoma mRNA specimens.  FAK staining was present in 51 of the 70 tumor specimens (73%).  Immunohistochem. staining of p125FAK in the ganglion-type tumor cells correlated with advanced International Neuroblastoma Staging System tumor stages and FAK mRNA abundance.  In addn., p125FAK staining was significantly increased in stage IV tumors with amplification of the N-MYC oncogene.  These novel findings provide evidence that FAK is expressed by advanced-stage neuroblastoma and provide a rationale for targeting FAK in the treatment of this tumor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ05dypioR1bVg90H21EOLACvtfcHk0lizJa0ogS21JQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmslygs7c%253D&md5=214b9cf6ca82f325422ba519958fad95</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-1511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-1511%26sid%3Dliteratum%253Aachs%26aulast%3DBeierle%26aufirst%3DE.%2BA.%26aulast%3DMassoll%26aufirst%3DN.%2BA.%26aulast%3DHartwich%26aufirst%3DJ.%26aulast%3DKurenova%26aufirst%3DE.%2BV.%26aulast%3DGolubovskaya%26aufirst%3DV.%2BM.%26aulast%3DCance%26aufirst%3DW.%2BG.%26aulast%3DMcGrady%26aufirst%3DP.%26aulast%3DLondon%26aufirst%3DW.%2BB.%26atitle%3DFocal%2520adhesion%2520kinase%2520expression%2520in%2520human%2520neuroblastoma%253A%2520immunohistochemical%2520and%2520real-time%2520PCR%2520analyses%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D3299%26epage%3D3305%26doi%3D10.1158%2F1078-0432.CCR-07-1511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furuyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyoda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koizumi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kida, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, K.</span></span> <span> </span><span class="NLM_article-title">Clinical significance of focal adhesion kinase in resectable pancreatic cancer</span>. <i>World J. Surg.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">219</span>â <span class="NLM_lpage">226</span>, <span class="refDoi">Â DOI: 10.1007/s00268-005-0165-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1007%2Fs00268-005-0165-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=16425085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BD28%252FltFOhsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2006&pages=219-226&author=K.+Furuyamaauthor=R.+Doiauthor=T.+Moriauthor=E.+Toyodaauthor=D.+Itoauthor=K.+Kamiauthor=M.+Koizumiauthor=A.+Kidaauthor=Y.+Kawaguchiauthor=K.+Fujimoto&title=Clinical+significance+of+focal+adhesion+kinase+in+resectable+pancreatic+cancer&doi=10.1007%2Fs00268-005-0165-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical significance of focal adhesion kinase in resectable pancreatic cancer</span></div><div class="casAuthors">Furuyama Kenichiro; Doi Ryuichiro; Mori Tomohiko; Toyoda Eiji; Ito Daisuke; Kami Kazuhiro; Koizumi Masayuki; Kida Atsushi; Kawaguchi Yoshiya; Fujimoto Koji</div><div class="citationInfo"><span class="NLM_cas:title">World journal of surgery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">219-26</span>
        ISSN:<span class="NLM_cas:issn">0364-2313</span>.
    </div><div class="casAbstract">Focal adhesion kinase (FAK) is a non-receptor, cytoplasmic protein tyrosine kinase that is involved in the regulation of cellular signaling, migration, apoptosis, and cell cycle progression.  Previous reports have shown that FAK is expressed in various kinds of cancer tissues and cancer cell lines; however, no information is available about human pancreatic carcinoma specimens.  Tissue such specimens were obtained from 50 patients who underwent pancreatic resection for pancreatic invasive ductal carcinoma at our institute from 1996 to 2002.  Immunohistochemical analysis of FAK was performed in the resected specimens.  Focal adhesion kinase expression in seven human pancreatic cancer cell lines was analyzed by reverse transcription polymerase chain reaction (PCR) analysis and Western blot analysis.  Focal adhesion kinase expression was detected in 24 of 50 cases (48%).  There was a statistically significant correlation between FAK expression and tumor size (P=0.004), although FAK expression did not significantly correlate with other factors such as tumor histological grade, lymph node metastasis, distant metastasis, histological stage, and overall survival.  Reverse transcription PCR analysis and Western blot analysis showed that FAK was expressed in all seven pancreatic cancer cell lines.  Focal adhesion kinase expression was not directly related to clinicopathological factors except tumor size in pancreatic carcinoma.  Focal adhesion kinase expression may not be a prognostic marker for pancreatic cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTIG5v5mnIkWbt7lRqEFUJVfW6udTcc2eYSUzDEg81kDLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28%252FltFOhsQ%253D%253D&md5=efab3182eaa09482332afb178f1aaa8b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs00268-005-0165-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00268-005-0165-z%26sid%3Dliteratum%253Aachs%26aulast%3DFuruyama%26aufirst%3DK.%26aulast%3DDoi%26aufirst%3DR.%26aulast%3DMori%26aufirst%3DT.%26aulast%3DToyoda%26aufirst%3DE.%26aulast%3DIto%26aufirst%3DD.%26aulast%3DKami%26aufirst%3DK.%26aulast%3DKoizumi%26aufirst%3DM.%26aulast%3DKida%26aufirst%3DA.%26aulast%3DKawaguchi%26aufirst%3DY.%26aulast%3DFujimoto%26aufirst%3DK.%26atitle%3DClinical%2520significance%2520of%2520focal%2520adhesion%2520kinase%2520in%2520resectable%2520pancreatic%2520cancer%26jtitle%3DWorld%2520J.%2520Surg.%26date%3D2006%26volume%3D30%26spage%3D219%26epage%3D226%26doi%3D10.1007%2Fs00268-005-0165-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Nimwegen, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkoeijen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Buren, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Water, B. V.</span></span> <span> </span><span class="NLM_article-title">Requirement for focal adhesion kinase in the early phase of mammary adenocarcinoma lung metastasis formation</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">4698</span>â <span class="NLM_lpage">4706</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-04-4126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1158%2F0008-5472.CAN-04-4126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=15930288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Ohtbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=4698-4706&author=M.+J.+van%0ANimwegenauthor=S.+Verkoeijenauthor=L.+van+Burenauthor=D.+Burgauthor=B.+V.+de+Water&title=Requirement+for+focal+adhesion+kinase+in+the+early+phase+of+mammary+adenocarcinoma+lung+metastasis+formation&doi=10.1158%2F0008-5472.CAN-04-4126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement for Focal Adhesion Kinase in the Early Phase of Mammary Adenocarcinoma Lung Metastasis Formation</span></div><div class="casAuthors">van Nimwegen, Maroesja J.; Verkoeijen, Saertje; Van Buren, Liesbeth; Burg, Danny; Van de Water, Bob</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4698-4706</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">An increased expression of focal adhesion kinase (FAK) in a variety of cancers is assocd. with a poor disease prognosis.  To study the role of FAK in breast tumor growth and metastasis formation, we used conditional doxycycline-regulated expression of a dominant-neg. acting splice variant of FAK, FAK-related non-kinase (FRNK), in MTLn3 mammary adenocarcinoma cells in a syngeneic Fischer 344 rat tumor and metastasis model.  In cell culture, doxycycline-mediated expression of FRNK inhibited MTLn3 cell spreading and migration in assocn. with reduced formation of focal adhesions and phosphorylation of FAK on Tyr397, but FRNK did not cause apoptosis.  Continuous expression of FRNK decreased the primary tumor growth in the mammary fat pad by 60%, which was not due to induction of apoptosis.  Lung metastasis formation was almost completely prevented when FRNK was already expressed 1 day before tumor cell injection, whereas expression of FRNK 11 days after injection did not affect lung metastasis formation.  FRNK expression during the first 5 days was sufficient to block metastasis formation, excluding the possibility of FRNK-induced dormancy of tumor cells.  Together, these data fit with a model wherein FAK is required for breast tumor cell invasion/migration processes that take place in the early phase of metastasis formation.  Our findings suggest that FAK is a good candidate for therapeutic intervention of metastasis formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrn9ojTuaPzrVg90H21EOLACvtfcHk0lizJa0ogS21JQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Ohtbo%253D&md5=3936071404b3179fff382bf9b685ed64</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-4126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-4126%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BNimwegen%26aufirst%3DM.%2BJ.%26aulast%3DVerkoeijen%26aufirst%3DS.%26aulast%3Dvan%2BBuren%26aufirst%3DL.%26aulast%3DBurg%26aufirst%3DD.%26aulast%3Dde%2BWater%26aufirst%3DB.%2BV.%26atitle%3DRequirement%2520for%2520focal%2520adhesion%2520kinase%2520in%2520the%2520early%2520phase%2520of%2520mammary%2520adenocarcinoma%2520lung%2520metastasis%2520formation%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D4698%26epage%3D4706%26doi%3D10.1158%2F0008-5472.CAN-04-4126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Golubovskaya, V. M.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase as a cancer therapy target</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">735</span>â <span class="NLM_lpage">741</span>, <span class="refDoi">Â DOI: 10.2174/187152010794728648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.2174%2F187152010794728648" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=21214510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslagt7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=735-741&author=V.+M.+Golubovskaya&title=Focal+adhesion+kinase+as+a+cancer+therapy+target&doi=10.2174%2F187152010794728648"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion kinase as a cancer therapy target</span></div><div class="casAuthors">Golubovskaya, Vita M.</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">735-741</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that resides at the sites of at focal adhesions.  The 125 kDa FAK protein is encoded by the FAK gene located on human chromosome 8q24.  Structurally, FAK consists of an amino-terminal regulatory FERM domain, a central catalytic kinase domain, and a carboxy-terminal focal adhesion targeting domain.  FAK has been shown to be an important mediator of cell adhesion, growth, proliferation, survival, angiogenesis and migration, all of which are often disrupted in cancer cells.  Normal tissues have low expression of FAK, while primary and metastatic tumors significantly overexpress this protein.  This review summarizes expression of FAK by immunohistochem. staining in different tumor types and presents several FAK inhibition therapy approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojPHf4gDk2PbVg90H21EOLACvtfcHk0liKL9GGgs-PCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslagt7o%253D&md5=0fdbd318a7e404803a18feff4c7773d4</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.2174%2F187152010794728648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152010794728648%26sid%3Dliteratum%253Aachs%26aulast%3DGolubovskaya%26aufirst%3DV.%2BM.%26atitle%3DFocal%2520adhesion%2520kinase%2520as%2520a%2520cancer%2520therapy%2520target%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2010%26volume%3D10%26spage%3D735%26epage%3D741%26doi%3D10.2174%2F187152010794728648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navajas, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lietha, D.</span></span> <span> </span><span class="NLM_article-title">FAK structure and regulation by membrane interactions and force in focal adhesions</span>. <i>Biomolecules</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">179</span>â <span class="NLM_lpage">194</span>, <span class="refDoi">Â DOI: 10.3390/biom10020179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.3390%2Fbiom10020179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjslCju7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=179-194&author=P.+T.+Martinezauthor=P.+L.+Navajasauthor=D.+Lietha&title=FAK+structure+and+regulation+by+membrane+interactions+and+force+in+focal+adhesions&doi=10.3390%2Fbiom10020179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">FAK structure and regulation by membrane interactions and force in focal adhesions</span></div><div class="casAuthors">Martinez, Paula Tapial; Navajas, Pilar Lopez; Lietha, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecules</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179</span>CODEN:
                <span class="NLM_cas:coden">BIOMHC</span>;
        ISSN:<span class="NLM_cas:issn">2218-273X</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase with key roles in the regulation of cell adhesion migration, proliferation and survival.  In cancer FAK is a major driver of invasion and metastasis and its upregulation is assocd. with poor patient prognosis.  FAK is autoinhibited in the cytosol, but activated upon localisation into a protein complex, known as focal adhesion complex.  This complex forms upon cell adhesion to the extracellular matrix (ECM) at the cytoplasmic side of the plasma membrane at sites of ECM attachment.  FAK is anchored to the complex via multiple sites, including direct interactions with specific membrane lipids and connector proteins that attach focal adhesions to the actin cytoskeleton.  In migrating cells, the contraction of actomyosin stress fibers attached to the focal adhesion complex apply a force to the complex, which is likely transmitted to the FAK protein, causing stretching of the FAK mol.  In this review we discuss the current knowledge of the FAK structure and how specific structural features are involved in the regulation of FAK signalling.  We focus on two major regulatory mechanisms known to contribute to FAK activation, namely interactions with membrane lipids and stretching forces applied to FAK, and discuss how they might induce structural changes that facilitate FAK activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC2hY9ihLIibVg90H21EOLACvtfcHk0liKL9GGgs-PCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjslCju7g%253D&md5=26ce7c20467ed267058d4df2ebffebfb</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.3390%2Fbiom10020179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fbiom10020179%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez%26aufirst%3DP.%2BT.%26aulast%3DNavajas%26aufirst%3DP.%2BL.%26aulast%3DLietha%26aufirst%3DD.%26atitle%3DFAK%2520structure%2520and%2520regulation%2520by%2520membrane%2520interactions%2520and%2520force%2520in%2520focal%2520adhesions%26jtitle%3DBiomolecules%26date%3D2020%26volume%3D10%26spage%3D179%26epage%3D194%26doi%3D10.3390%2Fbiom10020179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mousson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dujardin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Mey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronde, P.</span></span> <span> </span><span class="NLM_article-title">Targeting focal adhesion kinase using inhibitors of protein-protein interactions</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">278</span>â <span class="NLM_lpage">306</span>, <span class="refDoi">Â DOI: 10.3390/cancers10090278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.3390%2Fcancers10090278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVyhtrbP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=278-306&author=A.+Moussonauthor=E.+Sickauthor=P.+Carlauthor=D.+Dujardinauthor=J.+De+Meyauthor=P.+Ronde&title=Targeting+focal+adhesion+kinase+using+inhibitors+of+protein-protein+interactions&doi=10.3390%2Fcancers10090278"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting focal adhesion kinase using inhibitors of protein-protein interactions</span></div><div class="casAuthors">Mousson, Antoine; Sick, Emilie; Carl, Philippe; Dujardin, Denis; De Mey, Jan; Ronde, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">278/1-278/29</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Focal adhesion kinase (FAK) is a cytoplasmic non-receptor protein tyrosine kinase that is overexpressed and activated in many human cancers.  FAK transmits signals to a wide range of targets through both kinase-dependant and independent mechanism thereby playing essential roles in cell survival, proliferation, migration and invasion.  In the past years, small mols. that inhibit FAK kinase function have been developed and show reduced cancer progression and metastasis in several preclin. models.  Clin. trials have been conducted and these mols. display limited adverse effect in patients.  FAK contain multiple functional domains and thus exhibit both important scaffolding functions.  In this review, we describe the major FAK interactions relevant in cancer signalling and discuss how such knowledge provide rational for the development of Protein-Protein Interactions (PPI) inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-KUqDj7cnnbVg90H21EOLACvtfcHk0liKL9GGgs-PCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVyhtrbP&md5=4fbde422a29c412a95cbda787b11ee68</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.3390%2Fcancers10090278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers10090278%26sid%3Dliteratum%253Aachs%26aulast%3DMousson%26aufirst%3DA.%26aulast%3DSick%26aufirst%3DE.%26aulast%3DCarl%26aufirst%3DP.%26aulast%3DDujardin%26aufirst%3DD.%26aulast%3DDe%2BMey%26aufirst%3DJ.%26aulast%3DRonde%26aufirst%3DP.%26atitle%3DTargeting%2520focal%2520adhesion%2520kinase%2520using%2520inhibitors%2520of%2520protein-protein%2520interactions%26jtitle%3DCancers%26date%3D2018%26volume%3D10%26spage%3D278%26epage%3D306%26doi%3D10.3390%2Fcancers10090278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dontenwill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoeckel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronde, P.</span></span> <span> </span><span class="NLM_article-title">Regulation of focal adhesion dynamics and disassembly by phosphorylation of FAK at tyrosine 397</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">4415</span>â <span class="NLM_lpage">4425</span>, <span class="refDoi">Â DOI: 10.1242/jcs.02565</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1242%2Fjcs.02565" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=16159962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Wnur3K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2005&pages=4415-4425&author=A.+Hamadiauthor=M.+Boualiauthor=M.+Dontenwillauthor=H.+Stoeckelauthor=K.+Takedaauthor=P.+Ronde&title=Regulation+of+focal+adhesion+dynamics+and+disassembly+by+phosphorylation+of+FAK+at+tyrosine+397&doi=10.1242%2Fjcs.02565"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of focal adhesion dynamics and disassembly by phosphorylation of FAK at tyrosine 397</span></div><div class="casAuthors">Hamadi, Abdelkader; Bouali, Maya; Dontenwill, Monique; Stoeckel, Herrade; Takeda, Kenneth; Ronde, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4415-4425</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">One of the major tyrosine phosphorylation activities linked to integrin signaling is that of focal adhesion kinase (FAK).  High amts. of FAK are located at specialized subcellular compartments known as focal adhesions.  FAK tyrosine phosphorylation at focal adhesions is increased by various stimuli including integrin engagement during migration processes, growth factors and oncogene transformation.  Phosphorylation of FAK at various tyrosine residues regulates focal adhesion turnover by mechanisms that are not well understood.  We made a fluorescent FAK mutant (Y397F-FAK/YCam) to analyze, in living cells, how phosphorylation of FAK regulates the turnover of focal adhesions.  We found that expression of Y397F-FAK/YCam in human astrocytoma cells decreases the level of phosphorylation of FAK at endogenous Tyr-397 residues and at both endogenous and exogenous Tyr-576 residues, in the putative activation loop of the kinase.  This corresponds to a decrease in phosphorylation of FAK at focal adhesions in Y397F-FAK/YCam cells, since the cellular localization of FAK phosphoTyr-576 in cells expressing Y397F-FAK/YCam or FAK/YCam was not different.  Furthermore, FRAP anal. showed that phosphorylation of FAK at Tyr-397 increases specifically the time-residency of FAK at focal adhesions but not in cytosol.  This in turn induces disassembly of focal adhesions at the cell tail and promotes cell motility as shown by the decrease in microtubule-mediated turnover of Y397F-FAK/YCam-contg. focal adhesions.  Our data show that phosphorylation of FAK at Tyr-397 is a key determinant of how FAK controls focal adhesion turnover.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd9I1y9b-DyLVg90H21EOLACvtfcHk0liKL9GGgs-PCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Wnur3K&md5=8d8d473b1137ee5af167fc54ff1194c2</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1242%2Fjcs.02565&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.02565%26sid%3Dliteratum%253Aachs%26aulast%3DHamadi%26aufirst%3DA.%26aulast%3DBouali%26aufirst%3DM.%26aulast%3DDontenwill%26aufirst%3DM.%26aulast%3DStoeckel%26aufirst%3DH.%26aulast%3DTakeda%26aufirst%3DK.%26aulast%3DRonde%26aufirst%3DP.%26atitle%3DRegulation%2520of%2520focal%2520adhesion%2520dynamics%2520and%2520disassembly%2520by%2520phosphorylation%2520of%2520FAK%2520at%2520tyrosine%2520397%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2005%26volume%3D118%26spage%3D4415%26epage%3D4425%26doi%3D10.1242%2Fjcs.02565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dunty, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabarra-Niecko, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceccarelli, D. F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaller, M. D.</span></span> <span> </span><span class="NLM_article-title">FERM domain interaction promotes FAK signaling</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">5353</span>â <span class="NLM_lpage">5368</span>, <span class="refDoi">Â DOI: 10.1128/MCB.24.12.5353-5368.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1128%2FMCB.24.12.5353-5368.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=15169899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkvFOqtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=5353-5368&author=J.+M.+Duntyauthor=V.+Gabarra-Nieckoauthor=M.+L.+Kingauthor=D.+F.+J.+Ceccarelliauthor=M.+J.+Eckauthor=M.+D.+Schaller&title=FERM+domain+interaction+promotes+FAK+signaling&doi=10.1128%2FMCB.24.12.5353-5368.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">FERM domain interaction promotes FAK signaling</span></div><div class="casAuthors">Dunty, Jill M.; Gabarra-Niecko, Veronica; King, Michelle L.; Ceccarelli, Derek F. J.; Eck, Michael J.; Schaller, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5353-5368</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">From the results of deletion analyses, the FERM domain of FAK has been proposed to inhibit enzymic activity and repress FAK signaling.  We have identified a sequence in the FERM domain that is important for FAK signaling in vivo.  Point mutations in this sequence had little effect upon catalytic activity in vitro.  However, the mutant exhibits reduced tyrosine phosphorylation and dramatically reduced Src family kinase binding.  Further, the abilities of the mutant to transduce biochem. signals and to promote cell migration were severely impaired.  The results implicate a FERM domain interaction in cell adhesion-dependent activation of FAK and downstream signaling.  We also show that the purified FERM domain of FAK interacts with full-length FAK in vitro, and mutation of this sequence disrupts the interaction.  These findings are discussed in the context of models of FAK regulation by its FERM domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgEt5IZQluLLVg90H21EOLACvtfcHk0lg4BsiwgDqdMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkvFOqtL4%253D&md5=95bac015a863e4d8fe394559b399c822</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1128%2FMCB.24.12.5353-5368.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.24.12.5353-5368.2004%26sid%3Dliteratum%253Aachs%26aulast%3DDunty%26aufirst%3DJ.%2BM.%26aulast%3DGabarra-Niecko%26aufirst%3DV.%26aulast%3DKing%26aufirst%3DM.%2BL.%26aulast%3DCeccarelli%26aufirst%3DD.%2BF.%2BJ.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSchaller%26aufirst%3DM.%2BD.%26atitle%3DFERM%2520domain%2520interaction%2520promotes%2520FAK%2520signaling%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2004%26volume%3D24%26spage%3D5353%26epage%3D5368%26doi%3D10.1128%2FMCB.24.12.5353-5368.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehart, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. S.</span></span> <span> </span><span class="NLM_article-title">Understanding the roles of FAK in cancer: inhibitors, genetic models, and new insights</span>. <i>J. Histochem. Cytochem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">114</span>â <span class="NLM_lpage">128</span>, <span class="refDoi">Â DOI: 10.1369/0022155414561498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1369%2F0022155414561498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=25380750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2MXislWrtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2015&pages=114-128&author=H.+Yoonauthor=J.+P.+Dehartauthor=J.+M.+Murphyauthor=S.+S.+Lim&title=Understanding+the+roles+of+FAK+in+cancer%3A+inhibitors%2C+genetic+models%2C+and+new+insights&doi=10.1369%2F0022155414561498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding the roles of FAK in cancer: inhibitors, genetic models, and new insights</span></div><div class="casAuthors">Yoon, Hyunho; Dehart, Joshua P.; Murphy, James M.; Lim, Ssang-Taek Steve</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Histochemistry and Cytochemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">114-128/1-114-128/15, 15 pp.</span>CODEN:
                <span class="NLM_cas:coden">JHCYAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-1554</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Focal adhesion kinase (FAK) is a protein tyrosine kinase that regulates cellular adhesion, motility, proliferation and survival in various types of cells.  Interestingly, FAK is activated and/or overexpressed in advanced cancers, and promotes cancer progression and metastasis.  For this reason, FAK became a potential therapeutic target in cancer, and small mol. FAK inhibitors have been developed and are being tested in clin. phase trials.  These inhibitors have demonstrated to be effective by inducing tumor cell apoptosis in addn. to reducing metastasis and angiogenesis.  Furthermore, several genetic FAK mouse models have made advancements in understanding the specific role of FAK both in tumors and in the tumor environment.  In this review, we discuss FAK inhibitors as well as genetic mouse models to provide mechanistic insights into FAK signaling and its potential in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro8FZcK4GQb7Vg90H21EOLACvtfcHk0lg4BsiwgDqdMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXislWrtb8%253D&md5=64ffaaef86e9fc737ba3bd825a64dd02</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1369%2F0022155414561498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1369%252F0022155414561498%26sid%3Dliteratum%253Aachs%26aulast%3DYoon%26aufirst%3DH.%26aulast%3DDehart%26aufirst%3DJ.%2BP.%26aulast%3DMurphy%26aufirst%3DJ.%2BM.%26aulast%3DLim%26aufirst%3DS.%2BS.%26atitle%3DUnderstanding%2520the%2520roles%2520of%2520FAK%2520in%2520cancer%253A%2520inhibitors%252C%2520genetic%2520models%252C%2520and%2520new%2520insights%26jtitle%3DJ.%2520Histochem.%2520Cytochem.%26date%3D2015%26volume%3D63%26spage%3D114%26epage%3D128%26doi%3D10.1369%2F0022155414561498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Golubovskaya, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kweh, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massoll, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell
Thompson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cance, W. G.</span></span> <span> </span><span class="NLM_article-title">P53 regulates FAK expression in human tumor cells</span>. <i>Mol. Carcinog.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">373</span>â <span class="NLM_lpage">382</span>, <span class="refDoi">Â DOI: 10.1002/mc.20395</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1002%2Fmc.20395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=17999388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1cXls1ajsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=373-382&author=V.+M.+Golubovskayaauthor=R.+Finchauthor=F.+Kwehauthor=N.+A.+Massollauthor=M.+Campbell%0AThompsonauthor=M.+R.+Wallaceauthor=W.+G.+Cance&title=P53+regulates+FAK+expression+in+human+tumor+cells&doi=10.1002%2Fmc.20395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">p53 regulates FAK expression in human tumor cells</span></div><div class="casAuthors">Golubovskaya, Vita M.; Finch, Richard; Kweh, Frederick; Massoll, Nicole A.; Campbell-Thompson, Martha; Wallace, Margaret R.; Cance, William G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Carcinogenesis</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">373-382</span>CODEN:
                <span class="NLM_cas:coden">MOCAE8</span>;
        ISSN:<span class="NLM_cas:issn">0899-1987</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Attenuation of the p53 protein is one of the most common abnormalities in human tumors.  Another important marker of tumorigenesis is focal adhesion kinase (FAK), a 125-kDa tyrosine kinase that is overexpressed at the mRNA and protein levels in a variety of human tumors.  FAK is a crit. regulator of adhesion, motility, metastasis, and survival signaling.  We have characterized the FAK promoter and demonstrated that p53 can inhibit the FAK promoter activity in vitro.  In the present study, we showed that p53 can bind the FAK promoter-chromatin region in vivo by chromatin immunopptn. (ChIP) assay.  Furthermore, we demonstrated down-regulation of FAK mRNA and protein levels by adenoviral overexpression of p53.  We introduced plasmids with different mutations in the DNA-binding domain of p53 (R175H, p53 R248W and R273H) into HCT p53-/- cells and showed that these mutations of p53 did not bind FAK promoter and did not inhibit FAK promoter activity, unlike wild type p53.  We analyzed primary breast and colon cancers for p53 mutations and FAK expression, and showed that FAK expression was increased in tumors contg. mutations of p53 compared to tumors with wild type p53.  In addn., tumor-derived missense mutations in the DNA-binding domain (R282, R249, and V173) also led to increased FAK promoter activity.  Thus, the present data show that p53 can regulate FAK expression during tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDfe6O9z8h8bVg90H21EOLACvtfcHk0lg4BsiwgDqdMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXls1ajsbs%253D&md5=3e5110d3f2ea61af0c3e27f0cad77532</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fmc.20395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmc.20395%26sid%3Dliteratum%253Aachs%26aulast%3DGolubovskaya%26aufirst%3DV.%2BM.%26aulast%3DFinch%26aufirst%3DR.%26aulast%3DKweh%26aufirst%3DF.%26aulast%3DMassoll%26aufirst%3DN.%2BA.%26aulast%3DCampbell%2BThompson%26aufirst%3DM.%26aulast%3DWallace%26aufirst%3DM.%2BR.%26aulast%3DCance%26aufirst%3DW.%2BG.%26atitle%3DP53%2520regulates%2520FAK%2520expression%2520in%2520human%2520tumor%2520cells%26jtitle%3DMol.%2520Carcinog.%26date%3D2008%26volume%3D47%26spage%3D373%26epage%3D382%26doi%3D10.1002%2Fmc.20395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ossovskaya, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ota, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlaepfer, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilic, D.</span></span> <span> </span><span class="NLM_article-title">FAK nuclear export signal sequences</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>582</i></span>,  <span class="NLM_fpage">2402</span>â <span class="NLM_lpage">2406</span>, <span class="refDoi">Â DOI: 10.1016/j.febslet.2008.06.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.febslet.2008.06.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=18549812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvVKnsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=582&publication_year=2008&pages=2402-2406&author=V.+Ossovskayaauthor=S.+Limauthor=N.+Otaauthor=D.+D.+Schlaepferauthor=D.+Ilic&title=FAK+nuclear+export+signal+sequences&doi=10.1016%2Fj.febslet.2008.06.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">FAK nuclear export signal sequences</span></div><div class="casAuthors">Ossovskaya, Valeria; Lim, Ssang-Taek; Ota, Nobuyuki; Schlaepfer, David D.; Ilic, Dusko</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">582</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2402-2406</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Ubiquitously expressed focal adhesion kinase (FAK), a crit. component in transducing signals from sites of cell contacts with extracellular matrix, was named after its typical localization in focal adhesions.  A nuclear localization of FAK has been also reported and its scaffolding role in nucleus and requirement for p53 ubiquitination were only recently described.  Whereas FAK nuclear localization signal (NLS) was found in F2 lobe of FERM domain, nuclear export signal (NES) sequences have not been yet detd.  Here we demonstrate that FAK has two NES sequences, NES1 in F1 lobe of FERM domain and NES2 in kinase domain.  Although, both NES1 and NES2 are evolutionary conserved, and present as well in FAK-related protein kinase Pyk2, only NES2 demonstrates full biol. nuclear export activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5QBtb9Ydw-LVg90H21EOLACvtfcHk0lijMP304Mzx7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvVKnsrY%253D&md5=0153bf6d951f3c786dd89f671525b49d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.febslet.2008.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.febslet.2008.06.004%26sid%3Dliteratum%253Aachs%26aulast%3DOssovskaya%26aufirst%3DV.%26aulast%3DLim%26aufirst%3DS.%26aulast%3DOta%26aufirst%3DN.%26aulast%3DSchlaepfer%26aufirst%3DD.%2BD.%26aulast%3DIlic%26aufirst%3DD.%26atitle%3DFAK%2520nuclear%2520export%2520signal%2520sequences%26jtitle%3DFEBS%2520Lett.%26date%3D2008%26volume%3D582%26spage%3D2402%26epage%3D2406%26doi%3D10.1016%2Fj.febslet.2008.06.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eilers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span> <span> </span><span class="NLM_article-title">Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">1253</span>â <span class="NLM_lpage">1263</span>, <span class="refDoi">Â DOI: 10.1038/bjc.2016.331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fbjc.2016.331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=27736841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yqs73O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2016&pages=1253-1263&author=W.+Ouauthor=M.+Luauthor=G.+Eilersauthor=H.+Liauthor=J.+Dingauthor=X.+Mengauthor=Y.+Wuauthor=Q.+Heauthor=Q.+Shengauthor=H.+M.+Zhouauthor=J.+A.+Fletcher&title=Co-targeting+of+FAK+and+MDM2+triggers+additive+anti-proliferative+effects+in+mesothelioma+via+a+coordinated+reactivation+of+p53&doi=10.1038%2Fbjc.2016.331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53</span></div><div class="casAuthors">Ou, Wen-Bin; Lu, Minmin; Eilers, Grant; Li, Hailong; Ding, Jiongyan; Meng, Xuli; Wu, Yuehong; He, Quan; Sheng, Qing; Zhou, Hai-Meng; Fletcher, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1253-1263</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Improved mesothelioma patient survival will require development of novel and more effective pharmacol. interventions.  TP53 genomic mutations are uncommon in mesothelioma, and recent data indicate that p53 remains functional, and therefore is a potential therapeutic target in these cancers.  In addn., the tumor suppressor NF2 is inactivated by genomic mechanisms in more than 80% of mesothelioma, causing upregulation of FAK activity.  Because FAK is a neg. regulator of p53, NF2 regulation of FAK-p53-MDM2 signalling loops were evaluated.  Methods: Interactions of FAK-p53 or NF2-FAK were evaluated by phosphotyrosine-p53 immunoaffinity purifn. and tandem mass spectrometry, and p53, FAK, and NF2 immunopptns.  Activation and/or expression of FAK, p53, and NF2 were also evaluated in mesotheliomas.  Effects of combination MDM2 and FAK inhibitors/shRNAs were assessed by measuring mesothelioma cell viability/growth, expression of cell cycle checkpoints, and cell cycle alterations.  Results: We obsd. constitutive activation of FAK, a known neg. regulator of p53, in each of 10 mesothelioma cell lines and each of nine mesothelioma surgical specimens, and FAK was assocd. with p53 in five of five mesothelioma cell lines.  In four mesotheliomas with wild-type p53, FAK silencing by RNAi induced expression and phosphorylation of p53.  However, FAK regulation of mesothelioma proliferation was not restricted to p53-dependent pathways, as demonstrated by immunoblots after FAK knockdown in JMN1B mesothelioma cells, which have mutant/inactivated p53, compared with four mesothelioma cell lines with nonmutant p53.  Additive effects were obtained through a coordinated reactivation of p53, by FAK knockdown/inhibition and MDM2 inhibition, as demonstrated by immunoblots, cell viability, and cell-cycle analyses, showing increased p53 expression, apoptosis, anti-proliferative effects, and cell-cycle arrest, as compared with either intervention alone.  Our results also indicate that NF2 regulates the interaction of FAK-p53 and MDM2-p53.  Conclusions: These findings highlight novel therapeutic opportunities in mesothelioma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreeIWtKftmtLVg90H21EOLACvtfcHk0lijMP304Mzx7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yqs73O&md5=6cfbd37273fd2bf42dfb7d4fc93bdc96</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2016.331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2016.331%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DEilers%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DQ.%26aulast%3DSheng%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DH.%2BM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DCo-targeting%2520of%2520FAK%2520and%2520MDM2%2520triggers%2520additive%2520anti-proliferative%2520effects%2520in%2520mesothelioma%2520via%2520a%2520coordinated%2520reactivation%2520of%2520p53%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2016%26volume%3D115%26spage%3D1253%26epage%3D1263%26doi%3D10.1038%2Fbjc.2016.331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard-Trifilo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uryu, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canete-Soler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlaepfer, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nalbant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bokoch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterman-Storer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlaepfer, D. D.</span></span> <span> </span><span class="NLM_article-title">PyK2 and FAK connections to p190Rho guanine nucleotide exchange factor regulate RhoA activity, focal adhesion formation, and cell motility</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">187</span>â <span class="NLM_lpage">203</span>, <span class="refDoi">Â DOI: 10.1083/jcb.200708194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1083%2Fjcb.200708194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=18195107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsFyltQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2008&pages=187-203&author=Y.+Limauthor=S.+T.+Limauthor=A.+Tomarauthor=M.+Gardelauthor=J.+A.+Bernard-Trifiloauthor=X.+L.+Chenauthor=S.+A.+Uryuauthor=R.+Canete-Solerauthor=J.+Zhaiauthor=H.+Linauthor=W.+W.+Schlaepferauthor=P.+Nalbantauthor=G.+Bokochauthor=D.+Ilicauthor=C.+Waterman-Storerauthor=D.+D.+Schlaepfer&title=PyK2+and+FAK+connections+to+p190Rho+guanine+nucleotide+exchange+factor+regulate+RhoA+activity%2C+focal+adhesion+formation%2C+and+cell+motility&doi=10.1083%2Fjcb.200708194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">PyK2 and FAK connections to p190Rho guanine nucleotide exchange factor regulate RhoA activity, focal adhesion formation, and cell motility</span></div><div class="casAuthors">Lim, Yangmi; Lim, Ssang-Taek; Tomar, Alok; Gardel, Margaret; Bernard-Trifilo, Joie A.; Chen, Xiao Lei; Uryu, Sean A.; Canete-Soler, Rafaela; Zhai, Jinbin; Lin, Hong; Schlaepfer, William W.; Nalbant, Perihan; Bokoch, Gary; Ilic, Dusko; Waterman-Storer, Clare; Schlaepfer, David D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">187-203</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Integrin binding to matrix proteins such as fibronectin (FN) leads to formation of focal adhesion (FA) cellular contact sites that regulate migration.  RhoA GTPases facilitate FA formation, yet FA-assocd. RhoA-specific guanine nucleotide exchange factors (GEFs) remain unknown.  Here, we show that proline-rich kinase-2 (Pyk2) levels increase upon loss of focal adhesion kinase (FAK) in mouse embryonic fibroblasts (MEFs).  Addnl., we demonstrate that Pyk2 facilitates deregulated RhoA activation, elevated FA formation, and enhanced cell proliferation by promoting p190RhoGEF expression.  In normal MEFs, p190RhoGEF knockdown inhibits FN-assocd. RhoA activation, FA formation, and cell migration.  Knockdown of p190RhoGEF-related GEFH1 does not affect FA formation in FAK-/- or normal MEFs.  P190RhoGEF overexpression enhances RhoA activation and FA formation in MEFs dependent on FAK binding and assocd. with p190RhoGEF FA recruitment and tyrosine phosphorylation.  These studies elucidate a compensatory function for Pyk2 upon FAK loss and identify the FAK-p190RhoGEF complex as an important integrin-proximal regulator of FA formation during FN-stimulated cell motility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn0jRG0IgcFrVg90H21EOLACvtfcHk0lijMP304Mzx7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsFyltQ%253D%253D&md5=cf060fb45adb1bdfb8eee719d2b9874a</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1083%2Fjcb.200708194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.200708194%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DY.%26aulast%3DLim%26aufirst%3DS.%2BT.%26aulast%3DTomar%26aufirst%3DA.%26aulast%3DGardel%26aufirst%3DM.%26aulast%3DBernard-Trifilo%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DX.%2BL.%26aulast%3DUryu%26aufirst%3DS.%2BA.%26aulast%3DCanete-Soler%26aufirst%3DR.%26aulast%3DZhai%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DSchlaepfer%26aufirst%3DW.%2BW.%26aulast%3DNalbant%26aufirst%3DP.%26aulast%3DBokoch%26aufirst%3DG.%26aulast%3DIlic%26aufirst%3DD.%26aulast%3DWaterman-Storer%26aufirst%3DC.%26aulast%3DSchlaepfer%26aufirst%3DD.%2BD.%26atitle%3DPyK2%2520and%2520FAK%2520connections%2520to%2520p190Rho%2520guanine%2520nucleotide%2520exchange%2520factor%2520regulate%2520RhoA%2520activity%252C%2520focal%2520adhesion%2520formation%252C%2520and%2520cell%2520motility%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2008%26volume%3D180%26spage%3D187%26epage%3D203%26doi%3D10.1083%2Fjcb.200708194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohba, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, T.</span></span> <span> </span><span class="NLM_article-title">Interaction of two proline-rich sequences of cell adhesion kinase beta with SH3 domains of p130Cas-related proteins and a GTPase-activating protein, Graf</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>330</i></span>,  <span class="NLM_fpage">1249</span>â <span class="NLM_lpage">1254</span>, <span class="refDoi">Â DOI: 10.1042/bj3301249</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1042%2Fbj3301249" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=9494093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADyaK1cXit1eqtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=1998&pages=1249-1254&author=T.+Ohbaauthor=M.+Ishinoauthor=H.+Aotoauthor=T.+Sasaki&title=Interaction+of+two+proline-rich+sequences+of+cell+adhesion+kinase+beta+with+SH3+domains+of+p130Cas-related+proteins+and+a+GTPase-activating+protein%2C+Graf&doi=10.1042%2Fbj3301249"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of two proline-rich sequences of cell adhesion kinase Î² with SH3 domains of p130Cas-related proteins and a GTPase-activating protein, Graf</span></div><div class="casAuthors">Ohba, Takeaki; Ishino, Masaho; Aoto, Hiroshi; Sasaki, Terukatsu</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1249-1254</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Cell adhesion kinase Î² (CAKÎ²) is a protein tyrosine kinase closely related to focal adhesion kinase (FAK) in structure.  CAKÎ² contains two proline-rich sequences within its C-terminal region.  Since proline-rich sequences present in the corresponding region of FAK are known to mediate protein-protein interactions by binding to SH3 domains, we investigated binding of CAKÎ² to a panel of SH3 domains.  Affinity pptn. from rat brain lysate revealed selective interactions of CAKÎ² with glutathione S-transferase (GST)-fused SH3 domains of p130cas (Cas)-related proteins and Graf.  Mutational anal. indicated that the proline-rich sequences of CAKÎ² mediate this interaction.  Each of the two proline-rich sequences fused to GST bound directly to these SH3 domains in dot blot anal.  A competitive binding assay revealed that the first proline-rich sequence of CAKÎ² preferentially assocd. with the SH3 domain of Cas.  The second proline-rich sequence of CAKÎ² bound to the SH3 domain of Graf with higher specificity than the corresponding proline-rich sequence of FAK.  Finally, we showed co-immunopptn. of CAKÎ² with Graf from rat brain lysate.  These results indicate that CAKÎ² assocs. in vivo with Graf through its SH3 domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCAW0bA2k04LVg90H21EOLACvtfcHk0lh1WszVwcfdRQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXit1eqtb0%253D&md5=9d0bdc53b99a4dc34234d5543f3b645b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1042%2Fbj3301249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj3301249%26sid%3Dliteratum%253Aachs%26aulast%3DOhba%26aufirst%3DT.%26aulast%3DIshino%26aufirst%3DM.%26aulast%3DAoto%26aufirst%3DH.%26aulast%3DSasaki%26aufirst%3DT.%26atitle%3DInteraction%2520of%2520two%2520proline-rich%2520sequences%2520of%2520cell%2520adhesion%2520kinase%2520beta%2520with%2520SH3%2520domains%2520of%2520p130Cas-related%2520proteins%2520and%2520a%2520GTPase-activating%2520protein%252C%2520Graf%26jtitle%3DBiochem.%2520J.%26date%3D1998%26volume%3D330%26spage%3D1249%26epage%3D1254%26doi%3D10.1042%2Fbj3301249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scheswohl, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrell, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajfur, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaller, M. D.</span></span> <span> </span><span class="NLM_article-title">Multiple paxillin binding sites regulate FAK function</span>. <i>J. Mol. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">11</span>, <span class="refDoi">Â DOI: 10.1186/1750-2187-3-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1186%2F1750-2187-3-1" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=1-11&author=D.+M.+Scheswohlauthor=J.+R.+Harrellauthor=Z.+Rajfurauthor=G.+Gaoauthor=S.+L.+Campbellauthor=M.+D.+Schaller&title=Multiple+paxillin+binding+sites+regulate+FAK+function&doi=10.1186%2F1750-2187-3-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1186%2F1750-2187-3-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1750-2187-3-1%26sid%3Dliteratum%253Aachs%26aulast%3DScheswohl%26aufirst%3DD.%2BM.%26aulast%3DHarrell%26aufirst%3DJ.%2BR.%26aulast%3DRajfur%26aufirst%3DZ.%26aulast%3DGao%26aufirst%3DG.%26aulast%3DCampbell%26aufirst%3DS.%2BL.%26aulast%3DSchaller%26aufirst%3DM.%2BD.%26atitle%3DMultiple%2520paxillin%2520binding%2520sites%2520regulate%2520FAK%2520function%26jtitle%3DJ.%2520Mol.%2520Signaling%26date%3D2014%26volume%3D3%26spage%3D1%26epage%3D11%26doi%3D10.1186%2F1750-2187-3-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uryu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderwood, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlaepfer, D. D.</span></span> <span> </span><span class="NLM_article-title">FAK promotes recruitment of talin to nascent adhesions to control cell motility</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>196</i></span>,  <span class="NLM_fpage">223</span>â <span class="NLM_lpage">232</span>, <span class="refDoi">Â DOI: 10.1083/jcb.201108078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1083%2Fjcb.201108078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=22270917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFymtLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=196&publication_year=2012&pages=223-232&author=C.+Lawsonauthor=S.+T.+Limauthor=S.+Uryuauthor=X.+L.+Chenauthor=D.+A.+Calderwoodauthor=D.+D.+Schlaepfer&title=FAK+promotes+recruitment+of+talin+to+nascent+adhesions+to+control+cell+motility&doi=10.1083%2Fjcb.201108078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">FAK promotes recruitment of talin to nascent adhesions to control cell motility</span></div><div class="casAuthors">Lawson, Christine; Lim, Ssang-Taek; Uryu, Sean; Chen, Xiao Lei; Calderwood, David A.; Schlaepfer, David D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">196</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">223-232</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Cell migration is a dynamic process that involves the continuous formation, maturation, and turnover of matrix-cell adhesion sites.  New (nascent) adhesions form at the protruding cell edge in a tension-independent manner and are comprised of integrin receptors, signaling, and cytoskeletal-assocd. proteins.  Integrins recruit focal adhesion kinase (FAK) and the cytoskeletal protein talin to nascent adhesions.  Canonical models support a role for talin in mediating FAK localization and activation at adhesions.  Here, alternatively, we show that FAK promotes talin recruitment to nascent adhesions occurring independently of talin binding to Î²1 integrins.  The direct binding site for talin on FAK was identified, and a point mutation in FAK (E1015A) prevented talin assocn. and talin localization to nascent adhesions but did not alter integrin-mediated FAK recruitment and activation at adhesions.  Moreover, FAK E1015A inhibited cell motility and proteolytic talin cleavage needed for efficient adhesion dynamics.  These results support an alternative linkage for FAK-talin interactions within nascent adhesions essential for the control of cell migration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKeUkveqKk5LVg90H21EOLACvtfcHk0lh1WszVwcfdRQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFymtLY%253D&md5=1913ece822fd74862aa7e803773fab7e</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1083%2Fjcb.201108078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.201108078%26sid%3Dliteratum%253Aachs%26aulast%3DLawson%26aufirst%3DC.%26aulast%3DLim%26aufirst%3DS.%2BT.%26aulast%3DUryu%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DX.%2BL.%26aulast%3DCalderwood%26aufirst%3DD.%2BA.%26aulast%3DSchlaepfer%26aufirst%3DD.%2BD.%26atitle%3DFAK%2520promotes%2520recruitment%2520of%2520talin%2520to%2520nascent%2520adhesions%2520to%2520control%2520cell%2520motility%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2012%26volume%3D196%26spage%3D223%26epage%3D232%26doi%3D10.1083%2Fjcb.201108078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Subauste, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamson, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, K. M.</span></span> <span> </span><span class="NLM_article-title">Vinculin modulation of paxillin-FAK interactions regulates ERK to control survival and motility</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">371</span>â <span class="NLM_lpage">381</span>, <span class="refDoi">Â DOI: 10.1083/jcb.200308011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1083%2Fjcb.200308011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=15138291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvFKjs70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2004&pages=371-381&author=M.+C.+Subausteauthor=O.+Pertzauthor=E.+D.+Adamsonauthor=C.+E.+Turnerauthor=S.+Jungerauthor=K.+M.+Hahn&title=Vinculin+modulation+of+paxillin-FAK+interactions+regulates+ERK+to+control+survival+and+motility&doi=10.1083%2Fjcb.200308011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Vinculin modulation of paxillin-FAK interactions regulates ERK to control survival and motility</span></div><div class="casAuthors">Subauste, M. Cecilia; Pertz, Olivier; Adamson, Eileen D.; Turner, Christopher E.; Junger, Sachiko; Hahn, Klaus M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">371-381</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Cells lacking vinculin are highly metastatic and motile.  The reasons for this finding have remained unclear.  Both enhanced survival and motility are crit. to metastasis.  Here, we show that vinculin null (vin-/-) cells and cells expressing a vinculin Y822F mutant have increased survival due to up-regulated activity of extracellular signal-regulated kinase (ERK).  This increase is shown to result from vinculin's modulation of paxillin-FAK interactions.  A vinculin fragment (amino acids 811-1066) contg. the paxillin binding site restored apoptosis and suppressed ERK activity in vin-/- cells.  Both vinY822F and vin-/- cells exhibit increased interaction between paxillin and focal adhesion kinase (FAK) and increased paxillin and FAK phosphorylation.  Transfection with paxillin Y31FY118F dominant-neg. mutant in these cells inhibits ERK activation and restores apoptosis.  The enhanced motility of vin-/- and vinY822F cells is also shown to be due to a similar mechanism.  Thus, vinculin regulates survival and motility via ERK by controlling the accessibility of paxillin for FAK interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHaQzHRKIsTbVg90H21EOLACvtfcHk0lgXnw7aH7w2JQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvFKjs70%253D&md5=1c39db7eed2fc8c0baceee41c0eef961</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1083%2Fjcb.200308011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.200308011%26sid%3Dliteratum%253Aachs%26aulast%3DSubauste%26aufirst%3DM.%2BC.%26aulast%3DPertz%26aufirst%3DO.%26aulast%3DAdamson%26aufirst%3DE.%2BD.%26aulast%3DTurner%26aufirst%3DC.%2BE.%26aulast%3DJunger%26aufirst%3DS.%26aulast%3DHahn%26aufirst%3DK.%2BM.%26atitle%3DVinculin%2520modulation%2520of%2520paxillin-FAK%2520interactions%2520regulates%2520ERK%2520to%2520control%2520survival%2520and%2520motility%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2004%26volume%3D165%26spage%3D371%26epage%3D381%26doi%3D10.1083%2Fjcb.200308011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muralidharan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vila-Perello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raleigh, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muir, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, A. G.,  III</span></span> <span> </span><span class="NLM_article-title">Tuning protein autoinhibition by domain destabilization</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">550</span>â <span class="NLM_lpage">555</span>, <span class="refDoi">Â DOI: 10.1038/nsmb.2039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fnsmb.2039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=21532593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVGlsL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=550-555&author=J.+H.+Choauthor=V.+Muralidharanauthor=M.+Vila-Perelloauthor=D.+P.+Raleighauthor=T.+W.+Muirauthor=A.+G.+Palmer&title=Tuning+protein+autoinhibition+by+domain+destabilization&doi=10.1038%2Fnsmb.2039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Tuning protein autoinhibition by domain destabilization</span></div><div class="casAuthors">Cho, Jae-Hyun; Muralidharan, Vasant; Vila-Perello, Miquel; Raleigh, Daniel P.; Muir, Tom W.; Palmer, Arthur G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">550-555</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activation of many multidomain signaling proteins requires rearrangement of autoinhibitory interdomain interactions that occlude activator binding sites.  In one model for activation, the major inactive conformation exists in equil. with activated-like conformations that can be stabilized by ligand binding or post-translational modifications.  We established the mol. basis for this model for the archetypal signaling adaptor protein Crk-II by measuring the thermodn. and kinetics of the equil. between autoinhibited and activated-like states.  We used fluorescence and NMR spectroscopies together with segmental isotopic labeling by means of expressed protein ligation.  The results demonstrate that intramol. domain-domain interactions both stabilize the autoinhibited state and induce the activated-like conformation.  A combination of favorable interdomain interactions and unfavorable intradomain structural changes fine-tunes the population of the activated-like conformation and allows facile response to activators.  This mechanism suggests a general strategy for optimization of autoinhibitory interactions of multidomain proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8jZJW-7MyXrVg90H21EOLACvtfcHk0lgXnw7aH7w2JQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVGlsL4%253D&md5=25f58c41f6da3b172b58225979e83f52</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2039%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DJ.%2BH.%26aulast%3DMuralidharan%26aufirst%3DV.%26aulast%3DVila-Perello%26aufirst%3DM.%26aulast%3DRaleigh%26aufirst%3DD.%2BP.%26aulast%3DMuir%26aufirst%3DT.%2BW.%26aulast%3DPalmer%26aufirst%3DA.%2BG.%26atitle%3DTuning%2520protein%2520autoinhibition%2520by%2520domain%2520destabilization%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2011%26volume%3D18%26spage%3D550%26epage%3D555%26doi%3D10.1038%2Fnsmb.2039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boerner, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaller, M. D.</span></span> <span> </span><span class="NLM_article-title">SH2- and SH3-mediated interactions between focal adhesion kinase and Src</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>273</i></span>,  <span class="NLM_fpage">577</span>â <span class="NLM_lpage">583</span>, <span class="refDoi">Â DOI: 10.1074/jbc.273.1.577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1074%2Fjbc.273.1.577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=9417118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADyaK1cXjvFSktw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1998&pages=577-583&author=J.+W.+Thomasauthor=B.+Ellisauthor=R.+J.+Boernerauthor=W.+B.+Knightauthor=G.+C.+Whiteauthor=M.+D.+Schaller&title=SH2-+and+SH3-mediated+interactions+between+focal+adhesion+kinase+and+Src&doi=10.1074%2Fjbc.273.1.577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">SH2- and SH3-mediated interactions between focal adhesion kinase and Src</span></div><div class="casAuthors">Thomas, Jeffrey W.; Ellis, Byron; Boerner, Renee J.; Knight, Wilson B.; White, Gilbert C., II; Schaller, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">577-583</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Intramol. SH2 and SH3 interactions mediate enzymic repression of the Src kinases.  One mechanism of activation is disruption of these interactions by the formation of higher affinity SH2 and SH3 interactions with specific ligands.  We show that a consensus Src SH3-binding site residing upstream of the Src SH2-binding site in FAK can function as a ligand for the Src SH3 domain.  Surface plasmon resonance expts. indicate that a FAK peptide contg. both the Src SH2- and SH3-binding sites exhibits increased affinity for Src.  Furthermore, the presence of both sites in vitro more potently activates c-Src.  A FAK mutant (FAKPro-2) with substitutions destroying the SH3-binding site shows reduced binding to Src in vivo.  This mutation also reduces Src-dependent tyrosine phosphorylation on the mutant itself and downstream substrates, such as paxillin.  These observations suggest that an SH3-mediated interaction between Src-like kinases and FAK may be important for complex formation and downstream signaling in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoetwSyBSedc7Vg90H21EOLACvtfcHk0lgXnw7aH7w2JQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjvFSktw%253D%253D&md5=7d953ac8521f7caf21981585ff0d3551</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1074%2Fjbc.273.1.577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.273.1.577%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DJ.%2BW.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DBoerner%26aufirst%3DR.%2BJ.%26aulast%3DKnight%26aufirst%3DW.%2BB.%26aulast%3DWhite%26aufirst%3DG.%2BC.%26aulast%3DSchaller%26aufirst%3DM.%2BD.%26atitle%3DSH2-%2520and%2520SH3-mediated%2520interactions%2520between%2520focal%2520adhesion%2520kinase%2520and%2520Src%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1998%26volume%3D273%26spage%3D577%26epage%3D583%26doi%3D10.1074%2Fjbc.273.1.577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sulzmaier, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlaepfer, D. D.</span></span> <span> </span><span class="NLM_article-title">FAK in cancer: mechanistic findings and clinical applications</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">598</span>â <span class="NLM_lpage">610</span>, <span class="refDoi">Â DOI: 10.1038/nrc3792</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fnrc3792" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=25098269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht12nu7vJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=598-610&author=F.+J.+Sulzmaierauthor=C.+Jeanauthor=D.+D.+Schlaepfer&title=FAK+in+cancer%3A+mechanistic+findings+and+clinical+applications&doi=10.1038%2Fnrc3792"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">FAK in cancer: mechanistic findings and clinical applications</span></div><div class="casAuthors">Sulzmaier, Florian J.; Jean, Christine; Schlaepfer, David D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">598-610</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Focal adhesion kinase (FAK) is a cytoplasmic protein tyrosine kinase that is overexpressed and activated in several advanced-stage solid cancers.  FAK promotes tumor progression and metastasis through effects on cancer cells, as well as stromal cells of the tumor microenvironment.  The kinase-dependent and kinase-independent functions of FAK control cell movement, invasion, survival, gene expression and cancer stem cell self-renewal.  Small mol. FAK inhibitors decrease tumor growth and metastasis in several preclin. models and have initial clin. activity in patients with limited adverse events.  In this Review, we discuss FAK signalling effects on both tumor and stromal cell biol. that provide rationale and support for future therapeutic opportunities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmKc7m7dsY67Vg90H21EOLACvtfcHk0liuuSThik5dzw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht12nu7vJ&md5=f498bcf7af890d2f92eda68e42f979d1</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnrc3792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3792%26sid%3Dliteratum%253Aachs%26aulast%3DSulzmaier%26aufirst%3DF.%2BJ.%26aulast%3DJean%26aufirst%3DC.%26aulast%3DSchlaepfer%26aufirst%3DD.%2BD.%26atitle%3DFAK%2520in%2520cancer%253A%2520mechanistic%2520findings%2520and%2520clinical%2520applications%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D598%26epage%3D610%26doi%3D10.1038%2Fnrc3792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, J. T.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase: the first ten years</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">1409</span>â <span class="NLM_lpage">1416</span>, <span class="refDoi">Â DOI: 10.1242/jcs.00373</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1242%2Fjcs.00373" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=12640026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtlyrtLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2003&pages=1409-1416&author=J.+T.+Parsons&title=Focal+adhesion+kinase%3A+the+first+ten+years&doi=10.1242%2Fjcs.00373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion kinase: The first ten years</span></div><div class="casAuthors">Parsons, J. Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1409-1416</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  The protein tyrosine kinase focal adhesion kinase (FAK) plays a prominent role in integrin signaling.  FAK activation, demonstrated by an increase in phosphorylation of Tyr397 as well as other sites in the protein, is best understood in the context of the engagement of integrins at the cell surface.  Activation of FAK results in recruitment of a no. of SH2-domain- and SH3-domain-contg. proteins, which mediate signaling to several downstream pathways.  FAK-dependent activation of these pathways has been implicated in a diverse array of cellular processes, including cell migration, growth factor signaling, cell cycle progression and cell survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUsZCpbwOe67Vg90H21EOLACvtfcHk0liuuSThik5dzw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtlyrtLw%253D&md5=7fdb8c6c1ab6d5f46991d1b79d84105a</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1242%2Fjcs.00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.00373%26sid%3Dliteratum%253Aachs%26aulast%3DParsons%26aufirst%3DJ.%2BT.%26atitle%3DFocal%2520adhesion%2520kinase%253A%2520the%2520first%2520ten%2520years%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2003%26volume%3D116%26spage%3D1409%26epage%3D1416%26doi%3D10.1242%2Fjcs.00373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sieg, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauck, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klingbeil, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damsky, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlaepfer, D. D.</span></span> <span> </span><span class="NLM_article-title">FAK integrates growth-factor and integrin signals to promote cell migration</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">249</span>â <span class="NLM_lpage">256</span>, <span class="refDoi">Â DOI: 10.1038/35010517</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2F35010517" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10806474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktlOqs7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2000&pages=249-256&author=D.+J.+Siegauthor=C.+R.+Hauckauthor=D.+Ilicauthor=C.+K.+Klingbeilauthor=E.+Schaeferauthor=C.+H.+Damskyauthor=D.+D.+Schlaepfer&title=FAK+integrates+growth-factor+and+integrin+signals+to+promote+cell+migration&doi=10.1038%2F35010517"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">FAK integrates growth-factor and integrin signals to promote cell migration</span></div><div class="casAuthors">Sieg, David J.; Hauck, Christof R.; Ilic, Dusko; Kingbeil, Candice K.; Schaefer, Erik; Damsky, Caroline H.; Schlaepfer, David D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">249-256</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we show that cells lacking focal adhesion kinase (FAK) are refractory to motility signals from platelet-derived and epidermal growth factors (PDGF and EGF resp.), and that stable re-expression of FAK rescues these defects.  FAK assocs. with activated PDGF- and EGF-receptor (PDGFR and EGFR) signalling complexes, and expression of the band-4.1-like domain at the FAK amino terminus is sufficient to mediate an interaction with activated EGFR.  However, efficient EGF-stimulated cell migration also requires FAK to be targeted, by its carboxy-terminal domain, to sites of integrin-receptor clustering.  Although the kinase activity of FAK is not needed to promote PDGF- or EGF-stimulated cell motility, kinase-inactive FAK is transphosphorylated at the indispensable Src-kinase-binding site, FAK Y397, after EGF stimulation of cells.  Our results establish that FAK is an important receptor-proximal link between growth-factor-receptor and integrin signalling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8_jbj9KKEerVg90H21EOLACvtfcHk0liuuSThik5dzw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktlOqs7o%253D&md5=8dd638fbecfd120065bedda6eb0a3ecd</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2F35010517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35010517%26sid%3Dliteratum%253Aachs%26aulast%3DSieg%26aufirst%3DD.%2BJ.%26aulast%3DHauck%26aufirst%3DC.%2BR.%26aulast%3DIlic%26aufirst%3DD.%26aulast%3DKlingbeil%26aufirst%3DC.%2BK.%26aulast%3DSchaefer%26aufirst%3DE.%26aulast%3DDamsky%26aufirst%3DC.%2BH.%26aulast%3DSchlaepfer%26aufirst%3DD.%2BD.%26atitle%3DFAK%2520integrates%2520growth-factor%2520and%2520integrin%2520signals%2520to%2520promote%2520cell%2520migration%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2000%26volume%3D2%26spage%3D249%26epage%3D256%26doi%3D10.1038%2F35010517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michael, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumbauld, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanks, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A. J.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase modulates cell adhesion strengthening via integrin activation</span>. <i>Mol. Biol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2508</span>â <span class="NLM_lpage">2519</span>, <span class="refDoi">Â DOI: 10.1091/mbc.e08-01-0076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1091%2Fmbc.e08-01-0076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=19297531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotVyquro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2009&pages=2508-2519&author=K.+E.+Michaelauthor=D.+W.+Dumbauldauthor=K.+L.+Burnsauthor=S.+K.+Hanksauthor=A.+J.+Garcia&title=Focal+adhesion+kinase+modulates+cell+adhesion+strengthening+via+integrin+activation&doi=10.1091%2Fmbc.e08-01-0076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion kinase modulates cell adhesion strengthening via integrin activation</span></div><div class="casAuthors">Michael, Kristin E.; Dumbauld, David W.; Burns, Kellie L.; Hanks, Steven K.; Garcia, Andres J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Biology of the Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2508-2519</span>CODEN:
                <span class="NLM_cas:coden">MBCEEV</span>;
        ISSN:<span class="NLM_cas:issn">1939-4586</span>.
    
            (<span class="NLM_cas:orgname">American Society for Cell Biology</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) is an essential nonreceptor tyrosine kinase regulating cell migration, adhesive signaling, and mechanosensing.  Using FAK-null cells expressing FAK under an inducible promoter, we demonstrate that FAK regulates the time-dependent generation of adhesive forces.  During the early stages of adhesion, FAK expression in FAK-null cells enhances integrin activation to promote integrin binding and, hence, the adhesion strengthening rate.  Importantly, FAK expression regulated integrin activation, and talin was required for the FAK-dependent effects.  A role for FAK in integrin activation was confirmed in human fibroblasts with knocked-down FAK expression.  The FAK autophosphorylation Y397 site was required for the enhancements in adhesion strengthening and integrin-binding responses.  This work demonstrates a novel role for FAK in integrin activation and the time-dependent generation of cell-ECM forces.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos_2S15_hJBLVg90H21EOLACvtfcHk0liuuSThik5dzw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotVyquro%253D&md5=103a7bad610a0bbd7710025f20978ba0</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1091%2Fmbc.e08-01-0076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1091%252Fmbc.e08-01-0076%26sid%3Dliteratum%253Aachs%26aulast%3DMichael%26aufirst%3DK.%2BE.%26aulast%3DDumbauld%26aufirst%3DD.%2BW.%26aulast%3DBurns%26aufirst%3DK.%2BL.%26aulast%3DHanks%26aufirst%3DS.%2BK.%26aulast%3DGarcia%26aufirst%3DA.%2BJ.%26atitle%3DFocal%2520adhesion%2520kinase%2520modulates%2520cell%2520adhesion%2520strengthening%2520via%2520integrin%2520activation%26jtitle%3DMol.%2520Biol.%2520Cell%26date%3D2009%26volume%3D20%26spage%3D2508%26epage%3D2519%26doi%3D10.1091%2Fmbc.e08-01-0076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rozengurt, E.</span></span> <span> </span><span class="NLM_article-title">Mitogenic signaling pathways induced by G protein-coupled receptors</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>213</i></span>,  <span class="NLM_fpage">589</span>â <span class="NLM_lpage">602</span>, <span class="refDoi">Â DOI: 10.1002/jcp.21246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1002%2Fjcp.21246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=17786953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht12jtbfI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=213&publication_year=2007&pages=589-602&author=E.+Rozengurt&title=Mitogenic+signaling+pathways+induced+by+G+protein-coupled+receptors&doi=10.1002%2Fjcp.21246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Mitogenic signaling pathways induced by G protein-coupled receptors</span></div><div class="casAuthors">Rozengurt, Enrique</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">213</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">589-602</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptor (GPCR) agonists, including neurotransmitters, hormones, chemokines, and bioactive lipids, act as potent cellular growth factors and have been implicated in a variety of normal and abnormal processes, including development, inflammation, and malignant transformation.  Typically, the binding of an agonistic ligand to its cognate GPCR triggers the activation of multiple signal transduction pathways that act in a synergistic and combinatorial fashion to relay the mitogenic signal to the nucleus and promote cell proliferation.  A rapid increase in the activity of phospholipases C, D, and A2 leading to the synthesis of lipid-derived 2nd messengers, Ca2+ fluxes, and subsequent activation of protein phosphorylation cascades, including PKC/PKD, Raf/MEK/ERK, and Akt/mTOR/p70S6K, is an important early response to mitogenic GPCR agonists.  The EGF receptor (EGFR) tyrosine kinase has emerged as a transducer in the signaling by GPCRs, a process termed transactivation.  GPCR signal transduction also induces striking morphol. changes and rapid tyrosine phosphorylation of multiple cellular proteins, including non-receptor tyrosine kinases Src, focal adhesion kinase (FAK), and adaptor proteins CAS and paxillin.  The pathways stimulated by GPCRs are extensively interconnected by synergistic and antagonistic crosstalks that play a crit. role in signal transmission, integration, and dissemination.  Here, the author reviews recent advances in defining the pathways that play a role in transducing mitogenic responses induced by GPCR agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeYdFoM9JEc7Vg90H21EOLACvtfcHk0ljyPaYoKDUm_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht12jtbfI&md5=6ee41ac5020b6449e434fc3574b46501</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fjcp.21246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.21246%26sid%3Dliteratum%253Aachs%26aulast%3DRozengurt%26aufirst%3DE.%26atitle%3DMitogenic%2520signaling%2520pathways%2520induced%2520by%2520G%2520protein-coupled%2520receptors%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2007%26volume%3D213%26spage%3D589%26epage%3D602%26doi%3D10.1002%2Fjcp.21246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dales, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charafe-Jauffret, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpentier-Meunier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrac-Meyer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacquemier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andonian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavaut, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allasia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charpin, C.</span></span> <span> </span><span class="NLM_article-title">Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">49</span>â <span class="NLM_lpage">58</span>, <span class="refDoi">Â DOI: 10.3892/ijo.31.1.49</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.3892%2Fijo.31.1.49" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=17549404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BD2szjs1ymtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2007&pages=49-58&author=S.+Garciaauthor=J.+P.+Dalesauthor=E.+Charafe-Jauffretauthor=S.+Carpentier-Meunierauthor=L.+Andrac-Meyerauthor=J.+Jacquemierauthor=C.+Andonianauthor=M.+N.+Lavautauthor=C.+Allasiaauthor=P.+Bonnierauthor=C.+Charpin&title=Overexpression+of+c-Met+and+of+the+transducers+PI3K%2C+FAK+and+JAK+in+breast+carcinomas+correlates+with+shorter+survival+and+neoangiogenesis&doi=10.3892%2Fijo.31.1.49"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis</span></div><div class="casAuthors">Garcia Stephane; Dales Jean-Philippe; Charafe-Jauffret Emmanuelle; Carpentier-Meunier Severine; Andrac-Meyer Lucile; Jacquemier Jocelyne; Andonian Claudine; Lavaut Marie-Noelle; Allasia Claude; Bonnier Pascal; Charpin Colette</div><div class="citationInfo"><span class="NLM_cas:title">International journal of oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-58</span>
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    </div><div class="casAbstract">c-Met is responsible for cell motility and tumour spreading. c-Met expression and signal transducers reflecting c-Met functionality were investigated in breast carcinomas, in correlation with patient outcome and tumour vasculature.  Tissue microarrays of 930 breast carcinomas were constructed, categorised according to patients' follow-up (4- to 10-year follow-up; median, 6.5 years).  Standardised immunocytochemical procedures were performed using anti-c-Met, -PI3K, -FAK, -JAK, and -CD146, -FYN and an automated autostainer (Ventana).  High-throughput densitometry measuring the extent of immunoprecipitates was assessed by image analysis (SAMBA). c-Met overexpression correlated with poor survival along with PI3K and FAK reflecting c-Met functionality and CD146 and FYN expression in endothelial cells.  Automated quantification of immunocytochemical precipitates using image analysis was shown to provide an objective means of measuring cellular proteins that are potentially relevant for current practice in pathological diagnosis and for specific therapy combining inhibitors of both c-Met and downstream transducer pathways, and of tumour angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS9oRTX60a0VthSDZx9hyjKfW6udTcc2eYP900rQzgIC7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2szjs1ymtQ%253D%253D&md5=ffced0cd1ff6c06df0e44b8d3b1e3262</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.3892%2Fijo.31.1.49&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.31.1.49%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia%26aufirst%3DS.%26aulast%3DDales%26aufirst%3DJ.%2BP.%26aulast%3DCharafe-Jauffret%26aufirst%3DE.%26aulast%3DCarpentier-Meunier%26aufirst%3DS.%26aulast%3DAndrac-Meyer%26aufirst%3DL.%26aulast%3DJacquemier%26aufirst%3DJ.%26aulast%3DAndonian%26aufirst%3DC.%26aulast%3DLavaut%26aufirst%3DM.%2BN.%26aulast%3DAllasia%26aufirst%3DC.%26aulast%3DBonnier%26aufirst%3DP.%26aulast%3DCharpin%26aufirst%3DC.%26atitle%3DOverexpression%2520of%2520c-Met%2520and%2520of%2520the%2520transducers%2520PI3K%252C%2520FAK%2520and%2520JAK%2520in%2520breast%2520carcinomas%2520correlates%2520with%2520shorter%2520survival%2520and%2520neoangiogenesis%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2007%26volume%3D31%26spage%3D49%26epage%3D58%26doi%3D10.3892%2Fijo.31.1.49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lietha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceccarelli, D. F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaller, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Structural basis for the autoinhibition of focal adhesion kinase</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">1177</span>â <span class="NLM_lpage">1187</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2007.05.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.cell.2007.05.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=17574028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntVOnt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2007&pages=1177-1187&author=D.+Liethaauthor=X.+Caiauthor=D.+F.+J.+Ceccarelliauthor=Y.+Liauthor=M.+D.+Schallerauthor=M.+J.+Eck&title=Structural+basis+for+the+autoinhibition+of+focal+adhesion+kinase&doi=10.1016%2Fj.cell.2007.05.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the autoinhibition of focal adhesion kinase</span></div><div class="casAuthors">Lietha, Daniel; Cai, Xinming; Ceccarelli, Derek F. J.; Li, Yiqun; Schaller, Michael D.; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1177-1187</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Appropriate tyrosine kinase signaling depends on coordinated sequential coupling of protein-protein interactions with catalytic activation.  Focal adhesion kinase (FAK) integrates signals from integrin and growth factor receptors to regulate cellular responses including cell adhesion, migration, and survival.  Here, we describe crystal structures representing both autoinhibited and active states of FAK.  The inactive structure reveals a mechanism of inhibition in which the N-terminal FERM domain directly binds the kinase domain, blocking access to the catalytic cleft and protecting the FAK activation loop from Src phosphorylation.  Addnl., the FERM domain sequesters the Tyr397 autophosphorylation and Src recruitment site, which lies in the linker connecting the FERM and kinase domains.  The active phosphorylated FAK kinase adopts a conformation that is immune to FERM inhibition.  Our biochem. and structural anal. shows how the architecture of autoinhibited FAK orchestrates an activation sequence of FERM domain displacement, linker autophosphorylation, Src recruitment, and full catalytic activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrePRTd6WBaCLVg90H21EOLACvtfcHk0ljyPaYoKDUm_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntVOnt7g%253D&md5=db42c6f45345fbf5bba3f92fb6362aa5</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.05.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.05.041%26sid%3Dliteratum%253Aachs%26aulast%3DLietha%26aufirst%3DD.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DCeccarelli%26aufirst%3DD.%2BF.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DSchaller%26aufirst%3DM.%2BD.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructural%2520basis%2520for%2520the%2520autoinhibition%2520of%2520focal%2520adhesion%2520kinase%26jtitle%3DCell%26date%3D2007%26volume%3D129%26spage%3D1177%26epage%3D1187%26doi%3D10.1016%2Fj.cell.2007.05.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimenti, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barber, D. L.</span></span> <span> </span><span class="NLM_article-title">PH sensing by FAK-His58 regulates focal adhesion remodeling</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>202</i></span>,  <span class="NLM_fpage">849</span>â <span class="NLM_lpage">859</span>, <span class="refDoi">Â DOI: 10.1083/jcb.201302131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1083%2Fjcb.201302131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=24043700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2ksbnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=202&publication_year=2013&pages=849-859&author=C.+H.+Choiauthor=B.+A.+Webbauthor=M.+S.+Chimentiauthor=M.+P.+Jacobsonauthor=D.+L.+Barber&title=PH+sensing+by+FAK-His58+regulates+focal+adhesion+remodeling&doi=10.1083%2Fjcb.201302131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">pH sensing by FAK-His58 regulates focal adhesion remodeling</span></div><div class="casAuthors">Choi, Chang-Hoon; Webb, Bradley A.; Chimenti, Michael S.; Jacobson, Matthew P.; Barber, Diane L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">202</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">849-859</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Intracellular pH (pHi) dynamics regulates diverse cellular processes, including remodeling of focal adhesions.  We now report that focal adhesion kinase (FAK), a key regulator of focal adhesion remodeling, is a pH sensor responding to physiol. changes in pH.  The initial step in FAK activation is autophosphorylation of Tyr397, which increased with higher pHi.  We used a genetically encoded biosensor to show increased pH at focal adhesions as they mature during cell spreading.  We also show that cells with reduced pHi had attenuated FAK-pY397 as well as defective cell spreading and focal adhesions.  Mutagenesis studies indicated FAK-His58 is crit. for pH sensing and mol. dynamics simulations suggested a model in which His58 deprotonation drives conformational changes that may modulate accessibility of Tyr397 for autophosphorylation.  Expression of FAK-H58A in fibroblasts was sufficient to restore defective autophosphorylation and cell spreading at low pHi.  These data are relevant to understanding cancer metastasis, which is dependent on increased pHi and FAK activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxuZ0Fzfcr8rVg90H21EOLACvtfcHk0lgpYNFpoGtuGA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2ksbnJ&md5=027c96457ed53114d80d213b03ba13e2</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1083%2Fjcb.201302131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.201302131%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DC.%2BH.%26aulast%3DWebb%26aufirst%3DB.%2BA.%26aulast%3DChimenti%26aufirst%3DM.%2BS.%26aulast%3DJacobson%26aufirst%3DM.%2BP.%26aulast%3DBarber%26aufirst%3DD.%2BL.%26atitle%3DPH%2520sensing%2520by%2520FAK-His58%2520regulates%2520focal%2520adhesion%2520remodeling%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2013%26volume%3D202%26spage%3D849%26epage%3D859%26doi%3D10.1083%2Fjcb.201302131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cance, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golubovskaya, V. M.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase versus p53: apoptosis or survival?</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">22</span>â <span class="NLM_lpage">29</span>, <span class="refDoi">Â DOI: 10.1126/stke.120pe22</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1126%2Fstke.120pe22" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2008&pages=22-29&author=W.+G.+Canceauthor=V.+M.+Golubovskaya&title=Focal+adhesion+kinase+versus+p53%3A+apoptosis+or+survival%3F&doi=10.1126%2Fstke.120pe22"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1126%2Fstke.120pe22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fstke.120pe22%26sid%3Dliteratum%253Aachs%26aulast%3DCance%26aufirst%3DW.%2BG.%26aulast%3DGolubovskaya%26aufirst%3DV.%2BM.%26atitle%3DFocal%2520adhesion%2520kinase%2520versus%2520p53%253A%2520apoptosis%2520or%2520survival%253F%26jtitle%3DSci.%2520Signaling%26date%3D2008%26volume%3D1%26spage%3D22%26epage%3D29%26doi%3D10.1126%2Fstke.120pe22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonoda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichikawa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriko, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadashi, K.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase determines the fate of death or survival of cells in response to TNF alpha in the presence of actinomycin D</span>. <i>Biochim. Biophys. Acta, Gen. Subj.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>1770</i></span>,  <span class="NLM_fpage">518</span>â <span class="NLM_lpage">526</span>, <span class="refDoi">Â DOI: 10.1016/j.bbagen.2006.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bbagen.2006.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2sXit1Ggs7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1770&publication_year=2007&pages=518-526&author=R.+Takahashiauthor=Y.+Sonodaauthor=D.+Ichikawaauthor=N.+Yoshidaauthor=A.+Y.+Erikoauthor=K.+Tadashi&title=Focal+adhesion+kinase+determines+the+fate+of+death+or+survival+of+cells+in+response+to+TNF+alpha+in+the+presence+of+actinomycin+D&doi=10.1016%2Fj.bbagen.2006.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion kinase determines the fate of death or survival of cells in response to TNFÎ± in the presence of actinomycin D</span></div><div class="casAuthors">Takahashi, Reiko; Sonoda, Yoshiko; Ichikawa, Daiju; Yoshida, Naomi; Eriko, Aizu-Yokota; Tadashi, Kasahara</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1770</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">518-526</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The authors speculated that focal adhesion kinase (FAK) might play a crit. role in the TNFÎ±-induced cell death.  In this study, the authors found that FAK-/- cells are more sensitive to TNFÎ±-induced apoptosis in the presence of actinomycin D (Act D) compared to FAK+/- cells.  Prosurvival pathways are activated by the rapid recruitment of complex I, comprising TNFR1, TRADD, RIP and TRAF2, which leads to the activation of the NF-ÎºB pathway.  Proapoptotic pathways are activated by complex II, the death-inducing signaling complex (DISC), which contains TNFR1, TRADD, RIP, and FADD, and procaspase-8 proteins.  As TNFR1, TRADD, and RIP are included in both Complex I and DISC, the authors speculated that RIP might be a key protein.  Coimmunopptn. assays revealed that RIP is included in complex I in FAK+/- cells, and FAK was assocd. with RIP.  RIP is included in DISC in FAK-/- cells.  FAK might be a key protein in the formation of complex I and the activation of NF-ÎºB.  Furthermore, Akt was activated in FAK+/- cells, but not FAK-/- cells.  In conclusion, the authors first demonstrated that FAK dets. the pathway leading to death or survival in TNFÎ±/ActD-stimulated fibroblasts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHn6ryPWMnp7Vg90H21EOLACvtfcHk0lgpYNFpoGtuGA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXit1Ggs7s%253D&md5=05a9c20853d2aab0e42cc06814075a81</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2006.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2006.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DR.%26aulast%3DSonoda%26aufirst%3DY.%26aulast%3DIchikawa%26aufirst%3DD.%26aulast%3DYoshida%26aufirst%3DN.%26aulast%3DEriko%26aufirst%3DA.%2BY.%26aulast%3DTadashi%26aufirst%3DK.%26atitle%3DFocal%2520adhesion%2520kinase%2520determines%2520the%2520fate%2520of%2520death%2520or%2520survival%2520of%2520cells%2520in%2520response%2520to%2520TNF%2520alpha%2520in%2520the%2520presence%2520of%2520actinomycin%2520D%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2007%26volume%3D1770%26spage%3D518%26epage%3D526%26doi%3D10.1016%2Fj.bbagen.2006.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thamilselvan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craig, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basson, M. D.</span></span> <span> </span><span class="NLM_article-title">FAK association with multiple signal proteins mediates pressure-induced colon cancer cell adhesion via a Src-dependent PI3K/Akt pathway</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1730</span>â <span class="NLM_lpage">1741</span>, <span class="refDoi">Â DOI: 10.1096/fj.06-6545com</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1096%2Ffj.06-6545com" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=17317726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsVWlu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=1730-1741&author=V.+Thamilselvanauthor=D.+H.+Craigauthor=M.+D.+Basson&title=FAK+association+with+multiple+signal+proteins+mediates+pressure-induced+colon+cancer+cell+adhesion+via+a+Src-dependent+PI3K%2FAkt+pathway&doi=10.1096%2Ffj.06-6545com"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">FAK association with multiple signal proteins mediates pressure-induced colon cancer cell adhesion via a Src-dependent PI3K/Akt pathway</span></div><div class="casAuthors">Thamilselvan, Vijayalakshmi; Craig, David H.; Basson, Marc D.</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1730-1741, 10.1096/fj.06-6545com</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Cancer cell adhesion is traditionally viewed as random, occurring if the cell's receptors match the substrate.  Cancer cells are subjected to pressure and shear during growth against a constraining stroma, surgical manipulation, and passage through the venous and lymphatic system.  Cells shed into a cavity such as the abdomen postoperatively also experience increased pressure from postoperative edema.  Increased extracellular pressure stimulates integrin-mediated cancer cell adhesion via FAK and Src.  PI 3-kinase (PI3K) inhibitors (LY294002 or wortmannin), Akt inhibitors, or Akt1 siRNA blocked adhesion stimulated by 15 mmHg pressure in SW620 or primary human malignant colonocytes.  Pressure activated PI3K, tyrosine-phosphorylated and membrane-translocated the p85 subunit, and phosphorylated Akt.  PI3K inhibitor (LY294002) prevented pressure-stimulated Akt Ser473 and FAK Tyr397, but not FAK576 or Src416 phosphorylation.  PP2 inhibited PI3K activity and Akt phosphorylation.  FAK siRNA did not affect pressure-induced PI3K activation but blocked Akt phosphorylation.  Pressure also stimulated FAK or FAKY397F mutant translocation to the membrane.  Akt inhibitor IV blocked pressure-induced Akt and FAK translocation.  Pressure activated Src- and PI3K-dependently induced p85 interaction with FAK, and FAK with Î²1 integrin.  These results delineate a novel force-activated inside-out Src/PI3K/FAK/Akt pathway by which cancer cells regulate their own adhesion.  These signals may be potential targets for inhibition of metastatic adhesion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLWDplUiEzRrVg90H21EOLACvtfcHk0lgpYNFpoGtuGA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsVWlu7c%253D&md5=599d5f49555224bc7dceb8873d3017ba</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1096%2Ffj.06-6545com&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.06-6545com%26sid%3Dliteratum%253Aachs%26aulast%3DThamilselvan%26aufirst%3DV.%26aulast%3DCraig%26aufirst%3DD.%2BH.%26aulast%3DBasson%26aufirst%3DM.%2BD.%26atitle%3DFAK%2520association%2520with%2520multiple%2520signal%2520proteins%2520mediates%2520pressure-induced%2520colon%2520cancer%2520cell%2520adhesion%2520via%2520a%2520Src-dependent%2520PI3K%252FAkt%2520pathway%26jtitle%3DFASEB%2520J.%26date%3D2007%26volume%3D21%26spage%3D1730%26epage%3D1741%26doi%3D10.1096%2Ffj.06-6545com" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rounds, S.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase and endothelial cell apoptosis</span>. <i>Microvasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">56</span>â <span class="NLM_lpage">63</span>, <span class="refDoi">Â DOI: 10.1016/j.mvr.2011.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.mvr.2011.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=21624380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFOqtr7P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2012&pages=56-63&author=Q.+Luauthor=S.+Rounds&title=Focal+adhesion+kinase+and+endothelial+cell+apoptosis&doi=10.1016%2Fj.mvr.2011.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion kinase and endothelial cell apoptosis</span></div><div class="casAuthors">Lu, Qing; Rounds, Sharon</div><div class="citationInfo"><span class="NLM_cas:title">Microvascular Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-63</span>CODEN:
                <span class="NLM_cas:coden">MIVRA6</span>;
        ISSN:<span class="NLM_cas:issn">0026-2862</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Focal adhesion kinase (FAK) is a key component of cell-substratum adhesions, known as focal adhesion complexes.  Growing evidence indicates that FAK is important in maintenance of normal cell survival and that disruption of FAK signaling results in loss of substrate adhesion and anoikis (apoptosis) of anchorage-dependent cells, such as endothelial cells.  Basal FAK activity in non-stimulated endothelial cells is important in maintaining cell adhesion to integrins via PI3 kinase/Akt signaling.  FAK activity is dependent upon small GTPase signaling.  FAK also appears to be important in cardiomyocyte hypertrophy and hypoxia/reoxygenation-induced cell death.  This review summarizes the signaling pathways of FAK in prevention of apoptosis and the role of FAK in mediating adenosine and homocysteine-induced endothelial cell apoptosis and in cardiovascular diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3cXCIr_k1WrVg90H21EOLACvtfcHk0li8ui3ceOGmeQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFOqtr7P&md5=9a6077f2f9c96dd99b2158c07bc8603e</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.mvr.2011.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mvr.2011.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DQ.%26aulast%3DRounds%26aufirst%3DS.%26atitle%3DFocal%2520adhesion%2520kinase%2520and%2520endothelial%2520cell%2520apoptosis%26jtitle%3DMicrovasc.%2520Res.%26date%3D2012%26volume%3D83%26spage%3D56%26epage%3D63%26doi%3D10.1016%2Fj.mvr.2011.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pestell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, J. L.</span></span> <span> </span><span class="NLM_article-title">Transcriptional activation of cyclin D1 promoter by FAK contributes to cell cycle progression</span>. <i>Mol. Biol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">4066</span>â <span class="NLM_lpage">4077</span>, <span class="refDoi">Â DOI: 10.1091/mbc.12.12.4066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1091%2Fmbc.12.12.4066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=11739801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD3MXpt1Giu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2001&pages=4066-4077&author=J.+Zhaoauthor=R.+Pestellauthor=J.+L.+Guan&title=Transcriptional+activation+of+cyclin+D1+promoter+by+FAK+contributes+to+cell+cycle+progression&doi=10.1091%2Fmbc.12.12.4066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Transcriptional activation of cyclin D1 promoter by FAK contributes to cell cycle progression</span></div><div class="casAuthors">Zhao, Jihe; Pestell, Richard; Guan, Jun-Lin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Biology of the Cell</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4066-4077</span>CODEN:
                <span class="NLM_cas:coden">MBCEEV</span>;
        ISSN:<span class="NLM_cas:issn">1059-1524</span>.
    
            (<span class="NLM_cas:orgname">American Society for Cell Biology</span>)
        </div><div class="casAbstract">Integrin-mediated cell adhesion to the extracellular matrix is required for normal cell growth.  Cyclin D1 is a key regulator of G1-to-S phase progression of the cell cycle.  Our previous studies have demonstrated that integrin signaling through focal adhesion kinase (FAK) plays a role in the regulation of cell cycle progression, which correlates with changes in the expression of cyclin D1 and the cdk inhibitor, p21, induced by FAK.  In this report, we first investigated the roles of both cyclin D1 and p21 in the regulation of cell cycle progression by FAK.  We found that overexpression of a dominant-neg. FAK mutant ÎC14 suppressed cell cycle progression in p21-/- cells as effectively as in the control p21+/+ cells.  Furthermore, we found that overexpression of ectopic cyclin D1 could rescue cell cycle inhibition by ÎC14.  These results suggested that cyclin D1, but not p21, was the primary functional target of FAK signaling pathways in cell cycle regulation.  We then investigated the mechanisms underlying the regulation of cyclin D1 expression by FAK signaling.  Using Northern blotting and cyclin D1 promoter/luciferase assays, we showed that FAK signaling regulated cyclin D1 expression at the transcriptional level.  Using a series of cyclin D1 promoter mutants in luciferase assays as well as electrophoretic mobility shift assays (EMSA), we showed that the EtsB binding site mediated cyclin D1 promoter regulation by FAK.  Finally, we showed that FAK regulation of cyclin D1 depends on integrin-mediated cell adhesion and is likely through its activation of the Erk signaling pathway.  Together, these studies demonstrate that transcriptional regulation of cyclin D1 by FAK signaling pathways contributes to the regulation of cell cycle progression in cell adhesion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYtJnIF79xkrVg90H21EOLACvtfcHk0li8ui3ceOGmeQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXpt1Giu7k%253D&md5=7e28c47174f9d4d5350ac0e8a85606ac</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1091%2Fmbc.12.12.4066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1091%252Fmbc.12.12.4066%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DPestell%26aufirst%3DR.%26aulast%3DGuan%26aufirst%3DJ.%2BL.%26atitle%3DTranscriptional%2520activation%2520of%2520cyclin%2520D1%2520promoter%2520by%2520FAK%2520contributes%2520to%2520cell%2520cycle%2520progression%26jtitle%3DMol.%2520Biol.%2520Cell%26date%3D2001%26volume%3D12%26spage%3D4066%26epage%3D4077%26doi%3D10.1091%2Fmbc.12.12.4066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagoshi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tachikawa, T.</span></span> <span> </span><span class="NLM_article-title">Expression of FAK-related non-kinase (FRNK) coincides with morphological change in the early stage of cell adhesion</span>. <i>Med. Mol. Morphol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">154</span>â <span class="NLM_lpage">160</span>, <span class="refDoi">Â DOI: 10.1007/s00795-006-0325-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1007%2Fs00795-006-0325-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=16998626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvFaktL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2006&pages=154-160&author=Y.+Nagoshiauthor=G.+Yamamotoauthor=T.+Irieauthor=T.+Tachikawa&title=Expression+of+FAK-related+non-kinase+%28FRNK%29+coincides+with+morphological+change+in+the+early+stage+of+cell+adhesion&doi=10.1007%2Fs00795-006-0325-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of FAK-related non-kinase (FRNK) coincides with morphological change in the early stage of cell adhesion</span></div><div class="casAuthors">Nagoshi, Yuuki; Yamamoto, Gou; Irie, Tarou; Tachikawa, Tetsuhiko</div><div class="citationInfo"><span class="NLM_cas:title">Medical Molecular Morphology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">154-160</span>CODEN:
                <span class="NLM_cas:coden">MMMECK</span>;
        ISSN:<span class="NLM_cas:issn">1860-1480</span>.
    
            (<span class="NLM_cas:orgname">Springer Tokyo</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK), a protein tyrosine kinase, has recently been suggested to play a role in signal transduction through integrins.  In fact, FAK is involved in cell proliferation and cell motility by performing signal transduction through integrins.  FAK-related non-kinase (FRNK) has been found to be an inhibitor of FAK.  As the expression level of FRNK in the cell is very low, the study of FRNK up to now has been preferentially performed by gene overexpression, and the role of constitutive FRNK in cells remains unclear.  We hypothesized that FRNK is involved in the adhesion of cells to the extracellular matrix (ECM) and investigated the expression of FRNK by time kinetic anal. shortly after cell seeding.  We found that FRNK expression was significantly increased in the cells during the early stage of cell adhesion to the ECM.  These data indicated that FRNK plays an important role in cell adhesion during the very early stages of cell culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-LqH1MbbiwbVg90H21EOLACvtfcHk0li8ui3ceOGmeQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvFaktL8%253D&md5=089747908550ca7b0c127886d5b288d1</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1007%2Fs00795-006-0325-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00795-006-0325-8%26sid%3Dliteratum%253Aachs%26aulast%3DNagoshi%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DG.%26aulast%3DIrie%26aufirst%3DT.%26aulast%3DTachikawa%26aufirst%3DT.%26atitle%3DExpression%2520of%2520FAK-related%2520non-kinase%2520%2528FRNK%2529%2520coincides%2520with%2520morphological%2520change%2520in%2520the%2520early%2520stage%2520of%2520cell%2520adhesion%26jtitle%3DMed.%2520Mol.%2520Morphol.%26date%3D2006%26volume%3D39%26spage%3D154%26epage%3D160%26doi%3D10.1007%2Fs00795-006-0325-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hood, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frausto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiosses, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheresh, D. A.</span></span> <span> </span><span class="NLM_article-title">Differential alphav integrin-mediated Ras-ERK signaling during two pathways of angiogenesis</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">933</span>â <span class="NLM_lpage">943</span>, <span class="refDoi">Â DOI: 10.1083/jcb.200304105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1083%2Fjcb.200304105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=12952943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD3sXntFeqsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2003&pages=933-943&author=J.+D.+Hoodauthor=R.+Fraustoauthor=W.+B.+Kiossesauthor=M.+A.+Schwartzauthor=D.+A.+Cheresh&title=Differential+alphav+integrin-mediated+Ras-ERK+signaling+during+two+pathways+of+angiogenesis&doi=10.1083%2Fjcb.200304105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Differential Î±v integrin-mediated Ras-ERK signaling during two pathways of angiogenesis</span></div><div class="casAuthors">Hood, John D.; Frausto, Ricardo; Kiosses, William B.; Schwartz, Martin A.; Cheresh, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">933-943</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Antagonists of Î±vÎ²3 and Î±vÎ²5 disrupt angiogenesis in response to bFGF and VEGF, resp.  These Î±v integrins differentially contribute to sustained Ras-extracellular signal-related kinase (Ras-ERK) signaling in blood vessels, a requirement for endothelial cell survival and angiogenesis.  Inhibition of FAK or Î±vÎ²5 disrupted VEGF-mediated Ras and c-Raf activity on the chick chorioallantoic membrane, whereas blockade of FAK or integrin Î±vÎ²3 had no effect on bFGF-mediated Ras activity, but did suppress c-Raf activation.  Furthermore, retroviral delivery of active Ras or c-Raf promoted ERK activity and angiogenesis, which anti-Î±vÎ²5 blocked upstream of Ras, whereas anti-Î±vÎ²3 blocked downstream of Ras, but upstream of c-Raf.  The activation of c-Raf by bFGF/Î±vÎ²3 not only depended on FAK, but also required p21-activated kinase-dependent phosphorylation of serine 338 on c-Raf, whereas VEGF-mediated c-Raf phosphorylation/activation depended on Src, but not Pak.  Thus, integrins Î±vÎ²3 and Î±vÎ²5 differentially regulate the Ras-ERK pathway, accounting for distinct vascular responses during two pathways of angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU0UDA9OptFbVg90H21EOLACvtfcHk0li8ui3ceOGmeQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXntFeqsbs%253D&md5=2f60d0c4cd182cbfbb68f1cf932cfbd4</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1083%2Fjcb.200304105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.200304105%26sid%3Dliteratum%253Aachs%26aulast%3DHood%26aufirst%3DJ.%2BD.%26aulast%3DFrausto%26aufirst%3DR.%26aulast%3DKiosses%26aufirst%3DW.%2BB.%26aulast%3DSchwartz%26aufirst%3DM.%2BA.%26aulast%3DCheresh%26aufirst%3DD.%2BA.%26atitle%3DDifferential%2520alphav%2520integrin-mediated%2520Ras-ERK%2520signaling%2520during%2520two%2520pathways%2520of%2520angiogenesis%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2003%26volume%3D162%26spage%3D933%26epage%3D943%26doi%3D10.1083%2Fjcb.200304105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vo, T.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howerton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larocque, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlaepfer, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilic, D.</span></span> <span> </span><span class="NLM_article-title">Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">9</span>â <span class="NLM_lpage">22</span>, <span class="refDoi">Â DOI: 10.1016/j.molcel.2007.11.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.molcel.2007.11.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=18206965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlWjt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=9-22&author=S.-T.+Limauthor=X.+L.+Chenauthor=Y.+Limauthor=D.+A.+Hansonauthor=T.-T.+Voauthor=K.+Howertonauthor=N.+Larocqueauthor=S.+J.+Fisherauthor=D.+D.+Schlaepferauthor=D.+Ilic&title=Nuclear+FAK+promotes+cell+proliferation+and+survival+through+FERM-enhanced+p53+degradation&doi=10.1016%2Fj.molcel.2007.11.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation</span></div><div class="casAuthors">Lim, Ssang-Taek; Chen, Xiao Lei; Lim, Yangmi; Hanson, Dan A.; Vo, Thanh-Trang; Howerton, Kyle; Larocque, Nicholas; Fisher, Susan J.; Schlaepfer, David D.; Ilic, Dusko</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-22</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">FAK is known as an integrin- and growth factor-assocd. tyrosine kinase promoting cell motility.  Here we show that, during mouse development, FAK inactivation results in p53- and p21-dependent mesodermal cell growth arrest.  Reconstitution of primary FAK-/-p21-/- fibroblasts revealed that FAK, in a kinase-independent manner, facilitates p53 turnover via enhanced Mdm2-dependent p53 ubiquitination.  P53 inactivation by FAK required FAK FERM F1 lobe binding to p53, FERM F2 lobe-mediated nuclear localization, and FERM F3 lobe for connections to Mdm2 and proteasomal degrdn.  Staurosporine or loss of cell adhesion enhanced FERM-dependent FAK nuclear accumulation.  In primary human cells, FAK knockdown raised p53-p21 levels and slowed cell proliferation but did not cause apoptosis.  Notably, FAK knockdown plus cisplatin triggered p53-dependent cell apoptosis, which was rescued by either full-length FAK or FAK FERM re-expression.  These studies define a scaffolding role for nuclear FAK in facilitating cell survival through enhanced p53 degrdn. under conditions of cellular stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdS7DXtKran7Vg90H21EOLACvtfcHk0lg7Sa-zyy4y9w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlWjt7g%253D&md5=e10f327978a82ada4df353390b0edced</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2007.11.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2007.11.031%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DS.-T.%26aulast%3DChen%26aufirst%3DX.%2BL.%26aulast%3DLim%26aufirst%3DY.%26aulast%3DHanson%26aufirst%3DD.%2BA.%26aulast%3DVo%26aufirst%3DT.-T.%26aulast%3DHowerton%26aufirst%3DK.%26aulast%3DLarocque%26aufirst%3DN.%26aulast%3DFisher%26aufirst%3DS.%2BJ.%26aulast%3DSchlaepfer%26aufirst%3DD.%2BD.%26aulast%3DIlic%26aufirst%3DD.%26atitle%3DNuclear%2520FAK%2520promotes%2520cell%2520proliferation%2520and%2520survival%2520through%2520FERM-enhanced%2520p53%2520degradation%26jtitle%3DMol.%2520Cell%26date%3D2008%26volume%3D29%26spage%3D9%26epage%3D22%26doi%3D10.1016%2Fj.molcel.2007.11.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cox, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stettner, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gladson, C. L.</span></span> <span> </span><span class="NLM_article-title">New concepts regarding focal adhesion kinase promotion of cell migration and proliferation</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">35</span>â <span class="NLM_lpage">52</span>, <span class="refDoi">Â DOI: 10.1002/jcb.20956</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1002%2Fjcb.20956" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=16823799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BD28rhtFGgug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2006&pages=35-52&author=B.+D.+Coxauthor=M.+Natarajanauthor=M.+R.+Stettnerauthor=C.+L.+Gladson&title=New+concepts+regarding+focal+adhesion+kinase+promotion+of+cell+migration+and+proliferation&doi=10.1002%2Fjcb.20956"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">New concepts regarding focal adhesion kinase promotion of cell migration and proliferation</span></div><div class="casAuthors">Cox Braden D; Natarajan Meera; Stettner Michelle R; Gladson Candece L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of cellular biochemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-52</span>
        ISSN:<span class="NLM_cas:issn">0730-2312</span>.
    </div><div class="casAbstract">Focal adhesion kinase (FAK) is a non-receptor cytoplasmic tyrosine kinase that plays a key role in the regulation of proliferation and migration of normal and tumor cells.  FAK associates with integrin receptors and recruits other molecules to the site of this interaction thus forming a signaling complex that transmits signals from the extracellular matrix to the cell cytoskeleton.  Crk-associated substrate (CAS) family members appear to play a pivotal role in FAK regulation of cell migration.  Cellular Src bound to FAK phosphorylates CAS proteins leading to the recruitment of a Crk family adaptor molecule and activation of a small GTPase and c-Jun N-terminal kinase (JNK) promoting membrane protrusion and cell migration.  The relocalization of CAS and signaling through specific CAS family members appears to determine the outcome of this pathway.  FAK also plays an important role in regulating cell cycle progression through transcriptional control of the cyclin D1 promoter by the Ets B and Kruppel-like factor 8 (KLF8) transcription factors.  FAK regulation of cell cycle progression in tumor cells requires Erk activity, cyclin D1 transcription, and the cyclin-dependent kinase (cdk) inhibitor p27Kip1.  The ability of FAK to integrate integrin and growth factor signals resulting in synergistic promotion of cell migration and proliferation, and its potential regulation by nuclear factor kappa B (NFkappaB) and p53 and a ubiquitously expressed inhibitory protein, suggest that it is remarkable in its capacity to integrate multiple extracellular and intracellular stimuli.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJXl7Nm0CVcjAEfvC7EH1LfW6udTcc2ea257xOc3t5Krntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28rhtFGgug%253D%253D&md5=418bfd01c7dacb9607c4c591973b30b5</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Fjcb.20956&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.20956%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DB.%2BD.%26aulast%3DNatarajan%26aufirst%3DM.%26aulast%3DStettner%26aufirst%3DM.%2BR.%26aulast%3DGladson%26aufirst%3DC.%2BL.%26atitle%3DNew%2520concepts%2520regarding%2520focal%2520adhesion%2520kinase%2520promotion%2520of%2520cell%2520migration%2520and%2520proliferation%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2006%26volume%3D99%26spage%3D35%26epage%3D52%26doi%3D10.1002%2Fjcb.20956" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Provenzano, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keely, P. J.</span></span> <span> </span><span class="NLM_article-title">The role of focal adhesion kinase in tumor initiation and progression</span>. <i>Cell Adhes. Migr.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">347</span>â <span class="NLM_lpage">350</span>, <span class="refDoi">Â DOI: 10.4161/cam.3.4.9458</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.4161%2Fcam.3.4.9458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=19690467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BD1MjovF2hsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2009&pages=347-350&author=P.+P.+Provenzanoauthor=P.+J.+Keely&title=The+role+of+focal+adhesion+kinase+in+tumor+initiation+and+progression&doi=10.4161%2Fcam.3.4.9458"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The role of focal adhesion kinase in tumor initiation and progression</span></div><div class="casAuthors">Provenzano Paolo P; Keely Patricia J</div><div class="citationInfo"><span class="NLM_cas:title">Cell adhesion & migration</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">347-50</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Focal adhesion kinase (FAK) is a nonreceptor tyrosine kinase that acts as a primary regulator of focal adhesion signaling to regulate cell proliferation, survival and migration.  While FAK is known to directly influence many fundamental adhesion and growth factor signaling pathways important in cancer and FAK is overexpressed in multiple human cancers studies addressing a causal role for FAK in tumor initiation and progression using transgenic models of human cancer had not been performed.  Recently, using tissue-specific FAK-knockout in mouse models of human cancer, the consequences of FAK ablation in carcinoma were demonstrated by multiple independent research groups.  Strong consensus evidence indicates that epithelial cells are able to transform in the absence of FAK, but do not undergo a malignant conversion to invasive carcinoma, and as such, metastasis is impaired.  This is likely the consequence of decreased Src and p130Cas activation in concert with misregulated actin cytoskeleton dynamics and Rho GTPase signaling.  Hence, FAK, as well as the FAK-regulating/regulated signaling network, are viable candidates for cancer metastasis therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQSKpjb2A3ZN4HWj6b1v8uTfW6udTcc2ea257xOc3t5Krntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MjovF2hsg%253D%253D&md5=b3f87614a88c83c60c13b5c8c8273867</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.4161%2Fcam.3.4.9458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcam.3.4.9458%26sid%3Dliteratum%253Aachs%26aulast%3DProvenzano%26aufirst%3DP.%2BP.%26aulast%3DKeely%26aufirst%3DP.%2BJ.%26atitle%3DThe%2520role%2520of%2520focal%2520adhesion%2520kinase%2520in%2520tumor%2520initiation%2520and%2520progression%26jtitle%3DCell%2520Adhes.%2520Migr.%26date%3D2009%26volume%3D3%26spage%3D347%26epage%3D350%26doi%3D10.4161%2Fcam.3.4.9458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Z. X.</span></span> <span> </span><span class="NLM_article-title">Sonic hedgehog signaling pathway induces cell migration and invasion through focal adhesion kinase/AKT signaling-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9 in liver cancer</span>. <i>Carcinogenesis</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">10</span>â <span class="NLM_lpage">19</span>, <span class="refDoi">Â DOI: 10.1093/carcin/bgs274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1093%2Fcarcin%2Fbgs274" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=22948179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFShtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=10-19&author=J.+S.+Chenauthor=X.+H.+Huangauthor=Q.+Wangauthor=J.+Q.+Huangauthor=L.+J.+Zhangauthor=X.+L.+Chenauthor=J.+Leiauthor=Z.+X.+Cheng&title=Sonic+hedgehog+signaling+pathway+induces+cell+migration+and+invasion+through+focal+adhesion+kinase%2FAKT+signaling-mediated+activation+of+matrix+metalloproteinase+%28MMP%29-2+and+MMP-9+in+liver+cancer&doi=10.1093%2Fcarcin%2Fbgs274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Sonic hedgehog signaling pathway induces cell migration and invasion through focal adhesion kinase/AKT signaling-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9 in liver cancer</span></div><div class="casAuthors">Chen, Jing-Song; Huang, Xiao-hui; Wang, Qian; Huang, Jiong-Qiang; Zhang, Long-juan; Chen, Xi-Lin; Lei, Jian; Cheng, Zhi-Xiang</div><div class="citationInfo"><span class="NLM_cas:title">Carcinogenesis</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10-19</span>CODEN:
                <span class="NLM_cas:coden">CRNGDP</span>;
        ISSN:<span class="NLM_cas:issn">0143-3334</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The aberrant activation of sonic hedgehog (SHH) pathway contributes to initiation and progression of various malignancies.  However, the roles and underlying mechanisms of SHH signaling pathway in invasion and metastasis of liver cancer have not been well understood.  In this study, we found that SHH signaling was activated and correlated with invasion and metastasis in hepatocellular carcinoma (HCC).  Enhanced SHH signaling by recombinant human SHH N-terminal peptide (rSHH-N) promoted hepatoma cell adhesion, migration and invasion, whereas blockade of SHH signaling with SHH neutralizing antibody or cyclopamine suppressed hepatoma cell adhesion, migration and invasion.  Furthermore, matrix metalloproteinase (MMP)-2 and MMP-9 expressions and activities were upregulated and downregulated by rSHH-N and SHH signaling inhibitor, resp.  The rSHH-N-mediated hepatoma cell migration and invasion was blocked by MMP-specific inhibitors or neutralizing antibodies to MMP-2 and MMP-9.  In addn., phosphorylations of AKT and focal adhesion kinase (FAK) were increased and decreased by rSHH-N and SHH signaling inhibitor, resp.  Further investigations showed that activation of AKT and FAK were required for rSHH-N-mediated upregulation of MMP-2 and MMP-9, cell migration and invasion.  Finally, we found that SHH protein expression was pos. correlated with phosphorylatd FAK Tyr397, phosphorylatd AKT Ser473, MMP-2 and MMP-9 protein expressions in HCC samples.  Taken together, our findings suggest that SHH pathway induces cell migration and invasion through FAK/AKT signaling-mediated MMP-2 and MMP-9 prodn. and activation in liver cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGG0YUNI5-47Vg90H21EOLACvtfcHk0ljJzS8nSWw8jA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFShtw%253D%253D&md5=c10ad0d036d241386f3c4282342d0409</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1093%2Fcarcin%2Fbgs274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcarcin%252Fbgs274%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%2BS.%26aulast%3DHuang%26aufirst%3DX.%2BH.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DJ.%2BQ.%26aulast%3DZhang%26aufirst%3DL.%2BJ.%26aulast%3DChen%26aufirst%3DX.%2BL.%26aulast%3DLei%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DZ.%2BX.%26atitle%3DSonic%2520hedgehog%2520signaling%2520pathway%2520induces%2520cell%2520migration%2520and%2520invasion%2520through%2520focal%2520adhesion%2520kinase%252FAKT%2520signaling-mediated%2520activation%2520of%2520matrix%2520metalloproteinase%2520%2528MMP%2529-2%2520and%2520MMP-9%2520in%2520liver%2520cancer%26jtitle%3DCarcinogenesis%26date%3D2013%26volume%3D34%26spage%3D10%26epage%3D19%26doi%3D10.1093%2Fcarcin%2Fbgs274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, J. L.</span></span> <span> </span><span class="NLM_article-title">FAK-mediated src phosphorylation of endophilin A2 inhibits endocytosis of MT1-MMP and promotes ECM degradation</span>. <i>Dev. Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">185</span>â <span class="NLM_lpage">196</span>, <span class="refDoi">Â DOI: 10.1016/j.devcel.2005.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.devcel.2005.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=16054026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2MXovFSgsrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2005&pages=185-196&author=X.+Wuauthor=B.+Ganauthor=Y.+Yooauthor=J.+L.+Guan&title=FAK-mediated+src+phosphorylation+of+endophilin+A2+inhibits+endocytosis+of+MT1-MMP+and+promotes+ECM+degradation&doi=10.1016%2Fj.devcel.2005.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">FAK-mediated Src phosphorylation of endophilin A2 inhibits endocytosis of MT1-MMP and promotes ECM degradation</span></div><div class="casAuthors">Wu, Xiaoyang; Gan, Boyi; Yoo, Youngdong; Guan, Jun-Lin</div><div class="citationInfo"><span class="NLM_cas:title">Developmental Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">185-196</span>CODEN:
                <span class="NLM_cas:coden">DCEEBE</span>;
        ISSN:<span class="NLM_cas:issn">1534-5807</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) is an important mediator of integrin signaling in the regulation of cell proliferation, survival, migration, and invasion.  To understand how FAK contributes to cell invasion, we explored the regulation of matrix metalloproteinases (MMPs) by FAK.  We found that v-Src-transformed cells activate a FAK-dependent mechanism that attenuates endocytosis of MT1-MMP.  This in turn increases cell-surface expression of MT1-MMP and cellular degrdn. of extracellular matrix.  Further, we identified an interaction between FAK's second Pro-rich motif and endophilin A2's SH3 domain.  This interaction served as an autophosphorylation-dependent scaffold to allow Src phosphorylation of endophilin A2 at Tyr315.  Tyr315 phosphorylation inhibited endophilin/dynamin interactions, and blockade of Tyr315 phosphorylation promoted endocytosis of MT1-MMP.  Together, these results suggest a regulatory mechanism of cell invasion whereby FAK promotes cell-surface presentation of MT1-MMP by inhibiting endophilin A2-dependent endocytosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnxJDusftK47Vg90H21EOLACvtfcHk0ljJzS8nSWw8jA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXovFSgsrs%253D&md5=0943cc91d3f9f1b3bafc985708f6d318</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.devcel.2005.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.devcel.2005.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DX.%26aulast%3DGan%26aufirst%3DB.%26aulast%3DYoo%26aufirst%3DY.%26aulast%3DGuan%26aufirst%3DJ.%2BL.%26atitle%3DFAK-mediated%2520src%2520phosphorylation%2520of%2520endophilin%2520A2%2520inhibits%2520endocytosis%2520of%2520MT1-MMP%2520and%2520promotes%2520ECM%2520degradation%26jtitle%3DDev.%2520Cell%26date%3D2005%26volume%3D9%26spage%3D185%26epage%3D196%26doi%3D10.1016%2Fj.devcel.2005.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobie, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span> <span> </span><span class="NLM_article-title">MicroRNA-7 inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via targeting FAK expression</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e41523</span> <span class="refDoi">Â DOI: 10.1371/journal.pone.0041523</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1371%2Fjournal.pone.0041523" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=22876288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFKht7nF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&author=X.+Kongauthor=G.+Liauthor=Y.+Yuanauthor=Y.+Heauthor=X.+Wuauthor=W.+Zhangauthor=Z.+Wuauthor=T.+Chenauthor=W.+Wuauthor=P.+E.+Lobieauthor=T.+Zhu&title=MicroRNA-7+inhibits+epithelial-to-mesenchymal+transition+and+metastasis+of+breast+cancer+cells+via+targeting+FAK+expression&doi=10.1371%2Fjournal.pone.0041523"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">MicroRNA-7 inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via targeting FAK expression</span></div><div class="casAuthors">Kong, Xiangjun; Li, Gaopeng; Yuan, Yan; He, Yan; Wu, Xiaoli; Zhang, Weijie; Wu, Zhengsheng; Chen, Tingting; Wu, Wenyong; Lobie, Peter E.; Zhu, Tao</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e41523</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) is an important mediator of extracellular matrix integrin signaling, cell motility, cell proliferation and cell survival.  Increased FAK expression is obsd. in a variety of solid human tumors and increased FAK expression and activity frequently correlate with metastatic disease and poor prognosis.  Herein we identify miR-7 as a direct regulator of FAK expression.  MiR-7 expression is decreased in malignant vs. normal breast tissue and its expression correlates inversely with metastasis in human breast cancer patients.  Forced expression of miR-7 produced increased E-cadherin and decreased fibronectin and vimentin expression in breast cancer cells.  The levels of miR-7 expression was pos. correlated with E-cadherin mRNA and neg. correlated with vimentin mRNA levels in breast cancer samples.  Forced expression of miR-7 in aggressive breast cancer cell lines suppressed tumor cell monolayer proliferation, anchorage independent growth, 3D growth in Matrigel, migration and invasion.  Conversely, inhibition of miR-7 in the HBL-100 mammary epithelial cell line promoted cell proliferation and anchorage independent growth.  Rescue of FAK expression reversed miR-7 suppression of migration and invasion.  MiR-7 also inhibited primary breast tumor development, local invasion and metastatic colonization of breast cancer xenografts.  Thus, miR-7 expression is decreased in metastatic breast cancer, correlates with the level of epithelial differentiation of the tumor and inhibits metastatic progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5ivAoV6FlMLVg90H21EOLACvtfcHk0ljJzS8nSWw8jA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFKht7nF&md5=e9d4e6c80f87bc0304a1623e036b84fe</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0041523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0041523%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DLobie%26aufirst%3DP.%2BE.%26aulast%3DZhu%26aufirst%3DT.%26atitle%3DMicroRNA-7%2520inhibits%2520epithelial-to-mesenchymal%2520transition%2520and%2520metastasis%2520of%2520breast%2520cancer%2520cells%2520via%2520targeting%2520FAK%2520expression%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26doi%3D10.1371%2Fjournal.pone.0041523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlaepfer, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dressler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, S. J.</span></span> <span> </span><span class="NLM_article-title">Snail1 controls epithelial-mesenchymal lineage commitment in focal adhesion kinase-null embryonic cells</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>195</i></span>,  <span class="NLM_fpage">729</span>â <span class="NLM_lpage">738</span>, <span class="refDoi">Â DOI: 10.1083/jcb.201105103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1083%2Fjcb.201105103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=22105351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Shsb3F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=195&publication_year=2011&pages=729-738&author=X.+Y.+Liauthor=X.+Zhouauthor=R.+G.+Roweauthor=Y.+Huauthor=D.+D.+Schlaepferauthor=D.+Ilicauthor=G.+Dresslerauthor=A.+Parkauthor=J.+L.+Guanauthor=S.+J.+Weiss&title=Snail1+controls+epithelial-mesenchymal+lineage+commitment+in+focal+adhesion+kinase-null+embryonic+cells&doi=10.1083%2Fjcb.201105103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Snail1 controls epithelial-mesenchymal lineage commitment in focal adhesion kinase-null embryonic cells</span></div><div class="casAuthors">Li, Xiao-Yan; Zhou, Xiaoming; Rowe, R. Grant; Hu, Yuexian; Schlaepfer, David D.; Ilic, Dusko; Dressler, Gregory; Park, Ann; Guan, Jun-Lin; Weiss, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">195</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">729-738</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Mouse embryonic cells isolated from focal adhesion kinase (FAK)-null animals at embryonic day 7.5 display multiple defects in focal adhesion remodeling, microtubule dynamics, mechanotransduction, proliferation, directional motility, and invasion.  To date, the ability of FAK to modulate cell function has been ascribed largely to its control of posttranscriptional signaling cascades in this embryonic cell population.  In this paper, we demonstrate that FAK unexpectedly exerts control over an epithelial-mesenchymal transition (EMT) program that commits embryonic FAK-null cells to an epithelial status highlighted by the expression of E-cadherin, desmoplakin, and cytokeratins.  FAK rescue reestablished the mesenchymal characteristics of FAK-null embryonic cells to generate committed mouse embryonic fibroblasts via an extracellular signal-related kinase- and Akt-dependent signaling cascade that triggered Snail1 gene expression and Snail1 protein stabilization.  These findings identify FAK as a novel regulator of Snail1-dependent EMT in embryonic cells and suggest that multiple defects in FAK-/- cell behavior can be attributed to an inappropriate commitment of these cells to an epithelial, rather than fibroblastic, phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqWY6u9fxsH7Vg90H21EOLACvtfcHk0liBOppX3gvnIg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Shsb3F&md5=a2d30bd912fa7ea6dc001d59140b1e42</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1083%2Fjcb.201105103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.201105103%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%2BY.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DRowe%26aufirst%3DR.%2BG.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DSchlaepfer%26aufirst%3DD.%2BD.%26aulast%3DIlic%26aufirst%3DD.%26aulast%3DDressler%26aufirst%3DG.%26aulast%3DPark%26aufirst%3DA.%26aulast%3DGuan%26aufirst%3DJ.%2BL.%26aulast%3DWeiss%26aufirst%3DS.%2BJ.%26atitle%3DSnail1%2520controls%2520epithelial-mesenchymal%2520lineage%2520commitment%2520in%2520focal%2520adhesion%2520kinase-null%2520embryonic%2520cells%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2011%26volume%3D195%26spage%3D729%26epage%3D738%26doi%3D10.1083%2Fjcb.201105103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Spiegelaere, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casteleyn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den Broeck, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plendl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahramsoltani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simoens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djonov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornillie, P.</span></span> <span> </span><span class="NLM_article-title">Intussusceptive angiogenesis: a biologically relevant form of angiogenesis</span>. <i>J. Vasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">390</span>â <span class="NLM_lpage">404</span>, <span class="refDoi">Â DOI: 10.1159/000338278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1159%2F000338278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=22739226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BC38jltl2quw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2012&pages=390-404&author=W.+De%0ASpiegelaereauthor=C.+Casteleynauthor=W.+Van+den+Broeckauthor=J.+Plendlauthor=M.+Bahramsoltaniauthor=P.+Simoensauthor=V.+Djonovauthor=P.+Cornillie&title=Intussusceptive+angiogenesis%3A+a+biologically+relevant+form+of+angiogenesis&doi=10.1159%2F000338278"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Intussusceptive angiogenesis: a biologically relevant form of angiogenesis</span></div><div class="casAuthors">De Spiegelaere Ward; Casteleyn Christophe; Van den Broeck Wim; Plendl Johanna; Bahramsoltani Mahtab; Simoens Paul; Djonov Valentin; Cornillie Pieter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of vascular research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">390-404</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Angiogenesis, i.e. the development and growth of blood vessels, is a major topic of research as it plays an important role in normal development and in various pathologies.  Recent evidence revealed the existence of different mechanisms of blood vessel growth, including sprouting and intussusceptive angiogenesis, vascular mimicry, and blood vessel cooption.  The latter two have only been observed in tumor growth, but sprouting and intussusceptive angiogenesis also occur in healthy, physiologically growing tissues.  Despite this variety of angiogenic mechanisms, most of the current research is focused on the mechanism of sprouting angiogenesis because this mechanism was first described and because most existing experimental models are related to sprouting angiogenesis.  Consequently, the mechanism of intussusceptive angiogenesis is often overlooked in angiogenesis research.  Here, the mechanism of intussusceptive angiogenesis is reviewed and the current techniques and models for investigating intussusceptive angiogenesis are summarized.  In addition, other mechanisms of vascular growth are briefly reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ5rIFf53X9dXp3bfzSLaX5fW6udTcc2ebbLI3YfUIYJbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38jltl2quw%253D%253D&md5=46b1458050b12c337bc8c9443c27f478</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1159%2F000338278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000338278%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSpiegelaere%26aufirst%3DW.%26aulast%3DCasteleyn%26aufirst%3DC.%26aulast%3DVan%2Bden%2BBroeck%26aufirst%3DW.%26aulast%3DPlendl%26aufirst%3DJ.%26aulast%3DBahramsoltani%26aufirst%3DM.%26aulast%3DSimoens%26aufirst%3DP.%26aulast%3DDjonov%26aufirst%3DV.%26aulast%3DCornillie%26aufirst%3DP.%26atitle%3DIntussusceptive%2520angiogenesis%253A%2520a%2520biologically%2520relevant%2520form%2520of%2520angiogenesis%26jtitle%3DJ.%2520Vasc.%2520Res.%26date%3D2012%26volume%3D49%26spage%3D390%26epage%3D404%26doi%3D10.1159%2F000338278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, O. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, M. J.</span></span> <span> </span><span class="NLM_article-title">Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2003</span>â <span class="NLM_lpage">2012</span>, <span class="refDoi">Â DOI: 10.1016/j.cellsig.2007.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.cellsig.2007.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=17658244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFylsLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2007&pages=2003-2012&author=K.+Holmesauthor=O.+L.+Robertsauthor=A.+M.+Thomasauthor=M.+J.+Cross&title=Vascular+endothelial+growth+factor+receptor-2%3A+structure%2C+function%2C+intracellular+signalling+and+therapeutic+inhibition&doi=10.1016%2Fj.cellsig.2007.05.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition</span></div><div class="casAuthors">Holmes, Katherine; Roberts, Owain Ll; Thomas, Angharad M.; Cross, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2003-2012</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Vascular endothelial growth factors (VEGFs) regulate vascular development, angiogenesis and lymphangiogenesis by binding to a no. of receptors.  VEGFR-1 is required for the recruitment of hematopoietic stem cells and the migration of monocytes and macrophages, VEGFR-2 regulates vascular endothelial function and VEGFR-3 regulates lymphatic endothelial cell function.  Over the last decade, considerable progress has been made in delineating the VEGFR-2 specific intracellular signaling cascades leading to proliferation, migration, survival and increased permeability, each of which contributes to the angiogenic response.  Furthermore, therapeutic inhibition of VEGFR-2 action is now having an impact in the clinic for the treatment of a no. of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTYxPMokVV57Vg90H21EOLACvtfcHk0liBOppX3gvnIg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFylsLs%253D&md5=44a935f36d29b000d2a9ff514709e9c2</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2007.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2007.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DHolmes%26aufirst%3DK.%26aulast%3DRoberts%26aufirst%3DO.%2BL.%26aulast%3DThomas%26aufirst%3DA.%2BM.%26aulast%3DCross%26aufirst%3DM.%2BJ.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520receptor-2%253A%2520structure%252C%2520function%252C%2520intracellular%2520signalling%2520and%2520therapeutic%2520inhibition%26jtitle%3DCell.%2520Signalling%26date%3D2007%26volume%3D19%26spage%3D2003%26epage%3D2012%26doi%3D10.1016%2Fj.cellsig.2007.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eliceiri, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puente, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stupack, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlaepfer, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheppard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheresh, D. A.</span></span> <span> </span><span class="NLM_article-title">Src-mediated coupling of focal adhesion kinase to integrin Î±vÎ²5 in vascular endothelial growth factor signaling</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">149</span>â <span class="NLM_lpage">159</span>, <span class="refDoi">Â DOI: 10.1083/jcb.200109079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1083%2Fjcb.200109079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=11927607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1Knsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2002&pages=149-159&author=B.+P.+Eliceiriauthor=X.+S.+Puenteauthor=J.+D.+Hoodauthor=D.+G.+Stupackauthor=D.+D.+Schlaepferauthor=X.+Z.+Huangauthor=D.+Sheppardauthor=D.+A.+Cheresh&title=Src-mediated+coupling+of+focal+adhesion+kinase+to+integrin+%CE%B1v%CE%B25+in+vascular+endothelial+growth+factor+signaling&doi=10.1083%2Fjcb.200109079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Src-mediated coupling of focal adhesion kinase to integrin Î±vÎ²5 in vascular endothelial growth factor signaling</span></div><div class="casAuthors">Eliceiri, Brian P.; Puente, Xose S.; Hood, John D.; Stupack, Dwayne G.; Schlaepfer, David D.; Huang, Xiaozhu Z.; Sheppard, Dean; Cheresh, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">149-159</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Vascular endothelial growth factor (VEGF) promotes vascular permeability (VP) and neovascularization, and is required for development.  The authors find that VEGF-stimulated Src activity in chick embryo blood vessels induces the coupling of focal adhesion kinase (FAK) to integrin Î±vÎ²5, a crit. event in VEGF-mediated signaling and biol. responsiveness.  In contrast, FAK is constitutively assocd. with Î²1 and Î²3 integrins in the presence or absence of growth factors.  In cultured endothelial cells, VEGF, but not basic fibroblast growth factor, promotes the Src-mediated phosphorylation of FAK on tyrosine 861, which contributes to the formation of a FAK/Î±vÎ²5 signaling complex.  Moreover, formation of this FAK/Î±vÎ²5 complex is significantly reduced in pp60c-src-deficient mice.  Supporting these results, mice deficient in either pp60c-src or integrin Î²5, but not integrin Î²3, have a reduced VP response to VEGF.  This FAK/Î±vÎ²5 complex was also detected in epidermal growth factor-stimulated epithelial cells, suggesting a function for this complex outside the endothelium.  The authors' findings indicate that Src can coordinate specific growth factor-and extracellular matrix inputs by recruiting integrin Î±vÎ²5 into a FAK-contg. signaling complex during growth factor-mediated biol. responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzzJeqoz_BELVg90H21EOLACvtfcHk0lijuowts6KTFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1Knsbw%253D&md5=189ae93bcda7c1272c3ec217ce0d494d</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1083%2Fjcb.200109079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.200109079%26sid%3Dliteratum%253Aachs%26aulast%3DEliceiri%26aufirst%3DB.%2BP.%26aulast%3DPuente%26aufirst%3DX.%2BS.%26aulast%3DHood%26aufirst%3DJ.%2BD.%26aulast%3DStupack%26aufirst%3DD.%2BG.%26aulast%3DSchlaepfer%26aufirst%3DD.%2BD.%26aulast%3DHuang%26aufirst%3DX.%2BZ.%26aulast%3DSheppard%26aufirst%3DD.%26aulast%3DCheresh%26aufirst%3DD.%2BA.%26atitle%3DSrc-mediated%2520coupling%2520of%2520focal%2520adhesion%2520kinase%2520to%2520integrin%2520%25CE%25B1v%25CE%25B25%2520in%2520vascular%2520endothelial%2520growth%2520factor%2520signaling%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2002%26volume%3D157%26spage%3D149%26epage%3D159%26doi%3D10.1083%2Fjcb.200109079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, J. L.</span></span> <span> </span><span class="NLM_article-title">Nuclear FAK and its kinase activity regulate VEGFR2 transcription in angiogenesis of adult mice</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2550</span>â <span class="NLM_lpage">2560</span>, <span class="refDoi">Â DOI: 10.1038/s41598-018-20930-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fs41598-018-20930-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=29416084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BC1MvovV2gsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=2550-2560&author=S.+Sunauthor=H.+J.+Wuauthor=J.+L.+Guan&title=Nuclear+FAK+and+its+kinase+activity+regulate+VEGFR2+transcription+in+angiogenesis+of+adult+mice&doi=10.1038%2Fs41598-018-20930-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Nuclear FAK and its kinase activity regulate VEGFR2 transcription in angiogenesis of adult mice</span></div><div class="casAuthors">Sun Shaogang; Wu Hsin-Jung; Guan Jun-Lin</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2550</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Focal adhesion kinase (FAK) is essential in embryonic angiogenesis by regulating endothelial cell (EC) survival and barrier functions through its kinase-independent and -dependent activities.  Here, we generated EC-specific tamoxifen-inducible FAK knockout and FAK kinase-defective (KD) mutant knockin mice to investigate the role of FAK and its kinase activity in angiogenesis of adult animals.  Unlike previous observations of their differential defects in embryonic vascular development, both FAK ablation and inactivation of its kinase activity resulted in deficient angiogenesis in wound-healing as well as retinal angiogenesis models.  Consistent with these phenotypes, loss of FAK or its kinase activity decreased EC proliferation and migration to similar extents, suggesting FAK primarily acts as a kinase for the regulation of adult EC-mediated angiogenesis.  Further mechanistic analyses were carried out using an established mouse EC line MS1 cells.  Interestingly, we found that FAK regulated the expression of VEGFR2, a central mediator of various EC functions and angiogenesis, which requires both FAK kinase activity and its translocation into the nucleus.  Moreover, nuclear FAK was detected in the RNA polymerase II complex associated with VEGFR2 promoter, suggesting its direct participation in the transcriptional regulation of VEGFR2.  Together, our results provide significant insights into the signaling mechanisms of FAK in angiogenesis that may contribute to future design of more effective angiogenesis related therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRWIOh1FM9PF4kFb3mqPUYDfW6udTcc2eaJ_06CRjZbobntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvovV2gsw%253D%253D&md5=eb4e2071267f246b4f404a8272a708b3</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fs41598-018-20930-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-018-20930-z%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DH.%2BJ.%26aulast%3DGuan%26aufirst%3DJ.%2BL.%26atitle%3DNuclear%2520FAK%2520and%2520its%2520kinase%2520activity%2520regulate%2520VEGFR2%2520transcription%2520in%2520angiogenesis%2520of%2520adult%2520mice%26jtitle%3DSci.%2520Rep.%26date%3D2018%26volume%3D8%26spage%3D2550%26epage%3D2560%26doi%3D10.1038%2Fs41598-018-20930-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tavora, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batista, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadeja, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostourou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruttiger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodivala-Dilke, K. M.</span></span> <span> </span><span class="NLM_article-title">Endothelial FAK is required for tumour angiogenesis</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">516</span>â <span class="NLM_lpage">528</span>, <span class="refDoi">Â DOI: 10.1002/emmm.201000106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1002%2Femmm.201000106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=21154724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFehsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=516-528&author=B.+Tavoraauthor=S.+Batistaauthor=L.+E.+Reynoldsauthor=S.+Jadejaauthor=S.+Robinsonauthor=V.+Kostourouauthor=I.+Hartauthor=M.+Fruttigerauthor=M.+Parsonsauthor=K.+M.+Hodivala-Dilke&title=Endothelial+FAK+is+required+for+tumour+angiogenesis&doi=10.1002%2Femmm.201000106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelial FAK is required for tumour angiogenesis</span></div><div class="casAuthors">Tavora, Bernardo; Batista, Silvia; Reynolds, Louise E.; Jadeja, Shalini; Robinson, Stephen; Kostourou, Vassiliki; Hart, Ian; Fruttiger, Marcus; Parsons, Maddy; Hodivala-Dilke, Kairbaan M.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">516-528</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase that plays a fundamental role in integrin and growth factor mediated signalling and is an important player in cell migration and proliferation, processes vital for angiogenesis.  However, the role of FAK in adult pathol. angiogenesis is unknown.  We have generated endothelial-specific tamoxifen-inducible FAK knockout mice by crossing FAK-floxed (FAKfl/fl) mice with the platelet derived growth factor b (Pdgfb)-iCreER mice.  Tamoxifen-treatment of Pdgfb-iCreER;FAKfl/fl mice results in FAK deletion in adult endothelial cells (ECs) without any adverse effects.  Importantly however, endothelial FAK-deletion in adult mice inhibited tumor growth and reduced tumor angiogenesis.  Furthermore, in in vivo angiogenic assays FAK deletion impairs vascular endothelial growth factor (VEGF)-induced neovascularization.  In addn., in vitro deletion of FAK in ECs resulted in reduced VEGF-stimulated Akt phosphorylation and correlating reduced cellular proliferation as well as increased cell death.  Our data suggest that FAK is required for adult pathol. angiogenesis and validates FAK as a possible target for anti-angiogenic therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7F0jECcbicrVg90H21EOLACvtfcHk0lijuowts6KTFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFehsg%253D%253D&md5=e1727f709428667a487c2dd61ee9ff9a</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1002%2Femmm.201000106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Femmm.201000106%26sid%3Dliteratum%253Aachs%26aulast%3DTavora%26aufirst%3DB.%26aulast%3DBatista%26aufirst%3DS.%26aulast%3DReynolds%26aufirst%3DL.%2BE.%26aulast%3DJadeja%26aufirst%3DS.%26aulast%3DRobinson%26aufirst%3DS.%26aulast%3DKostourou%26aufirst%3DV.%26aulast%3DHart%26aufirst%3DI.%26aulast%3DFruttiger%26aufirst%3DM.%26aulast%3DParsons%26aufirst%3DM.%26aulast%3DHodivala-Dilke%26aufirst%3DK.%2BM.%26atitle%3DEndothelial%2520FAK%2520is%2520required%2520for%2520tumour%2520angiogenesis%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2010%26volume%3D2%26spage%3D516%26epage%3D528%26doi%3D10.1002%2Femmm.201000106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokol, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcaraz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassalli, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, J. L.</span></span> <span> </span><span class="NLM_article-title">Overexpression of focal adhesion kinase in vascular endothelial cells promotes angiogenesis in transgenic mice</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">421</span>â <span class="NLM_lpage">430</span>, <span class="refDoi">Â DOI: 10.1016/j.cardiores.2004.07.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.cardiores.2004.07.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=15537495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpslOqur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=421-430&author=X.+Pengauthor=H.+Uedaauthor=H.+Zhouauthor=T.+Stokolauthor=T.+L.+Shenauthor=A.+Alcarazauthor=T.+Nagyauthor=J.+D.+Vassalliauthor=J.+L.+Guan&title=Overexpression+of+focal+adhesion+kinase+in+vascular+endothelial+cells+promotes+angiogenesis+in+transgenic+mice&doi=10.1016%2Fj.cardiores.2004.07.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of focal adhesion kinase in vascular endothelial cells promotes angiogenesis in transgenic mice</span></div><div class="casAuthors">Peng, Xu; Ueda, Hiroki; Zhou, Hongming; Stokol, Tracy; Shen, Tang-Long; Alcaraz, Ana; Nagy, Tamas; Vassalli, Jean-Dominique; Guan, Jun-Lin</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">421-430</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Objective: Focal adhesion kinase is implicated in the regulation of cell adhesion, migration, survival, and cell-cycle progression.  However, the functions of focal adhesion kinase in endothelial cell (EC) in vivo remain unclear.  This study aims to examine the role of FAK in EC function and angiogenesis in vivo by transgenic mice approach.  Method: We generated transgenic mice which overexpressed chicken FAK in vascular endothelial cell under the control of the Tie-2 promoter and enhancer.  FAK transgene was detected by RT-PCR, immunopptn., and Western blot.  The effect of FAK overexpression on angiogenesis was detd. using skin wound healing and ischemia skeleton muscle models.  Results: Expression of FAK transgene was detected in all vessel-rich tissues.  Expression of FAK protein was verified by antibody specific for the exogenous chicken FAK in lung homogenates and isolated EC.  In the wound-induced angiogenesis model, the no. of vessels in the granulation tissue of healing wound was significantly increased in the transgenic mouse compared to that of wild-type control mice.  Similarly, in the ischemia skeletal muscle model, the d. of capillaries was significantly increased in the transgenic mouse.  Conclusion: These results indicate that FAK may play an important role in the promotion of angiogenesis in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1cPqtDruvXbVg90H21EOLACvtfcHk0lgj8NgmIKVAFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpslOqur4%253D&md5=580dc9765012b88f180df1478cc2a50c</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.cardiores.2004.07.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cardiores.2004.07.012%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DUeda%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DStokol%26aufirst%3DT.%26aulast%3DShen%26aufirst%3DT.%2BL.%26aulast%3DAlcaraz%26aufirst%3DA.%26aulast%3DNagy%26aufirst%3DT.%26aulast%3DVassalli%26aufirst%3DJ.%2BD.%26aulast%3DGuan%26aufirst%3DJ.%2BL.%26atitle%3DOverexpression%2520of%2520focal%2520adhesion%2520kinase%2520in%2520vascular%2520endothelial%2520cells%2520promotes%2520angiogenesis%2520in%2520transgenic%2520mice%26jtitle%3DCardiovasc.%2520Res.%26date%3D2004%26volume%3D64%26spage%3D421%26epage%3D430%26doi%3D10.1016%2Fj.cardiores.2004.07.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kornberg, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spoerri, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caballero, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, M. B.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase overexpression induces enhanced pathological retinal angiogenesis</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">4463</span>â <span class="NLM_lpage">4469</span>, <span class="refDoi">Â DOI: 10.1167/iovs.03-1201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1167%2Fiovs.03-1201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=15557455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BD2crosVGkug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2004&pages=4463-4469&author=L.+J.+Kornbergauthor=L.+C.+Shawauthor=P.+E.+Spoerriauthor=S.+Caballeroauthor=M.+B.+Grant&title=Focal+adhesion+kinase+overexpression+induces+enhanced+pathological+retinal+angiogenesis&doi=10.1167%2Fiovs.03-1201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion kinase overexpression induces enhanced pathological retinal angiogenesis</span></div><div class="casAuthors">Kornberg Lori J; Shaw Lynn C; Spoerri Polyxenie E; Caballero Sergio; Grant Maria B</div><div class="citationInfo"><span class="NLM_cas:title">Investigative ophthalmology & visual science</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4463-9</span>
        ISSN:<span class="NLM_cas:issn">0146-0404</span>.
    </div><div class="casAbstract">PURPOSE:  Focal adhesion kinase (FAK) is involved in processes integral to angiogenesis, such as cell growth, survival, and migration.  FAK is activated by angiogenic growth factors, such as insulin-like growth factor (IGF)-I, vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF).  The study was conducted to determine whether overexpression of FAK or FAK-related nonkinase (FRNK), an inhibitor of FAK, could influence human retinal endothelial cell (HREC) migration and in vivo angiogenesis.  METHODS:  Migration in response to a combination of growth factors was examined in transfected HRECs overexpressing FAK or FRNK.  The effect of FAK or FRNK overexpression on preretinal neovascularization was examined in a mouse model of oxygen-induced retinopathy.  RESULTS:  Overexpression of FAK in HRECs resulted in a 102% +/- 13% increase (P = 1.4 x 10(-4)) in cell migration, whereas overexpression of FRNK resulted in a 20% +/- 8% decrease (P = 0.01).  Overexpression of FAK in mouse eyes led to formation of numerous large vascular tufts resembling glomeruli and a 57% +/- 7% increase in preretinal neovascularization (P = 3 x 10(-9)), whereas FRNK resulted in a 55% +/- 15% reduction (P = 5 x 10(-5)).  CONCLUSIONS:  Modulating the FAK/FRNK system may provide a novel approach to inhibiting pathologic retinal angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSUCQIXDWngcdts4TFFB11gfW6udTcc2eY72rGFs36Icrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2crosVGkug%253D%253D&md5=30309e15374c6057b8f868ee7818d92e</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1167%2Fiovs.03-1201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.03-1201%26sid%3Dliteratum%253Aachs%26aulast%3DKornberg%26aufirst%3DL.%2BJ.%26aulast%3DShaw%26aufirst%3DL.%2BC.%26aulast%3DSpoerri%26aufirst%3DP.%2BE.%26aulast%3DCaballero%26aufirst%3DS.%26aulast%3DGrant%26aufirst%3DM.%2BB.%26atitle%3DFocal%2520adhesion%2520kinase%2520overexpression%2520induces%2520enhanced%2520pathological%2520retinal%2520angiogenesis%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2004%26volume%3D45%26spage%3D4463%26epage%3D4469%26doi%3D10.1167%2Fiovs.03-1201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vitillo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iskender, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiting, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimber, S. J.</span></span> <span> </span><span class="NLM_article-title">Integrin-associated focal adhesion kinase protects human embryonic stem cells from apoptosis, detachment, and differentiation</span>. <i>Stem Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">167</span>â <span class="NLM_lpage">176</span>, <span class="refDoi">Â DOI: 10.1016/j.stemcr.2016.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.stemcr.2016.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=27509133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtleqt7%252FP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=167-176&author=L.+Vitilloauthor=M.+Baxterauthor=B.+Iskenderauthor=P.+Whitingauthor=S.+J.+Kimber&title=Integrin-associated+focal+adhesion+kinase+protects+human+embryonic+stem+cells+from+apoptosis%2C+detachment%2C+and+differentiation&doi=10.1016%2Fj.stemcr.2016.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Integrin-Associated Focal Adhesion Kinase Protects Human Embryonic Stem Cells from Apoptosis, Detachment, and Differentiation</span></div><div class="casAuthors">Vitillo, Loriana; Baxter, Melissa; Iskender, Banu; Whiting, Paul; Kimber, Susan J.</div><div class="citationInfo"><span class="NLM_cas:title">Stem Cell Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-176</span>CODEN:
                <span class="NLM_cas:coden">SCRTFL</span>;
        ISSN:<span class="NLM_cas:issn">2213-6711</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Human embryonic stem cells (hESCs) can be maintained in a fully defined niche on extracellular matrix substrates, to which they attach through integrin receptors.  However, the underlying integrin signaling mechanisms, and their contribution to hESC behavior, are largely unknown.  Here, we show that focal adhesion kinase (FAK) transduces integrin activation and supports hESC survival, substrate adhesion, and maintenance of the undifferentiated state.  After inhibiting FAK kinase activity we show that hESCs undergo cell detachment-dependent apoptosis or differentiation.  We also report deactivation of FAK downstream targets, AKT and MDM2, and upregulation of p53, all key players in hESC regulatory networks.  Loss of integrin activity or FAK also induces cell aggregation, revealing a role in the cell-cell interactions of hESCs.  This study provides insight into the integrin signaling cascade activated in hESCs and reveals in FAK a key player in the maintenance of hESC survival and undifferentiated state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogTTbcfl_k9LVg90H21EOLACvtfcHk0lgj8NgmIKVAFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtleqt7%252FP&md5=603f2498d735901be97fdb02ff08d91d</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.stemcr.2016.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.stemcr.2016.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DVitillo%26aufirst%3DL.%26aulast%3DBaxter%26aufirst%3DM.%26aulast%3DIskender%26aufirst%3DB.%26aulast%3DWhiting%26aufirst%3DP.%26aulast%3DKimber%26aufirst%3DS.%2BJ.%26atitle%3DIntegrin-associated%2520focal%2520adhesion%2520kinase%2520protects%2520human%2520embryonic%2520stem%2520cells%2520from%2520apoptosis%252C%2520detachment%252C%2520and%2520differentiation%26jtitle%3DStem%2520Cell%2520Rep.%26date%3D2016%26volume%3D7%26spage%3D167%26epage%3D176%26doi%3D10.1016%2Fj.stemcr.2016.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vitillo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimber, S. J.</span></span> <span> </span><span class="NLM_article-title">Integrin and FAK regulation of human pluripotent stem cells</span>. <i>Curr. Stem Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">358</span>â <span class="NLM_lpage">365</span>, <span class="refDoi">Â DOI: 10.1007/s40778-017-0100-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1007%2Fs40778-017-0100-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=29177133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1GqtbbO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=358-365&author=L.+Vitilloauthor=S.+J.+Kimber&title=Integrin+and+FAK+regulation+of+human+pluripotent+stem+cells&doi=10.1007%2Fs40778-017-0100-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Integrin and FAK Regulation of Human Pluripotent Stem Cells</span></div><div class="casAuthors">Vitillo, Loriana; Kimber, Susan J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Stem Cell Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">358-365</span>CODEN:
                <span class="NLM_cas:coden">CSCRFC</span>;
        ISSN:<span class="NLM_cas:issn">2198-7866</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Purpose of review: Human pluripotent stem cells (hPSCs) are anchorage-dependent cells that can be cultured on a variety of matrixes and express integrins and the machinery for integrin signaling.  Until recently, there has been limited understanding of exactly how integrin signaling regulates pluripotent stem cell (PSC) behavior.  This review summarizes our knowledge of how integrins and focal adhesion kinase (FAK) regulate different aspects of hPSC biol.  Recent findings: The latest research suggests that mouse and human embryonic stem cells utilize similar integrin signaling players but with different biol. outcomes, reflecting the known developmental difference in their pluripotent status.  Notably, attachment cues via FAK signaling are crucial for hPSCs survival and pluripotency maintenance.  FAK may be found cortically but also in the nucleus of hPSCs intersecting core pluripotency networks.  Summary: Integrins and FAK have been consigned to the conventional role of cell adhesion receptor systems in PSCs.  This review highlights data indicating that they are firmly integrated in pluripotency circuits, with implications for both research PSC culture and scale up and use in clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFq8wH6gWCyrVg90H21EOLACvtfcHk0lgj8NgmIKVAFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1GqtbbO&md5=284b07a20c848e8004678d51160e5aec</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1007%2Fs40778-017-0100-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40778-017-0100-x%26sid%3Dliteratum%253Aachs%26aulast%3DVitillo%26aufirst%3DL.%26aulast%3DKimber%26aufirst%3DS.%2BJ.%26atitle%3DIntegrin%2520and%2520FAK%2520regulation%2520of%2520human%2520pluripotent%2520stem%2520cells%26jtitle%3DCurr.%2520Stem%2520Cell%2520Rep.%26date%3D2017%26volume%3D3%26spage%3D358%26epage%3D365%26doi%3D10.1007%2Fs40778-017-0100-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, C. T.</span></span> <span> </span><span class="NLM_article-title">The increasing complexity of the cancer stem cell paradigm</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>324</i></span>,  <span class="NLM_fpage">1670</span>â <span class="NLM_lpage">1673</span>, <span class="refDoi">Â DOI: 10.1126/science.1171837</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1126%2Fscience.1171837" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=19556499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsFOmtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=2009&pages=1670-1673&author=J.+M.+Rosenauthor=C.+T.+Jordan&title=The+increasing+complexity+of+the+cancer+stem+cell+paradigm&doi=10.1126%2Fscience.1171837"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">The Increasing Complexity of the Cancer Stem Cell Paradigm</span></div><div class="casAuthors">Rosen, Jeffrey M.; Jordan, Craig T.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">324</span>
        (<span class="NLM_cas:issue">5935</span>),
    <span class="NLM_cas:pages">1670-1673</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  The investigation and study of cancer stem cells (CSCs) have received enormous attention over the past 5 to 10 years but remain topics of considerable controversy.  Opinions about the validity of the CSC hypothesis, the biol. properties of CSCs, and the relevance of CSCs to cancer therapy differ widely.  In the following commentary, we discuss the nature of the debate, the parameters by which CSCs can or cannot be defined, and the identification of new potential therapeutic targets elucidated by considering cancer as a problem in stem cell biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjo2Ctm2OEuLVg90H21EOLACvtfcHk0lgsAx1Jsdrk1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsFOmtb8%253D&md5=6bf760e35c322979d09acb7d8725fcbb</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1126%2Fscience.1171837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1171837%26sid%3Dliteratum%253Aachs%26aulast%3DRosen%26aufirst%3DJ.%2BM.%26aulast%3DJordan%26aufirst%3DC.%2BT.%26atitle%3DThe%2520increasing%2520complexity%2520of%2520the%2520cancer%2520stem%2520cell%2520paradigm%26jtitle%3DScience%26date%3D2009%26volume%3D324%26spage%3D1670%26epage%3D1673%26doi%3D10.1126%2Fscience.1171837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Islam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, A. K. Y.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cell: fundamental experimental pathological concepts and updates</span>. <i>Exp. Mol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">184</span>â <span class="NLM_lpage">191</span>, <span class="refDoi">Â DOI: 10.1016/j.yexmp.2015.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.yexmp.2015.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=25659759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVShurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2015&pages=184-191&author=F.+Islamauthor=B.+Qiaoauthor=R.+A.+Smithauthor=V.+Gopalanauthor=A.+K.+Y.+Lam&title=Cancer+stem+cell%3A+fundamental+experimental+pathological+concepts+and+updates&doi=10.1016%2Fj.yexmp.2015.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer stem cell: Fundamental experimental pathological concepts and updates</span></div><div class="casAuthors">Islam, Farhadul; Qiao, Bin; Smith, Robert A.; Gopalan, Vinod; Lam, Alfred K.-Y.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental and Molecular Pathology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">184-191</span>CODEN:
                <span class="NLM_cas:coden">EXMPA6</span>;
        ISSN:<span class="NLM_cas:issn">0014-4800</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Cancer stem cells (CSCs) are a subset of cancer cells which play a key role in predicting the biol. aggressiveness of cancer due to its ability of self-renewal and multi-lineage differentiation (stemness).  The CSC model is a dynamic one with a functional subpopulation of cancer cells rather than a stable cell population responsible for tumor regeneration.  Hypotheses regarding the origins of CSCs include (1) malignant transformation of normal stem cells; (2) mature cancer cell de-differentiation with epithelial-mesenchymal transition and (3) induced pluripotent cancer cells.  Surprisingly, the cancer stem cell hypothesis originated in the late nineteenth century and the existence of hematopoietic stem cells was demonstrated a century later, demonstrating that the concept was possible.  In the last decade, CSCs have been identified and isolated in different cancers.  The hallmark traits of CSCs include their heterogeneity, interaction with microenvironments and plasticity.  Understanding these basic concepts of CSCs is important for translational applications using CSCs in the management of patients with cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLXSCUdViS17Vg90H21EOLACvtfcHk0lgsAx1Jsdrk1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVShurg%253D&md5=4972b1065d99c28eeb4f1c0e7002b043</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.yexmp.2015.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexmp.2015.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DIslam%26aufirst%3DF.%26aulast%3DQiao%26aufirst%3DB.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26aulast%3DGopalan%26aufirst%3DV.%26aulast%3DLam%26aufirst%3DA.%2BK.%2BY.%26atitle%3DCancer%2520stem%2520cell%253A%2520fundamental%2520experimental%2520pathological%2520concepts%2520and%2520updates%26jtitle%3DExp.%2520Mol.%2520Pathol.%26date%3D2015%26volume%3D98%26spage%3D184%26epage%3D191%26doi%3D10.1016%2Fj.yexmp.2015.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guan, J. L.</span></span> <span> </span><span class="NLM_article-title">Integrin signaling through FAK in the regulation of mammary stem cells and breast cancer</span>. <i>IUBMB Life</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">268</span>â <span class="NLM_lpage">276</span>, <span class="refDoi">Â DOI: 10.1002/iub.303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1002%2Fiub.303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=20101634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktVCkt7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=268-276&author=J.+L.+Guan&title=Integrin+signaling+through+FAK+in+the+regulation+of+mammary+stem+cells+and+breast+cancer&doi=10.1002%2Fiub.303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Integrin signaling through FAK in the regulation of mammary stem cells and breast cancer</span></div><div class="casAuthors">Guan, Jun-Lin</div><div class="citationInfo"><span class="NLM_cas:title">IUBMB Life</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">268-276</span>CODEN:
                <span class="NLM_cas:coden">IULIF8</span>;
        ISSN:<span class="NLM_cas:issn">1521-6543</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Inc.</span>)
        </div><div class="casAbstract">A review.  Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase identified as a key mediator of intracellular signaling by integrins, a major family of cell surface receptors for extracellular matrix, in the regulation of different cellular functions in a variety of cells.  Upon activation by integrins through disruption of an autoinhibitory mechanism, FAK undergoes autophosphorylation and forms a complex with Src and other cellular proteins to trigger downstream signaling through its kinase activity or scaffolding function.  A no. of integrins are identified as surface markers for mammary stem cells (MaSCs), and both integrins and FAK are found to play crucial roles in the maintenance of MaSCs in studies using mouse models, suggesting that integrin signaling through FAK may serve as a functional marker for MaSCs.  Consistent with previous studies linking increased expression and activation of FAK to human breast cancer, these findings suggest a novel cellular mechanism of FAK promotion of mammary tumorigenesis by maintaining the pools of MaSCs as targets of oncogenic transformation.  Furthermore, FAK inactivation in mouse models of breast cancer also reduced the pool of mammary cancer stem cells (MaCSCs), decreased their self-renewal in vitro, and compromised their tumorigenicity and maintenance in vivo, suggesting a potential role of integrin signaling through FAK in breast cancer growth and progression through its functions in MaCSCs.  This review discusses these recent advances and future studies into the mechanism of integrin signaling through FAK in breast cancer through regulation of MaCSCs that may lead to development of novel therapies for this deadly disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvsXqcHLeK-LVg90H21EOLACvtfcHk0lgsAx1Jsdrk1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktVCkt7w%253D&md5=8ae587cfc215d598bdb5811d14936fba</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1002%2Fiub.303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fiub.303%26sid%3Dliteratum%253Aachs%26aulast%3DGuan%26aufirst%3DJ.%2BL.%26atitle%3DIntegrin%2520signaling%2520through%2520FAK%2520in%2520the%2520regulation%2520of%2520mammary%2520stem%2520cells%2520and%2520breast%2520cancer%26jtitle%3DIUBMB%2520Life%26date%3D2010%26volume%3D62%26spage%3D268%26epage%3D276%26doi%3D10.1002%2Fiub.303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zajac-Kaye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochwald, S. N.</span></span> <span> </span><span class="NLM_article-title">A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">3143</span>â <span class="NLM_lpage">3149</span>, <span class="refDoi">Â DOI: 10.4161/15384101.2014.949550</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.4161%2F15384101.2014.949550" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=25486573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCgsLfN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=3143-3149&author=J.+Zhangauthor=D.+H.+Heauthor=M.+Zajac-Kayeauthor=S.+N.+Hochwald&title=A+small+molecule+FAK+kinase+inhibitor%2C+GSK2256098%2C+inhibits+growth+and+survival+of+pancreatic+ductal+adenocarcinoma+cells&doi=10.4161%2F15384101.2014.949550"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells</span></div><div class="casAuthors">Zhang, Jianliang; He, Di-Hua; Zajac-Kaye, Maria; Hochwald, Steven N.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3143-3149</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) hyperactivation is common in pancreatic ductal adenocarcinoma (PDAC).  A small mol., GSK2256098 (GlaxoSmithKline), has been developed to inhibit FAK activity through targeting the phosphorylation site of FAK, tyrosine (Y) 397.  We sought to det. whether GSK2256098 inhibition of FAK Y397 phosphorylation attenuates PDAC-assocd. cell proliferation, motility and survival.  Cultured PDAC cells were used as cellular models of GSK2256098-impaired abnormal growth.  Western blot anal., cell viability anal., clonogenic survival, soft-agar and wound healing assays were performed.  The responses of 6 PDAC cell lines in regards to FAK Y397 phosphorylation or activity to GSK2256098 treatments (0.1-10 Î¼M) ranged from low (less than 20% inhibition) to high (more than 90% inhibition).  The least and most sensitive cell lines (PANC-1 and L3.6P1) were selected for further anal.  GSK2256098 inhibition of FAK Y397 phosphorylation correlated with decreased levels of phosphorylated Akt and ERK in L3.6P1 cells.  GSK2256098 decreased cell viability, anchorage-independent growth, and motility in a dose dependent manner.  Current studies demonstrate that small mol. kinase inhibitors targeting FAK Y397 phosphorylation can inhibit PDAC cell growth.  Assessments of FAK Y397 phosphorylation in biopsies may be used as a biomarker to select the subgroup of responsive patients and/or monitor the effects of GSK2256098 on FAK-modulated tumor growth during treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAxUbBT_oKFLVg90H21EOLACvtfcHk0lhPgltUY0f4Bg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCgsLfN&md5=dc429dd3c276670338da9eec6dce6d2e</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.4161%2F15384101.2014.949550&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252F15384101.2014.949550%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DD.%2BH.%26aulast%3DZajac-Kaye%26aufirst%3DM.%26aulast%3DHochwald%26aufirst%3DS.%2BN.%26atitle%3DA%2520small%2520molecule%2520FAK%2520kinase%2520inhibitor%252C%2520GSK2256098%252C%2520inhibits%2520growth%2520and%2520survival%2520of%2520pancreatic%2520ductal%2520adenocarcinoma%2520cells%26jtitle%3DCell%2520Cycle%26date%3D2014%26volume%3D13%26spage%3D3143%26epage%3D3149%26doi%3D10.4161%2F15384101.2014.949550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N. F</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkenau, H.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, R. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auger, K. R</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenox, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plisson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Searle, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saleem, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagden, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulholland, P.</span></span> <span> </span><span class="NLM_article-title">A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098</span>. <i>Neuro-Oncology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1634</span>â <span class="NLM_lpage">1642</span>, <span class="refDoi">Â DOI: 10.1093/neuonc/noy078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1093%2Fneuonc%2Fnoy078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=29788497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlKisb3E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2018&pages=1634-1642&author=N.+F+Brownauthor=M.+Williamsauthor=H.-T.+Arkenauauthor=R.+A+Flemingauthor=J.+Tolsonauthor=L.+Yanauthor=J.+Zhangauthor=R.+Singhauthor=K.+R+Augerauthor=L.+Lenoxauthor=D.+Coxauthor=Y.+Lewisauthor=C.+Plissonauthor=G.+Searleauthor=A.+Saleemauthor=S.+Blagdenauthor=P.+Mulholland&title=A+study+of+the+focal+adhesion+kinase+inhibitor+GSK2256098+in+patients+with+recurrent+glioblastoma+with+evaluation+of+tumor+penetration+of+%5B11C%5DGSK2256098&doi=10.1093%2Fneuonc%2Fnoy078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098</span></div><div class="casAuthors">Brown, Nicholas F.; Williams, Matthew; Arkenau, Hendrik-Tobias; Fleming, Ronald A.; Tolson, Jerry; Yan, Li; Zhang, Jianping; Swartz, Lisa; Singh, Rajendra; Auger, Kurt R.; Lenox, Laurie; Cox, David; Lewis, Yvonne; Plisson, Christophe; Searle, Graham; Saleem, Azeem; Blagden, Sarah; Mulholland, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Neuro-Oncology (Cary, NC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1634-1642</span>CODEN:
                <span class="NLM_cas:coden">NEURJR</span>;
        ISSN:<span class="NLM_cas:issn">1523-5866</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background.  GSK2256098 is a novel oral focal adhesion kinase (FAK) inhibitor.  Preclin. studies demonstrate growth inhibition in glioblastoma cell lines.  However, rodent studies indicate limited blood-brain barrier (BBB) penetration.  In this expansion cohort within a phase I study, the safety, tolerability, pharmacokinetics (PK), and clin. activity of GSK2256098 were evaluated in patients with recurrent glioblastoma.  Biodistribution and kinetics of [11C]GSK2256098 were assessed in a substudy using positron-emission tomog. (PET).  Patients were treated with GSK2256098 until disease progression or withdrawal due to adverse events (AEs).  Serial PK samples were collected on day 1.  On a single day between days 9 and 20, patients received a microdose of i.v. [11C]GSK2256098 and were scanned with PET over 90 min with parallel PK sample collection.  Response was assessed by MRI every 6 wk.  Thirteen patients were treated in 3 dose cohorts (1000 mg, 750 mg, 500 mg; all dosed twice daily).  The max. tolerated dose was 1000 mg twice daily.  Dose-limiting toxicities were related to cerebral edema.  Treatment-related AEs (>25%) were diarrhea, fatigue, and nausea.  Eight patients participated in the PET substudy, with [11C]GSK2256098 VT (vol. of distribution) ests. of 0.9 in tumor tissue, 0.5 in surrounding T2 enhancing areas, and 0.4 in normal brain.  Best response of stable disease was obsd. in 3 patients, including 1 patient on treatment for 11.3 mo.  Conclusions.  GSK2256098 was tolerable in patients with relapsed glioblastoma.  GSK2256098 crossed the BBB at low levels into normal brain, but at markedly higher levels into tumor, consistent with tumor-assocd. BBB disruption.  Addnl. clin. trials of GSK2256098 are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWQtMrUNJlabVg90H21EOLACvtfcHk0lhPgltUY0f4Bg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlKisb3E&md5=7d3a897bb8ee9360e7cf424c40dec48d</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1093%2Fneuonc%2Fnoy078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fneuonc%252Fnoy078%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DN.%2BF%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DArkenau%26aufirst%3DH.-T.%26aulast%3DFleming%26aufirst%3DR.%2BA%26aulast%3DTolson%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DAuger%26aufirst%3DK.%2BR%26aulast%3DLenox%26aufirst%3DL.%26aulast%3DCox%26aufirst%3DD.%26aulast%3DLewis%26aufirst%3DY.%26aulast%3DPlisson%26aufirst%3DC.%26aulast%3DSearle%26aufirst%3DG.%26aulast%3DSaleem%26aufirst%3DA.%26aulast%3DBlagden%26aufirst%3DS.%26aulast%3DMulholland%26aufirst%3DP.%26atitle%3DA%2520study%2520of%2520the%2520focal%2520adhesion%2520kinase%2520inhibitor%2520GSK2256098%2520in%2520patients%2520with%2520recurrent%2520glioblastoma%2520with%2520evaluation%2520of%2520tumor%2520penetration%2520of%2520%255B11C%255DGSK2256098%26jtitle%3DNeuro-Oncology%26date%3D2018%26volume%3D20%26spage%3D1634%26epage%3D1642%26doi%3D10.1093%2Fneuonc%2Fnoy078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mak, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagden, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebot, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazumdar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazzah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzuto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greystoke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auger, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkenau, H. T.</span></span> <span> </span><span class="NLM_article-title">A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">975</span>â <span class="NLM_lpage">981</span>, <span class="refDoi">Â DOI: 10.1038/s41416-019-0452-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fs41416-019-0452-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=30992546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFWmsLrF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2019&pages=975-981&author=G.+Makauthor=J.+C.+Soriaauthor=S.+P.+Blagdenauthor=R.+Plummerauthor=R.+A.+Flemingauthor=N.+Nebotauthor=J.+Zhangauthor=J.+Mazumdarauthor=D.+Roganauthor=A.+Gazzahauthor=I.+Rizzutoauthor=A.+Greystokeauthor=L.+Yanauthor=J.+Tolsonauthor=K.+R.+Augerauthor=H.+T.+Arkenau&title=A+phase+Ib+dose-finding%2C+pharmacokinetic+study+of+the+focal+adhesion+kinase+inhibitor+GSK2256098+and+trametinib+in+patients+with+advanced+solid+tumours&doi=10.1038%2Fs41416-019-0452-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours</span></div><div class="casAuthors">Mak, Gabriel; Soria, Jean-Charles; Blagden, Sarah P.; Plummer, Ruth; Fleming, Ronald A.; Nebot, Noelia; Zhang, Jianping; Mazumdar, Jolly; Rogan, Debra; Gazzah, Anas; Rizzuto, Ivana; Greystoke, Alastair; Yan, Li; Tolson, Jerry; Auger, Kurt R.; Arkenau, Hendrik-Tobias</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">975-981</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Background: Combined focal adhesion kinase (FAK) and MEK inhibition may provide greater anticancer effect than FAK monotherapy.  Methods: This dose-finding phase Ib study (adaptive 3 + 3 design) detd. the max. tolerated dose (MTD) of trametinib and the FAK inhibitor GSK2256098 in combination.  Eligible patients had mesothelioma or other solid tumors with probable mitogen activated protein kinase pathway activation.  Adverse events (AEs), dose-limiting toxicities, disease progression and pharmacokinetics/pharmacodynamics were analyzed.  Results: Thirty-four subjects were enrolled.  The GSK2256098/trametinib MTDs were 500 mg twice daily (BID)/0.375 mg once daily (QD) (high/low) and 250 mg BID/0.5 mg QD (low/high).  The most common AEs were nausea, diarrhoea, decreased appetite, pruritus, fatigue and rash; none were grade 4.  Systemic exposure to trametinib increased when co-administered with GSK2256098, vs. trametinib monotherapy; GSK2256098 pharmacokinetics were unaffected by concomitant trametinib.  Median progression-free survival (PFS) was 11.8 wk (95% CI: 6.1-24.1) in subjects with mesothelioma and was longer with Merlin-neg. vs. Merlin-pos. tumors (15.0 vs 7.3 wk).  Conclusions: Trametinib exposure increased when co-administered with GSK2256098, but not vice versa.  Mesothelioma patients with loss of Merlin had longer PFS than subjects with wild-type, although support for efficacy with this combination was limited.  Safety profiles were acceptable up to the MTD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovNTEJjHaRLLVg90H21EOLACvtfcHk0lhPgltUY0f4Bg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFWmsLrF&md5=3303a98dfafb0360b04050962b8d7cc5</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fs41416-019-0452-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41416-019-0452-3%26sid%3Dliteratum%253Aachs%26aulast%3DMak%26aufirst%3DG.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DBlagden%26aufirst%3DS.%2BP.%26aulast%3DPlummer%26aufirst%3DR.%26aulast%3DFleming%26aufirst%3DR.%2BA.%26aulast%3DNebot%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DMazumdar%26aufirst%3DJ.%26aulast%3DRogan%26aufirst%3DD.%26aulast%3DGazzah%26aufirst%3DA.%26aulast%3DRizzuto%26aufirst%3DI.%26aulast%3DGreystoke%26aufirst%3DA.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DTolson%26aufirst%3DJ.%26aulast%3DAuger%26aufirst%3DK.%2BR.%26aulast%3DArkenau%26aufirst%3DH.%2BT.%26atitle%3DA%2520phase%2520Ib%2520dose-finding%252C%2520pharmacokinetic%2520study%2520of%2520the%2520focal%2520adhesion%2520kinase%2520inhibitor%2520GSK2256098%2520and%2520trametinib%2520in%2520patients%2520with%2520advanced%2520solid%2520tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2019%26volume%3D120%26spage%3D975%26epage%3D981%26doi%3D10.1038%2Fs41416-019-0452-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tiede, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer-Schaller, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalathur, R. K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagiani, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmassmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stillhard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafliger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraut, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweifer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waizenegger, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bill, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christofori, G.</span></span> <span> </span><span class="NLM_article-title">The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer</span>. <i>Oncogenesis</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">73</span>â <span class="NLM_lpage">91</span>, <span class="refDoi">Â DOI: 10.1038/s41389-018-0083-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fs41389-018-0083-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=30237500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BB3czhtVamtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=73-91&author=S.+Tiedeauthor=N.+Meyer-Schallerauthor=R.+K.+R.+Kalathurauthor=R.+Ivanekauthor=E.+Fagianiauthor=P.+Schmassmannauthor=P.+Stillhardauthor=S.+Hafligerauthor=N.+Krautauthor=N.+Schweiferauthor=I.+C.+Waizeneggerauthor=R.+Billauthor=G.+Christofori&title=The+FAK+inhibitor+BI+853520+exerts+anti-tumor+effects+in+breast+cancer&doi=10.1038%2Fs41389-018-0083-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer</span></div><div class="casAuthors">Tiede Stefanie; Meyer-Schaller Nathalie; Kalathur Ravi Kiran Reddy; Ivanek Robert; Fagiani Ernesta; Schmassmann Philip; Stillhard Patrick; Hafliger Simon; Bill Ruben; Christofori Gerhard; Kalathur Ravi Kiran Reddy; Ivanek Robert; Kraut Norbert; Schweifer Norbert; Waizenegger Irene C</div><div class="citationInfo"><span class="NLM_cas:title">Oncogenesis</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">73</span>
        ISSN:<span class="NLM_cas:issn">2157-9024</span>.
    </div><div class="casAbstract">Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase that regulates a plethora of downstream signaling pathways essential for cell migration, proliferation and death, processes that are exploited by cancer cells during malignant progression.  These well-established tumorigenic activities, together with its high expression and activity in different cancer types, highlight FAK as an attractive target for cancer therapy.  We have assessed and characterized the therapeutic potential and the biological effects of BI 853520, a novel small chemical inhibitor of FAK, in several preclinical mouse models of breast cancer.  Treatment with BI 853520 elicits a significant reduction in primary tumor growth caused by an anti-proliferative activity by BI 853520.  In contrast, BI 853520 exerts effects with varying degrees of robustness on the different stages of the metastatic cascade.  Together, the data demonstrate that the repression of FAK activity by the specific FAK inhibitor BI 853520 offers a promising anti-proliferative approach for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSPh9ctMIKK5LxanA7vODO6fW6udTcc2eZH-3mHHxcwULntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czhtVamtA%253D%253D&md5=9875efe4b07431bf3399fd19a3f7f289</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fs41389-018-0083-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41389-018-0083-1%26sid%3Dliteratum%253Aachs%26aulast%3DTiede%26aufirst%3DS.%26aulast%3DMeyer-Schaller%26aufirst%3DN.%26aulast%3DKalathur%26aufirst%3DR.%2BK.%2BR.%26aulast%3DIvanek%26aufirst%3DR.%26aulast%3DFagiani%26aufirst%3DE.%26aulast%3DSchmassmann%26aufirst%3DP.%26aulast%3DStillhard%26aufirst%3DP.%26aulast%3DHafliger%26aufirst%3DS.%26aulast%3DKraut%26aufirst%3DN.%26aulast%3DSchweifer%26aufirst%3DN.%26aulast%3DWaizenegger%26aufirst%3DI.%2BC.%26aulast%3DBill%26aufirst%3DR.%26aulast%3DChristofori%26aufirst%3DG.%26atitle%3DThe%2520FAK%2520inhibitor%2520BI%2520853520%2520exerts%2520anti-tumor%2520effects%2520in%2520breast%2520cancer%26jtitle%3DOncogenesis%26date%3D2018%26volume%3D7%26spage%3D73%26epage%3D91%26doi%3D10.1038%2Fs41389-018-0083-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laszlo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valko, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozsvar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garay, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoda, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klikovits, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockhammer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aigner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klepetko, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grusch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tovari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waizenegger, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dome, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegedus, B.</span></span> <span> </span><span class="NLM_article-title">The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma</span>. <i>J. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">231</span>â <span class="NLM_lpage">242</span>, <span class="refDoi">Â DOI: 10.1007/s00109-018-1725-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1007%2Fs00109-018-1725-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=30539198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFWrur7I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2019&pages=231-242&author=V.+Laszloauthor=Z.+Valkoauthor=J.+Ozsvarauthor=I.+Kovacsauthor=T.+Garayauthor=M.+A.+Hodaauthor=T.+Klikovitsauthor=P.+Stockhammerauthor=C.+Aignerauthor=M.+Grogerauthor=W.+Klepetkoauthor=W.+Bergerauthor=M.+Gruschauthor=J.+Tovariauthor=I.+C.+Waizeneggerauthor=B.+Domeauthor=B.+Hegedus&title=The+FAK+inhibitor+BI+853520+inhibits+spheroid+formation+and+orthotopic+tumor+growth+in+malignant+pleural+mesothelioma&doi=10.1007%2Fs00109-018-1725-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma</span></div><div class="casAuthors">Laszlo, Viktoria; Valko, Zsuzsanna; Ozsvar, Judit; Kovacs, Ildiko; Garay, Tamas; Hoda, Mir Alireza; Klikovits, Thomas; Stockhammer, Paul; Aigner, Clemens; Groeger, Marion; Klepetko, Walter; Berger, Walter; Grusch, Michael; Tovari, Jozsef; Waizenegger, Irene C.; Dome, Balazs; Hegedus, Balazs</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Medicine (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">231-242</span>CODEN:
                <span class="NLM_cas:coden">JMLME8</span>;
        ISSN:<span class="NLM_cas:issn">0946-2716</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: No tyrosine kinase inhibitors are approved for malignant pleural mesothelioma (MPM).  Preclin. studies identified focal adhesion kinase (FAK) as a target in MPM.  Accordingly, we assessed the novel, highly selective FAK inhibitor (BI 853520) in 2D and 3D cultures and in vivo.  IC50 values were measured by adherent cell viability assay.  Cell migration and 3D growth were quantified by video microscopy and spheroid formation, resp.  Phosphorylation of FAK, Akt, S6, and Erk was measured by immunoblot.  The mRNA expression of the putative tumor stem cell markers SOX2, Nanog, CD44, ALDH1, c-myc, and Oct4 was analyzed by qPCR.  Cell proliferation, apoptosis, and tumor tissue microvessel d. (MVD) were investigated in orthotopic MPM xenografts.  In all 12 MPM cell lines, IC50 exceeded 5 Î¼M and loss of NF2 did not correlate with sensitivity.  No synergism was found with cisplatin in adherent cells.  BI 853520 decreased migration in 3 out of 4 cell lines.  FAK phosphorylation was reduced upon treatment but activation of Erk, Akt, or S6 remained unaffected.  Nevertheless, BI 853520 inhibited spheroid growth and significantly reduced tumor wt., cell proliferation, and MVD in vivo.  BI 853520 has limited effect in adherent cultures but demonstrates potent activity in spheroids and in orthotopic tumors in vivo.  Based on our findings, further studies are warranted to explore the clin. utility of BI 853520 in human MPM.  Key messages: Response to FAK inhibition in MPM is independent of NF2 expression or histotype.  FAK inhibition strongly interfered with MPM spheroid formation.  BI 853520 has been shown to exert anti-tumor effect in MPM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprwFPhW-QqqrVg90H21EOLACvtfcHk0ljBg4jIldZ4Hw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFWrur7I&md5=8bc9bddf2ab350890cbc3c72490f101d</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1007%2Fs00109-018-1725-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00109-018-1725-7%26sid%3Dliteratum%253Aachs%26aulast%3DLaszlo%26aufirst%3DV.%26aulast%3DValko%26aufirst%3DZ.%26aulast%3DOzsvar%26aufirst%3DJ.%26aulast%3DKovacs%26aufirst%3DI.%26aulast%3DGaray%26aufirst%3DT.%26aulast%3DHoda%26aufirst%3DM.%2BA.%26aulast%3DKlikovits%26aufirst%3DT.%26aulast%3DStockhammer%26aufirst%3DP.%26aulast%3DAigner%26aufirst%3DC.%26aulast%3DGroger%26aufirst%3DM.%26aulast%3DKlepetko%26aufirst%3DW.%26aulast%3DBerger%26aufirst%3DW.%26aulast%3DGrusch%26aufirst%3DM.%26aulast%3DTovari%26aufirst%3DJ.%26aulast%3DWaizenegger%26aufirst%3DI.%2BC.%26aulast%3DDome%26aufirst%3DB.%26aulast%3DHegedus%26aufirst%3DB.%26atitle%3DThe%2520FAK%2520inhibitor%2520BI%2520853520%2520inhibits%2520spheroid%2520formation%2520and%2520orthotopic%2520tumor%2520growth%2520in%2520malignant%2520pleural%2520mesothelioma%26jtitle%3DJ.%2520Mol.%2520Med.%26date%3D2019%26volume%3D97%26spage%3D231%26epage%3D242%26doi%3D10.1007%2Fs00109-018-1725-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Jonge, M. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steeghs, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lolkema, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotte, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirte, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Biessen, D. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul Razak, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vos, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verheijen, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pronk, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, L. L.</span></span> <span> </span><span class="NLM_article-title">Phase I study of BI 853520, an inhibitor of focal adhesion kinase, in patients with advanced or metastatic nonhematologic malignancies</span>. <i>Target. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">43</span>â <span class="NLM_lpage">55</span>, <span class="refDoi">Â DOI: 10.1007/s11523-018-00617-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1007%2Fs11523-018-00617-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=30756308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BB3cfis1ymsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=43-55&author=M.+J.+A.+De%0AJongeauthor=N.+Steeghsauthor=M.+P.+Lolkemaauthor=S.+J.+Hotteauthor=H.+W.+Hirteauthor=D.+A.+J.+van+der+Biessenauthor=A.+R.+Abdul+Razakauthor=F.+De+Vosauthor=R.+B.+Verheijenauthor=D.+Schnellauthor=L.+C.+Pronkauthor=M.+Jansenauthor=L.+L.+Siu&title=Phase+I+study+of+BI+853520%2C+an+inhibitor+of+focal+adhesion+kinase%2C+in+patients+with+advanced+or+metastatic+nonhematologic+malignancies&doi=10.1007%2Fs11523-018-00617-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies</span></div><div class="casAuthors">de Jonge Maja J A; Lolkema Martijn P; van der Biessen Diane A J; Steeghs Neeltje; Verheijen Remy B; Lolkema Martijn P; De Vos Filip Y F L; Hotte Sebastien J; Hirte Hal W; Abdul Razak Albiruni R; Siu Lillian L; Schnell David; Pronk Linda C; Jansen Monique</div><div class="citationInfo"><span class="NLM_cas:title">Targeted oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-55</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Overexpression/activation of focal adhesion kinase (FAK) in human malignancies has led to its evaluation as a therapeutic target.  We report the first-in-human phase I study of BI 853520, a novel, potent, highly selective FAK inhibitor.  OBJECTIVE:  Our objectives were to identify the maximum tolerated dose (MTD), and to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), biomarker expression, and preliminary activity.  PATIENTS AND METHODS:  The study comprised a standard 3 + 3 dose-escalation phase followed by an expansion phase in patients with selected advanced, nonhematologic malignancies.  RESULTS:  Thirty-three patients received BI 853520 in the dose-escalation phase; the MTD was 200 mg once daily (QD).  Dose-limiting toxicities included proteinuria and fatigue, both of which were grade 3.  Preliminary PK data supported QD dosing.  In the expansion cohort, 63 patients received BI 853520 200 mg QD.  Drug-related adverse events (AEs) in > 10% of patients included proteinuria (57%), nausea (57%), fatigue (51%), diarrhea (48%), vomiting (40%), decreased appetite (19%), and peripheral edema (16%).  Most AEs were grade 1-2; grade 3 proteinuria, reported in 13 patients (21%), was generally reversible upon treatment interruption.  Nineteen patients underwent dose reduction due to AEs, and three drug-related serious AEs were reported, none of which were fatal.  Preliminary PD analysis indicated target engagement.  Of 63 patients, 49 were evaluable; 17 (27%) achieved a best response of stable disease (4 with 150 + days), and 32 (51%) patients had progressive disease.  CONCLUSIONS:  BI 853520 has a manageable and acceptable safety profile, favorable PK, and modest antitumor activity at an MTD of 200 mg QD in patients with selected advanced nonhematologic malignancies.  CLINICALTRIALS.  GOV IDENTIFIER:  NCT01335269.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcjPd2J9N9MIhLSh9fo81bfW6udTcc2eZH-3mHHxcwULntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfis1ymsQ%253D%253D&md5=f4dc4b1f7c08a07ddfe93c1a26d4ef0b</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1007%2Fs11523-018-00617-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-018-00617-1%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BJonge%26aufirst%3DM.%2BJ.%2BA.%26aulast%3DSteeghs%26aufirst%3DN.%26aulast%3DLolkema%26aufirst%3DM.%2BP.%26aulast%3DHotte%26aufirst%3DS.%2BJ.%26aulast%3DHirte%26aufirst%3DH.%2BW.%26aulast%3Dvan%2Bder%2BBiessen%26aufirst%3DD.%2BA.%2BJ.%26aulast%3DAbdul%2BRazak%26aufirst%3DA.%2BR.%26aulast%3DDe%2BVos%26aufirst%3DF.%26aulast%3DVerheijen%26aufirst%3DR.%2BB.%26aulast%3DSchnell%26aufirst%3DD.%26aulast%3DPronk%26aufirst%3DL.%2BC.%26aulast%3DJansen%26aufirst%3DM.%26aulast%3DSiu%26aufirst%3DL.%2BL.%26atitle%3DPhase%2520I%2520study%2520of%2520BI%2520853520%252C%2520an%2520inhibitor%2520of%2520focal%2520adhesion%2520kinase%252C%2520in%2520patients%2520with%2520advanced%2520or%2520metastatic%2520nonhematologic%2520malignancies%26jtitle%3DTarget.%2520Oncol.%26date%3D2019%26volume%3D14%26spage%3D43%26epage%3D55%26doi%3D10.1007%2Fs11523-018-00617-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shitara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarashina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pronk, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. C.</span></span> <span> </span><span class="NLM_article-title">Phase I study of the focal adhesion kinase inhibitor BI 853520 in Japanese and Taiwanese patients with advanced or metastatic solid tumors</span>. <i>Target. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">57</span>â <span class="NLM_lpage">65</span>, <span class="refDoi">Â DOI: 10.1007/s11523-019-00620-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1007%2Fs11523-019-00620-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=30725402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BB3cjps1Cmsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=57-65&author=T.+Doiauthor=J.+C.+Yangauthor=K.+Shitaraauthor=Y.+Naitoauthor=A.+L.+Chengauthor=A.+Sarashinaauthor=L.+C.+Pronkauthor=Y.+Takeuchiauthor=C.+C.+Lin&title=Phase+I+study+of+the+focal+adhesion+kinase+inhibitor+BI+853520+in+Japanese+and+Taiwanese+patients+with+advanced+or+metastatic+solid+tumors&doi=10.1007%2Fs11523-019-00620-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors</span></div><div class="casAuthors">Doi Toshihiko; Yang James Chih-Hsin; Cheng Ann-Lii; Lin Chia-Chi; Shitara Kohei; Naito Yoichi; Sarashina Akiko; Pronk Linda C; Takeuchi Yoshito</div><div class="citationInfo"><span class="NLM_cas:title">Targeted oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-65</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Focal adhesion kinase (FAK) inhibitors have demonstrated anti-tumor activity preclinically and are currently being evaluated in humans.  A first-in-human study evaluating the novel FAK inhibitor BI 853520 in a predominantly Caucasian population with advanced or metastatic non-hematologic malignancies demonstrated acceptable tolerability and favorable pharmacokinetics.  OBJECTIVE:  This study was undertaken to investigate the safety, tolerability, and maximum tolerated dose (MTD) of BI 853520 in Japanese and Taiwanese patients with advanced solid tumors.  PATIENTS AND METHODS:  In this open-label, phase I, dose-finding study, BI 853520 was administered once daily (QD) in a continuous daily dosing regimen with 28-day cycles and escalating doses to sequential cohorts of patients.  Twenty-one patients (62% male; median age 65 years) were treated at two sites in Japan and Taiwan.  RESULTS:  The median duration of treatment was 1.2 months (range 0.2-7.7).  As no dose-limiting toxicities were observed during cycle 1 in the 50, 100, or 200 mg cohorts, the MTD of BI 853520 was determined to be 200 mg QD.  Drug-related adverse events were reported in 19 patients (90%), and all except one were of grade 1 or 2.  Pharmacokinetic parameters were supportive of a once-daily dosing schedule.  A confirmed objective response rate of 5% and disease control rate of 29% were achieved; median duration of disease control was 3.7 months.  CONCLUSIONS:  This trial demonstrated a manageable and acceptable safety profile, favorable pharmacokinetics, and potential anti-tumor activity of BI 853520 in pretreated Japanese and Taiwanese patients with advanced or metastatic solid tumors.  CLINICAL TRIALS REGISTRATION:  NCT01905111.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTpzuGISfNqg8zK395ZObgVfW6udTcc2eYlLs5-2GInibntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjps1Cmsg%253D%253D&md5=aecf271c8c3f0e5fc5a56a53eeaab421</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1007%2Fs11523-019-00620-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-019-00620-0%26sid%3Dliteratum%253Aachs%26aulast%3DDoi%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DShitara%26aufirst%3DK.%26aulast%3DNaito%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DA.%2BL.%26aulast%3DSarashina%26aufirst%3DA.%26aulast%3DPronk%26aufirst%3DL.%2BC.%26aulast%3DTakeuchi%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DC.%2BC.%26atitle%3DPhase%2520I%2520study%2520of%2520the%2520focal%2520adhesion%2520kinase%2520inhibitor%2520BI%2520853520%2520in%2520Japanese%2520and%2520Taiwanese%2520patients%2520with%2520advanced%2520or%2520metastatic%2520solid%2520tumors%26jtitle%3DTarget.%2520Oncol.%26date%3D2019%26volume%3D14%26spage%3D57%26epage%3D65%26doi%3D10.1007%2Fs11523-019-00620-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ott, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Learn, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingrich, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisko, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesaros, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quail, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrzanski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albom, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angeles, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells-Knecht, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aimone, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruckheimer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ator, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of clinical candidate CEP-37440, a selective inhibitor of focal adhesion kinase (FAK) and anaplastic lymphoma kinase (ALK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7478</span>â <span class="NLM_lpage">7496</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00487</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00487" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlaru77P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7478-7496&author=G.+R.+Ottauthor=M.+Chengauthor=K.+S.+Learnauthor=J.+Wagnerauthor=D.+E.+Gingrichauthor=J.+G.+Liskoauthor=M.+Curryauthor=E.+F.+Mesarosauthor=A.+K.+Ghoseauthor=M.+R.+Quailauthor=W.+Wanauthor=L.+Luauthor=P.+Dobrzanskiauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=K.+Wells-Knechtauthor=Z.+Huangauthor=L.+D.+Aimoneauthor=E.+Bruckheimerauthor=N.+Andersonauthor=J.+Friedmanauthor=S.+V.+Fernandezauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=B.+D.+Dorsey&title=Discovery+of+clinical+candidate+CEP-37440%2C+a+selective+inhibitor+of+focal+adhesion+kinase+%28FAK%29+and+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1021%2Facs.jmedchem.6b00487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Ott, Gregory R.; Cheng, Mangeng; Learn, Keith S.; Wagner, Jason; Gingrich, Diane E.; Lisko, Joseph G.; Curry, Matthew; Mesaros, Eugen F.; Ghose, Arup K.; Quail, Matthew R.; Wan, Weihua; Lu, Lihui; Dobrzanski, Pawel; Albom, Mark S.; Angeles, Thelma S.; Wells-Knecht, Kevin; Huang, Zeqi; Aimone, Lisa D.; Bruckheimer, Elizabeth; Anderson, Nathan; Friedman, Jay; Fernandez, Sandra V.; Ator, Mark A.; Ruggeri, Bruce A.; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7478-7496</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Analogs structurally related to anaplastic lymphoma kinase (ALK) inhibitor (CEP-28122) were optimized for metabolic stability.  The results from this endeavor not only led to improved metabolic stability, pharmacokinetic parameters, and in vitro activity against clin. derived resistance mutations but also led to the incorporation of activity for focal adhesion kinase (FAK).  FAK activation, via amplification and/or overexpression, is characteristic of multiple invasive solid tumors and metastasis.  The discovery of the clin. stage, dual FAK/ALK inhibitor 27b (CEP-37440), including details surrounding SAR, in vitro/in vivo pharmacol., and pharmacokinetics, is reported herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9Ojryum63_LVg90H21EOLACvtfcHk0lhX2gMy9Rl_UA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlaru77P&md5=3fcd1342d901b2379d0efbd118d3049f</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00487%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DLearn%26aufirst%3DK.%2BS.%26aulast%3DWagner%26aufirst%3DJ.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DLisko%26aufirst%3DJ.%2BG.%26aulast%3DCurry%26aufirst%3DM.%26aulast%3DMesaros%26aufirst%3DE.%2BF.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DDobrzanski%26aufirst%3DP.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DWells-Knecht%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DBruckheimer%26aufirst%3DE.%26aulast%3DAnderson%26aufirst%3DN.%26aulast%3DFriedman%26aufirst%3DJ.%26aulast%3DFernandez%26aufirst%3DS.%2BV.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DDiscovery%2520of%2520clinical%2520candidate%2520CEP-37440%252C%2520a%2520selective%2520inhibitor%2520of%2520focal%2520adhesion%2520kinase%2520%2528FAK%2529%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7478%26epage%3D7496%26doi%3D10.1021%2Facs.jmedchem.6b00487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salem, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsalahi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chervoneva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aburto, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Addya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristofanilli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, S. V.</span></span> <span> </span><span class="NLM_article-title">The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">37</span>â <span class="NLM_lpage">51</span>, <span class="refDoi">Â DOI: 10.1186/s13058-016-0694-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1186%2Fs13058-016-0694-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=27009091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisVOhsL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=37-51&author=I.+Salemauthor=M.+Alsalahiauthor=I.+Chervonevaauthor=L.+D.+Aburtoauthor=S.+Addyaauthor=G.+R.+Ottauthor=B.+A.+Ruggeriauthor=M.+Cristofanilliauthor=S.+V.+Fernandez&title=The+effects+of+CEP-37440%2C+an+inhibitor+of+focal+adhesion+kinase%2C+in+vitro+and+in+vivo+on+inflammatory+breast+cancer+cells&doi=10.1186%2Fs13058-016-0694-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells</span></div><div class="casAuthors">Salem, Israa; Alsalahi, Manal; Chervoneva, Inna; Aburto, Lucy D.; Addya, Sankar; Ott, Gregory R.; Ruggeri, Bruce A.; Cristofanilli, Massimo; Fernandez, Sandra V.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37/1-37/15</span>CODEN:
                <span class="NLM_cas:coden">BRCRFS</span>;
        ISSN:<span class="NLM_cas:issn">1465-542X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Inflammatory breast cancer (IBC) is an aggressive type of advanced breast cancer with a poor prognosis.  We recently found that focal adhesion kinase 1 (FAK1) is upregulated and phosphorylated (active) in IBC.  In this study, we investigated the effect of CEP-37440, a dual inhibitor of FAK1 and anaplastic lymphoma kinase (ALK), using human IBC cell lines and preclin. models of IBC.  Cell proliferation assays were performed in the presence of several concns. of CEP-37440 using IBC and triple-neg. breast cancer non-IBC cell lines.  In vitro, we studied the expression of total FAK1, phospho-FAK1 (Tyr 397), total ALK and phospho-ALK (Tyr 1604).  In vivo, we tested CEP-37440 using FC-IBC02, SUM149, and SUM190 IBC xenograft mouse models.  CEP-37440 at low concn. decreased the proliferation of the IBC cell lines FC-IBC02, SUM190, and KPL4, while not affecting the proliferation of normal breast epithelial cells.  At higher concn., CEP-37440 was also able to inhibit the proliferation of the IBC cell line MDA-IBC03 and the triple-neg. non-IBC cell lines MDA-MB-231 and MDA-MB-468; the IBC cell line SUM149 showed a slight response to the drug.  CEP-37440 decreased the cell proliferation of FC-IBC02, SUM190, and KPL4 by blocking the autophosphorylation kinase activity of FAK1 (Tyr 397).  None of the cells evaluated expressed ALK.  In vivo, after 7 wk of CEP-37440 treatment, the SUM190, FC-IBC02, and SUM149 breast tumor xenografts were smaller in mice treated with 55 mg/kg bid CEP-37440 compared to the controls; the tumor growth inhibition (TGI) was 79.7 %, 33 %, and 23 %, resp.  None of the FC-IBC02 breast xenografts mice treated with CEP-37440 developed brain metastasis while 20 % of the mice in the control group developed brain metastasis.  Expression array analyses in FC-IBC02 cells showed that CEP-37440 affects the expression of genes related to apoptosis, interferon signaling, and cytokines.  CEP-37440 is effective against some IBC cells that express phospho-FAK1 (Tyr 397), and its antiproliferative activity is related to its ability to decrease phospho-FAK1.  Our results suggest that combinational therapies could be more effective than using CEP-37440 as a single agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouzKOMoopU8rVg90H21EOLACvtfcHk0ljMQXfc8D_tcg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisVOhsL8%253D&md5=d69c00c3a502a33f80d58dcc04337596</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1186%2Fs13058-016-0694-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-016-0694-4%26sid%3Dliteratum%253Aachs%26aulast%3DSalem%26aufirst%3DI.%26aulast%3DAlsalahi%26aufirst%3DM.%26aulast%3DChervoneva%26aufirst%3DI.%26aulast%3DAburto%26aufirst%3DL.%2BD.%26aulast%3DAddya%26aufirst%3DS.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DCristofanilli%26aufirst%3DM.%26aulast%3DFernandez%26aufirst%3DS.%2BV.%26atitle%3DThe%2520effects%2520of%2520CEP-37440%252C%2520an%2520inhibitor%2520of%2520focal%2520adhesion%2520kinase%252C%2520in%2520vitro%2520and%2520in%2520vivo%2520on%2520inflammatory%2520breast%2520cancer%2520cells%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2016%26volume%3D18%26spage%3D37%26epage%3D51%26doi%3D10.1186%2Fs13058-016-0694-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanjoni, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uryu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, J.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mielgo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMahon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stupack, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlaepfer, D. D.</span></span> <span> </span><span class="NLM_article-title">PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">764</span>â <span class="NLM_lpage">777</span>, <span class="refDoi">Â DOI: 10.4161/cbt.9.10.11434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.4161%2Fcbt.9.10.11434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=20234191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKrtrnI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=764-777&author=I.+Tanjoniauthor=C.+Walshauthor=S.+Uryuauthor=A.+Tomarauthor=J.-O.+Namauthor=A.+Mielgoauthor=S.-T.+Limauthor=C.+Liangauthor=M.+Koenigauthor=N.+Patelauthor=C.+Kwokauthor=G.+McMahonauthor=D.+G.+Stupackauthor=D.+D.+Schlaepfer&title=PND-1186+FAK+inhibitor+selectively+promotes+tumor+cell+apoptosis+in+three-dimensional+environments&doi=10.4161%2Fcbt.9.10.11434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments</span></div><div class="casAuthors">Tanjoni, Isabelle; Walsh, Colin; Uryu, Sean; Tomar, Alok; Nam, Ju-Ock; Mielgo, Ainhoa; Lim, Ssang-Taek; Liang, Congxin; Koenig, Marcel; Sun, Connie; Patel, Neela; Kwok, Cheni; McMahon, Gerald; Stupack, Dwayne G.; Schlaepfer, David D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">764-777</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Tumor cells can grow in an anchorage-independent manner.  This is mediated in part through survival signals that bypass normal growth restraints controlled by integrin cell surface receptors.  Focal adhesion kinase (FAK) is a cytoplasmic protein-tyrosine kinase that assocs. with integrins and modulates various cellular processes including growth, survival and migration.  As increased FAK expression and tyrosine phosphorylation are assocd. with tumor progression, inhibitors of FAK are being tested for anti-tumor effects.  Here, we analyze PND-1186, a substituted pyridine reversible inhibitor of FAK activity with a 50% inhibitory concn. (IC50) of 1.5 nM in vitro.  PND-1186 has an IC50 of â¼100 nM in breast carcinoma cells as detd. by anti-phospho-specific immunoblotting to FAK Tyr-397.  PND-1186 did not alter c-Src or p130Cas tyrosine phosphorylation in adherent cells, yet functioned to restrain cell movement.  Notably, 1.0 Î¼M PND-1186 (>5-fold above IC50) had limited effects on cell proliferation.  However, under non-adherent conditions as spheroids and as colonies in soft agar, 0.1 Î¼M PND-1186 blocked FAK and p130Cas tyrosine phosphorylation, promoted caspase-3 activation, and triggered cell apoptosis.  PND-1186 inhibited 4T1 breast carcinoma s.c. tumor growth correlated with elevated tumor cell apoptosis and caspase 3 activation.  Addn. of PND-1186 to the drinking water of mice was well tolerated and inhibited ascites- and peritoneal membrane-assocd. ovarian carcinoma tumor growth assocd. with the inhibition of FAK Tyr-397 phosphorylation.  Our results with low-level PND-1186 treatment support the conclusion that FAK activity selectively promotes tumor cell survival in three-dimensional environments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsLnD2EGHjs7Vg90H21EOLACvtfcHk0ljMQXfc8D_tcg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKrtrnI&md5=5cb6370e769d6e4f88ef5e27d70a7996</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.4161%2Fcbt.9.10.11434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.9.10.11434%26sid%3Dliteratum%253Aachs%26aulast%3DTanjoni%26aufirst%3DI.%26aulast%3DWalsh%26aufirst%3DC.%26aulast%3DUryu%26aufirst%3DS.%26aulast%3DTomar%26aufirst%3DA.%26aulast%3DNam%26aufirst%3DJ.-O.%26aulast%3DMielgo%26aufirst%3DA.%26aulast%3DLim%26aufirst%3DS.-T.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DKoenig%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DKwok%26aufirst%3DC.%26aulast%3DMcMahon%26aufirst%3DG.%26aulast%3DStupack%26aufirst%3DD.%2BG.%26aulast%3DSchlaepfer%26aufirst%3DD.%2BD.%26atitle%3DPND-1186%2520FAK%2520inhibitor%2520selectively%2520promotes%2520tumor%2520cell%2520apoptosis%2520in%2520three-dimensional%2520environments%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D764%26epage%3D777%26doi%3D10.4161%2Fcbt.9.10.11434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurmasheva, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorlick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keir, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lock, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carol, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houghton, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. A.</span></span> <span> </span><span class="NLM_article-title">Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the pediatric preclinical testing program</span>. <i>Pediatr. Blood Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>64</i></span>, <span class="NLM_elocation-id">e26304</span> <span class="refDoi">Â DOI: 10.1002/pbc.26304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1002%2Fpbc.26304" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2017&author=R.+T.+Kurmashevaauthor=R.+Gorlickauthor=E.+A.+Kolbauthor=S.+T.+Keirauthor=J.+M.+Marisauthor=R.+B.+Lockauthor=H.+Carolauthor=M.+Kangauthor=C.+P.+Reynoldsauthor=J.+Wuauthor=P.+J.+Houghtonauthor=M.+A.+Smith&title=Initial+testing+of+VS-4718%2C+a+novel+inhibitor+of+focal+adhesion+kinase+%28FAK%29%2C+against+pediatric+tumor+models+by+the+pediatric+preclinical+testing+program&doi=10.1002%2Fpbc.26304"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1002%2Fpbc.26304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpbc.26304%26sid%3Dliteratum%253Aachs%26aulast%3DKurmasheva%26aufirst%3DR.%2BT.%26aulast%3DGorlick%26aufirst%3DR.%26aulast%3DKolb%26aufirst%3DE.%2BA.%26aulast%3DKeir%26aufirst%3DS.%2BT.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26aulast%3DLock%26aufirst%3DR.%2BB.%26aulast%3DCarol%26aufirst%3DH.%26aulast%3DKang%26aufirst%3DM.%26aulast%3DReynolds%26aufirst%3DC.%2BP.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DHoughton%26aufirst%3DP.%2BJ.%26aulast%3DSmith%26aufirst%3DM.%2BA.%26atitle%3DInitial%2520testing%2520of%2520VS-4718%252C%2520a%2520novel%2520inhibitor%2520of%2520focal%2520adhesion%2520kinase%2520%2528FAK%2529%252C%2520against%2520pediatric%2520tumor%2520models%2520by%2520the%2520pediatric%2520preclinical%2520testing%2520program%26jtitle%3DPediatr.%2520Blood%2520Cancer%26date%3D2017%26volume%3D64%26doi%3D10.1002%2Fpbc.26304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegde, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knolhoff, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herndon, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nywening, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachter, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang-Gillam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeNardo, D. G.</span></span> <span> </span><span class="NLM_article-title">Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">851</span>â <span class="NLM_lpage">860</span>, <span class="refDoi">Â DOI: 10.1038/nm.4123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fnm.4123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=27376576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtV2msLfN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=851-860&author=H.+Jiangauthor=S.+Hegdeauthor=B.+L.+Knolhoffauthor=Y.+Zhuauthor=J.+M.+Herndonauthor=M.+A.+Meyerauthor=T.+M.+Nyweningauthor=W.+G.+Hawkinsauthor=I.+M.+Shapiroauthor=D.+T.+Weaverauthor=J.+A.+Pachterauthor=A.+Wang-Gillamauthor=D.+G.+DeNardo&title=Targeting+focal+adhesion+kinase+renders+pancreatic+cancers+responsive+to+checkpoint+immunotherapy&doi=10.1038%2Fnm.4123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy</span></div><div class="casAuthors">Jiang, Hong; Hegde, Samarth; Knolhoff, Brett L.; Zhu, Yu; Herndon, John M.; Meyer, Melissa A.; Nywening, Timothy M.; Hawkins, William G.; Shapiro, Irina M.; Weaver, David T.; Pachter, Jonathan A.; Wang-Gillam, Andrea; DeNardo, David G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">851-860</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Single-agent immunotherapy has achieved limited clin. benefit to date in patients with pancreatic ductal adenocarcinoma (PDAC).  This may be a result of the presence of a uniquely immunosuppressive tumor microenvironment (TME).  Crit. obstacles to immunotherapy in PDAC tumors include a high no. of tumor-assocd. immunosuppressive cells and a uniquely desmoplastic stroma that functions as a barrier to T cell infiltration.  We identified hyperactivated focal adhesion kinase (FAK) activity in neoplastic PDAC cells as an important regulator of the fibrotic and immunosuppressive TME.  We found that FAK activity was elevated in human PDAC tissues and correlated with high levels of fibrosis and poor CD8+ cytotoxic T cell infiltration.  Single-agent FAK inhibition using the selective FAK inhibitor VS-4718 substantially limited tumor progression, resulting in a doubling of survival in the p48-Cre;LSL-KrasG12D;Trp53flox/+ (KPC) mouse model of human PDAC.  This delay in tumor progression was assocd. with markedly reduced tumor fibrosis and decreased nos. of tumor-infiltrating immunosuppressive cells.  We also found that FAK inhibition rendered the previously unresponsive KPC mouse model responsive to T cell immunotherapy and PD-1 antagonists.  These data suggest that FAK inhibition increases immune surveillance by overcoming the fibrotic and immunosuppressive PDAC TME and renders tumors responsive to immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7vp95t6jl9bVg90H21EOLACvtfcHk0lhk47AhoXd9TQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtV2msLfN&md5=1f715175ab16c97f696999001422df4c</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1038%2Fnm.4123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4123%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DHegde%26aufirst%3DS.%26aulast%3DKnolhoff%26aufirst%3DB.%2BL.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DHerndon%26aufirst%3DJ.%2BM.%26aulast%3DMeyer%26aufirst%3DM.%2BA.%26aulast%3DNywening%26aufirst%3DT.%2BM.%26aulast%3DHawkins%26aufirst%3DW.%2BG.%26aulast%3DShapiro%26aufirst%3DI.%2BM.%26aulast%3DWeaver%26aufirst%3DD.%2BT.%26aulast%3DPachter%26aufirst%3DJ.%2BA.%26aulast%3DWang-Gillam%26aufirst%3DA.%26aulast%3DDeNardo%26aufirst%3DD.%2BG.%26atitle%3DTargeting%2520focal%2520adhesion%2520kinase%2520renders%2520pancreatic%2520cancers%2520responsive%2520to%2520checkpoint%2520immunotherapy%26jtitle%3DNat.%2520Med.%26date%3D2016%26volume%3D22%26spage%3D851%26epage%3D860%26doi%3D10.1038%2Fnm.4123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gottesman, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fojo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span> <span> </span><span class="NLM_article-title">Multidrug resistance in cancer: role of ATP-dependent transporters</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">48</span>â <span class="NLM_lpage">58</span>, <span class="refDoi">Â DOI: 10.1038/nrc706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fnrc706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=11902585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD38XhvF2jtL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=48-58&author=M.+M.+Gottesmanauthor=T.+Fojoauthor=S.+E.+Bates&title=Multidrug+resistance+in+cancer%3A+role+of+ATP-dependent+transporters&doi=10.1038%2Fnrc706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Multidrug resistance in cancer: role of ATP-dependent transporters</span></div><div class="casAuthors">Gottesman, Michael M.; Fojo, Tito; Bates, Susan E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-58</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chemotherapeutics are the most effective treatment for metastatic tumors.  However, the ability of cancer cells to become simultaneously resistant to different drugs, a trait known as multidrug resistance, remains a significant impediment to successful chemotherapy.  Three decades of multidrug-resistance research have identified a myriad of ways in which cancer cells can elude chemotherapy, and it has become apparent that resistance exists against every effective drug, even our newest agents.  Therefore, the ability to predict and circumvent drug resistance is likely to improve chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRJtnCZv-ZtrVg90H21EOLACvtfcHk0lhk47AhoXd9TQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhvF2jtL8%253D&md5=ec5284e1fe4a878c5ffc30ee83bccc9d</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1038%2Fnrc706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc706%26sid%3Dliteratum%253Aachs%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26aulast%3DFojo%26aufirst%3DT.%26aulast%3DBates%26aufirst%3DS.%2BE.%26atitle%3DMultidrug%2520resistance%2520in%2520cancer%253A%2520role%2520of%2520ATP-dependent%2520transporters%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26spage%3D48%26epage%3D58%26doi%3D10.1038%2Fnrc706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eckford, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharom, F. J.</span></span> <span> </span><span class="NLM_article-title">ABC efflux pump-based resistance to chemotherapy drugs</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">2989</span>â <span class="NLM_lpage">3011</span>, <span class="refDoi">Â DOI: 10.1021/cr9000226</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr9000226" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlslSmtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2009&pages=2989-3011&author=P.+D.+Eckfordauthor=F.+J.+Sharom&title=ABC+efflux+pump-based+resistance+to+chemotherapy+drugs&doi=10.1021%2Fcr9000226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">ABC Efflux Pump-Based Resistance to Chemotherapy Drugs</span></div><div class="casAuthors">Eckford, Paul D. W.; Sharom, Frances J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2989-3011</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Over 1 million new cases of all types of cancer are diagnosed each year in the United States alone, and 559, 650 cancer-related deaths were expected to occur in 2007.  Chemotherapeutic treatment of cancers is an important tool to combat this devastating disease.  However, chemotherapy can fail due to the development of tumor cell resistance to multiple drugs, a phenomenon known as multidrug resistance (MDR), and essentially all cancer-related deaths are considered to be a result of chemotherapy failure.  MDR can have many causes, but one important mechanism of drug resistance is the expression of active drug efflux pumps in the membranes of cancer cells.  The efflux pump proteins mediating MDR in human cancers belong to the ATP-Binding Cassette (ABC) superfamily of proteins.  This is a diverse group of (primarily) active membrane transporters and is one of the largest known protein families.  Its members include proteins that mediate a variety of transport processes, in both prokaryotes (e.g., membrane-embedded importers for sugars and amino acids, and drug exporters) and eukaryotes, where only ABC exporters are known.  The 49 ABC proteins identified in the human genome (there appear to be 48 functional proteins) are involved in the efflux of substrates such as phospholipids, sterols, bile salts, and amphipathic drugs.  While as many as 15 ABC transporters have been obsd. to export chemotherapy drugs using in vitro exptl. systems, only 3 transporters have thus far been implicated as major contributors to MDR in cancer.  Discovered over 30 years ago, P-glycoprotein (Pgp; MDR1; ABCB1), was the first mammalian ABC protein to be identified.  Multidrug resistance-assocd. protein 1 (MRP1 or ABCC1) and more recently ABCG2 (also termed the breast cancer resistance protein, BCRP, or mitoxantrone resistance protein, MXR) also appear to function as clin. relevant drug efflux pumps.  All three proteins were discovered as factors over-expressed in MDR cell lines in culture, and they have since been detected in MDR tumors in patients.  Considerable effort has been made to understand the structure and function of these three drug pumps, which possess a unique ability to recognize and transport a broad array of structurally diverse compds. out of the cell.  The development of compds. known as modulators, which are able to reverse MDR by blocking or inhibiting the ATP-dependent transport function of these proteins, is also an important goal of researchers in this field.  This review will summarize our understanding of the substrate specificity of the mammalian drug efflux pumps, their structure, the mol. mechanisms by which they exert their function, and the progress made to date in reversing pump-mediated MDR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZIkwCqe_qg7Vg90H21EOLACvtfcHk0lhk47AhoXd9TQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlslSmtbg%253D&md5=5009e7a7cac6977a296fd5bbf97d7df7</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Fcr9000226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr9000226%26sid%3Dliteratum%253Aachs%26aulast%3DEckford%26aufirst%3DP.%2BD.%26aulast%3DSharom%26aufirst%3DF.%2BJ.%26atitle%3DABC%2520efflux%2520pump-based%2520resistance%2520to%2520chemotherapy%2520drugs%26jtitle%3DChem.%2520Rev.%26date%3D2009%26volume%3D109%26spage%3D2989%26epage%3D3011%26doi%3D10.1021%2Fcr9000226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stavrovskaya, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stromskaya, T. P.</span></span> <span> </span><span class="NLM_article-title">Transport proteins of the ABC family and multidrug resistance of tumor cells</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">592</span>â <span class="NLM_lpage">604</span>, <span class="refDoi">Â DOI: 10.1134/S0006297908050118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1134%2FS0006297908050118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=18605983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsFKhu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=592-604&author=A.+A.+Stavrovskayaauthor=T.+P.+Stromskaya&title=Transport+proteins+of+the+ABC+family+and+multidrug+resistance+of+tumor+cells&doi=10.1134%2FS0006297908050118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Transport proteins of the ABC family and multidrug resistance of tumor cells</span></div><div class="casAuthors">Stavrovskaya, A. A.; Stromskaya, T. P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry (Moscow)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">592-604</span>CODEN:
                <span class="NLM_cas:coden">BIORAK</span>;
        ISSN:<span class="NLM_cas:issn">0006-2979</span>.
    
            (<span class="NLM_cas:orgname">Pleiades Publishing, Ltd.</span>)
        </div><div class="casAbstract">A review.  Some new data concerning the role of transport proteins of the ABC family in multidrug resistance (MDR) of human tumor cells, and problems connected with regulation of these proteins are considered.  MDR is a complex phenomenon that may be caused simultaneously by several mechanisms functioning in one and the same cell.  Among them there may be the alterations of activity of several transport proteins.  Activation of these proteins may be assocd. with alterations of activities of different cell protective systems and of the signal transduction pathways involved in regulation of proliferation, differentiation, and apoptosis.  Clin. significance of multifactor MDR is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrElh5UjnAuqbVg90H21EOLACvtfcHk0lhk47AhoXd9TQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsFKhu78%253D&md5=c66e8b327c8ec154f22f9ac35a2b2735</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1134%2FS0006297908050118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1134%252FS0006297908050118%26sid%3Dliteratum%253Aachs%26aulast%3DStavrovskaya%26aufirst%3DA.%2BA.%26aulast%3DStromskaya%26aufirst%3DT.%2BP.%26atitle%3DTransport%2520proteins%2520of%2520the%2520ABC%2520family%2520and%2520multidrug%2520resistance%2520of%2520tumor%2520cells%26jtitle%3DBiochemistry%26date%3D2008%26volume%3D73%26spage%3D592%26epage%3D604%26doi%3D10.1134%2FS0006297908050118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ji, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, Z. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, Q. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D. H.</span></span> <span> </span><span class="NLM_article-title">VS-4718 antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells by inhibiting the efflux function of ABC transporters</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1236</span>â <span class="NLM_lpage">1247</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2018.01236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.3389%2Ffphar.2018.01236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=30425643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVGmtLjJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1236-1247&author=N.+Jiauthor=Y.+Yangauthor=C.+Y.+Caiauthor=Z.+N.+Leiauthor=J.+Q.+Wangauthor=P.+Guptaauthor=Q.+X.+Tengauthor=Z.+S.+Chenauthor=D.+Kongauthor=D.+H.+Yang&title=VS-4718+antagonizes+multidrug+resistance+in+ABCB1-+and+ABCG2-overexpressing+cancer+cells+by+inhibiting+the+efflux+function+of+ABC+transporters&doi=10.3389%2Ffphar.2018.01236"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">VS-4718 antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells by inhibiting the efflux function of ABC transporters</span></div><div class="casAuthors">Ji, Ning; Yang, Yuqi; Cai, Chao-Yun; Lei, Zi-Ning; Wang, Jing-Quan; Gupta, Pranav; Teng, Qiu-Xu; Chen, Zhe-Sheng; Kong, Dexin; Yang, Dong-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1236</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Overexpression of ATP-binding cassette (ABC) transporters is one of the most important mechanisms responsible for multi-drug resistance (MDR).  VS-4718, a tyrosine kinase inhibitor targeting focal adhesion kinase (FAK) with a potential anticancer effect, is currently evaluated in clin. trials.  In this study, we investigated whether VS-4718 could reverse MDR mediated by ABC transporters, including ABCB1, ABCG2, and ABCC1.  The results showed that VS-4718 significantly reversed ABCB1- and ABCG2-mediated MDR, but not MDR mediated by ABCC1.  Treatment of VS-4718 did not alter the protein level and subcellular localization of ABCB1 or ABCG2.  Mechanism studies indicated that the reversal effects of VS-4718 were related to attenuation of the efflux activity of ABCB1 and ABCG2 transporters.  ATPase anal. indicated that VS-4718 stimulated the ATPase activity of ABCB1 and ABCG2.  Docking study showed that VS-4718 interacted with the substrate-binding sites of both ABCB1 and ABCG2, suggesting that VS-4718 may affect the activity of ABCB1 and ABCG2 competitively.  This study provided a novel insight for MDR cancer treatment.  It indicated that combination of VS-4718 with antineoplastic drugs could attenuate MDR mediated by ABCB1 or ABCG2 in ABCB1- or ABCG2-overexpressing cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1TjxRKt8f37Vg90H21EOLACvtfcHk0lh9AHe5X7V13w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVGmtLjJ&md5=412291789178a7f08247278a3a1091fc</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.01236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.01236%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DN.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DC.%2BY.%26aulast%3DLei%26aufirst%3DZ.%2BN.%26aulast%3DWang%26aufirst%3DJ.%2BQ.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DTeng%26aufirst%3DQ.%2BX.%26aulast%3DChen%26aufirst%3DZ.%2BS.%26aulast%3DKong%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DD.%2BH.%26atitle%3DVS-4718%2520antagonizes%2520multidrug%2520resistance%2520in%2520ABCB1-%2520and%2520ABCG2-overexpressing%2520cancer%2520cells%2520by%2520inhibiting%2520the%2520efflux%2520function%2520of%2520ABC%2520transporters%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D1236%26epage%3D1247%26doi%3D10.3389%2Ffphar.2018.01236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crompton, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlton, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorner, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calicchio, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohl, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegmaier, K.</span></span> <span> </span><span class="NLM_article-title">High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">2873</span>â <span class="NLM_lpage">2883</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-12-1944</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1158%2F0008-5472.CAN-12-1944" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=23536552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvVShtbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=2873-2883&author=B.+D.+Cromptonauthor=A.+L.+Carltonauthor=A.+R.+Thornerauthor=A.+L.+Christieauthor=J.+Duauthor=M.+L.+Calicchioauthor=M.+N.+Riveraauthor=M.+D.+Flemingauthor=N.+E.+Kohlauthor=A.+L.+Kungauthor=K.+Stegmaier&title=High-throughput+tyrosine+kinase+activity+profiling+identifies+FAK+as+a+candidate+therapeutic+target+in+Ewing+sarcoma&doi=10.1158%2F0008-5472.CAN-12-1944"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">High-Throughput Tyrosine Kinase Activity Profiling Identifies FAK as a Candidate Therapeutic Target in Ewing Sarcoma</span></div><div class="casAuthors">Crompton, Brian D.; Carlton, Anne L.; Thorner, Aaron R.; Christie, Amanda L.; Du, Jinyan; Calicchio, Monica L.; Rivera, Miguel N.; Fleming, Mark D.; Kohl, Nancy E.; Kung, Andrew L.; Stegmaier, Kimberly</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2873-2883</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Limited progress has been made in the treatment of advanced-stage pediatric solid tumors despite the accelerated pace of cancer discovery over the last decade.  Tyrosine kinase inhibition is one tractable therapeutic modality for treating human malignancy.  However, little is known about the kinases crit. to the development or maintenance of many pediatric solid tumors such as Ewing sarcoma.  Using a fluorescent, bead-based technol. to profile activated tyrosine kinases, we identified focal adhesion kinase (FAK,PTK2) as a candidate target in Ewing sarcoma.  FAK is a tyrosine kinase crit. for cellular adhesion, growth, and survival.  As such, it is a compelling target for cancer-based therapy.  In this study, we have shown that FAK is highly phosphorylated in primary Ewing sarcoma tumor samples and that downregulation of FAK by short hairpin RNA and treatment with a FAK-selective kinase inhibitor, PF-562271, impaired growth and colony formation in Ewing sarcoma cell lines.  Moreover, treatment of Ewing sarcoma cell lines with PF-562271 induced apoptosis and led to downregulation of AKT/mTOR and CAS activity.  Finally, we showed that small-mol. inhibition of FAK attenuated Ewing sarcoma tumor growth in vivo.  With FAK inhibitors currently in early-phase clin. trials for adult malignancies, these findings may bear immediate relevance to patients with Ewing sarcoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdtuvxP4NKR7Vg90H21EOLACvtfcHk0lh9AHe5X7V13w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvVShtbc%253D&md5=bba21db9d669c827f91ee1f9426f9a94</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-1944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-1944%26sid%3Dliteratum%253Aachs%26aulast%3DCrompton%26aufirst%3DB.%2BD.%26aulast%3DCarlton%26aufirst%3DA.%2BL.%26aulast%3DThorner%26aufirst%3DA.%2BR.%26aulast%3DChristie%26aufirst%3DA.%2BL.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DCalicchio%26aufirst%3DM.%2BL.%26aulast%3DRivera%26aufirst%3DM.%2BN.%26aulast%3DFleming%26aufirst%3DM.%2BD.%26aulast%3DKohl%26aufirst%3DN.%2BE.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DStegmaier%26aufirst%3DK.%26atitle%3DHigh-throughput%2520tyrosine%2520kinase%2520activity%2520profiling%2520identifies%2520FAK%2520as%2520a%2520candidate%2520therapeutic%2520target%2520in%2520Ewing%2520sarcoma%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D2873%26epage%3D2883%26doi%3D10.1158%2F0008-5472.CAN-12-1944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baggerly, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armaiz-Pena, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanguino, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thanapprapasr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottsford-Miller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zand, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akbani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nick, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeGeest, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Berestein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutgendorf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, A. K.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">919</span>â <span class="NLM_lpage">929</span>, <span class="refDoi">Â DOI: 10.4161/cbt.28882</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.4161%2Fcbt.28882" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=24755674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslOqu7nE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=919-929&author=R.+L.+Stoneauthor=K.+A.+Baggerlyauthor=G.+N.+Armaiz-Penaauthor=Y.+Kangauthor=A.+M.+Sanguinoauthor=D.+Thanapprapasrauthor=H.+J.+Daltonauthor=J.+Bottsford-Millerauthor=B.+Zandauthor=R.+Akbaniauthor=L.+Diaoauthor=A.+M.+Nickauthor=K.+DeGeestauthor=G.+Lopez-Beresteinauthor=R.+L.+Colemanauthor=S.+Lutgendorfauthor=A.+K.+Sood&title=Focal+adhesion+kinase%3A+an+alternative+focus+for+anti-angiogenesis+therapy+in+ovarian+cancer&doi=10.4161%2Fcbt.28882"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion kinase : an alternative focus for anti-angiogenesis therapy in ovarian cancer</span></div><div class="casAuthors">Stone, Rebecca L.; Baggerly, Keith A.; Armaiz-Pena, Guillermo N.; Kang, Yu; Sanguino, Angela M.; Thanapprapasr, Duangmani; Dalton, Heather J.; Bottsford-Miller, Justin; Zand, Behrouz; Akbani, Rehan; Diao, Lixia; Nick, Alpa M.; DeGeest, Koen; Lopez-Berestein, Gabriel; Coleman, Robert L.; Lutgendorf, Susan; Sood, Anil K.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">919-929</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">This investigation describes the clin. significance of phosphorylated focal adhesion kinase (FAK) at the major activating tyrosine site (Y397) in epithelial ovarian cancer (EOC) cells and tumor-assocd. endothelial cells.  FAK gene amplification as a mechanism for FAK overexpression and the effects of FAK tyrosine kinase inhibitor VS-6062 on tumor growth, metastasis, and angiogenesis were examd.  FAK and phospho-FAKY397 were quantified in tumor (FAK-T; pFAK-T) and tumor-assocd. endothelial (FAK-endo; pFAK-endo) cell compartments of EOCs using immunostaining and qRT-PCR.  Assocns. between expression levels and clin. variables were evaluated.  Data from The Cancer Genome Atlas were used to correlate FAK gene copy no. and expression levels in EOC specimens.  The in vitro and in vivo effects of VS-6062 were assayed in preclin. models.  FAK-T and pFAK-T overexpression was significantly assocd. with advanced stage disease and increased microvessel d. (MVD).  High MVD was obsd. in tumors with elevated endothelial cell FAK (59%) and pFAK (44%).  Survival was adversely affected by FAK-T overexpression (3.03 vs 2.06 y, P = 0.004), pFAK-T (2.83 vs 1.78 y, P < 0.001), and pFAK-endo (2.33 vs 2.17 y, P = 0.005).  FAK gene copy no. was increased in 34% of tumors and correlated with expression levels (P < 0.001).  VS-6062 significantly blocked EOC and endothelial cell migration as well as endothelial cell tube formation in vitro.  VS-6062 reduced mean tumor wt. by 56% (P = 0.005), tumor MVD by 40% (P = 0.0001), and extraovarian metastasis (P < 0.01) in orthotopic EOC mouse models.  FAK may be a unique therapeutic target in EOC given the dual anti-angiogenic and anti-metastatic potential of FAK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUEr0JWPie47Vg90H21EOLACvtfcHk0lh9AHe5X7V13w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslOqu7nE&md5=f45619177d7ac6000dd774bd85864145</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.4161%2Fcbt.28882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.28882%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DR.%2BL.%26aulast%3DBaggerly%26aufirst%3DK.%2BA.%26aulast%3DArmaiz-Pena%26aufirst%3DG.%2BN.%26aulast%3DKang%26aufirst%3DY.%26aulast%3DSanguino%26aufirst%3DA.%2BM.%26aulast%3DThanapprapasr%26aufirst%3DD.%26aulast%3DDalton%26aufirst%3DH.%2BJ.%26aulast%3DBottsford-Miller%26aufirst%3DJ.%26aulast%3DZand%26aufirst%3DB.%26aulast%3DAkbani%26aufirst%3DR.%26aulast%3DDiao%26aufirst%3DL.%26aulast%3DNick%26aufirst%3DA.%2BM.%26aulast%3DDeGeest%26aufirst%3DK.%26aulast%3DLopez-Berestein%26aufirst%3DG.%26aulast%3DColeman%26aufirst%3DR.%2BL.%26aulast%3DLutgendorf%26aufirst%3DS.%26aulast%3DSood%26aufirst%3DA.%2BK.%26atitle%3DFocal%2520adhesion%2520kinase%253A%2520an%2520alternative%2520focus%2520for%2520anti-angiogenesis%2520therapy%2520in%2520ovarian%2520cancer%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2014%26volume%3D15%26spage%3D919%26epage%3D929%26doi%3D10.4161%2Fcbt.28882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mileshkin, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, E. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rischin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fingert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shreeve, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, L. L.</span></span> <span> </span><span class="NLM_article-title">Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1527</span>â <span class="NLM_lpage">1533</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2011.38.9346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1200%2FJCO.2011.38.9346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=22454420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC38XptlyrtL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=1527-1533&author=J.+R.+Infanteauthor=D.+R.+Camidgeauthor=L.+R.+Mileshkinauthor=E.+X.+Chenauthor=R.+J.+Hicksauthor=D.+Rischinauthor=H.+Fingertauthor=K.+J.+Pierceauthor=H.+Xuauthor=W.+G.+Robertsauthor=S.+M.+Shreeveauthor=H.+A.+Burrisauthor=L.+L.+Siu&title=Safety%2C+pharmacokinetic%2C+and+pharmacodynamic+phase+I+dose-escalation+trial+of+PF-00562271%2C+an+inhibitor+of+focal+adhesion+kinase%2C+in+advanced+solid+tumors&doi=10.1200%2FJCO.2011.38.9346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, pharmacokinetic, and pharmacodynamic Phase I dose-escalation trial ofPF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors</span></div><div class="casAuthors">Infante, Jeffrey R.; Camidge, D. Ross; Mileshkin, Linda R.; Chen, Eric X.; Hicks, Rodney J.; Rischin, Danny; Fingert, Howard; Pierce, Kristen J.; Xu, Huiping; Roberts, W. Gregory; Shreeve, S. Martin; Burris, Howard A.; Siu, Lillian L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1527-1533</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: PF-00562271 is a novel inhibitor of focal adhesion kinase (FAK).  The objectives of this study were to identify the recommended phase II dose (RP2D) and assess safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of PF-00562271.  Patients and Methods: Part 1 was a dose escalation without and with food.  Part 2 enrolled specific tumor types in an expansion at the RP2D and also assessed the effect of PF-00562271 on single-dose midazolam PK in a subgroup of patients.  Results: Ninety-nine patients (median age, 60 years; 98% with Eastern Cooperative Oncol. Group performance status of 0 or 1) were treated in 12 fasting and three fed cohorts.  The 125-mg twice-per-day fed dose was deemed the max.-tolerated dose (MTD) and RP2D.  Grade 3 dose-limiting toxicities included headache, nausea/vomiting, dehydration, and edema.  Nausea was the most frequently obsd. toxicity (60% of patients, all grades 1 or 2 at RP2D).  PF-00562271 exposure increased with increasing dose; serum concn.-time profiles showed characteristic nonlinear disposition.  Steady-state exposures were reached within 1 wk.  On coadministration, geometric mean values of midazolam maximal obsd. serum concn. and area under the serum concn.-time curve increased by 60% and more than two-fold, resp.  Of 14 patients evaluable by [18F]fluorodeoxyglucose positron emission tomog. in the expansion cohorts, seven metabolic responses were obsd.  With conventional imaging, 31 patients had stable disease at first restaging scans, and 15 of these remained stable for six or more cycles.  Conclusion: The MTD and RP2D of PF-00562271 is 125 mg twice per day with food.  PF-00562271 displayed time- and dose-dependent nonlinear PK and is likely a potent CYP 3A inhibitor.  This first-in-class study supports further investigation of FAK as a promising therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1Gt4MNB5hlrVg90H21EOLACvtfcHk0lh-PMqTjJUH9Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptlyrtL8%253D&md5=a4f5c95a6cfb8c494a1044ccf463f031</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.38.9346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.38.9346%26sid%3Dliteratum%253Aachs%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DMileshkin%26aufirst%3DL.%2BR.%26aulast%3DChen%26aufirst%3DE.%2BX.%26aulast%3DHicks%26aufirst%3DR.%2BJ.%26aulast%3DRischin%26aufirst%3DD.%26aulast%3DFingert%26aufirst%3DH.%26aulast%3DPierce%26aufirst%3DK.%2BJ.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DW.%2BG.%26aulast%3DShreeve%26aufirst%3DS.%2BM.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DSiu%26aufirst%3DL.%2BL.%26atitle%3DSafety%252C%2520pharmacokinetic%252C%2520and%2520pharmacodynamic%2520phase%2520I%2520dose-escalation%2520trial%2520of%2520PF-00562271%252C%2520an%2520inhibitor%2520of%2520focal%2520adhesion%2520kinase%252C%2520in%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D1527%26epage%3D1533%26doi%3D10.1200%2FJCO.2011.38.9346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedley, D. W.</span></span> <span> </span><span class="NLM_article-title">Targeting focal adhesion kinase signaling in tumor growth and metastasis</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">77</span>â <span class="NLM_lpage">94</span>, <span class="refDoi">Â DOI: 10.1517/14728220903460340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1517%2F14728220903460340" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=20001212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFCitbvM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=77-94&author=J.+Schwockauthor=N.+Dhaniauthor=D.+W.+Hedley&title=Targeting+focal+adhesion+kinase+signaling+in+tumor+growth+and+metastasis&doi=10.1517%2F14728220903460340"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting focal adhesion kinase signaling in tumor growth and metastasis</span></div><div class="casAuthors">Schwock, Joerg; Dhani, Neesha; Hedley, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-94</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: Focal adhesion kinase (FAK), a crucial mediator of integrin and growth factor signaling, is a novel and promising target in cancer therapy.  FAK resides within focal adhesions which are contact points between extracellular matrix (ECM) and cytoskeleton, and increased expression of the kinase has been linked with cancer cell migration, proliferation and survival.  The aim of this review is to summarize the current research in the area and to assess the potential of different FAK-targeting strategies for cancer therapy.  Areas covered in this review: We briefly examine the evidence pointing towards FAK as potential anti-cancer target since its discovery in 1992.  Then, we summarize different approaches developed to interfere with FAK signaling and important results reported from these expts.  Finally, we discuss the potential of these strategies to accomplish inhibition of tumor growth and distant spread as well as potentially meaningful combinations with other therapeutic modalities in the context of the currently available evidence.  What the reader will gain: The review emphasizes the link between FAK biol. and the consequences of interference with FAK signaling.  Based on this foundation an opinion is formed with regard to the future of FAK as therapeutic target.  Take home message: Inhibition of FAK harbors the potential to restrain malignant growth and progression with minimal side effects in normal tissues.  Small mol. inhibitors of the kinase should be examd. in further clin. studies and combinations with existing therapies need to be explored.  More efforts are required to identify markers which predict response towards FAK inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZSMva2-GtqbVg90H21EOLACvtfcHk0lh-PMqTjJUH9Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFCitbvM&md5=feed68cfd6aece3dc89d3568a16c1b36</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1517%2F14728220903460340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728220903460340%26sid%3Dliteratum%253Aachs%26aulast%3DSchwock%26aufirst%3DJ.%26aulast%3DDhani%26aufirst%3DN.%26aulast%3DHedley%26aufirst%3DD.%2BW.%26atitle%3DTargeting%2520focal%2520adhesion%2520kinase%2520signaling%2520in%2520tumor%2520growth%2520and%2520metastasis%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2010%26volume%3D14%26spage%3D77%26epage%3D94%26doi%3D10.1517%2F14728220903460340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecot, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zand, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupaimoole, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradeep, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, A. K.</span></span> <span> </span><span class="NLM_article-title">Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">1485</span>â <span class="NLM_lpage">1495</span>, <span class="refDoi">Â DOI: 10.1093/jnci/djt210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1093%2Fjnci%2Fdjt210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=24062525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsF2ht7fO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2013&pages=1485-1495&author=Y.+Kangauthor=W.+Huauthor=C.+Ivanauthor=H.+J.+Daltonauthor=T.+Miyakeauthor=C.+V.+Pecotauthor=B.+Zandauthor=T.+Liuauthor=J.+Huangauthor=N.+B.+Jenningsauthor=R.+Rupaimooleauthor=M.+Taylorauthor=S.+Pradeepauthor=S.+Y.+Wuauthor=C.+Luauthor=Y.+Wenauthor=J.+Huangauthor=J.+Liuauthor=A.+K.+Sood&title=Role+of+focal+adhesion+kinase+in+regulating+YB-1-mediated+paclitaxel+resistance+in+ovarian+cancer&doi=10.1093%2Fjnci%2Fdjt210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Focal Adhesion Kinase in Regulating YB-1-Mediated Paclitaxel Resistance in Ovarian Cancer</span></div><div class="casAuthors">Kang, Yu; Hu, Wei; Ivan, Cristina; Dalton, Heather J.; Miyake, Takahito; Pecot, Chad V.; Zand, Behrouz; Liu, Tao; Huang, Jie; Jennings, Nicholas B.; Rupaimoole, Rajesha; Taylor, Morgan; Pradeep, Sunila; Wu, Sherry Y.; Lu, Chunhua; Wen, Yunfei; Huang, Jianfei; Liu, Jinsong; Sood, Anil K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1485-1495</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: We previously found focal adhesion kinase (FAK) inhibition sensitizes ovarian cancer to taxanes; however, the mechanisms are not well understood.  Methods: We characterized the biol. response of taxane-resistant and taxane-sensitive ovarian cancer models to a novel FAK inhibitor (VS-6063).  We used reverse-phase protein arrays (RPPA) to identify novel downstream targets in taxane-resistant cell lines.  Furthermore, we correlated clin. and pathol. data with nuclear and cytoplasmic expression of FAK and YB-1 in 105 ovarian cancer samples.  Statistical tests were two-sided, and P values were calcd. with Student t test or Fisher exact test.  Results: We found that VS-6063 inhibited FAK phosphorylation at the Tyr397 site in a time- and dose-dependent manner.  The combination of VS-6063 and paclitaxel markedly decreased proliferation and increased apoptosis, which resulted in 92.7% to 97.9% redns. in tumor wt.  RPPA data showed that VS-6063 reduced levels of AKT and YB-1 in taxane-resistant cell lines.  FAK inhibition enhanced chemosensitivity in taxane-resistant cells by decreasing YB-1 phosphorylation and subsequently CD44 in an AKT-dependent manner.  In human ovarian cancer samples, nuclear FAK expression was assocd. with increased nuclear YB-1 expression (Ï2 = 37.7; P < .001).  Coexpression of nuclear FAK and YB-1 was assocd. with statistically significantly worse median overall survival (24.9 vs 67.3 mo; hazard ratio = 2.64; 95% confidence interval = 1.38 to 5.05; P = .006).  Conclusions: We have identified a novel pathway whereby FAK inhibition with VS-6063 overcomes YB-1-mediated paclitaxel resistance by an AKT-dependent pathway.  These findings have implications for clin. trials aimed at targeting FAK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr21t0jEcw81LVg90H21EOLACvtfcHk0lh-PMqTjJUH9Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsF2ht7fO&md5=d851fd3dc80015f8345cde1bae22dff6</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjt210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjt210%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DIvan%26aufirst%3DC.%26aulast%3DDalton%26aufirst%3DH.%2BJ.%26aulast%3DMiyake%26aufirst%3DT.%26aulast%3DPecot%26aufirst%3DC.%2BV.%26aulast%3DZand%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DJennings%26aufirst%3DN.%2BB.%26aulast%3DRupaimoole%26aufirst%3DR.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DPradeep%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DS.%2BY.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DWen%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DSood%26aufirst%3DA.%2BK.%26atitle%3DRole%2520of%2520focal%2520adhesion%2520kinase%2520in%2520regulating%2520YB-1-mediated%2520paclitaxel%2520resistance%2520in%2520ovarian%2520cancer%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2013%26volume%3D105%26spage%3D1485%26epage%3D1495%26doi%3D10.1093%2Fjnci%2Fdjt210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castillo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spielman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grogan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kench, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stricker, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haynes, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Centenera, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shreeve, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horvath, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, R. J.</span></span> <span> </span><span class="NLM_article-title">Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer</span>. <i>Prostate</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">308</span>â <span class="NLM_lpage">317</span>, <span class="refDoi">Â DOI: 10.1002/pros.23476</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1002%2Fpros.23476" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=29314097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslSjsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=308-317&author=H.+M.+Linauthor=B.+Y.+Leeauthor=L.+Castilloauthor=C.+Spielmanauthor=J.+Groganauthor=N.+K.+Yeungauthor=J.+G.+Kenchauthor=P.+D.+Strickerauthor=A.+M.+Haynesauthor=M.+M.+Centeneraauthor=L.+M.+Butlerauthor=S.+M.+Shreeveauthor=L.+G.+Horvathauthor=R.+J.+Daly&title=Effect+of+FAK+inhibitor+VS-6063+%28defactinib%29+on+docetaxel+efficacy+in+prostate+cancer&doi=10.1002%2Fpros.23476"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer</span></div><div class="casAuthors">Lin, Hui-Ming; Lee, Brian Y.; Castillo, Lesley; Spielman, Calan; Grogan, Judith; Yeung, Nicole K.; Kench, James G.; Stricker, Phillip D.; Haynes, Anne-Maree; Centenera, Margaret M.; Butler, Lisa M.; Shreeve, S. Martin; Horvath, Lisa G.; Daly, Roger J.</div><div class="citationInfo"><span class="NLM_cas:title">Prostate (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">308-317</span>CODEN:
                <span class="NLM_cas:coden">PRSTDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-4137</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background : Docetaxel, the std. chemotherapy for metastatic castration-resistant prostate cancer (CRPC) also enhances the survival of patients with metastatic castration-sensitive prostate cancer (CSPC) when combined with androgen-deprivation therapy.  Focal Adhesion Kinase (FAK) activation is a mediator of docetaxel resistance in prostate cancer cells.  The aim of this study was to investigate the effect of the second generation FAK inhibitor VS-6063 on docetaxel efficacy in pre-clin. CRPC and CSPC models.  Methods : Docetaxel-resistant CRPC cells, mice with PC3 xenografts, and ex vivo cultures of patient-derived primary prostate tumors were treated with VS-6063 and/or docetaxel, or vehicle control.  Cell counting, immunoblotting, and immunohistochem. techniques were used to evaluate the treatment effects.  Results : Docetaxel and VS-6063 co-treatment caused a greater decrease in the viability of docetaxel-resistant CRPC cells, and a greater inhibition in PC3 xenograft growth compared to either monotherapy.  FAK expression in human primary prostate cancer was pos. assocd. with advanced tumor stage.  Patient-derived prostate tumor explants cultured with both docetaxel and VS-6063 displayed a higher percentage of apoptosis in cancer cells, than monotherapy treatment.  Conclusions : Our findings suggest that co-administration of the FAK inhibitor, VS-6063, with docetaxel represents a potential therapeutic strategy to overcome docetaxel resistance in prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3_T7Eg71A9LVg90H21EOLACvtfcHk0lio_dZfRYZqqA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslSjsrY%253D&md5=106cdce4729a5ceb846787369b7d4321</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1002%2Fpros.23476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpros.23476%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DH.%2BM.%26aulast%3DLee%26aufirst%3DB.%2BY.%26aulast%3DCastillo%26aufirst%3DL.%26aulast%3DSpielman%26aufirst%3DC.%26aulast%3DGrogan%26aufirst%3DJ.%26aulast%3DYeung%26aufirst%3DN.%2BK.%26aulast%3DKench%26aufirst%3DJ.%2BG.%26aulast%3DStricker%26aufirst%3DP.%2BD.%26aulast%3DHaynes%26aufirst%3DA.%2BM.%26aulast%3DCentenera%26aufirst%3DM.%2BM.%26aulast%3DButler%26aufirst%3DL.%2BM.%26aulast%3DShreeve%26aufirst%3DS.%2BM.%26aulast%3DHorvath%26aufirst%3DL.%2BG.%26aulast%3DDaly%26aufirst%3DR.%2BJ.%26atitle%3DEffect%2520of%2520FAK%2520inhibitor%2520VS-6063%2520%2528defactinib%2529%2520on%2520docetaxel%2520efficacy%2520in%2520prostate%2520cancer%26jtitle%3DProstate%26date%3D2018%26volume%3D78%26spage%3D308%26epage%3D317%26doi%3D10.1002%2Fpros.23476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendell, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleary, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Razak, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandya, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedard, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houk, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shreeve, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span> <span> </span><span class="NLM_article-title">A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1100</span>â <span class="NLM_lpage">1107</span>, <span class="refDoi">Â DOI: 10.1007/s10637-015-0282-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1007%2Fs10637-015-0282-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=26334219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFSit7%252FN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=1100-1107&author=S.+F.+Jonesauthor=L.+L.+Siuauthor=J.+C.+Bendellauthor=J.+M.+Clearyauthor=A.+R.+Razakauthor=J.+R.+Infanteauthor=S.+S.+Pandyaauthor=P.+L.+Bedardauthor=K.+J.+Pierceauthor=B.+Houkauthor=W.+G.+Robertsauthor=S.+M.+Shreeveauthor=G.+I.+Shapiro&title=A+phase+I+study+of+VS-6063%2C+a+second-generation+focal+adhesion+kinase+inhibitor%2C+in+patients+with+advanced+solid+tumors&doi=10.1007%2Fs10637-015-0282-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors</span></div><div class="casAuthors">Jones, Suzanne F.; Siu, Lillian L.; Bendell, Johanna C.; Cleary, James M.; Razak, Albiruni R. A.; Infante, Jeffrey R.; Pandya, Shuchi S.; Bedard, Philippe L.; Pierce, Kristen J.; Houk, Brett; Roberts, W. Gregory; Shreeve, S. Martin; Shapiro, Geoffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1100-1107</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Objective VS-6063 (also known as defactinib or PF-04554878) is a second-generation inhibitor of focal adhesion kinase (FAK) and proline-rich tyrosine kinase-2 (Pyk2).  This phase I dose-escalation study was conducted in patients with advanced solid malignancies.  Methods Using a traditional 3 + 3 design, VS-6063 was administered orally twice daily (b.i.d.) in 21-day cycles to cohorts of three to six patients.  In cycle 1, a lead-in dose was administered to assess single-dose pharmacokinetics; steady-state pharmacokinetics was assessed after 15 days of continuous dosing.  Dose escalation was performed in the fasted state, and repeated in two addnl. cohorts in the fed state.  Results Forty-six patients were treated across nine dose levels (12.5-750 mg b.i.d.).  Dose-limiting toxicities, comprising headache (n = 1), fatigue (n = 1) and unconjugated hyperbilirubinemia (n = 3), occurred at the 300- or 425-mg b.i.d. dose level and were reversible.  Frequent adverse events included nausea (37 %), fatigue (33 %), vomiting (28 %), diarrhea (22 %) and headache (22 %).  A max.-tolerated dose was not defined.  Dose escalation was stopped at the 750-mg b.i.d. dose due to decreased serum exposure in the 500- and 750-mg vs. 300- and 425-mg groups.  Food delayed the time to peak serum concn. without affecting serum drug exposure.  No radiog. responses were reported.  Disease stabilization at â¼12 wk occurred in six of 37 (16 %) patients receiving doses â¥100 mg b.i.d.  Conclusions VS-6063 has an acceptable safety profile.  Treatment-related adverse events were mild to moderate, and reversible.  The recommended phase II fasting dose of VS-6063 is 425 mg b.i.d.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWgn43uEabk7Vg90H21EOLACvtfcHk0lio_dZfRYZqqA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFSit7%252FN&md5=ddf589d6f9d3f95a3d70fb0fa9455841</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1007%2Fs10637-015-0282-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-015-0282-y%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DS.%2BF.%26aulast%3DSiu%26aufirst%3DL.%2BL.%26aulast%3DBendell%26aufirst%3DJ.%2BC.%26aulast%3DCleary%26aufirst%3DJ.%2BM.%26aulast%3DRazak%26aufirst%3DA.%2BR.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DPandya%26aufirst%3DS.%2BS.%26aulast%3DBedard%26aufirst%3DP.%2BL.%26aulast%3DPierce%26aufirst%3DK.%2BJ.%26aulast%3DHouk%26aufirst%3DB.%26aulast%3DRoberts%26aufirst%3DW.%2BG.%26aulast%3DShreeve%26aufirst%3DS.%2BM.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520VS-6063%252C%2520a%2520second-generation%2520focal%2520adhesion%2520kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2015%26volume%3D33%26spage%3D1100%26epage%3D1107%26doi%3D10.1007%2Fs10637-015-0282-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgensztern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cetnar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigel, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaglioni, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaikus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horobin, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, T. F.</span></span> <span> </span><span class="NLM_article-title">Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">60</span>â <span class="NLM_lpage">67</span>, <span class="refDoi">Â DOI: 10.1016/j.lungcan.2019.10.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.lungcan.2019.10.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=31739184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BB3MfgtlOltA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2020&pages=60-67&author=D.+E.+Gerberauthor=D.+R.+Camidgeauthor=D.+Morgenszternauthor=J.+Cetnarauthor=R.+J.+Kellyauthor=S.+S.+Ramalingamauthor=D.+R.+Spigelauthor=W.+Jeongauthor=P.+P.+Scaglioniauthor=S.+Zhangauthor=M.+Liauthor=D.+T.+Weaverauthor=L.+Vaikusauthor=M.+Keeganauthor=J.+C.+Horobinauthor=T.+F.+Burns&title=Phase+2+study+of+the+focal+adhesion+kinase+inhibitor+defactinib+%28VS-6063%29+in+previously+treated+advanced+KRAS+mutant+non-small+cell+lung+cancer&doi=10.1016%2Fj.lungcan.2019.10.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer</span></div><div class="casAuthors">Gerber David E; Scaglioni Pier P; Zhang Song; Camidge D Ross; Morgensztern Daniel; Cetnar Jeremey; Kelly Ronan J; Ramalingam Suresh S; Spigel David R; Jeong Woondong; Li Marilyn; Weaver David T; Vaikus Louis; Keegan Mitchell; Horobin Joanna C; Burns Timothy F</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">60-67</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  KRAS mutations, which occur in approximately 25% of lung adenocarcinoma cases, represent a major unmet clinical need in thoracic oncology.  Preclinical studies have demonstrated that KRAS mutant NSCLC cell lines and xenografts with additional alterations in either TP53 or CDKN2A (INK4A/ARF) loci are sensitive to focal adhesion kinase (FAK) inhibition.  Defactinib (VS-6063) is a selective oral inhibitor of FAK.  MATERIALS AND METHODS:  Patients with previously treated advanced KRAS mutant NSCLC were prospectively assigned to one of four molecularly defined cohorts based on the presence or absence of TP53 or CDKN2A alterations and received treatment with defactinib 400 mg orally BID until disease progression or intolerable toxicity.  The primary endpoint was progression-free survival (PFS) at 12 weeks.  RESULTS:  Fifty-five patients were enrolled.  Mean age was 62 years; 51% were female.  The median number of prior lines of therapy was 4 (range 1-8).  Fifteen (28%) patients met the 12-week PFS endpoint, with one patient achieving a partial response.  Median PFS was 45 days.  Clinical efficacy did not correlate with TP53 or CDKN2A status.  The most common adverse events were fatigue, gastrointestinal, and increased bilirubin, and were generally grade 1 or 2 in severity.  CONCLUSION:  In heavily pretreated patients with KRAS mutant NSCLC, defactinib monotherapy demonstrated modest clinical activity.  Efficacy was not associated with TP53 and CDKN2A status.  Defactinib was generally well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRHRrJNXQ9psJp6t8nS6Nc3fW6udTcc2ebNHqvRJrfZuLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MfgtlOltA%253D%253D&md5=298f9f8fb6364770cfc7302f4ae30069</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2019.10.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2019.10.033%26sid%3Dliteratum%253Aachs%26aulast%3DGerber%26aufirst%3DD.%2BE.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DMorgensztern%26aufirst%3DD.%26aulast%3DCetnar%26aufirst%3DJ.%26aulast%3DKelly%26aufirst%3DR.%2BJ.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DSpigel%26aufirst%3DD.%2BR.%26aulast%3DJeong%26aufirst%3DW.%26aulast%3DScaglioni%26aufirst%3DP.%2BP.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DWeaver%26aufirst%3DD.%2BT.%26aulast%3DVaikus%26aufirst%3DL.%26aulast%3DKeegan%26aufirst%3DM.%26aulast%3DHorobin%26aufirst%3DJ.%2BC.%26aulast%3DBurns%26aufirst%3DT.%2BF.%26atitle%3DPhase%25202%2520study%2520of%2520the%2520focal%2520adhesion%2520kinase%2520inhibitor%2520defactinib%2520%2528VS-6063%2529%2520in%2520previously%2520treated%2520advanced%2520KRAS%2520mutant%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DLung%2520Cancer%26date%3D2020%26volume%3D139%26spage%3D60%26epage%3D67%26doi%3D10.1016%2Fj.lungcan.2019.10.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schultze, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiedler, W.</span></span> <span> </span><span class="NLM_article-title">Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">777</span>â <span class="NLM_lpage">788</span>, <span class="refDoi">Â DOI: 10.1517/13543784.2010.489548</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1517%2F13543784.2010.489548" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=20465362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFOisLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=777-788&author=A.+Schultzeauthor=W.+Fiedler&title=Therapeutic+potential+and+limitations+of+new+FAK+inhibitors+in+the+treatment+of+cancer&doi=10.1517%2F13543784.2010.489548"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer</span></div><div class="casAuthors">Schultze, Alexander; Fiedler, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">777-788</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: Activation of the non-receptor tyrosine kinase focal adhesion kinase (FAK) has been implicated in progression of multiple mesenchymal and epithelial malignant tumors.  FAK plays an important role in regulation of proliferation, migration and apoptosis of neoplastic cells.  Areas covered in this review: We review the importance of FAK expression as a prognostic marker in cancer patients, discuss the available small-mol. inhibitors of FAK, summarize the available data from early-phase clin. trials with FAK inhibitors and cover the antiangiogenic properties of FAK inhibitors, as well as their potential to overcome chemoresistance.  What the reader will gain: This review enables the reader to overview current knowledge about FAK inhibition in cancer therapy and its role in the clin. setting.  The reader will be able to consider FAK inhibitors not only as direct antitumor but also as antineoangiogenic agents and drugs that can overcome the problem of chemoresistance.  Take home message: Emerging data from early-phase clin. trials with orally available small-mol. inhibitors of FAK are promising.  There are early indicators of clin. efficacy.  In the future, combination therapy with cytotoxic or antiangiogenic drugs may help to overcome chemoresistance and enhance efficacy of antivascular therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKbTg2U-JLsLVg90H21EOLACvtfcHk0lhLiTcwRS7mvg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFOisLk%253D&md5=3e9ead05b7770778b90f9ec48c317a56</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1517%2F13543784.2010.489548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2010.489548%26sid%3Dliteratum%253Aachs%26aulast%3DSchultze%26aufirst%3DA.%26aulast%3DFiedler%26aufirst%3DW.%26atitle%3DTherapeutic%2520potential%2520and%2520limitations%2520of%2520new%2520FAK%2520inhibitors%2520in%2520the%2520treatment%2520of%2520cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2010%26volume%3D19%26spage%3D777%26epage%3D788%26doi%3D10.1517%2F13543784.2010.489548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slack-Davis, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilghman, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwanicki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ung, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Autry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzzio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, J. T.</span></span> <span> </span><span class="NLM_article-title">Cellular characterization of a novel focal adhesion kinase inhibitor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>282</i></span>,  <span class="NLM_fpage">14845</span>â <span class="NLM_lpage">14852</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M606695200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1074%2Fjbc.M606695200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=17395594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltFemtbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=14845-14852&author=J.+K.+Slack-Davisauthor=K.+H.+Martinauthor=R.+W.+Tilghmanauthor=M.+Iwanickiauthor=E.+J.+Ungauthor=C.+Autryauthor=M.+J.+Luzzioauthor=B.+Cooperauthor=J.+C.+Kathauthor=W.+G.+Robertsauthor=J.+T.+Parsons&title=Cellular+characterization+of+a+novel+focal+adhesion+kinase+inhibitor&doi=10.1074%2Fjbc.M606695200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular Characterization of a Novel Focal Adhesion Kinase Inhibitor</span></div><div class="casAuthors">Slack-Davis, Jill K.; Martin, Karen H.; Tilghman, Robert W.; Iwanicki, Marcin; Ung, Ethan J.; Autry, Christopher; Luzzio, Michael J.; Cooper, Beth; Kath, John C.; Roberts, W. Gregory; Parsons, J. Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">14845-14852</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) is a member of a family of non-receptor protein-tyrosine kinases that regulates integrin and growth factor signaling pathways involved in cell migration, proliferation, and survival.  FAK expression is increased in many cancers, including breast and prostate cancer.  Here we describe perturbation of adhesion-mediated signaling with a FAK inhibitor, PF-573,228.  In vitro, this compd. inhibited purified recombinant catalytic fragment of FAK with an IC50 of 4 nM.  In cultured cells, PF-573,228 inhibited FAK phosphorylation on Tyr397 with an IC50 of 30-100 nM.  Treatment of cells with concns. of PF-573,228 that significantly decreased FAK Tyr397 phosphorylation failed to inhibit cell growth or induce apoptosis.  In contrast, treatment with PF-573,228 inhibited both chemotactic and haptotactic migration concomitant with the inhibition of focal adhesion turnover.  These studies show that PF-573,228 serves as a useful tool to dissect the functions of FAK in integrin-dependent signaling pathways in normal and cancer cells and forms the basis for the generation of compds. amenable for preclin. and patient trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_48hzQ-vWhrVg90H21EOLACvtfcHk0lhLiTcwRS7mvg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltFemtbY%253D&md5=38e97c67d37fbcbde006e6937ae4e360</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M606695200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M606695200%26sid%3Dliteratum%253Aachs%26aulast%3DSlack-Davis%26aufirst%3DJ.%2BK.%26aulast%3DMartin%26aufirst%3DK.%2BH.%26aulast%3DTilghman%26aufirst%3DR.%2BW.%26aulast%3DIwanicki%26aufirst%3DM.%26aulast%3DUng%26aufirst%3DE.%2BJ.%26aulast%3DAutry%26aufirst%3DC.%26aulast%3DLuzzio%26aufirst%3DM.%2BJ.%26aulast%3DCooper%26aufirst%3DB.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DRoberts%26aufirst%3DW.%2BG.%26aulast%3DParsons%26aufirst%3DJ.%2BT.%26atitle%3DCellular%2520characterization%2520of%2520a%2520novel%2520focal%2520adhesion%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D14845%26epage%3D14852%26doi%3D10.1074%2Fjbc.M606695200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanteti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirzapoiazova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riehm, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhanasingh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mambetsariev, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaushik, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seshacharyulu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponnusamy, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindler, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasser, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batra, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgia, R.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">316</span>â <span class="NLM_lpage">327</span>, <span class="refDoi">Â DOI: 10.1080/15384047.2017.1416937</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1080%2F15384047.2017.1416937" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=29303405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjslOisL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=316-327&author=R.+Kantetiauthor=T.+Mirzapoiazovaauthor=J.+J.+Riehmauthor=I.+Dhanasinghauthor=B.+Mambetsarievauthor=J.+Wangauthor=P.+Kulkarniauthor=G.+Kaushikauthor=P.+Seshacharyuluauthor=M.+P.+Ponnusamyauthor=H.+L.+Kindlerauthor=M.+W.+Nasserauthor=S.+K.+Batraauthor=R.+Salgia&title=Focal+adhesion+kinase+a+potential+therapeutic+target+for+pancreatic+cancer+and+malignant+pleural+mesothelioma&doi=10.1080%2F15384047.2017.1416937"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma</span></div><div class="casAuthors">Kanteti, Rajani; Mirzapoiazova, Tamara; Riehm, Jacob J.; Dhanasingh, Immanuel; Mambetsariev, Bolot; Wang, Jiale; Kulkarni, Prakash; Kaushik, Garima; Seshacharyulu, Parthasarathy; Ponnusamy, Moorthy P.; Kindler, Hedy L.; Nasser, Mohd. W.; Batra, Surinder K.; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">316-327</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1555-8576</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The non-receptor cytoplasmic tyrosine kinase, Focal Adhesion Kinase (FAK) is known to play a key role in a variety of normal and cancer cellular functions such as survival, proliferation, migration and invasion.  It is highly active and overexpressed in various cancers including Pancreatic Ductal Adenocarcinoma (PDAC) and Malignant Pleural Mesothelioma (MPM).  Here, initially, we demonstrate that FAK is overexpressed in both PDAC and MPM cell lines.  Then we analyze effects of two small mol. inhibitors PF-573228, and PF-431396, which are dual specificity inhibitors of FAK and proline rich tyrosine kinase 2 (PYK2), as well as VS-6063, another small mol. inhibitor that specifically inhibits FAK but not PYK2 for cell growth, motility and invasion of PDAC and MPM cell lines.  Treatment with PF-573228, PF-431396 and VS-6063 cells resulted in a dose-dependent inhibition of growth and anchorage-independent colony formation in both cancer cell lines.  Furthermore, these compds. suppressed the phosphorylation of FAK at its active site, Y397, and functionally induced significant apoptosis and cell cycle arrest in both cell lines.  Using the ECIS (Elec. cell-substrate impedance sensing) system, we found that treatment of both PF compds. suppressed adherence and migration of PDAC cells on fibronectin.  Interestingly, 3D-tumor organoids derived from autochthonous KC (Kras;PdxCre) mice treated with PF-573228 revealed a significant decrease in tumor organoid size and increase in organoid cell death.  Taken together, our results show that FAK is an important target for mesothelioma and pancreatic cancer therapy that merit further translational studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwRiE9kWhYWrVg90H21EOLACvtfcHk0lhLiTcwRS7mvg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjslOisL8%253D&md5=05e366f4dd47a6fb92bcf0ff61e79618</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1080%2F15384047.2017.1416937&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384047.2017.1416937%26sid%3Dliteratum%253Aachs%26aulast%3DKanteti%26aufirst%3DR.%26aulast%3DMirzapoiazova%26aufirst%3DT.%26aulast%3DRiehm%26aufirst%3DJ.%2BJ.%26aulast%3DDhanasingh%26aufirst%3DI.%26aulast%3DMambetsariev%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DKulkarni%26aufirst%3DP.%26aulast%3DKaushik%26aufirst%3DG.%26aulast%3DSeshacharyulu%26aufirst%3DP.%26aulast%3DPonnusamy%26aufirst%3DM.%2BP.%26aulast%3DKindler%26aufirst%3DH.%2BL.%26aulast%3DNasser%26aufirst%3DM.%2BW.%26aulast%3DBatra%26aufirst%3DS.%2BK.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DFocal%2520adhesion%2520kinase%2520a%2520potential%2520therapeutic%2520target%2520for%2520pancreatic%2520cancer%2520and%2520malignant%2520pleural%2520mesothelioma%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2018%26volume%3D19%26spage%3D316%26epage%3D327%26doi%3D10.1080%2F15384047.2017.1416937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukazawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakurama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motoki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takaoka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatakeyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omori, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanabe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirakawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamatsuji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naomoto, Y.</span></span> <span> </span><span class="NLM_article-title">TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1473</span>â <span class="NLM_lpage">1477</span>, <span class="refDoi">Â DOI: 10.3892/or_00000168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.3892%2For_00000168" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1994&pages=1473-1477&author=Z.+G.+Wangauthor=T.+Fukazawaauthor=T.+Nishikawaauthor=N.+Watanabeauthor=K.+Sakuramaauthor=T.+Motokiauthor=M.+Takaokaauthor=S.+Hatakeyamaauthor=O.+Omoriauthor=T.+Oharaauthor=S.+Tanabeauthor=Y.+Fujiwaraauthor=Y.+Shirakawaauthor=T.+Yamatsujiauthor=N.+Tanakaauthor=Y.+Naomoto&title=TAE226%2C+a+dual+inhibitor+for+FAK+and+IGF-IR%2C+has+inhibitory+effects+on+mTOR+signaling+in+esophageal+cancer+cells&doi=10.3892%2For_00000168"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.3892%2For_00000168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For_00000168%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%2BG.%26aulast%3DFukazawa%26aufirst%3DT.%26aulast%3DNishikawa%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DN.%26aulast%3DSakurama%26aufirst%3DK.%26aulast%3DMotoki%26aufirst%3DT.%26aulast%3DTakaoka%26aufirst%3DM.%26aulast%3DHatakeyama%26aufirst%3DS.%26aulast%3DOmori%26aufirst%3DO.%26aulast%3DOhara%26aufirst%3DT.%26aulast%3DTanabe%26aufirst%3DS.%26aulast%3DFujiwara%26aufirst%3DY.%26aulast%3DShirakawa%26aufirst%3DY.%26aulast%3DYamatsuji%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DN.%26aulast%3DNaomoto%26aufirst%3DY.%26atitle%3DTAE226%252C%2520a%2520dual%2520inhibitor%2520for%2520FAK%2520and%2520IGF-IR%252C%2520has%2520inhibitory%2520effects%2520on%2520mTOR%2520signaling%2520in%2520esophageal%2520cancer%2520cells%26jtitle%3DOncol.%2520Rep.%26date%3D1994%26volume%3D20%26spage%3D1473%26epage%3D1477%26doi%3D10.3892%2For_00000168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naomoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakurama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomono, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukazawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirakawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamatsuji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takaoka, M.</span></span> <span> </span><span class="NLM_article-title">Progress in researches about focal adhesion kinase in gastrointestinal tract</span>. <i>World J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">5916</span>â <span class="NLM_lpage">5923</span>, <span class="refDoi">Â DOI: 10.3748/wjg.15.5916</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.3748%2Fwjg.15.5916" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=20014455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFyrur3L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=5916-5923&author=H.+F.+Haoauthor=Y.+Naomotoauthor=X.+H.+Baoauthor=N.+Watanabeauthor=K.+Sakuramaauthor=K.+Nomaauthor=Y.+Tomonoauthor=T.+Fukazawaauthor=Y.+Shirakawaauthor=T.+Yamatsujiauthor=J.+Matsuokaauthor=M.+Takaoka&title=Progress+in+researches+about+focal+adhesion+kinase+in+gastrointestinal+tract&doi=10.3748%2Fwjg.15.5916"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in researches about focal adhesion kinase in gastrointestinal tract</span></div><div class="casAuthors">Hao, Hui Fang; Naomoto, Yoshio; Bao, Xiao-Hong; Watanabe, Nobuyuki; Sakurama, Kazufumi; Noma, Kazuhiro; Tomono, Yasuko; Fukazawa, Takuya; Shirakawa, Yasuhiro; Yamatsuji, Tomoki; Matsuoka, Junji; Takaoka, Munenori</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">5916-5923</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">1007-9327</span>.
    
            (<span class="NLM_cas:orgname">WJG Press and Beijing Baishideng BioMed Scientific Co., Ltd.</span>)
        </div><div class="casAbstract">A review.  Focal adhesion kinase (FAK) is a 125-kDa non-receptor protein tyrosine.  Growth factors or the clustering of integrins facilitate the rapid phosphorylation of FAK at Tyr-397 and this in turn recruits Src-family protein tyrosine kinases, resulting in the phosphorylation of Tyr-576 and Tyr-577 in the FAK activation loop and full catalytic FAK activation.  FAK plays a crit. role in the biol. processes of normal and cancer cells including the gastrointestinal tract.  FAK also plays an important role in the restitution, cell survival and apoptosis and carcinogenesis of the gastrointestinal tract.  FAK is overexpressed in cancer cells and its over-expression and elevated activities are assocd. with motility and invasion of cancer cells.  FAK has been proposed as a potential target in cancer therapy.  Small mol. inhibitors effectively inhibit the kinase activity of FAK and show a potent inhibitory effect for the proliferation and migration of tumor cells, indicating a high potential for application in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8-4ghHmavELVg90H21EOLACvtfcHk0lg9VbajOXcDjw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFyrur3L&md5=1cf31a97462bbccac352c68eab1bf0ed</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.3748%2Fwjg.15.5916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.15.5916%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DH.%2BF.%26aulast%3DNaomoto%26aufirst%3DY.%26aulast%3DBao%26aufirst%3DX.%2BH.%26aulast%3DWatanabe%26aufirst%3DN.%26aulast%3DSakurama%26aufirst%3DK.%26aulast%3DNoma%26aufirst%3DK.%26aulast%3DTomono%26aufirst%3DY.%26aulast%3DFukazawa%26aufirst%3DT.%26aulast%3DShirakawa%26aufirst%3DY.%26aulast%3DYamatsuji%26aufirst%3DT.%26aulast%3DMatsuoka%26aufirst%3DJ.%26aulast%3DTakaoka%26aufirst%3DM.%26atitle%3DProgress%2520in%2520researches%2520about%2520focal%2520adhesion%2520kinase%2520in%2520gastrointestinal%2520tract%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2009%26volume%3D15%26spage%3D5916%26epage%3D5923%26doi%3D10.3748%2Fwjg.15.5916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomioka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatakeyama, S.</span></span> <span> </span><span class="NLM_article-title">Pharmacological profiling of a dual FAK/IGF-1R kinase inhibitor TAE226 in cellular and in vivo tumor models</span>. <i>BMC Res. Notes</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">347</span>â <span class="NLM_lpage">353</span>, <span class="refDoi">Â DOI: 10.1186/s13104-019-4389-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1186%2Fs13104-019-4389-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=31215459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1CqtbrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=347-353&author=S.+Fukamiauthor=D.+Tomiokaauthor=Y.+Murakamiauthor=T.+Hondaauthor=S.+Hatakeyama&title=Pharmacological+profiling+of+a+dual+FAK%2FIGF-1R+kinase+inhibitor+TAE226+in+cellular+and+in+vivo+tumor+models&doi=10.1186%2Fs13104-019-4389-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological profiling of a dual fak/igf-1r kinase inhibitor tae226 in cellular and in vivo tumor models</span></div><div class="casAuthors">Fukami, Shigemi; Tomioka, Daisaku; Murakami, Yutaka; Honda, Toshiyuki; Hatakeyama, Shinji</div><div class="citationInfo"><span class="NLM_cas:title">BMC Research Notes</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">347</span>CODEN:
                <span class="NLM_cas:coden">BRNMAT</span>;
        ISSN:<span class="NLM_cas:issn">1756-0500</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A dual inhibitor of focal adhesion kinase (FAK) and insulin-like growth factor 1 receptor (IGF-1R), TAE226, was evaluated in a panel of cancer cell lines, MIA PaCa-2 human pancreatic tumor and 4T1 murine breast tumor models.  The profiling data were generated during the drug discovery research prior to the first publication of TAE226 appeared in 2007.  In a panel of 37 cancer cell lines, TAE226 showed a mean GI50 value of 0.76Î¼mol/L.  In the MIA PaCa-2 model, TAE226 inhibited phosphorylation of Y397-FAK and phosphorylation of S473-Akt as IGF-1R signaling in the cell culture in vitro and the tumor in mice.  Oral administration of TAE226 induced tumor stasis at 30 mg/kg and tumor regression at 100 mg/kg in the s.c. tumor, and inhibited the orthotopic tumor growth in a dose-dependent manner.  Similarly in the 4T1 model, TAE226 inhibited phosphorylation of Y397-FAK and S473-Akt in the cell culture in vitro and the tumor in mice.  Oral administration of TAE226 inhibited the orthotopic tumor growth and metastasis to the lung in a dose-dependent manner.  Thus, TAE226 represents a novel class of selective and small mol. kinase inhibitor with a potent in vivo activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5SgxwAozCN7Vg90H21EOLACvtfcHk0lg9VbajOXcDjw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1CqtbrL&md5=765476c3eba803257e56d29995953397</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1186%2Fs13104-019-4389-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13104-019-4389-7%26sid%3Dliteratum%253Aachs%26aulast%3DFukami%26aufirst%3DS.%26aulast%3DTomioka%26aufirst%3DD.%26aulast%3DMurakami%26aufirst%3DY.%26aulast%3DHonda%26aufirst%3DT.%26aulast%3DHatakeyama%26aufirst%3DS.%26atitle%3DPharmacological%2520profiling%2520of%2520a%2520dual%2520FAK%252FIGF-1R%2520kinase%2520inhibitor%2520TAE226%2520in%2520cellular%2520and%2520in%2520vivo%2520tumor%2520models%26jtitle%3DBMC%2520Res.%2520Notes%26date%3D2019%26volume%3D12%26spage%3D347%26epage%3D353%26doi%3D10.1186%2Fs13104-019-4389-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tai, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, T. L.</span></span> <span> </span><span class="NLM_article-title">Emerging roles of focal adhesion kinase in cancer</span>. <i>BioMed Res. Int.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">13</span>, <span class="refDoi">Â DOI: 10.1155/2015/690690</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1155%2F2015%2F690690" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=1-13&author=Y.+L.+Taiauthor=L.+C.+Chenauthor=T.+L.+Shen&title=Emerging+roles+of+focal+adhesion+kinase+in+cancer&doi=10.1155%2F2015%2F690690"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1155%2F2015%2F690690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F690690%26sid%3Dliteratum%253Aachs%26aulast%3DTai%26aufirst%3DY.%2BL.%26aulast%3DChen%26aufirst%3DL.%2BC.%26aulast%3DShen%26aufirst%3DT.%2BL.%26atitle%3DEmerging%2520roles%2520of%2520focal%2520adhesion%2520kinase%2520in%2520cancer%26jtitle%3DBioMed%2520Res.%2520Int.%26date%3D2015%26volume%3D2015%26spage%3D1%26epage%3D13%26doi%3D10.1155%2F2015%2F690690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hjelmeland, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keir, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohmori, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigner, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, J. N.</span></span> <span> </span><span class="NLM_article-title">A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth</span>. <i>Mol. Carcinog.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">488</span>â <span class="NLM_lpage">496</span>, <span class="refDoi">Â DOI: 10.1002/mc.20297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1002%2Fmc.20297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=17219439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2sXms1Olsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=488-496&author=Q.+Shiauthor=A.+B.+Hjelmelandauthor=S.+T.+Keirauthor=L.+Songauthor=S.+Wickmanauthor=D.+Jacksonauthor=O.+Ohmoriauthor=D.+D.+Bignerauthor=H.+S.+Friedmanauthor=J.+N.+Rich&title=A+novel+low-molecular+weight+inhibitor+of+focal+adhesion+kinase%2C+TAE226%2C+inhibits+glioma+growth&doi=10.1002%2Fmc.20297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth</span></div><div class="casAuthors">Shi, Qing; Hjelmeland, Anita B.; Keir, Stephen T.; Song, Linhua; Wickman, Sarah; Jackson, Dowdy; Ohmori, Osamu; Bigner, Darell D.; Friedman, Henry S.; Rich, Jeremy N.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Carcinogenesis</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">488-496</span>CODEN:
                <span class="NLM_cas:coden">MOCAE8</span>;
        ISSN:<span class="NLM_cas:issn">0899-1987</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Glioblastomas are highly lethal cancers that resist current therapies.  Novel therapies under development target mol. mechanisms that promote glioblastoma growth.  In glioblastoma patient specimens, the non-receptor tyrosine kinase focal adhesion kinase (FAK) is overexpressed.  Upon growth factor receptor stimulation or integrin engagement, FAK is activated by phosphorylation on crit. tyrosine residues.  Activated FAK initiates a signal transduction cascade which promotes glioma growth and invasion by increasing cellular adhesion, migration, invasion, and proliferation.  We find that human glioma cell lines express different levels of total FAK protein and activating phosphorylation of tyrosine residues Tyr397, Tyr861, and Tyr925.  As all glioma cell lines examd. expressed phosphorylated FAK, we examd. the efficacy of a novel low-mol. wt. inhibitor of FAK, TAE226, against human glioma cell lines.  TAE226 inhibited the phosphorylation of FAK as well as the downstream effectors AKT, extracellular signal-related kinase, and S6 ribosomal protein in multiple glioma cell lines.  TAE226 induced a concn.-dependent decrease in cellular proliferation with an assocd. G2 cell cycle arrest in every cell line and an increase in apoptosis in a cell-line-specific manner.  TAE226 also decreased glioma cell adhesion, migration, and invasion through an artificial extracellular matrix.  Together, these data demonstrate the potential benefit of TAE226 for glioma therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXL0wEDuHo9bVg90H21EOLACvtfcHk0lhcxQKm9g8wjw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXms1Olsrg%253D&md5=83711a44fe2472eae4baf568ee4332a4</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1002%2Fmc.20297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmc.20297%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DHjelmeland%26aufirst%3DA.%2BB.%26aulast%3DKeir%26aufirst%3DS.%2BT.%26aulast%3DSong%26aufirst%3DL.%26aulast%3DWickman%26aufirst%3DS.%26aulast%3DJackson%26aufirst%3DD.%26aulast%3DOhmori%26aufirst%3DO.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26aulast%3DFriedman%26aufirst%3DH.%2BS.%26aulast%3DRich%26aufirst%3DJ.%2BN.%26atitle%3DA%2520novel%2520low-molecular%2520weight%2520inhibitor%2520of%2520focal%2520adhesion%2520kinase%252C%2520TAE226%252C%2520inhibits%2520glioma%2520growth%26jtitle%3DMol.%2520Carcinog.%26date%3D2007%26volume%3D46%26spage%3D488%26epage%3D496%26doi%3D10.1002%2Fmc.20297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFortune, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohmori, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatakeyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Groot, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yung, W. K.</span></span> <span> </span><span class="NLM_article-title">Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1357</span>â <span class="NLM_lpage">1367</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-06-0476</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1158%2F1535-7163.MCT-06-0476" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=17431114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktFams7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=1357-1367&author=T.+J.+Liuauthor=T.+LaFortuneauthor=T.+Hondaauthor=O.+Ohmoriauthor=S.+Hatakeyamaauthor=T.+Meyerauthor=D.+Jacksonauthor=J.+de+Grootauthor=W.+K.+Yung&title=Inhibition+of+both+focal+adhesion+kinase+and+insulin-like+growth+factor-I+receptor+kinase+suppresses+glioma+proliferation+in+vitro+and+in+vivo&doi=10.1158%2F1535-7163.MCT-06-0476"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo</span></div><div class="casAuthors">Liu, Ta-Jen; LaFortune, Tiffany; Honda, Toshiyuki; Ohmori, Osamu; Hatakeyama, Shinji; Meyer, Thomas; Jackson, Dowdy; de Groot, John; Yung, W. K. Alfred</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1357-1367</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Multiple genetic aberrations in human gliomas contribute to their highly infiltrative and rapid growth characteristics.  Focal adhesion kinase (FAK) regulates tumor migration and invasion.  Insulin-like growth factor-I receptor (IGF-IR), whose expression correlates with tumor grade, is involved in proliferation and survival.  We hypothesized that inhibiting the phosphorylation of FAK and IGF-IR by NVP-TAE226 (hereafter called TAE226), a novel dual tyrosine kinase inhibitor of FAK and IGF-IR, would suppress the growth and invasion of glioma cells.  In culture, TAE226 inhibited extracellular matrix-induced autophosphorylation of FAK (Tyr397).  TAE226 also inhibited IGF-I-induced phosphorylation of IGF-IR and activity of its downstream target genes such as MAPK and Akt.  TAE226 retarded tumor cell growth as assessed by a cell viability assay and attenuated G2-M cell cycle progression assocd. with a decrease in cyclin B1 and phosphorylated cdc2 (Tyr15) protein expression.  TAE226 treatment inhibited tumor cell invasion by at least 50% compared with the control in an in vitro Matrigel invasion assay.  Interestingly, TAE226 treatment of tumor cells contg. wild-type p53 mainly exhibited G2-M arrest, whereas tumor cells bearing mutant p53 underwent apoptosis.  Induction of apoptosis by TAE226 was substantiated by detection of caspase-3/7 activation and poly(ADP-ribose) polymerase cleavage and by an Annexin V apoptosis assay.  More importantly, TAE226 treatment significantly increased the survival rate of animals in an intracranial glioma xenograft model.  Collectively, these data show that blocking the signaling pathways of FAK and IGF-IR with TAE226 has the potential to be an efficacious treatment for human gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQMIquqcQABrVg90H21EOLACvtfcHk0lhcxQKm9g8wjw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktFams7o%253D&md5=1659c50e987e8bbb24c998e0aae14861</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0476%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DT.%2BJ.%26aulast%3DLaFortune%26aufirst%3DT.%26aulast%3DHonda%26aufirst%3DT.%26aulast%3DOhmori%26aufirst%3DO.%26aulast%3DHatakeyama%26aufirst%3DS.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DJackson%26aufirst%3DD.%26aulast%3Dde%2BGroot%26aufirst%3DJ.%26aulast%3DYung%26aufirst%3DW.%2BK.%26atitle%3DInhibition%2520of%2520both%2520focal%2520adhesion%2520kinase%2520and%2520insulin-like%2520growth%2520factor-I%2520receptor%2520kinase%2520suppresses%2520glioma%2520proliferation%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D1357%26epage%3D1367%26doi%3D10.1158%2F1535-7163.MCT-06-0476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schultze, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiedler, W.</span></span> <span> </span><span class="NLM_article-title">Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">593</span>â <span class="NLM_lpage">599</span>, <span class="refDoi">Â DOI: 10.2174/187152011796817727</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.2174%2F187152011796817727" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=21787277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Gns7%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=593-599&author=A.+Schultzeauthor=W.+Fiedler&title=Clinical+importance+and+potential+use+of+small+molecule+inhibitors+of+focal+adhesion+kinase&doi=10.2174%2F187152011796817727"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase</span></div><div class="casAuthors">Schultze, Alexander; Fiedler, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">593-599</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Since its first description Focal Adhesion Kinase (FAK), a cytoplasmic tyrosine kinase, was implicated in the formation and progression of solid and liq. malignant tumors.  Therefore orally available selective small mol. inhibitors of FAK were developed, 3 of them (PF-562-271, PF-04554878 and GSK2256098) are already in clin. testing.  This review discusses the recent data obtained from these Phase 1 trials.  We also discuss available data on the mechanisms of action of these inhibitors in carcinogenesis and demonstrate that FAK plays an important role in neoangiogenesis which is a crucial step in cancer growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGvtUUThNxpbVg90H21EOLACvtfcHk0lhcxQKm9g8wjw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Gns7%252FM&md5=4754e8e948523f8c1e1fcc2dfc239123</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.2174%2F187152011796817727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152011796817727%26sid%3Dliteratum%253Aachs%26aulast%3DSchultze%26aufirst%3DA.%26aulast%3DFiedler%26aufirst%3DW.%26atitle%3DClinical%2520importance%2520and%2520potential%2520use%2520of%2520small%2520molecule%2520inhibitors%2520of%2520focal%2520adhesion%2520kinase%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D593%26epage%3D599%26doi%3D10.2174%2F187152011796817727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lietha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of the FAK kinase in complex with TAE226 and related bis-anilino pyrimidine inhibitors reveal a helical DFG conformation</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">e3800</span> <span class="refDoi">Â DOI: 10.1371/journal.pone.0003800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1371%2Fjournal.pone.0003800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=19030106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BD1cjmtF2muw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&author=D.+Liethaauthor=M.+J.+Eck&title=Crystal+structures+of+the+FAK+kinase+in+complex+with+TAE226+and+related+bis-anilino+pyrimidine+inhibitors+reveal+a+helical+DFG+conformation&doi=10.1371%2Fjournal.pone.0003800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the FAK kinase in complex with TAE226 and related bis-anilino pyrimidine inhibitors reveal a helical DFG conformation</span></div><div class="casAuthors">Lietha Daniel; Eck Michael J</div><div class="citationInfo"><span class="NLM_cas:title">PloS one</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e3800</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Focal Adhesion Kinase (FAK) is a non-receptor tyrosine kinase required for cell migration, proliferation and survival.  FAK overexpression has been documented in diverse human cancers and is associated with a poor clinical outcome.  Recently, a novel bis-anilino pyrimidine inhibitor, TAE226, was reported to efficiently inhibit FAK signaling, arrest tumor growth and invasion and prolong the life of mice with glioma or ovarian tumor implants.  Here we describe the crystal structures of the FAK kinase bound to TAE226 and three related bis-anilino pyrimidine compounds.  TAE226 induces a conformation of the N-terminal portion of the kinase activation loop that is only observed in FAK, but is distinct from the conformation in both the active and inactive states of the kinase.  This conformation appears to require a glycine immediately N-terminal to the "DFG motif", which adopts a helical conformation stabilized by interactions with TAE226.  The presence of a glycine residue in this position contributes to the specificity of TAE226 and related compounds for FAK.  Our work highlights the fact that kinases can access conformational space that is not necessarily utilized for their native catalytic regulation, and that such conformations can explain and be exploited for inhibitor specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQsjpXJZjhGaWZyxfu64m4ffW6udTcc2eYTlGOMJ40WErntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cjmtF2muw%253D%253D&md5=60c1f8e0ae9da7c5b6f638afdff195e1</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0003800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0003800%26sid%3Dliteratum%253Aachs%26aulast%3DLietha%26aufirst%3DD.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DCrystal%2520structures%2520of%2520the%2520FAK%2520kinase%2520in%2520complex%2520with%2520TAE226%2520and%2520related%2520bis-anilino%2520pyrimidine%2520inhibitors%2520reveal%2520a%2520helical%2520DFG%2520conformation%26jtitle%3DPLoS%2520One%26date%3D2008%26volume%3D3%26doi%3D10.1371%2Fjournal.pone.0003800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span> <span> </span><span class="NLM_article-title">Structure-based modification of carbonyl-diphenylpyrimidines (Car-DPPYs) as a novel focal adhesion kinase (FAK) inhibitor against various stubborn cancer cells</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">154</span>â <span class="NLM_lpage">162</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2019.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.ejmech.2019.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=30978560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnsVSgtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2019&pages=154-162&author=L.+Wangauthor=M.+Aiauthor=J.+Yuauthor=L.+Jinauthor=C.+Wangauthor=Z.+Liuauthor=X.+Shuauthor=Z.+Tangauthor=K.+Liuauthor=H.+Luoauthor=W.+Guanauthor=X.+Sunauthor=X.+Ma&title=Structure-based+modification+of+carbonyl-diphenylpyrimidines+%28Car-DPPYs%29+as+a+novel+focal+adhesion+kinase+%28FAK%29+inhibitor+against+various+stubborn+cancer+cells&doi=10.1016%2Fj.ejmech.2019.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based modification of carbonyl-diphenylpyrimidines (Car-DPPYs) as a novel focal adhesion kinase (FAK) inhibitor against various stubborn cancer cells</span></div><div class="casAuthors">Wang, Luhong; Ai, Min; Yu, Jiawen; Jin, Lingling; Wang, Changyuan; Liu, Zhihao; Shu, Xiaohong; Tang, Zeyao; Liu, Kexin; Luo, Hui; Guan, Wenshun; Sun, Xiuli; Ma, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">154-162</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A family of carbonyl-substituted diphenylpyrimidine derivs. (Car-DPPYs) with strong activity against focal adhesion kinase (FAK), were described in this manuscript.  Among them, compds. 7a(I) (IC50 = 5.17 nM) and 7f(II) (IC50 = 2.58 nM) displayed equal anti-FAK enzymic activity to the lead compd. TAE226 (6.79 nM).  In particular, I also exhibited strong antiproliferative activity against several stubborn cancer cells, including AsPC-1 cells (IC50 = 0.105 Î¼M), BxPC-3 cells (IC50 = 0.090 Î¼M), and MCF-7/ADR cells (IC50 = 0.59 Î¼M).  Addnl., I also showed great antitumor efficacy in vivo via aAsPC-1 cancer Xenograft mouse model.  The preliminary mechanism study by Western blot anal. revealed that I repressed FAK phosphorylation in AsPC cancer cells.  Taken together, the results indicate that I may serve as a promising preclin. candidate for treatment of stubborn cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3jTLS3BSpz7Vg90H21EOLACvtfcHk0lhxoAmY7Bk-VQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnsVSgtbg%253D&md5=1e37d0d16bf3d6c86238ff2bcde12259</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DAi%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DShu%26aufirst%3DX.%26aulast%3DTang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DLuo%26aufirst%3DH.%26aulast%3DGuan%26aufirst%3DW.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DX.%26atitle%3DStructure-based%2520modification%2520of%2520carbonyl-diphenylpyrimidines%2520%2528Car-DPPYs%2529%2520as%2520a%2520novel%2520focal%2520adhesion%2520kinase%2520%2528FAK%2529%2520inhibitor%2520against%2520various%2520stubborn%2520cancer%2520cells%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D172%26spage%3D154%26epage%3D162%26doi%3D10.1016%2Fj.ejmech.2019.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Claudio
Viegas-Junior</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eliezer J. Barreiro</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlos Alberto Manssour Fraga</span></span> <span> </span><span class="NLM_article-title">Molecular hybridization: a useful tool in the design of new drug prototypes</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1829</span>â <span class="NLM_lpage">1852</span>, <span class="refDoi">Â DOI: 10.2174/092986707781058805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.2174%2F092986707781058805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=17627520" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=1829-1852&author=+Claudio%0AViegas-Juniorauthor=+Eliezer+J.+Barreiroauthor=+Carlos+Alberto+Manssour+Fraga&title=Molecular+hybridization%3A+a+useful+tool+in+the+design+of+new+drug+prototypes&doi=10.2174%2F092986707781058805"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.2174%2F092986707781058805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986707781058805%26sid%3Dliteratum%253Aachs%26aulast%3DClaudio%2BViegas-Junior%26aulast%3DEliezer%2BJ.%2BBarreiro%26aulast%3DCarlos%2BAlberto%2BManssour%2BFraga%26atitle%3DMolecular%2520hybridization%253A%2520a%2520useful%2520tool%2520in%2520the%2520design%2520of%2520new%2520drug%2520prototypes%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2007%26volume%3D14%26spage%3D1829%26epage%3D1852%26doi%3D10.2174%2F092986707781058805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.-F.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antitumor activity of novel dithiocarbamate substituted chromones</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">3687</span>â <span class="NLM_lpage">3696</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2009.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.ejmech.2009.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=19410339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1MXoslGhs7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2009&pages=3687-3696&author=W.+Huangauthor=Y.+Dingauthor=Y.+Miaoauthor=M.-Z.+Liuauthor=Y.+Liauthor=G.-F.+Yang&title=Synthesis+and+antitumor+activity+of+novel+dithiocarbamate+substituted+chromones&doi=10.1016%2Fj.ejmech.2009.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antitumor activity of novel dithiocarbamate substituted chromones</span></div><div class="casAuthors">Huang, Wei; Ding, Yu; Miao, Yan; Liu, Ming-Zhen; Li, Yan; Yang, Guang-Fu</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3687-3696</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of chromone derivs. bearing diverse dithiocarbamate moieties were designed and synthesized via a three-component reaction protocol.  Their in vitro antitumor activities were evaluated by MTT method against HCCLM-7, Hela, MDA-MB-435S, SW-480, Hep-2 and MCF-7.  Compds. I and II were identified as the most promising candidates due to their high potency and broad-spectrum.  Further flow-activated cell sorting anal. revealed that compds. I and II arrested the cell cycle of SW-480 and MDA-MB-435s, both in G2/M phase, with dose-dependent effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppumNJLdfY_LVg90H21EOLACvtfcHk0lhxoAmY7Bk-VQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXoslGhs7o%253D&md5=1db9d61a1eaca2a40e3b72fa9f15bd5c</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2009.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2009.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DMiao%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DM.-Z.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DG.-F.%26atitle%3DSynthesis%2520and%2520antitumor%2520activity%2520of%2520novel%2520dithiocarbamate%2520substituted%2520chromones%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2009%26volume%3D44%26spage%3D3687%26epage%3D3696%26doi%3D10.1016%2Fj.ejmech.2009.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R. T.</span></span> <span> </span><span class="NLM_article-title">Novel EGFR inhibitors prepared by combination of dithiocarbamic acid esters and 4-anilinoquinazolines</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3637</span>â <span class="NLM_lpage">3640</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2011.04.096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmcl.2011.04.096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=21570843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntFKhs7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=3637-3640&author=R.+D.+Liauthor=X.+Zhangauthor=Q.+Y.+Liauthor=Z.+M.+Geauthor=R.+T.+Li&title=Novel+EGFR+inhibitors+prepared+by+combination+of+dithiocarbamic+acid+esters+and+4-anilinoquinazolines&doi=10.1016%2Fj.bmcl.2011.04.096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Novel EGFR inhibitors prepared by combination of dithiocarbamic acid esters and 4-anilinoquinazolines</span></div><div class="casAuthors">Li, Ri-Dong; Zhang, Xin; Li, Qiao-Yan; Ge, Ze-Mei; Li, Run-Tao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3637-3640</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">On the basis of combination strategy, a novel series of EGFR inhibitors were designed and synthesized by combination of dithiocarbamic acid esters and 4-anilinoquinazolines.  The effect of the synthesized compds. on cell proliferation was evaluated by MTT assay in three human cancer cell lines: MDA-MB-468, SK-BR-3 and HCT-116.  Some compds. were found more potent against all three cell lines and other compds. were found more potent against both MDA-MB-468 and SK-BR-3 than Lapatinib.  SAR studies revealed that the substituents on C6 and C7 positions of quinazoline, the amine component of dithiocarbamate moiety and the linker greatly affected the activity.  This work provides a promising new strategy for the prepn. of potent tyrosine kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo92wKhvesdvrVg90H21EOLACvtfcHk0lizMHhOEo9Q3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntFKhs7s%253D&md5=e76bffa5c3d8b62e357442dfcf74686c</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.04.096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.04.096%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DR.%2BD.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DQ.%2BY.%26aulast%3DGe%26aufirst%3DZ.%2BM.%26aulast%3DLi%26aufirst%3DR.%2BT.%26atitle%3DNovel%2520EGFR%2520inhibitors%2520prepared%2520by%2520combination%2520of%2520dithiocarbamic%2520acid%2520esters%2520and%25204-anilinoquinazolines%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D3637%26epage%3D3640%26doi%3D10.1016%2Fj.bmcl.2011.04.096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kamal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sathish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayak, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasulu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavitha, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tangella, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thummuri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagul, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shankaraiah, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagesh, N.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of dithiocarbamate linked beta-carboline derivatives: DNA topoisomerase II inhibition with DNA binding and apoptosis inducing ability</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5511</span>â <span class="NLM_lpage">5526</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2015.07.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmc.2015.07.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=26264845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1CrtLrJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=5511-5526&author=A.+Kamalauthor=M.+Sathishauthor=V.+L.+Nayakauthor=V.+Srinivasuluauthor=B.+Kavithaauthor=Y.+Tangellaauthor=D.+Thummuriauthor=C.+Bagulauthor=N.+Shankaraiahauthor=N.+Nagesh&title=Design+and+synthesis+of+dithiocarbamate+linked+beta-carboline+derivatives%3A+DNA+topoisomerase+II+inhibition+with+DNA+binding+and+apoptosis+inducing+ability&doi=10.1016%2Fj.bmc.2015.07.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of dithiocarbamate linked Î²-carboline derivatives: DNA topoisomerase II inhibition with DNA binding and apoptosis inducing ability</span></div><div class="casAuthors">Kamal, Ahmed; Sathish, Manda; Nayak, V. Lakshma; Srinivasulu, Vunnam; Kavitha, Botla; Tangella, Yellaiah; Thummuri, Dinesh; Bagul, Chandrakant; Shankaraiah, Nagula; Nagesh, Narayana</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5511-5526</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of new Î²-carboline-dithiocarbamate derivs. bearing Ph, dithiocarbamate and H/methyl substitutions at position-1, 3 and 9, resp., were designed and synthesized.  These derivs. 8a-l and 13a-l and their starting precursors (7a-d and 12a-d) have been evaluated for their in vitro cytotoxic activity on selected human cancer cell lines.  Among the derivs. tested, 7c, 12c, 8a, 8d, 8i, 8j, 8k, 8l and 13d-l exhibited considerable cytotoxicity against most of the tested cancer cell lines (IC50 <10 Î¼M).  Interestingly, most of the derivs. (8a-l and 13a-l) exhibited enhanced activity than their precursors (7a-d and 12a-d), which indicates that the combination of dithiocarbamate with Î²-carboline enhances the cytotoxicity of 8a-l and 13a-l.  Moreover, the derivs. 8j and 13g exhibited significant cytotoxic activity with IC50 values of 1.34 Î¼M and 0.79 Î¼M on DU-145 cancer cells, resp.  Further, the induction of apoptosis by these derivs. was confirmed by Annexin V-FITC and Hoechst staining assays.  However, both biophys. as well as mol. docking studies suggested a combilexin-type of interaction between these derivs. and DNA, unlike simple Î²-carbolines.  With a view to understand their mechanism of action, DNA topoisomerase II (topo II) inhibition assay was also performed.  Overall, the present study emphasizes the importance of linking a dithiocarbamate moiety to the Î²-carboline scaffold for exhibiting profound activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2JbzggrG7v7Vg90H21EOLACvtfcHk0lizMHhOEo9Q3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1CrtLrJ&md5=8b85c9edc23342973d0ee6b5aa08cd5c</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.07.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.07.037%26sid%3Dliteratum%253Aachs%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DSathish%26aufirst%3DM.%26aulast%3DNayak%26aufirst%3DV.%2BL.%26aulast%3DSrinivasulu%26aufirst%3DV.%26aulast%3DKavitha%26aufirst%3DB.%26aulast%3DTangella%26aufirst%3DY.%26aulast%3DThummuri%26aufirst%3DD.%26aulast%3DBagul%26aufirst%3DC.%26aulast%3DShankaraiah%26aufirst%3DN.%26aulast%3DNagesh%26aufirst%3DN.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520dithiocarbamate%2520linked%2520beta-carboline%2520derivatives%253A%2520DNA%2520topoisomerase%2520II%2520inhibition%2520with%2520DNA%2520binding%2520and%2520apoptosis%2520inducing%2520ability%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D5511%26epage%3D5526%26doi%3D10.1016%2Fj.bmc.2015.07.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Y.</span></span> <span> </span><span class="NLM_article-title">New pyridin-3-ylmethyl carbamodithioic esters activate pyruvate kinase M2 and potential anticancer lead compounds</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4815</span>â <span class="NLM_lpage">4823</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2015.05.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmc.2015.05.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=26081759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFaqsLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=4815-4823&author=Y.+Zhangauthor=B.+Liuauthor=X.+Wuauthor=R.+Liauthor=X.+Ningauthor=Y.+Liuauthor=Z.+Liuauthor=Z.+Geauthor=R.+Liauthor=Y.+Yin&title=New+pyridin-3-ylmethyl+carbamodithioic+esters+activate+pyruvate+kinase+M2+and+potential+anticancer+lead+compounds&doi=10.1016%2Fj.bmc.2015.05.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">New pyridin-3-ylmethyl carbamodithioic esters activate pyruvate kinase M2 and potential anticancer lead compounds</span></div><div class="casAuthors">Zhang, Yu; Liu, Bin; Wu, Xingyu; Li, Ridong; Ning, Xianling; Liu, Yu; Liu, Zhenming; Ge, Zemei; Li, Runtao; Yin, Yuxin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4815-4823</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pyruvate kinase M2 (PKM2) is a key protein responsible for cancer's Warburg effect.  Activation of PKM2 may alter aberrant metab. in cancer cells, which suggests PKM2 as a tumor selective therapeutic target.  In this paper, the lead compd. 8 was first discovered as a new kind of PKM2 activator from a random screening of an inhouse compd. library.  Then, a series of lead compd. 8 analogs were designed, synthesized and evaluated for their activation of PKM2 and anticancer activities. 7-Azaindole analog 32 was identified as the most potent PKM2 activator.  Compds. with potent enzyme activity also exhibited selective anti-proliferation activity on cancer cell lines HCT116, Hela and H1299 compared with non-tumor cell line BEAS-2B.  The structure-activity relationships of these compds. were supported by mol. docking results.  Preliminary pharmacol. studies also showed that compd. 32 arrests the cell cycle at the G2/M phase in HCT116 cell line.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwdPOEDQGPNbVg90H21EOLACvtfcHk0lizMHhOEo9Q3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFaqsLc%253D&md5=bc3875399546250b821599b369a12804</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.05.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.05.041%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DNing%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DGe%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DYin%26aufirst%3DY.%26atitle%3DNew%2520pyridin-3-ylmethyl%2520carbamodithioic%2520esters%2520activate%2520pyruvate%2520kinase%2520M2%2520and%2520potential%2520anticancer%2520lead%2520compounds%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D4815%26epage%3D4823%26doi%3D10.1016%2Fj.bmc.2015.05.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. Q.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological activities of dithiocarbamates containing 2(5H)-furanone-piperazine</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">165</span>â <span class="NLM_lpage">170</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2018.05.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.ejmech.2018.05.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=29886320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFWisL%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2018&pages=165-170&author=M.+X.+Weiauthor=J.+Zhangauthor=F.+L.+Maauthor=M.+Liauthor=J.+Y.+Yuauthor=W.+Luoauthor=X.+Q.+Li&title=Synthesis+and+biological+activities+of+dithiocarbamates+containing+2%285H%29-furanone-piperazine&doi=10.1016%2Fj.ejmech.2018.05.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological activities of dithiocarbamates containing 2(5H)-furanone-piperazine</span></div><div class="casAuthors">Wei, Meng-Xue; Zhang, Jiao; Ma, Fu-Li; Li, Ming; Yu, Jia-Ying; Luo, Wei; Li, Xue-Qiang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">165-170</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of new dithiocarbamates contg. a 2(5H)-furanone-piperazine group was synthesized.  These compds. show good in vitro cytotoxic activity.  Among them, compd. I exhibits the best inhibitory activity against HeLa cell lines with an IC50 of 0.06 Â± 0.01 Î¼M for 72 h, and it has good inhibitory activity against SMMC-7721 cell lines with an IC50 of 0.006 Â± 0.04 Î¼M for 72 h, but the toxicity was lower against LO2 cell lines with an IC50 of 45.76 Â± 0.01 Î¼M.  The result showed that compd. I is far more cytotoxic towards cancer cell lines than towards benign cell lines compared with cytosine arabinoside (ARA) in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoadcy_kDbuX7Vg90H21EOLACvtfcHk0lhPTyKRSwmD9g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFWisL%252FE&md5=947bfa4da48d898730c96224996dc570</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.05.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.05.056%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DM.%2BX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DF.%2BL.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DJ.%2BY.%26aulast%3DLuo%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DX.%2BQ.%26atitle%3DSynthesis%2520and%2520biological%2520activities%2520of%2520dithiocarbamates%2520containing%25202%25285H%2529-furanone-piperazine%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D155%26spage%3D165%26epage%3D170%26doi%3D10.1016%2Fj.ejmech.2018.05.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>177</i></span>,  <span class="NLM_fpage">32</span>â <span class="NLM_lpage">46</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2019.05.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.ejmech.2019.05.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=31129452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVKqtbnP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2019&pages=32-46&author=Y.+Suauthor=R.+Liauthor=X.+Ningauthor=Z.+Linauthor=X.+Zhaoauthor=J.+Zhouauthor=J.+Liuauthor=Y.+Jinauthor=Y.+Yin&title=Discovery+of+2%2C4-diarylaminopyrimidine+derivatives+bearing+dithiocarbamate+moiety+as+novel+FAK+inhibitors+with+antitumor+and+anti-angiogenesis+activities&doi=10.1016%2Fj.ejmech.2019.05.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities</span></div><div class="casAuthors">Su, Yue; Li, Ridong; Ning, Xianling; Lin, Zhiqiang; Zhao, Xuyang; Zhou, Juntuo; Liu, Jia; Jin, Yan; Yin, Yuxin</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">32-46</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 2,4-diarylaminopyrimidine derivs. contg. dithiocarbamate moiety were designed by mol. hybridization strategy and synthesized for screening as inhibitors of focal adhesion kinase (FAK).  Most of these compds. exhibit significant antiproliferative activities on human cancer cell lines expressing high levels of FAK at nanomolar concns.  The compd. I was identified as the most potent FAK inhibitor among these candidates.  I has excellent anti-proliferative effect with IC50 values from 0.001 Î¼M to 0.06 Î¼M on HCT116, PC-3, U87-MG and MCF-7 cell lines and relatively less cytotoxicity to a nonmalignant cell line MCF-10A compared with MCF-7 cells (SI value > 10).  I also exhibits significant FAK inhibitory activity (IC50 = 0.07 nM).  In addn., compd. I causes cell cycle arrest at G2/M and prompted apoptosis in both HCT116 and MCF-7 cells in a dose-dependent manner.  Further studies show that compd. I inhibits migration of MCF-7 and has anti-angiogenesis effect on HUVEC cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgwdZ9buP0o7Vg90H21EOLACvtfcHk0lhPTyKRSwmD9g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVKqtbnP&md5=2189190e90190c7a4c1eceef341f29fb</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.05.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.05.048%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DNing%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DYin%26aufirst%3DY.%26atitle%3DDiscovery%2520of%25202%252C4-diarylaminopyrimidine%2520derivatives%2520bearing%2520dithiocarbamate%2520moiety%2520as%2520novel%2520FAK%2520inhibitors%2520with%2520antitumor%2520and%2520anti-angiogenesis%2520activities%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D177%26spage%3D32%26epage%3D46%26doi%3D10.1016%2Fj.ejmech.2019.05.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huttunen, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rautio, J.</span></span> <span> </span><span class="NLM_article-title">Prodrugs - an efficient way to breach delivery and targeting barriers</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2265</span>â <span class="NLM_lpage">2287</span>, <span class="refDoi">Â DOI: 10.2174/156802611797183230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.2174%2F156802611797183230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=21671868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Omt7%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=2265-2287&author=K.+M.+Huttunenauthor=J.+Rautio&title=Prodrugs+-+an+efficient+way+to+breach+delivery+and+targeting+barriers&doi=10.2174%2F156802611797183230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs - an efficient way to breach delivery and targeting barriers</span></div><div class="casAuthors">Huttunen, Kristiina M.; Rautio, Jarkko</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2265-2287</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The study of prodrugs that are chem. modified bioreversible derivs. of active drug compds. to alter their undesired properties has been expanded widely during the last decades.  Despite the com. success the prodrugs have afforded, the concept is still quite unknown among many scientist.  Furthermore, many scientists regard prodrugs as a pure interest of academic research groups and not as a feasible soln. to improve the delivery or targeting properties of new chem. entities, drug candidates failed in clin. trials, or drugs withdrawn from the market.  Although there are still unmet needs that require addressing, prodrugs should be seen as fine-tuning tools for the successful drug research and development.  This review represents the potential of prodrugs to improve the drug delivery by enhanced aq. soly. or permeability as well as describes several targeted prodrug strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkj5wHsNs0rbVg90H21EOLACvtfcHk0lhPTyKRSwmD9g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Omt7%252FL&md5=9674c0c859bbc3b33dce4caac8e8add3</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.2174%2F156802611797183230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611797183230%26sid%3Dliteratum%253Aachs%26aulast%3DHuttunen%26aufirst%3DK.%2BM.%26aulast%3DRautio%26aufirst%3DJ.%26atitle%3DProdrugs%2520-%2520an%2520efficient%2520way%2520to%2520breach%2520delivery%2520and%2520targeting%2520barriers%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D2265%26epage%3D2287%26doi%3D10.2174%2F156802611797183230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kamiyama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabuchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kojima-Yuasa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsui-Yuasa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiratake, J.</span></span> <span> </span><span class="NLM_article-title">Phosphonate-based irreversible inhibitors of human gamma-glutamyl transpeptidase (GGT). GGsTop is a non-toxic and highly selective inhibitor with critical electrostatic interaction with an active-site residue Lys562 for enhanced inhibitory activity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">5340</span>â <span class="NLM_lpage">5352</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2016.08.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmc.2016.08.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=27622749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsV2rs7jO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=5340-5352&author=A.+Kamiyamaauthor=M.+Nakajimaauthor=L.+Hanauthor=K.+Wadaauthor=M.+Mizutaniauthor=Y.+Tabuchiauthor=A.+Kojima-Yuasaauthor=I.+Matsui-Yuasaauthor=H.+Suzukiauthor=K.+Fukuyamaauthor=B.+Watanabeauthor=J.+Hiratake&title=Phosphonate-based+irreversible+inhibitors+of+human+gamma-glutamyl+transpeptidase+%28GGT%29.+GGsTop+is+a+non-toxic+and+highly+selective+inhibitor+with+critical+electrostatic+interaction+with+an+active-site+residue+Lys562+for+enhanced+inhibitory+activity&doi=10.1016%2Fj.bmc.2016.08.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphonate-based irreversible inhibitors of human Î³-glutamyl transpeptidase (GGT). GGsTop is a non-toxic and highly selective inhibitor with critical electrostatic interaction with an active-site residue Lys562 for enhanced inhibitory activity</span></div><div class="casAuthors">Kamiyama, Akane; Nakajima, Mado; Han, Liyou; Wada, Kei; Mizutani, Masaharu; Tabuchi, Yukiko; Kojima-Yuasa, Akiko; Matsui-Yuasa, Isao; Suzuki, Hideyuki; Fukuyama, Keiichi; Watanabe, Bunta; Hiratake, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5340-5352</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Î³-Glutamyl transpeptidase (GGT, EC 2.3.2.2) that catalyzes the hydrolysis and transpeptidation of glutathione and its S-conjugates is involved in a no. of physiol. and pathol. processes through glutathione metab. and is an attractive pharmaceutical target.  We report here the evaluation of a phosphonate-based irreversible inhibitor, 2-amino-4-{[3-(carboxymethyl)phenoxy](methoyl)phosphoryl}butanoic acid (GGsTop) and its analogs as a mechanism-based inhibitor of human GGT.  GGsTop is a stable compd., but inactivated the human enzyme significantly faster than the other phosphonates, and importantly did not inhibit a glutamine amidotransferase.  The structure-activity relationships, X-ray crystallog. with Escherichia coli GGT, sequence alignment and site-directed mutagenesis of human GGT revealed a crit. electrostatic interaction between the terminal carboxylate of GGsTop and the active-site residue Lys562 of human GGT for potent inhibition.  GGsTop showed no cytotoxicity toward human fibroblasts and hepatic stellate cells up to 1 mM.  GGsTop serves as a non-toxic, selective and highly potent irreversible GGT inhibitor that could be used for various in vivo as well as in vitro biochem. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCZep_mhh5g7Vg90H21EOLACvtfcHk0lhCCyaWidStpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsV2rs7jO&md5=26bd230309dff2fabe956dd4ae99e71b</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.08.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.08.050%26sid%3Dliteratum%253Aachs%26aulast%3DKamiyama%26aufirst%3DA.%26aulast%3DNakajima%26aufirst%3DM.%26aulast%3DHan%26aufirst%3DL.%26aulast%3DWada%26aufirst%3DK.%26aulast%3DMizutani%26aufirst%3DM.%26aulast%3DTabuchi%26aufirst%3DY.%26aulast%3DKojima-Yuasa%26aufirst%3DA.%26aulast%3DMatsui-Yuasa%26aufirst%3DI.%26aulast%3DSuzuki%26aufirst%3DH.%26aulast%3DFukuyama%26aufirst%3DK.%26aulast%3DWatanabe%26aufirst%3DB.%26aulast%3DHiratake%26aufirst%3DJ.%26atitle%3DPhosphonate-based%2520irreversible%2520inhibitors%2520of%2520human%2520gamma-glutamyl%2520transpeptidase%2520%2528GGT%2529.%2520GGsTop%2520is%2520a%2520non-toxic%2520and%2520highly%2520selective%2520inhibitor%2520with%2520critical%2520electrostatic%2520interaction%2520with%2520an%2520active-site%2520residue%2520Lys562%2520for%2520enhanced%2520inhibitory%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D5340%26epage%3D5352%26doi%3D10.1016%2Fj.bmc.2016.08.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span> <span> </span><span class="NLM_article-title">Phosphamide-containing diphenylpyrimidine analogues (PA-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with enhanced activity against pancreatic cancer cell lines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">6313</span>â <span class="NLM_lpage">6321</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2017.09.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmc.2017.09.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=29102081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslagu7bE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=6313-6321&author=H.+Liuauthor=B.+Wuauthor=Y.+Geauthor=J.+Huangauthor=S.+Songauthor=C.+Wangauthor=J.+Yaoauthor=K.+Liuauthor=Y.+Liauthor=Y.+Liauthor=X.+Ma&title=Phosphamide-containing+diphenylpyrimidine+analogues+%28PA-DPPYs%29+as+potent+focal+adhesion+kinase+%28FAK%29+inhibitors+with+enhanced+activity+against+pancreatic+cancer+cell+lines&doi=10.1016%2Fj.bmc.2017.09.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphamide-containing diphenylpyrimidine analogues (PA-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with enhanced activity against pancreatic cancer cell lines</span></div><div class="casAuthors">Liu, He; Wu, Bin; Ge, Yang; Huang, Jiaxin; Song, Shijie; Wang, Changyuan; Yao, Jihong; Liu, Kexin; Li, Yanxia; Li, Yongming; Ma, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6313-6321</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A family of phosphamide-contg. diphenylpyrimidine analogs (PA-DPPYs) were synthesized as potent focal adhesion kinase (FAK) inhibitors.  The PA-DPPY derivs. could significantly inhibit the FAK enzymic activity at concns. lower than 10.69 nM.  Among them, compds. I and II were two of the most active FAK inhibitors, possessing IC50 values of 4.25 nM and 4.65 nM, resp.  In particular, compd. II also displayed strong activity against AsPC cell line, with an IC50 of 1.66 Î¼M, but show low activity against the normal HPDE6-C7 cells (IC50 > 20 Î¼M), indicating its low cell cytotoxicity.  Addnl., flow cytometry anal. showed that after treatment with II (8 Î¼M, 72 h), both AsPC and Panc cells growth were almost totally inhibited, with a cell viability rate of 16.8% and 18.1%, resp.  Overall, compd. II may be served as a valuable FAK inhibitor for the treatment of pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoChPrVzSD6obVg90H21EOLACvtfcHk0lhCCyaWidStpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslagu7bE&md5=d179a0922f2b04149aef12ba0c3e0272</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.09.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.09.041%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DGe%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DX.%26atitle%3DPhosphamide-containing%2520diphenylpyrimidine%2520analogues%2520%2528PA-DPPYs%2529%2520as%2520potent%2520focal%2520adhesion%2520kinase%2520%2528FAK%2529%2520inhibitors%2520with%2520enhanced%2520activity%2520against%2520pancreatic%2520cancer%2520cell%2520lines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D6313%26epage%3D6321%26doi%3D10.1016%2Fj.bmc.2017.09.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of sulfonamide-substituted diphenylpyrimidine derivatives (Sul-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with antitumor activity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3989</span>â <span class="NLM_lpage">3996</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2017.05.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmc.2017.05.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=28576633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovVKgtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=3989-3996&author=M.+Quauthor=Z.+Liuauthor=D.+Zhaoauthor=C.+Wangauthor=J.+Zhangauthor=Z.+Tangauthor=K.+Liuauthor=X.+Shuauthor=H.+Yuanauthor=X.+Ma&title=Design%2C+synthesis+and+biological+evaluation+of+sulfonamide-substituted+diphenylpyrimidine+derivatives+%28Sul-DPPYs%29+as+potent+focal+adhesion+kinase+%28FAK%29+inhibitors+with+antitumor+activity&doi=10.1016%2Fj.bmc.2017.05.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of sulfonamide-substituted diphenylpyrimidine derivatives (Sul-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with antitumor activity</span></div><div class="casAuthors">Qu, Menghua; Liu, Zhihao; Zhao, Dan; Wang, Changyuan; Zhang, Jianbin; Tang, Zeyao; Liu, Kexin; Shu, Xiaohong; Yuan, Hong; Ma, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3989-3996</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A class of sulfonamide-substituted diphenylpyrimidines (Sul-DPPYs) were synthesized to improve activity against the focal adhesion kinase (FAK).  Most of these new Sul-DPPYs displayed moderate activity against the FAK enzyme with IC50 values of less than 100 nM; regardless, they could effectively inhibit several classes of refractory cancer cell lines with IC50 values of less than 10 Î¼M, including the pancreatic cancer cell lines (AsPC-1, Panc-1 and BxPC-3), the NSCLC-resistant H1975 cell line, and the B lymphocyte cell line (Ramos cells).  Results of flow cytometry indicated that inhibitor 7e promoted apoptosis of pancreatic cancer cells in a dose-dependent manner.  In addn., it almost completely induced the apoptosis at a concn. of 10 Î¼M.  Compd. 7e may be selected as a potent FAK inhibitor for the treatment of pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-GsN0yXpjyrVg90H21EOLACvtfcHk0lii3Kt6I5R26Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovVKgtLk%253D&md5=ef2a94ac6339178f66a88f63467ccbf5</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.05.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.05.044%26sid%3Dliteratum%253Aachs%26aulast%3DQu%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DShu%26aufirst%3DX.%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DMa%26aufirst%3DX.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520sulfonamide-substituted%2520diphenylpyrimidine%2520derivatives%2520%2528Sul-DPPYs%2529%2520as%2520potent%2520focal%2520adhesion%2520kinase%2520%2528FAK%2529%2520inhibitors%2520with%2520antitumor%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D3989%26epage%3D3996%26doi%3D10.1016%2Fj.bmc.2017.05.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farand, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekhar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newby, Z. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Veldhuizen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loyer-Drew, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkataramani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zherebina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilbert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zablocki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mourey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Notte, G. T.</span></span> <span> </span><span class="NLM_article-title">Selectivity switch between FAK and Pyk2: macrocyclization of FAK inhibitors improves Pyk2 potency</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5926</span>â <span class="NLM_lpage">5930</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2016.10.092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmcl.2016.10.092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=27876318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFaitrjP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=5926-5930&author=J.+Farandauthor=N.+Maiauthor=J.+Chandrasekharauthor=Z.+E.+Newbyauthor=J.+Van+Veldhuizenauthor=J.+Loyer-Drewauthor=C.+Venkataramaniauthor=J.+Guerreroauthor=A.+Kwokauthor=N.+Liauthor=Y.+Zherebinaauthor=S.+Wilbertauthor=J.+Zablockiauthor=G.+Phillipsauthor=W.+J.+Watkinsauthor=R.+Moureyauthor=G.+T.+Notte&title=Selectivity+switch+between+FAK+and+Pyk2%3A+macrocyclization+of+FAK+inhibitors+improves+Pyk2+potency&doi=10.1016%2Fj.bmcl.2016.10.092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity switch between FAK and Pyk2: Macrocyclization of FAK inhibitors improves Pyk2 potency</span></div><div class="casAuthors">Farand, Julie; Mai, Nicholas; Chandrasekhar, Jayaraman; Newby, Zachary E.; Van Veldhuizen, Josh; Loyer-Drew, Jennifer; Venkataramani, Chandrasekar; Guerrero, Juan; Kwok, Amy; Li, Ning; Zherebina, Yelena; Wilbert, Sibylle; Zablocki, Jeff; Phillips, Gary; Watkins, William J.; Mourey, Robert; Notte, Gregory T.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5926-5930</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein, we describe the synthesis of Pyk2 inhibitors via macrocyclization of FAK and dual Pyk2-FAK inhibitors.  We identified one macrocycle as a highly potent Pyk2 inhibitor (IC50 = 0.7 nM), with â¼175-fold improvement in Pyk2 potency as compared to its acyclic counterpart.  In many cases, macrocyclization improved Pyk2 potency while weakening FAK potency, thereby improving the Pyk2/FAK selectivity ratio for this structural class of inhibitors.  Various macrocyclic linkers were studied in an attempt to optimize Pyk2 selectivity.  We obsd. macrocyclic atropisomerism during the synthesis of 19-membered macrocycles and successfully obtained crystallog. evidence of one atropisomer preferentially bound to Pyk2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyXQWxon-oWrVg90H21EOLACvtfcHk0lii3Kt6I5R26Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFaitrjP&md5=7c114af68a6484040f4250f941d759bc</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.10.092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.10.092%26sid%3Dliteratum%253Aachs%26aulast%3DFarand%26aufirst%3DJ.%26aulast%3DMai%26aufirst%3DN.%26aulast%3DChandrasekhar%26aufirst%3DJ.%26aulast%3DNewby%26aufirst%3DZ.%2BE.%26aulast%3DVan%2BVeldhuizen%26aufirst%3DJ.%26aulast%3DLoyer-Drew%26aufirst%3DJ.%26aulast%3DVenkataramani%26aufirst%3DC.%26aulast%3DGuerrero%26aufirst%3DJ.%26aulast%3DKwok%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DZherebina%26aufirst%3DY.%26aulast%3DWilbert%26aufirst%3DS.%26aulast%3DZablocki%26aufirst%3DJ.%26aulast%3DPhillips%26aufirst%3DG.%26aulast%3DWatkins%26aufirst%3DW.%2BJ.%26aulast%3DMourey%26aufirst%3DR.%26aulast%3DNotte%26aufirst%3DG.%2BT.%26atitle%3DSelectivity%2520switch%2520between%2520FAK%2520and%2520Pyk2%253A%2520macrocyclization%2520of%2520FAK%2520inhibitors%2520improves%2520Pyk2%2520potency%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D5926%26epage%3D5930%26doi%3D10.1016%2Fj.bmcl.2016.10.092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Determann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totzke, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schachtele, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubbutat, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunick, C.</span></span> <span> </span><span class="NLM_article-title">2-Anilino-4-(benzimidazol-2-yl)pyrimidines- a multikinase inhibitor scaffold with antiproliferative activity toward cancer cell lines</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">254</span>â <span class="NLM_lpage">263</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2012.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.ejmech.2012.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=22560627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvVygsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2012&pages=254-263&author=R.+Determannauthor=J.+Dreherauthor=K.+Baumannauthor=L.+Preuauthor=P.+G.+Jonesauthor=F.+Totzkeauthor=C.+Schachteleauthor=M.+H.+Kubbutatauthor=C.+Kunick&title=2-Anilino-4-%28benzimidazol-2-yl%29pyrimidines-+a+multikinase+inhibitor+scaffold+with+antiproliferative+activity+toward+cancer+cell+lines&doi=10.1016%2Fj.ejmech.2012.04.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">2-Anilino-4-(benzimidazol-2-yl)pyrimidines - A multikinase inhibitor scaffold with antiproliferative activity toward cancer cell lines</span></div><div class="casAuthors">Determann, Renate; Dreher, Jan; Baumann, Knut; Preu, Lutz; Jones, Peter G.; Totzke, Frank; Schaechtele, Christoph; Kubbutat, Michael H. G.; Kunick, Conrad</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">254-263</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">2-Anilino-4-(benzimidazol-2-yl)-pyrimidines, synthesized by reaction of a readily available benzimidazole-substituted enaminone with suitable arylguanidines, were shown to inhibit four cancer-related protein kinases (Aurora B, PLK1, FAK, and VEGF-R2).  The most potent deriv. exhibited antiproliferative activity for several cancer cell lines of the NCI in vitro cell line panel in submicromolar concns.  Both the anilinopyrimidine structure and the substitution pattern at the aniline ring appear to be important for the protein kinase inhibitory activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7v4Z7M2wm37Vg90H21EOLACvtfcHk0lii3Kt6I5R26Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvVygsbY%253D&md5=ea27d61cfd92b93e25a20b4bf5a302cc</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DDetermann%26aufirst%3DR.%26aulast%3DDreher%26aufirst%3DJ.%26aulast%3DBaumann%26aufirst%3DK.%26aulast%3DPreu%26aufirst%3DL.%26aulast%3DJones%26aufirst%3DP.%2BG.%26aulast%3DTotzke%26aufirst%3DF.%26aulast%3DSchachtele%26aufirst%3DC.%26aulast%3DKubbutat%26aufirst%3DM.%2BH.%26aulast%3DKunick%26aufirst%3DC.%26atitle%3D2-Anilino-4-%2528benzimidazol-2-yl%2529pyrimidines-%2520a%2520multikinase%2520inhibitor%2520scaffold%2520with%2520antiproliferative%2520activity%2520toward%2520cancer%2520cell%2520lines%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D53%26spage%3D254%26epage%3D263%26doi%3D10.1016%2Fj.ejmech.2012.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, R. A.</span></span> <span> </span><span class="NLM_article-title">Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1061</span>â <span class="NLM_lpage">1073</span>, <span class="refDoi">Â DOI: 10.1016/j.drudis.2015.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.drudis.2015.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=26002380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptlOnu7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=1061-1073&author=R.+A.+Bauer&title=Covalent+inhibitors+in+drug+discovery%3A+from+accidental+discoveries+to+avoided+liabilities+and+designed+therapies&doi=10.1016%2Fj.drudis.2015.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies</span></div><div class="casAuthors">Bauer, Renato A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1061-1073</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Drugs that covalently bond to their biol. targets have a long history in drug discovery.  A look at drug approvals in recent years suggests that covalent drugs will continue to make impacts on human health for years to come.  Although fraught with concerns about toxicity, the high potencies and prolonged effects achievable with covalent drugs may result in less-frequent drug dosing and in wide therapeutic margins for patients.  Covalent inhibition can also dissoc. drug pharmacodynamics (PD) from pharmacokinetics (PK), which can result in desired drug efficacy for inhibitors that have short systemic exposure.  Evidence suggests that there is a reduced risk for the development of resistance against covalent drugs, which is a major challenge in areas such as oncol. and infectious disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMkBDsUEu4arVg90H21EOLACvtfcHk0ljilEos2c1oog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptlOnu7s%253D&md5=6ba5b016d2804c7d56838a2724b9a0b9</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DR.%2BA.%26atitle%3DCovalent%2520inhibitors%2520in%2520drug%2520discovery%253A%2520from%2520accidental%2520discoveries%2520to%2520avoided%2520liabilities%2520and%2520designed%2520therapies%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2015%26volume%3D20%26spage%3D1061%26epage%3D1073%26doi%3D10.1016%2Fj.drudis.2015.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarray, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Coq, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lietha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loukaci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepelletier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadj-Slimane, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis of novel diarylamino-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4552</span>â <span class="NLM_lpage">4556</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2013.06.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmcl.2013.06.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=23845217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtV2ltb7J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4552-4556&author=P.+Daoauthor=R.+Jarrayauthor=J.+Le+Coqauthor=D.+Liethaauthor=A.+Loukaciauthor=Y.+Lepelletierauthor=R.+Hadj-Slimaneauthor=C.+Garbayauthor=F.+Raynaudauthor=H.+Chen&title=Synthesis+of+novel+diarylamino-1%2C3%2C5-triazine+derivatives+as+FAK+inhibitors+with+anti-angiogenic+activity&doi=10.1016%2Fj.bmcl.2013.06.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of novel diarylamino-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity</span></div><div class="casAuthors">Dao, Pascal; Jarray, Rafika; Le Coq, Johanne; Lietha, Daniel; Loukaci, Ali; Lepelletier, Yves; Hadj-Slimane, Reda; Garbay, Christiane; Raynaud, Francoise; Chen, Huixiong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4552-4556</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We report herein the synthesis of novel diarylamino-1,3,5-triazine derivs. as FAK (focal adhesion kinase) inhibitors and the evaluation of their anti-angiogenic activity on HUVEC cells.  Generally, the effects of these compds. on endothelial cells could be correlated with their kinase inhibitory activity.  The most efficient compds. displayed inhibition of viability against HUVEC cells in the micromolar range, as obsd. with TAE-226, which was designed by Novartis Pharma AG.  X-ray crystallog. anal. of the co-crystal structure for compd. I revealed that the mode of interaction with the FAK kinase domain is highly similar to that obsd. in the complex of TAE-226.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm3OngYamrNbVg90H21EOLACvtfcHk0ljilEos2c1oog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtV2ltb7J&md5=d4329a4e242f2fb42c59f12136f9c1ce</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.06.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.06.038%26sid%3Dliteratum%253Aachs%26aulast%3DDao%26aufirst%3DP.%26aulast%3DJarray%26aufirst%3DR.%26aulast%3DLe%2BCoq%26aufirst%3DJ.%26aulast%3DLietha%26aufirst%3DD.%26aulast%3DLoukaci%26aufirst%3DA.%26aulast%3DLepelletier%26aufirst%3DY.%26aulast%3DHadj-Slimane%26aufirst%3DR.%26aulast%3DGarbay%26aufirst%3DC.%26aulast%3DRaynaud%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DH.%26atitle%3DSynthesis%2520of%2520novel%2520diarylamino-1%252C3%252C5-triazine%2520derivatives%2520as%2520FAK%2520inhibitors%2520with%2520anti-angiogenic%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4552%26epage%3D4556%26doi%3D10.1016%2Fj.bmcl.2013.06.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lietha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etheve-Quelquejeu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis of novel 1,2,4-triazine scaffold as FAK inhibitors with antitumor activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1727</span>â <span class="NLM_lpage">1730</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2017.02.072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmcl.2017.02.072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=28284808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktVCrsrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=1727-1730&author=P.+Daoauthor=D.+Liethaauthor=M.+Etheve-Quelquejeuauthor=C.+Garbayauthor=H.+Chen&title=Synthesis+of+novel+1%2C2%2C4-triazine+scaffold+as+FAK+inhibitors+with+antitumor+activity&doi=10.1016%2Fj.bmcl.2017.02.072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of novel 1,2,4-triazine scaffold as FAK inhibitors with antitumor activity</span></div><div class="casAuthors">Dao, Pascal; Lietha, Daniel; Etheve-Quelquejeu, Melanie; Garbay, Christiane; Chen, Huixiong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1727-1730</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Bis(arylamino)chloro-1,2,4-triazines I [R = 3,4,5-(MeO)3C6H2, 4-H2NCH2C6H4, 4-Cl-2-MeO-5-MeC6H2, 4-(4-morpholinyl)phenyl, 2-MeO-4-(4-morpholinyl)phenyl; R1 = 3-MeSO2NHC6H4, 2-MeNHCOC6H4] were prepd. as inhibitors of focal adhesion kinase (FAK) for potential use as antitumor agents; their inhibition of FAK, of human cancer cells, and of tumorigenesis in cancer cells was detd.  I [R = 2-MeO-4-(4-morpholinyl)phenyl; R1 = 2-MeNHCOC6H4] inhibited FAK with an IC50 value of 230 nM and was toxic to cancer cells with IC50 values of 13 Î¼M and 0.19 Î¼M; colony formation in cancer cells was inhibited by I [R = 2-MeO-4-(4-morpholinyl)phenyl; R1 = 2-MeNHCOC6H4] with IC50 values of 1.5 Î¼M and 1.0 Î¼M.  The structure of I [R = 2-MeO-4-(4-morpholinyl)phenyl; R1 = 2-MeNHCOC6H4] bound to FAK was detd. by mol. docking calcns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrttOnuoEdP27Vg90H21EOLACvtfcHk0ljilEos2c1oog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktVCrsrw%253D&md5=b8161c2296506e27dc336e6006678637</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.02.072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.02.072%26sid%3Dliteratum%253Aachs%26aulast%3DDao%26aufirst%3DP.%26aulast%3DLietha%26aufirst%3DD.%26aulast%3DEtheve-Quelquejeu%26aufirst%3DM.%26aulast%3DGarbay%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DH.%26atitle%3DSynthesis%2520of%2520novel%25201%252C2%252C4-triazine%2520scaffold%2520as%2520FAK%2520inhibitors%2520with%2520antitumor%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D1727%26epage%3D1730%26doi%3D10.1016%2Fj.bmcl.2017.02.072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomkiewicz-Raulet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen-Pon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camacho-Artacho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lietha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbeuval, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coumoul, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of novel imidazo[1,2-a][1,3,5]triazines and their derivatives as focal adhesion kinase inhibitors with antitumor activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">237</span>â <span class="NLM_lpage">251</span>, <span class="refDoi">Â DOI: 10.1021/jm500784e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500784e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtLzE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=237-251&author=P.+Daoauthor=N.+Smithauthor=C.+Tomkiewicz-Rauletauthor=E.+Yen-Ponauthor=M.+Camacho-Artachoauthor=D.+Liethaauthor=J.+P.+Herbeuvalauthor=X.+Coumoulauthor=C.+Garbayauthor=H.+Chen&title=Design%2C+synthesis%2C+and+evaluation+of+novel+imidazo%5B1%2C2-a%5D%5B1%2C3%2C5%5Dtriazines+and+their+derivatives+as+focal+adhesion+kinase+inhibitors+with+antitumor+activity&doi=10.1021%2Fjm500784e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of Novel Imidazo[1,2-a][1,3,5]triazines and Their Derivatives as Focal Adhesion Kinase Inhibitors with Antitumor Activity</span></div><div class="casAuthors">Dao, Pascal; Smith, Nikaia; Tomkiewicz-Raulet, Celine; Yen-Pon, Expedite; Camacho-Artacho, Marta; Lietha, Daniel; Herbeuval, Jean-Phillipe; Coumoul, Xavier; Garbay, Christiane; Chen, Huixiong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">237-251</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of triazinic inhibitors of focal adhesion kinase (FAK) have been recently shown to exert antiangiogenic activity against HUVEC cells and anticancer efficacy against several cancer cell lines.  We report herein that we further explored the heterocyclic core of these inhibitors by a fused imidazole ring with the triazine to provide imidazo[1,2-a][1,3,5]triazines, e.g., I.  Importantly, these new compds. displayed 10-7-10-8 M IC50 values, and the best inhibitor showed IC50 value of 50 nM against FAK enzymic activity.  Several inhibitors potently inhibited the proliferation of a panel of cancer cell lines expressing high levels of FAK.  Apoptosis anal. in U87-MG and HCT-116 cell lines suggested that these compds. delayed cell cycle progression by arresting cells in the G2/M phase of the cell cycle, retarding cell growth.  Further investigation demonstrated that these compds. strongly inhibited cell-matrix adhesion, migration, and invasion of U87-MG cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3lpXckaeVGrVg90H21EOLACvtfcHk0lhqTT4PNKAUzw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtLzE&md5=0d2c7ef1b00e45bd462ea913b1bdc128</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Fjm500784e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500784e%26sid%3Dliteratum%253Aachs%26aulast%3DDao%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DN.%26aulast%3DTomkiewicz-Raulet%26aufirst%3DC.%26aulast%3DYen-Pon%26aufirst%3DE.%26aulast%3DCamacho-Artacho%26aufirst%3DM.%26aulast%3DLietha%26aufirst%3DD.%26aulast%3DHerbeuval%26aufirst%3DJ.%2BP.%26aulast%3DCoumoul%26aufirst%3DX.%26aulast%3DGarbay%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DH.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520novel%2520imidazo%255B1%252C2-a%255D%255B1%252C3%252C5%255Dtriazines%2520and%2520their%2520derivatives%2520as%2520focal%2520adhesion%2520kinase%2520inhibitors%2520with%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D237%26epage%3D251%26doi%3D10.1021%2Fjm500784e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">111716</span>â <span class="NLM_lpage">111732</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2019.111716</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.ejmech.2019.111716" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=31550660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVGns7rJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2019&pages=111716-111732&author=R.+Wangauthor=Y.+Chenauthor=X.+Zhaoauthor=S.+Yuauthor=B.+Yangauthor=T.+Wuauthor=J.+Guoauthor=C.+Haoauthor=D.+Zhaoauthor=M.+Cheng&title=Design%2C+synthesis+and+biological+evaluation+of+novel+7H-pyrrolo%5B2%2C3-d%5Dpyrimidine+derivatives+as+potential+FAK+inhibitors+and+anticancer+agents&doi=10.1016%2Fj.ejmech.2019.111716"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents</span></div><div class="casAuthors">Wang, Ruifeng; Chen, Yixuan; Zhao, Xiangxin; Yu, Sijia; Yang, Bowen; Wu, Tianxiao; Guo, Jing; Hao, Chenzhou; Zhao, Dongmei; Cheng, Maosheng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111716</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 7H-pyrrolo[2,3-d]pyrimidine derivs. possessing a dimethylphosphine oxide moiety I (20a-i, R5, R6, R7 = H, R3 = acylamino, sulfamoyl, phosphonomethyl, carbamoyl, amino; 25a-h, R3 = 4-piperidinylaminocarbonyl, R5 = H, halo, alkoxy, CF3, R6 = H, Me, F, R7 = H, F) and II (22a-g, R4 = Me. CHF2CH2, MeOCH2CH2, tetrahydropyranyl, piperidinyl, CH2CONMe2) were designed, synthesized and evaluated as novel Focal adhesion kinase (FAK) inhibitors.  Most compds. potently suppressed the enzymic activities of FAK, with IC50 values in the 10-8-10-9 M range, and potently inhibited the proliferation of breast (MDA-MB-231) and lung (A549) cancer cell lines.  The representative compd. 25b (R5 = OMe, R6 = R7 = H) exhibited potent enzyme inhibition (IC50 = 5.4 nM) and good selectivity when tested on a panel of 26 kinases.  Compd. 25b exhibited antiproliferative activity against A549 cells (IC50 = 3.2 Î¼M) and relatively less cytotoxicity to a normal human cell line HK2.  Compd. 25b also induced apoptosis and suppressed the migration of A549 cells in a concn.-dependent manner.  Further profiling of compd. 25b revealed it had good metabolic stability in mouse, rat and human liver microsomes in vitro and showed weak inhibitory activity against various subtypes of human cytochrome P 450.  The docking study of compd. 25b was performed to elucidate its possible binding modes and to provide a structural basis for further structure-guided design of FAK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdK0cQH-LWPbVg90H21EOLACvtfcHk0lhqTT4PNKAUzw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVGns7rJ&md5=6d098ce43cad86c9b1ed612980ddb579</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111716%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DHao%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DD.%26aulast%3DCheng%26aufirst%3DM.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520novel%25207H-pyrrolo%255B2%252C3-d%255Dpyrimidine%2520derivatives%2520as%2520potential%2520FAK%2520inhibitors%2520and%2520anticancer%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D183%26spage%3D111716%26epage%3D111732%26doi%3D10.1016%2Fj.ejmech.2019.111716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">112024</span>â <span class="NLM_lpage">112040</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2019.112024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.ejmech.2019.112024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=31923858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFCjtLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2020&pages=112024-112040&author=R.+Wangauthor=S.+Yuauthor=X.+Zhaoauthor=Y.+Chenauthor=B.+Yangauthor=T.+Wuauthor=C.+Haoauthor=D.+Zhaoauthor=M.+Cheng&title=Design%2C+synthesis%2C+biological+evaluation+and+molecular+docking+study+of+novel+thieno%5B3%2C2-d%5Dpyrimidine+derivatives+as+potent+FAK+inhibitors&doi=10.1016%2Fj.ejmech.2019.112024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors</span></div><div class="casAuthors">Wang, Ruifeng; Yu, Sijia; Zhao, Xiangxin; Chen, Yixuan; Yang, Bowen; Wu, Tianxiao; Hao, Chenzhou; Zhao, Dongmei; Cheng, Maosheng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112024</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 2,7-disubstituted thieno[3,2-d]pyrimidine derivs. I [R1 = 2-methoxy, 3-acetyl, 3-methylsulfonyl, etc.], II [R2 = methylcarbamoyl, piperidine-3-carbonylamino, diethoxyphosphorylmethyl, etc.], III [R3 = H, Me, ethoxy, etc.; R4 = H, fluoro, methyl; R5 = H, fluoro] and IV [R6 = pyrrolidin-3-yl, tetrahydro-2H-pyran-4-yl, piperidin-3-ylmethyl, etc.] were synthesized and evaluated as novel focal adhesion kinase (FAK) inhibitors.  The novel 2,7-disubstituted thieno[3,2-d]pyrimidine scaffold was designed as a new kinase inhibitor platform that mimics the bioactive conformation of the well-known diaminopyrimidine motif.  Most of the compds. potently suppressed the enzymic activities of FAK and potently inhibited the proliferation of U-87MG, A-549 and MDA-MB-231 cancer cell lines.  Among these derivs., the optimized compd. III [R3 = R5 = H, R4 = fluoro] potently inhibited the enzyme (IC50 = 28.2 nM) and displayed stronger potency than TAE-226 in U-87MG, A-549 and MDA-MB-231 cells, with IC50 values of 0.16, 0.27, and 0.19Î¼M, resp.  Compd. III [R3 = R5 = H, R4 = fluoro] also exhibited relatively less cytotoxicity (IC50 = 3.32Î¼M) toward a normal human cell line, HK2.  According to the flow cytometry results, compd. III [R3 = R5 = H, R4 = fluoro] induced the apoptosis of MDA-MB-231 cells in a dose-dependent manner and effectively arrested MDA-MB-231 cells in G0/G1 phase.  Further investigations revealed that compd. III [R3 = R5 = H, R4 = fluoro] potently suppressed the migration of MDA-MB-231 cells.  Collectively, these data support the further development of compd. III [R3 = R5 = H, R4 = fluoro] as a lead compd. for FAK-targeted anticancer drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomCT88btJhfLVg90H21EOLACvtfcHk0lhqTT4PNKAUzw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFCjtLY%253D&md5=d606012fd0605da340ba78b6f7319ff7</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.112024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.112024%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DHao%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DD.%26aulast%3DCheng%26aufirst%3DM.%26atitle%3DDesign%252C%2520synthesis%252C%2520biological%2520evaluation%2520and%2520molecular%2520docking%2520study%2520of%2520novel%2520thieno%255B3%252C2-d%255Dpyrimidine%2520derivatives%2520as%2520potent%2520FAK%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D188%26spage%3D112024%26epage%3D112040%26doi%3D10.1016%2Fj.ejmech.2019.112024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zificsak, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingrich, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breslin, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milkiewicz, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theroff, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thieu, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Underiner, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aimone, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albom, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saville, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angeles, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâKane, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrzanski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span> <span> </span><span class="NLM_article-title">Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">133</span>â <span class="NLM_lpage">137</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2011.11.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmcl.2011.11.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=22169263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC38XivVOrsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=133-137&author=C.+A.+Zificsakauthor=D.+E.+Gingrichauthor=H.+J.+Breslinauthor=D.+D.+Dunnauthor=K.+L.+Milkiewiczauthor=J.+P.+Theroffauthor=T.+V.+Thieuauthor=T.+L.+Underinerauthor=L.+R.+Weinbergauthor=L.+D.+Aimoneauthor=M.+S.+Albomauthor=J.+L.+Masonauthor=L.+Savilleauthor=J.+Hustenauthor=T.+S.+Angelesauthor=J.+P.+Finnauthor=M.+Janauthor=T.+M.+O%E2%80%99Kaneauthor=P.+Dobrzanskiauthor=B.+D.+Dorsey&title=Optimization+of+a+novel+kinase+inhibitor+scaffold+for+the+dual+inhibition+of+JAK2+and+FAK+kinases&doi=10.1016%2Fj.bmcl.2011.11.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases</span></div><div class="casAuthors">Zificsak, Craig A.; Gingrich, Diane E.; Breslin, Henry J.; Dunn, Derek D.; Milkiewicz, Karen L.; Theroff, Jay P.; Thieu, Tho V.; Underiner, Ted L.; Weinberg, Linda R.; Aimone, Lisa D.; Albom, Mark S.; Mason, Jennifer L.; Saville, Lisa; Husten, Jean; Angeles, Thelma S.; Finn, James P.; Jan, Mahfuza; O'Kane, Teresa M.; Dobrzanski, Pawel; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">133-137</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The elaboration of a novel scaffold for the inhibition of JAK2 and FAK kinases was targeted in order to provide a dual inhibitor that could target divergent pathways for tumor cell progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFjTGeVZ-5KLVg90H21EOLACvtfcHk0lj4Ftx_WLax1A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivVOrsQ%253D%253D&md5=849448a392e70c11a0b1df1c9d54e8b5</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.11.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.11.049%26sid%3Dliteratum%253Aachs%26aulast%3DZificsak%26aufirst%3DC.%2BA.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DBreslin%26aufirst%3DH.%2BJ.%26aulast%3DDunn%26aufirst%3DD.%2BD.%26aulast%3DMilkiewicz%26aufirst%3DK.%2BL.%26aulast%3DTheroff%26aufirst%3DJ.%2BP.%26aulast%3DThieu%26aufirst%3DT.%2BV.%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DWeinberg%26aufirst%3DL.%2BR.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DMason%26aufirst%3DJ.%2BL.%26aulast%3DSaville%26aufirst%3DL.%26aulast%3DHusten%26aufirst%3DJ.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DFinn%26aufirst%3DJ.%2BP.%26aulast%3DJan%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Kane%26aufirst%3DT.%2BM.%26aulast%3DDobrzanski%26aufirst%3DP.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DOptimization%2520of%2520a%2520novel%2520kinase%2520inhibitor%2520scaffold%2520for%2520the%2520dual%2520inhibition%2520of%2520JAK2%2520and%2520FAK%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D133%26epage%3D137%26doi%3D10.1016%2Fj.bmcl.2011.11.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H. L.</span></span> <span> </span><span class="NLM_article-title">Synthesis, biological evaluation and molecular docking studies of 1,3,4-thiadiazole derivatives containing 1,4-benzodioxan as potential antitumor agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">6116</span>â <span class="NLM_lpage">6121</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2011.08.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmcl.2011.08.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=21889345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtF2qsr7M" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=6116-6121&author=J.+Sunauthor=Y.+S.+Yangauthor=W.+Liauthor=Y.+B.+Zhangauthor=X.+L.+Wangauthor=J.+F.+Tangauthor=H.+L.+Zhu&title=Synthesis%2C+biological+evaluation+and+molecular+docking+studies+of+1%2C3%2C4-thiadiazole+derivatives+containing+1%2C4-benzodioxan+as+potential+antitumor+agents&doi=10.1016%2Fj.bmcl.2011.08.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, biological evaluation and molecular docking studies of 1,3,4-thiadiazole derivatives containing 1,4-benzodioxan as potential antitumor agents</span></div><div class="casAuthors">Sun, Juan; Yang, Yu-Shun; Li, Wei; Zhang, Yan-Bin; Wang, Xiao-Liang; Tang, Jian-Feng; Zhu, Hai-Liang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6116-6121</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of 1,3,4-thiadiazole derivs. contg. 1,4-benzodioxane have been synthesized to screen for FAK inhibitory activity.  Compd. I showed the most potent biol. activity against HEPG2 cancer cell line (EC50 = 10.28 Î¼g/mL for HEPG2 and EC50 = 10.79 Î¼M for FAK), which was comparable to the pos. control.  Docking simulation was performed to position compd. I into the FAK structure active site to det. the probable binding model.  The results of antiproliferative and Western-blot assay demonstrated that compd. I possessed good antiproliferative activity against HEPG2 cancer cell line.  Therefore, compd. I with potent FAK inhibitory activity may be a potential anticancer agent against HEPG2 cancer cell.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6dV5qu00OrLVg90H21EOLACvtfcHk0lj4Ftx_WLax1A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtF2qsr7M&md5=8e668b7764f57f980403388c81743493</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.08.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.08.039%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DY.%2BS.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%2BB.%26aulast%3DWang%26aufirst%3DX.%2BL.%26aulast%3DTang%26aufirst%3DJ.%2BF.%26aulast%3DZhu%26aufirst%3DH.%2BL.%26atitle%3DSynthesis%252C%2520biological%2520evaluation%2520and%2520molecular%2520docking%2520studies%2520of%25201%252C3%252C4-thiadiazole%2520derivatives%2520containing%25201%252C4-benzodioxan%2520as%2520potential%2520antitumor%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D6116%26epage%3D6121%26doi%3D10.1016%2Fj.bmcl.2011.08.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H. L.</span></span> <span> </span><span class="NLM_article-title">Synthesis, biological evaluation, and molecular docking studies of 1,3,4-thiadiazol-2-amide derivatives as novel anticancer agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2789</span>â <span class="NLM_lpage">2795</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2012.03.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmc.2012.03.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=22503364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsFGisrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=2789-2795&author=X.+H.+Yangauthor=L.+Xiangauthor=X.+Liauthor=T.+T.+Zhaoauthor=H.+Zhangauthor=W.+P.+Zhouauthor=X.+M.+Wangauthor=H.+B.+Gongauthor=H.+L.+Zhu&title=Synthesis%2C+biological+evaluation%2C+and+molecular+docking+studies+of+1%2C3%2C4-thiadiazol-2-amide+derivatives+as+novel+anticancer+agents&doi=10.1016%2Fj.bmc.2012.03.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, biological evaluation, and molecular docking studies of 1,3,4-thiadiazol-2-amide derivatives as novel anticancer agents</span></div><div class="casAuthors">Yang, Xian-Hui; Xiang, Lu; Li, Xi; Zhao, Ting-Ting; Zhang, Hui; Zhou, Wen-Ping; Wang, Xiao-Ming; Gong, Hai-Bin; Zhu, Hai-Liang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2789-2795</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of 1,3,4-thiadiazol-2-amide derivs. (5a-5y) have been designed and synthesized, and their biol. activities were also evaluated as potential antiproliferation and FAK inhibitors.  Among all the compds., 5h showed the most potent activity in vitro, which inhibited the growth of MCF-7 and B16-F10 cell lines with IC50 values of 0.45 and 0.31 Î¼M, resp.  Compd. 5h also exhibited significant FAK inhibitory activity (IC50 = 5.32 Î¼M).  Docking simulation was performed to position compd. 5h into the FAK structure active site to det. the probable binding model.  The results of antiproliferative and Western-blot assay demonstrated that compd. 5h possessed good antiproliferative activity.  Therefore, compd. 5h with potent FAK inhibitory activity may be a potential anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzBY1xBDazwrVg90H21EOLACvtfcHk0lgqojNzngORFg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsFGisrk%253D&md5=6c9546c5648719682ee04da9099d10a2</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.03.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.03.040%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%2BH.%26aulast%3DXiang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DT.%2BT.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DW.%2BP.%26aulast%3DWang%26aufirst%3DX.%2BM.%26aulast%3DGong%26aufirst%3DH.%2BB.%26aulast%3DZhu%26aufirst%3DH.%2BL.%26atitle%3DSynthesis%252C%2520biological%2520evaluation%252C%2520and%2520molecular%2520docking%2520studies%2520of%25201%252C3%252C4-thiadiazol-2-amide%2520derivatives%2520as%2520novel%2520anticancer%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D2789%26epage%3D2795%26doi%3D10.1016%2Fj.bmc.2012.03.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, F. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H. L.</span></span> <span> </span><span class="NLM_article-title">Discovery of a series of 1,3,4-oxadiazole-2(3H)-thione derivatives containing piperazine skeleton as potential FAK inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2593</span>â <span class="NLM_lpage">2600</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2017.03.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmc.2017.03.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=28363444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlt1Cjsbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=2593-2600&author=J.+Sunauthor=S.+Z.+Renauthor=X.+Y.+Luauthor=J.+J.+Liauthor=F.+Q.+Shenauthor=C.+Xuauthor=H.+L.+Zhu&title=Discovery+of+a+series+of+1%2C3%2C4-oxadiazole-2%283H%29-thione+derivatives+containing+piperazine+skeleton+as+potential+FAK+inhibitors&doi=10.1016%2Fj.bmc.2017.03.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a series of 1,3,4-oxadiazole-2(3H)-thione derivatives containing piperazine skeleton as potential FAK inhibitors</span></div><div class="casAuthors">Sun, Juan; Ren, Shen-Zhen; Lu, Xiao-Yuan; Li, Jing-Jing; Shen, Fa-Qian; Xu, Chen; Zhu, Hai-Liang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2593-2600</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) is an important drug target that plays a fundamental role in mediating signal transduction system.  We report herein the discovery of a novel class of 1,3,4-oxadiazole-2(3H)-thione derivs. contg. piperazine skeleton with improved potency toward FAK.  All of the 17 new synthesized compds. were assayed for the anticancer activities against four cancer cells, HepG2, Hela, SW116 and BGC823.  Because of the combination of 1,4-benzodioxan, 1,3,4-oxadiazole and piperazine ring, most of them exhibited remarkable antitumor activities.  Notably, compd. 5m showed the most potent biol. activities (IC50 = 5.78 Î¼M for HepG2, and IC50 = 47.15 Î¼M for SW1116), and its anti-FAK inhibitory activity (IC50 = 0.78 Î¼M) was also the best.  Computational docking studies also showed that compd. 5m has interaction with FAK key residues in the active site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTvkYSfXjf2rVg90H21EOLACvtfcHk0lgqojNzngORFg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlt1Cjsbo%253D&md5=2cf62f6391c7310f09c1a78dc9f0d0f2</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.03.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.03.038%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DS.%2BZ.%26aulast%3DLu%26aufirst%3DX.%2BY.%26aulast%3DLi%26aufirst%3DJ.%2BJ.%26aulast%3DShen%26aufirst%3DF.%2BQ.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DH.%2BL.%26atitle%3DDiscovery%2520of%2520a%2520series%2520of%25201%252C3%252C4-oxadiazole-2%25283H%2529-thione%2520derivatives%2520containing%2520piperazine%2520skeleton%2520as%2520potential%2520FAK%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D2593%26epage%3D2600%26doi%3D10.1016%2Fj.bmc.2017.03.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makawana, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teraiya, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thumar, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H. L.</span></span> <span> </span><span class="NLM_article-title">Synthesis, biological evaluation, and molecular docking studies of novel 2-styryl-5-nitroimidazole derivatives containing 1,4-benzodioxan moiety as FAK inhibitors with anticancer activity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2947</span>â <span class="NLM_lpage">2954</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2014.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmc.2014.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=24792811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntFygtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=2947-2954&author=Y.+T.+Duanauthor=Y.+F.+Yaoauthor=W.+Huangauthor=J.+A.+Makawanaauthor=S.+B.+Teraiyaauthor=N.+J.+Thumarauthor=D.+J.+Tangauthor=X.+X.+Taoauthor=Z.+C.+Wangauthor=A.+Q.+Jiangauthor=H.+L.+Zhu&title=Synthesis%2C+biological+evaluation%2C+and+molecular+docking+studies+of+novel+2-styryl-5-nitroimidazole+derivatives+containing+1%2C4-benzodioxan+moiety+as+FAK+inhibitors+with+anticancer+activity&doi=10.1016%2Fj.bmc.2014.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, biological evaluation, and molecular docking studies of novel 2-styryl-5-nitroimidazole derivatives containing 1,4-benzodioxan moiety as FAK inhibitors with anticancer activity</span></div><div class="casAuthors">Duan, Yong-Tao; Yao, Yong-Fang; Huang, Wei; Makawana, Jigar A.; Teraiya, Shashikant B.; Thumar, Nilesh j.; Tang, Dan-Jie; Tao, Xiang-Xiang; Wang, Zhong-Chang; Jiang, Ai-Qin; Zhu, Hai-Liang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2947-2954</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of 2-styryl-5-nitroimidazole derivs. contg. 1,4-benzodioxan moiety has been designed, synthesized and their biol. activities were also evaluated as potential antiproliferation and focal adhesion kinase (FAK) inhibitors.  Among all the compds., (I) showed the most potent activity in vitro which inhibited the growth of A549 with IC50 value of 3.11 Î¼M and Hela with IC50 value of 2.54 Î¼M resp.  Compd. I also exhibited significant FAK inhibitory activity (IC50 = 0.45 Î¼M).  Docking simulation was performed for compd. I into the FAK structure active site to det. the probable binding model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_Wm3MnQHEprVg90H21EOLACvtfcHk0lhUQL0PfqjaSg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntFygtb0%253D&md5=4cbefdd1f7ab66f6d7e3ae5f4ff9069c</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DY.%2BT.%26aulast%3DYao%26aufirst%3DY.%2BF.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DMakawana%26aufirst%3DJ.%2BA.%26aulast%3DTeraiya%26aufirst%3DS.%2BB.%26aulast%3DThumar%26aufirst%3DN.%2BJ.%26aulast%3DTang%26aufirst%3DD.%2BJ.%26aulast%3DTao%26aufirst%3DX.%2BX.%26aulast%3DWang%26aufirst%3DZ.%2BC.%26aulast%3DJiang%26aufirst%3DA.%2BQ.%26aulast%3DZhu%26aufirst%3DH.%2BL.%26atitle%3DSynthesis%252C%2520biological%2520evaluation%252C%2520and%2520molecular%2520docking%2520studies%2520of%2520novel%25202-styryl-5-nitroimidazole%2520derivatives%2520containing%25201%252C4-benzodioxan%2520moiety%2520as%2520FAK%2520inhibitors%2520with%2520anticancer%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D2947%26epage%3D2954%26doi%3D10.1016%2Fj.bmc.2014.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Altintop, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sever, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akalin Ciftci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turan-Zitouni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplancikli, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozdemir, A.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, in vitro and in silico evaluation of a new series of oxadiazole-based anticancer agents as potential Akt and FAK inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">905</span>â <span class="NLM_lpage">924</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2018.06.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.ejmech.2018.06.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=29966916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Kqtr3I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2018&pages=905-924&author=M.+D.+Altintopauthor=B.+Severauthor=G.+Akalin+Ciftciauthor=G.+Turan-Zitouniauthor=Z.+A.+Kaplancikliauthor=A.+Ozdemir&title=Design%2C+synthesis%2C+in+vitro+and+in+silico+evaluation+of+a+new+series+of+oxadiazole-based+anticancer+agents+as+potential+Akt+and+FAK+inhibitors&doi=10.1016%2Fj.ejmech.2018.06.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, in vitro and in silico evaluation of a new series of oxadiazole-based anticancer agents as potential Akt and FAK inhibitors</span></div><div class="casAuthors">Altintop, Mehlika Dilek; Sever, Belgin; Akalin Ciftci, Gulsen; Turan-Zitouni, Gulhan; Kaplancikli, Zafer Asim; Ozdemir, Ahmet</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">905-924</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In the current work, new 1,3,4-oxadiazole derivs. were synthesized and studied for their cytotoxic effects on A549 human lung adenocarcinoma, C6 rat glioma and NIH/3T3 mouse embryonic fibroblast cell lines.  Compds. N-(6-Fluorobenzothiazol-2-yl)-2-[[5-[((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)methyl]-1,3,4-oxadiazol-2-yl]thio]acetamide, N-(6-methoxybenzothiazol-2-yl)-2-[[5-[((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)methyl]-1,3,4-oxadiazol-2-yl]thio]acetamide and N-(5-Nitrothiazol-2-yl)-2-[[5-[((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)methyl]-1,3,4-oxadiazol-2-yl]thio]acetamide are the most potent anticancer agents against A549 and C6 cell lines and therefore their effects on apoptosis, caspase-3 activation, Akt, FAK, mitochondrial membrane potential and ultrastructural morphol. changes were evaluated.  N-(5-Nitrothiazol-2-yl)-2-[[5-[((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)methyl]-1,3,4-oxadiazol-2-yl]thio]acetamide increased early and late apoptotic cell population in A549 and C6 cells more than cisplatin and caused more mitochondrial membrane depolarization in both cell lines than cisplatin.  However, N-(6-methoxybenzothiazol-2-yl)-2-[[5-[((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)methyl]-1,3,4-oxadiazol-2-yl]thio]acetamide caused higher caspase-3 activation than cisplatin in both cell lines.  Compd. N-(6-methoxybenzothiazol-2-yl)-2-[[5-[((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)methyl]-1,3,4-oxadiazol-2-yl]thio]acetamide showed significant Akt inhibitory activity in both cell lines.  Moreover, compd. N-(6-methoxybenzothiazol-2-yl)-2-[[5-[((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)methyl]-1,3,4-oxadiazol-2-yl]thio]acetamide significantly inhibited FAK (Phospho-Tyr397) activity in C6 cell line.  Mol. docking simulations demonstrated that compd. N-(6-methoxybenzothiazol-2-yl)-2-[[5-[((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)methyl]-1,3,4-oxadiazol-2-yl]thio]acetamide fitted into the active sites of Akt and FAK with high affinity and substrate-specific interactions.  Furthermore, compds. N-(6-Fluorobenzothiazol-2-yl)-2-[[5-[((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)methyl]-1,3,4-oxadiazol-2-yl]thio]acetamide, N-(6-Methoxybenzothiazol-2-yl)-2-[[5-[((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)methyl]-1,3,4-oxadiazol-2-yl]thio]acetamide and N-(5-Nitrothiazol-2-yl)-2-[[5-[((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)methyl]-1,3,4-oxadiazol-2-yl]thio]acetamide caused apoptotic morphol. changes in both cell lines obtained from micrographs by TEM.  A computational study for the prediction of ADME properties of all compds. was also performed.  These compds. did not violate Lipinski's rule, making them potential orally bioavailable anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_8VEjQH4e5bVg90H21EOLACvtfcHk0lhUQL0PfqjaSg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Kqtr3I&md5=cba9f08c9e5dcf6b335d0999622d64e0</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.06.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.06.049%26sid%3Dliteratum%253Aachs%26aulast%3DAltintop%26aufirst%3DM.%2BD.%26aulast%3DSever%26aufirst%3DB.%26aulast%3DAkalin%2BCiftci%26aufirst%3DG.%26aulast%3DTuran-Zitouni%26aufirst%3DG.%26aulast%3DKaplancikli%26aufirst%3DZ.%2BA.%26aulast%3DOzdemir%26aufirst%3DA.%26atitle%3DDesign%252C%2520synthesis%252C%2520in%2520vitro%2520and%2520in%2520silico%2520evaluation%2520of%2520a%2520new%2520series%2520of%2520oxadiazole-based%2520anticancer%2520agents%2520as%2520potential%2520Akt%2520and%2520FAK%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D155%26spage%3D905%26epage%3D924%26doi%3D10.1016%2Fj.ejmech.2018.06.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohren, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlovsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitehead, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuffa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spessard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banotai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaney, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebolt-Leopold, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flamme, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tecle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasemann, C. A.</span></span> <span> </span><span class="NLM_article-title">Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1192</span>â <span class="NLM_lpage">1197</span>, <span class="refDoi">Â DOI: 10.1038/nsmb859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fnsmb859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=15543157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVens7jM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=1192-1197&author=J.+F.+Ohrenauthor=H.+Chenauthor=A.+Pavlovskyauthor=C.+Whiteheadauthor=E.+Zhangauthor=P.+Kuffaauthor=C.+Yanauthor=P.+McConnellauthor=C.+Spessardauthor=C.+Banotaiauthor=W.+T.+Muellerauthor=A.+Delaneyauthor=C.+Omerauthor=J.+Sebolt-Leopoldauthor=D.+T.+Dudleyauthor=I.+K.+Leungauthor=C.+Flammeauthor=J.+Warmusauthor=M.+Kaufmanauthor=S.+Barrettauthor=H.+Tecleauthor=C.+A.+Hasemann&title=Structures+of+human+MAP+kinase+kinase+1+%28MEK1%29+and+MEK2+describe+novel+noncompetitive+kinase+inhibition&doi=10.1038%2Fnsmb859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition</span></div><div class="casAuthors">Ohren, Jeffrey F.; Chen, Huifen; Pavlovsky, Alexander; Whitehead, Christopher; Zhang, Erli; Kuffa, Peter; Yan, Chunhong; McConnell, Patrick; Spessard, Cindy; Banotai, Craig; Mueller, W. Thomas; Delaney, Amy; Omer, Charles; Sebolt-Leopold, Judith; Dudley, David T.; Leung, Iris K.; Flamme, Cathlin; Warmus, Joseph; Kaufman, Michael; Barrett, Stephen; Tecle, Haile; Hasemann, Charles A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1192-1197</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">MEK1 and MEK2 kinases are closely related, dual-specificity tyrosine/threonine protein kinases found in the Ras/Raf/MEK/ERK MAP kinase (MAPK) signaling pathway.  Approx. 30% of all human cancers have a constitutively activated MAPK pathway, and constitutive activation of MEK1 results in cellular transformation.  Here, the authors present the x-ray crystal structures of human MEK1 and MEK2 kinases, each detd. as a ternary complex with MgATP and an inhibitor to a resoln. of 2.4 and 3.2 Ã, resp.  The structures revealed that MEK1 and MEK2 each had a unique inhibitor-binding pocket adjacent to the MgATP-binding site.  The presence of the potent inhibitors induced several conformational changes in the unphosphorylated MEK1 and MEK2 kinases that locked them into a closed but catalytically inactive species.  Thus, the structures reported here reveal a novel, noncompetitive mechanism for protein kinase inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIY9begVVfW7Vg90H21EOLACvtfcHk0lhUQL0PfqjaSg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVens7jM&md5=79ebbc2e3a9cdd3fbecb8bb35ea9dba3</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1038%2Fnsmb859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb859%26sid%3Dliteratum%253Aachs%26aulast%3DOhren%26aufirst%3DJ.%2BF.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DPavlovsky%26aufirst%3DA.%26aulast%3DWhitehead%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DE.%26aulast%3DKuffa%26aufirst%3DP.%26aulast%3DYan%26aufirst%3DC.%26aulast%3DMcConnell%26aufirst%3DP.%26aulast%3DSpessard%26aufirst%3DC.%26aulast%3DBanotai%26aufirst%3DC.%26aulast%3DMueller%26aufirst%3DW.%2BT.%26aulast%3DDelaney%26aufirst%3DA.%26aulast%3DOmer%26aufirst%3DC.%26aulast%3DSebolt-Leopold%26aufirst%3DJ.%26aulast%3DDudley%26aufirst%3DD.%2BT.%26aulast%3DLeung%26aufirst%3DI.%2BK.%26aulast%3DFlamme%26aufirst%3DC.%26aulast%3DWarmus%26aufirst%3DJ.%26aulast%3DKaufman%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DS.%26aulast%3DTecle%26aufirst%3DH.%26aulast%3DHasemann%26aufirst%3DC.%2BA.%26atitle%3DStructures%2520of%2520human%2520MAP%2520kinase%2520kinase%25201%2520%2528MEK1%2529%2520and%2520MEK2%2520describe%2520novel%2520noncompetitive%2520kinase%2520inhibition%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2004%26volume%3D11%26spage%3D1192%26epage%3D1197%26doi%3D10.1038%2Fnsmb859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leister, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnett, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Defeo-Jones, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huff, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, M. E.</span></span> <span> </span><span class="NLM_article-title">Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">761</span>â <span class="NLM_lpage">764</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2004.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmcl.2004.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=15664853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD2MXnsVKquw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=761-764&author=C.+W.+Lindsleyauthor=Z.+Zhaoauthor=W.+H.+Leisterauthor=R.+G.+Robinsonauthor=S.+F.+Barnettauthor=D.+Defeo-Jonesauthor=R.+E.+Jonesauthor=G.+D.+Hartmanauthor=J.+R.+Huffauthor=H.+E.+Huberauthor=M.+E.+Duggan&title=Allosteric+Akt+%28PKB%29+inhibitors%3A+discovery+and+SAR+of+isozyme+selective+inhibitors&doi=10.1016%2Fj.bmcl.2004.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors</span></div><div class="casAuthors">Lindsley, Craig W.; Zhao, Zhijian; Leister, William H.; Robinson, Ronald G.; Barnett, Stanley F.; Defeo-Jones, Deborah; Jones, Raymond E.; Hartman, George D.; Huff, Joel R.; Huber, Hans E.; Duggan, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">761-764</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This letter describes the development of two series of potent and selective allosteric Akt kinase inhibitors that display an unprecedented level of selectivity for either Akt1, Akt2 or both Akt1/Akt2.  An iterative analog library synthesis approach quickly provided a highly selective Akt1/Akt2 inhibitor that induces apoptosis in tumor cells and inhibits Akt phosphorylation in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxuCBcX4Ew8LVg90H21EOLACvtfcHk0lgZ5gHzSacNiw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXnsVKquw%253D%253D&md5=064636872476fd8e344dfa151dca218f</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DLeister%26aufirst%3DW.%2BH.%26aulast%3DRobinson%26aufirst%3DR.%2BG.%26aulast%3DBarnett%26aufirst%3DS.%2BF.%26aulast%3DDefeo-Jones%26aufirst%3DD.%26aulast%3DJones%26aufirst%3DR.%2BE.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DHuff%26aufirst%3DJ.%2BR.%26aulast%3DHuber%26aufirst%3DH.%2BE.%26aulast%3DDuggan%26aufirst%3DM.%2BE.%26atitle%3DAllosteric%2520Akt%2520%2528PKB%2529%2520inhibitors%253A%2520discovery%2520and%2520SAR%2520of%2520isozyme%2520selective%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D761%26epage%3D764%26doi%3D10.1016%2Fj.bmcl.2004.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwatani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okabe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skene, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aramaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosfield, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baba, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miki, H.</span></span> <span> </span><span class="NLM_article-title">Discovery and characterization of novel allosteric FAK inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">49</span>â <span class="NLM_lpage">60</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2012.06.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.ejmech.2012.06.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=22819505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFOks7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2013&pages=49-60&author=M.+Iwataniauthor=H.+Iwataauthor=A.+Okabeauthor=R.+J.+Skeneauthor=N.+Tomitaauthor=Y.+Hayashiauthor=Y.+Aramakiauthor=D.+J.+Hosfieldauthor=A.+Horiauthor=A.+Babaauthor=H.+Miki&title=Discovery+and+characterization+of+novel+allosteric+FAK+inhibitors&doi=10.1016%2Fj.ejmech.2012.06.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and characterization of novel allosteric FAK inhibitors</span></div><div class="casAuthors">Iwatani, Misa; Iwata, Hidehisa; Okabe, Atsutoshi; Skene, Robert J.; Tomita, Naoki; Hayashi, Yoko; Aramaki, Yoshio; Hosfield, David J.; Hori, Akira; Baba, Atsuo; Miki, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">49-60</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) regulates cell survival and proliferation pathways.  Here we report the discovery of a highly selective series of 1,5-dihydropyrazolo[4,3-c][2,1]benzothiazines that demonstrate a novel mode of allosteric inhibition of FAK.  These compds. showed slow dissocn. from unphosphorylated FAK and were noncompetitive with ATP after long preincubation.  Co-crystal structural anal. revealed that the compds. target a novel allosteric site within the C-lobe of the kinase domain, which induces disruption of ATP pocket formation leading to the inhibition of kinase activity.  The potency of allosteric inhibition was reduced by phosphorylation of FAK.  Coupled SAR anal. revealed that N-substitution of the fused pyrazole is crit. to achieve allosteric binding and high selectivity among kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkySXIj4BDgrVg90H21EOLACvtfcHk0lgZ5gHzSacNiw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFOks7g%253D&md5=1b0f8d1e6c422b369645be532d16596e</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.06.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.06.035%26sid%3Dliteratum%253Aachs%26aulast%3DIwatani%26aufirst%3DM.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DOkabe%26aufirst%3DA.%26aulast%3DSkene%26aufirst%3DR.%2BJ.%26aulast%3DTomita%26aufirst%3DN.%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DAramaki%26aufirst%3DY.%26aulast%3DHosfield%26aufirst%3DD.%2BJ.%26aulast%3DHori%26aufirst%3DA.%26aulast%3DBaba%26aufirst%3DA.%26aulast%3DMiki%26aufirst%3DH.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520novel%2520allosteric%2520FAK%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D61%26spage%3D49%26epage%3D60%26doi%3D10.1016%2Fj.ejmech.2012.06.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tomita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oomori, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aramaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwatani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okabe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awazu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isono, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skene, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosfield, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baba, A.</span></span> <span> </span><span class="NLM_article-title">Structure-based discovery of cellular-active allosteric inhibitors of FAK</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1779</span>â <span class="NLM_lpage">1785</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2013.01.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bmcl.2013.01.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=23414845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3sXis1Wrtrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=1779-1785&author=N.+Tomitaauthor=Y.+Hayashiauthor=S.+Suzukiauthor=Y.+Oomoriauthor=Y.+Aramakiauthor=Y.+Matsushitaauthor=M.+Iwataniauthor=H.+Iwataauthor=A.+Okabeauthor=Y.+Awazuauthor=O.+Isonoauthor=R.+J.+Skeneauthor=D.+J.+Hosfieldauthor=H.+Mikiauthor=T.+Kawamotoauthor=A.+Horiauthor=A.+Baba&title=Structure-based+discovery+of+cellular-active+allosteric+inhibitors+of+FAK&doi=10.1016%2Fj.bmcl.2013.01.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based discovery of cellular-active allosteric inhibitors of FAK</span></div><div class="casAuthors">Tomita, Naoki; Hayashi, Yoko; Suzuki, Shinkichi; Oomori, Yoshimasa; Aramaki, Yoshio; Matsushita, Yoshihiro; Iwatani, Misa; Iwata, Hidehisa; Okabe, Atsutoshi; Awazu, Yoshiko; Isono, Osamu; Skene, Robert J.; Hosfield, David J.; Miki, Hiroshi; Kawamoto, Tomohiro; Hori, Akira; Baba, Atsuo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1779-1785</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In order to develop potent and selective focal adhesion kinase (FAK) inhibitors, synthetic studies on pyrazolo[4,3-c][2,1]benzothiazines targeted for the FAK allosteric site were carried out.  Based on the X-ray structural anal. of the co-crystal of the lead compd., 8-(4-ethylphenyl)-5-methyl-1,5-dihydropyrazolo[4,3-c][2,1]benzothiazine 4,4-dioxide 1 with FAK, we designed and prepd. 1,5-dimethyl-1,5-dihydropyrazolo[4,3-c][2,1]benzothiazin derivs. which selectively inhibited kinase activity of FAK without affecting seven other kinases.  The optimized compd., N-(4-tert-butylbenzyl)-1,5-dimethyl-1,5-dihydropyrazolo[4,3-c][2,1]benzothiazin-8-amine 4,4-dioxide 30 possessed significant FAK kinase inhibitory activities both in cell-free (IC50 = 0.64 Î¼M) and in cellular assays (IC50 = 7.1 Î¼M).  These results clearly demonstrated a potential of FAK allosteric inhibitors as antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqr-Jxocxt917Vg90H21EOLACvtfcHk0lgZ5gHzSacNiw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXis1Wrtrk%253D&md5=309362a2ca95be142bb6d8e29520f367</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.01.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.01.047%26sid%3Dliteratum%253Aachs%26aulast%3DTomita%26aufirst%3DN.%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DS.%26aulast%3DOomori%26aufirst%3DY.%26aulast%3DAramaki%26aufirst%3DY.%26aulast%3DMatsushita%26aufirst%3DY.%26aulast%3DIwatani%26aufirst%3DM.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DOkabe%26aufirst%3DA.%26aulast%3DAwazu%26aufirst%3DY.%26aulast%3DIsono%26aufirst%3DO.%26aulast%3DSkene%26aufirst%3DR.%2BJ.%26aulast%3DHosfield%26aufirst%3DD.%2BJ.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DKawamoto%26aufirst%3DT.%26aulast%3DHori%26aufirst%3DA.%26aulast%3DBaba%26aufirst%3DA.%26atitle%3DStructure-based%2520discovery%2520of%2520cellular-active%2520allosteric%2520inhibitors%2520of%2520FAK%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D1779%26epage%3D1785%26doi%3D10.1016%2Fj.bmcl.2013.01.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Golubovskaya, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baotran, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cance, W. G.</span></span> <span> </span><span class="NLM_article-title">Mitoxantrone targets the ATP-binding site of FAK, binds the FAK kinase domain and decreases FAK, Pyk-2, c-Src, and IGF-1R in vitro kinase activities</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">546</span>â <span class="NLM_lpage">554</span>, <span class="refDoi">Â DOI: 10.2174/1871520611313040003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.2174%2F1871520611313040003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=22292772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSmsrvN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=546-554&author=V.+M.+Golubovskayaauthor=H.+Baotranauthor=M.+Zhengauthor=A.+Magisauthor=D.+Ostrovauthor=W.+G.+Cance&title=Mitoxantrone+targets+the+ATP-binding+site+of+FAK%2C+binds+the+FAK+kinase+domain+and+decreases+FAK%2C+Pyk-2%2C+c-Src%2C+and+IGF-1R+in+vitro+kinase+activities&doi=10.2174%2F1871520611313040003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Mitoxantrone targets the ATP-binding site of FAK, binds the FAK kinase domain and decreases FAK, Pyk-2, c-Src, and IGF-1R in vitro kinase activities</span></div><div class="casAuthors">Golubovskaya, Vita M.; Ho, Baotran; Zheng, Min; Magis, Andrew; Ostrov, David; Cance, William G.</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">546-554</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Focal Adhesion Kinase (FAK) is a non-receptor kinase that is overexpressed in many types of tumors and plays a key role in cell adhesion, spreading, motility, proliferation, invasion, angiogenesis, and survival.  Recently, FAK has been proposed as a target for cancer therapy, and we performed computer modeling and screening of the National Cancer Institute (NCI) small mol. compds. database to target the ATP-binding site of FAK, K454.  More than 140,000 small mol. compds. were docked into the crystal structure of the kinase domain of FAK in 100 different orientations using DOCK5.1 that identified small mol. compds., targeting the K454 site, called A-compds.  To find the therapeutic efficacy of these compds., we examd. the effect of twenty small mol. compds. on cell viability by MTT assays in different cancer cell lines.  One compd., A18 (1,4-bis(diethylamino)-5,8-dihydroxy anthraquinone) was a mitoxantrone deriv. and significantly decreased viability in most of the cells comparable to the to the level of FAK kinase inhibitors TAE-226 (Novartis, Inc) and PF-573,228 (Pfizer).  The A18 compd. specifically blocked autophosphorylation of FAK like TAE-226 and PF-228.  ForteBio Octet Binding assay demonstrated that mitoxantrone 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione directly binds the FAK-kinase domain.  In addn., mitoxantrone significantly decreased the viability of breast cancer cells in a dose-dependent manner and inhibited the kinase activity of FAK and Y56/577 FAK phosphorylation at 10-20 Î¼M.  Mitoxantrone did not affect phosphorylation of EGFR, but decreased Pyk-2, c-Src, and IGF-1R kinase activities.  The data demonstrate that mitoxantrone decreases cancer viability, binds FAK-Kinase domain, inhibits its kinase activity, and also inhibits in vitro kinase activities of Pyk-2 and IGF-1R.  Thus, this novel function of the mitoxantrone drug can be crit. for future development of anti-cancer agents and FAK-targeted therapy research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojYXwoPe-7nbVg90H21EOLACvtfcHk0ljhWVsz6bHE9g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSmsrvN&md5=0e1775725e49e5d395b55afa2186a8b8</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.2174%2F1871520611313040003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520611313040003%26sid%3Dliteratum%253Aachs%26aulast%3DGolubovskaya%26aufirst%3DV.%2BM.%26aulast%3DBaotran%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DMagis%26aufirst%3DA.%26aulast%3DOstrov%26aufirst%3DD.%26aulast%3DCance%26aufirst%3DW.%2BG.%26atitle%3DMitoxantrone%2520targets%2520the%2520ATP-binding%2520site%2520of%2520FAK%252C%2520binds%2520the%2520FAK%2520kinase%2520domain%2520and%2520decreases%2520FAK%252C%2520Pyk-2%252C%2520c-Src%252C%2520and%2520IGF-1R%2520in%2520vitro%2520kinase%2520activities%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D546%26epage%3D554%26doi%3D10.2174%2F1871520611313040003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Golubovskaya, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kweh, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cance, W. G.</span></span> <span> </span><span class="NLM_article-title">A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">7405</span>â <span class="NLM_lpage">7416</span>, <span class="refDoi">Â DOI: 10.1021/jm800483v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800483v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlCgur%252FF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7405-7416&author=V.+M.+Golubovskayaauthor=C.+Nybergauthor=M.+Zhengauthor=F.+Kwehauthor=A.+Magisauthor=D.+Ostrovauthor=W.+G.+Cance&title=A+small+molecule+inhibitor%2C+1%2C2%2C4%2C5-benzenetetraamine+tetrahydrochloride%2C+targeting+the+y397+site+of+focal+adhesion+kinase+decreases+tumor+growth&doi=10.1021%2Fjm800483v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">A Small Molecule Inhibitor, 1,2,4,5-Benzenetetraamine Tetrahydrochloride, Targeting the Y397 Site of Focal Adhesion Kinase Decreases Tumor Growth</span></div><div class="casAuthors">Golubovskaya, Vita M.; Nyberg, Carl; Zheng, Min; Kweh, Frederick; Magis, Andrew; Ostrov, David; Cance, William G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7405-7416</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) is a nonreceptor kinase that is overexpressed in many types of tumors.  We developed a novel cancer-therapy approach, targeting the main autophosphorylation site of FAK, Y397, by computer modeling and screening of the National Cancer Institute (NCI) small mol. compds. database.  More than 140 000 small mol. compds. were docked into the N-terminal domain of the FAK crystal structure in 100 different orientations that identified 35 compds.  One compd., 14 (1,2,4,5-benzenetetraamine tetrahydrochloride), significantly decreased viability in most of the cells to the levels equal to or higher than control FAK inhibitor 1a (2-[5-chloro-2-[2-methoxy-4-(4-morpholinyl)phenylamino]pyrimidin-4-ylamino]-N-methylbenzamide, TAE226) from Novartis, Inc.  Compd. 14 specifically and directly blocked phosphorylation of Y397-FAK in a dose- and time-dependent manner.  It increased cell detachment and inhibited cell adhesion in a dose-dependent manner.  Furthermore, 14 effectively caused breast tumor regression in vivo.  Thus, targeting the Y397 site of FAK with 14 inhibitor can be effectively used in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7LO4qrMpaarVg90H21EOLACvtfcHk0ljhWVsz6bHE9g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlCgur%252FF&md5=d7402a373c3b94ab8115b48ab00a9c21</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1021%2Fjm800483v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800483v%26sid%3Dliteratum%253Aachs%26aulast%3DGolubovskaya%26aufirst%3DV.%2BM.%26aulast%3DNyberg%26aufirst%3DC.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DKweh%26aufirst%3DF.%26aulast%3DMagis%26aufirst%3DA.%26aulast%3DOstrov%26aufirst%3DD.%26aulast%3DCance%26aufirst%3DW.%2BG.%26atitle%3DA%2520small%2520molecule%2520inhibitor%252C%25201%252C2%252C4%252C5-benzenetetraamine%2520tetrahydrochloride%252C%2520targeting%2520the%2520y397%2520site%2520of%2520focal%2520adhesion%2520kinase%2520decreases%2520tumor%2520growth%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7405%26epage%3D7416%26doi%3D10.1021%2Fjm800483v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Golubovskaya, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yemma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrov, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelman, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cance, W. G.</span></span> <span> </span><span class="NLM_article-title">A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1(3,7)]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo</span>. <i>Carcinogenesis</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1004</span>â <span class="NLM_lpage">1013</span>, <span class="refDoi">Â DOI: 10.1093/carcin/bgs120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1093%2Fcarcin%2Fbgs120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=22402131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt1yit7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=1004-1013&author=V.+M.+Golubovskayaauthor=S.+Figelauthor=B.+T.+Hoauthor=C.+P.+Johnsonauthor=M.+Yemmaauthor=G.+Huangauthor=M.+Zhengauthor=C.+Nybergauthor=A.+Magisauthor=D.+A.+Ostrovauthor=I.+H.+Gelmanauthor=W.+G.+Cance&title=A+small+molecule+focal+adhesion+kinase+%28FAK%29+inhibitor%2C+targeting+Y397+site%3A+1-%282-hydroxyethyl%29-3%2C+5%2C+7-triaza-1-azoniatricyclo+%5B3.3.1.1%283%2C7%29%5Ddecane%3B+bromide+effectively+inhibits+FAK+autophosphorylation+activity+and+decreases+cancer+cell+viability%2C+clonogenicity+and+tumor+growth+in+vivo&doi=10.1093%2Fcarcin%2Fbgs120"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl) -3, 5, 7-triaza-1-azoniatricyclo [3.3.1.13,7]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo</span></div><div class="casAuthors">Golubovskaya, Vita M.; Figel, Sheila; Ho, Baotran T.; Johnson, Christopher P.; Yemma, Michael; Huang, Grace; Zheng, Min; Nyberg, Carl; Magis, Andrew; Ostrov, David A.; Gelman, Irwin H.; Cance, William G.</div><div class="citationInfo"><span class="NLM_cas:title">Carcinogenesis</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1004-1013</span>CODEN:
                <span class="NLM_cas:coden">CRNGDP</span>;
        ISSN:<span class="NLM_cas:issn">0143-3334</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) is a protein tyrosine kinase that is overexpressed in most solid types of tumors and plays an important role in the survival signaling.  Recently, we have developed a novel computer modeling combined with a functional assay approach to target the main autophosphorylation site of FAK (Y397).  Using these approaches, we identified 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.13,7]decane; bromide, called Y11, a small mol. inhibitor targeting Y397 site of FAK.  Y11 significantly and specifically decreased FAK autophosphorylation, directly bound to the N-terminal domain of FAK.  In addn., Y11 decreased Y397-FAK autophosphorylation, inhibited viability and clonogenicity of colon SW620 and breast BT474 cancer cells and increased detachment and apoptosis in vitro.  Moreover, Y11 significantly decreased tumor growth in the colon cancer cell mouse xenograft model.  Finally, tumors from the Y11-treated mice demonstrated decreased Y397-FAK autophosphorylation and activation of poly (ADP ribose) polymerase and caspase-3.  Thus, targeting the major autophosphorylation site of FAK with Y11 inhibitor is crit. for development of cancer therapeutics and carcinogenesis field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_gOZRHcVifrVg90H21EOLACvtfcHk0ljhWVsz6bHE9g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt1yit7g%253D&md5=15da7f6f57dd78e0e69bc64970d4dec1</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1093%2Fcarcin%2Fbgs120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcarcin%252Fbgs120%26sid%3Dliteratum%253Aachs%26aulast%3DGolubovskaya%26aufirst%3DV.%2BM.%26aulast%3DFigel%26aufirst%3DS.%26aulast%3DHo%26aufirst%3DB.%2BT.%26aulast%3DJohnson%26aufirst%3DC.%2BP.%26aulast%3DYemma%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DG.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DNyberg%26aufirst%3DC.%26aulast%3DMagis%26aufirst%3DA.%26aulast%3DOstrov%26aufirst%3DD.%2BA.%26aulast%3DGelman%26aufirst%3DI.%2BH.%26aulast%3DCance%26aufirst%3DW.%2BG.%26atitle%3DA%2520small%2520molecule%2520focal%2520adhesion%2520kinase%2520%2528FAK%2529%2520inhibitor%252C%2520targeting%2520Y397%2520site%253A%25201-%25282-hydroxyethyl%2529-3%252C%25205%252C%25207-triaza-1-azoniatricyclo%2520%255B3.3.1.1%25283%252C7%2529%255Ddecane%253B%2520bromide%2520effectively%2520inhibits%2520FAK%2520autophosphorylation%2520activity%2520and%2520decreases%2520cancer%2520cell%2520viability%252C%2520clonogenicity%2520and%2520tumor%2520growth%2520in%2520vivo%26jtitle%3DCarcinogenesis%26date%3D2012%26volume%3D33%26spage%3D1004%26epage%3D1013%26doi%3D10.1093%2Fcarcin%2Fbgs120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sajeevan, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naman, C. B.</span></span> <span> </span><span class="NLM_article-title">A systematic review of recently reported marine derived natural product kinase inhibitors</span>. <i>Mar. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">493</span>â <span class="NLM_lpage">529</span>, <span class="refDoi">Â DOI: 10.3390/md17090493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.3390%2Fmd17090493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BB3cXms1WgsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&pages=493-529&author=T.+Liauthor=N.+Wangauthor=T.+Zhangauthor=B.+Zhangauthor=T.+P.+Sajeevanauthor=V.+Josephauthor=L.+Armstrongauthor=S.+Heauthor=X.+Yanauthor=C.+B.+Naman&title=A+systematic+review+of+recently+reported+marine+derived+natural+product+kinase+inhibitors&doi=10.3390%2Fmd17090493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">A systematic review of recently reported marine derived natural product kinase inhibitors</span></div><div class="casAuthors">Li, Te; Wang, Ning; Zhang, Ting; Zhang, Bin; Sajeevan, Thavarool P.; Joseph, Valsamma; Armstrong, Lorene; He, Shan; Yan, Xiaojun; Naman, C. Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Marine Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">493</span>CODEN:
                <span class="NLM_cas:coden">MDARE6</span>;
        ISSN:<span class="NLM_cas:issn">1660-3397</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Protein kinases are validated drug targets for a no. of therapeutic areas, as kinase deregulation is known to play an essential role in many disease states.  Many investigated protein kinase inhibitors are natural product small mols. or their derivs.  Many marine-derived natural products from various marine sources, such as bacteria and cyanobacteria, fungi, animals, algae, soft corals, sponges, etc. have been found to have potent kinase inhibitory activity, or desirable pharmacophores for further development.  This review covers the new compds. reported from the beginning of 2014 through the middle of 2019 as having been isolated from marine organisms and having potential therapeutic applications due to kinase inhibitory and assocd. bioactivities.  Moreover, some existing clin. drugs based on marine-derived natural product scaffolds are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG1uYwteAPuLVg90H21EOLACvtfcHk0li8TnqjKp22Og"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXms1WgsLw%253D&md5=d64a23e5d67fed4aef76c546a600c1e4</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.3390%2Fmd17090493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmd17090493%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DSajeevan%26aufirst%3DT.%2BP.%26aulast%3DJoseph%26aufirst%3DV.%26aulast%3DArmstrong%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DYan%26aufirst%3DX.%26aulast%3DNaman%26aufirst%3DC.%2BB.%26atitle%3DA%2520systematic%2520review%2520of%2520recently%2520reported%2520marine%2520derived%2520natural%2520product%2520kinase%2520inhibitors%26jtitle%3DMar.%2520Drugs%26date%3D2019%26volume%3D17%26spage%3D493%26epage%3D529%26doi%3D10.3390%2Fmd17090493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foudah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebrahim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayed, K.</span></span> <span> </span><span class="NLM_article-title">The marine-derived sipholenol A-4-O-3â²,4â²-dichlorobenzoate inhibits breast cancer growth and motility in vitro and in vivo through the suppression of Brk and FAK signaling</span>. <i>Mar. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2282</span>â <span class="NLM_lpage">2304</span>, <span class="refDoi">Â DOI: 10.3390/md12042282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.3390%2Fmd12042282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=24736807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BC2cnktlSgtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=2282-2304&author=M.+Aklauthor=A.+Foudahauthor=H.+Ebrahimauthor=S.+Meyerauthor=K.+Sayed&title=The+marine-derived+sipholenol+A-4-O-3%E2%80%B2%2C4%E2%80%B2-dichlorobenzoate+inhibits+breast+cancer+growth+and+motility+in+vitro+and+in+vivo+through+the+suppression+of+Brk+and+FAK+signaling&doi=10.3390%2Fmd12042282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">The marine-derived sipholenol A-4-O-3',4'-dichlorobenzoate inhibits breast cancer growth and motility in vitro and in vivo through the suppression of Brk and FAK signaling</span></div><div class="casAuthors">Akl Mohamed R; Foudah Ahmed I; Ebrahim Hassan Y; El Sayed Khalid A; Meyer Sharon A</div><div class="citationInfo"><span class="NLM_cas:title">Marine drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2282-304</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sipholenol A is a natural sipholane triterpenoid isolated from the Red Sea sponge, Callyspongia siphonella.  Previous studies showed the antimigratory and antiproliferative activities of the semisynthetic sipholenol A esters against breast cancer cell lines.  This study investigated the effects of sipholenol A-4-O-3',4'-dichlorobenzoate (SPA) on the growth, migration and invasion of diverse human breast cancer cells.  Results showed that SPA inhibited the growth of the human breast cancer cells, MDA-MB-231, MCF-7, BT-474 and T-47D, in a dose-dependent manner.  Immunofluorescent analysis showed that SPA significantly reduced Ki-67-positive cells in MDA-MB-231 cells.  Flow cytometry and Western blot analyses revealed that SPA treatment suppressed MDA-MB-231 cell growth by inducing cell cycle arrest at the G1 phase.  In addition, SPA suppressed breast cancer cell migration, invasion and decreased Brk and FAK activation in a dose-dependent manner.  Molecular docking study suggested a perfect fitting at the FAK's FERM domain, inhibiting the main autophosphorylation site, Y397, which was further confirmed by Western blot analysis.  Most known small molecule FAK inhibitors target the kinase domain, creating several off-target side effects.  The in vivo studies showed that SPA treatment suppressed breast tumor growth and Ki-67, CD31, p-Brk and p-FAK expression in orthotopic breast cancer in nude mice.  In conclusion, SPA inhibited the growth, invasion and migration of breast cancer cells possibly via deactivating Brk and FAK signaling, suggesting good potential for therapeutic use to control invasive breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQC_8YW6oK0rMNIRw0GKUoEfW6udTcc2eakNNKgPd3BH7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnktlSgtQ%253D%253D&md5=cf8be5a98501477bcda403432de12b67</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.3390%2Fmd12042282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmd12042282%26sid%3Dliteratum%253Aachs%26aulast%3DAkl%26aufirst%3DM.%26aulast%3DFoudah%26aufirst%3DA.%26aulast%3DEbrahim%26aufirst%3DH.%26aulast%3DMeyer%26aufirst%3DS.%26aulast%3DSayed%26aufirst%3DK.%26atitle%3DThe%2520marine-derived%2520sipholenol%2520A-4-O-3%25E2%2580%25B2%252C4%25E2%2580%25B2-dichlorobenzoate%2520inhibits%2520breast%2520cancer%2520growth%2520and%2520motility%2520in%2520vitro%2520and%2520in%2520vivo%2520through%2520the%2520suppression%2520of%2520Brk%2520and%2520FAK%2520signaling%26jtitle%3DMar.%2520Drugs%26date%3D2014%26volume%3D12%26spage%3D2282%26epage%3D2304%26doi%3D10.3390%2Fmd12042282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thiyagarajan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chia, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, C. F.</span></span> <span> </span><span class="NLM_article-title">A novel inhibitor, 16-hydroxy-cleroda-3,13-dien-16,15-olide, blocks the autophosphorylation site of focal adhesion kinase (Y397) by molecular docking</span>. <i>Biochim. Biophys. Acta, Gen. Subj.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1830</i></span>,  <span class="NLM_fpage">4091</span>â <span class="NLM_lpage">4101</span>, <span class="refDoi">Â DOI: 10.1016/j.bbagen.2013.04.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bbagen.2013.04.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVyrsbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1830&publication_year=2013&pages=4091-4101&author=V.+Thiyagarajanauthor=S.+H.+Linauthor=Y.+C.+Chiaauthor=C.+F.+Weng&title=A+novel+inhibitor%2C+16-hydroxy-cleroda-3%2C13-dien-16%2C15-olide%2C+blocks+the+autophosphorylation+site+of+focal+adhesion+kinase+%28Y397%29+by+molecular+docking&doi=10.1016%2Fj.bbagen.2013.04.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">A novel inhibitor, 16-hydroxy-cleroda-3,13-dien-16,15-olide, blocks the autophosphorylation site of focal adhesion kinase (Y397) by molecular docking</span></div><div class="casAuthors">Thiyagarajan, Varadharajan; Lin, Shih-Hung; Chia, Yi-Chen; Weng, Ching-Feng</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1830</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4091-4101</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) is a nonreceptor protein tyrosine plays an important role in a no. of cell signaling pathways, including cell migration, proliferation, and cell survival.  This study was aimed to identify novel and specific inhibitors from natural compds. via mol. docking of FAK (Y397).  The 3D structure of FAK (PDB ID: 2AL6) was used for docking 109 natural compds.  Based on high affinity and energy interaction, four of ten candidate compds., 16-hydroxy-cleroda-3,13-dien-16,15-olide (HCD), curcumin, quercetin, and catechin hydrate, were hit, and the inhibitory activity against FAK was validated in these compds. in C6 glioma and N18 neuroblastoma cell lines.  HCD showed a potential effect on cell viability by MTT assay and cell arrest in the G0-G1 phase, and a TUNEL assay confirmed further apoptosis.  Treatment with HCD decreased anti-apoptotic proteins and increased pro-apoptotic proteins.  Atomic force microscopy data depicted that the formation of filopodia on the intracellular surface decreased in treated cells compared with the control.  Zymog. showed that HCD inhibited the activity of MMP-2 and MMP-9.  The protein levels of FAK, pFAK, Rac1 and Cdc42, which are the key regulators for the formation of filopodia, were decreased.  Addnl., HCD regulated the expression of epithelial mesenchymal transition proteins.  HCD effectively interacted at the autophosphorylation site of FAK and interaction anal. indicated an H-bond with the Arg 86 and Arg 125 residues.  This study suggests that HCD could be a potential inhibitor of FAK and could be used for anti-tumorigenesis and anti-metastasis treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUUc9o-MA5QbVg90H21EOLACvtfcHk0li8TnqjKp22Og"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVyrsbk%253D&md5=def84c65d830883c623813b63dd0c599</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2013.04.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2013.04.027%26sid%3Dliteratum%253Aachs%26aulast%3DThiyagarajan%26aufirst%3DV.%26aulast%3DLin%26aufirst%3DS.%2BH.%26aulast%3DChia%26aufirst%3DY.%2BC.%26aulast%3DWeng%26aufirst%3DC.%2BF.%26atitle%3DA%2520novel%2520inhibitor%252C%252016-hydroxy-cleroda-3%252C13-dien-16%252C15-olide%252C%2520blocks%2520the%2520autophosphorylation%2520site%2520of%2520focal%2520adhesion%2520kinase%2520%2528Y397%2529%2520by%2520molecular%2520docking%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2013%26volume%3D1830%26spage%3D4091%26epage%3D4101%26doi%3D10.1016%2Fj.bbagen.2013.04.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Golubovskaya, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palma, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baotran, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cance, W. G.</span></span> <span> </span><span class="NLM_article-title">A small-molecule Inhibitor, 5 â-O-tritylthymidine, targets FAK and Mdm-2 interaction, and blocks breast and colon tumorigenesis in vivo</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">532</span>â <span class="NLM_lpage">545</span>, <span class="refDoi">Â DOI: 10.2174/1871520611313040002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.2174%2F1871520611313040002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=22292771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSmsrvM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=532-545&author=V.+M.+Golubovskayaauthor=N.+L.+Palmaauthor=M.+Zhengauthor=H.+Baotranauthor=A.+Magisauthor=D.+Ostrovauthor=W.+G.+Cance&title=A+small-molecule+Inhibitor%2C+5+%E2%80%98-O-tritylthymidine%2C+targets+FAK+and+Mdm-2+interaction%2C+and+blocks+breast+and+colon+tumorigenesis+in+vivo&doi=10.2174%2F1871520611313040002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule inhibitor, 5'-O-Tritylthymidine, targets FAK and Mdm-2 interaction, and blocks breast and colon tumorigenesis in vivo</span></div><div class="casAuthors">Golubovskaya, Vita M.; Palma, Nadia L.; Zheng, Min; Ho, Baotran; Magis, Andrew; Ostrov, David; Cance, William G.</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">532-545</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Focal Adhesion Kinase (FAK) is overexpressed in many types of tumors and plays an important role in survival.  We developed a novel approach, targeting FAK-protein interactions by computer modeling and screening of NCI small mol. drug database.  In this report we targeted FAK and Mdm-2 protein interaction to decrease tumor growth.  By macromol. modeling we found a model of FAK and Mdm-2 interaction and performed screening of >200,000 small mol. compds. from NCI database with drug-like characteristics, targeting the FAK-Mdm-2 interaction.  We identified 5'-O-Tritylthymidine, called M13 compd. that significantly decreased viability in different cancer cells.  M13 was docked into the pocket of FAK and Mdm-2 interaction and was directly bound to the FAK-N terminal domain by ForteBio Octet assay.  In addn., M13 compd. affected FAK and Mdm-2 levels and decreased complex of FAK and Mdm-2 proteins in breast and colon cancer cells.  M13 re-activated p53 activity inhibited by FAK with Mdm-2 promoter.  M13 decreased viability, clonogenicity, increased detachment and apoptosis in a dose-dependent manner in BT474 breast and in HCT116 colon cancer cells in vitro.  M13 decreased FAK, activated p53 and caspase-8 in both cell lines.  In addn., M13 decreased breast and colon tumor growth in vivo.  M13 activated p53 and decreased FAK in tumor samples consistent with decreased tumor growth.  The data demonstrate a novel approach for targeting FAK and Mdm-2 protein interaction, provide a model of FAK and Mdm-2 interaction, identify M13 compd. targeting this interaction and decreasing tumor growth that is crit. for future targeted therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn7cfbykfJ87Vg90H21EOLACvtfcHk0lhh28xH8mseYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSmsrvM&md5=414fc75bd609f73cb768fdfe183ed273</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.2174%2F1871520611313040002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520611313040002%26sid%3Dliteratum%253Aachs%26aulast%3DGolubovskaya%26aufirst%3DV.%2BM.%26aulast%3DPalma%26aufirst%3DN.%2BL.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DBaotran%26aufirst%3DH.%26aulast%3DMagis%26aufirst%3DA.%26aulast%3DOstrov%26aufirst%3DD.%26aulast%3DCance%26aufirst%3DW.%2BG.%26atitle%3DA%2520small-molecule%2520Inhibitor%252C%25205%2520%25E2%2580%2598-O-tritylthymidine%252C%2520targets%2520FAK%2520and%2520Mdm-2%2520interaction%252C%2520and%2520blocks%2520breast%2520and%2520colon%2520tumorigenesis%2520in%2520vivo%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D532%26epage%3D545%26doi%3D10.2174%2F1871520611313040002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Golubovskaya, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cance, W. G.</span></span> <span> </span><span class="NLM_article-title">Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">342</span>â <span class="NLM_lpage">355</span>, <span class="refDoi">Â DOI: 10.1186/1471-2407-13-342</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1186%2F1471-2407-13-342" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=23841915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1WjsLzM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=342-355&author=V.+M.+Golubovskayaauthor=B.+Hoauthor=M.+Zhengauthor=A.+Magisauthor=D.+Ostrovauthor=C.+Morrisonauthor=W.+G.+Cance&title=Disruption+of+focal+adhesion+kinase+and+p53+interaction+with+small+molecule+compound+R2+reactivated+p53+and+blocked+tumor+growth&doi=10.1186%2F1471-2407-13-342"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Disruption of Focal Adhesion Kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth</span></div><div class="casAuthors">Golubovskaya, Vita M.; Ho, Baotran; Zheng, Min; Magis, Andrew; Ostrov, David; Morrison, Carl; Cance, William G.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">342</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Focal Adhesion Kinase (FAK) is a 125 kDa non-receptor kinase that plays a major role in cancer cell survival and metastasis.  Methods: We performed computer modeling of the p53 peptide contg. the site of interaction with FAK, predicted the peptide structure and docked it into the three-dimensional structure of the N-terminal domain of FAK involved in the complex with p53.  We screened small mol. compds. that targeted the site of the FAK-p53 interaction and identified compds. (called Roslins, or R compds.) docked in silico to this site.  Results: By different assays in isogenic HCT116 p53+/+ and HCT116 p53-/- cells we identified a small mol. compd. called Roslin 2 (R2) that bound FAK, disrupted the binding of FAK and p53 and decreased cancer cell viability and clonogenicity in a p53-dependent manner.  In addn., dual-luciferase assays demonstrated that the R2 compd. increased p53 transcriptional activity that was inhibited by FAK using p21, Mdm-2, and Bax-promoter targets.  R2 also caused increased expression of p53 targets: p21, Mdm-2 and Bax proteins.  Furthermore, R2 significantly decreased tumor growth, disrupted the complex of FAK and p53, and up-regulated p21 in HCT116 p53+/+ but not in HCT116 p53-/- xenografts in vivo.  In addn., R2 sensitized HCT116 p53+/+ cells to doxorubicin and 5-fluorouracil.  Conclusions: Thus, disruption of the FAK and p53 interaction with a novel small mol. reactivated p53 in cancer cells in vitro and in vivo and can be effectively used for development of FAK-p53 targeted cancer therapy approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiQffBjvnrgrVg90H21EOLACvtfcHk0lhh28xH8mseYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1WjsLzM&md5=e5326d7d8a0be1008b118841d8105227</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-13-342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-13-342%26sid%3Dliteratum%253Aachs%26aulast%3DGolubovskaya%26aufirst%3DV.%2BM.%26aulast%3DHo%26aufirst%3DB.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DMagis%26aufirst%3DA.%26aulast%3DOstrov%26aufirst%3DD.%26aulast%3DMorrison%26aufirst%3DC.%26aulast%3DCance%26aufirst%3DW.%2BG.%26atitle%3DDisruption%2520of%2520focal%2520adhesion%2520kinase%2520and%2520p53%2520interaction%2520with%2520small%2520molecule%2520compound%2520R2%2520reactivated%2520p53%2520and%2520blocked%2520tumor%2520growth%26jtitle%3DBMC%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D342%26epage%3D355%26doi%3D10.1186%2F1471-2407-13-342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pollak, M.</span></span> <span> </span><span class="NLM_article-title">Insulin and insulin-like growth factor signalling in neoplasia</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">915</span>â <span class="NLM_lpage">928</span>, <span class="refDoi">Â DOI: 10.1038/nrc2536</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fnrc2536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=19029956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7rL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=915-928&author=M.+Pollak&title=Insulin+and+insulin-like+growth+factor+signalling+in+neoplasia&doi=10.1038%2Fnrc2536"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin and insulin-like growth factor signalling in neoplasia</span></div><div class="casAuthors">Pollak, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">915-928</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Insulin and insulin-like growth factors (IGFs) are well known as key regulators of energy metab. and growth.  There is now considerable evidence that these hormones and the signal transduction networks they regulate have important roles in neoplasia.  Epidermiol., clin. and lab. research methods are being used to investigate novel cancer prevention and treatment strategies related to insulin and IGF signaling.  Pharmacol. strategies under study include the use of novel receptor-specific antibodies, receptor kinase inhibitors and AMP-activated protein kinase activators such as metformin.  There is evidence that insulin and IGF signaling may also be relevant to dietary and lifestyle factors that influence cancer risk and cancer prognosis.  Recent results are encouraging and have justified the expansion of many translational research programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4Q6Nlh1d68rVg90H21EOLACvtfcHk0lhh28xH8mseYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7rL&md5=9a7b5e7c67599c7396033f83276f2cb0</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1038%2Fnrc2536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2536%26sid%3Dliteratum%253Aachs%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DInsulin%2520and%2520insulin-like%2520growth%2520factor%2520signalling%2520in%2520neoplasia%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2008%26volume%3D8%26spage%3D915%26epage%3D928%26doi%3D10.1038%2Fnrc2536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golubovskaya, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurenova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massoll, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cance, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochwald, S. N.</span></span> <span> </span><span class="NLM_article-title">A novel strategy to inhibit FAK and IGF-1R decreases growth of pancreatic cancer xenografts</span>. <i>Mol. Carcinog.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">200</span>â <span class="NLM_lpage">209</span>, <span class="refDoi">Â DOI: 10.1002/mc.20590</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1002%2Fmc.20590" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=200-209&author=D.+Zhengauthor=V.+Golubovskayaauthor=E.+Kurenovaauthor=C.+Woodauthor=N.+A.+Massollauthor=D.+Ostrovauthor=W.+G.+Canceauthor=S.+N.+Hochwald&title=A+novel+strategy+to+inhibit+FAK+and+IGF-1R+decreases+growth+of+pancreatic+cancer+xenografts&doi=10.1002%2Fmc.20590"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1002%2Fmc.20590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmc.20590%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DD.%26aulast%3DGolubovskaya%26aufirst%3DV.%26aulast%3DKurenova%26aufirst%3DE.%26aulast%3DWood%26aufirst%3DC.%26aulast%3DMassoll%26aufirst%3DN.%2BA.%26aulast%3DOstrov%26aufirst%3DD.%26aulast%3DCance%26aufirst%3DW.%2BG.%26aulast%3DHochwald%26aufirst%3DS.%2BN.%26atitle%3DA%2520novel%2520strategy%2520to%2520inhibit%2520FAK%2520and%2520IGF-1R%2520decreases%2520growth%2520of%2520pancreatic%2520cancer%2520xenografts%26jtitle%3DMol.%2520Carcinog.%26date%3D2009%26volume%3D49%26spage%3D200%26epage%3D209%26doi%3D10.1002%2Fmc.20590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ucar, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magis, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebti, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurenova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zajac-Kaye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochwald, S. N.</span></span> <span> </span><span class="NLM_article-title">Inhibiting the interaction of cMET and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells in vitro and in vivo</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">595</span>â <span class="NLM_lpage">602</span>, <span class="refDoi">Â DOI: 10.2174/1871520611313040009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.2174%2F1871520611313040009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=23272972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSmsrjN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=595-602&author=D.+A.+Ucarauthor=A.+T.+Magisauthor=D.+H.+Heauthor=N.+J.+Lawrenceauthor=S.+M.+Sebtiauthor=E.+Kurenovaauthor=M.+Zajac-Kayeauthor=J.+Zhangauthor=S.+N.+Hochwald&title=Inhibiting+the+interaction+of+cMET+and+IGF-1R+with+FAK+effectively+reduces+growth+of+pancreatic+cancer+cells+in+vitro+and+in+vivo&doi=10.2174%2F1871520611313040009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting the interaction of cMET and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells in vitro and in vivo</span></div><div class="casAuthors">Ucar, Deniz A.; Magis, Andrew T.; He, Di-Hua; Lawrence, Nicholas J.; Sebti, Said M.; Kurenova, Elena; Zajac-Kaye, Maria; Zhang, Jianliang; Hochwald, Steven N.</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">595-602</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Pancreatic cancer is one of the most lethal diseases with no effective treatment.  Previously, we have shown that FAK is overexpressed in pancreatic cancer and plays a key role in cancer cell survival and proliferation.  FAK has been shown to interact with growth factor receptors including cMET and IGF-1R.  As a novel therapeutic approach, we targeted the protein interaction of FAK with growth factor receptors to block tumor growth, alter signaling pathways and sensitize cells to chemotherapy.  We have selected a small mol. compd. (INT2-31) that decreases phosphorylation of AKT via disrupting interaction of FAK with cMET and IGF-1R.  Our results demonstrate that interaction of a small mol. compd. with FAK decreases phosphorylation of FAK Y397 while increasing FAK Y407 phosphorylation, without inhibiting the kinase activity of FAK and dramatically reduces downstream signaling to AKT.  Our lead compd., INT2-31, demonstrates significant inhibition of tumor cell growth in two orthotopic models of pancreatic cancer.  In addn., INT2-31increases sensitivity to gemcitabine chemotherapy in a direct fresh biopsy xenograft model of pancreatic cancer growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhgvXiu8WtibVg90H21EOLACvtfcHk0lgkXfI2LlXpCw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSmsrjN&md5=8c8608ccff031eaa449b458326248ac3</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.2174%2F1871520611313040009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520611313040009%26sid%3Dliteratum%253Aachs%26aulast%3DUcar%26aufirst%3DD.%2BA.%26aulast%3DMagis%26aufirst%3DA.%2BT.%26aulast%3DHe%26aufirst%3DD.%2BH.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26aulast%3DKurenova%26aufirst%3DE.%26aulast%3DZajac-Kaye%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHochwald%26aufirst%3DS.%2BN.%26atitle%3DInhibiting%2520the%2520interaction%2520of%2520cMET%2520and%2520IGF-1R%2520with%2520FAK%2520effectively%2520reduces%2520growth%2520of%2520pancreatic%2520cancer%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D595%26epage%3D602%26doi%3D10.2174%2F1871520611313040009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garces, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurenova, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golubovskaya, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cance, W. G.</span></span> <span> </span><span class="NLM_article-title">Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1446</span>â <span class="NLM_lpage">1454</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-05-1661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1158%2F0008-5472.CAN-05-1661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=16452200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVehug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=1446-1454&author=C.+A.+Garcesauthor=E.+V.+Kurenovaauthor=V.+M.+Golubovskayaauthor=W.+G.+Cance&title=Vascular+endothelial+growth+factor+receptor-3+and+focal+adhesion+kinase+bind+and+suppress+apoptosis+in+breast+cancer+cells&doi=10.1158%2F0008-5472.CAN-05-1661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular Endothelial Growth Factor Receptor-3 and Focal Adhesion Kinase Bind and Suppress Apoptosis in Breast Cancer Cells</span></div><div class="casAuthors">Garces, Christopher A.; Kurenova, Elena V.; Golubovskaya, Vita M.; Cance, William G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1446-1454</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) and vascular endothelial growth factor receptor-3 (VEGFR-3) are protein tyrosine kinases that are overexpressed in human cancer and play an important role in survival signaling.  In addn. to its involvement with cell survival, VEGFR-3 is a primary factor in lymphatic angiogenesis.  Because FAK function is regulated by its COOH terminus (FAK-CD), we used FAK-CD as a target to identify binding partners.  We isolated a peptide from a phage library that bound to FAK-CD, specifically the focal adhesion targeting domain of FAK and was homologous to VEGFR-3, suggesting these two tyrosine kinases phys. interact.  We have also shown that VEGFR-3 is overexpressed in human breast tumors and cancer cell lines.  For the first time, we have shown the phys. assocn. of FAK and VEGFR-3.  The assocn. between the NH2 terminus of VEGFR-3, contg. the peptide identified by phage display, and the COOH terminus of FAK was detected by in vitro and in vivo binding studies.  We then coupled a 12-amino-acid VEGFR-3 peptide, AV3, to a TAT cellular penetration sequence and showed that AV3 and not control-scrambled peptide caused specific displacement of FAK from the focal adhesions and affected colocalization of FAK and VEGFR-3.  In addn., AV3 peptide decreased proliferation and caused cell detachment and apoptosis in breast cancer cell lines but not in normal breast cells.  Thus, the FAK/VEGFR-3 interaction may have a potential use to develop novel mol. therapeutics to target the signaling between FAK and VEGFR-3 in human tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod9mUYmoenhrVg90H21EOLACvtfcHk0lgkXfI2LlXpCw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVehug%253D%253D&md5=889ef9ed6935fe6ebe4b1ec6933369b6</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-1661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-1661%26sid%3Dliteratum%253Aachs%26aulast%3DGarces%26aufirst%3DC.%2BA.%26aulast%3DKurenova%26aufirst%3DE.%2BV.%26aulast%3DGolubovskaya%26aufirst%3DV.%2BM.%26aulast%3DCance%26aufirst%3DW.%2BG.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520receptor-3%2520and%2520focal%2520adhesion%2520kinase%2520bind%2520and%2520suppress%2520apoptosis%2520in%2520breast%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D1446%26epage%3D1454%26doi%3D10.1158%2F0008-5472.CAN-05-1661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurenova, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magis, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrov, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cance, W. G.</span></span> <span> </span><span class="NLM_article-title">Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">4716</span>â <span class="NLM_lpage">4724</span>, <span class="refDoi">Â DOI: 10.1021/jm900159g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900159g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD1MXoslCnt70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4716-4724&author=E.+V.+Kurenovaauthor=D.+L.+Huntauthor=D.+Heauthor=A.+T.+Magisauthor=D.+A.+Ostrovauthor=W.+G.+Cance&title=Small+molecule+chloropyramine+hydrochloride+%28C4%29+targets+the+binding+site+of+focal+adhesion+kinase+and+vascular+endothelial+growth+factor+receptor+3+and+suppresses+breast+cancer+growth+in+vivo&doi=10.1021%2Fjm900159g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Chloropyramine Hydrochloride (C4) Targets the Binding Site of Focal Adhesion Kinase and Vascular Endothelial Growth Factor Receptor 3 and Suppresses Breast Cancer Growth in Vivo</span></div><div class="casAuthors">Kurenova, Elena V.; Hunt, Darell L.; He, Dihua; Magis, Andrew T.; Ostrov, David A.; Cance, William G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4716-4724</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">FAK is a tyrosine kinase that functions as a key orchestrator of signals leading to invasion and metastasis.  Since FAK interacts directly with a no. of crit. proteins involved in survival signaling in tumor cells, we hypothesized that targeting a key protein-protein interface with druglike small mols. was a feasible strategy for inhibiting tumor growth.  In this study, we targeted the protein-protein interface between FAK and VEGFR-3 and identified compd. C4 (chloropyramine hydrochloride) as a drug capable of (1) inhibiting the biochem. function of VEGFR-3 and FAK, (2) inhibiting proliferation of a diverse set of cancer cell types in vitro, and (3) reducing tumor growth in vivo.  Chloropyramine hydrochloride reduced tumor growth as a single agent, while concomitant administration with doxorubicin had a pronounced synergistic effect.  Our data demonstrate that the FAK-VEGFR-3 interaction can be targeted by small druglike mols. and this interaction can provide the basis for highly specific novel cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWNwqHRfkXabVg90H21EOLACvtfcHk0liO19fed4enZQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXoslCnt70%253D&md5=a9ea7e44d7de5a6d94d29f3b6b2f2a71</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1021%2Fjm900159g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900159g%26sid%3Dliteratum%253Aachs%26aulast%3DKurenova%26aufirst%3DE.%2BV.%26aulast%3DHunt%26aufirst%3DD.%2BL.%26aulast%3DHe%26aufirst%3DD.%26aulast%3DMagis%26aufirst%3DA.%2BT.%26aulast%3DOstrov%26aufirst%3DD.%2BA.%26aulast%3DCance%26aufirst%3DW.%2BG.%26atitle%3DSmall%2520molecule%2520chloropyramine%2520hydrochloride%2520%2528C4%2529%2520targets%2520the%2520binding%2520site%2520of%2520focal%2520adhesion%2520kinase%2520and%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%25203%2520and%2520suppresses%2520breast%2520cancer%2520growth%2520in%2520vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4716%26epage%3D4724%26doi%3D10.1021%2Fjm900159g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gogate, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurenova, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magis, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cance, W. G.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">154</span>â <span class="NLM_lpage">166</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2014.04.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.ejmech.2014.04.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=24780592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovValtLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2014&pages=154-166&author=P.+N.+Gogateauthor=M.+Ethirajanauthor=E.+V.+Kurenovaauthor=A.+T.+Magisauthor=R.+K.+Pandeyauthor=W.+G.+Cance&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+FAK+scaffold+inhibitors+targeting+the+FAK-VEGFR3+protein-protein+interaction&doi=10.1016%2Fj.ejmech.2014.04.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction</span></div><div class="casAuthors">Gogate, Priyanka N.; Ethirajan, Manivannan; Kurenova, Elena V.; Magis, Andrew T.; Pandey, Ravindra K.; Cance, William G.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">154-166</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) and vascular endothelial growth factor receptor 3 (VEGFR3) are tyrosine kinases, which function as key modulators of survival and metastasis signals in cancer cells.  Previously, we reported that small mol. chlorpyramine hydrochloride (C4) specifically targets the interaction between FAK and VEGFR3 and exhibits anti-tumor efficacy.  In this study, we designed and synthesized a series of 1 (C4) analogs on the basis of structure activity relationship and mol. modeling.  The resulting new compds. were evaluated for their binding to the FAT domain of FAK and anti-cancer activity.  Amongst all tested analogs, compd. 29 augmented anti-proliferative activity in multiple cancer cell lines with stronger binding to the FAT domain of FAK and disrupted the FAK-VEGFR3 interaction.  In conclusion, we hope that this work will contribute to further studies of more potent and selective FAK-VEGFR3 protein-protein interaction inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl_XFYonxwS7Vg90H21EOLACvtfcHk0liO19fed4enZQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovValtLw%253D&md5=d80c176ed988cdea856ce4202352fcf3</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.04.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.04.041%26sid%3Dliteratum%253Aachs%26aulast%3DGogate%26aufirst%3DP.%2BN.%26aulast%3DEthirajan%26aufirst%3DM.%26aulast%3DKurenova%26aufirst%3DE.%2BV.%26aulast%3DMagis%26aufirst%3DA.%2BT.%26aulast%3DPandey%26aufirst%3DR.%2BK.%26aulast%3DCance%26aufirst%3DW.%2BG.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520FAK%2520scaffold%2520inhibitors%2520targeting%2520the%2520FAK-VEGFR3%2520protein-protein%2520interaction%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D80%26spage%3D154%26epage%3D166%26doi%3D10.1016%2Fj.ejmech.2014.04.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Churcher, I.</span></span> <span> </span><span class="NLM_article-title">Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">444</span>â <span class="NLM_lpage">452</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b01272</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01272" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWqtbvJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=444-452&author=I.+Churcher&title=Protac-induced+protein+degradation+in+drug+discovery%3A+breaking+the+rules+or+just+making+new+ones%3F&doi=10.1021%2Facs.jmedchem.7b01272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?</span></div><div class="casAuthors">Churcher, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">444-452</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Targeted protein degrdn., using bifunctional small mols. (Protacs) to remove specific proteins from within cells, has emerged as a novel drug discovery strategy with the potential to offer therapeutic interventions not achievable with existing approaches.  In this perspective, the brief history of the field is surveyed from a drug discovery perspective with a focus on the key advances in knowledge which have led to the definition and exemplification of protein degrdn. concepts, and their resulting applications to medicine discovery.  The approach has the potential to bring disruptive change to drug discovery - the many potential advantages and outstanding challenges which lie ahead of this technol. are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9n8I_0MhtkbVg90H21EOLACvtfcHk0liO19fed4enZQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWqtbvJ&md5=e60f1777de8bd860c5001137d8583f1f</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01272%26sid%3Dliteratum%253Aachs%26aulast%3DChurcher%26aufirst%3DI.%26atitle%3DProtac-induced%2520protein%2520degradation%2520in%2520drug%2520discovery%253A%2520breaking%2520the%2520rules%2520or%2520just%2520making%2520new%2520ones%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D444%26epage%3D452%26doi%3D10.1021%2Facs.jmedchem.7b01272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bondeson, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mares, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, I. E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miah, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulholland, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Routly, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinn, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergamini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faelth-Savitski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willard, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casillas, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Votta, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">den Besten, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Famm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruidenier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harling, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churcher, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Catalytic in vivo protein knockdown by small-molecule PROTACs</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">611</span>â <span class="NLM_lpage">617</span>, <span class="refDoi">Â DOI: 10.1038/nchembio.1858</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fnchembio.1858" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=26075522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7rP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=611-617&author=D.+P.+Bondesonauthor=A.+Maresauthor=I.+E.+D.+Smithauthor=E.+Koauthor=S.+Camposauthor=A.+H.+Miahauthor=K.+E.+Mulhollandauthor=N.+Routlyauthor=D.+L.+Buckleyauthor=J.+L.+Gustafsonauthor=N.+Zinnauthor=P.+Grandiauthor=S.+Shimamuraauthor=G.+Bergaminiauthor=M.+Faelth-Savitskiauthor=M.+Bantscheffauthor=C.+Coxauthor=D.+A.+Gordonauthor=R.+R.+Willardauthor=J.+J.+Flanaganauthor=L.+N.+Casillasauthor=B.+J.+Vottaauthor=W.+den+Bestenauthor=K.+Fammauthor=L.+Kruidenierauthor=P.+S.+Carterauthor=J.+D.+Harlingauthor=I.+Churcherauthor=C.+M.+Crews&title=Catalytic+in+vivo+protein+knockdown+by+small-molecule+PROTACs&doi=10.1038%2Fnchembio.1858"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic in vivo protein knockdown by small-molecule PROTACs</span></div><div class="casAuthors">Bondeson, Daniel P.; Mares, Alina; Smith, Ian E. D.; Ko, Eunhwa; Campos, Sebastien; Miah, Afjal H.; Mulholland, Katie E.; Routly, Natasha; Buckley, Dennis L.; Gustafson, Jeffrey L.; Zinn, Nico; Grandi, Paola; Shimamura, Satoko; Bergamini, Giovanna; Faelth-Savitski, Maria; Bantscheff, Marcus; Cox, Carly; Gordon, Deborah A.; Willard, Ryan R.; Flanagan, John J.; Casillas, Linda N.; Votta, Bartholomew J.; den Besten, Willem; Famm, Kristoffer; Kruidenier, Laurens; Carter, Paul S.; Harling, John D.; Churcher, Ian; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">611-617</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The current predominant therapeutic paradigm is based on maximizing drug-receptor occupancy to achieve clin. benefit.  This strategy, however, generally requires excessive drug concns. to ensure sufficient occupancy, often leading to adverse side effects.  Here, we describe major improvements to the proteolysis targeting chimeras (PROTACs) method, a chem. knockdown strategy in which a heterobifunctional mol. recruits a specific protein target to an E3 ubiquitin ligase, resulting in the target's ubiquitination and degrdn.  These compds. behave catalytically in their ability to induce the ubiquitination of super-stoichiometric quantities of proteins, providing efficacy that is not limited by equil. occupancy.  We present two PROTACs that are capable of specifically reducing protein levels by >90% at nanomolar concns.  In addn., mouse studies indicate that they provide broad tissue distribution and knockdown of the targeted protein in tumor xenografts.  Together, these data demonstrate a protein knockdown system combining many of the favorable properties of small-mol. agents with the potent protein knockdown of RNAi and CRISPR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonhnajD3CxS7Vg90H21EOLACvtfcHk0lhdN3zR5FM6vA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7rP&md5=31eb8756c5661f78ab4527a50dc1e251</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1858%26sid%3Dliteratum%253Aachs%26aulast%3DBondeson%26aufirst%3DD.%2BP.%26aulast%3DMares%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DI.%2BE.%2BD.%26aulast%3DKo%26aufirst%3DE.%26aulast%3DCampos%26aufirst%3DS.%26aulast%3DMiah%26aufirst%3DA.%2BH.%26aulast%3DMulholland%26aufirst%3DK.%2BE.%26aulast%3DRoutly%26aufirst%3DN.%26aulast%3DBuckley%26aufirst%3DD.%2BL.%26aulast%3DGustafson%26aufirst%3DJ.%2BL.%26aulast%3DZinn%26aufirst%3DN.%26aulast%3DGrandi%26aufirst%3DP.%26aulast%3DShimamura%26aufirst%3DS.%26aulast%3DBergamini%26aufirst%3DG.%26aulast%3DFaelth-Savitski%26aufirst%3DM.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DCox%26aufirst%3DC.%26aulast%3DGordon%26aufirst%3DD.%2BA.%26aulast%3DWillard%26aufirst%3DR.%2BR.%26aulast%3DFlanagan%26aufirst%3DJ.%2BJ.%26aulast%3DCasillas%26aufirst%3DL.%2BN.%26aulast%3DVotta%26aufirst%3DB.%2BJ.%26aulast%3Dden%2BBesten%26aufirst%3DW.%26aulast%3DFamm%26aufirst%3DK.%26aulast%3DKruidenier%26aufirst%3DL.%26aulast%3DCarter%26aufirst%3DP.%2BS.%26aulast%3DHarling%26aufirst%3DJ.%2BD.%26aulast%3DChurcher%26aufirst%3DI.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DCatalytic%2520in%2520vivo%2520protein%2520knockdown%2520by%2520small-molecule%2520PROTACs%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D11%26spage%3D611%26epage%3D617%26doi%3D10.1038%2Fnchembio.1858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clague, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heride, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbe, S.</span></span> <span> </span><span class="NLM_article-title">The demographics of the ubiquitin system</span>. <i>Trends Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">417</span>â <span class="NLM_lpage">426</span>, <span class="refDoi">Â DOI: 10.1016/j.tcb.2015.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.tcb.2015.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=25906909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVGqtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=417-426&author=M.+J.+Clagueauthor=C.+Herideauthor=S.+Urbe&title=The+demographics+of+the+ubiquitin+system&doi=10.1016%2Fj.tcb.2015.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">The demographics of the ubiquitin system</span></div><div class="casAuthors">Clague, Michael J.; Heride, Claire; Urbe, Sylvie</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">417-426</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The ubiquitin system is a major coordinator of cellular physiol. through regulation of both protein degrdn. and signalling pathways.  A key building block of a systems-level understanding has been generated by global proteomic studies, which provide copy no. ests. for each component.  The aggregate of ubiquitin, conjugating enzymes (E1, E2, and E3s), and deubiquitylases (DUBs) represents â¼1.3% of total cellular protein.  Complementary approaches have generated quant. measurements of various ubiquitin pools and further subdivision into different ubiquitin chain topologies.  Systematic studies aimed at assocg. specific enzymes (E2s and DUBs) with the dynamics of these different pools have also made significant progress.  Here, we delineate the emerging picture of the most significant determinants of the cellular ubiquitin economy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZQMwzCvXv5bVg90H21EOLACvtfcHk0lhdN3zR5FM6vA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVGqtbw%253D&md5=38563c26b5d83eab2bb0dc193041d1e5</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2015.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2015.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DClague%26aufirst%3DM.%2BJ.%26aulast%3DHeride%26aufirst%3DC.%26aulast%3DUrbe%26aufirst%3DS.%26atitle%3DThe%2520demographics%2520of%2520the%2520ubiquitin%2520system%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2015%26volume%3D25%26spage%3D417%26epage%3D426%26doi%3D10.1016%2Fj.tcb.2015.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burslem, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McQuaid, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondeson, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crew, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">The advantages of targeted protein degradation over inhibition: an RTK case study</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">67</span>â <span class="NLM_lpage">77</span>, <span class="refDoi">Â DOI: 10.1016/j.chembiol.2017.09.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.chembiol.2017.09.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=29129716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2lsrjM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=67-77&author=G.+M.+Burslemauthor=B.+E.+Smithauthor=A.+C.+Laiauthor=S.+Jaime-Figueroaauthor=D.+C.+McQuaidauthor=D.+P.+Bondesonauthor=M.+Toureauthor=H.+Dongauthor=Y.+Qianauthor=J.+Wangauthor=A.+P.+Crewauthor=J.+Hinesauthor=C.+M.+Crews&title=The+advantages+of+targeted+protein+degradation+over+inhibition%3A+an+RTK+case+study&doi=10.1016%2Fj.chembiol.2017.09.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study</span></div><div class="casAuthors">Burslem, George M.; Smith, Blake E.; Lai, Ashton C.; Jaime-Figueroa, Saul; McQuaid, Daniel C.; Bondeson, Daniel P.; Toure, Momar; Dong, Hanqing; Qian, Yimin; Wang, Jing; Crew, Andrew P.; Hines, John; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-77.e3</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Proteolysis targeting chimera (PROTAC) technol. has emerged over the last two decades as a powerful tool for targeted degrdn. of endogenous proteins.  Herein we describe the development of PROTACs for receptor tyrosine kinases, a protein family yet to be targeted for induced protein degrdn.  The use of VHL-recruiting PROTACs against this protein family reveals several advantages of degrdn. over inhibition alone: direct comparisons of fully functional, target-degrading PROTACs with target-inhibiting variants that contain an inactivated E3 ligase-recruiting ligand show that degrdn. leads to more potent inhibition of cell proliferation and a more durable and sustained downstream signaling response, and thus addresses the kinome rewiring challenge seen with many receptor tyrosine kinase inhibitors.  Combined, these findings demonstrate the ability to target receptor tyrosine kinases for degrdn. using the PROTAC technol. and outline the advantages of this degrdn.-based approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4yDhRDWqNv7Vg90H21EOLACvtfcHk0lhdN3zR5FM6vA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2lsrjM&md5=0ac39a6f5836ea3772a0396356efb630</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DBurslem%26aufirst%3DG.%2BM.%26aulast%3DSmith%26aufirst%3DB.%2BE.%26aulast%3DLai%26aufirst%3DA.%2BC.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DMcQuaid%26aufirst%3DD.%2BC.%26aulast%3DBondeson%26aufirst%3DD.%2BP.%26aulast%3DToure%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DCrew%26aufirst%3DA.%2BP.%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DThe%2520advantages%2520of%2520targeted%2520protein%2520degradation%2520over%2520inhibition%253A%2520an%2520RTK%2520case%2520study%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D67%26epage%3D77%26doi%3D10.1016%2Fj.chembiol.2017.09.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neklesa, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted protein degradation by PROTACs</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">138</span>â <span class="NLM_lpage">144</span>, <span class="refDoi">Â DOI: 10.1016/j.pharmthera.2017.02.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.pharmthera.2017.02.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=28223226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtVemsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2017&pages=138-144&author=T.+K.+Neklesaauthor=J.+D.+Winklerauthor=C.+M.+Crews&title=Targeted+protein+degradation+by+PROTACs&doi=10.1016%2Fj.pharmthera.2017.02.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted protein degradation by PROTACs</span></div><div class="casAuthors">Neklesa, Taavi K.; Winkler, James D.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">138-144</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Targeted protein degrdn. using the PROTAC technol. is emerging as a novel therapeutic method to address diseases driven by the aberrant expression of a disease-causing protein.  PROTAC mols. are bifunctional small mols. that simultaneously bind a target protein and an E3-ubiquitin ligase, thus causing ubiquitination and degrdn. of the target protein by the proteasome.  Like small mols., PROTAC mols. possess good tissue distribution and the ability to target intracellular proteins.  Herein, we highlight the advantages of protein degrdn. using PROTACs, and provide specific examples where degrdn. offers therapeutic benefit over classical enzyme inhibition.  Foremost, PROTACs can degrade proteins regardless of their function.  This includes the currently "undruggable" proteome, which comprises approx. 85% of all human proteins.  Other beneficial aspects of protein degrdn. include the ability to target overexpressed and mutated proteins, as well as the potential to demonstrate prolonged pharmacodynamics effect beyond drug exposure.  Lastly, due to their catalytic nature and the pre-requisite ubiquitination step, an exquisitely potent mols. with a high degree of degrdn. selectivity can be designed.  Impressive preclin. in vitro and in vivo PROTAC data have been published, and these data have propelled the development of clin. viable PROTACs.  With the mol. wt. falling in the 700-1000 Da range, the delivery and bioavailability of PROTACs remain the largest hurdles on the way to the clinic.  Solving these issues and demonstrating proof of concept clin. data will be the focus of many labs over the next few years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4RSLWYqqBMrVg90H21EOLACvtfcHk0lj8VahD021gUg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtVemsbg%253D&md5=08a74402a274a13c8c484cd68167a5a1</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.02.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.02.027%26sid%3Dliteratum%253Aachs%26aulast%3DNeklesa%26aufirst%3DT.%2BK.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520protein%2520degradation%2520by%2520PROTACs%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D174%26spage%3D138%26epage%3D144%26doi%3D10.1016%2Fj.pharmthera.2017.02.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deshaies, R. J.</span></span> <span> </span><span class="NLM_article-title">Multispecific drugs herald a new era of biopharmaceutical innovation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>580</i></span>,  <span class="NLM_fpage">329</span>â <span class="NLM_lpage">338</span>, <span class="refDoi">Â DOI: 10.1038/s41586-020-2168-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fs41586-020-2168-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=32296187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntFOqtLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=580&publication_year=2020&pages=329-338&author=R.+J.+Deshaies&title=Multispecific+drugs+herald+a+new+era+of+biopharmaceutical+innovation&doi=10.1038%2Fs41586-020-2168-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Multispecific drugs herald a new era of biopharmaceutical innovation</span></div><div class="casAuthors">Deshaies, Raymond J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">580</span>
        (<span class="NLM_cas:issue">7803</span>),
    <span class="NLM_cas:pages">329-338</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: The modern biopharmaceutical industry traces its roots to the dawn of the twentieth century, coincident with marketing of aspirin-a signature event in the history of modern drug development.  Although the archetypal discovery process did not change markedly in the first seven decades of the industry, the past fifty years have seen two successive waves of transformative innovation in the development of drug mols.: the rise of 'rational drug discovery' methodol. in the 1970s, followed by the invention of recombinant protein-based therapeutic agents in the 1980s.  An incipient fourth wave is the advent of multispecific drugs.  The successful development of prospectively designed multispecific drugs has the potential to reconfigure our ideas of how target-based therapeutic mols. can work, and what it is possible to achieve with them.  Here I review the two major classes of multispecific drugs: those that enrich a therapeutic agent at a particular site of action and those that link a therapeutic target to a biol. effector.  The latter class-being freed from the constraint of having to directly modulate the target upon binding-may enable access to components of the proteome that currently cannot be targeted by drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2zqgRhbT71LVg90H21EOLACvtfcHk0lj8VahD021gUg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntFOqtLg%253D&md5=9fd080b5177e4de5163d76a385f7dcc1</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-2168-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-2168-1%26sid%3Dliteratum%253Aachs%26aulast%3DDeshaies%26aufirst%3DR.%2BJ.%26atitle%3DMultispecific%2520drugs%2520herald%2520a%2520new%2520era%2520of%2520biopharmaceutical%2520innovation%26jtitle%3DNature%26date%3D2020%26volume%3D580%26spage%3D329%26epage%3D338%26doi%3D10.1038%2Fs41586-020-2168-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span> <span> </span><span class="NLM_article-title">PROTACs: great opportunities for academia and industry</span>. <i>Signal Transduction Targeted Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">64</span>â <span class="NLM_lpage">96</span>, <span class="refDoi">Â DOI: 10.1038/s41392-019-0101-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fs41392-019-0101-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=31885879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BB3MbkvFCrtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=64-96&author=X.+Sunauthor=H.+Gaoauthor=Y.+Yangauthor=M.+Heauthor=Y.+Wuauthor=Y.+Songauthor=Y.+Tongauthor=Y.+Rao&title=PROTACs%3A+great+opportunities+for+academia+and+industry&doi=10.1038%2Fs41392-019-0101-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">PROTACs: great opportunities for academia and industry</span></div><div class="casAuthors">Sun Xiuyun; Gao Hongying; Yang Yiqing; He Ming; Wu Yue; Song Yugang; Tong Yan; Rao Yu; Sun Xiuyun; Gao Hongying; Yang Yiqing; Rao Yu</div><div class="citationInfo"><span class="NLM_cas:title">Signal transduction and targeted therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">64</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although many kinds of therapies are applied in the clinic, drug-resistance is a major and unavoidable problem.  Another disturbing statistic is the limited number of drug targets, which are presently only 20-25% of all protein targets that are currently being studied.  Moreover, the focus of current explorations of targets are their enzymatic functions, which ignores the functions from their scaffold moiety.  As a promising and appealing technology, PROteolysis TArgeting Chimeras (PROTACs) have attracted great attention both from academia and industry for finding available approaches to solve the above problems.  PROTACs regulate protein function by degrading target proteins instead of inhibiting them, providing more sensitivity to drug-resistant targets and a greater chance to affect the nonenzymatic functions.  PROTACs have been proven to show better selectivity compared to classic inhibitors.  PROTACs can be described as a chemical knockdown approach with rapidity and reversibility, which presents new and different biology compared to other gene editing tools by avoiding misinterpretations that arise from potential genetic compensation and/or spontaneous mutations.  PRTOACs have been widely explored throughout the world and have outperformed not only in cancer diseases, but also in immune disorders, viral infections and neurodegenerative diseases.  Although PROTACs present a very promising and powerful approach for crossing the hurdles of present drug discovery and tool development in biology, more efforts are needed to gain to get deeper insight into the efficacy and safety of PROTACs in the clinic.  More target binders and more E3 ligases applicable for developing PROTACs are waiting for exploration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQretvERU2xT-_Q9URG6Dx8fW6udTcc2eZ1IfkPMWrUjrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MbkvFCrtA%253D%253D&md5=7d9545a21e3a78cededf2977a31e8f7d</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1038%2Fs41392-019-0101-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41392-019-0101-6%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DTong%26aufirst%3DY.%26aulast%3DRao%26aufirst%3DY.%26atitle%3DPROTACs%253A%2520great%2520opportunities%2520for%2520academia%2520and%2520industry%26jtitle%3DSignal%2520Transduction%2520Targeted%2520Ther.%26date%3D2019%26volume%3D4%26spage%3D64%26epage%3D96%26doi%3D10.1038%2Fs41392-019-0101-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schapira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calabrese, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted protein degradation: expanding the toolbox</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">949</span>â <span class="NLM_lpage">963</span>, <span class="refDoi">Â DOI: 10.1038/s41573-019-0047-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fs41573-019-0047-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=31666732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVKrtLrM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=949-963&author=M.+Schapiraauthor=M.+F.+Calabreseauthor=A.+N.+Bullockauthor=C.+M.+Crews&title=Targeted+protein+degradation%3A+expanding+the+toolbox&doi=10.1038%2Fs41573-019-0047-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted protein degradation: expanding the toolbox</span></div><div class="casAuthors">Schapira, Matthieu; Calabrese, Matthew F.; Bullock, Alex N.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">949-963</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review. Proteolysis-targeting chimeras (PROTACs) and related mols. that induce targeted protein degrdn. by the ubiquitin-proteasome system represent a new therapeutic modality and are the focus of great interest, owing to potential advantages over traditional occupancy-based inhibitors with respect to dosing, side effects, drug resistance and modulating 'undruggable' targets.  However, the technol. is still maturing, and the design elements for successful PROTAC-based drugs are currently being elucidated.  Importantly, fewer than 10 of the more than 600 E3 ubiquitin ligases have so far been exploited for targeted protein degrdn., and expansion of knowledge in this area is a key opportunity.  Here, we briefly discuss lessons learned about targeted protein degrdn. in chem. biol. and drug discovery and systematically review the expression profile, domain architecture and chem. tractability of human E3 ligases that could expand the toolbox for PROTAC discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwUvM27MU3WrVg90H21EOLACvtfcHk0lj8VahD021gUg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVKrtLrM&md5=9bfd48c6c47fc1cce15129495fea7079</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1038%2Fs41573-019-0047-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41573-019-0047-y%26sid%3Dliteratum%253Aachs%26aulast%3DSchapira%26aufirst%3DM.%26aulast%3DCalabrese%26aufirst%3DM.%2BF.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520protein%2520degradation%253A%2520expanding%2520the%2520toolbox%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26spage%3D949%26epage%3D963%26doi%3D10.1038%2Fs41573-019-0047-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paiva, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted protein degradation: elements of PROTAC design</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">111</span>â <span class="NLM_lpage">119</span>, <span class="refDoi">Â DOI: 10.1016/j.cbpa.2019.02.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.cbpa.2019.02.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=31004963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1MXns1yrt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2019&pages=111-119&author=S.+L.+Paivaauthor=C.+M.+Crews&title=Targeted+protein+degradation%3A+elements+of+PROTAC+design&doi=10.1016%2Fj.cbpa.2019.02.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted protein degradation: elements of PROTAC design</span></div><div class="casAuthors">Paiva, Stacey-Lynn; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111-119</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Targeted protein degrdn. using Proteolysis Targeting Chimeras (PROTACs) has emerged as a novel therapeutic modality in drug discovery.  PROTACs mediate the degrdn. of select proteins of interest (POIs) by hijacking the activity of E3 ubiquitin ligases for POI ubiquitination and subsequent degrdn. by the 26S proteasome.  This hijacking mechanism has been used to degrade various types of disease-relevant POIs.  In this review, we aim to highlight the recent advances in targeted protein degrdn. and describe the challenges that need to be addressed in order to efficiently develop potent PROTACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol6Nk0VkUdzLVg90H21EOLACvtfcHk0li3MGU0tMy6kg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXns1yrt7s%253D&md5=5783311db47da378180c14d67526a398</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2019.02.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2019.02.022%26sid%3Dliteratum%253Aachs%26aulast%3DPaiva%26aufirst%3DS.%2BL.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520protein%2520degradation%253A%2520elements%2520of%2520PROTAC%2520design%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D50%26spage%3D111%26epage%3D119%26doi%3D10.1016%2Fj.cbpa.2019.02.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bondeson, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burslem, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhimschi, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishchenko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Lessons in PROTAC design from selective degradation with a promiscuous warhead</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">78</span>â <span class="NLM_lpage">87</span>, <span class="refDoi">Â DOI: 10.1016/j.chembiol.2017.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.chembiol.2017.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=29129718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2lsrjN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=78-87&author=D.+P.+Bondesonauthor=B.+E.+Smithauthor=G.+M.+Burslemauthor=A.+D.+Buhimschiauthor=J.+Hinesauthor=S.+Jaime-Figueroaauthor=J.+Wangauthor=B.+D.+Hammanauthor=A.+Ishchenkoauthor=C.+M.+Crews&title=Lessons+in+PROTAC+design+from+selective+degradation+with+a+promiscuous+warhead&doi=10.1016%2Fj.chembiol.2017.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead</span></div><div class="casAuthors">Bondeson, Daniel P.; Smith, Blake E.; Burslem, George M.; Buhimschi, Alexandru D.; Hines, John; Jaime-Figueroa, Saul; Wang, Jing; Hamman, Brian D.; Ishchenko, Alexey; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">78-87.e5</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Inhibiting protein function selectively is a major goal of modern drug discovery.  Here, we report a previously understudied benefit of small mol. proteolysis-targeting chimeras (PROTACs) that recruit E3 ubiquitin ligases to target proteins for their ubiquitination and subsequent proteasome-mediated degrdn.  Using promiscuous CRBN- and VHL-recruiting PROTACs that bind >50 kinases, we show that only a subset of bound targets is degraded.  The basis of this selectivity relies on protein-protein interactions between the E3 ubiquitin ligase and the target protein, as illustrated by engaged proteins that are not degraded as a result of unstable ternary complexes with PROTAC-recruited E3 ligases.  In contrast, weak PROTAC:target protein affinity can be stabilized by high-affinity target:PROTAC:ligase trimer interactions, leading to efficient degrdn.  This study highlights design guidelines for generating potent PROTACs as well as possibilities for degrading undruggable proteins immune to traditional small-mol. inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoISOBudOLyFrVg90H21EOLACvtfcHk0li3MGU0tMy6kg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2lsrjN&md5=30fac502705a2344c4261cf531e6bf9d</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DBondeson%26aufirst%3DD.%2BP.%26aulast%3DSmith%26aufirst%3DB.%2BE.%26aulast%3DBurslem%26aufirst%3DG.%2BM.%26aulast%3DBuhimschi%26aufirst%3DA.%2BD.%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHamman%26aufirst%3DB.%2BD.%26aulast%3DIshchenko%26aufirst%3DA.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DLessons%2520in%2520PROTAC%2520design%2520from%2520selective%2520degradation%2520with%2520a%2520promiscuous%2520warhead%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D78%26epage%3D87%26doi%3D10.1016%2Fj.chembiol.2017.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neklesa, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted protein degradation by PROTACs</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">138</span>â <span class="NLM_lpage">144</span>, <span class="refDoi">Â DOI: 10.1016/j.pharmthera.2017.02.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.pharmthera.2017.02.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=28223226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtVemsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2017&pages=138-144&author=T.+K.+Neklesaauthor=J.+D.+Winklerauthor=C.+M.+Crews&title=Targeted+protein+degradation+by+PROTACs&doi=10.1016%2Fj.pharmthera.2017.02.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted protein degradation by PROTACs</span></div><div class="casAuthors">Neklesa, Taavi K.; Winkler, James D.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">138-144</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Targeted protein degrdn. using the PROTAC technol. is emerging as a novel therapeutic method to address diseases driven by the aberrant expression of a disease-causing protein.  PROTAC mols. are bifunctional small mols. that simultaneously bind a target protein and an E3-ubiquitin ligase, thus causing ubiquitination and degrdn. of the target protein by the proteasome.  Like small mols., PROTAC mols. possess good tissue distribution and the ability to target intracellular proteins.  Herein, we highlight the advantages of protein degrdn. using PROTACs, and provide specific examples where degrdn. offers therapeutic benefit over classical enzyme inhibition.  Foremost, PROTACs can degrade proteins regardless of their function.  This includes the currently "undruggable" proteome, which comprises approx. 85% of all human proteins.  Other beneficial aspects of protein degrdn. include the ability to target overexpressed and mutated proteins, as well as the potential to demonstrate prolonged pharmacodynamics effect beyond drug exposure.  Lastly, due to their catalytic nature and the pre-requisite ubiquitination step, an exquisitely potent mols. with a high degree of degrdn. selectivity can be designed.  Impressive preclin. in vitro and in vivo PROTAC data have been published, and these data have propelled the development of clin. viable PROTACs.  With the mol. wt. falling in the 700-1000 Da range, the delivery and bioavailability of PROTACs remain the largest hurdles on the way to the clinic.  Solving these issues and demonstrating proof of concept clin. data will be the focus of many labs over the next few years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4RSLWYqqBMrVg90H21EOLACvtfcHk0li3MGU0tMy6kg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtVemsbg%253D&md5=08a74402a274a13c8c484cd68167a5a1</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.02.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.02.027%26sid%3Dliteratum%253Aachs%26aulast%3DNeklesa%26aufirst%3DT.%2BK.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520protein%2520degradation%2520by%2520PROTACs%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D174%26spage%3D138%26epage%3D144%26doi%3D10.1016%2Fj.pharmthera.2017.02.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robb, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contreras, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kour, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonawane, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murry, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rana, S.</span></span> <span> </span><span class="NLM_article-title">Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC)</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">7577</span>â <span class="NLM_lpage">7580</span>, <span class="refDoi">Â DOI: 10.1039/C7CC03879H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1039%2FC7CC03879H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=28636052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpvFyjsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2017&pages=7577-7580&author=C.+M.+Robbauthor=J.+I.+Contrerasauthor=S.+Kourauthor=M.+A.+Taylorauthor=M.+Abidauthor=Y.+A.+Sonawaneauthor=M.+Zahidauthor=D.+J.+Murryauthor=A.+Natarajanauthor=S.+Rana&title=Chemically+induced+degradation+of+CDK9+by+a+proteolysis+targeting+chimera+%28PROTAC%29&doi=10.1039%2FC7CC03879H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC)</span></div><div class="casAuthors">Robb, Caroline M.; Contreras, Jacob I.; Kour, Smit; Taylor, Margaret A.; Abid, Mohammad; Sonawane, Yogesh A.; Zahid, Muhammad; Murry, Daryl J.; Natarajan, Amarnath; Rana, Sandeep</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">54</span>),
    <span class="NLM_cas:pages">7577-7580</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 9 (CDK9), a member of the cyclin-dependent protein kinase (CDK) family, is involved in transcriptional elongation of several target genes.  CDK9 is ubiquitously expressed and has been shown to contribute to a variety of malignancies such as pancreatic, prostate and breast cancers.  Here we report the development of a heterobifunctional small mol. proteolysis targeting chimera (PROTAC) capable of cereblon (CRBN)-mediated proteasomal degrdn. of CDK9.  In HCT116 cells, it selectively degrades CDK9 while sparing other CDK family members.  This is the first example of a PROTAC that selectively degrades CDK9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXgLtOTwvlnbVg90H21EOLACvtfcHk0lhmjacCmi9yYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpvFyjsLw%253D&md5=a9aa8ebf8109f11206740efd1b5e09a2</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1039%2FC7CC03879H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7CC03879H%26sid%3Dliteratum%253Aachs%26aulast%3DRobb%26aufirst%3DC.%2BM.%26aulast%3DContreras%26aufirst%3DJ.%2BI.%26aulast%3DKour%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DM.%2BA.%26aulast%3DAbid%26aufirst%3DM.%26aulast%3DSonawane%26aufirst%3DY.%2BA.%26aulast%3DZahid%26aufirst%3DM.%26aulast%3DMurry%26aufirst%3DD.%2BJ.%26aulast%3DNatarajan%26aufirst%3DA.%26aulast%3DRana%26aufirst%3DS.%26atitle%3DChemically%2520induced%2520degradation%2520of%2520CDK9%2520by%2520a%2520proteolysis%2520targeting%2520chimera%2520%2528PROTAC%2529%26jtitle%3DChem.%2520Commun.%26date%3D2017%26volume%3D53%26spage%3D7577%26epage%3D7580%26doi%3D10.1039%2FC7CC03879H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J. Y.</span></span> <span> </span><span class="NLM_article-title">Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC)</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>505</i></span>,  <span class="NLM_fpage">542</span>â <span class="NLM_lpage">547</span>, <span class="refDoi">Â DOI: 10.1016/j.bbrc.2018.09.169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.bbrc.2018.09.169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=30274779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVejs7fE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=505&publication_year=2018&pages=542-547&author=C.+H.+Kangauthor=D.+H.+Leeauthor=C.+O.+Leeauthor=J.+D.+Haauthor=C.+H.+Parkauthor=J.+Y.+Hwang&title=Induced+protein+degradation+of+anaplastic+lymphoma+kinase+%28ALK%29+by+proteolysis+targeting+chimera+%28PROTAC%29&doi=10.1016%2Fj.bbrc.2018.09.169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC)</span></div><div class="casAuthors">Kang, Chung Hyo; Lee, Dong Ho; Lee, Chong Ock; Du Ha, Jae; Park, Chi Hoon; Hwang, Jong Yeon</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">505</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">542-547</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recently, proteolysis targeting chimera (PROTAC) technol. is highlighted in drug discovery area as a new therapeutic approach.  PROTAC as a heterobifunctional mol. is comprised of two ligands, which recruit target protein and E3 ligase, resp.  To degrade the anaplastic lymphoma kinase (ALK) fusion protein, such as NPM-ALK or EML4-ALK, we generated several ALK-PROTAC mols. consisted of ceritinib, one of the ALK inhibitors, and ligand of von Hippel-Lindau (VHL) E3 ligase.  Among these mols., TD-004 effectively induced ALK degrdn. and inhibited the growth of ALK fusion pos. cell lines, SU-DHL-1 and H3122.  We also confirmed that TD-004 significantly reduced the tumor growth in H3122 xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8JUOZ5fYNW7Vg90H21EOLACvtfcHk0lhmjacCmi9yYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVejs7fE&md5=cac9252fca98ebec4ad8e5aeed7b7550</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2018.09.169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2018.09.169%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DC.%2BH.%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DLee%26aufirst%3DC.%2BO.%26aulast%3DHa%26aufirst%3DJ.%2BD.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DHwang%26aufirst%3DJ.%2BY.%26atitle%3DInduced%2520protein%2520degradation%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520by%2520proteolysis%2520targeting%2520chimera%2520%2528PROTAC%2529%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2018%26volume%3D505%26spage%3D542%26epage%3D547%26doi%3D10.1016%2Fj.bbrc.2018.09.169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cromm, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samarasinghe, K. T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Addressing kinase-independent functions of Fak via PROTAC-mediated degradation</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">17019</span>â <span class="NLM_lpage">17026</span>, <span class="refDoi">Â DOI: 10.1021/jacs.8b08008</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.8b08008" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1CitLnF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2018&pages=17019-17026&author=P.+M.+Crommauthor=K.+T.+G.+Samarasingheauthor=J.+Hinesauthor=C.+M.+Crews&title=Addressing+kinase-independent+functions+of+Fak+via+PROTAC-mediated+degradation&doi=10.1021%2Fjacs.8b08008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation</span></div><div class="casAuthors">Cromm, Philipp M.; Samarasinghe, Kusal T. G.; Hines, John; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">17019-17026</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Enzymic inhibition proved to be a successful modality for the development of many small-mol. drugs.  In recent years, small-mol.-induced protein degrdn. has emerged as an orthogonal therapeutic strategy that has the potential to expand the druggable target space.  Focal adhesion kinase (Fak) is a key player in tumor invasion and metastasis, acting simultaneously as a kinase and a scaffold for several signaling proteins.  While previous efforts to modulate Fak activity were limited to kinase inhibitors with low success in clin. studies, protein degrdn. offers a possibility to simultaneously block Fak's kinase signaling and scaffolding capabilities.  Here, the authors report the development of a selective and potent Fak degrader, PROTAC-3, which outperforms a clin. candidate, defactinib, with respect to Fak activation as well as Fak-mediated cell migration and invasion.  These results underline the potential that PROTACs offer in expanding the druggable space and controlling protein functions that are not easily addressed by traditional small-mol. therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTn8r4NmDDObVg90H21EOLACvtfcHk0lhmjacCmi9yYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1CitLnF&md5=b97b1a646a8f9dbf7a2bed640d0f001d</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Fjacs.8b08008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.8b08008%26sid%3Dliteratum%253Aachs%26aulast%3DCromm%26aufirst%3DP.%2BM.%26aulast%3DSamarasinghe%26aufirst%3DK.%2BT.%2BG.%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DAddressing%2520kinase-independent%2520functions%2520of%2520Fak%2520via%2520PROTAC-mediated%2520degradation%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2018%26volume%3D140%26spage%3D17019%26epage%3D17026%26doi%3D10.1021%2Fjacs.8b08008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Da, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span> <span> </span><span class="NLM_article-title">Targeted selective degradation of Brutonâs tyrosine kinase by PROTACs</span>. <i>Med. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">802</span>â <span class="NLM_lpage">808</span>, <span class="refDoi">Â DOI: 10.1007/s00044-020-02526-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1007%2Fs00044-020-02526-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktFWisL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2020&pages=802-808&author=S.+Liuauthor=Y.+Daauthor=F.+Wangauthor=R.+Yanauthor=Y.+Shuauthor=P.+Linauthor=J.+Lin&title=Targeted+selective+degradation+of+Bruton%E2%80%99s+tyrosine+kinase+by+PROTACs&doi=10.1007%2Fs00044-020-02526-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted selective degradation of Bruton's tyrosine kinase by PROTACs</span></div><div class="casAuthors">Liu, Shaodong; Da, Yang; Wang, Feng; Yan, Renjie; Shu, Yongzhi; Lin, Pei; Lin, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">802-808</span>CODEN:
                <span class="NLM_cas:coden">MCREEB</span>;
        ISSN:<span class="NLM_cas:issn">1054-2523</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: Bruton's tyrosine kinase (BTK) is crit. for B-cell receptor signaling and related to many types of human cancers.  However, the drug resistance and off-target effect of present traditional BTK inhibitors occurred over time.  As a new strategy for drug development, the proteolysis targeting chimera (PROTAC) has been proved to target varieties of proteins.  Here SPB5208 (4-(2-(2-(2-(2-(3-(4-amino-3-(4-phenoxy phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)ethoxy)ethoxy)ethoxy)ethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione) was synthesized as a new PROTAC degrdn. agent of BTK by linking Ibrutinib and Thalidomide.  In vitro study indicated that SPB5208 reduced the BTK enzyme activity with high selectivity and inhibited effectively cancer cell proliferation.  More than that, SPB5208 induced BTK protein degrdn. through a proteasome- and CRBN- dependent manner in JeKo-1 cells.  In addn., SPB5208 was also confirmed to induce significantly BTK protein degrdn. in vivo.  Thus, this study provides a new pharmacol. tool for further study of new BTK PROTAC and their mechanism of action in physiol. environment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEEHujG9LHG7Vg90H21EOLACvtfcHk0lhkzpEdOxcxgQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktFWisL4%253D&md5=c0bb9269eb76f0aeb59592e8825d1e88</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1007%2Fs00044-020-02526-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00044-020-02526-3%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DDa%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DYan%26aufirst%3DR.%26aulast%3DShu%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DP.%26aulast%3DLin%26aufirst%3DJ.%26atitle%3DTargeted%2520selective%2520degradation%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520by%2520PROTACs%26jtitle%3DMed.%2520Chem.%2520Res.%26date%3D2020%26volume%3D29%26spage%3D802%26epage%3D808%26doi%3D10.1007%2Fs00044-020-02526-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span> <span> </span><span class="NLM_article-title">FAK-targeting PROTAC as a chemical tool for the investigation of non-enzymatic FAK function in mice</span>. <i>Protein Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">534</span>â <span class="NLM_lpage">539</span>, <span class="refDoi">Â DOI: 10.1007/s13238-020-00732-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1007%2Fs13238-020-00732-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=32451721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVaiurbL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=534-539&author=H.+Gaoauthor=C.+Zhengauthor=J.+Duauthor=Y.+Wuauthor=Y.+Sunauthor=C.+Hanauthor=K.+Keeauthor=Y.+Rao&title=FAK-targeting+PROTAC+as+a+chemical+tool+for+the+investigation+of+non-enzymatic+FAK+function+in+mice&doi=10.1007%2Fs13238-020-00732-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">FAK-targeting PROTAC as a chemical tool for the investigation of non-enzymatic FAK function in mice</span></div><div class="casAuthors">Gao, Hongying; Zheng, Chunwei; Du, Jian; Wu, Yue; Sun, Yonghui; Han, Chunsheng; Kee, Kehkooi; Rao, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Protein & Cell</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">534-539</span>CODEN:
                <span class="NLM_cas:coden">PCREFB</span>;
        ISSN:<span class="NLM_cas:issn">1674-800X</span>.
    
            (<span class="NLM_cas:orgname">Higher Education Press</span>)
        </div><div class="casAbstract">This article studies about FAK-targeting PROTAC as chem. tool for investigation of non-enzymic FAK function in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp520chSxI_vbVg90H21EOLACvtfcHk0lhkzpEdOxcxgQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVaiurbL&md5=6e12490a063fba01cfa7dcf096fd77b7</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1007%2Fs13238-020-00732-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13238-020-00732-8%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DC.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DC.%26aulast%3DKee%26aufirst%3DK.%26aulast%3DRao%26aufirst%3DY.%26atitle%3DFAK-targeting%2520PROTAC%2520as%2520a%2520chemical%2520tool%2520for%2520the%2520investigation%2520of%2520non-enzymatic%2520FAK%2520function%2520in%2520mice%26jtitle%3DProtein%2520Cell%26date%3D2020%26volume%3D11%26spage%3D534%26epage%3D539%26doi%3D10.1007%2Fs13238-020-00732-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrovolsky, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doctor, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treon, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">A chemoproteomic approach to query the degradable kinome using a multi-kinase degrader</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">88</span>â <span class="NLM_lpage">99</span>, <span class="refDoi">Â DOI: 10.1016/j.chembiol.2017.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.chembiol.2017.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=29129717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2lsrjO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=88-99&author=H.+T.+Huangauthor=D.+Dobrovolskyauthor=J.+Paulkauthor=G.+Yangauthor=E.+L.+Weisbergauthor=Z.+M.+Doctorauthor=D.+L.+Buckleyauthor=J.+H.+Choauthor=E.+Koauthor=J.+Jangauthor=K.+Shiauthor=H.+G.+Choiauthor=J.+D.+Griffinauthor=Y.+Liauthor=S.+P.+Treonauthor=E.+S.+Fischerauthor=J.+E.+Bradnerauthor=L.+Tanauthor=N.+S.+Gray&title=A+chemoproteomic+approach+to+query+the+degradable+kinome+using+a+multi-kinase+degrader&doi=10.1016%2Fj.chembiol.2017.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader</span></div><div class="casAuthors">Huang, Hai-Tsang; Dobrovolsky, Dennis; Paulk, Joshiawa; Yang, Guang; Weisberg, Ellen L.; Doctor, Zainab M.; Buckley, Dennis L.; Cho, Joong-Heui; Ko, Eunhwa; Jang, Jaebong; Shi, Kun; Choi, Hwan Geun; Griffin, James D.; Li, Ying; Treon, Steven P.; Fischer, Eric S.; Bradner, James E.; Tan, Li; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-99.e6</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Heterobifunctional mols. that recruit E3 ubiquitin ligases, such as cereblon, for targeted protein degrdn. represent an emerging pharmacol. strategy.  A major unanswered question is how generally applicable this strategy is to all protein targets.  In this study, we designed a multi-kinase degrader by conjugating a highly promiscuous kinase inhibitor with a cereblon-binding ligand, and used quant. proteomics to discover 28 kinases, including BTK, PTK2, PTK2B, FLT3, AURKA, AURKB, TEC, ULK1, ITK, and nine members of the CDK family, as degradable.  This set of kinases is only a fraction of the intracellular targets bound by the degrader, demonstrating that successful degrdn. requires more than target engagement.  The results guided us to develop selective degraders for FLT3 and BTK, with potentials to improve disease treatment.  Together, this study demonstrates an efficient approach to triage a gene family of interest to identify readily degradable targets for further studies and pre-clin. developments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYNxhoPV3127Vg90H21EOLACvtfcHk0lhkzpEdOxcxgQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2lsrjO&md5=703cfbaca3edd24176472158563f895f</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DH.%2BT.%26aulast%3DDobrovolsky%26aufirst%3DD.%26aulast%3DPaulk%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DWeisberg%26aufirst%3DE.%2BL.%26aulast%3DDoctor%26aufirst%3DZ.%2BM.%26aulast%3DBuckley%26aufirst%3DD.%2BL.%26aulast%3DCho%26aufirst%3DJ.%2BH.%26aulast%3DKo%26aufirst%3DE.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DK.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DTreon%26aufirst%3DS.%2BP.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DA%2520chemoproteomic%2520approach%2520to%2520query%2520the%2520degradable%2520kinome%2520using%2520a%2520multi-kinase%2520degrader%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D88%26epage%3D99%26doi%3D10.1016%2Fj.chembiol.2017.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Powell, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donovan, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loehr, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahcall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Chemically induced degradation of anaplastic lymphoma kinase (ALK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4249</span>â <span class="NLM_lpage">4255</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b01655</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01655" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1cXns1OitrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4249-4255&author=C.+E.+Powellauthor=Y.+Gaoauthor=L.+Tanauthor=K.+A.+Donovanauthor=R.+P.+Nowakauthor=A.+Loehrauthor=M.+Bahcallauthor=E.+S.+Fischerauthor=P.+A.+Janneauthor=R.+E.+Georgeauthor=N.+S.+Gray&title=Chemically+induced+degradation+of+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1021%2Facs.jmedchem.7b01655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Powell, Chelsea E.; Gao, Yang; Tan, Li; Donovan, Katherine A.; Nowak, Radoslaw P.; Loehr, Amanda; Bahcall, Magda; Fischer, Eric S.; Janne, Pasi A.; George, Rani E.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4249-4255</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We present the development of the first small mol. degraders that can induce anaplastic lymphoma kinase (ALK) degrdn., including in non-small-cell lung cancer (NSCLC), anaplastic large-cell lymphoma (ALCL), and neuroblastoma (NB) cell lines.  These degraders were developed through conjugation of known pyrimidine-based ALK inhibitors, TAE684 or LDK378, and the cereblon ligand pomalidomide.  We demonstrate that in some cell types degrader potency is compromised by expression of drug transporter ABCB1.  In addn., proteomic profiling demonstrated that these compds. also promote the degrdn. of addnl. kinases including PTK2 (FAK), Aurora A, FER, and RPS6KA1 (RSK1).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7mDH7Sj8EqbVg90H21EOLACvtfcHk0lgRarEG_CBKSA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXns1OitrY%253D&md5=486db11b3fbc2283700f38b09cc39bd7</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01655%26sid%3Dliteratum%253Aachs%26aulast%3DPowell%26aufirst%3DC.%2BE.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DDonovan%26aufirst%3DK.%2BA.%26aulast%3DNowak%26aufirst%3DR.%2BP.%26aulast%3DLoehr%26aufirst%3DA.%26aulast%3DBahcall%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DChemically%2520induced%2520degradation%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4249%26epage%3D4255%26doi%3D10.1021%2Facs.jmedchem.7b01655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Popow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnhof, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciulli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dank, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmaschitz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greb, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karolyi-Ozguer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koegl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rieger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinnenthal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roessler, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrenk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steurer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainor, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traxler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieshofer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoephel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettmayer, P.</span></span> <span> </span><span class="NLM_article-title">Highly selective PTK2 proteolysis-targeting chimeras to probe focal adhesion kinase scaffolding functions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">2508</span>â <span class="NLM_lpage">2520</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b01826</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01826" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisl2ls78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=2508-2520&author=J.+Popowauthor=H.+Arnhofauthor=G.+Baderauthor=H.+Bergerauthor=A.+Ciulliauthor=D.+Coviniauthor=C.+Dankauthor=T.+Gmaschitzauthor=P.+Grebauthor=J.+Karolyi-Ozguerauthor=M.+Koeglauthor=D.+B.+McConnellauthor=M.+Pearsonauthor=M.+Riegerauthor=J.+Rinnenthalauthor=V.+Roesslerauthor=A.+Schrenkauthor=M.+Spinaauthor=S.+Steurerauthor=N.+Trainorauthor=E.+Traxlerauthor=C.+Wieshoferauthor=A.+Zoephelauthor=P.+Ettmayer&title=Highly+selective+PTK2+proteolysis-targeting+chimeras+to+probe+focal+adhesion+kinase+scaffolding+functions&doi=10.1021%2Facs.jmedchem.8b01826"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions</span></div><div class="casAuthors">Popow, Johannes; Arnhof, Heribert; Bader, Gerd; Berger, Helmut; Ciulli, Alessio; Covini, David; Dank, Christian; Gmaschitz, Teresa; Greb, Peter; Karolyi-Oezguer, Jale; Koegl, Manfred; McConnell, Darryl B.; Pearson, Mark; Rieger, Maria; Rinnenthal, Joerg; Roessler, Vanessa; Schrenk, Andreas; Spina, Markus; Steurer, Steffen; Trainor, Nicole; Traxler, Elisabeth; Wieshofer, Corinna; Zoephel, Andreas; Ettmayer, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2508-2520</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Focal adhesion tyrosine kinase (PTK2) is often overexpressed in human hepatocellular carcinoma (HCC), and several reports have linked PTK2 depletion and/or pharmacol. inhibition to reduced tumorigenicity.  However, the clin. relevance of targeting PTK2 still remains to be proven.  Here, we present two highly selective and functional PTK2 proteolysis-targeting chimeras utilizing von Hippel-Lindau and cereblon ligands to hijack E3 ligases for PTK2 degrdn.  BI-3663 (cereblon-based) degrades PTK2 with a median DC50 of 30 nM to >80% across a panel of 11 HCC cell lines.  Despite effective PTK2 degrdn., these compds. did not phenocopy the reported antiproliferative effects of PTK2 depletion in any of the cell lines tested.  By disclosing these compds., we hope to provide valuable tools for the study of PTK2 degrdn. across different biol. systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsL2R_QBrfk7Vg90H21EOLACvtfcHk0lgRarEG_CBKSA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisl2ls78%253D&md5=f0ad27d3ff46ab12e8a90e8d40a6f3c6</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01826&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01826%26sid%3Dliteratum%253Aachs%26aulast%3DPopow%26aufirst%3DJ.%26aulast%3DArnhof%26aufirst%3DH.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DBerger%26aufirst%3DH.%26aulast%3DCiulli%26aufirst%3DA.%26aulast%3DCovini%26aufirst%3DD.%26aulast%3DDank%26aufirst%3DC.%26aulast%3DGmaschitz%26aufirst%3DT.%26aulast%3DGreb%26aufirst%3DP.%26aulast%3DKarolyi-Ozguer%26aufirst%3DJ.%26aulast%3DKoegl%26aufirst%3DM.%26aulast%3DMcConnell%26aufirst%3DD.%2BB.%26aulast%3DPearson%26aufirst%3DM.%26aulast%3DRieger%26aufirst%3DM.%26aulast%3DRinnenthal%26aufirst%3DJ.%26aulast%3DRoessler%26aufirst%3DV.%26aulast%3DSchrenk%26aufirst%3DA.%26aulast%3DSpina%26aufirst%3DM.%26aulast%3DSteurer%26aufirst%3DS.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DTraxler%26aufirst%3DE.%26aulast%3DWieshofer%26aufirst%3DC.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DEttmayer%26aufirst%3DP.%26atitle%3DHighly%2520selective%2520PTK2%2520proteolysis-targeting%2520chimeras%2520to%2520probe%2520focal%2520adhesion%2520kinase%2520scaffolding%2520functions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D2508%26epage%3D2520%26doi%3D10.1021%2Facs.jmedchem.8b01826" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of highly potent FAK-targeting PROTACs</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1855</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.9b00372</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00372" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVajtrfJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1855&author=H.+Gaoauthor=Y.+Wuauthor=Y.+Sunauthor=Y.+Yangauthor=G.+Zhouauthor=Y.+Rao&title=Design%2C+synthesis%2C+and+evaluation+of+highly+potent+FAK-targeting+PROTACs&doi=10.1021%2Facsmedchemlett.9b00372"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of Highly Potent FAK-Targeting PROTACs</span></div><div class="casAuthors">Gao, Hongying; Wu, Yue; Sun, Yonghui; Yang, Yiqing; Zhou, Guangbiao; Rao, Yu</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1855-1862</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK), a cytoplasmic protein tyrosine kinase, exerts kinase-dependent enzymic functions and kinase-independent scaffolding functions, both of which are crucial in cancer development, early embryonic development, and reprodn.  However, previous efforts for FAK blocking mainly focus on kinase inhibitors.  Proteolysis targeting chimeras (PROTACs) are heterobifunctional mols. that allow direct post-translational knockdown of proteins via ubiquitination of a target protein by E3 ubiquitin ligase and subsequent proteasomal degrdn.  Here, we designed and synthesized a FAK PROTAC library with FAK inhibitor (PF562271 or VS6063) and CRBN E3 ligand.  A novel FAK-targeting PROTAC, FC-11, showed a rapid and reversible FAK degrdn. with a picomolar of DC50 in various cell lines in vitro, which imply that FAK-PROTACs could be useful as expand tools for studying functions of FAK in biol. system and as potential therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDJ4SVK5xRNrVg90H21EOLACvtfcHk0lgRarEG_CBKSA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVajtrfJ&md5=79cacdc66925d21441732c26c9b268d4</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00372%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DG.%26aulast%3DRao%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520highly%2520potent%2520FAK-targeting%2520PROTACs%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D1855%26doi%3D10.1021%2Facsmedchemlett.9b00372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekido, Y.</span></span> <span> </span><span class="NLM_article-title">E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">5522</span>â <span class="NLM_lpage">5531</span>, <span class="refDoi">Â DOI: 10.1038/onc.2017.147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fonc.2017.147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=28553954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosVyrtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2017&pages=5522-5531&author=T.+Katoauthor=T.+Satoauthor=K.+Yokoiauthor=Y.+Sekido&title=E-cadherin+expression+is+correlated+with+focal+adhesion+kinase+inhibitor+resistance+in+Merlin-negative+malignant+mesothelioma+cells&doi=10.1038%2Fonc.2017.147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells</span></div><div class="casAuthors">Kato, T.; Sato, T.; Yokoi, K.; Sekido, Y.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">5522-5531</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Malignant mesothelioma (MM) is an aggressive tumor commonly caused by asbestos exposure after a long latency.  Focal adhesion kinase (FAK) inhibitors inhibit the cell growth of Merlin-deficient MM cells; however, their clin. efficacy has not been clearly detd.  The aim of this study was to evaluate the growth inhibitory effect of the FAK inhibitor VS-4718 on MM cell lines and identify biomarkers for its efficacy.  Although most Merlin-deficient cell lines were sensitive to VS-4718 compared with control MeT-5A cells, a subset of these cell lines exhibited resistance to this drug.  Microarray and qRT-PCR analyses using RNA isolated from Merlin-deficient MM cell lines revealed a significant correlation between E-cadherin mRNA levels and VS-4718 resistance.  Merlin- and E-cadherin-neg. Y-MESO-22 cells underwent apoptosis upon treatment with a low concn. of VS-4718, whereas Merlin-neg., E-cadherin-pos. Y-MESO-9 cells did not undergo VS-4718-induced apoptosis.  Furthermore, E-cadherin knockdown in Merlin-neg. MM cells significantly sensitized cells to VS-4718 and induced apoptotic cell death upon VS-4718 treatment.  Together, our results suggest that E-cadherin serves as a predictive biomarker for mol. target therapy with FAK inhibitors for patients with mesothelioma and that its expression endows MM cells with resistance to FAK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqc2AZl866IXrVg90H21EOLACvtfcHk0ljfId6LvfiZ-Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosVyrtbk%253D&md5=34cc7fee7bf5ebae92ec406e34c1cf20</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1038%2Fonc.2017.147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2017.147%26sid%3Dliteratum%253Aachs%26aulast%3DKato%26aufirst%3DT.%26aulast%3DSato%26aufirst%3DT.%26aulast%3DYokoi%26aufirst%3DK.%26aulast%3DSekido%26aufirst%3DY.%26atitle%3DE-cadherin%2520expression%2520is%2520correlated%2520with%2520focal%2520adhesion%2520kinase%2520inhibitor%2520resistance%2520in%2520Merlin-negative%2520malignant%2520mesothelioma%2520cells%26jtitle%3DOncogene%26date%3D2017%26volume%3D36%26spage%3D5522%26epage%3D5531%26doi%3D10.1038%2Fonc.2017.147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jablonski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhanwar, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testa, J. R.</span></span> <span> </span><span class="NLM_article-title">Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">5960</span>â <span class="NLM_lpage">5968</span>, <span class="refDoi">Â DOI: 10.1038/sj.onc.1209587</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fsj.onc.1209587" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=16652148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVSnsL7L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=5960-5968&author=P.+I.+Poulikakosauthor=G.+H.+Xiaoauthor=R.+Gallagherauthor=S.+Jablonskiauthor=S.+C.+Jhanwarauthor=J.+R.+Testa&title=Re-expression+of+the+tumor+suppressor+NF2%2Fmerlin+inhibits+invasiveness+in+mesothelioma+cells+and+negatively+regulates+FAK&doi=10.1038%2Fsj.onc.1209587"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK</span></div><div class="casAuthors">Poulikakos, P. I.; Xiao, G-H.; Gallagher, R.; Jablonski, S.; Jhanwar, S. C.; Testa, J. R.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">5960-5968</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The neurofibromatosis type 2 NF2 gene product, merlin, is a tumor suppressor frequently inactivated in malignant mesothelioma (MM).  To investigate a possible correlation between merlin inactivation and MM invasiveness, we restored merlin expression in NF2-deficient MM cells.  Re-expression of merlin markedly inhibited cell motility, spreading and invasiveness, properties connected with the malignant phenotype of MM cells.  To test directly whether merlin inactivation promotes invasion in a nonmalignant system, we used small interfering RNA to silence Nf2 in mouse embryonic fibroblasts (MEFs) and found that downregulation of merlin resulted in enhanced cell spreading and invasion.  To delineate signaling events connected with this phenotype, we investigated the effect of merlin expression on focal adhesion kinase (FAK), a key component of cellular pathways affecting migration and invasion.  Expression of merlin attenuated FAK phosphorylation at the crit. phosphorylation site Tyr397 and disrupted the interaction of FAK with its binding partners Src and p85, the regulatory subunit of phosphatidylinositol-3-kinase.  In addn., NF2-null MM cells stably overexpressing FAK showed increased invasiveness, which decreased significantly when merlin expression was restored.  Collectively, these findings suggest that merlin inactivation is a crit. step in MM pathogenesis and is related, at least in part, with upregulation of FAK activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPtJjSYb6jmLVg90H21EOLACvtfcHk0ljfId6LvfiZ-Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVSnsL7L&md5=0dfead504a7aaa68dfd7d00128d81781</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1209587&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1209587%26sid%3Dliteratum%253Aachs%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DXiao%26aufirst%3DG.%2BH.%26aulast%3DGallagher%26aufirst%3DR.%26aulast%3DJablonski%26aufirst%3DS.%26aulast%3DJhanwar%26aufirst%3DS.%2BC.%26aulast%3DTesta%26aufirst%3DJ.%2BR.%26atitle%3DRe-expression%2520of%2520the%2520tumor%2520suppressor%2520NF2%252Fmerlin%2520inhibits%2520invasiveness%2520in%2520mesothelioma%2520cells%2520and%2520negatively%2520regulates%2520FAK%26jtitle%3DOncogene%26date%3D2006%26volume%3D25%26spage%3D5960%26epage%3D5968%26doi%3D10.1038%2Fsj.onc.1209587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolev, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidal, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadariya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ring, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menges, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padval, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClatchey, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testa, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachter, J. A.</span></span> <span> </span><span class="NLM_article-title">Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">237</span>â <span class="NLM_lpage">260</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.3008639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1126%2Fscitranslmed.3008639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1GrtLfK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=237-260&author=I.+M.+Shapiroauthor=V.+N.+Kolevauthor=C.+M.+Vidalauthor=Y.+Kadariyaauthor=J.+E.+Ringauthor=Q.+Wrightauthor=D.+T.+Weaverauthor=C.+Mengesauthor=M.+Padvalauthor=A.+I.+McClatcheyauthor=Q.+Xuauthor=J.+R.+Testaauthor=J.+A.+Pachter&title=Merlin+deficiency+predicts+FAK+inhibitor+sensitivity%3A+a+synthetic+lethal+relationship&doi=10.1126%2Fscitranslmed.3008639"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship</span></div><div class="casAuthors">Shapiro, Irina M.; Kolev, Vihren N.; Vidal, Christian M.; Kadariya, Yuwaraj; Ring, Jennifer E.; Wright, Quentin; Weaver, David T.; Menges, Craig; Padval, Mahesh; McClatchey, Andrea I.; Xu, Qunli; Testa, Joseph R.; Pachter, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Science Translational Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">237</span>),
    <span class="NLM_cas:pages">237ra68/1-237ra68/12, 12</span>CODEN:
                <span class="NLM_cas:coden">STMCBQ</span>;
        ISSN:<span class="NLM_cas:issn">1946-6242</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The goal of targeted therapy is to match a selective drug with a genetic lesion that predicts for drug sensitivity.  In a diverse panel of cancer cell lines, we found that the cells most sensitive to focal adhesion kinase (FAK) inhibition lack expression of the neurofibromatosis type 2 (NF2) tumor suppressor gene product, Merlin.  Merlin expression is often lost in malignant pleural mesothelioma (MPM), an asbestos-induced aggressive cancer with limited treatment options.  Our data demonstrate that low Merlin expression predicts for increased sensitivity of MPM cells to a FAK inhibitor, VS-4718, in vitro and in tumor xenograft models.  Disruption of MPM cell-cell or cell-extracellular matrix (ECM) contacts with blocking antibodies suggests that weak cell-cell adhesions in Merlinneg. MPM cells underlie their greater dependence on cell-ECM-induced FAK signaling.  This provides one explanation of why Merlin-neg. cells are vulnerable to FAK inhibitor treatment.  Furthermore, we validated aldehyde dehydrogenase as a marker of cancer stem cells (CSCs) in MPM, a cell population thought to mediate tumor relapse after chemotherapy.  Whereas pemetrexed and cisplatin, std.-of-care agents for MPM, enrich for CSCs, FAK inhibitor treatment preferentially eliminates these cells.  These preclin. results provide the rationale for a clin. trial in MPM patients using a FAK inhibitor as a single agent after first-line chemotherapy.  With this design, the FAK inhibitor could potentially induce a more durable clin. response through redn. of CSCs along with a strong antitumor effect.  Furthermore, our data suggest that patients with Merlin-neg. tumors may esp. benefit from FAK inhibitor treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2DmeG3F2N1LVg90H21EOLACvtfcHk0ljfId6LvfiZ-Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1GrtLfK&md5=0f2c12151b444fdb0cab1795d8c3fdc0</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3008639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3008639%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DI.%2BM.%26aulast%3DKolev%26aufirst%3DV.%2BN.%26aulast%3DVidal%26aufirst%3DC.%2BM.%26aulast%3DKadariya%26aufirst%3DY.%26aulast%3DRing%26aufirst%3DJ.%2BE.%26aulast%3DWright%26aufirst%3DQ.%26aulast%3DWeaver%26aufirst%3DD.%2BT.%26aulast%3DMenges%26aufirst%3DC.%26aulast%3DPadval%26aufirst%3DM.%26aulast%3DMcClatchey%26aufirst%3DA.%2BI.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DTesta%26aufirst%3DJ.%2BR.%26aulast%3DPachter%26aufirst%3DJ.%2BA.%26atitle%3DMerlin%2520deficiency%2520predicts%2520FAK%2520inhibitor%2520sensitivity%253A%2520a%2520synthetic%2520lethal%2520relationship%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2014%26volume%3D6%26spage%3D237%26epage%3D260%26doi%3D10.1126%2Fscitranslmed.3008639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doroshow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kummar, S.</span></span> <span> </span><span class="NLM_article-title">United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies</span>. <i>Curr. Probl. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">110</span>â <span class="NLM_lpage">144</span>, <span class="refDoi">Â DOI: 10.1016/j.currproblcancer.2013.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1016%2Fj.currproblcancer.2013.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=23972982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A280%3ADC%252BC3sbitlelsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2013&pages=110-144&author=W.+Jeongauthor=J.+H.+Doroshowauthor=S.+Kummar&title=United+States+Food+and+Drug+Administration+approved+oral+kinase+inhibitors+for+the+treatment+of+malignancies&doi=10.1016%2Fj.currproblcancer.2013.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies</span></div><div class="casAuthors">Jeong Woondong; Doroshow James H; Kummar Shivaani</div><div class="citationInfo"><span class="NLM_cas:title">Current problems in cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">110-44</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRazKlkC8sbaczK395ZObgVfW6udTcc2eZFVwG2ZKzfnbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbitlelsA%253D%253D&md5=b33b5be32688befaec3c784353447211</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2Fj.currproblcancer.2013.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.currproblcancer.2013.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DJeong%26aufirst%3DW.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DKummar%26aufirst%3DS.%26atitle%3DUnited%2520States%2520Food%2520and%2520Drug%2520Administration%2520approved%2520oral%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520malignancies%26jtitle%3DCurr.%2520Probl.%2520Cancer%26date%3D2013%26volume%3D37%26spage%3D110%26epage%3D144%26doi%3D10.1016%2Fj.currproblcancer.2013.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mak, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagden, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebot, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazumdar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazzah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzuto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greystoke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auger, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkenau, H.-T.</span></span> <span> </span><span class="NLM_article-title">A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">975</span>â <span class="NLM_lpage">981</span>, <span class="refDoi">Â DOI: 10.1038/s41416-019-0452-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=10.1038%2Fs41416-019-0452-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=30992546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFWmsLrF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2019&pages=975-981&author=G.+Makauthor=J.-C.+Soriaauthor=S.+P.+Blagdenauthor=R.+Plummerauthor=R.+A.+Flemingauthor=N.+Nebotauthor=J.+Zhangauthor=J.+Mazumdarauthor=D.+Roganauthor=A.+Gazzahauthor=I.+Rizzutoauthor=A.+Greystokeauthor=L.+Yanauthor=J.+Tolsonauthor=K.+R.+Augerauthor=H.-T.+Arkenau&title=A+phase+Ib+dose-finding%2C+pharmacokinetic+study+of+the+focal+adhesion+kinase+inhibitor+GSK2256098+and+trametinib+in+patients+with+advanced+solid+tumours&doi=10.1038%2Fs41416-019-0452-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours</span></div><div class="casAuthors">Mak, Gabriel; Soria, Jean-Charles; Blagden, Sarah P.; Plummer, Ruth; Fleming, Ronald A.; Nebot, Noelia; Zhang, Jianping; Mazumdar, Jolly; Rogan, Debra; Gazzah, Anas; Rizzuto, Ivana; Greystoke, Alastair; Yan, Li; Tolson, Jerry; Auger, Kurt R.; Arkenau, Hendrik-Tobias</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">975-981</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Background: Combined focal adhesion kinase (FAK) and MEK inhibition may provide greater anticancer effect than FAK monotherapy.  Methods: This dose-finding phase Ib study (adaptive 3 + 3 design) detd. the max. tolerated dose (MTD) of trametinib and the FAK inhibitor GSK2256098 in combination.  Eligible patients had mesothelioma or other solid tumors with probable mitogen activated protein kinase pathway activation.  Adverse events (AEs), dose-limiting toxicities, disease progression and pharmacokinetics/pharmacodynamics were analyzed.  Results: Thirty-four subjects were enrolled.  The GSK2256098/trametinib MTDs were 500 mg twice daily (BID)/0.375 mg once daily (QD) (high/low) and 250 mg BID/0.5 mg QD (low/high).  The most common AEs were nausea, diarrhoea, decreased appetite, pruritus, fatigue and rash; none were grade 4.  Systemic exposure to trametinib increased when co-administered with GSK2256098, vs. trametinib monotherapy; GSK2256098 pharmacokinetics were unaffected by concomitant trametinib.  Median progression-free survival (PFS) was 11.8 wk (95% CI: 6.1-24.1) in subjects with mesothelioma and was longer with Merlin-neg. vs. Merlin-pos. tumors (15.0 vs 7.3 wk).  Conclusions: Trametinib exposure increased when co-administered with GSK2256098, but not vice versa.  Mesothelioma patients with loss of Merlin had longer PFS than subjects with wild-type, although support for efficacy with this combination was limited.  Safety profiles were acceptable up to the MTD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovNTEJjHaRLLVg90H21EOLACvtfcHk0lhCUBCIzlQ7Cw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFWmsLrF&md5=3303a98dfafb0360b04050962b8d7cc5</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1038%2Fs41416-019-0452-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41416-019-0452-3%26sid%3Dliteratum%253Aachs%26aulast%3DMak%26aufirst%3DG.%26aulast%3DSoria%26aufirst%3DJ.-C.%26aulast%3DBlagden%26aufirst%3DS.%2BP.%26aulast%3DPlummer%26aufirst%3DR.%26aulast%3DFleming%26aufirst%3DR.%2BA.%26aulast%3DNebot%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DMazumdar%26aufirst%3DJ.%26aulast%3DRogan%26aufirst%3DD.%26aulast%3DGazzah%26aufirst%3DA.%26aulast%3DRizzuto%26aufirst%3DI.%26aulast%3DGreystoke%26aufirst%3DA.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DTolson%26aufirst%3DJ.%26aulast%3DAuger%26aufirst%3DK.%2BR.%26aulast%3DArkenau%26aufirst%3DH.-T.%26atitle%3DA%2520phase%2520Ib%2520dose-finding%252C%2520pharmacokinetic%2520study%2520of%2520the%2520focal%2520adhesion%2520kinase%2520inhibitor%2520GSK2256098%2520and%2520trametinib%2520in%2520patients%2520with%2520advanced%2520solid%2520tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2019%26volume%3D120%26spage%3D975%26epage%3D981%26doi%3D10.1038%2Fs41416-019-0452-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JKK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JKK','PDB','2JKK'); return false;">PDB: 2JKK</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EBV" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EBV','PDB','4EBV'); return false;">PDB: 4EBV</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4I4F" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4I4F','PDB','4I4F'); return false;">PDB: 4I4F</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01248&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-23%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01248" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01248" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66797d053d1e23e0","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
